<SEC-DOCUMENT>0001019056-19-000521.txt : 20190909
<SEC-HEADER>0001019056-19-000521.hdr.sgml : 20190909
<ACCEPTANCE-DATETIME>20190909172846
ACCESSION NUMBER:		0001019056-19-000521
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		63
FILED AS OF DATE:		20190909
DATE AS OF CHANGE:		20190909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-232377
		FILM NUMBER:		191083840

	BUSINESS ADDRESS:	
		STREET 1:		800 WEST VALLEY PARKWAY
		STREET 2:		SUITE 203
		CITY:			ESCONDIDO
		STATE:			CA
		ZIP:			92025
		BUSINESS PHONE:		949-370-9062

	MAIL ADDRESS:	
		STREET 1:		800 WEST VALLEY PARKWAY
		STREET 2:		SUITE 203
		CITY:			ESCONDIDO
		STATE:			CA
		ZIP:			92025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>modular_s1a1.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 2pt; text-align: center"><FONT STYLE="font-size: 10pt"><B> As
filed with the Securities and Exchange Commission September 9, 2019 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><B> File
No. 333-232377 </B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED
STATES</B></FONT><BR>
<FONT STYLE="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT><BR>
<FONT STYLE="font-size: 12pt"><B>Washington, D.C. 20549</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: center"> <FONT STYLE="font-size: 16pt"><B>Pre-effective</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: center"> <FONT STYLE="font-size: 16pt"><B>AMENDMENT
NO. 1</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: center"> <FONT STYLE="font-size: 16pt"><B>TO</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0pt; text-align: center"><FONT STYLE="font-size: 16pt"><B>FORM S-1</B><BR> <B>REGISTRATION STATEMENT</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B><I>UNDER</I></B></FONT><BR> <FONT STYLE="font-size: 10pt"><B><I>THE
SECURITIES ACT OF 1933</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: center"><FONT STYLE="font-size: 24pt"><B>MODULAR
MEDICAL, INC.</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(Exact name of registrant as specified in its charter)</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 45%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 43%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>87-0620495</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other
    jurisdiction of</B></FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>(IRS Employer</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>incorporation or
    organization)</B></FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Identification Number)</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>800
West Valley Parkway, Suite 203</B><BR>
<B>Escondido, California 92025</B><BR>
<B>(949) 370-9062</B><BR>
<B>(Address, including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Paul
DiPerna</B><BR>
<B>Chairman, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer</B><BR>
<B>Modular Medical, Inc.</B><BR>
<B>800 West Valley Parkway, Suite 203</B><BR>
<B>Escondido, California 92025</B><BR>
<B>(949) 370-9062</B><BR>
<B>(Name, address, including zip code, and telephone number, including area code, of agent for service)</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><I>With
copy to:</I></B><BR>
<BR>
<B>Lawrence G Nusbaum, Esq.</B><BR>
<B>Howard F. Mulligan, Esq.</B><BR>
<B>Gusrae Kaplan Nusbaum PLLC</B><BR>
<B>120 Wall Street</B><BR>
<B>New York, New York 10005</B><BR>
<B>Telephone: (212) 269-1400</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public:</B> From time to time after the effective date of this Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">If any
of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box. <FONT STYLE="font-family: Wingdings"> x </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">If this
Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
<FONT STYLE="font-family: Wingdings">o</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">If this
Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act of 1933, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">o</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">If this
Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">o</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller
reporting company&rdquo; in rule 12b-2 of the Exchange Act.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Large accelerated filer</FONT></td>
    <TD STYLE="width: 51%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Wingdings">o</FONT></td>
    <TD STYLE="width: 26%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></td>
    <TD STYLE="width: 2%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Wingdings">o</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Wingdings">o</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Wingdings">x</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT> </td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">If an emerging growth company,
    indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
    or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.</FONT> </td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Wingdings">o</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>CALCULATION
OF REGISTRATION FEE</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 34%; border-top: Black 2.5pt double; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title
    of Each Class of</B> <BR>
    <B>Securities to be Registered</B></FONT></td>
    <TD STYLE="width: 1%; border-top: Black 2.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 1%; border-top: Black 2.5pt double; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 16%; border-top: Black 2.5pt double; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B><BR>
    <B>to be</B><BR>
    <B>Registered(1)(2)</B></FONT></td>
    <TD STYLE="width: 1%; border-top: Black 2.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 1%; border-top: Black 2.5pt double; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 14%; border-top: Black 2.5pt double; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Proposed</B><BR>
    <B>Maximum</B><BR>
    <B>Offering Price</B><BR>
    <B>Per Share(3)</B></FONT></td>
    <TD STYLE="width: 1%; border-top: Black 2.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 1%; border-top: Black 2.5pt double; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 16%; border-top: Black 2.5pt double; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Proposed</B><BR>
    <B>Maximum</B><BR>
    <B>Aggregate</B> <BR>
    <B>Offering Price(3)</B></FONT></td>
    <TD STYLE="width: 1%; border-top: Black 2.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 1%; border-top: Black 2.5pt double; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 12%; border-top: Black 2.5pt double; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount
    of</B> <BR>
    <B>Registration</B><BR>
    <B>Fee</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Common
    Stock, par value $0.001 per share</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">9,658,201
    shares</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">$3.00</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">$28,974,603</FONT></td>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">$3,511.72</FONT></td></tr>
</table>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 10pt; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The
                                         shares of common stock to be offered for resale by selling shareholders consists of:
                                         7,801,213 shares issued in the 2017 Placement (as defined herein) and (ii) 1,856,988
                                         shares issued in the 2018 Placement (as defined herein).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Pursuant
                                         to Rule 416 under the Securities Act, this registration statement also covers an indeterminate
                                         number of shares that may be issued upon stock splits, stock dividends or similar transactions.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Estimated
                                         in accordance with Rule 457(c) under the Securities Act of 1933, as amended, solely for
                                         the purpose of calculating the registration fee.</FONT></TD></TR></TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>The
registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until
the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective
on such date as the Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 2 -->

    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; color: red"><FONT STYLE="font-size: 10pt"><B>The
information in this prospectus is not complete and may be changed. The selling shareholders may not sell these securities until
the registration statement filed with the Securities and Exchange Commission relating to these securities is effective. This prospectus
is not an offer to sell these securities and it is not a solicitation of an offer to buy these securities in any jurisdiction
where such offer, solicitation or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; color: red"> <FONT STYLE="font-size: 10pt"><B>Subject
to Completion, dated September 9, 2019</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>MODULAR
MEDICAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>9,658,201
SHARES OF COMMON STOCK</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This prospectus
relates to the offer and sale of up to 9,658,201 shares of our common stock, par value $0.001 per share, by the selling shareholders
identified in this prospectus. The shares being offered consist exclusively of:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">7,801,213
                                         shares issued to selling shareholders in the private placement completed on July 24,
                                         2017 (the &ldquo;2017 Placement&rdquo;);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1,856,988
                                         shares issued to selling shareholders in the private placement conducted between November
                                         2018 through March 29, 2019 (the &ldquo;2018 Placement&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
selling shareholders will sell all or a portion of these shares from time to time, at a fixed price of $3.00 per share until our
common stock is quoted on the OTC Bulletin Board, OTCQX or OTCQB, and, thereafter, at prevailing market prices or privately negotiated
prices. The shares may be sold by any means described in the section of this prospectus entitled &ldquo;Plan of Distribution&rdquo;
beginning on page 24 of this prospectus.</FONT> <FONT STYLE="font-size: 10pt"> We will pay the expenses relating to the registration
under the Securities Act of 1933, as amended, of the offer and sale by the selling shareholders of the shares covered by this
prospectus including legal and accounting fees. Each selling shareholder, however, will pay and be responsible for all brokerage
commissions and similar charges, if any, incurred by such person in connection with sales of such person&rsquo;s shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We will
not receive any proceeds from the sale of these shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Our
common stock is quoted on the OTC Pink Open Market under the trading symbol &ldquo;MODD.&rdquo; On September 4, 2019, the closing
price of our common stock was $0.20 per share.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; under the federal securities laws and are subject to reduced public company reporting
requirements for this prospectus and future filings.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Investing
in our common stock involves risks. You should read and carefully consider the &ldquo;<U>Risk Factors</U>&rdquo; section beginning
on page 7 of this prospectus before investing in our common stock.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state regulatory agency has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>The date
of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2019.</B></FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 5%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara001"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara002"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">2</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara003"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">7</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara004"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">21</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara005"><FONT STYLE="font-size: 10pt">SELLING SHAREHOLDERS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">21</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara006"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">24</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara007"><FONT STYLE="font-size: 10pt">DETERMINATION OF OFFERING PRICE</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">26</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara008"><FONT STYLE="font-size: 10pt">DESCRIPTION OF COMMON STOCK</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">26</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara009"><FONT STYLE="font-size: 10pt">OUR BUSINESS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">28</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara010"><FONT STYLE="font-size: 10pt">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">35</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara011"><FONT STYLE="font-size: 10pt">MANAGEMENT</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">39</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara012"><FONT STYLE="font-size: 10pt">EXECUTIVE COMPENSATION</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">43</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara013"><FONT STYLE="font-size: 10pt">STOCK OWNERSHIP BY PRINCIPAL SHAREHOLDERS AND MANAGEMENT</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">46</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara014"><FONT STYLE="font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">47</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara015"><FONT STYLE="font-size: 10pt">MARKET FOR OUR COMMON STOCK AND RELATED SHAREHOLDER MATTERS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">47</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara016"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">47</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara017"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">48</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara018"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">48</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#modulara019"><FONT STYLE="font-size: 10pt">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">49</FONT> </td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>In
making your investment decision, you should rely only on the information contained in this prospectus. We have not authorized
anyone to provide you with different or additional information.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>We
are not making an offer to sell or seeking an offer to buy any shares of common stock in any jurisdiction where the offer or sale
is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>You
should not assume that the information contained in this prospectus is complete and accurate as of any date other than the date
of this prospectus, regardless of the time of delivery of this prospectus or any sale of securities offered hereby&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara001"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">This
prospectus contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to
predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such
as &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;projects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;anticipates&rdquo; and variations thereof, or the use of future tense, identify forward-looking statements,
but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not guarantees of
performance and actual results could differ materially from those contained in or expressed by such statements. In evaluating
all such statements we urge you to specifically consider various risk factors identified in this prospectus, including the matters
set forth under the heading &ldquo;Risk Factors,&rdquo; any of which could cause actual results to differ materially from those
indicated by our forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Our
forward-looking statements reflect our current views with respect to future events and are based on currently available financial,
economic, scientific, regulatory, industry and competitive data and information on our business plans. You should not place undue
reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i)
our ability to achieve a marketable product (i.e., our insulin pump), (ii) the timely and costs of obtaining all regulatory approvals
and clearances relating to our insulin pump including those of the FDA, (iii) the sufficiency of our cash position, (iv) our ability
to raise additional financing when needed and the terms and timing thereof, (v) that we have accurately analyzed our target market
for our insulin pump, (vi) market acceptance of our product by our target market, (vii) the existence or development of products
for diabetes that are viewed by medical professionals, third party payors and insulin dependent people with diabetes as superior
and/or more preferable to, or more affordable or cost efficient than our product, (viii) regulatory initiatives, compliance with
governmental regulations and the regulatory approval process, (ix) general economic and business conditions, (x) our ability and
the timing of us to successfully commercialize our product (xi) changes in United States economic, political and social conditions,
(xii) our ability to recruit and retain (and replace if necessary on a timely basis) competent professionals including third party
consultants and advisors and their ability to timely and competently perform their services for us, (xiii) litigation related
to our intellectual property rights and patents and claims against us for infringement on such rights of others as well as potential
product liability claims against us, (xiv) issues relating to the thinly traded market for our shares of common stock, (xv) our
ability to compete in the diabetes marketplace with larger and more substantial medical device companies, (xvi) the specific risk
factors discussed under the heading &ldquo;Risk Factors&rdquo; below, and (xvii) various other matters, many of which are beyond
our control.</FONT> <FONT STYLE="font-size: 10pt"> Should one or more of these risks or uncertainties develop, or should underlying
assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated,
or otherwise indicated by our forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">We intend
that all forward-looking statements made in this prospectus will be subject to the safe harbor protection of the federal securities
laws pursuant to Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), to the extent applicable.
</FONT> <FONT STYLE="font-size: 10pt">Except as required by law, we do not undertake any responsibility to update these forward-looking
statements to take into account events or circumstances that occur after the date of this prospectus. Additionally, we do not
undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ
from those expressed or implied by these forward-looking statements.</FONT></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<DIV STYLE="border: black 1px solid; padding: 6pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara002"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>This
summary highlights information contained elsewhere in this prospectus and does not contain all of the information you should consider
before investing in shares of our common stock. You should read this entire prospectus carefully, including the sections entitled
&ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
before you decide to invest in shares of our common stock.</I> <I>Unless the context otherwise requires, references in this prospectus
to &ldquo;Modular Medical,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; or &ldquo;us&rdquo; are to Modular
Medical, Inc. and its subsidiaries.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Overview</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
are a development stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps
for insulin dependent people with diabetes.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
International Diabetes Federation, or IDF, estimates that in 2017, approximately 425&nbsp;million people had diabetes worldwide
and that by 2045, this number will increase to 629&nbsp;million people. According to the Centers for Disease Control and Prevention,
or CDC, 2017 National Diabetes Statistics Report, approximately 23&nbsp;million people in the United States have diagnosed diabetes,
of which type 1 diabetes accounts for approximately 5% to 10%, or approximately 1.2 to 2.3&nbsp;million people. All people with
type 1 diabetes require daily insulin. Of people with type 2 diabetes in the United States, according to the CDC, approximately
14%, or 3.2&nbsp;million people, require insulin to manage their diabetes. We refer in this prospectus to people with type 1 diabetes
and people with type 2 diabetes who require daily insulin as &ldquo;insulin-dependent people with diabetes.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Currently,
there are two primary therapies available for insulin-dependent people with diabetes: multiple daily insulin injections directly
into the body through syringes or insulin pens, referred to as Multiple Daily Injection (MDI) therapy, or the use of an insulin
pump to deliver a continuous subcutaneous insulin infusion into the body, and user directed infusions as appropriate (Continuous
Subcutaneous Insulin Injections (CSII) therapy. Generally, CSII therapy is considered to provide a number of advantages over MDI
therapy primarily in that the continuous infusion of insulin allows absorption of glucose in a controlled manner minimizing large
doses of insulin required before meals. This has proven to improve glucose control and reduce emergency room visits associated
with low glucose.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Notwithstanding
these advantages, the difficulty in use resulting from the complexity and cumbersome design of available insulin pumps, as well
as high and often prohibitive costs, has resulted not only in dissatisfaction among many existing pump users, but also has severely
limited the adoption rate of insulin pumps by a segment of the diabetes population, who we refer to in this prospectus as &ldquo;almost
pumpers.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
generally define almost pumpers as persons with insulin dependent diabetes who are aware of pumps and the potential benefits,
but because of the shortcomings and problems prevalent in available insulin pumps, continue to receive their daily insulin through
insulin injections.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Our
initial target market for our insulin pump is the almost pumper population located in the United States.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"> According
to a market research study commissioned by us and conducted by our independent marketing consultant, Kinetic Innovations, Inc.
now known as Kirk Brote Consulting (&ldquo;Kirk Brote&rdquo;), only an estimated 35% of Americans with type 1 diabetes use insulin
pump therapy and an estimated 30% of Americans with type 1 diabetes are who we classify as &ldquo;almost pumpers&rdquo;. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">Our design
and development team is led by Paul DiPerna, our chairman, chief executive officer and a 40% shareholder. Mr. DiPerna has over
30 years of high level experience in developing, designing, obtaining FDA approval, managing and the commercialization of medical
devices, including consumer and hospital based insulin pumps while working for such industry leading medical device companies
as Baxter Healthcare, Inc., a supplier of drug therapies and associated pumping technologies and Tandem Diabetes Care, Inc, a
leading supplier of pumping technology to the existing insulin pumping marketplace, which was originally founded by Mr. DiPerna.</FONT> </P></DIV>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<DIV STYLE="border: black 1px solid; padding: 6pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Our
Insulin Pump Prototype</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Over
the past two years we have designed and developed working prototypes of our insulin pump.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">During
this period, we also have and continue to devote substantial time and resources to better understand the needs and preferences
of almost pumpers to enable us to modify and refine our insulin pump to the needs and preferences of this target market. We continue
to engage Kirk Brote, to provide specific feedback and information from our target market and their care givers through one on
one interviews, human factors testing, on-line and in person surveys, focus groups both at industry related tradeshows and conferences.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Pre-Commercialization
Steps</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">While
we have substantially completed the general engineering and mechanical aspects of our current insulin pump prototype, prior to,
commercializing, we still must successfully complete a number of material steps including:</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Continue
                                         to modify, refine and finalize our prototype so that it:</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">meets
                                         the general needs and preferences of our almost pumper target market based in large part
                                         on the recommendations from Kirk Brote resulting from their analysis of feedback and
                                         other information obtained from almost pumpers and their caregivers</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">meets
                                         the general guidelines of third party payors, private and public insurance companies,
                                         preferred provider organizations and other managed care providers with particular focus
                                         on the guidelines established by the Center for Medicare and Medicaid Services, CMS which
                                         administrates the United States Medicare program. To assist us in making such modifications
                                         and refinements, we have retained PrecisionXtract Inc., an independent consulting firm,
                                         who is focused on ensuring that our product satisfies the coverage and reimbursement
                                         criteria of such third party payors.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Continue
                                         to work closely with, Susan Finnerman, of Regulatory Compliance Experts, Inc., referred
                                         to in this prospectus as &#8220;our FDA regulatory consultant,&#8221; to complete, finalize
                                         and file our FDA submission including our pre-market notification to the FDA for 510(k)
                                         clearance and all other documentation necessary to obtain FDA approval of our insulin
                                         pump. This will include the following:</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">engage
                                         the FDA in a pre-submission conference to ensure that we understand and meet the FDA&#8217;s
                                         requirements, expectations and standards with regard to approval of our product. At this
                                         meeting, our team, including our FDA regulatory consultant, will receive FDA comments
                                         and guidance regarding our proposed submission during the pre-market notification period
                                         for 510(K) clearance (including any suggested modifications to the device description,
                                         indications for use or summary of supporting data contained in the notification). We
                                         currently expect such conference will be conducted near the end of the third quarter
                                         of 2019.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Prepare
                                         and ensure that our pre-market notification that will be part of our FDA submission,
                                         demonstrates that our insulin pump is substantially equivalent to an insulin pump previously
                                         cleared by the FDA and legally marketed to the public.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">prepare
                                         our submission to the FDA, to include all of the appropriate results of tests (relating
                                         to, among other things, user effectiveness, sterility, pump efficiency and shipping compatibility)
                                         demonstrating safety and efficacy of our insulin pump in satisfaction of the mandates
                                         of the Federal Food, Drug and Cosmetics Act (the &#8220;FDCA&#8221;), including requirements
                                         with regard to registration and listing, labeling, medical device reporting and good
                                         manufacturing practices.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">We
                                         currently expect to make this submission near the end of the last quarter of 2019 or
                                         in the first quarter of 2020.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Together
                                         with our FDA regulatory consultant, take such actions, if any, as may be required by
                                         the FDA as a condition to granting approval and providing 510(k) clearance for our insulin
                                         pump</FONT> </TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P></DIV>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: black 1px solid; padding: 6pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">At
                                         the point that we feel confident of the FDA approval and clearance process relating to
                                         our insulin pump, select a manufacturer of our insulin pump through a competitive bidding
                                         process</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Retain
                                         appropriate sales and marketing personnel to develop, implement and launch a promotional
                                         campaign for our insulin pump substantially focused on our target market</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">As
with any medical device attempting to enter and successfully compete with existing products in an established and competitive
marketplace, we will face significant hurdles to accomplish the above steps to commercialization including:</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Obtaining
                                         FDA 510(K) clearance to market and sell our insulin pump to the public</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Obtaining
                                         all other FDA approvals with regard to our product required by the FDCA</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Educating
                                         endocrinologists, who typically prescribe pump usage, as to the superior qualities of
                                         our product</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Demonstrating
                                         to general practitioners, who have been historically skeptical of the heightened support
                                         inherent in insulin pumps, of our product&#8217;s ease of use and convenience</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Ensuring
                                         that our final product does in fact meet the needs of almost pumpers.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Overcoming
                                         the historic obstacles and reluctance of almost pumpers to using insulin pumps to treat
                                         their diabetes</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Ensuring
                                         that third party payors agree to cover all or a substantial portion of the purchase price
                                         and recurring costs of the use of our insulin pump</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>The
Private Placement Transactions</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The shares
of our common stock being offered for resale by selling shareholders named herein pursuant to this prospectus were issued in connection
with two private placement transactions described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>2017
Placement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">On July
24, 2017, we sold to accredited investors in a private placement (the &ldquo;2017 Placement&rdquo;) an aggregate 7,801,213 shares
of our common stock at a purchase price of $0.66 per share, resulting in gross proceeds to us of $4,731,872. We are registering
for resale by the selling shareholders named herein the 7,801,213 shares of our common stock issued to such persons in the 2017
Placement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>2018
Placement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Between
November 2018 and March 29, 2019, in a private placement (the &ldquo;2018 Placement&rdquo;) 1,856,988 shares of our common stock
at a purchase price of $2.25 per share, resulting in gross proceeds to us of $4,142,666. We are registering for resale by the
selling shareholders named herein the 1,856,988 shares of our common stock issued in the 2018 Placement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">All
of the 9,658,201 Shares purchased in the 2017 Placement and the 2018 Placement were issued for cash except for 568,182 shares
issued in the 2017 Placement to Manchester, at the same $0.66 per share purchase price paid by other investors, in exchange for
the cancellation of the 2,900,000 shares Manchester purchased in April 2017 for $375,000 (or $0.13 per share). See &ldquo;Prospectus
Summary &ndash; Corporate History and Background &ndash; The Control Block Acquisition.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">Our offer
and sale of all of the foregoing shares in connection with the 2017 Placement and the 2018 Placement were intended to be exempt
from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) of the Securities Act and the safe harbor
provisions of Rule 506(b) of Regulation D thereunder, as applicable to sales of securities exclusively to accredited investors,
as that term is defined in Rule 501(a) of Regulation D.</FONT> </P></DIV>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<DIV STYLE="border: black 1px solid; padding: 6pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>This
Offering</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 27%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Securities being offered:</FONT></td>
    <TD STYLE="width: 73%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Up to
    9,658,201 shares of common stock, consisting of (i) 7,801,213 shares issued in the 2017 Placement and (ii) 1,856,988 shares
    issued in the 2018 Placement. See &ldquo;Selling Shareholders,&rdquo; below.</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Use of proceeds:</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">We will not receive
    any of the proceeds from the sale or other disposition of shares of our common stock by the selling shareholders. See &ldquo;Use
    of Proceeds.&rdquo;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Market symbol for <BR>
    common stock:</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Our common stock
    is quoted on the OTC Pink Open Market under the trading symbol &ldquo;MODD.&rdquo;</FONT> </td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Risk factors:</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">See &ldquo;Risk
    Factors&rdquo; beginning on page 7 for risks you should consider before investing in our shares.</FONT> </td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Corporate
History and Background</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
were formed as a corporation under the laws of the State of Nevada on October 22, 1998 under the name Bear Lake Recreation, Inc.
</FONT> <FONT STYLE="font-size: 10pt">We had no material business operations from 2002 until approximately April 26, 2017 when
we acquired Quasuras, Inc., a Delaware corporation (&ldquo;Quasuras&rdquo;), in the Acquisition (as defined below). Prior to the
Acquisition and, since at least 2002, we were a shell company as defined in Rule 12b-2 promulgated under the Securities Exchange
Act of 1934 (the &ldquo;Exchange Act&rdquo;). On June 27, 2017, in anticipation of the closing of the Acquisition, we changed
our name from &ldquo;Bear Lake Recreation, Inc.&rdquo; to &ldquo;Modular Medical, Inc.&rdquo; and changed our trading symbol from
&ldquo;BLKE&rdquo; to &ldquo;MODD.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>The
Control Block Acquisition. </I>On April 26, 2017, pursuant to a Common Stock Purchase Agreement, dated as of July 24, 2017, by
and among Manchester Explorer, LP, a Delaware limited partnership (&ldquo;Manchester&rdquo;), the Company and certain other persons
named therein, Manchester purchased from us 2,900,000 shares of our common stock representing in excess of a majority of our then
issued and outstanding common stock, for a purchase price of $375,000 (the &ldquo;Control Block Acquisition&rdquo;), resulting
in a change in control of the Company. In connection with the Control Block Acquisition, James E. Besser was appointed our president
and a director and Morgan C. Frank was appointed our chief executive officer, chief financial officer, secretary, treasurer and
a director and immediately following such appointments, our then officers and directors resigned. Mr. Besser is the managing member
of and Mr. Frank is the portfolio manager and a consultant to Manchester Management Company, LLC, a Delaware limited liability
company (&ldquo;MMC&rdquo;). MMC is the general partner of Manchester and JEB Partners, L.P. (&ldquo;JEB Partners&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>The
Acquisition. </I>On July 24, 2017, pursuant to a Reorganization and Share Exchange Agreement, by and among the Company, Mr. DiPerna,
the sole officer, director and a controlling stockholder of Quasuras, Messrs. Besser and Frank (Messrs. Besser, Frank and DiPerna,
collectively, the &ldquo;3 Quasuras Shareholders&rdquo;), and Quasuras (the &ldquo;2017 Acquisition Agreement&rdquo;), the Company
acquired all of the issued and outstanding shares of Quasuras owned by the 3 Quasuras Shareholders in exchange for 7,582,060 shares
of our common stock of which Messrs DiPerna, Besser and Frank received 7,220,400 shares, 180,830 shares and 180,830 shares, respectively,
resulting in Quasuras becoming our wholly-owned subsidiary (the &ldquo;Acquisition&rdquo;). Messrs. Besser and Frank each previously
purchased for $50,000 approximately 2.25% of the capital stock of Quasuras, and as a result each received 180,830 shares of our
common stock in the Acquisition. Simultaneously with the closing of the Acquisition, we completed the 2017 Placement, Manchester
cancelled the 2,900,000 shares of our common stock it purchased in the April 2017 Control Block Acquisition, Mr. Besser resigned
as our president and a director and Mr. Frank resigned as our chief executive officer, chief financial officer, secretary, and
treasurer, but remained a director and Mr. DiPerna was appointed our chairman, chief executive officer, chief financial officer,
secretary and treasurer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">On
July 28, 2017, we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), a Current Report on Form 8-K, our
Super 8-K, disclosing the Acquisition, the 2017 Placement, the cancellation of the 2,900,000 Control Block and related transactions.
As a result of the filing of our Super 8-K we ceased being a shell company.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Implications
of being an emerging growth company</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">We are an
&ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging
growth company until the earliest to occur of: the last day of the fiscal year in which we have more than $1.07&nbsp;billion in
annual revenue; the date we qualify as a &ldquo;large accelerated filer,&rdquo; with at least $700&nbsp;million of equity securities
held by&nbsp;non-affiliates;&nbsp;the issuance, in any three-year period, by us of more than $1&nbsp;billion in&nbsp;non-convertible&nbsp;debt
securities; and the last day of the fiscal year ending after the fifth anniversary of our initial public offering. We refer to
the Jumpstart Our Business Startups Act of 2012 herein as the &ldquo;JOBS Act,&rdquo; and any reference herein to &ldquo;emerging
growth company&rdquo; has the meaning ascribed to it in the JOBS Act.</FONT> </P></DIV>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: black 1px solid; padding: 6pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-align: justify"> <FONT STYLE="font-size: 10pt">An
emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies.
These provisions include, but are not limited to:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.15pt; background-color: white; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </td>
    <TD STYLE="vertical-align: top; width: 3%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-size: 10pt">being
    permitted to present only two years of audited financial statements and only two years of related Management&rsquo;s Discussion
    and Analysis of Financial Condition and Results of Operations in this prospectus;</FONT> </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.15pt; background-color: white; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </td>
    <TD STYLE="vertical-align: top; width: 3%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-size: 10pt">not
    being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002,
    as amended;</FONT> </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.15pt; background-color: white; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </td>
    <TD STYLE="vertical-align: top; width: 3%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-size: 10pt">reduced
    disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements;
    and</FONT> </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.15pt; background-color: white; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </td>
    <TD STYLE="vertical-align: top; width: 3%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-size: 10pt">exemptions
    from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden
    parachute payments not previously approved.</FONT> </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; background-color: white; text-align: justify"> <FONT STYLE="font-size: 10pt">We
have elected to take advantage of certain of the reduced disclosure obligations in this prospectus and may elect to take advantage
of other reduced reporting requirements in our future filings with the SEC. As a result, the information that we provide to our
stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or
revised accounting standards. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the
same new or revised accounting standards as other public companies that are not emerging growth companies.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Modular Medical,
Inc. is a Nevada corporation with its principal business office at 800 West Valley Parkway, Suite 203, Escondido, California 92025.
Our website can be found at www.modular-medical.com. We do not intend nor are we incorporating any contents from our website
into this prospectus. </FONT></P></DIV>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara003"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Investing
in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below
before making a decision to invest in our common stock. Our business, operating results or financial condition could be adversely
affected by any of these risks. The risks described below are not the only ones we face. The occurrence of any of the following
risks or future or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial
could materially and adversely affect our business, financial position, results of operations or cash flows. The trading price
of our common stock could also decline due to any of these risks, and, as a result, you may lose all or part of your investment.
Before deciding whether to invest in our common stock, you should also refer to the other information included in this prospectus,
including our consolidated financial statements and the related notes.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Risks
Related to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>We
are a developmental stage medical device company and have a history of significant operating losses; we expect to continue to
incur operating losses, and we may never achieve or maintain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">As a
development stage enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our
inception, we have incurred operating losses in each year due to costs incurred in connection with research and development activities
and general and administrative expenses associated with our operations. For the 3 month periods ending June 30. 2019 and 2018,
we incurred net losses of approximately $1,122,198 and $249,566, respectively, and for the fiscal years ended March 31, 2019 and
2018, we incurred net losses of approximately $2,539,498 million and $659,246 million, respectively. General administrative expenses
for the 3 months ending June 30, 2019 increased by 88.7% to $146,626 as compared to $77,691 for the same period in 2018. For the
fiscal year ended March 31, 2019, general and administrative expenses increased by 332% to $434,558 as compared to $100,561 for
2018. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
expect to incur losses for the foreseeable future as we continue the development of, and seek regulatory clearance and approvals
for, our insulin pump. Since our prototype insulin pump is currently our only product, if it fails to gain regulatory approval
and market acceptance, we will not be able to generate any revenue, or explore other opportunities to enhance shareholder value,
such as through a sale. If we fail to generate revenue and eventually become profitable, or if we are unable to fund our continuing
losses, our shareholders could lose all or a substantial part of their investment. See &ldquo;Management&rsquo;s Discussion and
Analysis of Financial Condition and Results of Operations,&rdquo; below.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>We
will need substantial additional funding to complete subsequent phases of our insulin pump product and to operate our business
and such funding may not be available or, if it is available, such financing is likely to substantially dilute our existing shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
discovery, development, and commercialization of new medical devices, such as our insulin pump, entails significant costs. While
we believe that we have generally completed the engineering and mechanical aspects of our insulin pump prototype, we still must
modify, refine and finalize our insulin pump to, among other things, meet the general needs and preferences of the almost pumper
marketplace and the guidelines of third party payors. To enable us to accomplish these and other related items and continue to
operate our business, we will need to raise substantial additional capital, or enter into strategic partnerships, to enable us
to:</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">fund
                                         clinical studies and seek regulatory approvals;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">build
                                         or access manufacturing and commercialization capabilities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">develop,
                                         test, and, if approved, market our product;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">acquire
                                         or license additional internal systems and other infrastructure; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">hire
                                         and support additional management, engineering and scientific personnel.</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Until
we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never achieve, we expect
to finance our cash needs primarily through public or private equity offerings, debt financings or through the establishment of
possible strategic alliances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If
we are not able to secure additional equity funding when needed, we may have to delay, reduce the scope of, or eliminate one or
more of our clinical studies, development programs or future commercialization initiatives.</FONT> <FONT STYLE="font-size: 10pt">
In addition, any additional equity funding that we do obtain will dilute the ownership held by our existing security holders.
The amount of this dilution may be substantially increased if the trading price of our common stock is lower at the time of any
financing. Regardless, the economic dilution to shareholders will be significant if our stock price does not increase significantly,
or if the effective price of any sale is below the price paid by a particular shareholder. Any debt financing that we obtain in
the future could involve substantial restrictions on activities and creditors could seek a pledge of some or all of our assets.
We have not identified potential sources for such financing that we will require, and we do not have commitments from any third
parties to provide any future debt financing. If we fail to obtain funding as needed, we may be forced to cease or scale back
operations, and our results, financial condition and stock price would be adversely affected. See &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>We
have a limited operating history and historical financial information upon which you may evaluate our performance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">You should
consider, among other factors, our prospects for success in light of the risks and uncertainties encountered by companies that,
like us, are in their early stages of development. We may not successfully address these risks and uncertainties or successfully
complete our studies and/or implement our existing and new products. If we fail to do so, it could materially harm our business
and impair the value of our common stock. Unanticipated problems, expenses and delays are frequently encountered in establishing
a new business, conducting research, and developing new products. These include, but are not limited to, inadequate funding,
failure to obtain regulatory approval, unforeseen research issues, lack of consumer acceptance, competition, sluggish product
development, and inadequate sales and marketing. The failure by us to meet any of these conditions would have a materially
adverse effect upon us and may force us to reduce or curtail operations. No assurance can be given that we can or will ever operate
profitably. See &ldquo;Our Business &ndash; Corporate History and Background,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>We
may not be able to meet our future capital needs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">To date,
we have no revenue and we have limited cash liquidity and capital resources. We will need additional capital in the near future.
Any equity financings will result in dilution and may contain other terms that are not favorable to our then-existing stockholders.
Although we currently do not have any debt financing, any sources of debt financing that we may obtain in the future may result
in a high interest expense. Any financing, if available, may be on unfavorable terms. If adequate funds are not obtained, we will
be required to reduce or curtail operations. See &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and
Results of Operations,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>The
amount of financing we require will depend on a number of factors, many of which are beyond our control. Our results of operations,
financial condition and stock price are likely to be adversely affected if our funding requirements increase or are otherwise
greater than we expect.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our future
funding requirements will depend on many factors, including, but not limited to:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">the
                                         costs of our clinical studies for our insulin pump product and other development activities
                                         conducted by us directly, and our ability to successfully conclude the studies and activities
                                         and achieve favorable results;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">our
                                         ability to attract future strategic partners to pay for or share costs related to our
                                         product development efforts;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">the
                                         costs and timing of seeking and obtaining regulatory clearance and approvals for our
                                         product;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">the
                                         costs of filing, prosecuting, maintaining and enforcing any patents and other intellectual
                                         property rights that we may have and defending against potential claims of infringement;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">decisions
                                         to hire additional scientific, engineering or administrative personnel or consultants;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">our
                                         ability to manage administrative and other costs of our operations; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">the
                                         presence or absence of adverse developments in our research program.</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">If any
of these factors cause our funding needs to be greater than expected, our operations, financial condition, ability to continue
operations and stock price may be adversely affected. See &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Our
future cash requirements may differ significantly from our current estimates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our cash
requirements may differ significantly from our estimates from time to time, depending on a number of factors, including:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">the
                                         costs and results of our clinical studies regarding our insulin pump product;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">the
                                         time and costs involved in obtaining regulatory clearance and approvals;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">whether
                                         we are able to obtain funding under future licensing agreements, strategic partnerships,
                                         or other collaborative relationships, if any;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">the
                                         costs of compliance with laws, regulations, or judicial decisions applicable to us; and</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">the
                                         costs of general and administrative infrastructure required to manage our business and
                                         protect corporate assets and shareholder interests</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">If we
fail to raise additional funds on a timely basis we will need to scale back our business plans, which would adversely affect our
business, financial condition, and stock price, and we may even be forced to discontinue our operations and liquidate our assets.
See &ldquo;Our Business &ndash; Keep costs low during our design and development process,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>Technological
breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump &nbsp;obsolete.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
diabetes treatment market is subject to rapid technological change and product innovation. Our insulin pump &nbsp;is based on
our proprietary technology, but a number of companies, medical researchers and existing pharmaceutical companies are pursuing
new delivery devices, delivery technologies, sensing technologies, procedures, drugs and other therapeutics for the monitoring,
treatment and/or prevention of insulin-dependent diabetes. Any technological breakthroughs in diabetes monitoring, treatment or
prevention could render our insulin pump&nbsp;obsolete, which, since our insulin pump is our only product, would have a material
adverse effect on our business, financial condition and results of operations and could result in shareholders losing their entire
investment.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Any
failure to attract and retain skilled directors, executives, employees and consultants could impair our product development and
commercialization activities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our business
depends on the skills, performance, and dedication of our directors, executive officers and key engineering, scientific and technical
advisors. Many of our current engineering or scientific advisors are independent contractors and are either self-employed or employed
by other organizations. As a result, they may have conflicts of interest or other commitments, such as consulting or advisory
contracts with other organizations, which may affect their ability to provide services to us in a timely manner. We may need to
recruit additional directors, executive management employees, and advisers, particularly engineering, scientific and technical
personnel, which will require additional financial resources. In addition, there is currently intense competition for skilled
directors, executives and employees with relevant engineering, scientific and technical expertise, and this competition is likely
to continue. If we are unable to attract and retain persons with sufficient engineering, scientific, technical and managerial
experience, we may be forced to limit or delay our product development activities or may experience difficulties in successfully
conducting our business, which would adversely affect our operations and financial condition. See &ldquo;Our Business &ndash;
Employ experienced engineers, recruited, supervised and led by Mr. DiPerna, a highly experienced respected engineer and executive
in the insulin pump industry.&rdquo; </FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>We
do not have internal research and development personnel, making us dependent on consulting relationships.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
consider research and development to be an important part of the process of designing, developing, obtaining regulatory required
approvals and the eventual commercialization of our insulin pump. For the quarter ending June 30, 2019, our research and development
expenditures increased approximately 518% to $703,783 from $135,789 during the same quarter in 2018. For our fiscal year ended
March 31, 2019, research and development expenditures increased by 466% to $1,882,345 as compared to $332,642 for fiscal year
2018. Such increases in research and development expenditure are attributable to effort and expenses incurred in designing and
developing our innovative insulin pump.</FONT> <FONT STYLE="font-size: 10pt"> We expect to continue to incur substantial costs
related to research and development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
currently have no research and development personnel, and rely and expect for the foreseeable future to continue to rely, on third
party consultants to perform such functions for us. As a result, we are and expect to continue for the foreseeable future to be
dependent on such third parties. Generally, our contracts with such third parties, are terminable for any reason by us or such
third parties on 2 weeks to 30 day notice (with one exception, providing for 90 days&rsquo; notice) and provide for no severance
or termination benefits to such third parties. As a result, such third parties may be able to terminate their contractual relationships
with us quickly and with little, if any, notice. Although we believe there is a relatively large and readily accessible network
of third parties that we can draw from to replace any of our then third party consultants, no assurances can be given that we
would be able to quickly and seamlessly find and hire suitable replacements. Any material interruption or delay in our research
and development activities performed by our third party consultants could impair our ability to meet any deadlines and materially
impair our then product design and development, regulatory approval and/or commercialization activities which could have a material
adverse effect on our business, financial condition and stock price. In addition, if we do not appropriately manage our relationships
with such third parties, we may not be able to efficiently manage the development, testing, regulatory approval and eventual commercialization
of our insulin pump, which also could have a material and adverse effect on our business, financial condition and stock price.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>We
will need to outsource and rely on third parties for various aspects relating to the development, manufacture, sales and marketing
of our insulin pump as well as in connection with assisting us in the preparation and filing of our FDA submission, and our future
success will be dependent on the timeliness and effectiveness of the efforts of these third parties.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
are dependent on our third party consultants, for important aspects of our product development strategy. We do not have the required
financial and human resources to carry out independently the development of our product, and do not have the capability or resources
to manufacture, market or sell our current product. As a result, we contract with and rely on third parties for important functions,
including in connection with the development and finalization of our insulin pump, the preparation and filing of our FDA submission
and eventual manufacturing and commercialization of our product.</FONT> <FONT STYLE="font-size: 10pt"> We have recently entered
into several agreements with third parties for such services. If problems develop in our relationships with third parties,
or if such parties fail to perform as expected, it could lead to delays or lack of progress in obtaining FDA clearance, significant
cost increases, changes in our strategies, and even failure of our product initiatives. See &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>We
may not be able to identify, negotiate and maintain the strategic alliances necessary to develop and commercialize our products
and technologies, and we will be dependent on our corporate partners if we do.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">We may seek
to enter into a strategic alliance with a diabetes related service providing company for the further development and approval
of our insulin pump product. At this time, we have not entered into any such strategic alliance. Strategic alliances, if entered
into, could potentially provide us with additional funds, expertise, access, and other resources in exchange for exclusive or
non-exclusive licenses or other rights to the product that we are currently developing or a product we may explore in the future.
We cannot give any assurance that we will be able to enter into strategic relationships with a diabetes related service providing
company or others in the near future or at all. In addition, we cannot assure you that any agreements that we do reach will achieve
our goals or be on terms that prove to be economically beneficial to us.</FONT> <FONT STYLE="font-size: 10pt"> When we do enter
into strategic or contractual relationships, we become dependent on the successful performance of our partners or counter-parties.
If they fail to perform as expected, such failure could adversely affect our financial condition, lead to increases in our capital
needs, or hinder or delay our development efforts. See &ldquo;Our Business &ndash; Number of Total Employees,&rdquo; below.</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>We
may not receive the necessary regulatory clearance or approvals for our insulin pump, and failure to timely obtain necessary clearances
and/or approvals could harm our then operations including to commercialize our product.</I></B></FONT> <FONT STYLE="font-size: 10pt"><B><I>
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Before
we can market a new medical device, such as our insulin pump, we must first receive clearance under Section&nbsp;510(k) of the
Federal Food, Drug, and Cosmetic Act, or the FDCA. In the 510(k) clearance process, before a device may be marketed, the FDA must
determine that such proposed device is &quot;substantially equivalent&quot; to a legally-marketed &quot;predicate&quot; device,
which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior
to May&nbsp;28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant to an approved pre-market
approval (&ldquo;PMA&rdquo;) and later down-classified, or a 510(k)-exempt device. To be &quot;substantially equivalent,&quot;
the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics
as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness
than the predicate device.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Certain
modifications made to our product, which we currently expect to be cleared through 510(k), may require a new 510(k) clearance.
The 510(k) clearance process can be expensive, lengthy and uncertain. The FDA's 510(k) clearance process usually takes from three
to 12&nbsp;months, but can last longer. Despite the time, effort and cost, a device may not be approved or cleared by the FDA.
Any delay or failure to obtain necessary regulatory approvals could harm our business, including our ability to commercialize
our product and our shareholders could lose their entire investment. Furthermore, even if we are granted the required regulatory
clearances, such clearances may be subject to significant limitations on the indicated uses for the device, which may limit the
market for our product.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">If
the FDA requires us to go through a lengthier, more rigorous examination for our product than we had expected, product introductions
or modifications could be delayed or canceled, which could adversely affect our ability to grow our business.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
FDA can delay, limit or deny clearance or approval for our insulin pump medical device for many reasons, including:</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         inability to demonstrate to the satisfaction of the FDA &nbsp;that our product is safe
                                         or effective for its intended use; </FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         disagreement of the FDA &nbsp;with the design or implementation of our clinical studies
                                         &nbsp;or the interpretation of data from our&nbsp;clinical studies; </FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious
                                         and unexpected adverse device effects experienced by participants in our clinical studies;
                                         </FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         data from clinical studies may be insufficient to support clearance or approval, where
                                         required; </FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         inability to demonstrate that the &nbsp;benefits of our pump outweigh the risks; </FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         manufacturing process or facilities we intend to use may not meet applicable requirements;
                                         and </FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         potential for approval policies or regulations of the FDA &nbsp;to change significantly
                                         in a manner rendering our data or regulatory filings insufficient for clearance or approval.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">In addition,
the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other
actions, which may prevent or delay approval or clearance of our product or impact our ability to modify our product after clearance
on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability
to obtain clearance for our pump, increase the costs of compliance or restrict our ability to maintain our current approval. For
example, as part of the Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted in 2012, Congress reauthorized
the Medical Device User Fee Amendments with various FDA performance goal commitments and enacted several &quot;Medical Device
Regulatory Improvements&quot; and miscellaneous reforms, which are further intended to clarify and improve medical device regulation
both pre- and post-clearance and approval. Some of these proposals and reforms could impose additional regulatory requirements
upon us that could delay our ability to obtain new clearance, increase the costs of compliance or restrict our ability to maintain
any clearance or approval we are able to obtain.</FONT> </P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">As
a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be
based, among other things, on the evaluation of data supporting the safety and performance of the products during normal conditions
of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions
of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits
of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable
evidence.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Our
competitors may develop products that are more effective, safer and less expensive than ours.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Existing
insulin pumps are expensive, with the more popular models having purchase prices exceeding $4,000 for individuals without health
insurance and often require significant patient copays. Others have daily use costs that exceed the reimbursement rates of many
health insurance plans, forcing some users to spend thousands of dollars a year in copays. We believe this makes insurers hesitant
to pay for pumps for any but their most technologically proficient and compliant patients and places pumps out of reach for many
patients who cannot afford such out of pocket expenses. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We are
engaged in the diabetes treatment sector of the healthcare marketplace, which is intensely competitive. There are current products
that are quite effective at addressing the effects of diabetes, and we expect that new developments by other companies and academic
institutions in the areas of diabetes treatment will continue. If approved for marketing by the FDA, depending on the approved
clinical indication, our product will be competing with existing and future products related to treatments for diabetes. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our competitors
may:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">develop
                                         product candidates and market products that increase the levels of safety or efficacy
                                         that our product candidates will need to show in order to obtain regulatory approval;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">develop
                                         product candidates and market products that are less expensive or more effective than
                                         ours;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">commercialize
                                         competing products before we can launch any products we are working to develop;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">hold
                                         or obtain proprietary rights that could prevent us from commercializing our products;
                                         or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">introduce
                                         therapies or market medical products that render our potential product candidates obsolete.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
expect to compete against large medical device companies, such as Medtronic, Inc., Tandem Diabetes Care, Inc. and Insulet Corporation
and smaller companies that are collaborating with larger medical device companies, new companies, academic institutions, government
agencies and other public and private research organizations.</FONT> <FONT STYLE="font-size: 10pt"> These competitors, in nearly
all cases, produce similar products relative to the treatment of diabetes that have substantially greater financial resources
than we do. Our competitors also have significantly greater experience in:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">developing
                                         medical device and other product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">undertaking
                                         testing and clinical studies;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">building
                                         relationships with key customers and opinion-leading physicians;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">obtaining
                                         and maintaining FDA and other regulatory approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">formulating
                                         and manufacturing medical devices;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">launching,
                                         marketing and selling medical devices; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">providing
                                         management oversight for all of the above-listed operational functions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">If we fail to
achieve superiority over other existing or newly developed products, we may be unable to obtain regulatory approval. If our
competitors market medical devices that are less expensive, safer or more effective than our insulin pump, or that gain or maintain
greater market acceptance, we may not be able to compete effectively. See &ldquo;Our Business &ndash; Competition,&rdquo;
below.</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>We
expect to rely on third party manufacturers and will be dependent on their quality and effectiveness.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Our
insulin pump requires precise, high-quality manufacturing. The failure to achieve and maintain high manufacturing standards, including
failure to detect or control anticipated or unanticipated manufacturing errors or the frequent occurrence of such errors, could
result in patient injury or death, discontinuance or delay of ongoing or planned clinical studies, delays or failures in product
testing or delivery, cost overruns, product recalls or withdrawals and other problems that could seriously hurt our business.
</FONT> <FONT STYLE="font-size: 10pt">Contract medical device manufacturers often encounter difficulties involving production
yields, quality control and quality assurance and shortages of qualified personnel. These manufacturers are subject to stringent
regulatory requirements, including the FDA&rsquo;s current good-manufacturing-practices regulations. If our contract manufacturers
fail to maintain ongoing compliance at any time, the production of our product could be interrupted, resulting in delays or discontinuance
of our clinical studies, additional costs and loss of potential revenues. See &ldquo;Our Business &ndash; Keep costs low during
design and development process,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>We
may not be able to successfully scale-up manufacturing of our product in sufficient quality and quantity, which would delay or
prevent us from developing our product and commercializing our product.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">In
order to conduct larger-scale or late-stage clinical studies and for commercialization of our insulin pump, if 501(k) clearance
is granted, we will need to manufacture it in larger quantities. We may not be able to successfully increase the manufacturing
capacity for our product in a timely or cost-effective manner, or at all.</FONT> <FONT STYLE="font-size: 10pt"> In addition,
quality issues may arise during scale-up activities. If we are unable to successfully scale up the manufacture of our product
in sufficient quality and quantity, the development and testing of our product and regulatory approval or commercial launch may
be delayed, which could significantly harm our business. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>We
may be subject to potential product liability and other claims that could materially impact our business and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
development and sale of our insulin pump exposes us to the risk of significant damages from product liability and other claims,
and the use of our product in clinical studies may result in adverse effects.</FONT> <FONT STYLE="font-size: 10pt"> We cannot
predict all the possible harms or adverse effects that may result. We maintain a modest amount of product liability insurance
to provide some protection from claims. Nonetheless, we may not have sufficient resources to pay for any liabilities resulting
from a personal injury or other claim, even if it is partially covered by insurance. In addition to the possibility of direct
claims, we may be required to indemnify third parties against damages and other liabilities arising out of our development, commercialization
and other business activities, which would increase our liability exposure. If third parties that have agreed to indemnify us
fail to do so, we may be held responsible for those damages and other liabilities as well.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Legislative,
regulatory, or medical cost reimbursement changes may adversely impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">New
laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to the
health care system in the U.S. and in other jurisdictions may change the nature of and regulatory requirements relating to innovations
in medical devices, testing and regulatory approvals, limit or eliminate payments for medical procedures and treatments, or subject
the pricing of medical devices to government control. In addition, third-party payors in the U.S. are increasingly attempting
to contain health care costs by limiting both coverage and the level of reimbursement of new products.</FONT> <FONT STYLE="font-size: 10pt">
Consequently, significant uncertainty exists as to the reimbursement status of newly approved health care products. Significant
changes in the health care system in the U.S. or elsewhere, including changes resulting from adverse trends in third-party reimbursement
programs, could have a material adverse effect on our projected future operating results and our ability to raise capital, commercialize
products, and remain in business. See &ldquo;Our Business &ndash; Government Regulations,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> <FONT STYLE="font-size: 10pt"><B><I>We
are subject to extensive regulation by the U.S.&nbsp;Food and Drug Administration, which could restrict the sales and marketing
of our insulin pump and could cause us to incur significant costs. </I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">Our insulin
pump is subject to extensive regulation by the FDA. These regulations relate to manufacturing, labeling, sale, promotion, distribution
and shipping. Before a new medical device, or a new use of or claim for an existing product, can be marketed in the United States,
it must first receive either 510(k) clearance or PMA from the FDA, unless an exemption applies. We may be required to obtain a
new 510(k) clearance &nbsp;for significant post-market modifications to our insulin pump. Each of these processes can be expensive
and lengthy, and entail significant user fees, unless exempt.</FONT> </P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"> <FONT STYLE="font-size: 10pt">Medical
devices may be marketed only for the indications for which they are approved or cleared. &nbsp;Further, 510(k) clearances can
be revoked if safety or effectiveness problems develop.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
current &nbsp;regulatory requirements to which we are subject may change in the future in a way that adversely affects us. If
we fail to comply with present or future regulatory requirements that are applicable to us, we may be subject to enforcement action
by the FDA, which may include any of the following sanctions:</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">untitled
                                         letters, warning letters, fines, injunctions, consent decrees and civil penalties;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">customer
                                         notification, or orders for repair, replacement or refunds</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">voluntary
                                         or mandatory recall or seizure of our current or future products;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">administrative
                                         detention by the FDA of medical devices believed to be adulterated or misbranded;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">imposing
                                         operating restrictions, suspension or shutdown of production;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">refusing
                                         our requests for 510(k) clearance or pre-market approval of any new products, new intended
                                         uses or modifications to our insulin pump;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">rescinding
                                         510(k) clearance that has already been granted; and</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">criminal
                                         prosecution.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
occurrence of any of these events would have a material adverse effect on our business, financial condition and results of operations
and could result in shareholders losing their entire investment.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>Our
success depends substantially upon our ability to obtain and maintain intellectual property protection relating to our product
and research technologies.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We have
applied to the U.S. Patent and Trademark Office for two US patents on our proprietary fluid movement technology and the configuration
of our insulin pump. There is no assurance that these patents will be issued, and no assurance that they will prevent other companies
from competing with us. We will continue to attempt to patent our innovations as appropriate to help ensure a sustainable competitive
advantage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Due to
evolving legal standards relating to the patentability, validity and enforceability of patents covering health care product inventions,
our ability to enforce our existing patents and to obtain and enforce patents that may issue from any pending or future patent
applications is uncertain and involves complex legal, scientific and factual questions. To date, no consistent policy has emerged
regarding the breadth of claims allowed in medical device patents. Thus, we cannot be sure that any patents will issue from any
pending or future patent applications owned by or licensed to us. Even if patents do issue, we cannot be sure that the claims
of these patents will be held valid or enforceable by a court of law, will provide us with any significant protection against
competing products, or will afford us a commercial advantage over competitive products. If, at some point in the future, one
or more products resulting from our product candidates is approved for sale by the FDA and we do not have adequate intellectual
property protection for those products, competitors could duplicate them for approval and sale in the United States without repeating
the extensive testing required of us to obtain FDA approval. See &ldquo;Our Business &ndash; Patents,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>If
we are sued for infringing on third-party intellectual property rights, it will be costly and time-consuming, and an unfavorable
outcome would have a significant adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">Our ability
to commercialize our product depends on our ability to use, manufacture and sell our product without infringing the patents or
other proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications owned by third
parties exist in the diabetes medical device area. There may be existing patents, unknown to us, on which our activities with
our insulin pump candidate could infringe.</FONT> </P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">If a
third party claims that our actions infringe on its patents or other proprietary rights, we could face a number of issues that
could seriously harm our competitive position, including, but not limited to:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">infringement
                                         and other intellectual property claims that, even if meritless, can be costly and time-consuming,
                                         delay the regulatory approval process and divert management&rsquo;s attention from our
                                         core business operations;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">substantial
                                         damages for infringement, including consequential damages for lost of profits or market
                                         share, if a court determines that our products or technologies infringe on a third party&rsquo;s
                                         patent or other proprietary rights;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">a
                                         court prohibiting us from selling or licensing our products or technologies unless the
                                         holder licenses the patent or other proprietary rights to us, which it is not required
                                         to do; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">even
                                         if a license is available from a holder, we may have to pay substantial royalties or
                                         grant cross-licenses to our patents or other proprietary rights.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">If any
of these events occur, it could significantly harm our operations and financial condition and negatively affect our stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>Healthcare
reform laws could adversely affect our product and financial condition.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">During
the past several years, the U.S. healthcare industry has been subject to an increase in governmental regulation at both the federal
and state levels. Efforts to control healthcare costs, including limiting access to care, alternative delivery models and changes
in the methods used to determine reimbursement scenarios and rates, are ongoing at the federal and state government levels. There
are provisions of law that provide for the creation of a new public-private Patient-Centered Outcomes Research Institute tasked
with identifying comparative effectiveness research priorities. For example, establishing a research project agenda and contracting
with entities to conduct the research in accordance with the agenda. Research findings published by this institute are publicly
disseminated. It is difficult at this time to determine whether a comparative effectiveness analysis impacting our business will
be done, and assuming one is, what impact that analysis will have on our insulin pump or our future financial results.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">In
addition, the Affordable Care Act and related healthcare reform laws, regulations and initiatives have significantly increased
regulation of managed care plans and decreased reimbursement to Medicare managed care. Some of these initiatives purport to, among
other things, require that health plan members have greater access to drugs not included on a plan&rsquo;s formulary. Moreover,
to alleviate budget shortfalls, states have reduced or frozen payments to Medicaid managed care plans. We cannot accurately predict
the complete impact of these healthcare reform initiatives, but they could lead to a decreased demand for medical devices such
as our insulin pump and other outcomes that could adversely impact our business and financial results.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">Some of the
provisions of the ACA have yet to be fully implemented, and certain provisions have been subject to judicial and Congressional
challenges. In addition, there have been efforts by the Trump administration to repeal or replace certain aspects of the ACA and
to alter the implementation of the ACA and related laws. For example, the Tax Cuts and Jobs Act enacted on December 22, 2017,
eliminated the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A
of the Internal Revenue Code of 1986, commonly referred to as the &quot;individual mandate&quot;, effective January 1, 2019. Further,
the Bipartisan Budget Act of 2018 among other things, amended the Medicare statute, effective January 1, 2019, to reduce the coverage
gap in most Medicare drug plans, commonly known as the &ldquo;donut hole,&rdquo; by raising the manufacturer discount under the
Medicare Part D coverage gap discount program to 70%. It is unclear how the ACA and its implementation, as well as efforts to
repeal or replace, or invalidate, the ACA, or portions thereof, will affect our insulin pump or our &nbsp;business. Additional
legislative changes, regulatory changes, and judicial challenges related to the ACA remain possible. It is possible that the ACA,
as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future,
could have an adverse effect on our industry generally and on our ability to commercialize &nbsp;our insulin pump and achieve
profitability.</FONT> </P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> <FONT STYLE="font-size: 10pt"><B><I>If
we are able to obtain all regulatory approvals and have completed all other steps needed to be taken to commercialize our insulin
pump, if we or any contract manufacturers we select fails to comply with the FDA&rsquo;s quality system regulations, the manufacturing
and distribution of our product could be interrupted, and our product sales and operating results could suffer.</I></B></FONT> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">A
material step in the process of the commercialization of our product will involve selecting a manufacturer or manufacturers for
our pump. We and any future contract manufacturers of our insulin pump will be required to comply with the FDA&rsquo;s quality
system regulations, which impose a complex regulatory framework that covers the procedures and documentation of the design, testing,
production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of medical devices. The FDA enforces
its quality system regulations through periodic unannounced inspections. We cannot assure you that, in the future, any manufacturing
facilities owned by us or any contract manufacturer will pass any quality system inspection. In the event that our or any contract
manufacturer&rsquo;s facilities fails a quality system inspection, the manufacturing or distribution of our product could be interrupted
and our operations disrupted. Failure to take adequate and timely corrective action in response to an adverse quality system inspection
could force a suspension or shutdown of any packaging and labeling operations or then manufacturing operations of any contract
manufacturers, or a recall of our insulin pump. If any of these events were to occur, we at such time would not be able to provide
our customers with the quantity of insulin pumps that &nbsp;they require on a timely basis, our reputation could be harmed and
we could lose any customers we then have, any or all of which could have a material adverse effect on our business, financial
condition and results of operations.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>We
may undertake infringement or other legal proceedings against third parties, causing us to spend substantial resources on litigation
and exposing our own intellectual property portfolio to challenge.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We may
come to believe that third parties are infringing on our patents or other proprietary rights. To prevent infringement or unauthorized
use, we may need to file infringement and/or misappropriation suits, which are very expensive and time-consuming, could result
in meritorious counterclaims against us and would distract management&rsquo;s attention. Also, in an infringement or misappropriation
proceeding, a court may decide that one or more of our patents is invalid, unenforceable, or both, in which case third parties
may be able to use our technology without paying license fees or royalties. Even if the validity of our patents is upheld,
a court may refuse to stop the other party from using the technology at issue on the grounds that the other party&rsquo;s activities
are not covered by our patents. See &ldquo;Our Business &ndash; Patents,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>We
may become involved in disputes with our present or future contract partners over intellectual property ownership or other matters,
which would have a significant effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Inventions
discovered in the course of performance of contracts with third parties or contractors may become jointly owned by such third
parties contractors and us, in some cases, and the exclusive property of one of us, in other cases.</FONT> <FONT STYLE="font-size: 10pt">
Under some circumstances, it may be difficult to determine who owns a particular invention or whether it is jointly owned, and
disputes could arise regarding ownership or use of those inventions or jointly developed improvements thereto. Other disputes
may also arise relating to the performance or alleged breach of our agreements with third parties. Any disputes could be costly
and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business. See &ldquo;Our Business
&ndash;Use of Proprietary Technology,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> <FONT STYLE="font-size: 10pt"><B><I>Assuming
our insulin pump receives FDA clearance or approval, our insulin pump will still be subject to recalls, which would harm our reputation,
business operations and financial results.</I></B></FONT> </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">Even assuming
we obtain FDA approval or clearance with regard to our insulin pump, the FDA has the authority to require the recall of our &nbsp;pump
if we commence manufacturing of our insulin pump and we or any contract manufacturers we retain fail to comply with relevant regulations
pertaining to manufacturing practices, labeling, advertising or promotional activities, or if new information is obtained concerning
the safety or efficacy of the product. A government-mandated recall could occur if the FDA finds that there is a reasonable probability
that our product would cause serious, adverse health consequences or death. A voluntary recall by us could occur as a result of
manufacturing defects, labeling deficiencies, packaging defects or other failures to comply with applicable regulations. Any recall
would divert management&rsquo;s attention and financial resources and harm our reputation with customers. A recall involving our
insulin pump would be particularly harmful to our business, financial condition and results of operations because it is currently
our only product.</FONT> </P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Any
disruption and/or instability in economic conditions and capital markets could adversely affect our ability to access the capital
markets, and thus adversely affect our business and liquidity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Negative
economic conditions and issues with regard to the financial markets, could have a negative impact on our ability to access the
capital markets, and thus have a negative impact on our then operations and liquidity. A general shortage of liquidity and credit
combined with the substantial losses in worldwide equity markets could lead to an extended worldwide recession in the future.
If such occurred, we would face significant challenges if conditions in the capital markets did not improve.</FONT> <FONT STYLE="font-size: 10pt">
Our ability to access the capital markets under such circumstances could be severely restricted at a time when we need to access
such markets, which could have a negative impact on our business plans. Even if we are able to raise capital under such circumstances,
it may not be at a price or on terms that are favorable to us. We cannot predict the occurrence of future disruptions or how long
such negative conditions might continue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>Because
our current insulin pump prototype is still in the development stage, it does not have reimbursement and is not approved for insurance
coverage. If in the future we are approved for and are otherwise able to commercialize our insulin pump, but are unable to obtain
adequate reimbursement or insurance coverage for such product from third-party payors, we will be unable to generate significant
revenue.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Because
our current insulin pump prototype is still in the development stage, it does not have reimbursement and is not approved for insurance
coverage. The future availability of insurance coverage and reimbursement for newly approved medical devices is highly uncertain.
In the United States, patients using insulin pumps are generally reimbursed for all or part of the product cost by Medicare or
other third-party payors. Any future commercial success of our insulin pump will be substantially dependent on whether third-party
coverage and reimbursement is available for future customers. Medicare, Medicaid, health maintenance organizations and other third-party
payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new
medical devices, and, as a result, they may not cover or provide adequate reimbursement for our insulin pump, assuming we are
able to fully develop and obtain all regulatory approval to market it in the United States. Accordingly, unless government and
other third-party payors provide coverage and reimbursement for our insulin pump, patients may not use it, which would cause investors
to lose their entire investment.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>We
are subject to the oversight of the SEC and other regulatory agencies. Investigations by those agencies could divert management&rsquo;s
focus and could have a material adverse effect on our reputation and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We are
subject to the regulation and oversight of the SEC and state regulatory agencies, in addition to the FDA. As a result, we may
face legal or administrative proceedings by these agencies. We are unable to predict the effect of any investigations on our business,
financial condition or reputation. In addition, publicity surrounding any investigation, even if ultimately resolved in our favor,
could have a material adverse effect on our business. See &ldquo;Our Business &ndash; Government Regulation,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Risks
Relating to Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>Our
shares of common stock are quoted on the OTC Pink Open Market; no active trading market for our common stock.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Our
shares of common stock are traded on the OTC Pink Open Market. There is currently no trading market, and for at least the prior
3 years there has not been any active trading market for our common stock. There can be no assurance that an active trading market
for our common stock will develop or if one develops, it will be sustained. Furthermore, because our shares of common stock are
traded on the OTC Pink Open Market,&nbsp;<FONT STYLE="background-color: white">the shares of our common stock covered by this
prospectus will only be offered and sold by selling shareholders at a fixed price of $3.00 per share until our shares are quoted
on the OTCQX or OTCQB marketplace of the OTC Link, and, thereafter, at prevailing market prices or privately negotiated prices.
</FONT></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>The
sale of shares by the selling shareholders may cause our stock price to decline.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">The selling
shareholders may sell, in accordance with the limitations set forth in this prospectus, up to the 9,658,201 shares of common stock
covered by this prospectus, in the public markets. Because of the lack of any active trading market for our shares, any such sales
that are able to be made will likely cause our stock price to decline. See &ldquo;Plan of Distribution,&rdquo; below.</FONT> </P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>We
do not expect any cash dividends to be paid on our shares in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We have
never declared or paid a cash dividend and we do not anticipate declaring or paying dividends for the foreseeable future. We expect
to use future financing proceeds and earnings, if any, to fund operating expenses. Consequently, shareholders&rsquo; only opportunity
to achieve a return on their investment is if the price of our stock appreciates and they sell their shares at a profit. We cannot
assure shareholders of a positive return on their investment when they sell their shares or that shareholders will not lose the
entire amount of their investment. See &ldquo;Description of Our Common Stock &ndash; Dividend Policy,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>If
the beneficial ownership of our stock continues to be highly concentrated, it may prevent you and other shareholders from influencing
significant corporate decisions; agreement to elect directors.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">As
of June 30, 2019, our executive officers, directors and certain persons who may be deemed their affiliates beneficially owned
substantially in excess of 50.1% of our issued and outstanding common stock. As a result, such persons may exercise substantial
influence over the outcome of corporate actions requiring shareholder approval including, without limitation, the election of
directors, certain mergers, consolidations and sales of all or substantially all of our assets or any other significant corporate
transactions. Such persons may also vote against a change of control, even if such a change of control would benefit our other
shareholders. In addition, pursuant to the July 24, 2017 agreement pursuant to which we acquired Quasuras, until July 24, 2022,
our board of directors will consist of no less than 2 and no more than 5 directors, of which Mr. DiPerna, in addition to being
our chairman, has the right to appoint 2 additional directors and Manchester has the right to appoint 2 directors, of which Mr.
Frank constitutes 1 such director. As a result of such agreement, until July 24, 2022, other shareholders will not have the ability
to elect any directors either at the annual meeting or by written consent, even if such other shareholders believe that our board
of directors is taking actions to which the shareholders object.</FONT> <FONT STYLE="font-size: 10pt"> See &ldquo;Stock Ownership
by Principal Shareholders and Management&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Sale
of our common stock by the selling shareholders could encourage short sales by third parties, which could contribute to the further
decline of our stock price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
significant downward pressure on the price of our common stock that would be caused by the sale of material amounts of our common
stock could encourage short sales by third parties.</FONT> <FONT STYLE="font-size: 10pt"> Such an event could place further
downward pressure on the price of our common stock. See &ldquo;Plan of Distribution,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>We
are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies
will make our common stock less attractive to investors.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">We are an
&ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;).
For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements
that are applicable to other public companies that are not emerging growth companies, including not being required to comply with
the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive
compensation in this prospectus and our periodic reports and proxy statements and exemptions from the requirements of holding
nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.
We could be an emerging growth company for up to five years following the year in which we complete this offering, although circumstances
could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (i)&nbsp;the last day
of the fiscal year (a)&nbsp;following the fifth anniversary of the completion of the first sale of shares covered by this prospectus,
(b)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a
large accelerated filer, which requires the market value of our common stock that is held by&nbsp;non-affiliates&nbsp;to exceed
$700.0&nbsp;million as of the prior June 30th, and (ii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in&nbsp;non-convertible
debt during the prior three-year period.</FONT> </P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Our
common shares may be classified as &ldquo;penny stock&rdquo; and trading of our shares may be restricted by the SEC&rsquo;s penny
stock regulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Our
common stock is traded on the OTC Pink Markets. Rules 15g-1 through 15g-9 promulgated under the Securities Exchange Act impose
sales practice and disclosure requirements on certain brokers-dealers who engage in transactions involving a &ldquo;penny stock.&rdquo;
</FONT> <FONT STYLE="font-size: 10pt">The SEC has adopted regulations which generally define &ldquo;penny stock&rdquo; to be
any equity security that has a market price of less than $5.00 per share or an exercise price of less than $5.00 per share, subject
to certain exceptions. Our common shares may be covered by the penny stock rules, which impose additional sales practice requirements
on broker-dealers who sell to persons other than established customers and &ldquo;accredited investors.&rdquo; The penny stock
rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized
risk disclosure document in a form prepared by the SEC, which provides information about penny stocks and the nature and level
of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for
the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements
showing the market value of each penny stock held in the customer&rsquo;s account. In addition, the penny stock rules require
that, prior to a transaction in a penny stock that is not otherwise exempt, the broker-dealer must make a special written determination
that the penny stock is a suitable investment for the purchaser and receive the purchaser&rsquo;s written agreement to the transaction.
These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for stock
that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to
trade our common stock. We believe that the penny stock rules may discourage investor interest in and limit the marketability
and reduce the level of trading activity of our common shares. The market price of our common stock may suffer as a result. See
&ldquo;Plan of Distribution,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Future
sales of our securities could adversely affect the market price of our common stock and our future capital-raising activities
could involve the issuance of equity securities, which would dilute your investment and could result in a decline in the trading
price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We may
sell securities in the public or private equity markets if and when conditions are favorable, or at prices per share below the
current market price of our common stock, even if we do not have an immediate need for additional capital at that time. Sales
of substantial amounts of shares of our common stock, or the perception that such sales could occur, could adversely affect the
prevailing market price of our shares and our ability to raise capital. We may issue additional shares of common stock in future
financing transactions or as incentive compensation for our executive management and other key personnel, consultants and advisors.
Issuing any equity securities would be dilutive to the equity interests represented by our then-outstanding shares of common stock.
Moreover, sales of substantial amounts of shares in the public market, or the perception that such sales could occur, may adversely
affect the prevailing market price of our common stock and make it more difficult for us to raise additional capital. See &ldquo;Description
of Common Stock - Stock Options&rdquo;, below. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Purchasers
in this offering may experience immediate and substantial dilution.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The current
trading price of the common stock that may be offered for resale pursuant to this prospectus is higher than the current net tangible
book value per share of our common stock. Therefore, if you purchase shares of common stock in this offering, you may incur immediate
and substantial dilution in the pro forma net tangible book value per share of common stock from the price per share that you
pay for the common stock. In addition, you may experience dilution if we issue additional shares of common stock that we are permitted
or required to issue under outstanding options and under our equity incentive plan or other compensation plans that may be implemented
in the future. See &ldquo;Description of Common Stock - Dilution,&rdquo; below. </FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>Our
certificate of incorporation allows for our board of directors to create new series of preferred stock without further approval
by our stockholders, which could adversely affect the rights of the holders of our common stock.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10; text-align: justify"> <FONT STYLE="font-size: 10pt">Our
board of directors has the authority to fix and determine the relative rights and preferences of preferred stock. Currently our
board of directors has the authority to designate and issue up to 5,000,000 shares of our preferred stock without further stockholder
approval. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to
holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed
to the holders of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption
of our common stock. In addition, our board of directors could authorize the issuance of a series of preferred stock that has
greater voting power than our common stock or that is convertible into our common stock, which could decrease the relative voting
power of our common stock or result in dilution to our existing stockholders.</FONT> <FONT STYLE="font-size: 10pt"> See &ldquo;Description
of the Common Stock &ndash; Preferred Stock,&rdquo; below.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>If
we are unable to effectively implement or maintain a system of internal control over financial reporting, we may not be able to
accurately or timely report our financial results and our stock price could be adversely affected.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Section&nbsp;404
of the Sarbanes-Oxley Act of 2002 and related regulations require our management to evaluate the effectiveness of our internal
control over financial reporting as of the end of each fiscal year. Based on its evaluations, our management concluded that there
were material weaknesses in our internal control over financial reporting and management concluded that the Company&rsquo;s internal
controls over financial reporting were not effective as of March 31, 2019. Such material weaknesses related to inadequate internal
controls over financial reporting, and the lack of segregation of duties in our financial reporting process. Specifically, management
noted that we do not have a separately designated audit committee or an independent director. Any failure to implement the new
or improved controls necessary to remedy the material weaknesses described above, or difficulties encountered in the implementation
or operation of these controls, could harm our operations, decrease the reliability of our financial reporting, and cause us to
fail to meet our financial reporting obligations, which could adversely affect our business and reduce our stock price.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B><I>Our
board of directors is able to adopt recapitalizations through forward or reverse splits of our outstanding shares of common stock
without shareholder approval.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">Pursuant
to Article IX of our second amended and restated articles of incorporation, our board of directors has the power, without obtaining
shareholder approval, to effectuate recapitalizations of the Company through forward or reverse splits of our outstanding common
stock. As a result of such provision, our board of directors can implement recapitalizations of the Company by effectuating a
forward or reverse stock split of our outstanding common stock, which would increase or decrease each of our shareholder&rsquo;s
number of shares owned, and our shareholders will have no right to approve or disapprove any such action even if such actions
have a material adverse effect on them.</FONT> </P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara004"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">This
prospectus relates to shares of our common stock that may be offered and sold from time to time by the selling shareholders. We
will receive no proceeds from the sale of shares of common stock by the selling shareholders. For more information about the selling
shareholders, See &ldquo;Selling Shareholders,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara005"></A>SELLING
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The table
below sets forth information concerning the resale of our shares by the selling shareholders. The selling shareholders acquired
our shares in private placement transactions. The total number of common shares sold under this prospectus may be adjusted to
reflect adjustments due to stock dividends, stock distributions, splits, combinations or recapitalizations with regard to the
common stock. Unless otherwise stated below in the footnotes, to our knowledge, no selling shareholder: (i) has held any position
or office with us during the three (3) years prior to the date of this prospectus, or (ii) is a broker-dealer, or an affiliate
of a broker-dealer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Set forth
below is the name of each selling shareholder and the amount and percentage of common stock owned by each prior to the offering,
the shares to be sold in the offering, and the amount and percentage of common stock to be owned by each after the offering assuming
all shares are sold. The footnotes provide information about persons who have voting and dispositive power with respect to shares
held by the selling shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
have registered up to 9,658,201 shares of common stock, consisting of (i) 7,801,213 shares issued in the 2017 Placement and (ii)
1,856,988 shares issued in the 2018 Placement. For a more complete summary of the foregoing transactions, refer to the disclosure
under the heading &ldquo;Prospectus Summary&mdash;The Private Placement Transactions&rdquo; beginning on page 4 of this prospectus.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The amounts
and percentages of shares beneficially owned are reported on the basis of SEC regulations governing the determination of beneficial
ownership of securities. Under SEC rules, a person is deemed a &ldquo;beneficial owner&rdquo; of a security if that person has
or shares voting power or investment power, which includes the power to dispose of or to direct the disposition of the security.
A person is also deemed a beneficial owner of any securities of which that person has a right to acquire beneficial ownership
within 60 days. Securities that can be acquired this way are deemed to be outstanding for purposes of computing a person&rsquo;s
ownership percentage, but not for purposes of computing any other person&rsquo;s percentage. Under these rules, more than one
person may be deemed a beneficial owner of the same securities, and a person may be deemed a beneficial owner of securities to
which that person has no economic interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">The following
table is based on information provided to us by the selling shareholders and is as of September 4, 2019.</FONT> <FONT STYLE="font-size: 10pt">
The selling shareholders may sell all or some of the shares of common stock they are offering and may sell unless indicated otherwise
in the footnotes below shares of our common stock otherwise pursuant to this prospectus. The tables below assume that each selling
shareholder sells all of the shares offered by it in offerings pursuant to this prospectus, and does not acquire any additional
shares. We are unable to determine the exact number of shares that will actually be sold or when or if these sales will occur.</FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 9pt">Name
    of Selling <BR> Shareholder</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Shares
    of<BR>
    Common<BR>
    Stock<BR>
    Beneficially<BR> Owned<BR>
    Pre-<BR>
Offering(1)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">%
    Owned<BR>
    Beneficially<BR>
    Pre-<BR>
    Offering(1)(2)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Shares
    of<BR>
    Common<BR>
    Stock to be<BR>
    offered for<BR>
    selling<BR>
    shareholder&rsquo;s<BR>
    account(3)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Shares
    of<BR> Common<BR> Stock<BR> Beneficially<BR> Owned<BR> Post-<BR> Offering(1)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">%
    Beneficially<BR> Owned<BR> Post-<BR> Offering(1)(2)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 35%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Atwood P.
    Collins (4)&#9;</FONT></TD><TD STYLE="width: 3%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 9pt">44,444</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 3%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 3%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 9pt">44,444</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 3%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 3%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Blackwell Partners LLC
    &ndash; Series A (4)(5)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">213,334</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">1.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">%</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">156,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Christopher Davis (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">400,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">2.24</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">400,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Christopher B. Davis
    Guardianship Dated 1/25/2007 (4)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">122,667</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">122,667</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Clive Anthony Caunter
    (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">227,273</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">1.27</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">227,273</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Dick Horn (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">76,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">76,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Dogma Holdings Inc.
    (4)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">22,002</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">22,002</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Frank Family 1996 Trust&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">489,999</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 9pt">2.74</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 9pt">%</FONT> </TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">489,899</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">(7)</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Harry Charles Mills
    Scio (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">40,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">40,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">James E. Besser&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">6,384,691</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">(8)</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 9pt">35.73</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 9pt">%</FONT> </TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">88,889</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">(4)</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">6,295,802</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 9pt">35.23</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 9pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Jason Pickett (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">151,515</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">151,515</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">JEB Partners, LP&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">6,384,691</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">(8)</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 9pt">35.73</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 9pt">%</FONT> </TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">917,576</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">(9)</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">5,467,115</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 9pt">30.60</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 9pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">JOJ Holdings, LLC (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">75,758</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">75,758</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Lawrence Groo (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">38,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">38,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Manchester Explorer,
    LP&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">6,384,691</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">(8)</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 9pt">35.73</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 9pt">%</FONT> </TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">5,016,566</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">(10)</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">1,368,125</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 9pt">7.66</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 9pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Michael Malouf (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">151,515</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">151,515</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Paul DiPerna Trust&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 9pt">7,638,117</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">(11)</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 9pt">42.74</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 9pt">%</FONT> </TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">303,030</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">(6)</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 9pt">7,335,087</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-size: 9pt">41.05</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-size: 9pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Pepper Grove Holdings
    Limited (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">151,515</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">151,515</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Peter Karabatos (4)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">13,333</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">13,333</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Ray Gallo (4)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">44,444</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">44,444</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Robert Andrade (4)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">11,111</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">11,111</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Robert Gambi (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Robin Russell (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">76,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">76,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Rostilav Raykov (12)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">89,092</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">89,092</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Samuel Davis Trust FBO
    Alma Davis David (4)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">44,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">44,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Sarah Ball (4)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">8,882</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">8,882</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Simon Ball (4)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">8,882</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">8,882</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">683 Capital Partners,
    LP (4)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">444,444</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">2.49</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">444,444</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Solas Capital Partners,
    LP (4)(5)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">213,334</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">1.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">%</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">21,778</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Solas Capital Partners
    II, LP (4)(5)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">213,334</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">1.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">%</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">35,556</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">The Entrust Group FBO
    William Meehan IRA 7230006842 (4)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">35,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">35,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 9pt">Varana Capital Focused,
    LP (6)&#9;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">303,030</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">1.70</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">303,030</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">*Represents
less than 1%</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Beneficial
                                         ownership includes shares of common stock as to which a person or group has sole or shared
                                         voting power or investment power. Shares of common stock subject to options, warrants
                                         or other convertible securities that are exercisable or convertible currently or within
                                         60 days, are deemed outstanding for purposes of computing the number of shares beneficially
                                         owned and percentage ownership of the person or group holding such options, warrants
                                         or convertible securities, but are not deemed outstanding for computing the percentage
                                         of any other person.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Percentages
                                         are based on 17,870,261 shares of common stock outstanding as of June 30, 2019.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Represents
                                         shares of our common stock issued exclusively in the 2017 Placement and the 2018 Placement.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Includes
                                         shares purchased in the 2018 Placement.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Includes
                                         (i) 156,000 shares directly held, which shares constitute a portion of the assets of
                                         Blackwell Partners, LLC-Series A for which Solas Capital Management, LLC (&ldquo;Solas
                                         Capital Management&rdquo;), acts as its investment manager for and has voting and dispositive
                                         power over; (ii) 21,778 shares held directly by Solas Capital Partners, LP, of which
                                         Solas Capital Management is the investment manager of and has voting and dispositive
                                         power over; and (iii) 35,556 shares held directly by Solas Capital Partners II, LP, of
                                         which Solas Capital Management is the investment manager of and has voting and dispositive
                                         power over. Such person disclaims beneficial ownership of all shares not held directly
                                         by such person and this prospectus shall not be deemed an admission that such person
                                         is the beneficial owner of such shares, except to the extent of such persons pecuniary
                                         interest therein. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Includes
                                         shares purchased in the 2017 Placement.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(7)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Includes
                                         (i) 378,778 shares purchased in the 2017 Placement, and (ii) 111,111 shares purchased
                                         in the 2018 Placement. The address for the Frank Family Trust is c/o Manchester Management,
                                         LLC, 3 West Hill Place, Boston, MA 02114. Such person disclaims beneficial ownership
                                         of all shares not held directly by such person and this prospectus shall not be deemed
                                         an admission that such person is the beneficial owner of such shares, except to the extent
                                         of such persons pecuniary interest therein. </FONT></TD></TR></TABLE>



<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(8)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Includes
                                         (i) 180,830 shares directly held by Mr. Besser, which shares were received in the Acquisition
                                         in exchange for Mr. Besser&rsquo;s shares of Quasuras; (ii) 88,889 shares directly held
                                         by Mr. Besser who purchased such shares in the 2018 Placement; (iii) 4,545,455 shares
                                         held by Manchester who purchased such shares in the 2017 Placement; (iv) 471,111 shares
                                         held by Manchester who purchased such shares in the 2018 Placement; (v) 757,576 shares
                                         held by JEB Partners who purchased such shares in the 2017 Placement; (vi) 160,000 shares
                                         held by JEB Partners who purchased such shares in the 2018 Placement; and (vii) 180,830
                                         shares held by Mr. Frank, which shares were received in the Acquisition in exchange for
                                         Mr. Frank&rsquo;s shares of Quasuras. Mr. Besser as the managing member and Mr. Frank
                                         as the portfolio manager and consultant of Manchester Management, LLC (&ldquo;MMC&rdquo;),
                                         the general partner of Manchester and JEB Partners, have shared voting and dispositive
                                         power over shares held by Manchester and JEB Partners. The address for Mr. Besser is
                                         c/o Manchester Management, LLC, 3 West Hill Place, Boston, MA 02114. Such person disclaims
                                         beneficial ownership of all shares not held directly by such person and this prospectus
                                         shall not be deemed an admission that such person is the beneficial owner of such shares,
                                         except to the extent of such persons pecuniary interest therein. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(9)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Includes
                                         (i) 757,576 shares directly held and purchased in the 2017 Placement; and (ii) 160,000
                                         shares directly held and purchased in the 2018 Placement. The address for JEB Partners
                                         is c/o Manchester Management, LLC, 3 West Hill Place, Boston, MA 02114. Such person
                                         disclaims beneficial ownership of all shares not held directly by such person and this
                                         prospectus shall not be deemed an admission that such person is the beneficial owner
                                         of such shares, except to the extent of such persons pecuniary interest therein. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(10)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Includes
                                         (i) 4,545,455 shares purchased by Manchester in the 2017 Placement; and (ii) 471,111
                                         shares purchased by Manchester in the 2018 Placement. The address for Manchester is c/o
                                         Manchester Management, LLC, 3 West Hill Place, Boston, MA 02114. Such person disclaims
                                         beneficial ownership of all shares not held directly by such person and this prospectus
                                         shall not be deemed an admission that such person is the beneficial owner of such shares,
                                         except to the extent of such persons pecuniary interest therein. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(11)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Includes
                                         (i) 303,030 shares held directly by the Paul DiPerna Trust, which shares were purchased
                                         by the Paul DiPerna Trust in the 2017 Placement; (ii) 7,270,400 shares acquired by Mr.
                                         DiPerna in the Acquisition in exchange for his shares of Quasuras; and (iii) 64,687 shares
                                         issuable upon exercise of fully vested stock options issued to Mr. DiPerna under our
                                         EIP (as defined below).</FONT> <FONT STYLE="font-size: 10pt"> Mr. DiPerna is our Chairman,
                                         Chief Executive Officer, Chief Financial Officer, Secretary and Director. The address
                                         for Mr. DiPerna is 800 West Valley Parkway, Suite 203, Escondido, CA 92025. Such person
                                         disclaims beneficial ownership of all shares not held directly by such person and this
                                         prospectus shall not be deemed an admission that such person is the beneficial owner
                                         of such shares, except to the extent of such persons pecuniary interest therein. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(12)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Includes
                                         (i) 75,758 shares purchased in the 2017 Placement; and (ii) 13,334 shares purchased in
                                         the 2018 Placement. Such person disclaims beneficial ownership of all shares not held
                                         directly by such person and this prospectus shall not be deemed an admission that such
                                         person is the beneficial owner of such shares, except to the extent of such persons pecuniary
                                         interest therein. </FONT></TD></TR></TABLE>




<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara006"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">We are
not offering any of the selling shareholders&rsquo; shares. Such shares may be sold by the selling shareholders from time to time
at prevailing market prices. We will not receive any of the proceeds from any sale by the selling shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">The selling
shareholders, which for this purpose includes donees, pledgees, transferees or other successors-in-interest selling shares of
common stock or interests in shares of common stock received after the date of this prospectus from a selling shareholder as a
gift, pledge, dividend, distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or
all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on
which the shares are traded, or in private transactions. These sales or other dispositions may be at fixed prices, at prevailing
market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time
of sale, or at negotiated prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">The selling
shareholders may use any one or more of the following methods when selling our shares or interests in our shares:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ordinary
                                         brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">block
                                         trades in which a broker-dealer will attempt to sell the shares as agent, but may position
                                         and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">purchases
                                         by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">on
                                         any national securities exchange or quotation service on which the shares may be listed
                                         or quoted at the time of sale;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">privately
                                         negotiated transactions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">short
                                         sales effected after the date the registration statement of which this prospectus is
                                         a part is declared effective by the SEC;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">through
                                         the writing or settlement of options or other hedging transactions, whether through an
                                         options exchange or otherwise;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">broker-dealers
                                         may agree with the selling shareholders to sell a specified number of such shares at
                                         a stipulated price per share;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">a
                                         combination of any such methods of sale; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">any
                                         other method permitted by applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">The selling
shareholders may, from time to time, pledge or grant a security interest in some or all of our shares owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common
stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable
provision of the Securities Act amending the list of selling shareholders to include the pledgee, transferee or other successors
in interest as selling shareholders under this prospectus. The selling shareholders may also transfer our shares in other circumstances,
in which case the transferees, pledgees or other successors will be the selling beneficial owners for purposes of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In connection
with the sale of our common shares or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of our shares in the course of hedging the positions
they assume. The selling shareholders may also sell shares of our common stock short and deliver these securities to close out
their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling
shareholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation
of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares
offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The aggregate
proceeds to the selling shareholders from the sale of the common stock offered by them will be the purchase price of the common
stock less discounts or commissions, if any. Each of the selling shareholders reserves the right to accept and, together with
their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through
agents. We will not receive any of the proceeds from sales of shares by the selling shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The selling
shareholders may also resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities
Act, provided that they meet the criteria and conform to the requirements of that rule, or under Section 4(1) of the Securities
Act, if available, rather than by means of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">In connection
with the sale of shares of common stock covered by this prospectus, broker-dealers may receive commissions or other compensation
from a selling shareholder in the form of commissions, discounts or concessions. Broker-dealers may also receive compensation
from purchasers of the shares of common stock for whom they act as agents or to whom they sell as principals or both. Compensation
as to a particular broker-dealer may be in excess of customary commissions or in amounts to be negotiated. In connection with
any underwritten offering, underwriters may receive compensation in the form of discounts, concessions or commissions from a selling
shareholder or from purchasers of the shares for whom they act as agents. Underwriters may sell the shares of common stock to
or through dealers, and such dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters
and/or commissions from the purchasers for whom they may act as agents. Any underwriters, broker-dealers, agents or other persons
acting on behalf of a selling shareholder that participate in the distribution of the shares of common stock may be deemed to
be &ldquo;underwriters&rdquo; within the meaning of the Securities Act, and any profit on the sale of the shares of common stock
by them and any discounts, commissions or concessions received by any of those underwriters, broker-dealers, agents or other persons
may be deemed to be underwriting discounts and commissions under the Securities Act. The aggregate amount of compensation in the
form of underwriting discounts, concessions, commissions or fees and any profit on the resale of shares by the selling shareholders
that may be deemed to be underwriting compensation pursuant to Financial Industry Regulatory Authority, Inc., rules and regulations
will not exceed applicable limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The selling
shareholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein
may be &ldquo;underwriters&rdquo; within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions
or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling
shareholders who are &ldquo;underwriters&rdquo; within the meaning of Section 2(11) of the Securities Act will be subject to the
prospectus delivery requirements of the Securities Act and may be subject to certain statutory liabilities, including but not
limited to, Sections 11, 12 and 17 of the Securities Act and Rule 10b-5 under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To the
extent required, the shares of our common stock to be sold, the names of the selling shareholders, the respective purchase prices
and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect
to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment
to the registration statement that includes this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">In order
to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through
registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered
or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We have
advised the selling shareholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of
shares in the market and to the activities of the selling shareholders and their affiliates. In addition, to the extent applicable,
we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling shareholders
for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling shareholders may indemnify
any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities
arising under the Securities Act. All of the foregoing may affect the marketability of the common stock and the ability of any
person or entity to engage in market-making activities with respect to our common stock.</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Penny
Stock Rules / Section 15(g) of the Exchange Act</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our shares
may be considered penny stock covered by Section 15(g) of the Securities Exchange Act of 1934, as amended, and Rules 15g-1 through
15g-6 promulgated thereunder. They impose additional sales practice requirements on broker/dealers who sell our securities to
persons other than established customers and accredited investors who are generally institutions with assets in excess of $5,000,000
or individuals with net worth in excess of $1,000,000 (including spouse&rsquo;s net worth and may include the fair market value
of home furnishings and automobiles, but excluding from the calculation the value any primary residence and the related amount
of any indebtedness on primary residence up to the fair market value of the primary residence (any indebtedness that exceeds the
fair market value of the primary residence must be deducted from net worth calculation)) or annual income exceeding $200,000 or
$300,000 jointly with their spouses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Rule 15g-1
exempts a number of specific transactions from the scope of the penny stock rules. Rule 15g-2 declares unlawful broker/dealer
transactions in penny stocks unless the broker/dealer has first provided to the customer a standardized disclosure document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Rule 15g-3
provides that it is unlawful for a broker/dealer to engage in a penny stock transaction unless the broker/dealer first discloses
and subsequently confirms to the customer current quotation prices or similar market information concerning the penny stock in
question.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Rule 15g-4
prohibits broker/dealers from completing penny stock transactions for a customer unless the broker/dealer first discloses to the
customer the amount of compensation or other remuneration received as a result of the penny stock transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Rule 15g-5
requires that a broker/dealer executing a penny stock transaction, other than one exempt under Rule 15g-1, disclose to its customer,
at the time of or prior to the transaction, information about the sales person&rsquo;s compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Rule 15g-6
requires broker/dealers selling penny stocks to provide their customers with monthly account statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Rule 15g-9
requires broker/dealers to approved the transaction for the customer&rsquo;s account; obtain a written agreement from the customer
setting forth the identity and quantity of the stock being purchased; obtain from the customer information regarding his investment
experience; make a determination that the investment is suitable for the investor; deliver to the customer a written statement
for the basis for the suitability determination and that it is unlawful to effect the transaction without written authorization
for the transaction from the customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The application
of the penny stock rules may affect your ability to resell your shares due to broker-dealer reluctance to undertake the above-described
regulatory burdens.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara007"></A>DETERMINATION
OF OFFERING PRICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The prices
at which the shares of common stock covered by this prospectus may actually be sold will be determined by the prevailing public
market price for shares of common stock, by negotiations between the selling shareholders and buyers of our common stock in private
transactions or as otherwise described in &ldquo;Plan of Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara008"></A>DESCRIPTION
OF COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We are
authorized to issue up to 50,000,000 shares of common stock, par value $0.001 per share. As of June 30, 2019, we had 17,870,261
common shares issued and outstanding held by approximately 91 holders of record. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Common
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Each shareholder
of our common stock is entitled to a pro rata share of any cash distributions made to shareholders, including any dividend payments.
The holders of our common stock are entitled to one vote for each share of record on all matters to be voted on by shareholders.
There is no cumulative voting with respect to the election of our directors or any other matter. Therefore, under our governing
documents, the holders of more than 50% of the shares voted for the election of those directors can elect all of the directors.
However, pursuant to the July 24, 2017 agreement in which we acquired Quasuras, until July 24, 2022, our board of directors will
consist of no less than 2 and no more than 5 directors, of which Mr. DiPerna in addition to being the chairman of our board has
the right to appoint 2 directors and Manchester has the right to appoint 2 directors, of which Mr. Frank constitutes 1 such director.
As a result, until July 24, 2022, shareholders will not have the ability to elect any directors either at the annual meeting or
by written consent. Our board of directors is elected as a single class. </FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
holders of our common stock are entitled to receive dividends when and if declared by our board of directors from funds legally
available therefore. Cash dividends are at the sole discretion of our board of directors.</FONT> <FONT STYLE="font-size: 10pt">
In the event of our liquidation, dissolution or winding up, the holders of common stock are entitled to share ratably in all assets
remaining available for distribution to them after payment of our liabilities and after provision has been made for each class
of stock, if any, having any preference in relation to our common stock. Holders of shares of our common stock have no conversion,
preemptive or other subscription rights, and there are no redemption provisions applicable to our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Dividend
Policy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We have
never paid dividends and have no current plans to do so. We currently anticipate that we will retain all of our future earnings,
if any, for use in the development and expansion of our business and for general corporate purposes. Any determination to pay
dividends in the future will be at the discretion of our board of directors and will depend upon our results of operations, financial
condition, and other factors that the board of directors, in its discretion, may deem relevant. There are no restrictions, other
than applicable law, on the ability of the board of directors to declare and pay dividends. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Preferred
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Our
board of directors is authorized to issue up to 5,000,000 shares of non-voting preferred stock, par value $0.001 per share, in
one or more series, without stockholder approval.</FONT> <FONT STYLE="font-size: 10pt"> We have not issued, nor established
any series for, any of our preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Stock
Options</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">On
October 19, 2018, our board of directors approved our 2017 Equity Incentive Plan (&ldquo;EIP&rdquo;) that reserves 3,000,000 shares
of common stock of the Company to be issued. Under the Company&rsquo;s EIP, eligible employees, directors and consultants are
granted options to purchase shares of common stock of the Company. The EIP is administered by the Company&rsquo;s board of directors
or, in the alternative, if necessary, a committee designated by the board of directors, and has the sole power over the exercise
of the EIP. The board of directors determines whether the EIP will allow for the issuance of shares of common stock or an option
to purchase shares of common stock, such option designated as either an incentive stock option or a non-qualified stock option.
As of June 30, 2019, stock options to purchase 1,557,019 shares have been granted under our EIP.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The exercise
or purchase price shall be calculated as follows:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.28in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">In
                                         the case of an incentive stock option, (A) granted to employees, directors and consultants
                                         who, at the time of the grant of such incentive stock option own stock representing more
                                         than ten percent (10%) of the voting power of all classes of stock of the Company, the
                                         per share exercise price shall be not less than one hundred ten percent (110%) of the
                                         fair market value per share on the date of grant; or (B) granted to employees, directors
                                         and consultants other than to employees, directors and consultants described in the preceding
                                         clause, the per share exercise price shall be not less than one hundred percent (100%)
                                         of the fair market value per share on the date of grant;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.28in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(ii)</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">In
                                         the case of a non-qualified stock option, the per share exercise price shall be not less
                                         than one hundred percent (100%) of the fair market value per share on the date of grant
                                         unless otherwise determined by the board of directors; and</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.28in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">In
                                         the case of other grants, such price as is determined by the board of directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">The board
of directors is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise
or purchase. The EIP generally does not allow for the transfer of the options, and the board of directors may amend, suspend or
terminate the EIP at any time.</FONT> </P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Dilution</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The current
trading price of the common stock that may be offered for resale pursuant to this prospectus is higher than the current net tangible
book value per share of our common stock. Therefore, if you purchase shares of common stock in this offering, you may incur immediate
and substantial dilution in the pro forma net tangible book value per share of common stock from the price per share that you
pay for the common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">This
offering is for sales of common stock by the selling shareholders on a continuous or delayed basis in the future. Neither sales
of common stock by the selling shareholders nor cash payments made by the purchasers of the common stock will result in a change
to the net tangible book value per share before and after the sale of the shares by the selling shareholders. Prospective investors
should be aware, however, that the price of shares of common stock may not bear any rational relationship to the net tangible
book value per share of the common stock. See &ldquo;Risk Factors &ndash; Purchases in this offering may experience immediate
and substantial dilution,&rdquo; above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara009"></A>OUR
BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
are a development stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump to address shortcomings and problems represented by limited adoption of currently available pumps for insulin dependent
people with diabetes.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">It is
our view that many people with diabetes currently experience a number of problems and/or shortcomings with the current products
in the insulin pump market and that, by alleviating these issues, we can expand the scope insulin pump usage. We believe that,
to achieve broader market acceptance, an insulin pump must be simpler and less time consuming to operate, as well as more intuitive
to both patients and physicians in order to reduce the friction of current products. We also believe that such a product must
be specifically designed to meet the general guidelines of third party payors, private and public insurance companies, preferred
provider organizations and other managed care providers with particular focus on the guidelines established by the Center for
Medicare and Medicaid Services, CMS, which administrates the United States Medicare program. This will increase the likelihood
&nbsp;that such &nbsp;third party payors will &nbsp;cover all or a substantial portion of the purchase price and recurring costs
of the use of our insulin pump (with manageable co-payments, as applicable), so that our product will be affordable by users.
See &ldquo;Risk Factor &ndash; Healthcare reform laws could adversely affect our product and financial condition,&rdquo; above. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Among
the more prominent issues are:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>Complexity</U>:
                                         Many existing pumps are highly complex and require significant technical expertise to
                                         be used effectively. We believe such pumps were designed for so called &ldquo;super users&rdquo;
                                         who have high levels of motivation and technical competence and that the complexity of
                                         such existing pumps proves daunting to less technically inclined users.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>Cumbersome</U>:
                                         We believe that a majority of existing pumps are bulky and difficult to manage, in many
                                         cases requiring additional equipment to introduce a catheter to the patient&rsquo;s body
                                         and 48 inches of tubing, which must be replaced frequently, to connect this catheter
                                         to a pump. This requires users to carry spare parts and other equipment adding to the
                                         cumbersomeness of using the pump.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>Cost</U>:
                                         Costs associated with insulin pump therapy are high and can be prohibitive, especially
                                         for those on fixed or limited incomes. Although, these costs vary by pump, multi thousand
                                         dollar upfront payments, often with substantial co-payments, in addition to possible
                                         daily co-payments on consumables are not uncommon. Such expenses often place current
                                         pumps out of reach for patients and make insurers very hesitant to pay for them, leading
                                         to limited or nonexistent reimbursement/coverage.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>The
Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Diabetes
is a chronic, life-threatening disease for which there is no known cure. Type 1 diabetes is an auto immune disease whereby the
immune system attacks and destroys beta cells in the pancreas leaving it unable to produce insulin. Type 2 diabetes is most commonly
caused by the development of insulin resistance that prevents the body from properly using insulin. Insulin is a life sustaining
hormone that allows cells in the body to absorb glucose and store it or covert it to energy. Those with diabetes are left unable
to properly process sugars resulting in excessive sugar in their bloodstream. If not closely monitored and properly treated, such
excess blood sugar can lead to serious medical complications including damage to organs and tissues, seizures, coma, and death.
By injecting controlled doses of insulin, people suffering from diabetes can reduce their blood glucose levels to mitigate these
complications and allow better processing and storage of sugars.</FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
International Diabetes Federation, or IDF, estimates that in 2017, approximately 425&nbsp;million people had diabetes worldwide
and that by 2045, this number will increase to 629&nbsp;million people worldwide. According to the Centers for Disease Control
and Prevention, or CDC, 2017 National Diabetes Statistics Report, approximately 23&nbsp;million people in the United States have
diagnosed diabetes, of which type 1 diabetes accounts for approximately 5% to 10%, or approximately 1.2 to 2.3&nbsp;million people.
All people with type 1 diabetes require daily insulin. Of people with type 2 diabetes in the United States, according to the CDC,
approximately 14%, or 3.2&nbsp;million people, require insulin to manage their diabetes.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Currently,
there are two primary therapies available for insulin-dependent people with diabetes: multiple daily insulin injections directly
into the body through syringes or insulin pens, referred to as Multiple Daily Injection (MDI) therapy, or the use of an insulin
pump to deliver a continuous subcutaneous insulin infusion into the body, and user directed infusions as appropriate (Continuous
Subcutaneous Insulin Injections (CSII)) therapy.</FONT> <FONT STYLE="font-size: 10pt"> Each is designed to supplement or replace
the insulin-producing function of the pancreas. Generally, CSII therapy is considered to provide a number of advantages over
MDI therapy primarily in that the continuous infusion of insulin allows absorption of glucose in a controlled manner minimizing
large doses of insulin required before meals. The steady flow of insulin and the easier application of mealtime boluses has
been shown by numerous studies to result in lower HbA1c&rsquo;s (a measure of the amount of glucose in the bloodstream) when compared
to MDI therapy. This has proven to improve glucose control and reduce overall long term adverse effects&nbsp; and emergency
room visits associated with low glucose. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Notwithstanding
the &nbsp;advantages of pump usage, the difficulty in use resulting from the complexity and cumbersome design of available insulin
pumps, as well as high and often prohibitive costs, has resulted not only in dissatisfaction among many existing pump users, but
also has severely limited the adoption rate of insulin pumps by a segment of the diabetes population, referred to herein &nbsp;as
&ldquo;almost pumpers.&rdquo; We generally define almost pumpers as persons with insulin dependent diabetes who are aware of pumps
and the potential benefits, however, because of the shortcomings and problems prevalent in available insulin pumps, continue to
receive their daily insulin through insulin injections. Our initial target market for our insulin pump is the almost pumper population
located in the United States.&nbsp; According to a market research study commissioned by us and conducted by Kirk Brote only an
estimated 35% of Americans with type 1 diabetes use insulin pump therapy and an estimated 30%&nbsp; of Americans with type 1 diabetes
are who we classify as &ldquo;almost pumpers.&rdquo; We believe our proposed product has the potential to substantially improve
the day to day quality of life of such persons. In addition to educating almost pumpers as to why our insulin pump is a &ldquo;better&rdquo;
solution to their treatment needs, with regard to physicians, we need&nbsp; to inform endocrinologists, who typically prescribe
pump usage, about the superior qualities of our product and convince &nbsp;general practitioners, who have been historically skeptical
of the heightened support inherent in insulin pumps, of our product&rsquo;s ease of use and convenience.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">In an article
entitled &ldquo;Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016&rdquo; published in the Journal of
Academy of Medical Sciences on August 12, 2019, Pooyan Kazemian PhD and various co-authors found that rates of adults diagnosed
with diabetes, achieving A1c, blood pressure and cholesterol targets, had not improved significantly from 2005 to 2016. Specifically,
the study found that only 1 in 4 adults with diabetes in the United States achieved composite goals during this period. The study
indicated that, although there have been significant advances in diabetes drugs, technology and clinical guidelines since 2005,
the most formidable challenges confronting future advances in diabetes care may be in providing access to high quality treatment.
We believe that the study&rsquo;s conclusions reflect the impact of the industry&rsquo;s singular focus on improving the care
of the highly motivated, well insured and technologically proficient people with the opportunity and capability of using pumps
currently prevalent in the market, leaving non pumpers behind. These patients are left with dated and less effective devices,
highlighting the opportunity of providing technology that is appropriate for this badly underserved segment of the population
of Americans with diabetes.</FONT> </P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>The
Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
believe an insulin pump having the correct mix of efficiency, reliability, features that are easy to understand and use, offer
and are offered at an affordable price point will drive a substantial percentage of &ldquo;almost pumpers&rdquo; to use insulin
pumps.</FONT> <FONT STYLE="font-size: 10pt"> We believe that such an insulin pump can improve glucose control, and, therefore,
the user&rsquo;s quality of life while substantially mitigating adverse diabetes related health risks and many if not all of the
challenges and shortcomings discussed herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">As set
forth in general terms herein, we believe existing pumps have numerous shortcomings and challenges including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Outdated
Style</I></B>. Consumer electronics devices have evolved in both form and function. Diabetes pumps have not experienced similar
progress. We believe that consumers will be more receptive to products designed with the user experience in mind and that many
have low tolerance for complex, difficult procedures for use and maintenance of products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Bulky
size. </I></B>We believe that consumers view traditional pumps, especially those with tubing, to be large, bulky, and inconvenient
to carry or wear, especially when compared to modern consumer electronic devices. The size of the pump further contributes to
users being embarrassed by the pump. We believe a simple patch style of pump will drive adoption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Pump
mechanism limitations. </I></B>Traditional pumps generally utilize a syringe and plunger mechanism to deliver insulin. We believe
this design limits the ability to reduce the size of the pump, and also potentially exposes the user to the unintended delivery
of the full volume of insulin within the pump, which can cause hypoglycemia or death. We believe that the fear of adverse health
events due to technical malfunctions related to traditional pump mechanism limitations deters the adoption of insulin pump therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Costs.
</I></B>Existing pumps are expensive, with the more popular models having purchase prices exceeding $4,000 (for individuals without
health insurance coverage) and often require significant patient copays (for those patients with insurance coverage). Others have
daily use costs that exceed the reimbursement rates of many health insurance plans, forcing some users to spend thousands of dollars
a year in copays. We believe this makes insurers hesitant to pay for pumps for any but their best and most compliant patients
and places such pumps out of reach for many patients who cannot afford such out of pocket expenses and/or do not have the clinical
care professionals to advocate for them with insurers. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Our
Solution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
Company&rsquo;s proposed pump is being designed and developed to address the above shortcomings and to appeal to the substantial
group of &ldquo;almost pumpers&rdquo; currently interested in using an insulin pump, but have not done so because of the complexity,
cost or cumbersome nature of existing products.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
&nbsp;have substantially completed the general engineering and mechanical aspects of our current insulin pump prototype. However,
we are continuing to modify, refine and fine tune &nbsp;our prototype so that it meets the general needs and preferences of our
almost pumper target market, based in large part on the recommendations from our independent marketing consultant, Kirk Brote.
&nbsp;These recommendations were predicated upon our consultants&rsquo; &nbsp;analysis of feedback and other information obtained
from almost pumpers and their caregivers. &nbsp;We are also in the process of modifying our product&nbsp; so that meets the general
guidelines of third party payors. To assist us in making these coverage driven &nbsp;modifications and refinements, we have retained
PrecisionXtract Inc., an independent consulting firm focused on ensuring that our product satisfies the coverage and reimbursement
criteria of such third party payors.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">Over the
past two years we have designed and developed working prototypes of our insulin pump. During this period, we also have and continue
to expend substantial time and resources to better understand the needs and preferences of almost pumpers to enable us to modify
and refine our insulin pump to the needs and preferences of this target market. We continue to engage Kirk Brote, to provide specific
feedback and information from our target market and their care givers through one on one interviews, human factors testing, on-line
and in person surveys, focus groups both at industry related tradeshows and conferences.</FONT> </P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
human factors studies that we have conducted, and will continue to conduct, under the direction and supervision of Kirk Brote,
take place in three stages. Stage 1 studies were conducted to validate the almost pumper market segment. Stage 2 studies have
been conducted to identify specific potential features and attributes for our prototype pump based on feedback from almost pumper
test participants. For example, based on participant feedback, we have modified our pump to meet several user preferences, such
as enhanced compatibility with smart phones, the flexibility for pump usage for limited periods of time without a controller and
the ability to temporarily remove the pump. Stage 3 studies, which we expect to conduct after obtaining 510(k) clearance from
the FDA, will be conducted to validate the design and functionality of our product based on actual treatment of participants (i.e.,
using our pump to inject insulin). Currently, we are at the very end of Stage 2.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our current
objective is to successfully design, develop and obtain all required regulatory approvals for our proposed insulin pump and, thereafter,
commercialize, market and sell the finished product. At the point that we feel confident of the FDA approval or clearance process
relating to our insulin pump, we will start manufacturing our insulin pump. For cost efficiency, we will select a manufacturer
or manufacturers &nbsp;through a competitive bidding process. We will need to be cognizant of our prospective &nbsp;manufacturer&rsquo;s
ability to comply , and maintain compliance with, the FDA&rsquo; quality system regulations. We intend to make our product available
to almost pumpers across mostly all socioeconomic groups in the United States. To that end, we intend to recruit and retain a
&nbsp;sales and marketing team, familiar with our product&rsquo;s regulatory environment, to launch a promotional&nbsp;campaign
for our insulin pump substantially focused on the almost pumper &nbsp;target market. For a general discussion of the steps to
commercialization of our pump and the hurdles that we will need to surmount, see &ldquo;Prospectus Summary &ndash; Pre-Commercialization
Steps.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To achieve
our above stated immediate and current goals, we intend to pursue the following business strategies:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Use
of Innovative proprietary technology. </I></B> Our design and development team is led by Paul DiPerna, our chairman, chief executive
officer and a 40% shareholder. Mr. DiPerna has over 30 years of high level experience in developing, designing, obtaining FDA
approval and the commercialization of medical devices, including consumer and hospital based insulin pumps while working for such
industry leading medical device companies as Baxter Healthcare, Inc., a supplier of drug therapies and associated pumping technologies
and founding Tandem Diabetes Care, Inc, a leading supplier of pumping technology to the existing insulin pumping marketplace.
Based upon Mr. DiPerna&rsquo;s substantial experience in engineering design and innovative technology in the medical device
industry and in particular with insulin pumps, we have created certain critical proprietary technology that will be incorporated
into our proposed insulin pump. We believe our technology will greatly assist us in creating a simpler user-friendly pump.
See &ldquo;Risk Factor &ndash; Technological Breakthroughs in diabetes monitoring, treatment or prevention could render our insulin
pump obsolete,&rdquo; above. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Keep
costs low during our design and development process. </I></B>To attempt to ensure that we have sufficient funds to design, develop
and obtain all required regulatory approvals for our proposed insulin pump without having to sacrifice quality and efficiency,
we intend to maintain a tight budget and limit expenditures where possible. We believe this will be possible because of the extensive
knowledge and experience of Mr. DiPerna, not only in the diabetes industry, but more specifically in the insulin pump device market.
In addition to his experience in designing and developing insulin pumps as well as other medical devices, Mr. DiPerna has demonstrated
a proven ability to manage a small and focused development team. We currently expect various other expenses, such as product
scale up, sales and marketing costs, will not be incurred until such time as development work is completed and regulatory clearance
and approvals are obtained. See &ldquo;Risk Factor &ndash; we are a developmental stage medical device company and have a history
of significant operating losses; we expect to continue to incur operating losses and we may never achieve or maintain profitability,&rdquo;
above. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Employ
experienced engineers recruited, supervised and led by Mr. DiPerna, a highly experienced and respected engineer and executive
in the insulin pump industry. </I></B> To attempt to ensure that our proposed insulin pump is functional and efficient as well
as to conserve funds, significantly all of our employees will initially be hand-picked engineers under the direct supervision
and leadership of Mr. DiPerna. We believe that there is a rich pool of engineers with significant applicable experience and
knowledge who we will be able to initially employ on a contract and/or outsource basis to help us design and develop our proposed
insulin pump. We believe by hiring such persons on an out-source basis, we will save substantial resources. Moreover, under Mr.
DiPerna&rsquo;s leadership, we believe that the team will be focused on the technological and mechanical aspects of our proposed
insulin pump, resulting in a cost efficient and precisely designed product. See &ldquo;Risk Factor &ndash; we do not have internal
research and development personnel, making us dependent on consulting relationships,&rdquo; above. </FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Government
Regulations</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Before
we can market our prototype insulin pump to the public, we will need to obtain FDA clearance. Our insulin pump is and will be
subject to extensive and ongoing regulation by the FDA and other federal, state, and local regulatory bodies. FDA regulations
govern, among other things, product design and development, pre-clinical and clinical testing, manufacturing, labeling, post-market
adverse event reporting, post-market surveillance, complaint handling, repair or recall of products, product storage, record keeping,
pre-market clearance or approval, advertising and promotion, and sales and distribution.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Unless
an exemption applies, each medical device, such as our insulin pump, that is intended to be commercially distributed in the United
States requires either prior 510(k) clearance or pre-market approval (&ldquo;PMA&rdquo;) from the FDA. Based on the FDA guidance
documents that we have reviewed and the opinion of our FDA regulatory consultant, we expect to be subject to the shorter and more
streamlined 510(k) process, which typically involves less risk of uncertainty and the submission of less supporting documentation,
and without the costly clinical trials associated with PMA. Generally, gaining 510(k) clearance for a product turns on demonstrating
that the subject product is &ldquo;substantially equivalent&rdquo; to a previously cleared 510(k) device.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
are &nbsp;working &nbsp;closely with our FDA regulatory consultant to complete, finalize and file our FDA submission, including
our pre-market notification to the FDA for 510(k) clearance and all other documentation necessary to obtain FDA approval of our
insulin pump. This will involve three material steps. First, we will engage the FDA in a pre-submission conference to ensure that
we understand and meet the FDA&rsquo;s requirements, expectations and standards with regard to approval of our product. At this
meeting, our team, including our FDA regulatory consultant, will receive FDA comments and guidance regarding our proposed submission
during the pre-market notification period for 510(K) clearance (including any suggested modifications to the device description,
indications for use or summary of supporting data contained in the notification). We currently expect such conference will be
conducted near the end of the third quarter of 2019. Second, we will prepare our pre-market notification to be part of our submission
to the FDA, demonstrating that our insulin pump is substantially equivalent to an insulin pump previously cleared by the FDA and
legally marketed to the public. Third, we will prepare our submission to the FDA, to include all of the appropriate results of
tests (relating to, among other things, user effectiveness, sterility, pump efficiency and shipping compatibility) demonstrating
safety and efficacy of the product in satisfaction of the mandates of the Federal Food, Drug and Cosmetics Act (the &ldquo;Act&rdquo;),
including requirements with regard to registration and listing, labeling, medical device reporting and good manufacturing practices.
We currently expect to make this submission near the end of the fourth &nbsp;quarter of 2019 or in the first quarter of 2020.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
FDA&rsquo;s 510(k) clearance pathway generally takes from three to twelve months from the date the application is completed, but,
if additional testing, verifications or other procedures (or even clinical trials in care instances) are required, can take significantly
longer (as compared to PMA which can extend from one to three years, or longer in certain instances). After a medical device receives
510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a significant
change in its intended use, requires a new 510(k) clearance or, depending on the modification, could require a PMA application.
The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree
with a manufacturer&rsquo;s determination. If the FDA disagrees with a manufacturer&rsquo;s determination regarding whether a
new premarket submission is required for the modification of an existing device, the FDA can, at its discretion, require the manufacturer
to cease marketing and/or recall the modified device until 510(k) clearance is obtained. Failure to comply with applicable regulatory
requirements can result in enforcement actions by the FDA and other regulatory agencies, which may include any of the following
sanctions: untitled letters or warning letters, fines, injunctions, consent decrees, civil or criminal penalties, recall or seizure
of our current or future products, operating restrictions, partial suspension or total shutdown of production, refusal of or delay
in granting 510(k) clearance of new products or modified products or rescinding previously granted 510(k) clearances. Any of these
sanctions could result in higher than anticipated costs and have a material adverse effect on our reputation, business and financial
condition. See &ldquo;Risk Factor &ndash; Government Regulation,&rdquo; above.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The FDA
can delay, limit or deny clearance or approval of our proposed pump device for many reasons, including:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">our
                                         inability to demonstrate that our product is safe and effective for its intended users&#894;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">our
                                         inability to demonstrate that our product is the &ldquo;substantial equivalent&rdquo;
                                         of a previously cleared device;</FONT> </TD></TR></TABLE>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">the
                                         data from our user studies may be insufficient to support clearance or approval&#894;
                                         and</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">failure
                                         of the manufacturing process or facilities we use to meet applicable requirements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">In
addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations,
or take other actions which may prevent or delay approval or clearance of our pump.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Any
delay in, or failure to receive or maintain, clearance or approval for our insulin pump could prevent us from generating revenue
therefrom or achieving profitability.</FONT> <FONT STYLE="font-size: 10pt"> Additionally, the FDA and other regulatory authorities
have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could dissuade some
customers from using our proposed product and adversely affect our reputation and the perceived safety and efficacy of our insulin
pump. If the FDA requires us to go through a more rigorous examination for our proposed product than we currently expect, such
as requiring additional testing further verification or other procedures, we may require substantial additional funding sooner
than anticipated and/or our product could be severely delayed. Being subject to an extended period of scrutiny or being required
to conduct expensive clinical trials would be particularly harmful to our business because our insulin pump is our only product. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Ongoing
Regulation by FDA.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Even
after a device such as our insulin pump receives FDA clearance and is placed on the market, numerous regulatory requirements apply.
These include:</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">establishment
                                         registration and device listing;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">quality
                                         system regulation, which requires manufacturers, including third party manufacturers,
                                         to follow stringent design, testing, control, documentation and other quality assurance
                                         procedures during all aspects of the manufacturing process;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">labeling
                                         regulations and FDA prohibitions against the promotion of products for uncleared, unapproved
                                         or &#8220;off-label&#8221; uses, and other requirements related to advertising and promotional
                                         activities;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">medical
                                         device reporting regulations, which require that manufacturers report to the FDA if their
                                         device may have caused or contributed to a death or serious injury or malfunctioned in
                                         a way that would likely cause or contribute to a death or serious injury if the malfunction
                                         were to recur;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">corrections
                                         and removals reporting regulations, which require that manufacturers report to the FDA
                                         field corrections and product recalls or removals if undertaken to reduce a risk to health
                                         posed by the device or to remedy a violation of the FDCA that may present a risk to health;
                                         and</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">post-market
                                         surveillance regulations, which apply when necessary to protect the public health or
                                         to provide additional safety and effectiveness data for the device.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Number
of Total Employees and Number of Full-Time Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
currently employ six (6) full-time employees, including one executive officer, Paul DiPerna, our chief executive officer, chief
financial officer, secretary, treasurer, and director.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">The medical
device industry, generally, and the diabetes segment of that industry particularly, is intensely competitive, subject to rapid
change and significantly affected by new product introductions and other market activities of industry participants. Our insulin
pump will &nbsp;compete with a number of existing &nbsp;devices, any new devices introduced in the future as well as other methods
for the treatment of people with insulin dependent diabetes. These products will be produced by competitors that, in many cases,
will be larger, substantially better capitalized with significantly more employees, market share and resources than us. As a consequence,
they will be able to spend more aggressively on product development, marketing, sales and other product initiatives than we can.
Many of these competitors have:</FONT> </P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">significantly
                                         greater name recognition and greater recognition by the FDA with regard to clearance
                                         process;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">established
                                         relations with regulators, healthcare professionals, customers and third-party payors;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">established
                                         distribution networks;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">additional
                                         lines of products, and the ability to offer rebates or bundle products to offer higher
                                         discounts or other incentives to gain a competitive advantage;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">greater
                                         experience in conducting research and development, manufacturing, clinical trials, clinical
                                         studies, marketing and obtaining regulatory approval for products; and</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">greater
                                         financial and human resources for product development, sales and marketing and patent
                                         litigation.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Medtronic
Inc., Tandem Diabetes Care, Inc. and Insulet Corporation are all much larger companies with substantially greater resources than
the Company&rsquo;s resources, make similar products for the more sophisticated, technically capable person with diabetes. The
Company does not intend to compete for those patients, instead by offering a simple to use more cost-effective solution, the Company
intends to attract more mainstream patients such as our almost pumper target market.</FONT> <FONT STYLE="font-size: 10pt">
See &ldquo;Risk Factors &ndash; Our competitors may develop products that are more effective, safer and less expensive than ours,&rdquo;
above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Patents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
has applied to the U.S. Patent and Trademark Office for two US patents on its proprietary fluid movement technology and the configuration
of its product offering. There is no assurance that these patents will be issued, and no assurance that they will prevent other
companies from competing with the Company. The Company will continue to attempt to patent its innovations as appropriate to help
ensure a sustainable competitive advantage. See &ldquo;Risk Factors &ndash; Our success depends substantially upon our ability
to obtain and maintain intellectual property protection relating to our product and research technologies,&rdquo; above. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Properties</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our principal
executive offices are located at 800 West Valley Parkway, Suite 203, Escondido, California 92025. We lease our executive offices
in a commercial office building pursuant to a standard sublease dated as of August 21, 2017. The term is from September 1, 2018
through December 14, 2019. The rental amount under the lease is $3,000 per month. The Company paid a security deposit of $7,500
upon execution of the lease on August 21, 2017. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Legal
Proceedings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We are
not a party to any pending legal proceeding. To the knowledge of our management, no federal, state or local governmental agency
is presently contemplating any proceeding against us. No director, executive officer or affiliate of ours or owner of record or
beneficially of more than five (5%) percent of our common stock is a party adverse to us or has a material interest adverse to
us in any proceeding.</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><A NAME="modulara010"></A><FONT STYLE="font-size: 10pt"><B>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>This
Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations is intended to provide a reader of
our financial statements with a narrative from the perspective of our management on our financial condition, results of operations,
liquidity and certain other factors that may affect our future results.</I> <I>You should read the following discussion and analysis
of our financial condition and results of operations in conjunction with the audited consolidated financial statements and related
notes included elsewhere in this prospectus. The following discussion contains forward-looking statements that are subject to
risks and uncertainties. See &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo; for a discussion of the uncertainties,
risks, and assumptions associated with those statements. Actual results could differ materially from those discussed in or implied
by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this prospectus,
particularly in &ldquo;Risk Factors.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
was incorporated under the laws of the State of Nevada on October 22, 1998 under the name Bear Lake Recreation Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
had no material business operations from 2002 through July 24, 2017 when we acquired Quasuras.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Our
acquisition of Quasuras was accounted for as a recapitalization effected by a share exchange and Quasuras was considered the acquirer
for accounting and financial reporting purposes.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Following
our acquisition of Quasuras, in addition to capital raising and general day to day business and administrative actions relating
to being a publicly traded reporting company, we have been singularly focused on activities relating to designing and developing
our innovative insulin pump.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> <FONT STYLE="font-size: 10pt">From
July 24, 2017 through March 29, 2019, we conducted two private placements, the 2017 Placement and the 2018 Placement, of shares
of our common stock discussed elsewhere herein pursuant to which we received in the aggregate $8,874,538 of gross proceeds. In
addition to costs and expenses in operating our business including general administrative costs and expenses as well as those
resulting from being a public reporting company, we are using the net proceeds from such private placements in connection with
activities relating to the design, development and obtaining required regulatory approvals of our insulin pump.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> <FONT STYLE="font-size: 10pt">In
April 2012, the JOBS Act was enacted. Section&nbsp;107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo;
may take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with
new or revised accounting standards. Therefore, an emerging growth company can delay the adoption of certain accounting standards
until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from new
or revised accounting standards, and, therefore, will not be subject to the same new or revised accounting standards as other
public companies that are not emerging growth companies.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Results
of Operations for Three Months Ended June 30, 2019 and Compared to Three Months Ended June 30, 2018</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> <FONT STYLE="font-size: 10pt">For
the quarters ended June 30:</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2019 </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2018 </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"> Operating expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"> Professional expenses&#9; </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 8%; text-align: right"> 287,831 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 8%; text-align: right"> 41,710 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"> Research and development&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 703,783 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,789 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"> General and administrative&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 146,626 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 77,691 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"> Total operating expenses&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 1,138,240 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 255,190 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"> Operating loss&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,138,240 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (255,190 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"> Interest income&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 16,042 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,624 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"> Income tax&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &mdash; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"> Net loss&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (1,122,198 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (249,566 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Overview:
</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
reported a net loss of $1,122,198 and $249,566 for the three months ended June 30, 2019 and 2018, respectively. The increase in
our net loss is primarily due to an increase in our research and development expenses.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Operating
Expenses:</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">During
the three months ended June 30, 2019, professional expenses increased by 590.1% to $287,831, as compared to $41,710 for the quarter
ended June 30, 2018. The increase is primarily due to an increase in fees paid to outside consultants and professional services
required for our required filings.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">For
the three months ended June 30, 2019, research and development expenses increased by 418.3% to $703,783 as compared to $135,789
for the quarter ended June 30, 2018. The increase in research and development expenses is primarily due to increased engineering
headcount and increasing outside expenses necessary to the design and development of our innovative insulin pump. By &ldquo;increasing
outside expenses,&rdquo; we mean that, as we continue to implement product design enhancements and progress along the path to
FDA clearance, these expenses will escalate.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">For
the three months ended June 30, 2019, general and administrative expenses increased by 88.7% to $146,626 as compared to $77,691
for the quarter ended June 30, 2018. The increase in our general and administrative expense is attributable primarily to an increase
in employee related cost.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Interest
Income:</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Interest
income for the three months ended June 30, 2019 and 2018 was $16,042 and $5,624, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
following tables summarizes our cash flows for the three months ended June 30, 2019 and June 30, 2018.</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"> 2019 </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"> 2018 </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"> Cash used in operating activities&#9; </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 8%; text-align: right"> (840,421 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 8%; text-align: right"> (236,219 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"> Cash used in investing activities&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (6,719 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (6,170 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt; text-indent: -8.65pt"> Cash provided by financing
    activities&#9; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &mdash; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (516 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"> Net change in cash and cash
    equivalents&#9; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (847,140 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (242,905 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt; text-indent: -8.65pt"> Cash and cash equivalents
    at beginning of period&#9; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 6,553,768 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 4,296,676 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt"> Net change in cash&#9; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 5,706,628 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 4,053,771 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">As
a development stage enterprise, the Company does not currently have revenues to generate cash flow to cover operating expenses.
The Company has historically raised capital through the 2017 Private Placement and the 2018 Private Placement. Management expects
to continue to raise capital through future equity offerings in order to finance its operations.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">As
of June 30, 2019, we had total current assets of $5,716,128 of which $ 5,706,628 were cash and cash equivalents, and current liabilities
of $253,474. As of March 31, 2019, we had total current assets of $6,569,358, of which $6,553,768 were cash and cash equivalents
and current liabilities of $178,929. As of June 30, 2019 and March 31, 2019, we had working capital of approximately of $5,462,654
and $6,390,429, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Net
Cash Used In Operating Activities</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
used $840,421 of cash to fund operating activities during the three months ended June 30, 2019, compared to $236,219 during the
comparable period in 2018. Increased cash usage was due to increasing operating expenses to fund research and development.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Net
Cash Used In Investing Activities</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">We used $6,719
of cash to purchase equipment during the three months ended June 30, 2019, compared to $6,170 during the three months ended June
30, 2018.</FONT> </P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Net
Cash Used In Financing Activities</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">We
used no cash for financing activities during the three months ended June 30, 2019, compared to $516 during the prior year quarter.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">As
of June 30, 2019, we had not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current
or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that is material to investors.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Results
of Operations for Fiscal Year Ended March 31, 2019 and Compared to Fiscal Year Ended March 31, 2018</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> <FONT STYLE="font-size: 10pt">For
the fiscal years ended March 31:</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Professional expenses&#9;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">260,396</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">232,961</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Research and development&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,882,345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">332,642</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"> General and administrative&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 4,34,558 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 100,561 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"> Total operating expenses&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 2,577,299 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 666,164 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Operating loss&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,577,299</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(666,164</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Interest income&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,390</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,518</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"> Income tax&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (1,589 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (1,600 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"> Net loss&#9; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (2,539,498 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (659,246 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We reported
a net loss of $2,539,498 and $659,246 for the fiscal years ended March 31, 2019 and 2018, respectively. The increase in our net
loss is primarily due to an increase in our research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Operating
Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">During
the fiscal year ended March 31, 2019, professional expenses increased by 12% to $260,396, as compared to $232,961 for the prior
fiscal year. The increase is primarily due to an increase in fees paid for consulting fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">During
the fiscal year ended March 31, 2019, research and development expenses increased by 466% to $1,882,345 as compared to $332,642
for the prior fiscal year. The increase in research and development expenses is primarily due to increased engineering headcount
and increasing outside expenses necessary to the design and development of our innovative insulin pump. By &ldquo;increasing
outside expenses,&rdquo; we mean that, as we continue to implement product design enhancements and progress along the path to
FDA clearance, these expenses will escalate. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">During
the fiscal year ended March 31, 2019, general and administrative expenses increased by 332% to $434,558 as compared to $100,561
for the prior fiscal year. The increase in our general and administrative expense is attributable primarily to an increase in
employee related cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Interest
Income</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Interest
income for  the fiscal year ended March 31, 2019 and 2018 was $39,390 and $8,518, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">The following
tables summarizes our cash flows for the fiscal years ended March 31, 2019 and March 31, 2018.</FONT> </P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Cash used in operating activities&#9;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">(1,807,934</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">(791,131</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Cash used in investing activities&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(77,124</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,332</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt; text-indent: -8.65pt">Cash provided by financing activities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,142,150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,711,132</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Net change in cash and cash equivalents&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,257,092</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,904,669</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt; text-indent: -8.65pt">Cash and cash equivalents at beginning of period&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,296,676</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">392,007</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Net change in cash&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,553,768</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,296,676</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">As
a development stage enterprise, the Company does not currently have revenues to generate cash flow to cover operating expenses.
The Company has historically raised capital through the 2017 Private Placement and the 2018 Private Placement. Management expects
to continue to raise capital through future equity offerings in order to finance its operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">As
of March 31, 2019, we had total current assets of $6,569,358 of which $ 6,553,768 were cash and cash equivalents, and current
liabilities of $178,929. As of March 31, 2018, we had total current assets of $4,313,480 and current liabilities of $15,471. As
of March 31, 2019 and 2018, we had working capital of approximately of $6,390,429 and $4,298,009, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Net
Cash Used In Operating Activities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We
used $1,807,934 of cash to fund operating activities during the fiscal year ended March 31, 2019, compared to $791,131 in 2018.
Increased cash usage during the recent fiscal year was due to increasing operating expenses to fund research and development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Net
Cash Used In Investing Activities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We
used $77,124 of cash to purchase equipment and intangible assets during the fiscal year ended March 31, 2019, compared to $15,332
in the prior fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Net
Cash Provided By Financing Activities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
2018 Private Placement accounted for an increase of $4,142,150 of cash from financing activities during fiscal year ended March
31, 2019, compared to $4,711,132 for the year ended March 31, 2018.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">As
of March 31, 2019, we had not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current
or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that is material to investors.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Critical
Accounting Policies and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Use
of Estimates</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The preparation
of financial statements in conformity with accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;)
requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting
periods. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could materially
differ from those estimates.</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara011"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The following
table sets forth information with respect to each of our directors, including their current principal occupation or employment
and age as of June 30, 2019.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 15%; border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></td>
    <TD STYLE="width: 8%; border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Age</B></FONT></td>
    <TD STYLE="width: 77%; border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Paul DiPerna</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">60</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Executive Officer, Chief Financial
    Officer, Secretary, Treasurer and Director (Chairman of the Board)</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Liam Burns</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">53</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Morgan C. Frank</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">47</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Paul
DiPerna</B>&nbsp;is and has been since our July 24, 2017 acquisition of Quasuras, our chairman, chief executive officer, chief
financial officer, secretary and treasurer.</FONT> <FONT STYLE="font-size: 10pt"> Mr. DiPerna began his career in approximately
1980 as a mechanical design engineer in the automated test equipment industry before moving in approximately 1989 to a start-up
in the blood separation sciences industry. This company was eventually acquired in approximately 1991 by Baxter Healthcare (&ldquo;Baxter&rdquo;).
Following such acquisition, Mr. DiPerna became employed by Baxter and held various positions during his approximate 12 years at
Baxter. While at Baxter, Mr. DiPerna worked on numerous projects and initiatives including leading a team of approximately
50 engineers in developing equipment in the blood separation sciences industry. In approximately 1996, Mr. DiPerna was promoted
to General Manager of Baxter&rsquo;s business development group to identify targets for Baxter&rsquo;s expansion opportunities
in the medical device industry. While holding such position, Mr. DiPerna led a team researching custom orthopedics, digital
dentistry and rapid prototyping. In such role, one of Mr. DiPerna&rsquo;s assignments was identifying synergistic opportunities
in the diabetes industry.&nbsp; As a result, Mr. DiPerna developed substantial expertise and knowledge in the diabetes industry
and led attempts by Baxter to acquire three insulin pump manufacturers. In 2003, Mr. DiPerna left Baxter and founded what subsequently
became Tandem Diabetes Care, Inc. (&ldquo;Tandem&rdquo;). While at Tandem, Mr. DiPerna held various positions, including as director,
chief executive officer and chief technology officer and was primarily responsible for the design concept and development of Tandem&rsquo;s
initial insulin pump, which subsequently was commercialized by Tandem. Tandem is a medical device company that designs, develops
and commercializes products for people with insulin dependent diabetes. In 2011,<B>&nbsp;</B>Mr. DiPerna resigned from his
executive officer position and board seat at Tandem but continued to assist the company through 2013. In approximately January,
2012, Mr. DiPerna was the co-inventor with regard to a private company with property rights in a medical device used for blood
borne infection control called the &ldquo;Curos Cap.&rdquo; Curos Cap was acquired by 3M Corporation in 2015. Thereafter, Mr.
DiPerna founded a company, Fuel Source Partners, LLC (&ldquo;FSP&rdquo;), where he is the manager of, to incubate early stage
medical device products and accumulate technical talent. One of such proposed products was spun-out to Quasuras in March 2015,
which we acquired in July 2017. Mr. DiPerna owns a variety of, patents and patents pending and is a member of the American
Diabetes Association. Mr. DiPerna received a Masters in Engineering Management from Northeastern University and a BS in Mechanical
Engineering from the University of Lowell.&nbsp; In January 2017, Mr. DiPerna joined National Cardiac Incorporated (&ldquo;Cardiac&rdquo;)
as the chief executive officer and a board member to leverage Cardiac&rsquo;s technology in the cardiac monitoring space. In addition
to FSP and Cardiac, Mr. DiPerna is one of 3 owners of Patient Focused Innovation Partners (&ldquo;PFIP&rdquo;), a company that
manages patent applications with regard to a gastric delivery system. Mr. DiPerna has informed us that he devotes less than 3
hours per month in the aggregate to his activities with FSP, Cardiac and PFIP, which he expects to further decrease over time.
We believe that Mr. DiPerna is qualified to serve as the chairman of our board of directors due to his extensive knowledge and
experience in the medical device industry generally, and, in particular, with regard to insulin pumps and the diabetes industry
as well as his management and leadership experience from holding director and senior executive positions in other public and private
companies and leading project development teams of medical device companies. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Liam Burns
</B>was elected a director of the Company in January 2019. Since that time, he has also been the Chief Executive Officer of Endo-TAGSS,
LLC, a privately-held company developing a novel surgical access system for treatment of gastrointestinal diseases. From December
2017 to December 2018, Mr. Burns was the Chief Executive Officer of CuraSeal Inc., a privately-held regenerative medical company.
From January 2014 to March &nbsp;2018, he was the Vice President, Global Sales and Marketing for Dextera Surgical Inc., which
marketed the world&rsquo;s smallest surgical stapler. Dexteria Surgical Inc. filed for bankruptcy protection on December 11, 2017
and was subsequently sold to B. Braun Aesculap in 2018. From January 2013 to September 2016, Mr. Burns was the managing member
and majority interest holder in Bensi Flemington LLC., which operated a restaurant in Flemington, New Jersey. Bensi Flemington
LLC filed for bankruptcy protection on August 11,2015. Prior to that, Mr. Burns held a variety of commercial leadership roles
at Ethicon (JNJ) and various early stage medical device companies. Mr. Burns received a B.A. in Economics from the College of
the Holy Cross and an Executive MBA from the Weatherhead School of Management at Case Western Reserve University. We believe
that Mr. Burns is qualified to serve as a member of our board of directors due to his extensive experience and background in developing
and launching new medical technologies, commercial strategy, marketing and branding, as well as his experience in metabolic health. </FONT></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Morgan
C. Frank</B> is and has been a director of the Company since April 26, 2017. Mr. Frank has worked with Manchester Explorer since
May 2002, and prior to such time, he was a founder and managing director at First Principles Group, a boutique consultancy and
principal investor specializing in corporate restructuring, restarts, intellectual property assessment and salvage, and spin outs.
Prior to such time, Mr. Frank spent approximately five years as an analyst and portfolio manager at Hollis Capital, a San Francisco
based hedge fund and prior thereto, Mr. Frank worked for an independent private client group at Paine Webber specializing in primary
research to develop investment ideas (particularly short sale ideas) for institutional clients. Prior to his employment at Paine
Webber, Mr. Frank was a currency trader for Eastern Vanguard. Mr. Frank holds a BA in Economics and in Political Science from
Brown University. We believe that Mr. Frank is qualified to serve as member of our board of directors due to his extensive
prior experience conducting financial analysis of public companies (certain of which were in the development stage), including
such public companies&rsquo; management teams, products, including products in the development stage, the potential markets for
such products and other factors that could effect the likelihood and timing of success and market penetration of such entities&rsquo;
products as well as his capital raising activities. We believe this provides us with valuable insights into the financial markets
and investment criteria of institutional and other investors as well as capital raising activities. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Arrangements
for Appointment of Directors</B>.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Until
July 24, 2022, our board of directors shall consist of no more than five (5) and no less than two (2) directors of which (i) Manchester
has the right to appoint two (2) directors, one of whom is Mr. Frank, and (ii) Mr. DiPerna, in addition to being our Chairman,
has the right to appoint 2 additional directors, one of which is Mr. Burns. See &ldquo;Risk Factors - If the beneficial ownership
of our stock continues to be highly concentrated, it may prevent you and other shareholders from influencing significant corporate
decisions; right of certain parties to appoint directors.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Significant
Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Marc
Goldman, our Head of Engineering, is expected to make a significant contribution to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Involvement
in Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Except
with regard to Mr. Burns, to the Company&rsquo;s knowledge, none of our officers or our directors has, during the last ten years:</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">been
                                         convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding
                                         traffic violations and other minor offenses);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">had
                                         any bankruptcy petition filed by or against the business or property of the person, or
                                         of any partnership, corporation or business association of which he was a general partner
                                         or executive officer, either at the time of the bankruptcy filing or within two years
                                         prior to that time;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">been
                                         subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
                                         of any court of competent jurisdiction or federal or state authority, permanently or
                                         temporarily enjoining, barring, suspending or otherwise limiting, his involvement in
                                         any type of business, securities, futures, commodities, investment, banking, savings
                                         and loan, or insurance activities, or to be associated with persons engaged in any such
                                         activity;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">been
                                         found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity
                                         Futures Trading Commission to have violated a federal or state securities or commodities
                                         law, and the judgment has not been reversed, suspended, or vacated;</FONT></TD></TR></TABLE>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">been
                                         the subject of, or a party to, any federal or state judicial or administrative order,
                                         judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including
                                         any settlement of a civil proceeding among private litigants), relating to an alleged
                                         violation of any federal or state securities or commodities law or regulation, any law
                                         or regulation respecting financial institutions or insurance companies including, but
                                         not limited to, a temporary or permanent injunction, order of disgorgement or restitution,
                                         civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition
                                         order, or any law or regulation prohibiting mail or wire fraud or fraud in connection
                                         with any business entity; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">been
                                         the subject of, or a party to, any sanction or order, not subsequently reversed, suspended
                                         or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the
                                         Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity
                                         Exchange Act), or any equivalent exchange, association, entity or organization that has
                                         disciplinary authority over its members or persons associated with a member.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">To the
Company&rsquo;s knowledge, there are no material proceedings to which any director, officer or affiliate of the Company, any owner
of record or beneficially of more than 5% of any class of voting securities of the Company, or any associate of any such director,
officer, affiliate of the Company, or security holder is a party adverse to the Company or any of its subsidiaries or has a material
interest adverse to the Company or any of its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>The
DiPerna Employment and Related Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We have
entered into an employment agreement dated August 1<SUP>st</SUP>, 2018 with Mr. DiPerna pursuant to which Mr. DiPerna is employed
by us as our Chief Executive Officer and President for a 2-year term with automatic one-year renewals. Pursuant to such agreement,
we have agreed to pay Mr. DiPerna an annual salary of $200,000, plus $100,000 per year in stock options with an exercise price
of $0.66 per share or a price determined by the board of directors in its sole discretion and an annual bonus of $300,000, payable
at the discretion of the board of directors in its sole discretion, either in shares of stock or in cash. If the Board chooses
to pay the bonus in shares of stock, such shares will be valued at $0.66 per share or a price determined by the board of directors.
In addition, pursuant to our employment agreement with Mr. DiPerna, in the event that we terminate Mr. DiPerna&rsquo;s employment
without cause or he resigns with good reason, we will pay Mr. DiPerna a lump sum of $200,000. In the event that we terminate Mr.
DiPerna&rsquo;s employment for cause, we are not obligated to make any severance payment and Mr. DiPerna will receive only his
base compensation through the last day of his employment. In the event of Mr. DiPerna&rsquo;s death or disability, he will receive
his base compensation through the last day of his employment and will remain eligible for all applicable benefits relative to
death or disability pursuant to any plans that we have in place at such time. In the event of a &ldquo;change in control&rdquo;
(as defined in the employment agreement), Mr. DiPerna will be paid a lump sum of $100,000 within sixty days of the time at which
such change of control takes place. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">In
connection with our July 24, 2017 acquisition of Quasuras, we entered into an Intellectual Property Transfer Agreement dated as
of July 24, 2017, with Quasuras and Mr. DiPerna (the &ldquo;IP Transfer Agreement&rdquo;), pursuant to which Mr. DiPerna transferred
to us all intellectual property rights owned directly and/or indirectly by him related to our business.</FONT> <FONT STYLE="font-size: 10pt">
Also in connection with the Acquisition, we agreed to pay Mr. DiPerna as part of his compensation for services to be performed
for us pursuant to a Technology and Royalty Agreement, dated as of July 24, 2017 (the &ldquo;Royalty Agreement&rdquo;), certain
fees based upon future sales, if any, of our potential product subject to a maximum $10,000,000 cap on the aggregate amount of
fees that Mr. DiPerna could earn from such arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Mr. DiPerna
is subject to confidentiality, non-compete and invention agreements with us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">There are
no family relationships among the members of our board of directors or our executive officers.</FONT> </P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Composition
of the Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">In
accordance with our articles of incorporation, our board of directors is to be elected annually as a single class. However, pursuant
to our by-laws, in lieu of electing the entire number of directors annually, our board may provide that the directors be divided
into either two or three classes, each class to be as nearly equal in number as possible, the term of office of the directors
of the first class to expire at the first annual meeting of shareholders after their election, that of the second class to expire
at the second annual meeting after their election, and that of the third class, if any, to expire at the third annual meeting
after their election. At each annual meeting after such classification, the number of directors equal to the number of the class
whose term expires at the time of such meeting shall be elected to hold office until the second succeeding annual meeting, if
there be two classes, or until the third succeeding annual meeting, if there be three classes. To date, no such election has been
made by our board. Pursuant to the July 24, 2017 agreement pursuant to which we acquired Quasuras, until July 24, 2022, our board
of directors will consist of no less than 2 and no more than 5 directors, of which Mr. DiPerna in addition to being the chairman
of our board has the right to appoint 2 directors, of which Mr. Burns constitutes one and Manchester has the right to appoint
2 directors, of which Mr. Frank constitutes 1 such director. As a result, until July 24, 2022, our shareholders will not have
the ability to elect any directors either at the annual meeting or by written consent, even if our shareholders believe that our
board of directors is taking actions to which the shareholders object. See &ldquo;Risk Factors - If the beneficial ownership of
our stock continues to be highly concentrated, it may prevent you and other shareholders from influencing significant corporate
decisions; right of certain parties to appoint directors.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Communications
with our board of directors </B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Our
stockholders may send correspondence to our board of directors c/o the corporate secretary at the address set forth on the cover
page of this prospectus. Our corporate secretary will forward stockholder communications to our board of directors prior to the
board of director&rsquo;s next regularly scheduled meeting following the receipt of the communication.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Corporate
Governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Board
Leadership Structure and Role in Risk Oversight</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Due to
the small size and early stage of the Company, we have not adopted a formal policy on whether the chairman and chief executive
officer positions should be separate or combined. Our board of directors is primarily responsible for overseeing our risk management
processes on behalf of the Company. Our board of directors receives and reviews periodic reports from management, auditors, legal
counsel, and others, as considered appropriate regarding our company&rsquo;s assessment of risks. Our board of directors will
focus on the most significant risks facing us and our general risk management strategy, and also ensure that risks undertaken
by our Company are consistent with the Board of Director&rsquo;s appetite for risk. While the board of directors oversees our
Company&rsquo;s risk management, management is responsible for day-to-day risk management processes. We believe this division
of responsibilities is the most effective approach for addressing the risks facing us and that our board leadership structure
supports this approach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Nominating
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We have
not established a Nominating Committee because, due to our lack of operations and the fact that we only have three (3) directors
and one (1) executive officer, we believe that we are able to effectively manage the issues normally considered by a Nominating
Committee. A further review of this issue will be undertaken by the new management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">If
we do establish a Nominating Committee, we will disclose this change to our procedures in recommending nominees to our board of
directors.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We have
not established an Audit Committee because, due to our lack of material operations and the fact that we only have three (3) directors
and one (1) executive officer, we believe that we are able to effectively manage the issues normally considered by an Audit Committee.
A further review of this issue will be undertaken by the new management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Director
Independence</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">As
of June 30, 2019, Liam Burns, who was appointed as a director in January 2019 is our only director considered to be independent,
in as much as he does not beneficially own greater than a 10% ownership interest in our common stock and is unrelated to any of
our shareholders who hold any such interest.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">We are not
a &ldquo;listed issuer&rdquo; as that term is used in Regulation S-K Item 407 adopted by the SEC.</FONT> </P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara012"></A>EXECUTIVE
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>All
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">On
October 19, 2017, our board of directors approved the 2017 Equity Incentive Plan (&ldquo;EIP&rdquo;) that reserves 3,000,000 shares
of common stock of the Company to be issued thereunder. Under the Company&rsquo;s EIP, eligible employees, directors and consultants
are granted options to purchase shares of common stock of the Company. The EIP is administered by the Company&rsquo;s board of
directors or, in the alternative, if necessary, a committee designated by the board of directors, and has the sole power over
the exercise of the EIP. The board of directors determines whether the EIP will allow for the issuance of shares of common stock
or an option to purchase shares of common stock, such option designated as either an incentive stock option or a non-qualified
stock option.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The exercise
or purchase price shall be calculated as follows:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.28in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">In
                                         the case of an incentive stock option, (A) granted to employees, directors and consultants
                                         who, at the time of the grant of such incentive stock option own stock representing more
                                         than ten percent (10%) of the voting power of all classes of stock of the Company, the
                                         per share exercise price shall be not less than one hundred ten percent (110%) of the
                                         fair market value per share on the date of grant; or (B) granted to employees, directors
                                         and consultants other than to employees, directors and consultants described in the preceding
                                         clause, the per share exercise price shall be not less than one hundred percent (100%)
                                         of the fair market value per share on the date of grant;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.28in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(ii)</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">In
                                         the case of a non-qualified stock option, the per share exercise price shall be not less
                                         than one hundred percent (100%) of the fair market value per share on the date of grant
                                         unless otherwise determined by the board of directors; and</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.28in; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(iii)</FONT> </TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">In
                                         the case of other grants, such price as is determined by the board of directors.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
board of directors is responsible for determining the consideration to be paid for the shares of common stock to be issued upon
exercise or purchase. The EIP generally does not allow for the transfer of the options, and the board of directors may amend,
suspend or terminate the EIP at any time.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">On August
15<SUP>th</SUP>, September 15<SUP>th</SUP> and October 15<SUP>th</SUP>, 2018, the Company granted 54,039 options to Mr. DiPerna
in lieu of salary. The options expire on August 14<SUP>th</SUP>, September 14<SUP>th</SUP> and October 14<SUP>th</SUP>, 2028 and
vest immediately. The fair value of these options, determined to be $24,840, was included in general and administrative and
research and development expenses for the relevant period. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">On November
15<SUP>th</SUP> and December 15<SUP>th</SUP> 2018, the Company granted 10,648 options to Mr. DiPerna in lieu of salary. The options
expire on November 14<SUP>th</SUP>, and December 14<SUP>th</SUP>, 2028 and vest immediately. The fair value of these options,
determined to be $17,921, was included in general and administrative and research and development expenses for the relevant period. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">On January
16, 2019, the Company granted 90,000 options to Mr. Burns. These options will be fully vested three years from the grant date,
and the vesting schedule provides that 33% of such options will vest on the first anniversary of the grant date. The 90,000 options
will expire on January 15, 2029. The fair value of the options was determined to be $163,620, of which the Company had recorded
$24,478 as and was included in general and administrative and research and development expenses for the period from January 15
through June 30, 2019. On April 15 and May 15, 2019, the Company granted 8,907 options to Mr. Burns. These options were fully
vested on the grant dates and will expire on April 14 and May 14. 2029, respectively. The fair value of the 8,907 options was
determined to be $15,000 and was recorded and was included in general and administrative and research and development expenses
during the quarter ended June 30, 2019. The following assumptions were used in the fair-value method calculation: volatility:
97.49%-104%; risk free rate of return: 2.15%-2.54%; and expected term: 5-5.88 years</FONT> </P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The following
table sets forth the aggregate compensation paid by us for services rendered during the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>SUMMARY
COMPENSATION TABLE (Executive Officers and Directors)</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0">Name and <BR> Principal<BR> Position</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year<BR> Ended<BR> March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock<BR> Awards<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR> Awards<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Equity<BR> Incentive<BR> Plan<BR> Compensation<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Qualified<BR> Deferred<BR> Compensation<BR> Earnings<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All<BR> Other<BR> Compensation<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 10%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Paul DiPerna,&#9;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">2019</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">192,510</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-0-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-0-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right"> 42,761 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-0-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-0-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-0-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 6%; text-align: right"> 235,271 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Secretary, Treasurer and Director (1) CEO,
    CFO,&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">105,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">135,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Morgan Frank, Director&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> -0- </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-left: 8.65pt; text-indent: -8.65pt">Liam Burns, Director (2)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 11,249 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 21,249 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Mr.
                                         DiPerna was named Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer
                                         and a Director of the Company on July 24, 2017 at an annual salary base of $180,000,
                                         which was increased to $300,000 in August 2018. Pursuant to his employment agreement
                                         then in effect,&nbsp;for the fiscal year ending March 31, 2018, Mr. DiPerna had received
                                         $105,000 as a consultant and $30,000 in salary which represented his base compensation
                                         through the end of that reporting period. &nbsp;During this period, the Company did not
                                         have employees, only consultants.&nbsp; The Company implemented a payroll provider through
                                         ADP in February 2018&nbsp;and certain key consultants, including Mr. DiPerna, were added
                                         to the Company&rsquo;s payroll as employees. On August 15<SUP>th</SUP>, September 15<SUP>th</SUP>&nbsp;and
                                         October 15<SUP>th</SUP>, 2018, the Company granted 54,039 options to Mr. DiPerna in lieu
                                         of salary. The options expire on August 14<SUP>th</SUP>, September 14<SUP>th</SUP>&nbsp;and
                                         October 14<SUP>th</SUP>, 2028 and vest immediately. The fair value of these options was
                                         determined to be $24,840. On November 15<SUP>th</SUP>&nbsp;and December 15<SUP>th</SUP>&nbsp;2018,
                                         the Company granted 10,648 options to Mr. DiPerna in lieu of salary. The options expire
                                         on November 14<SUP>th</SUP>, and December 14<SUP>th</SUP>, 2028 and vest immediately.
                                         The fair value of these options was determined to be $17,921. The following assumptions
                                         were used in the fair value method calculation: volatility: 71%&nbsp;&ndash; 112%; risk
                                         free rate of return: 2.73% &ndash; 3.01%; and expected term: 5 years. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Mr.
                                         Burns entered into a services contract to serve on our Board of Directors for an annual
                                         retainer of $10,000 paid quarterly together with a grant of 90,000 non-qualified stock
                                         options under our EIP with a three year vesting period and an exercise price of $2.25
                                         per share. On January 16, 2019, the Company granted 90,000 options to Mr. Burns, these
                                         options will be fully vested three years from the date granted (the vesting schedule
                                         provides that 33% of such options will vest on the first anniversary of the grant date).
                                         The 90,000 options will expire on January 15, 2029. The fair value of the options 90,000
                                         shares was determined to be $163,620 and $24,478 had accrued as of June 30, 2019. On
                                         April 15<SUP>th</SUP> and May 15<SUP>th</SUP> 2019, the Company granted 8,907 options
                                         to Liam Burns, these options will be fully vested on the grant date. The 8,907 options
                                         will expire on April 14 and May 14, 2029. The fair value of the 8,907 options was determined
                                         to be $15,000. The following assumptions were used in the fair value method calculation:
                                         volatility: 97.49% - 104%; risk free rate of return: 2.15% - 2.54%; and expected term:
                                         5 - 5.88 years.</FONT> </TD></TR></TABLE>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Outstanding
Equity Awards at Fiscal Year-End</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
following table shows certain information regarding outstanding equity awards held by our named executive officers and
director as of June 30, 2019. All option awards were granted under our EIP.</FONT> </P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Option
    Awards</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Name</FONT></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Number
    of<BR> Securities<BR> Underlying<BR> Unexercised<BR> Options<BR> Exercisable</FONT></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Number
    of<BR> Securities<BR> Underlying<BR> Unexercised<BR> Options<BR> Unexercisable</FONT></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Option<BR>
    Exercise<BR>
    Price</FONT></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Option<BR>
    Expiration<BR> Date</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Paul DiPerna</FONT></TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">18,013</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.66</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">08/14/2028</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">18,013</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.66</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">09/14/2028</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">18,013</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.66</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">10/14/2028</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">5,324</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">2.25</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">11/14/2028</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">5,324</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">2.25</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">12/14/2028</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Liam Burns</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">90,000</FONT><FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"></FONT>2.25</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">01/15/2029</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">4,382</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 2.25 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 04/14/2029 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">4,525</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 2.25 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> 05/14/2029 </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0; margin-top: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0"><FONT STYLE="font-size: 10pt"><B>Compensation
of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">Mr. Burns
entered into an agreement effective as of January 16, 2019 to serve on our board of directors for an annual retainer of $10,000,
paid quarterly, and a grant of 90,000 non-qualified stock options under our EIP with 3-year vesting and an exercise price of $2.25
per share. On April 15 and May 15, 2019, the Company granted 8,907 options to Mr. Burns at an exercise price of $2.25 per share.</FONT> </P>



<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara013"></A>STOCK
OWNERSHIP BY PRINCIPAL SHAREHOLDERS AND MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The
following table sets forth information as of June 30, 2019, concerning, except as indicated by the footnotes below: (i) each person
or group whom we believe beneficially owns more than 5% of our common stock; (ii) each of our directors, (iii) each of our executive
officers; and (iv) each of our directors and executive officers as a group. The following table assumes none of the persons set
forth in such table have sold any shares held by such persons pursuant to this prospectus.</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">We
                                         have determined beneficial ownership in accordance with the rules of the SEC. SEC Rule
                                         13d-3 generally provides that beneficial owners of securities include any person who,
                                         directly or indirectly, has or shares voting power and/or investment power with respect
                                         to such securities, and any person who has the right to acquire beneficial ownership
                                         of such security within 60 days. Any securities not outstanding which are subject to
                                         such options, warrants or conversion privileges exercisable within 60 days are treated
                                         as outstanding for the purpose of computing the percentage of outstanding securities
                                         owned by that person. Such securities are not treated as outstanding for the purpose
                                         of computing the percentage of the class owned by any other person.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Except
                                         as indicated by the footnotes below, we believe, based on the information furnished to
                                         us, that the persons and entities named in the table below have sole voting and investment
                                         power with respect to all shares of common stock that they beneficially own, subject
                                         to applicable community property laws.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The
                                         information provided in the table is based on our records, information filed with the
                                         SEC, and information provided to us, except where otherwise noted.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><FONT STYLE="font-size: 10pt">Name
    of Beneficial Owner</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Common<BR>
    Stock<BR> Beneficially<BR> Owned</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Percentage
    of<BR> Common<BR> Stock (1)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><FONT STYLE="font-size: 10pt">Directors
    and Officers:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 74%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Paul
    DiPerna (2)&#9;</FONT></TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">7,638,117</FONT> </TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">42.74</FONT> </TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Morgan
    C. Frank (3)&#9;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">6,384,691</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">35.73</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Liam
    Burns (4)&#9;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">8,907</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">All
    officers and directors as a group (3 persons) (5)&#9;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">14,031,715</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">78.52</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><FONT STYLE="font-size: 10pt">Beneficial
    owners of more than 5%:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">James
    E. Besser (6)&#9;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">6,384,691</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">35.73</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Manchester
    Management LLC (MMC) (6)&#9;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">6,384,691</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">35.73</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Manchester
    Explorer, L.P. (Manchester) (6)&#9;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">6,384,691</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">35.73</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">JEB
    Partners, L.P. (JEB Partners) (6)&#9;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">6,384,691</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">35.73</FONT> </TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">%</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10 0.25in; text-align: justify; text-indent: -0.25in"> <FONT STYLE="font-size: 10pt">*
Represents less than 1%</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Based
                                         upon 17,870,261 shares of our common stock outstanding on June 30, 2019.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">See
                                         footnote 11 to the selling shareholders table set forth in &ldquo;Selling Shareholders.&rdquo;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Includes
                                         (i) 180,830 shares directly held and received in the Acquisition in exchange for Mr.
                                         Frank&rsquo;s shares of Quasuras; (ii) 4,545,455 shares purchased by Manchester in the
                                         2017 Placement; (iii) 471,111 shares purchased by Manchester in the 2018 Placement; (iv)
                                         757,576 purchased by JEB Partners in the 2017 Placement; (vii) 160,000 shares purchased
                                         by JEB Partners in the 2018 Placement, and (viii) 269,717 shares held by Mr. Besser.
                                         Mr. Frank is one of our directors and 1 of 2 directors that MMC has the right to appoint
                                         to our board of directors pursuant to the 2017 Acquisition Agreement. Mr. Besser
                                         as the managing member and Mr. Frank as the portfolio manager and a consultant to MMC,
                                         the General Partner of Manchester and JEB Partners, Mr. Frank have shared voting and
                                         dispositive power of the shares owned by Manchester and JEB Partners. The address for
                                         Mr. Frank is c/o Manchester Management, LLC, 3 West Hill Place, Boston, MA 02114. Such
                                         person disclaims beneficial ownership of all shares not held directly by such person
                                         and this prospectus shall not be deemed an admission that such person is the beneficial
                                         owner of such shares, except to the extent of such persons pecuniary interest therein. </FONT></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Mr.
                                         Burns was appointed a director to our Board in January 26, 2019. Includes 8,907 shares
                                         of common stock issuable upon vested stock options granted to Mr. Burns under our EIP
                                         in April and May 2019 and excludes 90,000 shares of common stock issuable upon unvested
                                         stock options granted to Mr. Burns under our EIP in January 2019, in each case, at an
                                         exercise price of $2.25 per share. See &ldquo;Executive Compensation &ndash; All
                                         Compensation.&rdquo;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">See
                                         footnotes 2, 3, and 4.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">See
                                         footnote 8 to the selling shareholders table set forth in &ldquo;Selling Shareholders.&rdquo;</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara014"></A>RELATED
PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">A &ldquo;Related
Party Transaction&rdquo; means a transaction (including any series of related transactions or a material amendment or modification
to an existing Related Party Transaction) directly or indirectly involving any Related Party that would need to be disclosed under
Item 404(a) of Regulation S-K. Generally, under Item 404(a) of Regulation S-K, we are required to disclose any transaction
occurring since the beginning of the last two fiscal years preceding our last fiscal year, or any currently proposed transaction,
involving us or our subsidiary where the amount involved exceeds the lesser of (i) $120,000 or (ii) one percent of the average
of the Company&rsquo;s total assets at year-end for the last two completed fiscal years, and in which any Related Party had or
will have a direct or indirect material interest. A &ldquo;Related Party&rdquo; means any of the following: (i) any of our
directors of the Company or Director Nominees; (ii) any of our executive officers; (iii) a person known by us to be the beneficial
owner of more than 5% of our common stock or (iv) an immediate family member of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Except
as provided elsewhere in this prospectus with regard to Mr. DiPerna, no director, executive officer or affiliate of ours or owner
of record or beneficially of more than five (5%) percent of our common stock is a party to a Related Party Transaction with us.
See &ldquo;Management &ndash; The DiPerna Employment and Related Agreements.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara015"></A>MARKET
FOR OUR COMMON STOCK AND RELATED SHAREHOLDER MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Market
Information</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our common
stock is currently quoted on the OTC Pink Markets under the trading symbol &ldquo;MODD&rdquo;. As is typical for stocks quoted
on the OTC Pink Markets, trading in shares of our common stock is limited and sporadic. There is no established trading market
for shares of our common stock and no assurances can be given that any such trading market will develop or be maintained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">For the
periods indicated, the following table sets forth the high and low bid prices per share of common stock based on inter-dealer
prices, without retail mark-up, mark-down or commission and may not represent actual transactions. The below prices were obtained
from the OTC Market Group, Inc.</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> <FONT STYLE="font-size: 10pt">Fiscal
    Year ended March 31, 2018</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">High
    Bid</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Low
    Bid</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 74%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">First Quarter</FONT></TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Second Quarter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Third Quarter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Fourth Quarter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 8.65pt"> <FONT STYLE="font-size: 10pt">Fiscal
    Year ended March 31, 2019</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>High
    Bid</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Low
    Bid</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">First Quarter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Second Quarter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.38</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Third Quarter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1.01</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">0.20</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Fourth Quarter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1.01</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1.01</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">On
September 4, 2019, the closing price of our common stock was $0.20 per share.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Number
of Equity Security Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">As
of June 30, 2019, we had 91 holders of record of our common stock.</FONT> <FONT STYLE="font-size: 10pt"> This does not include
beneficial owners holding common stock in street name. As such, the number of beneficial holders of our shares could be substantially
larger than the number of shareholders of record.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara016"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The validity
of the securities offered in this prospectus is being passed upon for us by Gusrae Kaplan Nusbaum PLLC, New York, New York.</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara017"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We file
annual, quarterly and current reports and other information with the SEC, as required by the Exchange Act. The SEC maintains a
site on the internet at http://www.sec.gov/ which contains reports and other information that we file electronically with the
SEC. You may also review such reports and other documents we file with the SEC on our website at www.modular-medical.com. Information
included on our website is not a part of this prospectus. Our SEC reports and registration statements are also available from
commercial document retrieval services, such as CCH Washington Service Bureau, whose telephone number is 1-800-955-0219.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We have
filed a Registration Statement on Form S-1 to register the shares of common stock to be sold by the selling shareholders. This
prospectus is a part of that Registration Statement. As allowed by SEC rules, this prospectus does not contain all the information
you can find in the Registration Statement or the exhibits to that Registration Statement, which additional information can be
found and reviewed as described above. You can obtain a copy of the registration statement from the SEC&rsquo;s website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modulara018"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The consolidated
balance sheet of Modular Medical, Inc. as of March 31, 2019 and March 31, 2018, and the related consolidated statements of operations,
changes in stockholders&rsquo; equity, and cash flows for the years then ended have been audited by Farber Hass Harley LLP, an
independent registered public accounting firm, as stated in their report which is incorporated herein.</FONT><FONT STYLE="font-size: 10pt">
Such financial statements have been incorporated herein in reliance on the report of such firm given upon their authority as experts
in accounting and auditing.</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>MODULAR
MEDICAL, INC.</U></B><BR>
<B><U>(FKA BEAR LAKE RECREATION, INC.)</U></B><BR>
<B><U><A NAME="modulara019"></A>FINANCIAL STATEMENTS</U></B><BR>
<B><U>March 31, 2019 and June 30, 2019</U></B> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>TABLE
OF CONTENTS</U></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 94%; font: 10pt Times New Roman, Times, Serif"><A HREF="#modularb001"><FONT STYLE="font-size: 10pt">Reports of Independent Registered Accounting Firm</FONT></A></TD>
    <TD STYLE="width: 6%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">F-1</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#modularb002"><FONT STYLE="font-size: 10pt">Consolidated Balance Sheets as of March 31, 2019 and March 31, 2018</FONT></A></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#modularb003"><FONT STYLE="font-size: 10pt">Consolidated Statements of Operations for years ended March 31, 2019 and March 31, 2018</FONT></A></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#modularb004"><FONT STYLE="font-size: 10pt">Consolidated Statements of Stockholders&rsquo; Equity for years ended March 31, 2019 and March 31, 2018</FONT></A></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#modularb005"><FONT STYLE="font-size: 10pt">Consolidated Statements of Cash Flows for years ended March 31, 2019 and March 31, 2018</FONT></A></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#modularb006"><FONT STYLE="font-size: 10pt">Notes to Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><A HREF="#modularb007"> Consolidated
    Balance Sheets as of June 30, 2019 and March 31, 2019 </A></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">F-15</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><A HREF="#modularb008"> Consolidated
    Statements of Operations for quarters ended June 30, 2019 and 2018 </A></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">F-16</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><A HREF="#modularb009"> Consolidated
    Statements of Cash Flows for quarters ended June 30, 2019 and 2018 </A></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">F-17</FONT> </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><A HREF="#modularb010"> Notes to Financial
    Statements at June 30, 2019 </A></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">F-18</FONT> </TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><A NAME="modularb001"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 6pt"> <FONT STYLE="font-size: 10pt">To the board of directors
and</FONT> <BR>
<FONT STYLE="font-size: 10pt">Stockholders of Modular Medical, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have audited the accompanying consolidated balance sheets of Modular Medical, Inc. (the &ldquo;Company&rdquo;) as
of March 31, 2019 and 2018, and the related consolidated statements of operations, stockholders&rsquo; equity, and cash flows
for the years then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of March 31, 2019 and 2018, and
the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally
accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">These consolidated financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion
on the Company&rsquo;s consolidated financial statements based on our audits. We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to
the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">We conducted
our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to
obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting,
but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our audits
included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating
the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of
the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/&nbsp;Farber
    Hass Hurley LLP</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 82%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 18%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
    have served as the Company&rsquo;s auditor since 2018.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chatsworth,
    California</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    26, 2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<!-- Field: Page; Sequence: 54; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Modular Medical,
Inc. And its Subsidiary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(f/k/a- Bear
Lake Recreation, Inc.)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modularb002"></A>Consolidated
Balance Sheets</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>ASSETS</U></B></FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>March
    31,</B></FONT><FONT STYLE="font-size: 10pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2019</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>March
    31,</B></FONT><FONT STYLE="font-size: 10pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2018</B></FONT></FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 76%; padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CURRENT
    ASSETS</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,553,768</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,296,676</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
    current assets</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15,590</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16,804</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 34.6pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TOTAL
    CURRENT ASSETS</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,569,358</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,313,480</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Intangible
    assets, net</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">180</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">213</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Property
    and equipment,&nbsp;net</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">75,948</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13,259</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Security
    deposit</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7,500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7,500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 34.6pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TOTAL
    NON-CURRENT ASSETS</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">83,628</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20,972</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 25.95pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TOTAL
    ASSETS</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,652,986</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,334,452</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>LIABILITIES
    AND STOCKHOLDERS&rsquo; EQUITY</U></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CURRENT
    LIABILITIES</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accounts
    payable and accrued expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">178,929</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14,955</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Payable
    to related party</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">516</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 25.95pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TOTAL
    CURRENT LIABILITIES</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">178,929</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15,471</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Commitments
    and Contingencies</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 25.95pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TOTAL LIABILITIES</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">178,929</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15,471</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STOCKHOLDERS&rsquo;
    EQUITY</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Preferred
    Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, $0.001 par value, 50,000,000 shares authorized, 17,840,261 shares issued and outstanding as of March
    31, 2019 and 15,983,273 as of March 31, 2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17,840</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15,983</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Additional
    paid-in capital</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9,684,578</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,011,661</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common
    Stock Issuable</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19,800</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 17.3pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accumulated
    deficit</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3,248,161</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(708,663</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 34.6pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TOTAL
    STOCKHOLDERS&rsquo; EQUITY</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,474,057</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,318,981</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 25.95pt; text-indent: -8.65pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TOTAL
    LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,652,986</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,334,452</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">The accompanying
notes are an integral part of these audited consolidated financial statements</FONT>.</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Modular Medical,
Inc. And its Subsidiary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(f/k/a- Bear
Lake Recreation, Inc.)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modularb003"></A>Consolidated
Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>For The Fiscal
Years Ended March 31, 2019 and 2018</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2019</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left">Operating Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 8.65pt">Professional expenses</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">260,396</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">232,961</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,882,345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">332,642</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt">General and administration expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">420,090</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,700</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Depreciation expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,468</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,861</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 25.95pt">Total Operating Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,577,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">666,164</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Loss From Operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,577,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(666,164</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other Income (Expenses):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39,390</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,518</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 17.3pt">Loss Before Income Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,537,909</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(657,646</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,589</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,600</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Net Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,539,498</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(659,246</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold">Net Loss Per Share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt">Basic and Diluted:</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.15 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.05 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Weighted average number of shares used in computing basic and diluted net loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 8.65pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,589,633</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,336,309</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 8.65pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,589,633</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,336,309</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">The accompanying
notes are an integral part of these audited consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> <FONT STYLE="font-size: 10pt">Basic earnings
per share would have been diluted if the Company had outstanding convertible preferred shares, convertible debentures or warrants.
However, The Company has none of the foregoing outstanding.</FONT> </P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Modular Medical,
Inc. And its Subsidiary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(f/k/a- Bear
Lake Recreation, Inc.)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modularb004"></A>Consolidated
Statements of Stockholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Preferred Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Paid In</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Common<BR>
Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Accumulated</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Stockholders&rsquo;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issuable</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 20%; font-weight: bold; padding-left: 8.65pt; text-indent: -8.65pt">Balance as of March 31, 2017</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">7,582,060</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">7,582</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">404,467</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">(49,417</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">362,632</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Reverse Capitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,168,182</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,168</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(117,445</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(116,277</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Shares issued for cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,233,031</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,233</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,724,639</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,731,872</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt; text-indent: -8.65pt">Net loss for the fiscal year ended March 31, 2018</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(659,246</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(659,246</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; padding-left: 8.65pt; text-indent: -8.65pt">Balance as of March 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,983,273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,983</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,011,661</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(708,663</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,318,981</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Shares issued for cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,856,988</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,857</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,140,809</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,142,666</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Shares issuable for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">532,108</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">532,108</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt; text-indent: -8.65pt"> Net loss for the fiscal year
    ended March 31, 2019 </TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,539,498</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,539,498</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 8.65pt; text-indent: -8.65pt">Balance as of March 31, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,840,261</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,840</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,684,578</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,800</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,248,161</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,474,057</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;
The accompanying notes are an integral part of these audited consolidated financial statements.</FONT></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Modular Medical,
Inc. And its Subsidiary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(f/k/a- Bear
Lake Recreation, Inc.)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modularb005"></A>Consolidated
Statements of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>For The Fiscal
Years Ended March 31, 2019 and 2018</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2019</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 74%; text-align: left">Net loss</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">(2,539,498</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">(659,246</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">532,108</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,468</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,861</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD>Shares for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Increase in current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,998</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Decrease in current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">163,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(109,748</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,807,934</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(791,131</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt">Purchase of property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(77,124</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,119</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Purchase of intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(213</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(77,124</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,332</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt">Proceeds from private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,142,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,731,872</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Repayment to related party, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(516</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(20,740</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,142,150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,711,132</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left">Net increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,257,092</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,904,669</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents, at the beginning of the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,296,676</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">392,007</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, at the end of the period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,553,768</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,296,676</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left">Cash paid during the year for:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt">Income tax payments</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,589</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,600</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt">Interest payments</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">The accompanying
notes are an integral part of these audited consolidated financial statements</FONT>.</P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>MODULAR MEDICAL,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>F/K/A - BEAR
LAKE RECREATION, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="modularb006"></A>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>MARCH 31,
2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>NOTE 1 &ndash; ORGANIZATION AND SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Modular Medical,
Inc. (the &ldquo;Company&rdquo;) was organized under the laws of the State of Nevada on October 22, 1998, to engage in any lawful
purpose. The Company has at the present time, not paid any dividends and any dividends that may be paid in the future will depend
upon the financial requirements of the Company and other relevant factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Quasuras, Inc.
(&ldquo;Quasuras&rdquo;) was incorporated in Delaware on April 20, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Quasuras has
developed a hardware technology allowing people with diabetes to receive their daily insulin in two ways, through a continuous
&ldquo;basal&rdquo; delivery allowing a small amount of insulin to be in the blood at all times and a &ldquo;bolus&rdquo; delivery
to address meal time glucose input and to address when the blood glucose level becomes too high. By addressing the time and effort
required to effectively treat their condition, Quasuras believes it can address the less technically savvy, less motivated part
of the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Reorganization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">On July 24,
2017, pursuant to a Reorganization and Share Exchange Agreement, by and among the Company and Quasuras, the Company acquired one
hundred percent (100%) of the issued and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras
becoming a wholly-owned subsidiary of the Company. Since the major shareholder of Quasuras retained control of both the Company
and Quasuras, the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities
of Quasuras, acquired in the Reorganization, at their historical carrying amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant to
the reorganization, the Company changed the fiscal year end from June 30 to March 31, to coincide with the year end for Quasuras.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. The following summarizes the more significant of such policies:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Basis of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The preparation
of the consolidated financial statements in conformity with U.S. generally accepted accounting principles (&ldquo;GAAP&rdquo;)
requires management to make estimates and assumptions that affect reported amounts and related disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Principles
of Consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The consolidated
financial statements include the accounts of Modular Medical, Inc. and its wholly-owned subsidiary Quasuras, Inc., and are collectively
referred to as the &ldquo;Company&rdquo;. All material intercompany accounts, transactions and profits were eliminated in consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Use of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">The preparation
of the accompanying financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ
from those estimates.</FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Reportable Segment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
has one reportable segment. The Company&rsquo;s activities are interrelated and each activity is dependent upon and supportive
of the other. Accordingly, all significant operating decisions are based on analysis of financial products provided as a single
global business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Professional
Fees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
expenses the cost of legal, accounting, audit, tax and other professional services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
expenses the cost of research and development as incurred. Research and development costs charged to operations were approximately
$1,882,345 and $332,642 for the fiscal year ended March 31, 2019 and 2018, respectively.&#9; &#9; &#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>General and Administration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">General and
administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies
and meetings and travel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
utilizes Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 740, Income
Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that
were included in the consolidated financial statements or tax returns. Under this method, deferred income taxes are recognized
for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting
amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences
are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to
the amount expected to be realized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
accounts for uncertain tax positions in accordance with FASB ASC Topic 740. When tax returns are filed, it is likely that some
positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the
merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is
recognized in the consolidated financial statements in the period during which, based on all available evidence, management
believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals
or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet
the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax
positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits
in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable
to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense
and penalties are classified in selling, general and administrative expenses in the consolidated statements of income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">At March 31,
2019 and 2018, the Company had not taken any significant uncertain tax positions on its tax returns for periods ended March 31,
2019 and prior years or in computing its tax provision for 2019. Management has considered its tax positions and believes that
all of the positions taken by the Company in its Federal and State tax returns are more likely than not to be sustained upon examination.
The Company is subject to examination by U.S. Federal and State tax authorities for the period ended March 31, 2016 to the present,
generally for three years after they are filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Concentration
of Credit Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and accounts receivable.
The Company maintains cash balances at financial institutions within the United States, which are insured by the Federal Deposit
Insurance Corporation (FDIC) up to limits of approximately $250,000. The Company has not experienced any losses with regard to
its bank accounts and believes it is not exposed to any risk of loss on its cash bank accounts.</FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Risks and
Uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public
markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Certain conditions
may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but
which will only be resolved when one or more future events occur or fail to occur. The Company&rsquo;s management and legal counsel
assess such contingent liabilities, and such assessment inherently involves judgment. In assessing loss contingencies related
to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company&rsquo;s
legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of
the amount of relief sought or expected to be sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">If the assessment
of a contingency indicates it is probable that a material loss has been incurred and the amount of the liability can be estimated,
then the estimated liability would be accrued in the Company&rsquo;s consolidated financial statements. If the assessment
indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be
estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable
and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they
involve guarantees, in which case the guarantee would be disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Cash and Cash Equivalents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cash
and cash equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments
with original maturities of three months or less. At March 31, 2019 and March 31, 2018, the Company had $6,553,768 and $4,296,676,
respectively, in cash. Deposits at the bank are insured up to $250,000 by the Federal Deposit Insurance Corporation. The Company&rsquo;s
uninsured portion of the balances held at the bank aggregated to approximately $6,269,116 </FONT><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">and
$3,933,002, respectively. No reserve has been made in the financial statements for any possible loss due to any financial institution
failure.&nbsp;The Company has not experienced any losses in such accounts and believes we are not exposed to any significant risk
on cash and cash equivalents.&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Property, Plant &amp; Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Property
and equipment is stated at cost and depreciated using the straight-line method over the shorter of the estimated useful life of
the asset or the lease term. The estimated useful lives of our property and equipment are generally as follows: computer equipment
&amp; software developed or acquired for internal use, three to ten years; office equipment, two to three years; buildings and
improvements, five to fifteen years; leasehold improvements, two to ten years; and machinery and equipment, one to five years.</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">As of March 31, 2019 and March 31,
2018, property, plant and equipment amounted to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2018</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 74%; text-align: left">Computer equipment and software</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">20,565</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">15,103</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Office equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,724</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left">Machinery and  equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,937</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,278</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,844</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">75,948</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,259</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Depreciation
expenses for the year ended March 31, 2019 and 2018 was $14,435 </FONT><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">and
$1,844, respectively.</FONT>&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Fair Value of Financial Instrument</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">For certain
of the Company&rsquo;s financial instruments, including cash and equivalents, accrued liabilities and short-term debt, the carrying
amounts approximate their fair values due to their short maturities. ASC Topic 820, &ldquo;Fair Value Measurements and Disclosures,&rdquo;
requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, &ldquo;Financial Instruments,&rdquo;
defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances
disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables
and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the
short period of time between the origination of such instruments and their expected realization and their current market rate
of interest. The three levels of valuation hierarchy are defined as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Level 1 inputs
to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Level 2 inputs
to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable
for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Level 3 inputs
to the valuation methodology are unobservable and significant to the fair value measurement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Due to their
short-term nature, the carrying values of cash and equivalents, accounts receivable, accounts payable, and accrued expenses, approximate
fair value. Based on borrowing rates currently available to the Company for loans with similar terms, the carrying value of the
notes payable approximates fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Earnings Per Share (&ldquo;EPS&rdquo;)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Basic earnings per share are computed by
dividing earnings available to common stockholders by the weighted average number of outstanding common shares during the period.
Diluted earnings per share are computed by dividing net income by the weighted average number of shares outstanding during the
period increased to include the number of additional shares of common stock that would have been outstanding if the potentially
dilutive securities had been issued. During the fiscal years ended March 31, 2019 and 2018 we incurred losses. Therefore, the
effects of any common stock equivalent were anti-dilutive during those periods. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The following
table sets for the computation of basic and diluted earnings per share for the fiscal years ended March 31, 2019 and 2018:<B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2019</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="width: 74%; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 34.6pt">Net Loss</TD><TD NOWRAP STYLE="width: 3%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD NOWRAP STYLE="width: 8%; border-bottom: Black 2.5pt double; text-align: right">(2,539,498</TD><TD NOWRAP STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD><TD NOWRAP STYLE="width: 3%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD NOWRAP STYLE="width: 8%; border-bottom: Black 2.5pt double; text-align: right">(659,246</TD><TD NOWRAP STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-indent: -8.65pt; padding-left: 8.65pt">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-weight: bold; text-indent: -8.65pt; padding-left: 8.65pt">Net Loss Per Share</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Basic and Diluted:</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.15 </TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD NOWRAP STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.05 </TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-indent: -8.65pt; padding-left: 8.65pt">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Weighted average number of shares used in computing basic and diluted net loss per share:</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: right; text-indent: -8.65pt; padding-left: 8.65pt">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Basic</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right">16,589,633</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right">13,336,309</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Diluted</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right">16,589,633</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right">13,336,309</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt"><FONT STYLE="font-size: 10pt"><B>Recently Issued Accounting
Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB issued ASU 2014-09,&nbsp;<I>Revenue from Contracts with Customers</I>, issued as a new Topic, ASC Topic 606.
The new revenue recognition standard supersedes all existing revenue recognition guidance. Under this ASU, an entity should recognize
revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity
expects to be entitled in exchange for those goods or services. ASU 2015-14, issued in August 2015, deferred the effective date
of ASU 2014-09 to the first quarter of 2018, with early adoption permitted in the first quarter of 2018. The company has adopted
the new standard utilizing the modified retrospective approach. The adoption of this new accounting guidance does not have material
effects on results of operations, cash flows and financial position for the forceable future because the company does not have
revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In January 2016,
The FASB issued ASU No. 2016-01,<I>&nbsp;Financial Instruments - Recognition and Measurement of Financial Assets and Financial
Liabilities (Topic 825)</I>. ASU No. 2016-01 revises the classification and measurement of investments in certain equity investments
and the presentation of certain fair value changes for certain financial liabilities measured at fair value. ASU No. 2016-01 requires
the change in fair value of many equity investments to be recognized in net income. For non-public companies, ASU 2016-01 is effective
for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019.
We are currently evaluating the impact of the adoption of ASU 2016-01 will have on our consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">In August 2016,
the FASB issued ASU No. 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This update addresses a diversity
in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic
230, Statement of Cash Flows, and other Topics. The amendments in this Update are effective for public business entities for fiscal
years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including
adoption in an interim period. We adopted this ASU in 2016 and the implementation did not have a material impact on our financial
position or statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
August 2018, the FASB issued guidance that eases certain documentation and assessment requirements of hedge effectiveness and
modifies the accounting for components excluded from the assessment. Some of the modifications include the ineffectiveness of
derivative gain/loss in highly effective cash flow hedge to be recorded in other comprehensive income, the change in fair
value of derivative to be recorded in the same income statement line as hedged item, and additional disclosures required on the
cumulative basis adjustment in fair value hedges and the effect of hedging on financial statement lines for components excluded
from the assessment. The amendment also simplifies the application of hedge accounting in certain situations to permit new hedging
strategies to be eligible for hedge accounting. The guidance is effective for annual reporting periods and interim periods within
those annual reporting periods beginning after December 15, 2018, our fiscal 2020. Early adoption is permitted and the modified
retrospective transition method should be applied. We do not expect the adoption of this guidance to have a material impact on
our consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, FASB issued ASU No. 2016-02,
Leases (&ldquo;Topic 842&rdquo;). Topic 842 requires an entity to recognize right-of -use assets and lease liability on its balance
sheet and disclosure key information about leasing arrangements. For public companies, Topic 842 is effective for annual reporting
periods beginning after December 15, 2018, including interim periods within that reporting period, with early adoption permitted.
We have evaluated this ASU and believe this guidance will not have a material impact on our financial position and statement of
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Other recent
accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on
the Company&rsquo;s present or future consolidated financial statements.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Reclassification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flow.</FONT></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>NOTE 2 &ndash; REORGANIZATION AND
PRIVATE PLACEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
April 26, 2017, Modular Medical, Inc. issued 2,900,000 shares (the &ldquo;Control Block&rdquo;), of new, restricted common stock,
par value, $0.001, per share, for a purchase price of $375,000, resulting in a change in control of Modular Medical, Inc.</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">On July
24, 2017, pursuant to a Reorganization and Share Exchange Agreement, by and among, Modular Medical, Inc., 3 Quasuras Shareholders
and Quasuras (the &ldquo;Acquisition Agreement&rdquo;), the Company acquired all 4,400,000 shares of Quasuras&rsquo; common stock
which represented one hundred percent (100%) of the issued and outstanding shares of Quasuras for 7,582,060 shares of our common
stock, resulting in Quasuras becoming our wholly-owned subsidiary (the &ldquo;Acquisition&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Simultaneously
with the closing of the Acquisition and as a condition thereto, we sold (the &ldquo;2017 Private Placement&rdquo;), in a private
placement an aggregate of 7,233,031 for cash and 568,182 from reissuance of previously canceled shares of our common stock pursuant
to one or more exemptions from the registration requirements of the Securities Act, at a purchase price of $0.66 per share resulting
in net proceeds to us of approximately $4,731,872. Simultaneously with the Acquisition and Private Placement, the Company cancelled
all 2,900,000 Control Block shares it had issued in the Control Block Acquisition (the &ldquo;Share Cancellation&rdquo;). In connection
with the Private Placement, we paid $41,928 as compensation in connection with sales of our shares therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Following
the Acquisition, the 2017 Private Placement and the Share Cancellation, we had issued and outstanding 15,983,273 shares of our
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The cash received
in the private placement was recorded as the cash received in reorganization in the accompanying consolidated financial
statements.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Simultaneously
with and as a condition to the closing of the Acquisition and the Private Placement, pursuant to an Intellectual Property Transfer
Agreement, dated as of July 24, 2018, by and among us, Quasuras and Mr. DiPerna (the &ldquo;IP Transfer Agreement&rdquo;), Mr.
DiPerna transferred to us all intellectual property rights owned directly and/or indirectly by him related to our proposed business.
Separately, we agreed to pay Mr. DiPerna as part of his compensation for services to be performed for us pursuant to a Royalty
Agreement (the &ldquo;Royalty Agreement&rdquo;) certain fees based upon future sales, if any, of our proposed product subject
to a maximum $10,000,000 &ldquo;cap&rdquo; on the aggregate amount of fees that Mr. DiPerna could earn from such arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>NOTE 3 &ndash; ACCRUED EXPENSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">As of March
31, 2019, and 2018, accrued expenses amounted to $178,929 and $14,955, respectively. Accrued expenses comprised of accrued legal
and professional, consultant services and year end employee bonuses as of March 31, 2019 and March 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>NOTE&nbsp;4 &ndash; PAYABLE TO
RELATED PARTY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Payable to related
party comprises of the amounts paid by the major shareholder on behalf of the Company. The payable is unsecured, non-interest
bearing and due on demand. As of March 31, 2019 and 2018, respectively, the payable to related party amounted to $0 and $516.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>NOTE 5 &ndash; STOCKHOLDERS&rsquo;
EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Common stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">On July 24,
2017, pursuant to a Reorganization and Share Exchange Agreement by and among, the Company and Quasuras Inc., the Company acquired
one hundred percent (100%) of the issued and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in
Quasuras becoming a wholly-owned subsidiary of the Company. The historical equity for Quasuras was restated pursuant to the reorganization.</FONT></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
has 5,000,000 shares of preferred stock authorized. The par value of the shares is $0.001. As of March 31, 2019, none of the shares
of preferred stock of the Company were issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-size: 10pt"><B>2017 Equity Incentive Plan</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> On October 19, 2017, the board
of directors approved the 2017 Equity Incentive Plan (the &ldquo;EIP&rdquo;) that reserves 3,000,000 shares of common stock
of the Company to be issued. Under the Company&rsquo;s EIP, eligible employees, directors and consultants may be granted
options to purchase shares of common stock of the Company. The EIP is administered by the Company&rsquo;s board of directors
or, in the alternative, a committee designated by the board of directors, and has the sole power to adminster the EIP. The
board of directors determines whether the EIP will allow for the issuance of shares of common stock or an option to purchase
shares of common stock and whether such options are designated as either incentive or non-qualified
stock options. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">Under the
EIP, the exercise or purchase price shall be calculated as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
    the case of an incentive stock option, (A) granted to employees, directors and consultants who, at the time of the grant of
    such incentive stock option own stock representing more than ten percent (10%) of the voting power of all classes of stock
    of the Company, the per share exercise price shall be not less than one hundred ten percent (110%) of the fair market value
    per share on the date of grant; or (B) granted to employees, directors and consultants other than to employees, directors
    and consultants described in the preceding clause, the per share exercise price shall be not less than one hundred percent
    (100%) of the fair market value per share on the date of grant;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the case of a non-qualified stock option, the per share exercise price shall be not less than one hundred percent (100%) of
    the fair market value per share on the date of grant unless otherwise determined by the board of directors; and</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0"> In the case
                                         of other grants, such price as is determined by the board of directors. </P>


</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors is responsible for determining the consideration to be paid for the shares of common stock to be issued upon
exercise or purchase. The EIP generally doesn&rsquo;t allow for the transfer of the options, and the board of directors may amend,
suspend or terminate the EIP at any time.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0"> <FONT STYLE="font-size: 10pt">On
August 15, September 15, and October 15, 2018, the Company granted a total of 54,039 options to the chief executive officer of
the Company in lieu of salary. The options expire 10 years from the respective grant dates and vested immediately upon grant.
The fair value of these options was determined to be $24,840 and was included in general and administrative and research and development
expenses for the year ended March 31, 2019.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">On
November 15<SUP>th</SUP> and December 15<SUP>th</SUP> 2018, the Company granted 10,648 options to the officer of the Company
in lieu of salary. The options expire on November 14<SUP>th</SUP>, and December 14<SUP>th</SUP>, 2028 and vest immediately. The
fair value of these options determined to be $17,921 and was included in general and administrative and research and development
expenses for the year ended March 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0"> <FONT STYLE="font-size: 10pt">The
following assumptions were used in the fair value method calculations:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Volatility: 71%
    </FONT>&ndash; 112%</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk free rate
    of return: 2.73% &ndash; 3.01%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Expected term:
    5 years</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt"> During
the fiscal year ended March 31, 2019, the Company granted options to purchase 1,529,208 shares of common stock to certain employees
and consultants. The fair value of the options granted was $1,021,733, and the Company has been recording stock-based compensation
expense for each grant over the respective vesting periods. For the year ended March 31, 2019, the Company recorded stock-based
compensation expense of $532,108, which is less than the total fair value. This difference of $489,625 represents stock-based
compensation expense that will be recognized subsequent to March 31, 2019, so long as the option grants remain outstanding and
vesting continues. The table below provides a reconciliation of total fair value of the options granted and related expense recognized
by the Company during fiscal 2019. </FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"> Grantees </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Option<BR>
    Shares </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"> Vesting
    <BR>
    Periods </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Total Fair <BR>
    Value of<BR>
    Options </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> 2019 Stock-Based <BR>
    Compensation <BR>
    Expense </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Unrecognized <BR>
    expense at <BR>
    March 31, 2019 </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="width: 23%; padding-left: 0; text-indent: 0"> Consultants </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="width: 8%; text-align: right"> 1,280,000 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 22%; padding-left: 0; text-indent: 0"> July 25, 2018 to July 24, 2019 </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left"> $ </TD><TD NOWRAP STYLE="width: 8%; text-align: right"> 682,240 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left"> $ </TD><TD NOWRAP STYLE="width: 8%; text-align: right"> 466,197 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left"> $ </TD><TD NOWRAP STYLE="width: 8%; text-align: right"> 216,043 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-left: 0; text-indent: 0"> Consultants </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> 185,221 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="padding-left: 0; text-indent: 0"> January&nbsp;&nbsp;16, 2019 to January 15, 2022 </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> $ </TD><TD NOWRAP STYLE="text-align: right"> 336,732 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> $ </TD><TD NOWRAP STYLE="text-align: right"> 23,150 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> $ </TD><TD NOWRAP STYLE="text-align: right"> 313,582 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="text-align: left; padding-left: 0; text-indent: 0"> Chief Executive Officer </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> 64,687 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="padding-left: 0; text-indent: 0"> * </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> $ </TD><TD NOWRAP STYLE="text-align: right"> 42,761 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> $ </TD><TD NOWRAP STYLE="text-align: right"> 42,761 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> &mdash; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-left: 0; text-indent: 0"> Total </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> 1,529,908 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="padding-left: 0; text-indent: 0"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> $ </TD><TD NOWRAP STYLE="text-align: right"> 1,021,733 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> $ </TD><TD NOWRAP STYLE="text-align: right"> 532,108 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> $ </TD><TD NOWRAP STYLE="text-align: right"> 489,625 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"> * Options were fully vested as
of the grant date, as disclosed above. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0"> <FONT STYLE="font-size: 10pt">The
following assumptions were used in the fair value method calculation for the consultant options:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility:
    104% </FONT>&ndash; 110% </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    free rate of return: 2.54% &ndash; 2.82%</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term: 5.27 &ndash; 5.88 years</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The following is a rollforward
of the options outstanding and exercisable for the year ended March 31, 2019:</FONT></P>


<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted<BR>
Average<BR> Exercise<BR>
Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Average<BR>
Remaining<BR>
Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt">Outstanding and exercisable &ndash; March 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; padding-left: 8.65pt; text-indent: -8.65pt">Vested</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">918,020</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt">Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt">Outstanding and exercisable &ndash; March 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">918,020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.68</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.43</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"> <FONT STYLE="font-size: 10pt">The
fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes
simplified methods to establish the fair term of options as well as average volatility of three comparable
organizations.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; color: #7030A0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>NOTE 6 &ndash; INCOME TAXES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
on the available information and other factors, management believes it is more likely than not that the net deferred tax assets
at, March 31, 2019 and 2018, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against
its net deferred tax assets at, March 31, 2019 and 2018. At March 31, 2019 and 2018, the Company had federal net operating loss
carry-forwards of approximately $817,000 and </FONT><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">$182,500,
respectively, expiring beginning in 2037.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Deferred tax assets consist of the
following components:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 51.9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2019</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="width: 74%; text-align: left; padding-left: 8.65pt">Net loss carryforward</TD><TD NOWRAP STYLE="width: 3%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">$</TD><TD NOWRAP STYLE="width: 8%; text-align: right">817,000</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 3%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">$</TD><TD NOWRAP STYLE="width: 8%; text-align: right">182,500</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Valuation allowance</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: right">(817,000</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: right">(182,500</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="text-align: left; padding-bottom: 2.5pt">Total deferred tax assets</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>NOTE 7 &ndash; ROYALTY AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">On July
12, 2017, the Company entered into a royalty agreement with the founder and major shareholder. Pursuant to the agreement, the
founder and major shareholder is assigning and transferring all of his rights in the intellectual property in return for
royalty payments. The Company shall pay royalty to the founder on any sales of the royalty product sold or otherwise
commercialized by the Company, equal to (a) US $0.75 on each sale of a royalty product, or (b) five percent (5%) of the gross
sale price of the royalty product, whichever is less. The royalty payments shall cease and this agreement shall terminate, at
such time as the total sum of royalty payments actually paid to the founder, pursuant to this agreement, reaches $10,000,000.
The Company shall have the option to terminate this agreement at any time upon payment, to the founder, of the difference
between total royalty payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if
due, for the preceding quarter, shall be made by the Company within thirty days after the calendar quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>NOTE 8 &ndash; LEASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2017, the Company entered into a sublease agreement to rent office space. The term of the lease commences on September
1, 2017 and expires on December 14, 2019. The monthly rent for the lease is $3,000. For the remaining lease term, the rent
balance is $27,000, $3,000 payable monthly. The Company paid a deposit of $7,500 upon execution of the lease which has been recorded
as a security deposit in the accompanying consolidated financial statements.</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modular
Medical, Inc. and its Subsidiary</B><BR>
<B>(f/k/a- Bear Lake Recreation, Inc.)</B><BR>
<B><A NAME="modularb007"></A>Condensed Consolidated Balance Sheets</B></FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"> <U>ASSETS</U> </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> June 30, 2019<BR>
    (UNAUDITED) </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> March 31,<BR>
    2019 </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left"> CURRENT ASSETS </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 8.65pt"> Cash and cash equivalents </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 8%; text-align: right"> 5,706,628 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 8%; text-align: right"> 6,553,768 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> Other current assets </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 9,500 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 15,590 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 34.6pt"> TOTAL CURRENT ASSETS </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 5,716,128 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 6,569,358 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt"> Intangible assets, net </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 172 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 180 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt"> Property and equipment, net </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 75,961 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 75,948 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> Security deposit </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 7,500 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 7,500 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 34.6pt"> TOTAL NON-CURRENT ASSETS </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 83,633 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 83,628 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt"> TOTAL ASSETS </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 5,799,761 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 6,652,986 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center"> LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left"> CURRENT LIABILITIES </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> Accounts payable and accrued expenses </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 253,474 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 178,929 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 34.6pt"> TOTAL CURRENT LIABILITIES </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 253,474 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 178,929 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> TOTAL LIABILITIES </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 253,474 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 178,929 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left"> STOCKHOLDERS&rsquo; EQUITY </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"> Preferred Stock, $0.001 par value, 5,000,000 shares
    authorized, none issued and outstanding </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-indent: -8.65pt; padding-left: 17.3pt"> Common Stock, $0.001 par value, 50,000,000 shares authorized, 17,870,261<BR>
    shares issued and outstanding as of June 30, 2019 and 17,840,261 as of March 31, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 17,870 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 17,840 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt"> Additional paid-in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,898,776 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9,684,578 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt"> Common stock issuable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 19,800 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> Accumulated deficit </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (4,370,359 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (3,248,161 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 34.6pt"> TOTAL STOCKHOLDERS&rsquo; EQUITY </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 5,546,287 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 6,474,057 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt"> TOTAL LIABILITIES AND STOCKHOLDERS&rsquo;
    EQUITY </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 5,799,761 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 6,652,986 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements</FONT>. </P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modular
Medical, Inc. and its Subsidiary</B><BR>
<B>(f/k/a- Bear Lake Recreation, Inc.)</B><BR>
<B><A NAME="modularb008"></A>Consolidated Statements of Operations</B><BR>
<BR></FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Three Months Ended </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> June 30, 2019<BR>
    (UNAUDITED) </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> June 30, 2018 <BR>(UNAUDITED) </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left"> Operating Expenses: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 8.65pt"> Professional expenses </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 8%; text-align: right"> 287,831 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 8%; text-align: right"> 41,710 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt"> Research and development </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 703,783 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,789 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt"> General and administration expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 139,912 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 76,296 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> Depreciation and amortization expenses </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 6,714 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 1,395 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 25.95pt"> Total Operating Expenses </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 1,138,240 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 255,190 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt"> Loss From Operations </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (1,138,240 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (255,190 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Other Income (Expenses): </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt"> Interest income </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 16,042 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,624 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 17.3pt"> Loss Before Income Taxes </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,122,198 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (249,566 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> Provision for income taxes </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &mdash; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &mdash; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt"> Net Loss </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (1,122,198 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (249,566 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold"> Net Loss Per Share </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt"> Basic and Diluted: </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.06 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.02 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"> Weighted average number of
    shares used in computing basic and diluted net loss per share: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 8.65pt"> Basic </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 17,847,740 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 15,983,273 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 8.65pt"> Diluted </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 17,847,740 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 15,983,273 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</FONT> </P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modular
Medical, Inc. and its Subsidiary</B><BR>
<B>(f/k/a- Bear Lake Recreation, Inc.)</B><BR>
<B><A NAME="modularb009"></A>Consolidated Statements of Cash Flows</B><BR>
<BR></FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> Three Months Ended </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> June 30, 2019<BR>
    (UNAUDITED) </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> June 30, 2018 <BR>(UNAUDITED) </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 74%; text-align: left"> Net loss </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 8%; text-align: right"> (1,122,198 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 8%; text-align: right"> (249,566 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Adjustments to reconcile net loss to net cash used in operating activities: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD> Stock-Based Compensation </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 194,428 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Depreciation and amortization </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,714 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,395 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left"> Increase/Decrease in current assets: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt"> Other assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,090 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,248 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left"> Decrease in current liabilities: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> Accounts payable and accrued expenses </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 74,545 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 1,704 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"> Net cash used in operating activities </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (840,421 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (236,219 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> CASH FLOWS FROM INVESTING ACTIVITIES </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> Purchase of property, plant and equipment </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (6,719 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (6,170 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"> Net cash used in investing activities </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (6,719 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (6,170 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left"> CASH FLOWS FROM FINANCING ACTIVITIES </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> Repayment to related party </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &mdash; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (516 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"> Net cash used in financing activities </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &mdash; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (516 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Net increase in cash and cash equivalents </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (847,140 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (242,905 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> Cash and cash equivalents, at the beginning of the period </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 6,553,768 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 4,296,676 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"> Cash and cash equivalents, at the end of the period </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 5,706,628 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 4,053,771 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left"> SUPPLEMENTAL DISCLOSURES: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Cash paid during the year for: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt"> Income tax </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> &mdash; </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> &mdash; </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 8.65pt"> Interest </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> &mdash; </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> &mdash; </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
stock issuable was met.&nbsp; Therefore, $19,800 was re-classed from common stock issuable to common stock in the Stockholders&rsquo;
equity.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</FONT> </P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MODULAR
MEDICAL, INC.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F/K/A
BEAR LAKE RECREATION, INC.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="modularb010"></A>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUNE
30, 2019</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(UNAUDITED)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
1 &ndash; ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modular
Medical, Inc. (the &ldquo;Company&rdquo;) was organized under the laws of the State of Nevada on October 22, 1998, to engage in
any lawful purpose. The Company has at the present time, not paid any dividends and any dividends that may be paid in the future
will depend upon the financial requirements of the Company and other relevant factors.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quasuras,
Inc. (&ldquo;Quasuras&rdquo;) was incorporated in Delaware on April 20, 2015.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quasuras
has developed a hardware technology allowing people with insulin dependent diabetes to receive their daily insulin in two ways,
through a continuous &ldquo;basal&rdquo; delivery allowing a small amount of insulin to be in the blood at all times and a &ldquo;bolus&rdquo;
delivery to address meal time glucose input and to address when the blood glucose level becomes too high. By addressing the time
and effort required to effectively treat their condition, Quasuras believes it can address the less technically savvy, less motivated
part of the market.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reorganization</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2017, pursuant to a Reorganization and Share Exchange Agreement, by and among the Company and Quasuras, the Company acquired
one hundred percent (100%) of the issued and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in
Quasuras becoming a wholly-owned subsidiary of the Company. Since the major shareholder of Quasuras retained control of both the
Company and Quasuras, the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and
liabilities of Quasuras, acquired in the Reorganization, at their historical carrying amounts.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the reorganization, the Company changed the fiscal year end from June 30 to March 31, to coincide with the year end for Quasuras.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted
in the United States of America. The following summarizes the more significant of such policies:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of Presentation</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles (&ldquo;GAAP&rdquo;)
requires management to make estimates and assumptions that affect reported amounts and related disclosures.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principles
of Consolidation</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Modular Medical, Inc. and its wholly-owned subsidiary Quasuras, Inc.,
and are collectively referred to as the &ldquo;Company&rdquo;. All material intercompany accounts, transactions and profits were
eliminated in consolidation.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the accompanying financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Actual results
could differ from those estimates.</FONT> </P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reportable
Segment</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has one reportable segment. The Company&rsquo;s activities are interrelated and each activity is dependent upon and supportive
of the other. Accordingly, all significant operating decisions are based on analysis of financial products provided as a single
global business.<B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Professional
Fees</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses the cost of legal, accounting, audit, tax and other professional services.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses the cost of research and development as incurred. Research and development costs charged to operations were approximately
$703,783 and $135,789 for the fiscal quarter ended June 30, 2019 and 2018, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
and Administration</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies
and meetings and travel.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 740, Income Taxes,
which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that were
included in the consolidated financial statements or tax returns. Under this method, deferred income taxes are recognized for
the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting
amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences
are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to
the amount expected to be realized.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740. When tax returns are filed, it is likely that
some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about
the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management
believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals
or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet
the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax
positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits
in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the
taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and
penalties are classified in selling, general and administrative expenses in the consolidated statements of income.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2019 and 2018, the Company had not taken any significant uncertain tax positions on its tax returns for periods ended
June 30, 2019 and prior years or in computing its tax provision for 2019. Management has considered its tax positions and believes
that all of the positions taken by the Company in its Federal and State tax returns are more likely than not to be sustained upon
examination. The Company is subject to examination by U.S. Federal and State tax authorities for the period ended March 31, 2017
to the present, generally for three years after they are filed.</FONT> </P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Concentration
of Credit Risk</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and accounts receivable.
The Company maintains cash balances at financial institutions within the United States, which are insured by the Federal Deposit
Insurance Corporation (FDIC) up to limits of approximately $250,000. The Company has not experienced any losses with regard to
its bank accounts and believes it is not exposed to any risk of loss on its cash bank accounts.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
and Uncertainties</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated
with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of
public markets.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contingencies</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company
but which will only be resolved when one or more future events occur or fail to occur. The Company&rsquo;s management and legal
counsel assess such contingent liabilities, and such assessment inherently involves judgment. In assessing loss contingencies
related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the
Company&rsquo;s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived
merits of the amount of relief sought or expected to be sought.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the assessment of a contingency indicates it is probable that a material loss has been incurred and the amount of the liability
can be estimated, then the estimated liability would be accrued in the Company&rsquo;s consolidated financial statements. If the
assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but
cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable
and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they
involve guarantees, in which case the guarantee would be disclosed.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
and Cash Equivalents</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments
with original maturities of three months or less. At June 30, 2019 and March 31, 2019, the Company had $5,706,628 and $6,553,768,
respectively, in cash. Deposits at the bank are insured up to $250,000 by the Federal Deposit Insurance Corporation. The Company&rsquo;s
uninsured portion of the balances held at the bank aggregated to approximately $5,421,940 and $6,269,116 respectively. No reserve
has been made in the financial statements for any possible loss due to any financial institution failure.&nbsp;The Company has
not experienced any losses in such accounts and believes we are not exposed to any significant risk on cash and cash equivalents.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property,
Plant &amp; Equipment</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment is stated at cost and depreciated using the straight-line method over the shorter of the estimated useful life of
the asset or the lease term. The estimated useful lives of our property and equipment are generally as follows: computer equipment&amp;
software developed or acquired for internal use, three to ten years; office equipment, two to three years; buildings and improvements,
five to fifteen years; leasehold improvements, two to ten years; and machinery and equipment, one to five years.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2019 and March 31, 2019, property, plant and equipment amounted to:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> June 30, 2019<BR>
    (UNAUDITED) </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> March 31, 2019 </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="width: 74%; text-align: left"> Computer equipment and software </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left"> $ </TD><TD NOWRAP STYLE="width: 8%; text-align: right"> 25,028 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left"> $ </TD><TD NOWRAP STYLE="width: 8%; text-align: right"> 20,565 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: left"> Office equipment </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> 49,724 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> 49,724 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="text-align: left"> Machinery and equipment </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> 24,194 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> 21,937 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: left; padding-bottom: 1pt"> Less: accumulated depreciation </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: right"> (22,985 </TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: right"> (16,278 </TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="padding-bottom: 2.5pt"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right"> 75,961 </TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right"> 75,948 </TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expenses for the quarter ended June 30, 2019 and March 31, 2019 was $6,707 and $1,387 respectively.&nbsp;</FONT> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value of Financial Instrument</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain of the Company&rsquo;s financial instruments, including cash and equivalents, accrued liabilities and short-term debt,
the carrying amounts approximate their fair values due to their short maturities. ASC Topic 820, &ldquo;Fair Value Measurements
and Disclosures,&rdquo; requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, &ldquo;Financial
Instruments,&rdquo; defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement
that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets
for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values
because of the short period of time between the origination of such instruments and their expected realization and their current
market rate of interest. The three levels of valuation hierarchy are defined as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that
are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to their short-term nature, the carrying values of cash and equivalents, accounts receivable, accounts payable, and accrued expenses,
approximate fair value. Based on borrowing rates currently available to the Company for loans with similar terms, the carrying
value of the notes payable approximates fair value.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Earnings
Per Share (&ldquo;EPS&rdquo;)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share are computed by dividing earnings available to common stockholders by the weighted average number of outstanding
common shares during the period. Diluted earnings per share are computed by dividing net income by the weighted average number
of shares outstanding during the period increased to include the number of additional shares of common stock that would have been
outstanding if the potentially dilutive securities had been issued. During the fiscal quarter ended June 30, 2019 and 2018 we
incurred losses. Therefore, the effects of any common stock equivalent were anti-dilutive during those periods.</FONT> </P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets for the computation of basic and diluted earnings per share for the fiscal quarters ended June 30, 2019 and
June 30, 2018:<B>&nbsp;</B></FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> June 30, 2019<BR>
    (UNAUDITED) </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> June 30, 2018<BR>
    (UNAUDITED) </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 74%; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt"> Net Loss </TD><TD STYLE="width: 3%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 8%; border-bottom: Black 2.5pt double; text-align: right"> (1,122,198 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="width: 3%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 8%; border-bottom: Black 2.5pt double; text-align: right"> (249,566 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"> Net Loss Per Share </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt"> Basic and Diluted: </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.06 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.02 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"> Weighted average number of
    shares used in computing basic and diluted net loss <BR> per share: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 8.65pt"> Basic </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 17,847,740 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 15,983,273 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 8.65pt"> Diluted </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 17,847,740 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 15,983,273 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Issued Accounting Pronouncements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2014, the FASB issued ASU 2014-09,&nbsp;<I>Revenue from Contracts with Customers</I>, issued as a new Topic, ASC Topic 606.
The new revenue recognition standard supersedes all existing revenue recognition guidance. Under this ASU, an entity should recognize
revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity
expects to be entitled in exchange for those goods or services. ASU 2015-14, issued in August 2015, deferred the effective date
of ASU 2014-09 to the first quarter of 2018, with early adoption permitted in the first quarter of 2018. The company has adopted
the new standard utilizing the modified retrospective approach. The adoption of this new accounting guidance does not have material
effects on results of operations, cash flows and financial position for the forceable future because the company does not have
revenues.</FONT> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2016, The FASB issued ASU No. 2016-01,<I>&nbsp;Financial Instruments - Recognition and Measurement of Financial Assets
and Financial Liabilities (Topic 825)</I>. ASU No. 2016-01 revises the classification and measurement of investments in certain
equity investments and the presentation of certain fair value changes for certain financial liabilities measured at fair value.
ASU No. 2016-01 requires the change in fair value of many equity investments to be recognized in net income. For non-public companies,
ASU 2016-01 is effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning
after December 15, 2019. We are currently evaluating the impact of the adoption of ASU 2016-01 will have on our consolidated financial
statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and
Cash Payments. This update addresses a diversity in practice in how certain cash receipts and cash payments are presented and
classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. The amendments in this Update
are effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those
fiscal years. Early adoption is permitted, including adoption in an interim period. We adopted this ASU in 2016 and the implementation
did not have a material impact on our financial position or statement of operations.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB issued guidance that eases certain documentation and assessment requirements of hedge effectiveness and
modifies the accounting for components excluded from the assessment. Some of the modifications include the ineffectiveness of
derivative gain/loss in highly effective cash flow hedge to be recorded in other comprehensive income, the change in fair value
of derivative to be recorded in the same income statement line as hedged item, and additional disclosures required on the cumulative
basis adjustment in fair value hedges and the effect of hedging on financial statement lines for components excluded from the
assessment. The amendment also simplifies the application of hedge accounting in certain situations to permit new hedging strategies
to be eligible for hedge accounting. The guidance is effective for annual reporting periods and interim periods within those annual
reporting periods beginning after December 15, 2018, our fiscal 2020. Early adoption is permitted, and the modified retrospective
transition method should be applied. We do not expect the adoption of this guidance to have a material impact on our consolidated
financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, FASB issued ASU No. 2016-02, Leases (&ldquo;Topic 842&rdquo;). Topic 842 requires an entity to recognize right-of
-use assets and lease liability on its balance sheet and disclosure key information about leasing arrangements. For public companies,
Topic 842 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting
period, with early adoption permitted. We have evaluated this ASU and believe this guidance will not have a material impact on
our financial position and statement of operations.</FONT> </P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified
Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact
on the Company&rsquo;s present or future consolidated financial statements.&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reclassification</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flow.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 &ndash; REORGANIZATION AND PRIVATE PLACEMENT</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2017, Modular Medical, Inc. issued 2,900,000 shares (the &ldquo;Control Block&rdquo;), of new, restricted common stock,
par value, $0.001, per share, for a purchase price of $375,000, resulting in a change in control of Modular Medical, Inc.&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2017, pursuant to a Reorganization and Share Exchange Agreement, by and among, Modular Medical, Inc., 3 Quasuras Shareholders
and Quasuras (the &ldquo;Acquisition Agreement&rdquo;), the Company acquired all 4,400,000 shares of Quasuras&rsquo; common stock
which represented one hundred percent (100%) of the issued and outstanding shares of Quasuras for 7,582,060 shares of our common
stock, resulting in Quasuras becoming our wholly-owned subsidiary (the &ldquo;Acquisition&rdquo;).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the closing of the Acquisition and as a condition thereto, we sold (the &ldquo;2017 Private Placement&rdquo;), in a private
placement an aggregate of 7,233,031 for cash and 568,182 from reissuance of previously canceled shares of our common stock pursuant
to one or more exemptions from the registration requirements of the Securities Act, at a purchase price of $0.66 per share resulting
in net proceeds to us of approximately $4,731,872. Simultaneously with the Acquisition and Private Placement, the Company cancelled
all 2,900,000 Control Block shares it had issued in the Control Block Acquisition (the &ldquo;Share Cancellation&rdquo;). In connection
with the 2017 Private Placement, we paid $41,928 as compensation in connection with sales of our shares therein.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Acquisition, the 2017 Private Placement and the Share Cancellation, we had issued and outstanding 15,983,273 shares of our
common stock.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cash received in the private placement was recorded as the cash received in reorganization in the accompanying consolidated financial
statements.</FONT> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with and as a condition to the closing of the Acquisition and the 2017 Private Placement, pursuant to an Intellectual Property
Transfer Agreement, dated as of July 24, 2018, by and among us, Quasuras and Mr. DiPerna (the &ldquo;IP Transfer Agreement&rdquo;),
Mr. DiPerna transferred to us all intellectual property rights owned directly and/or indirectly by him related to our proposed
business. Separately, we agreed to pay Mr. DiPerna as part of his compensation for services to be performed for us pursuant to
a Royalty Agreement (the &ldquo;Royalty Agreement&rdquo;) certain fees based upon future sales, if any, of our proposed product
subject to a maximum $10,000,000 &ldquo;cap&rdquo; on the aggregate amount of fees that Mr. DiPerna could earn from such arrangement.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
3 &ndash; ACCRUED EXPENSES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2019 and March 31, 2019, accrued expenses amounted to $253,474 and $178,929 respectively. Accrued expenses comprised
of accrued legal and professional, consultant services as of June 30, 2019 and March 31, 2019.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE&nbsp;4
&ndash; PAYABLE TO RELATED PARTY</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payable
to related party comprises of the amounts paid by the major shareholder on behalf of the Company. The payable is unsecured, non-interest
bearing and due on demand. As of June 30, 2019 and March 31, 2019, respectively, there were no amounts payable to related party.</FONT> </P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 &ndash; STOCKHOLDERS&rsquo; EQUITY</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
stock</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2017, pursuant to a Reorganization and Share Exchange Agreement, by and among, the Company and Quasuras Inc., the Company
acquired one hundred percent (100%) of the issued and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting
in Quasuras becoming a wholly-owned subsidiary of the Company. The historical equity for Quasuras was restated pursuant to the
reorganization.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has 50,000,000 shares of common stock authorized. The par value of the shares is $0.001. In April 2019 the Company issued
30,000 shares for services bringing the outstanding balance to 17,870,261 shares of common stock.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has 5,000,000 shares of preferred stock authorized. The par value of the shares is $0.001. As of June 30, 2019, none of
the shares of preferred stock of the Company were issued.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Options</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 19, 2017, the Board of Directors approved the 2017 Equity Incentive Plan (&ldquo;EIP&rdquo;) that reserves 3,000,000 shares
of common stock of the Company to be issued. Under the Company&rsquo;s EIP, eligible employees, directors and consultants are
granted options to purchase shares of common stock of the Company. The EIP is administered by the Company&rsquo;s Board of Directors
or, in the alternative, if necessary, a committee designated by the Board of Directors, and has the sole power over the exercise
of the EIP. The Board of Directors determines whether the EIP will allow for the issuance of shares of common stock or an option
to purchase shares of common stock, such option designated as either an incentive stock option or a non-qualified stock option.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise or purchase price shall be calculated as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT> </TD>
    <TD STYLE="width: 96%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the case of an incentive stock option, (A) granted to employees, directors and consultants who, at the time of the grant of
    such incentive stock option own stock representing more than ten percent (10%) of the voting power of all classes of stock
    of the Company, the per share exercise price shall be not less than one hundred ten percent (110%) of the fair market value
    per share on the date of grant; or (B) granted to employees, directors and consultants other than to employees, directors
    and consultants described in the preceding clause, the per share exercise price shall be not less than one hundred percent
    (100%) of the fair market value per share on the date of grant;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT> </TD>
    <TD STYLE="width: 96%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the case of a non-qualified stock option, the per share exercise price shall be not less than one hundred percent (100%) of
    the fair market value per share on the date of grant unless otherwise determined by the Board of Directors; and</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT> </TD>
    <TD STYLE="width: 96%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the case of other grants, such price as is determined by the Board of Directors. </FONT> </TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 6pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Board of Directors are responsible
for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase. The EIP generally
doesn&rsquo;t allow for the transfer of the options, and the Board of Directors may amend, suspend or terminate the EIP at any
time. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="text-align: justify; text-indent: 0.5in; margin-right: 6.95pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 15, 2019, the Company granted 4,778 options to a consultant, these options are fully vested on the grant date. The 4,778
options will expire on April 14, 2029. The fair value of the options 4,778 shares is determined to be $8,173, was accrued in professional
expenses for the quarter ended June 30, 2019.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions were used in the fair value method calculation:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 24px; text-align: justify"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility: 101.85%</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free rate
    of return: 2.41%</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term:
    5 years</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 15<SUP>th</SUP> and May 15<SUP>th</SUP> 2019, the Company granted 8,908 options to a consultant, these options will be fully
vested on the grant date. The 8,908 options will expire on April 14<SUP>th</SUP> and May 14<SUP>th</SUP>, 2029. The fair value
of the options 8,908 shares is determined to be $15,000 was accrued in consulting expenses for the fiscal quarter ended June 30,
2019.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions were used in the fair value method calculation:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility: 97 &ndash; 102% </FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free rate of return: 2.15 &ndash; 2.37%</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term: 5 years</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 15<SUP>th</SUP>, 2019, the Company granted 9,000 options to an employee, these options will be fully vested three years
from the date granted. The 9,000 options will expire on April 14<SUP>th</SUP>, 2029. The fair value of the options 9,000 shares
is determined to be $16,258. During the quarter ended June 30, 2019, $447 was accrued monthly in general and administrative expenses.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions were used in the fair value method calculation:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility: 101.85% </FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free rate of return: 2.41%</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term: 6.0 years</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: justify; text-indent: 0; margin: 0; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">On
July 25, 2018, the Company granted 1,280,000 options to certain consultants, these options are fully vested one year from the
date granted. The 1,280,000 options will expire on August 31, 2019. The fair value of the options 1,280,000 shares is determined
to be $682,240, was accrued monthly in research and development expenses for the fiscal quarter ended June 30, 2019.</FONT> </P>

<P STYLE="text-align: justify; text-indent: 0.5in; margin: 0; font: 10pt Times New Roman, Times, Serif"> &nbsp; </P>

<P STYLE="text-align: justify; text-indent: 0; margin: 0; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">The
following assumptions were used in the fair value method calculation:</FONT> </P>

<P STYLE="text-align: justify; text-indent: 0.5in; margin: 0; font: 10pt Times New Roman, Times, Serif"> &nbsp; </P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">Volatility: 110%</FONT> </TD></TR>
</TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">Risk free rate of
    return: 2.82%</FONT> </TD></TR>
</TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">Expected term: 5.27
    years</FONT> </TD></TR>
</TABLE>
<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in"> &nbsp; </P>


<P STYLE="text-align: justify; text-indent: 0; margin: 0; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">On
January 16, 2019, the Company granted 185,221 options to certain consultants, these options will be fully vested three years from
the date granted. The 185,221 options will expire on January 15, 2029. The fair value of the options 185,221 shares is determined
to be $336,732, was accrued monthly in general and administrative expenses for the fiscal quarter ended June 30, 2019.</FONT> </P>

<P STYLE="text-align: justify; text-indent: 0.5in; margin: 0; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: justify; text-indent: 0; margin: 0; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">The
following assumptions were used in the fair value method calculation:</FONT> </P>

<P STYLE="text-align: justify; text-indent: 0.5in; margin: 0; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">Volatility: 104%</FONT> </TD></TR>
</TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">Risk free rate of
    return: 2.54%</FONT> </TD></TR>
</TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: &quot; font-size: 10pt">Expected term: 5.88
    years</FONT> </TD></TR>
</TABLE>

<P STYLE="text-align: justify; text-indent: 0.5in; margin-right: 6.95pt; font: 10pt Times New Roman, Times, Serif"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
relative fair value of each of the granted options set forth above has been calculated using the Black-Scholes-Merton pricing
model, which, for each such option, is based on the granted strike price, the three month average trading volatility of three
comparable companies (e.g., PODD, TNDM, VLRX), the five year, risk-free treasury bond interest rate on the applicable grant date
and a weighted average term using the simplified method calculation. It outlines calculation methods for sbc.</FONT> </P>

<P STYLE="text-align: justify; margin-right: 6.95pt; font: 10pt Times New Roman, Times, Serif; color: #7030a0; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a rollforward of the options outstanding and exercisable for the fiscal quarter ended June 30, 2019:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> Options </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> Weighted <BR>
    Average<BR> Exercise Price </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"> Average <BR>
    Remaining<BR>
    Life </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="width: 61%; text-indent: -8.65pt; padding-left: 8.65pt"> Outstanding and exercisable &ndash; March 31,
    2019 </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="width: 8%; text-align: right"> 918,020 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="width: 8%; text-align: right"> 0.68 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="width: 8%; text-align: right"> 9.43 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP> Vested </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> 280,352 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> 0.74 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> &nbsp; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="text-indent: -8.65pt; padding-left: 8.65pt"> Expired </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> &mdash; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> &mdash; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> &mdash; </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-indent: -8.65pt; padding-left: 8.65pt"> Outstanding and exercisable &ndash; June 30, 2019 </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> 1,198,372 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> $ </TD><TD NOWRAP STYLE="text-align: right"> 0.69 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP> &nbsp; </TD>
    <TD NOWRAP STYLE="text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="text-align: right"> 5.13 </TD><TD NOWRAP STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
6 &ndash; INCOME TAXES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the available information and other factors, management believes it is more likely than not that the net deferred tax assets
at, June 30, 2019 and March 31, 2019, will not be fully realizable. Accordingly, management has recorded a full valuation allowance
against its net deferred tax assets at June 30, 2019 and March 31, 2019. At June 30, 2019 and March 31, 2019, the Company had
federal net operating loss carryforwards of approximately $1,098,000 and $817,000 respectively, expiring beginning in 2037.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets consist of the following components:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 51.9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> June 30, 2019 </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> March 31, 2019 </TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="width: 74%; text-align: left; padding-left: 8.65pt"> Net loss carryforward </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left"> $ </TD><TD NOWRAP STYLE="width: 8%; text-align: right"> 1,098,000 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="width: 3%"> &nbsp; </TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left"> $ </TD><TD NOWRAP STYLE="width: 8%; text-align: right"> 817,000 </TD><TD NOWRAP STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"> Valuation allowance </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: right"> (1,098,000 </TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD NOWRAP STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: right"> (817,000 </TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="text-align: left; padding-bottom: 2.5pt"> Total deferred tax assets </TD><TD NOWRAP STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right"> &mdash; </TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD NOWRAP STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD NOWRAP STYLE="border-bottom: Black 2.5pt double; text-align: right"> &mdash; </TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
7 &ndash; ROYALTY AGREEMENT</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 12, 2017, the Company entered into a royalty agreement with the founder and major shareholder. Pursuant to the agreement,
the founder and major shareholder is assigning and transferring all of his rights in the intellectual property in return for royalty
payments. The Company shall pay royalty to the founder on any sales of the royalty product sold or otherwise commercialized by
the Company, equal to (a) US $0.75 on each sale of a royalty product, or (b) five percent (5%) of the gross sale price of the
royalty product, whichever is less. The royalty payments shall cease, and this agreement shall terminate, at such time as the
total sum of royalty payments actually paid to the founder, pursuant to this agreement, reaches $10,000,000. The Company shall
have the option to terminate this agreement at any time upon payment, to the founder, of the difference between total royalty
payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if due, for the preceding quarter,
shall be made by the Company within thirty days after the calendar quarter.</FONT> </P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Item
13. <U>Other Expenses of Issuance and Distribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">The following
table sets forth the estimated expenses payable by the registrant in connection with the sale of shares of our common stock covered
by this registration statement, other than sales commissions or discounts, and related expenses, which will be paid by the selling
shareholders. All amounts shown, except the SEC registration fee, are estimates:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 30%; text-align: left">SEC registration fee&#9;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">3500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printing expenses&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left">Legal fees and expenses&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting fees and expenses&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Miscellaneous fees and expenses&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">108,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Item
14. <U>Indemnification of Directors and Officers</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our Second
Amended and Restated Articles of Incorporation and our Amended and Restated Bylaws provide that each person who was or is made
a party or is threatened to be made a party to or is otherwise involved (including, without limitation, as a witness) in any action,
suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was one
of our directors or officers or is or was serving at our request as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, whether the basis of such action, suit or proceeding is alleged action
in an official capacity as a director, officer or trustee or in any other capacity while serving as a director, officer or trustee,
shall be indemnified and held harmless by us to the fullest extent authorized by the Nevada Revised Statutes, or NRS, against
all expense, liability and loss (including attorneys&rsquo; fees and amounts paid in settlement) reasonably incurred or suffered
by such.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">NRS 78.7502
permits a corporation to indemnify any director or officer of the corporation against expenses (including attorneys&rsquo; fees)
and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or proceeding brought by reason
of the fact that such person is or was a director or officer of the corporation, if such person (i) is not liable pursuant to
NRS 78.138 and (ii) acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best
interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the conduct
was unlawful. In a derivative action (i.e., one brought by or on behalf of the corporation), indemnification may be provided only
for expenses actually and reasonably incurred by any director or officer in connection with the defense or settlement of such
an action or the suit if such person (i) is not liable pursuant to NRS 78.138 and (ii) acted in good faith and in a manner which
he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification
shall be provided if such person shall have been adjudged to be liable to the corporation, unless and only to the extent that
the court in which the action or suit was brought or some other court of competent jurisdiction determines that such person is
fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our Second
Amended and Restated Articles of Incorporation provide that the liability of our directors and officers shall be eliminated or
limited to the fullest extent permitted by the NRS. NRS 78.138(7) provides that, subject to limited statutory exceptions and unless
the articles of incorporation or an amendment thereto (in each case filed on or after October 1, 2003) provide for greater individual
liability, a director or officer is not individually liable to a corporation or its stockholders or creditors for any damages
as a result of any act or failure to act in his or her capacity as a director or officer unless it is proven that: (i) the act
or failure to act constituted a breach of his or her fiduciary duties as a director or officer and (ii) the breach of those duties
involved intentional misconduct, fraud or a knowing violation of law.</FONT></P>


<!-- Field: Page; Sequence: 80; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The foregoing
discussion of our Second Amended and Restated Articles of Incorporation, Amended and Restated Bylaws and Nevada law is not intended
to be exhaustive and is qualified in its entirety by such Second Amended and Restated Articles of Incorporation, Amended and Restated
Bylaws, indemnification agreements, indemnity agreement, or law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Item
15. <U>Recent Sales of Unregistered Securities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">On April
26, 2017, pursuant to a Common Stock Purchase Agreement, dated as of July 24, 2017, by and among Manchester Explorer, LP, a Delaware
limited partnership (&ldquo;Manchester&rdquo;), the Company and certain other persons named therein, Manchester purchased from
us 2,900,000 shares of our common stock representing in excess of a majority of our then issued and outstanding common stock,
for a purchase price of $375,000 (the &ldquo;Control Block Acquisition&rdquo;), resulting in a change in control of the Company.
Simultaneously with the closing of the Acquisition (as defined below), Manchester cancelled the 2,900,000 shares of our common
stock it purchased in the April 2017 Control Block Acquisition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">On July
24, 2017, pursuant to a Reorganization and Share Exchange Agreement, by and among the Company, Mr. DiPerna, the sole officer,
director and a controlling stockholder of Quasuras, Messrs. Besser and Frank (Messrs. Besser, Frank and DiPerna, collectively,
the &ldquo;3 Quasuras Shareholders&rdquo;), and Quasuras, the Company acquired all of the issued and outstanding shares of Quasuras
owned by the 3 Quasuras Shareholders in exchange for 7,582,060 shares of our common stock of which Messrs DiPerna, Besser and
Frank received 7,220,400 shares, 180,830 shares and 180,830 shares, respectively, resulting in Quasuras becoming our wholly-owned
subsidiary (the &ldquo;Acquisition&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Messrs.
Besser and Frank each previously purchased for $50,000 approximately 2.25% of the capital stock of Quasuras, and as a result each
received 180,830 shares of our common stock in the Acquisition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">On July
24, 2017, simultaneously with the closing of the Acquisition, we sold in the 2017 Placement an aggregate of 7,801,213 shares of
our common stock at a purchase price of $0.66 per share resulting in gross proceeds to us of approximately $4,731,872. In connection
with the 2017 Placement, we paid $41,928 as compensation in connection with sales of our shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">During
our fiscal year ending March 31, 2019, we sold from November 2018 through March 29, 2019, in the 2018 Placement 1,856,988 shares
of our common stock at a purchase price of $2.25 per share resulting in gross proceeds to us of $4,142,666 (the &ldquo;2018 Private
Placement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">From
August 15, 2018 to January 16, 2019 we issued stock options to purchase 1,529,908 shares of our common stock at exercise prices
ranging from $0.66 to $2.25 all under our EIP.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The above
sales of our shares of common stock were made pursuant to exemptions from registration pursuant to Section 4(2) and/or Rule 506
of Regulation D of the Securities Act. We made such determinations based upon representations by the purchasers of such shares
including, without limitation, that such purchasers were &ldquo;accredited investors&rdquo; as defined in the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Item
16. <U>Exhibits</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Index
to Exhibits listing the exhibits required by Item 601 of Regulation S-K is located on the page immediately following the signature
page to this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Item
17. <U>Undertakings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The undersigned
registrant hereby undertakes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">(i)&#9;To
include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">(ii)&#9;To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
and of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate
offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">(iii)&#9;To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(A)
Paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-8, and the information
required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the
Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934, as amended (&ldquo;Securities
Exchange Act of 1934&rdquo;) (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(B)
Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the registration statement is on Form S-3 or
Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports
filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange
Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant
to Rule 424(b) that is part of the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That,
for the purpose of determining any liability under the Securities Act of 1933, as amended (&ldquo;Securities Act&rdquo;) each
such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at
the termination of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That,
for the purpose of determining any liability under the Securities Act, each Prospectus filed pursuant to Rule 424(b) as part of
a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than Prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is
first used after effectiveness. <I>Provided, however,</I> that no statement made in a registration statement or Prospectus that
is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or Prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior
to such first use, supersede or modify any statement that was made in the registration statement or Prospectus that was part of
the registration statement or made in any such document immediately prior to such date of first use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That,
for the purpose of determining liability under the Securities Act to any purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">(ii)&#9;If
the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating
to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A,
shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness.
Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement
or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part
of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in
any such document immediately prior to such date of first use.</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That,
for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant
pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if
the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">(i)&#9;&nbsp;&nbsp;&nbsp;Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">(ii)&#9;&nbsp;&nbsp;Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to
by the undersigned registrant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">(iii)&#9;&nbsp;The
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">(iv)&#9;&#9;Any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Insofar
                                         as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
                                         to directors, officers and controlling persons of the registrant pursuant to the foregoing
                                         provisions, or otherwise, the registrant has been advised that in the opinion of the
                                         Securities and Exchange Commission such indemnification is against public policy as expressed
                                         in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
                                         against such liabilities (other than the payment by the registrant of expenses incurred
                                         or paid by a director, officer or controlling person of the registrant in the successful
                                         defense of any action, suit or proceeding) is asserted by such director, officer or controlling
                                         person in connection with the securities being registered, the registrant will, unless
                                         in the opinion of its counsel the matter has been settled by controlling precedent, submit
                                         to a court of appropriate jurisdiction the question whether such indemnification by it
                                         is against public policy as expressed in the Act and will be governed by the final adjudication
                                         of such issue.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">(i)&#9;&nbsp;&nbsp;The
undersigned registrant hereby undertakes that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(1)
For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant
pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(2)
For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on
its behalf by the undersigned, thereunto duly authorized in La Jolla, California, on the 9<SUP>th</SUP> day of September, 2019.</FONT> <FONT STYLE="font-size: 10pt">&#9;&#9;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>MODULAR
MEDICAL, INC.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; padding-bottom: 1pt"> By: </TD>
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">/s/
    Paul DiPerna</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Paul
    DiPerna</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Chairman, Chief
    Executive Officer, <BR>
    President and Chief Financial Officer</FONT> </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated below.</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 3%"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 27%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; width: 4%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; width: 4%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 19%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-size: 10pt"><B>Signature</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Title</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Date</B></FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-bottom: 1pt; text-align: left"> <FONT STYLE="font-size: 10pt">By:&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-align: center; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; text-align: left"> <FONT STYLE="font-size: 10pt">/s/
    Paul DiPerna</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-align: center"> <FONT STYLE="font-size: 10pt">Chairman,
    Chief Executive Officer, President,</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-align: center"> <FONT STYLE="font-size: 10pt">September
    9,&nbsp;2019</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">Paul
    Diperna</FONT> </TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0"> <FONT STYLE="font-size: 10pt">&nbsp;and
    Chief Financial Officer<BR> (Principal Executive Officer and Principal <BR> Financial and Accounting Officer)</FONT> </TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0"></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">By:</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">*</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-align: center"> <FONT STYLE="font-size: 10pt">Director</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-align: center"> <FONT STYLE="font-size: 10pt">September
    9, 2019</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">Morgan
    C. Frank</FONT> </TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">By:</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">*</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-align: center"> <FONT STYLE="font-size: 10pt">Director</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-align: center"> <FONT STYLE="font-size: 10pt">September
    9, 2019</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">Liam
    Burns</FONT> </TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">By:&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">/s/
    Paul DiPerna</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-align: center"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-align: center"> <FONT STYLE="font-size: 10pt">September
    9, 2019</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">Paul
    Diperna<BR>
    Attorney-In-Fact</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: top; text-align: justify; text-indent: 0"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"> <FONT STYLE="font-size: 10pt"><B><U>EXHIBIT
INDEX</U></B></FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>No.</U></B></FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Description</U></B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.1</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex2_1.htm">Reorganization
    and Share Exchange Agreement, dated as of July 24, 2017, by and among Modular Medical, Inc., Quasuras, Inc., Paul DiPerna
    and the other stockholders of Quasuras, Inc. (incorporated by reference to Exhibit 2.1 to Current Report of the Company on Form 8-K filed on July 28, 2017 with the SEC)</A></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000593/ex3_1.htm">Second
    Amended and Restated Articles of Incorporation, as filed with the Secretary of State of Nevada on June 27, 2017 (incorporated by reference to Exhibit 3.1 to Current Report of the Company on Form 8-K filed on June 29, 2017 with the SEC)</A></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101041209000212/ex32amendedbylaws.htm">Amended
    Bylaws of Company (incorporated by reference to Exhibit 3.2 of Form 10-K-A of the Company for June 30, 2008 filed on September 2, 2009 with the SEC)</A></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905618000822/ex4_1.htm">2017
    Equity Incentive Plan (incorporated by reference to Exhibit 4.1 to Form 10-K of the Company for 2018 filed on June 29, 2018 with the SEC)</A></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT> </td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Opinion of Gusrae Kaplan Nusbaum PLLC</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101041217000014/stockpurchaseagreementbearla.htm">Common
    Stock Purchase Agreement, dated as of April 5, 2017, by and among Bear Lake Recreation, Inc., Manchester Explorer, LP, a Delaware
    limited partnership, and certain person named therein (incorporated by reference to Exhibit 10.2 to Current Report of the Company on Form 8-K filed on July 28, 2017 with the SEC)</A></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_2.htm">Common Stock Purchase Agreement, dated as of July 24, 2017, by and between the Company and the purchaser named therein (incorporated by reference to Exhibit 2.1 to Current Report of the Company on Form 8-K filed on July 28, 2017 with the SEC)</A>
    </FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905618001091/ex99_1.htm">Common Stock Purchase Agreement, dated as of November 19, 2018, by and among the Company and the Investors named therein (incorporated by reference to Exhibit 99.1 to Current Report of the Company on Form 8-K filed on November 20, 2018 with the SEC)</A></FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4<SUP>+**</SUP></FONT> </td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex10_4.htm">Employment Agreement, dated August 1, 2018, by and between the Company and Paul DiPerna</A></FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5<SUP>+</SUP></FONT> </td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10_5.htm"> Intellectual
    Property Assignment Agreement, dated July 24, 2017, by and between the Company, Quasuras, Inc. and Paul DiPerna </A></FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6<SUP>+</SUP></FONT> </td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10_6.htm"> Technology
    Royalty Agreement, dated as of July 24, 2017, by and between the Company, Quasuras, Inc. and Paul DiPerna </A></FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7<SUP>+**</SUP></FONT> </td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex10_7.htm">Services Agreement effective January 16, 2019 between the Company and Liam Burns</A></FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8<SUP>**</SUP></FONT> </td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex10_8.htm">Standard Sublease Agreement, dated August 21, 2017, between the Company and Western Education Corporation</A></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21.1</FONT></td>
    <TD STYLE="padding: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sole Subsidiary of the Company (as disclosed in Notes to Consolidated Financial Statements as of March 31, 2019 in the prospectus to this registration statement)</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.1</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex23_1.htm">Consent of Farber Haas Hurly LLP</A></FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2<SUP>*</SUP></FONT> </td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent of Gusrae Kaplan Nusbaum PLLC (included in Exhibit 5.1)</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></td>
    <TD STYLE="padding: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Instance Document</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></td>
    <TD STYLE="padding: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Schema</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></td>
    <TD STYLE="padding: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Calculation Linkbase</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></td>
    <TD STYLE="padding: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Definition Linkbase</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></td>
    <TD STYLE="padding: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Label Linkbase</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></td>
    <TD STYLE="padding: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Presentation Linkbase</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">* To be filed
by subsequent amendment</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-size: 10pt">** Previously
filed.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">+ Management
contract or compensatory plan arrangement.</FONT></P>


    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>ex10_4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P ALIGN=CENTER><IMG SRC="ex10_4page001.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_4page002.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_4page003.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_4page004.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_4page005.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_4page006.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_4page007.jpg"></P>

    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>ex10_5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>INTELLECTUAL
PROPERTY ASSIGNMENT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (this &ldquo;<B><U>Agreement</U></B>&rdquo;) is made and entered into as of July 24,
2017 (the &ldquo;<B><U>Effective Date</U></B>&rdquo;), by and between Paul M. DiPerna, having an address at 17995 Bear Valley
Lane, Escondido CA 92027 (the &ldquo;<B><U>Assignor</U></B>&rdquo;), Quasuras, Inc., a Delaware corporation (&ldquo;<B><U>Assignee</U></B>&rdquo;)
and Modular Medical, Inc. (&ldquo;<B><U>Modular</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>R
E</U> <U>C</U> <U>I</U> <U>T</U> <U>A</U> <U>L</U> <U>S</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>,
Assignor is the owner of the Assigned IP (as defined below);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>,
Assignee wishes to acquire all right, interest and title in the Assigned IP pursuant to and in accordance with the terms and conditions
set forth therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>,
as a condition to Modular taking the following actions on or prior to the Effective Date, Modular shall, among other items, (i)
acquire (the &ldquo;<B><U>Acquisition</U></B>&rdquo;) Assignee by issuing to Assignor (and the other shareholders of Assignee)
shares of common stock in Modular in exchange for all such persons&rsquo; shares of the Assignee (which equals 100% of the issued
and outstanding share of the Assignee), and (ii) agree to sell and certain investors agree to buy shares of common stock of Modular,
certain of the net proceeds which will be used in the business of Assignee;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>,
as a result of the Acquisition, Assignee will become a wholly-owned subsidiary of Modular;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW
THEREFORE</B>, in consideration of the above recitals and of the mutual promises and conditions in this Agreement, and other valuable
consideration, receipt of which is hereby acknowledged, it is agreed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>A
G</U> <U>R</U> <U>E</U> <U>E</U> <U>M</U> <U>E</U> <U>N</U> <U>T</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Definitions</U></B>.
As used in this Agreement, the following terms shall have the meanings set forth in this <B><U>Section 1</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B><U>Assigned
IP</U></B>&rdquo; (a) the patents and patent applications listed on <U>Schedule A</U> hereto, and any future patents that claim
priority from or the benefit of the filing date of any of the patents listed on <U>Schedule A</U>, and including any and all continuations,
divisions, reissues, extensions, supplementary protection certificates and the like with respect to any of the foregoing (the
&ldquo;<B><U>Patents</U></B>&rdquo;); (b) issued, pending and abandoned U.S. and foreign trademarks and trademark applications
set forth on <U>Schedule B</U> hereto (the &ldquo;<B><U>Trademarks</U></B>&rdquo;); and (c) all rights of any kind whatsoever
of Assignor accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and
conventions and otherwise throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B><U>Intellectual
Property</U></B>&rdquo; means all intellectual and technological property of whatever kind including but not limited to all source
code, object code, text, graphics, photos, database technology, ecommerce technology, server technology, operating systems, algorithms,
development tools relating to the Assigned IP.</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 2pt none"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B><U>Intellectual
Property Rights</U></B>&rdquo; means copyrights (including rights in software), patents, patent applications, trademarks, trademark
applications, trade names, service marks, business names (including internet domain names), design rights, database rights, rights
in undisclosed or confidential information (such as know-how, proprietary ideas, trade secrets, techniques, methods, specifications,
inventions (whether patentable or not) and the like) and all other intellectual property or similar proprietary rights of whatever
nature (whether registered or not and including applications to register or rights to apply for registration) in and to the Intellectual
Property which may now or in the future subsist anywhere in the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Transfer
and Assignment</U></B>. For good and valuable consideration including, but not limited to, the Acquisition and the Capital Raise,
the receipt and sufficiency of which are hereby acknowledged, Assignor hereby assigns, sells and transfers to Assignee all of
Assignor&rsquo;s right, title and interest in and to the Assigned IP, the Intellectual Property and the Intellectual Property
Rights, together with all goodwill related thereto and all rights to fully exploit, and to enforce all infringement claims in
respect of any of, such Intellectual Property (the &ldquo;<B><U>Assignment</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Ownership
of Intellectual Property</U></B>. Assignor represents and warrants to the Assignee and Modular that Assignor is the developer
and sole and exclusive owner of the Assigned IP, the Intellectual Property and Intellectual Property Rights, no person has rights
with respect thereto including, but not limited to, receive any proceeds herefrom or therefrom whether in a sale, license and/or
otherwise, has the full exclusive rights and power to enter into and perform this Agreement and to effect the Assignment and that
the execution and performance of this Agreement by such does not and will not violate or interfere with any agreement, understanding
or contract to which Assignor and/or any of his Affiliates is a party to and/or is effected by, does not violate any rights of
any other Person; does not violate any law, rule and/or regulation that no part of the Assigned IP, the Intellectual Property
or Intellectual Property Rights or the exercise of the rights granted hereunder violates or infringes upon any rights of any Person,
including, but not limited to, any such Person&rsquo;s copyrights, trademark rights, patent rights, trade secrets rights, or contractual,
common law or statutory rights and no Person has any rights to, including the proceeds from any sale, and/or Lien (as defined
below) on any of the Assigned IP, the Intellectual Property and/or the Intellectual Property Rights. The term &ldquo;<B><U>Lien</U></B>&rdquo;&nbsp;means
any lien, security interest, mortgage, deed of trust, charge, claim, encumbrance, pledge, option, right of first offer or first
refusal and any other right or interest of others of any kind or nature, actual or contingent, or other similar encumbrance of
any nature whatsoever.; and the term &ldquo;<B><U>Person</U></B>&rdquo; means an individual, a corporation, a partnership, an
association, a trust or other entity or organization, including a government or political subdivision or an agency or instrumentality
thereof.</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 2pt none"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Governing
Law; Venue</U></B>. This Agreement shall be governed by and construed solely and exclusively under and pursuant to the laws of
the State of New York as applied to releases among New York residents entered into and to be performed entirely within New York.
Each of the Parties expressly and irrevocably (i) agrees that any legal suit, action or proceeding arising out of or relating
to this Agreement will be instituted exclusively in either the New York State Supreme Court, County of New York, or in the United
States District Court for the Southern District of New York; (ii) waives any objection they may have now or hereafter to the venue
of any such suit, action or proceeding; and (iii) consents to the in personam jurisdiction of either the New York State Supreme
Court, County of New York, or the United States District Court for the Southern District of New York in any such suit, action
or proceeding. Each of the Parties hereto further agrees to accept and acknowledge service of any and all process which may be
served in any such suit, action or proceeding in either the New York State Supreme Court, County of New York, or in the United
States District Court for the Southern District of New York and agrees that service of process upon it mailed by certified mail
to its address will be deemed in every respect effective service of process upon it, in any such suit, action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Execution
and Counterparts</U></B>. This Agreement and any amendments, waivers, consents, or supplements may be executed in one or more
counterparts, each of which when so executed and delivered shall be deemed an original, but all of which counterparts together
shall constitute but one and the same instrument. This Agreement shall become effective upon the execution of a counterpart hereof
by each of the parties hereto. Delivery of an executed counterpart of a signature page to this Agreement, any amendments, waivers,
consents or supplements, by facsimile or email shall be as effective as delivery of a manually executed counterpart thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Severability</U></B>.
If any portion of this Agreement is held and/or found to be invalid, superseded and/or unenforceable, in whole or in part, the
remainder of this Agreement shall nevertheless remain in full force and effect and the invalid and unenforceable portions hereof
shall be deemed modified to the extent necessary to render that portion valid and enforceable to the maximum extent permitted
by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Entire
Agreemen</U></B><U>t</U>. This Agreement contains the entire understanding and agreement between the Parties with respect to the
matters contained herein, and replaces and supersedes any prior understandings or agreements between any and all of them, with
respect to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Successors
and Assign</U></B><U>s</U>. This Assignment shall be binding upon and shall inure to the benefit of the parties hereto and their
respective successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Third
Party Beneficiary</U></B>. The parties hereto expressly acknowledge and agree that Modular&nbsp;is a third-party beneficiary to
this Agreement&nbsp;and is entitled to the rights, remedies and benefits hereunder and may enforce the provisions hereof as if
it were a party hereto. Except as set forth in the preceding sentence, this Agreement shall not confer any rights, benefits or
remedies to any Person not a party hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">[Remainder of
page intentionally left blank]</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 2pt none"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><BR CLEAR="ALL"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>[SIGNATURE
PAGE OF IP ASSIGNMENT AGREEMENT]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, the parties hereto have hereby executed and delivered this Agreement as of the date first written above.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B><U>ASSIGNOR</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Paul DiPerna</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B><U>ASSIGNEE</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>QUASURAS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Paul DiPerna</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>MODULAR MEDICAL, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Morgan C. Frank</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>[END OF SIGNATURE
PAGE OF IP ASSIGNMENT AGREEMENT]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 2pt none"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>SCHEDULE
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Patents
and Patent Applications</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><U>U.S. Provisional Patent Application
No. 61/947,032, filed March 3, 2014, naming Paul DiPerna as inventor, and titled &ldquo;Fluid Delivery Damping and Delivery Pump&rdquo;</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><U>International Patent Application
No. PCT/US2015/018525, filed March 3, 2015, naming Paul DiPerna as inventor, and titled &ldquo;Fluid Delivery Pump&rdquo;</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><U>U.S. Non-provisional Patent
Application No. 15/122,132, filed August 26, 2016, naming Paul DiPerna as inventor, and titled &ldquo;Fluid Delivery Pump&rdquo;
</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><U>U.S. Provisional Patent Application
No. 62/529,086, filed July 6, 2017, naming Paul DiPerna as inventor, and titled &ldquo;Variable Flow Orifice with Dynamic Control
Feedback.&rdquo;</U></B></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 2pt none"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B></B><BR CLEAR="ALL"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>SCHEDULE
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Trademarks
and Trademark Applications</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">None.</FONT></P>


    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>4
<FILENAME>ex10_6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>Exhibit 10.6</B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>TECHNOLOGY
ROYALTY AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
Technology Royalty Agreement (hereinafter referred to as the &ldquo;Agreement&rdquo;), is entered into as of the 24<SUP>th</SUP>
day of July, 2017 by and among Paul M. DiPerna, an individual (&ldquo;DiPerna&rdquo;) and Quasuras, Inc., a Delaware corporation
(the &ldquo;Company&rdquo;) and Modular Medical, Inc., a Nevada corporation and owner of all of the issued and outstanding capital
stock of the Company (&ldquo;Modular&rdquo;). DiPerna, Modular and the Company are sometimes collectively referred to as the &ldquo;Parties&rdquo;,
and individually as a &ldquo;Party&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>RECITALS</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
DiPerna, the Company and Modular have entered into an Intellectual Property Assignment Agreement dated as of July 24, 2017 (the
&ldquo;IP Assignment Agreement&rdquo;) pursuant to which DiPerna is assigning and transferring to the Company all of DiPerna&rsquo;s
right, title and interest in and to certain intellectual property and related items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt"><B>NOW,
THEREFORE<FONT STYLE="font-variant: small-caps">, </FONT></B>in consideration for the promises set forth herein and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally
bound, do hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B><U>1. Definitions</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.66in"><FONT STYLE="font-size: 10pt">1.1
The capitalized terms &ldquo;Assigned IP&rdquo;, &ldquo;Intellectual Property&rdquo; and &ldquo;Intellectual Property Rights&rdquo;
as used herein shall have the meaning set forth in the IP Assignment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.66in"><FONT STYLE="font-size: 10pt">1.2
&ldquo;Royalty Product&rdquo; shall mean (i)&nbsp;any product or device which is covered in whole or claimed in any of the Assigned
IP; (ii)&nbsp;any product or device incorporating, utilizing or made by any process which utilizes the Assigned IP, the Intellectual
Property, or the Intellectual Property Rights and (iii) any other insulin or diabetes related product or device sold, licensed
or otherwise commercialized by the Company, Modular or any of their respective subsidiaries during the term of this Agreement.
For the avoidance of doubt, &ldquo;Royalty Product&rdquo; shall not include any devices or products of any entity that acquires
the Company or Modular that are in existence on the date of such acquisition;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt">2.
<B><U>Royalties</U>. </B>In consideration for the assignment by DiPerna to the Company of the Assigned IP, the Intellectual Property
and the Intellectual Property Rights pursuant to the IP Assignment Agreement, Company shall pay DiPerna royalties as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">2.1&nbsp;<B><U>Royalty
Rate</U></B>.&nbsp;&nbsp;Subject to the Royalty Cap set forth in Section 2.2, the Company shall pay DiPerna a royalty on sales
of any Royalty Product sold by the Company and/or Modular and each of their respective, subsidiaries and/or affiliate companies
anywhere in the world equal to: (i) US $0.75 on each Sale of a Royalty Product, or (ii) five percent (5%) of the Gross Sales Price
of a Royalty Product, whichever is less. For purposes of this Agreement, a &ldquo;Sale&rdquo; of a Royalty Product shall be deemed
to have been made when the Royalty Product is delivered to a customer and the Company and/or its parents, subsidiaries and/or
affiliate companies receives payment and such funds clear and become immediately available funds from the customer. &ldquo;Gross
Sales Price&rdquo; means the gross amount of money received by the Company and/or its parents, subsidiaries and/or affiliate companies
in connection with the Sale of a Royalty Product to customers, <U>minus</U> sales, use, V.A.T. and other taxes, shipping, insurance
and related costs and expenses paid by the Company, its parents, subsidiaries relating to such Royalty Product. Royalty Product
sold by a sublicensee pursuant to a sublicense agreement are subject to the royalties due DiPerna hereunder.</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 2pt none"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">2.2&nbsp;<B><U>Royalty
Cap</U>. </B>Payment of the royalties set forth in Section 2.1 shall cease, and this Agreement shall terminate, at such time as
the total sum of royalty payments actually paid to DiPerna pursuant to this Agreement equals Ten Million Dollars (US $10,000,000);
provided, however, that the Company shall have the option to terminate this Agreement at any time upon the payment to DiPerna
of the difference between (i) the total royalty payments actually paid to DiPerna to date and (ii) $10,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">2.3
<B><U>Best Efforts</U>.</B>&nbsp;&nbsp;The Company shall use its commercially reasonable best efforts to promote and market the
sale of Royalty Product and to maximize royalty payments to DiPerna pursuant to this Section 2.&nbsp;&nbsp;&ldquo;Best efforts&rdquo; means,
with respect to a given goal, the efforts consistent with the practice of comparable technology companies with respect to similar
products of comparable market potential that a reasonable person in the position of the Company would use so as to achieve that
goal as expeditiously as possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">2.4
<B><U>Effective Date</U></B>. This Agreement shall have no force and effect until such time that the Company and/or Modular sells
or licenses its first Royalty Product, at which time this Agreement shall become effective. For the avoidance of doubt, DiPerna
shall be paid the royalty payment due hereunder on the first sale or license of a Royalty Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.
<B><U>Payments, Reporting and Records</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 71.75pt; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 71.75pt; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt">3.1
Payment of the royalties specified in Section&nbsp;2.1, if any such royalty is due, for the preceding calendar quarter shall be
made by the Company to DiPerna within forty-five (45)&nbsp;days after March&nbsp;31, June&nbsp;30, September&nbsp;30 and December&nbsp;31
of each year during the term of this Agreement. After termination or expiration of this Agreement, a final payment shall be made
by the Company covering the last whole or partial calendar quarter. Each quarterly payment shall be accompanied by a written statement
of royalties due, as described in Section&nbsp;3.4 hereunder. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 71.75pt; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt">3.2
All monetary payments due hereunder are expressed in and shall be paid by check or wire transfer payable in United States dollars,
without deduction of exchange, collection or other charges, to DiPerna. &nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 71.75pt; margin-right: 0; margin-left: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">3.3
The Company shall keep and preserve, in accordance with U.S. Generally Accepted Accounting Principles (GAAP), consistently applied,
complete and accurate books, records and accounts containing particulars that are necessary for the purpose of showing the amounts
payable to DiPerna hereunder. Said books, records and accounts shall be kept at the Company&rsquo;s principal place of business
or the principal place of business of the appropriate division of the Company to which this Agreement relates. No more than once
per annum said books and supporting data shall be open, upon reasonable notice at all reasonable times and places during business
hours for two (2)&nbsp;years following the end of the calendar year to which they pertain, to the inspection of an independent
auditor engaged at DiPerna&rsquo;s cost mutually agreeable to the parties for the purpose of verifying the Company&rsquo;s royalty
statement or compliance in other respects with this Agreement.</FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 2pt none"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 71.75pt; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt">3.4
The Company shall, within forty five (45)&nbsp;days after March 31, June&nbsp;30, September&nbsp;30 and December 31, of each year,
deliver to DiPerna true and accurate reports, giving such particulars of the business conducted by the Company and its sublicensees
during the preceding calendar quarter under this Agreement as shall be pertinent to a royalty accounting hereunder. These reports
shall be duly signed by an authorized signatory of the Company on behalf of the Company and shall include at least the following:
(a)&nbsp;true and accurate information regarding sales of Royalty Product sufficient to determine and verify the royalties due
and owing, if any, pursuant to Section 2.1; (b)&nbsp;total royalties due, if any; and (c)&nbsp;names and addresses of all sublicensees
of the Company. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 1in; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt">3.5
With each such report submitted, the Company shall pay to DiPerna the royalties due and payable under this Agreement. If no royalties
are due, the Company shall so report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5pt; text-align: justify; text-indent: 35.5pt"><FONT STYLE="font-size: 10pt">4.
<B><U>[Reserved]</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5pt; text-align: justify; text-indent: 35.5pt"><FONT STYLE="font-size: 10pt">5.
<B><U>[Reserved]</U></B>. &nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5pt; text-align: justify; text-indent: 35.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5pt; text-align: justify; text-indent: 35.5pt"><FONT STYLE="font-size: 10pt">6.
<B><U>Assignment</U>. </B><FONT STYLE="background-color: white">During the term of this Agreement, neither Party shall assign
any benefit or burden under this Agreement without prior written consent of the other Party, which shall not be unreasonably withheld,
delayed or conditioned, except that (i)&nbsp;</FONT>the Company<FONT STYLE="background-color: white"> may assign its rights and
obligations under this Agreement to Modular or any company or person with which it may merge or consolidate or to any company
or person to whom it may transfer substantially all of its assets or to any company or person which may acquire such Party (including,
in each case, any company created as a new vehicle upon any such merger, transfer or acquisition), and (ii)&nbsp;DiPerna may freely
assign his royalty payment amount (and related information access, audit and other rights) in whole&nbsp; or in part but not to
any direct and/or indirect competitor of the Company and/or affiliate, officer, director, employee or shareholder of such competitor.
&nbsp;Any assignment by any Party of any benefit or burden under this Agreement in accordance with the provisions of this Section&nbsp;6
shall not release the assigning Party from any of its obligations under this Agreement. This Agreement shall be binding on and
inure to the benefit of the Parties hereto and their respective permitted successors and assigns.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5pt; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">7.
<B><U>Dispute Resolution</U>. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 1in; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 1in; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt">7.1
This Agreement is entered into in and shall be governed, construed and enforced in all respects solely and exclusively under the
laws of the State of New York, without giving effect to any law which would result in the application of a different body of law.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 1in; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt">7.2
Any and all claims, disputes or controversies arising under, out of, or in connection with this Agreement, including any dispute
relating to patent validity or infringement, which the Parties shall be unable to resolve within sixty (60)&nbsp;days, shall be
mediated in good faith. The Party raising such dispute shall promptly advise the other Party of such claim, dispute or controversy
in a writing which describes in reasonable detail the nature of such dispute. By not later than five (5)&nbsp;business days after
the recipient has received such notice of dispute, each Party shall have selected for itself a representative who shall have the
authority to bind such Party, and shall additionally have advised the other Party in writing of the name and title of such representative.
By not later than ten (10)&nbsp;business days after the date of such notice of dispute, the Party against whom the dispute shall
be raised shall select a mediation firm in New York, New York and such representatives shall schedule a date with such firm for
a mediation hearing. The Parties shall enter into good faith mediation and shall share the costs equally. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 1in; margin-right: 0; margin-left: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">7.3
If the representatives of the Parties have not been able to resolve a dispute within fifteen (15)&nbsp;business days after a mediation
hearing, as set forth in Section&nbsp;7.2, the Parties shall have the right to pursue any other remedies legally available to
resolve such dispute solely and exclusively in, and the parties hereby irrevocably consent to the exclusive jurisdiction and proper
venue of, the state and federal courts located in the County of New York, State of New York, USA, and waive any objections thereto
based on any ground including improper venue or Forum Non-Conveniens. The Parties agree that service of process may be effected
in accordance with Section 8.1. Any decision rendered by such court shall be binding, final and conclusive upon the Parties, and
a judgment thereon may be entered in, and enforced by, any court having jurisdiction over the Party against which an award is
entered or the location of such Party&rsquo;s assets. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 2pt none"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 1in; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt">7.4
Notwithstanding anything to the contrary herein, each Party shall be entitled to seek injunctive or other equitable relief, wherever
such Party deems appropriate in any jurisdiction, in order to preserve or enforce such Party&rsquo;s rights for any breach or
threatened breach of the other Party of any of the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt">8.
<B><U>Miscellaneous</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">8.1
<B><U>Notices</U></B>.&nbsp;&nbsp;Any payment, notice or other communication pursuant to this Agreement shall be sufficiently
made or given on the date of delivery if sent to such Party by recognized overnight courier or delivery service for next day delivery,
addressed to it at its address below or as it shall designate by written notice given to the other Party as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt"><U>If
to DiPerna</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Paul
M. DiPerna</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">17995
Bear Valley Lane</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Escondido,
CA 92027</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Email:
pmdiperna@gmail.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt"><U>If
to Company or Modular</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 71.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">3
West Hill Place</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 71.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Boston,
MA 02114</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 71.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Attention:
Morgan Frank</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 71.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Email:
mfrank@mgfund.com&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">8.2
<B><U>Integration</U></B>.&nbsp;&nbsp;This Agreement constitutes the entire understanding and agreement among the Parties with
respect to the transactions contemplated herein and supersede any and all prior or contemporaneous oral or written communications
with respect to the subject matter hereof, all of which are merged herein.&nbsp;&nbsp;This Agreement shall not be modified, amended
or in any way altered except by an agreement in writing signed by authorized representatives of the Party to be bound.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">8.3
<B><U>No Joint Venture</U></B>.&nbsp;&nbsp;Nothing contained herein will be deemed to create a joint venture or partnership or
agency relationship among the Parties.&nbsp;&nbsp;Neither Party will have the right or authority to, and each Party will not,
assume or create any obligation or responsibility, express or implied, on behalf of or in the name of the other Party or to bind
the other Party in any manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">8.4
<B><U>Severability</U></B>.&nbsp;&nbsp;If any provision hereof is found invalid or unenforceable pursuant to a judicial decree
or decision, the remainder of this Agreement will remain valid and enforceable according to its terms.&nbsp;&nbsp;Where any provision
herein has been adjudicated to exceed the maximum force allowable by law, the court will interpret such provision as providing
the maximum allowable protection provided by law.</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 2pt none"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">8.5
<B><U>Attorneys&rsquo; Fees</U></B>.&nbsp;&nbsp;The prevailing Party in any action or proceeding among the Parties arising out
of or related to this Agreement shall be entitled to recover from the other Party all of its costs and expenses including, without
limitation, its actual attorneys&rsquo; fees and costs incurred in connection with such action, including any appeal of such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">8.6
<B><U>Nonwaiver</U>. </B>The Parties agree that no failure to exercise, and no delay in exercising any right, power, or privilege
under this Agreement on the part of any Party shall operate as a waiver of any right, power, or privilege hereunder.&nbsp;&nbsp;The
Parties further agree that no single or partial of any right, power, or privilege under this Agreement shall preclude further
exercise thereof.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">8.7
<B><U>Authority</U></B>.&nbsp;&nbsp;Each person executing this Agreement on behalf of a Party has the authority of the entity
to execute this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">8.8
<B><U>Time Is Of The Essence</U></B>.&nbsp;&nbsp;The Parties agree that time is of the essence with respect to each and every
term and provision set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">8.9
<B><U>Recitals Incorporated</U></B>.&nbsp;&nbsp;The foregoing recitals are incorporated herein by reference and made a part of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.5pt"><FONT STYLE="font-size: 10pt">8.10
<B><U>Amendments, Modifications</U></B>. This Agreement may not be modified or amended in any manner except by an instrument in
writing specifically stating that it is a supplement, modification or amendment to the Agreement and signed by each of the Parties,
<U>provided</U>, <U>however</U>, that only Morgan C. Frank shall be permitted to sign for Modular, and if Mr. Frank is no longer
an officer or director of Modular, this Agreement may only be modified, amended or supplemented with the express written consent
of Manchester Management Company, LLC.</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 2pt none"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>IN WITNESS WHEREOF</B>, the Parties
have caused this Agreement to be executed by their duly authorized representatives as of the day and year first set forth above.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>PAUL M. DIPERNA</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>QUASURAS, INC., a Delaware</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Corporation</B>&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 52%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 34%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Paul
                                         M. DiPerna,</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>MODULAR
MEDICAL, INC., a Nevada Corporation</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Morgan
                                         C. Frank,</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Director</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>5
<FILENAME>ex10_7.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P ALIGN=CENTER><IMG SRC="ex10_7page001.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_7page002.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_7page003.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_7page004.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_7page005.jpg"></P>

    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>6
<FILENAME>ex10_8.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P ALIGN=CENTER><IMG SRC="ex10_8page001.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_8page002.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_8page003.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_8page004.jpg"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P ALIGN=CENTER><IMG SRC="ex10_8page005.jpg"></P>

    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>ex23_1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We consent to the use in this amendment No. 1 to the registration
statement on Form S-1 of Modular Medical, Inc. of our report dated June 26, 2019 on our audit of the financial statements of Modular
Medical, Inc. as of and for the years ended March 31, 2019 and 2018, filed with the Securities and Exchange Commission,
and the reference to us under the caption &ldquo;Experts.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ Farber Hass Hurley LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chatsworth, CA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> September 9, 2019 </P>


    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10_4page001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_4page001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *0GY@/6EI">10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !103@$CFD1MR!L8R,T +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !33_K!]*=2?Q_A0 M%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%%  3@$]:!TH/0]?PH'2@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;\WF?[./UIU)AMX((VXY&.
M<_YS2T %%%% !1110 4444 %%%% !1110 4444 %%%% !3?^6GX4ZFG[X^E
M#J*** "BBB@ HHHH :[K&NYC@9 _,XIU%% !1110 4444 %%-165G);(8Y ]
M.!3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  G R:.M!Z'%(@VH!G.!
M0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% #=O[S?N;IC;V^M.HHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "D_C_  I:3^/\* %HHHH **** "BBB@ HHHS0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4 8&!THHH :Z%F0AV4*<D#'
MS<=#3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***;&A1-
MI=G]VZT .HHHH **** "BBB@ HI,#=GN.*6@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *3^/\ "EIO_+0_2@!U%%% !1110 4444 %'.?:BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH  <T444 %%%% !17-^-GD2ST[R797>_C0@.4W @\$CM61JYGBLK>;3YK
MCS[#?<RH93\VWRV:/KR,,W'X4 =W17G]U<SS7^MS23S(S:4)XH]Y BR6Q@9X
M. OXYHN;?4;?PR]_-=.([AK,P(LS,4R4#G/^USQ0!Z!17+:[>^;KVD:7')(M
MHTQ6Y*,0"=FY$)'K@\5D31WDMCKIMKJ9(])NS+:L9&VE57+QGGE>* /0**XO
M5(KR]T*"\M)Y;>[OY?.0)*?D'E,RI^.T9]S5:#4)M5UF"YN)9H;>XTR258/,
M*A2N!NP#USN_#% '>T5Y_I#3S^&VEN+FX6XDLR8CYK$O\JMYF<\$,<?C6AHL
M5W<:E+IFJ23^=8QKF978"=-V4;ZD @_0T =A17-^"TDETI+Z:XF=W,B,KN6'
M$AP>3P0.*@M=:N!XN99]XL[Z$K:;N!NC)S@]]P.?RH ZO\*,YZ5PNG7J2:!8
MWVHS7KWE[>;2T3$;7#\1%2P &%Q56WO+E-;\D7-S K:P\2R/*63RPJDQ$9ZG
M/!^O- 'HE%<1H[RS:I>"YNKA88+^6-"9'8,"P41XSC'S?YQ5?0Y;B3299KJ[
MN1B.58W,SGSF!EXZ\%0BG_\ 70!W]%>;W>HZG'HC6;WERLMA>(DEQN(:178;
M,GO\K'..X%:/F3_\)1JELUY<Q6D!B=7$SD1#;N(QGG)H [>BN&D>^M=26&:X
MGFL;V^"6[B1LP.LI#(>?NE0:MV]C-_PETUDNH7>R&SBE!,S'YO,.<C..0,8H
M ZZBBB@ HHHH **** "BBB@ HHH[]: "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IO_ "T_"G4W^/\ "@!U
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 449YQWHH **** (9[2VN=OVFWBEV]-
MZ!L?G3$T^QCQY=G;KM! VQ 8!ZCIWJS10!5DTVPE),EE;.6ZEHE.?TIS6-F\
M"P/:0-$G*H8P57Z"K%% %5-,T^.$PI8VRQ%MQ01+@GUQCK4GV2U%M]F%O#Y'
M_//8-OY=*FHH K#3[%1$%L[<"$YB C'R'U'''X4U]+TZ1P\EA:LX7:&:%2<>
MG3I5NB@"G_96F[2O]GVN",$>2O(].E6/L\'_ #QCY3R_NC[OI]/:I** ((K*
MT@MVMX+:&.%L[HT0!3GKP*C&F:>/*Q8VP\G_ %>(E^3G/'''-6Z* *C:78-,
M9S9P>:3N\P( V>F<^OO2?V1IFQT_LZTVR,&<>2N&8=">.35RB@"DNCZ6C;DT
MVS4Y)R(%')X/:A='TM>%TVS7@CB!1P>O:KM% %233-/EC$<EE;O&N,*8P0,=
M./P%,_L;2_-,ITZU,A.2QB4DGMS5ZB@"O'8VD4>R*WC5=_F8"\;LYS]<T)96
MB71NEMXA<-P9=@WX],]<58HH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *9N7S,;AG'K3Z;_ !_A0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M94@CVI2<#)H ** 01D=** "BBB@ HI"P7EB!2T %%%% !1110 4444 %%%%
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M-=T[[$"@?+P3G'IP:N4 %%%% !110<]J "BBB@ HHHH **** "BBB@ HHHH
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M \0SE#<);P-;E]@7S?W@(95.0 1_%GCT]ZKWVM7<L=THAB$$<-UN"SE7;RV
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M@]/6@"O=^';N:,P@6IP\K*[,09 [AL,,=OQYQ1>^'+RXO+J1%M%CE25%^8C
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MJ!#Y94<<C(S^)KIZ** "BBB@ HI P)(!Y!P:6@ HHHH **** "BBB@ HHHH
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M!7H1Z'@?D* (+[6-VAC4=/.X>:B$,A)P9 K# [\GUIQ\1V"F /YR><^Q2T9
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MUV%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MA 92K $'@@TO3I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 -&_><A=F!@YYS_G%.IJ[][;MNW^''6G4
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MBBB@ HHHH **** "BBB@ HSSBBD_C/TH 6BBB@ HHHH **** "BBB@ HHHH
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M6N(9&;S3@QYW$A\]2>>F,Y_.J"6NJR?9\KJ"H3$+H><P)<,=S*0?NXZXXZ4
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M10 4444 %%%% !1110 4444 %)_&?I2TG\9^E "T444 %%%% !1110 4444
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MFU$V;VDD?SO&)"P(8J >@]C6K0 4444 %%(&!8KW%+0 4444 %%%% !1110
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M9?+.(CYX&S;(Q.[YN05(QUSC'%0V6FZDEA;VMQ9WJR+)#F2*XV*(QC<N _&
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M HHHH **** "BBB@ IH^^?I3J:/OGZ"@!U%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !67J6L?8=0MK7R#()B SAA\F6"CCZFM2J=
MWI5E>SK-<P!Y%  .XCH<CH><'^OK0!4T_6CJ%M>2QVQ5[8D;"W).,\^AK/TS
M6KI+3S+I99\QQ2S,2@\GS.!C'4<9]AZUN0Z;:013111%5F&'^=B2,8QG.1QT
M]*B_L33OW?[@_NU55'F-R%.5!YYP>F>E &-9:Q<6ZQSWDTLZBWD8J-HRPFVK
MV'/('I5J?Q(UN95FL7#P[@P#CE@ VT>I*G(_&KRZ'IJJ5%O\I1HR"[$;6.XC
M&?7FI$TFQ1(U, ?RY?.#2$NQ?&-Q)Y)QZT 9_P#PD:M<6T:6Q*7$H1)"X"D?
M+DCU/S'C_9-;4+.\0:2/RV/5<YQ5(:+IZF'; 5$ PBAR%'S;AD9P>>>:NQ1K
M#&(TW;1TW,6/YF@!]%%% !1110 8Q1110 4444 %-V+YF_G=C'6G44 %%%%
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M'Y69U;@]A\OYDFMC4[.XN7LY;=XEDMY=Y\P$@@J5/3ZT )8:U9W>F1WKSPQ
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MN>1L9>H^HH FM-3MKFP2[:1(E*AF#N/DST!]#5MI(UC\QG4)C.XGC'UKE/\
MA&KU8HPOV1O*6'Y-S*)63=G<0.^_/X5JW&E3'0[:S@,(DMVC<(<^6VTYVGJ<
M4 :?VFW)0">/,@R@W#YOIZTGVRV*N1<1$1C+X<?*#TSZ5S__  C]V7(/V79(
MT;DJ"/(V.6P@QT_+N>]10>&[R""-4%IF-(LH,A961V;YN.A!_,4 :MIKUO<6
MS74B>3;JC,7=U_A<KC .>WZU<BO8W21Y2D2)(4#,ZX;T/7].M<ZGAR\%I,C1
MV>]X'10&. S2L^,XZ8.*LKHEXDAE\JT?_2'F\DL0AWH%/\/!&/U- &]]I@,G
ME^='O_N[AGUZ4Z*:*9=\,J2*#C*L"*Y:W\,7-M&"JVCR@K\QR,J(3'C.,]3G
MZ5IZ/I5Q9Z3/9S2X,I;85;<8P0 !NP,GW- &I]JM]A?SXMJG:3O& ?2AKJW0
ME6FC#*,D;AD"N<AT*]B^S2-:Z>QA!1X5R%E&W;O)QUP!QCIGFH8/#%W$8PT=
MI(5=-TI8[G40F,Y^7U.<9H Z9+VWE@$L,J2;H_,15898>U.BNHI$C)=4>100
MA89Y&<5RH\.:BIMF$-F?*A$102$ _(R'^'G[P/\ G-2+X=O!<Q3F&T\Q%MUW
MASN&Q6#8.WOD?E0!TTEU#'"\OF*P3@X8=?3ZU#'?B72X;Z*%V$R(X3@'#8]\
M<9KGK7PW=VPA(BM)#$P#J\CD3 *R[CD$ _,.,>O/2M.;2[A_"L6F;8'GCBC3
MYB=N5QSG&>U &PLB,VU74L.H!Y%.KG].T:YM=72\,%M&"]P9#&_S,'92O\(S
MC!_.N@H **** $&<G)^E+110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %-'WS]!3J0??/TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KF?$EW<1W3P?:$2'RHW5,E69C(!USSTZ>F:Z:LG5=1T^TN-M
M]:ERL)D,GE!PJ @$GOC)% &<-4N/,DG*P/<1P2JF&*ABLNSH6QSQU[]ZVM*O
M&N]+CNI]JL=V[C:!@D=#TZ4C1Z4R%GCM-K#!)5>03T/U-/EFM;>W:&-$94"J
M84V\ G'3L.: ,&SU:Z36II;A7^S7L+/:*Q 4F// .?XE(/-%KX@O[M;80?8R
M)Y5C$A5AR8V<_+GMMQUYK5N3IDMP-+DA0,878%0!Y:C .#U4_,*;I^EZ?9/Y
MWF)-)(%5'=4& "< ;0!WZ]: ,F+Q3=R1H_V:(+.RK'\PRN68$$;O;N5Y..V2
MZ/Q%J$TZQI%9H=Z1%2Y;#%&8G(X(&WIW]:W8K?3KA+@10P.K2$3 (,,PZY]3
M4-Y+IEG")3;0R,6$:K&B[B0#QSZ &@#)A\374\D?E6\.WR8GDW.!RX)R"3D@
M8'0'//I2VVN:A=/8@K;QF66/>0204:)GQS[C^5:-U+I-O9QWD]G&#';M)'&8
M1YBICY@%[=>15C[+ILUODP6P4X'*+P<<?B,T 6+R5H["::$KN6-F4GD<"N6L
M-7O8;J.60B=9TMA(-QX+*Y)4=!TYKH&:RT;3X+?#>5Q%%& 69SZ =^]16*:5
M.I9-/B@:!UCVRP!"I R,?]]<8]: (] U>?4PQGACC5HDEC*L#D-G@\GICKQG
MTXJI'NOY-4EN;Z>VDMKGRXPLA41J,$?*,9W>_KBMRW@L[3>MO%#"6.YPBA<G
MKDTCV=E+=+<O;P-..DA0%N/>@##G\2SQPI*EK$R3"3RLR$$%75?FXXSG/MC%
M.?Q!?1)<&2RMP8HYV7$QPQB(!_AX!S^E:YL=,D,CM:VK>:<.3&IWD<\^M0WN
MBV5U:30Q00022(R>:D*[E#?>Q]: ,R;Q)<V[M%+:PM)'(RN$D)& $.1Q_P!-
M._I[T[_A(;W;,18PMY:S, LQ)(BD"-_#Z'('M6HVCZ:T$<<]E:NL>2,Q+C)Z
MG'O4%]I]G"D?V6%+69Y-BRP6ZEEW'YNW /<T 6M.NS?VC3[56-G81,K9WH#@
M-^-<_8Z_=6=@(YX&F<D"*1I22VZ8H-QQQV]:W;2XL5,6FVQ!583L !*E5(4C
M/0\T?V/I:1F/[#;A&381L&"N<X_/F@#)?Q)>1I.\FG1H+:'S)09^<[F4 8&.
MJC\#4!UJ]74VNI;78(+<B:W^T9 &]<,H Y;!'!Q701Z7I\2ND=G"HDC\M@$'
MS+Z'U'-)'I.G1^5Y=I$IA^YA>G.?Y\T 5=,U:>]O9+5[5(W@+B?]X3LP1L[#
M.X9/T%-O]<DM=4%E#9F8*(S(^_:%WL5';V__ %U=L;'[+)-++-YUQ.V7?;MR
M , 8'H*CU&VT\LMY=VHED3"!EC+,,GVYQDY]NM &5:>);N9H1)I\2B40DXG)
M($N0O\/48.1Z5!=:Y=W<$2&$VK/*C(\4N[($PC8-\HQU_&M*&VT86DEQ;VF$
MMFV<1MD&,D# ZG!)Q^E5=+LM,2(V4J&YE$[(\@A90&'[S!] -W';/O0 Z7Q)
M.D9EBL%DB/FF,^<=Q$9PV1MX[GOTIY\12 VQ-H@AN)2BR^:=NW>%#?=ZG)(!
MQTZ\U;ETNVFB>?3FBAEG!_?!=X*L<M@9QS_.HKZ'1]/6R6ZB),"A80JLV%7'
M) [#@Y/2@!->DN4N-,2"2X'FS,LB0,H+J(V/\7'4"JUOK-Q:O9VDT)EDN2=K
M2S@,IW9*-@<$ \>N*VKFPM+QT>YA61H\["?X<\'%0_V)IFPI]CC"DJV ,<@D
M@_F2: ,I?$<UR52.PVB:0);O))A7(8@YXXX&>,U-%X@G=</8HK^>L&!/N 8J
M3U [$8JS<Z'IICF*VL2/-(K,W0EMP/7MD^E2C1-,$T<OV./?&04ZX4@8!QTS
M[T 8MEK=Z(/MTUN)"UG!-(!.0BJQ;+ ;>HZGV'M5IO$D@F1(]/>1&^<LK](R
MY56Z8YP3C(X[UI6VCZ=:JZV]JB"2/RF&205].>W-,N['31+:-/:J70B*$A"<
M=P#CM\N>>.* &ZYJ_P#9%LLWD&;.[Y0V#@*6/8D]/3ZXIMEK(N]6FL#!Y9C3
M>"S<L..0,=.>H)Z=JMWVG6FH*BWD(D"9QR1U&#T]J2UTRSM)C+;P[7(VY+$X
M''3/3H,XZXH QM9U*^6]GM[=55('M2I$F&<O+@@\< C(IZ>)R\L42Z=,SG_7
M!#D1_O&3KC!Y4]<<5JSZ78W%R9YH TK!06R1G:<K^1JH=.T:*_MK<VZBX >2
M(?-R-P+<]QD@X/<T +K-Q<"\TZQ@F: 7<C!Y5 R JEL#/&3_ (UG7MU>Z1?(
MQN);Z*..>5H]RJ0JB/KQR1N/YCZUKZNU@8HHM0#$.^8]H;<&4$Y!7D' --72
M=-N8%<V[,KQL/G+!BKX+9SSDX&<\\4 9AU_[)-<1I!<74TERX2/=GY552<8'
M'48'OUJUI$MY?ZC>7,TKQP12^6D(8%2-BL,\9!YZY[^U6I-"TV5"DEON!D\W
M)=L[L8SG.>@Q]*=8)86UQ+;V0(9P)GP6*G/ .3QVQQZ4 8[W=Y_:][$MS=^3
M;W<:Y41^6JE58AB1G')Z=L58_P"$E*QW1DLR&MG6$J),[I&;  P.G0Y]^F16
M@^C6#SR3/$Y:5P\@\U]KL,8)7.#T'Y4R30=,D5U>W)5XQ&PWM@J#D=^H/.>M
M %1/$$TJGR].8/&H\Y))0A0DD#@CD97V/(XSQ4<GB"XD>%+6S3]XUN<O(1\L
MF[VZC::>EMX?-[!&L0,\;F! =_+ ;R#V;&=V3GFK*^'-)5"JVI .S_EHV1M)
MVX.>,9/X<4 4;?79+>*"*2WDE,ROY3M("7<2;=G0<\C'M5W3-:_M&]DA6SEC
MB7=LE;H^UMI'Y_7\*MQZ;9QI BP#%NYDBR2=K'.3D_4TEKI=E9W4US;PA))B
M2QR<9)R<#H,GKB@#-EN+N]U?4;>*ZDM4L8T*; I\QF7=DY'3MCZUE'6=6O+)
MKZ-C;^5:03;%88)?<#D$'V(],>]=!JMKIGSW5\K9$>'V,P+H#G!"_>'/3GK3
MY-&L)O-9HG F55<+*Z@A>@P#@8H R[/5+BU,]H1+>7?VAD1995!($:N0" .!
MG'3K4DGB=4%PZ6,[PPAAY@Z%EZC/3UQR>E7YM#TZ='66%FWR>829&SNQC(.<
MCCCCM39- TR1YF>V_P!< '5795[=@< X &1U% $TE[);Z5)>W< C>-"[1B0'
M&/\ :X%9@\3@HC?8)B-K,^&7Y0LFP]<$\GVK0OIM.G8Z3=R9:9=NSYAG.2/F
M'0\$]<\55&DZ(MP;7#>;*'^3SW.1N#-WXYP: "VU*2ZUN-55DMFBE"Y((=D=
M5SZCO6U5&WTBQMKL74,;K*"Q&96(&[EL G R1FKU !112'.#MQGMF@!:*1=V
M/F()]J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:/OGZ"G4T??/T
MH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5CZA
MI+ZAK$<MPB-9+;M$RB5E9B64\@=1\O0GO6Q6-=3W=UKQT^"Z:UCAMQ,SHJEG
M)8@#Y@1@8/YT 9USX;FDC)2WM23=22O&)"GFHV<98+P1NZ8-1?\ "-Z@'EPM
MJ0T2IS(3DAD.1\N1PGJ><=*U/[9DM D-S&TYA:.">=2 /-8#&!Z$L/IFH8/$
MS3>4QTV9(Y!"VXR*<+*<*<9]>U %*Y\/ZG,9PJVJLPG'G[SODWNK ,-O8+MZ
M]/RIK>%[@KE+6T4^4X56F9O+=G5N"5[8/0#KTK0B\3!HR\MC+$&#&,LZX?;)
ML//;!(/XTL7B4S>08M/FV3+$VYF48\PD*.N>HH FTW2Y[:SU"W*Q0&>21HY(
MCD@,203P.F?TK+7P_=&>UE:RM%6%X@\6_*MM5@7'R]3N'Y5N:5JRZD<+!)&0
MFY]Q'RG<R[?K\IIVLZFNDV:W#1-)N<( " ,GU)X'3\\4 9_B'29[ZYBFM;:W
ME?[-- 6E;;L+ 8(.#Z'\ZS[KPU=2C:MM;F$RDF 3E5YC5=V0O4%3V[GH:M:K
MX@F_LF=K6&6"?RIF5_E.UH^HQ4DFO!+L&XCN+=;<2^?&=I&%0,#GZ'C% %O4
M]-N)CIL]L8WEL9-^R0D"0%2IYYP><]ZKZC8WU\\4L]I;2QJ7!M6?CD8#%L<D
M<]N]+!XD%PA6'3[EKCYB(N 2H )()P#]X#ZU<TG4I-1>[#VS0K!,8U)8'=P#
MV^M '/IX9N=RF>VM;AQ*"\C2$%T\G81T[M@_A4-GI-Q+>/$D40O+58!).93D
M%8L$#')#>OU]*W$UV5I9HA8.\BS21QHCKE@@&2<GCJ/S%6I]34>'VU:VC:5!
M;^>J\ D;<\Y]J .<@\/7QMA!<6D1196DVF48.8=N, #^+_/K)8620WS2!4D^
MQP)+.G.!<(A7&['IS^1[U=M]>D@O;M=0BF6$/\KD+MC'E!RO!R3U]:U-)U./
M4X9'2"6(QMM8.!SP#D$<'K0!#J-N^JZ+'+'!LN0$FB23C:PP=I_D:R(/#M[;
MO"3Y<GDW*%2&V_N\EF^O+$ >@%::^(K8WC6GD3!UE6,YV\;F90<9R!E?U%4;
M[Q).T;_8[66,(L;^8P4]9=A&,^Q% %)O#MXL*I%91JT"2"(K* -QE5E;_OE:
MW=7T]M0O-/WVRR01.S2[F[%2 ,9YY(/X4C^(;983)]GN#L#M*H S$J-M8GGG
MGTST-1G7#/=0"W@N5B\]XBVQ2)2JMP.<CE>N* ,4:#JR6CI(DDDNX>8WG*RR
ML,X?:<<<X()SS["F66GW=[)>&TQ%<QR.CRK.=H/DA=@Y)^]SDCC&?:MJS\3)
M/:Q/+97"2RQK(B#:=X9@HV\\\D9K3U&]ATNR>ZDB8J",A ,Y/KG _.@#F;O1
M+Z9W>*RDCMR)#'!YP!1C& #P<<L,]>V>])-I6KM<7,D<$@,B)G,@Y(*=#NZ8
M4\$?SK:3Q':O=1Q+#<;)-A\TIA5WJ2N?K@TNE:K-J&J7">6R6WV>.6'<FTL&
M+#/4\$ >E &-<Z+?_P"GFWMY5>0SMO6;'G!SE%'/&#D\X].<U9&G7C:BLC6D
MHB:[:1LR# 0PA.0&]15W5=7DBO8;6T##]]Y<TACW!<QLX YZ\#\Z9#XBABLX
MGN%FD MDGDG$81<-G'4]21C% &5I&G-'=:?9@>6RP(;R$RDE"F"IX.!N)Z=P
M*U]:T^XN=4M;BUB^9()H_.W?ZMCC:<9YY!J2#7[2?#6]M<2L2 XC0,4YV@G!
MY&1U&1CGI5:#Q%D?:KB&:.'[,)3$$!*C>5W9SZ8R.U %.VTJZ>:W\RSN([8R
MKYL1F[B-PS<-R"Q3\LXK0U^TNYYH_(ADFB\AXU6.388Y#C:YYZ#!YY(]*EF\
M1V4$ZQ2AU)=E.<< -MW=>1GCCW]*M:9JD.IK*T$<BK&<!F PW7D8/M]: ,27
M1]57[8D,Q;">9"YD(+R, &'MC#8]-P]*@32[[>K-;7WE+#,51KE=RL=NT<'&
M<A_4<CZ#9O-?M[?SE2*5F0O&C;<(\BJ6*@Y]C^1J33;NZ;2#>WP#$KYBJB%"
M%P#@@GUSSZ8H Y]=-UC9;;XKG:&?:(I%0JV]2K/DM@8!!P3QVYQ3[.PU:*ZB
M>:*\8BX4S-YR[& +?,H!SCGOSTXXJ]9>(S-> W$4D4$T4+1Y3[C/NZGWP,5I
M:7K5EJK2+:.S&,!CD=0<X/Z&@#DY%U#3;(M)'=QF18P1-<##N)22NXMQE/I6
MSIQGF\)7(@$\EP?,"YDR22> K;B,#H.>U6)KO4+^;4(;&&U,=JWEA9U+>:^T
M-CJ !R!WI[Z_86D;"02*L0892,E24'S!<=<?T/I0!S[6&LNA)M]0$D4<WE$3
MJH+&0&/@/V&>OTYK0T^VOQXA@GN;2XRIN \[."A5BI3 SQ@+CI6@OB2Q9G#)
M<IL#E@\##!49(^N#G'I0?$FGK;&=A<*% )5HB&"E2P;'I@'\J ,[4[+4)=9,
MJV]Q($F#1R)( HC\EE( W#G<3^=0C3M5DM[AMEVMR+&%8BT^!Y@W>8!\Q&2"
M.<5L2>(K&.65"MP?*#;F6$D': Q ]3@Y^E.CU.2^E3^SH]T<<RK.9%QA2F[(
M.>O(]: ,>&TU#?")+;46A)!BW7 5HCNR=^T_=(/3DX'O56#3M6M],:WAM[U6
M%O''_KL?,),L1\W'RG\JZO3M3M]2$IMA)MC.,LN WN/4<&L:;Q#=6^I26KBV
M<K=I;J@#*[!@#NZD<9_2@#)U-[NW)MF:ZC$?G.,SC=&C2#8X)89. P S6WXA
MAO9]+MDTZ*X/4G8^''R';G)&><=^/>K$FM:<\C%X9',>?+<PD[R&"D(>^"0*
M/^$ET\^65\]E>)I2PB.$4$@DGZ@B@"C;6M\^I6\\MG,BB],S%BO"^1LR<'^]
M4^O6^H2W3?9HYG5K?$#12;1%+GJW(R,8]>A]:OZ3?O?M>;XR@AG\M59"K ;%
M;D'O\U17>OV=MYP*RL8RR A#M9U7<5!]<?U]* .=BAU2YMYWL7NVD5IUF?S3
MMD EP%3).&PK#M4@L-0\N9Q;ZB5CMF,"R7&&W%C@84XR%)]>W-;VCR74FDM<
MR);J\N98]D908(!^8'OG//<8-4(?$-T-/T^]NHH%AU!<1F/<3&Y0L 1_$/E/
M2@#+ELM6:V4BUU W"17,43"3;C)!C_CX&..<].]7;^#5FFN#"EYYIE+(ZOA/
M)\O&W&?O;OQS@]*OQ^)+2.!/M/G%Q DTCK P0!AD<GUZ 9Z\5/'XBTZ55:%Y
M90QP?+C9MAW%><=.010!S]Q::P+22*%;\L65QF0G+>4 PSNR 6[] >V*WM72
MY(LBD<SP"0_:$@8AL%#@@@@D!L4V'Q+8/!#+()HQ(H<YC;$:EMH+<< GO[&G
MKXBL'QM%QAG**3 PW$'!QD<X/6@"EX<L[J&^GDOHKD2M''^\=\JQ P>_7IV]
M<5GW.G7B7$_D6U\")+AD=)#SN7*8.[/45T^J7ILK5610TLLBQ1 ]"[' S[=S
M["LC_A)T6X4O'(MNAF28F!]V8\<@8Z<G/I0 W2DU8:V7O1<[2<YX\K85&.,G
M#!LC 'OFNEJA#K-A/J'V&.<&?G QP<<D ^HJ_0 4444 %%%% !1110 4444
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MB*>.]> S(5!MV(4K..X']WT[>]:]LUU'X<U!K=)DG$]RR#8=V#(Q! /7@Y%
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MQVX(_"H%U.>*658K^WB$EX%>980-R^2#N/X@#/O0!U45J8=/6TCF<;(_+63
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M-:U<YH>K7=WJ2Q7-Q$Z2),RHJX*[)2H[\Y'\JZ.@ HHHH **0'.>",''(I:
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M;JW=/LEHIR(UZ8&< ?B/SJG/K=]:VPGN]+6-&565A/D+E@N&XX.&SW[T^UT
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MBN6BA>%8)DVAC(JYP<GH>3S[TY?#T)M[>*2=W,%P\P8 #<&))0^Q)_2@"?\
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M4 %%%% !1110 4444 %(/OGZ4M(/OGZ4 +1110 4444 %%%% !1110 4444
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MF@\02SVQG4A+9&"0EED'F/N!..RG/![BJ=MJ&L3S112W5RA>81S!+;!A)W9
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M&Y+NTX6[:<3B<1KO7!& /;@#Z9K..OSI+'$UY"Q9X I\O!D5G9&8#/3@'/\
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M-"\B2JQP!LSLZ\/G/?H.E:5S>SV]CHAMKF-8Y2H<E=WF#RR< Y[X_/% #I=
MN7F\U;V-6,PD(\HX'[HQD?>]\TMKI3)JMH623996RQ/(0 LQ &P@9)XR]/T?
M5KJ]N(UF^SO'-:B=?)!!C.<%6R3GKUXZ'BJL.OW<WE;7LA]I<(@^;= <D8<9
MY.0!VY..V: -+4]-N+JZBGM;E(B(VA</'O!5B#D>XVCVK/E\-RRPK ]S&8XF
M<Q$QG=AG#D-SSTQ^M10>(-0EF3=':"+?%&^-Q)+NR9!STRN1ZBJ]OK-ZEL]V
MQMY[@6RMDEE S(1@KG''YT :*:+>I</(+F JPN!CRSG]Z0?7MBD70+F, QW,
M0>)8/*.PXS&"/FYY!R:KOXCO(5G$R6V^&.9N,@%HY%7')[AA5S3=:N+W59+=
MH8U@#2(IW#?E"!TSG!SGH.W7- %C3--N+.\EFDGCD6:- X5-OS#/3T'/2JE[
MX<^U7\LXN"D;R!Q&!QR L@_X$H _,U6BUO4%6:,FV>9#<R?,"H"1/MV]>ISU
M[>]6]4UR:UBLC;P(7N8FFQ*P4 * =N21SS^&#Q0!#<Z!>S1.J7, ,AN V5)
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MXK:RVQPK+-.J2 2'"@YZ';SQ[5D6.OW=I8)'<0&>1E4Q.9,ERTA4;N.,?C0
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M!(J+0+.\M[@--%+"@MU2422;_,E!.6')_/C.1Z4 :\]I;7,*PSPI)&I#!6'
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M\?I2T@^^?I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 8<VNO#.UVT+,A@)B59OE<&4*K$8P,Y!SGI3IO$T]LBM=6 BR&R#+D_*X!P
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MY7RK[1+>_@B$C?:%CE22&-@&E)"N,GHS8!_$UU5Y?062QF<MF0X140LS<9/
M]JRQ?C5]4:RCABFL%13(9(V^?(R"IZ>G'OGM0!D6SZE<;A#-?^8B7&(VWX23
M*-$C$CGY<]>M,6366MH=D^HB&1F#,;=S(C[1@8+9QNW<GY?PKI$O=*TQC9Q8
MB6/@[(SM#8S@D#&['..M2C48I]*EO;1L(J%D>6-E'3(.,9(^E ',2?VQ)',S
M3:DLF+G 0-C<"/+ P.F<_7Z4Z]?6GDO6$M^C!&\M8H6VE2HVD'/4'MC/7M6]
M%KUE^YBED;[0Z*Q58F(RR[AV[X.*>VNZ<L2R&8[719%_=MDAB0,#'7@\>U &
M+;&>#6H+BZ&H211+<HA*N>-ZE<\<Y4-^6/2NK+80M@],]*R9_$>F1Q&2.1YL
M*K#RXV8$';C!QC^-?SJ:37-.C\SS)V41ABQ,;8X&6 XY(SR.HH P;.QNX3:S
M6<;M;W$YDFA=2IBE&3N&1T/0^_XU&[:C*+=IGU$QJ83<+L8%9=YW;<#D8]..
M!727>HHFDRWT#!54$AID8 <XY&,TMOJUE/>&T27,ZDJ5V,!D $C.,9P0: .5
MMYKZUMDC@6_1796$?V9L)_I'(^[Q\AS4UQ?:G;)/*)[T[A.%#0G Q(OEA?EZ
MD%L=:Z>ZU*SM)EBN)@CL,XP3@9QDXZ#/&361-KEA?/'!=1(;&82AFD!SNC=5
MZ8X'.<_RH N>';A[BSF,DTSLLS#9,A5XUZA3D G@CFJ.J37HU.:.VDNU1Y+9
M=T<!.T%FWX;;C&,'VJ^FI:-IHE@2:.$1MEQM/)) Z]SD@4_4=5%KIT5[ @DC
MDEC7+97"LP&<8SGGI0 [0Y9I=*C-R93*&9294*L0&(!((';%<[=1W U*X :^
M5EO'D#I"6"KY! VG:1R>/RKHAK>FF(RBZ38%#DX/ W;<G\>/:DEU>V$BQPS1
MEQ,L;A\CJ2.#CDY!_(T <]/?ZG]ADDC:[64LA(\AD+'R>0#MX^8<<$9&.]==
M'(?LRR2*RG9N88R1Q[=ZHQ:]I<RR-'=JPC&6X/J1QQSR".*<NN:8P4K=H0R;
MP0#@#!/)[?=/7T- &%;W%U!K4>J2QNL&H!XVQ&Y,87)C+C'RXP0?]ZJ]K>ZG
M=>3$UU?1.\L*RH8"&4$-O<$IPI(7V'XUUL=Q:WMFTBLKV[!E;<,# X((/XUE
MVNH^'M/5C;SQ1YX.=Q;"C/?G !X[<T 8[7VL1_:B;FX)BD*RK]F8^6@D # ]
M\IS\ON>HIR7&LM( ;R]*YA576UP&5G<,<%3T4*?Q!KH!KNGYN0\VP6\@C8D'
MDE0W'KP?T-#Z_I,;,K7L?R$!B,D G&!GWR* ,!;[6?,LDFFN(=R\$VY/FL)"
M"& '!V@=<=2:@:[U-[:,7%U?9V0329@VE3YN&& OI@X]JZ&[\0Z?#:M)#=0/
M(8O,16<J".>2<' X/Y59;5[!7EC>Y0/"N9!_=Z?KR./<4 37<C)ILTD;,&6)
MF4A<G./3O]*XQ[K4/,%PT]R+B*&4"18MP?YX\ ';R#ACT!KK;?5["YEBB@N5
M=Y1N1<'D<_E]T\'T-2W>H6=DZ)=3I&S_ '0?RS[#D<T <C=WMW<&_BF^T/#D
M%%,+<%9\?W>/E]SQ@UT6@#"7_P I7-[*PRI&1GK5NVU*SNYI(K:=97B^^%YQ
MR1_,&H8];TR1Y$2]B+1*SOS]T*<$_@: ,G5+V_CUZ2WM[R1=JP,D B#!MSL'
MR<9Q@9Z]JJQ7>HBR@EEO[M?.BE?=Y )$JD;4QMX!&3[XZUL+?Z)#=/??:XUE
MG7:S-(>0O;:3QC/IWJ_=W]I9*C74Z1!SM7<>IQG ]\"@#C7NK^*&[&V51<?:
M"\(M]RA@BD'E><MD<]:MM+<0ZA>&VDDVRR,TD1A!4IY P_3^\ ,>_2NA_MG3
M-Q7[;"2$#G#=%(R#^54M0\1Q0LD=@(+J5XWD >;RQA2 ><'GGOCH: (=#DF.
MK.)[F9]]E ZQM& HZYQQQS_/VKHJI66J6MY.T$4BM,D:2.%.0 PR,'O5V@ H
MHHH **!S10 4444 %%%% !1110 4444 %%%% !1110 4444 %(/O&EI/XC]*
M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ )QCWHHHH *
MS'T2W:>>;S[I3<,&E EX?' &/3'%:=<CJ6H:O'=7XBDEC\O>$C6 L-H4%6!Q
MCD\=^IXXS0!JS:!IZ0RL\LT:D!G?S-N&4[@^?[P/.:7^QM.BDC>2>7,@"'?,
M?W[ E@6]2.2/_K5A7ES>EI5DN;ME1+I$_<@ASA2H(V^Y'T%68)[@ZB,S3.3<
MPG8\0VJAA[';Q\V10!JP>'K6#:5N+HLGE[2TF=NS(7''HQ%3Q:-:Q1V:_._V
M-B8F<Y//KZ^OU KECJVM?89)&GE\S(W)Y)!1P'R@)7'9<#GIUYK:UN^O+>[L
M4MWD"R$;D51EOG4=P<X!.1P><\XQ0!HV.EPV,TDD4LQ4YV1L^5C!.2%'N:B.
MEVUU,UTMU,PDF2;Y64KN48&..E4M%OKVXOL3S&1# 6N$*8\B4-C:..F,]?3/
M>LVVOKF#38HK21X@L3O BQ@B9_,;Y#GVQP,'G/:@#;F\/6DPE1I9Q"^\K&",
M1E_OD<=\GZ9.,5+!H\,-ZMT)YV=7=\,1@LP .<#V%<^VLZE'!/*;MI"8IV"&
M$?)ME"KC Y)4D\^U7[?5+AO#EY=K<L\J.0A9!NC7(V[A@#."": -&^T6WO[Z
M*ZN'D;RL$1Y&W(SSTR/O<X//&:9;:'%;R6[BZNI/LQ_=J[@@+M*A>GH3[UAV
MVM7TUQIZ23OEI2CJBC<W[T@$@J,C:!DC&.N*LZ]JVH6NI2Q6KL%6(LJJ@;D*
MQR01G' Y'T]Z -1M"MBLHC>2/S;A;@E2."#D 9'3.3CW-4;_ ,/B:UD6UN9)
M7+$,K,HX:02/SMX.152;7+F2258KPQP>=(([@0AAQ&A5<8Y!+-]=N,T[1KV1
M-;:%)4\BZN)BT>S!#!4.<^O6@#9T>QFM=-:VN&QEFVA2,HI[9 &3G)SCO6</
M"=G';^2]Y<>4VT,#L . %'\/7@<]<_6J=QX@OHM2O(DD4Q(S*N8^8@'52<=\
M D]??@=8[K4IY+A1+?12P$P&/?#A9/\ 2,;ASV !S^/% '1ZQI<.IVB033/$
MB-G*X.>".X([_G1-IT<FEQ6#7$@9-ACER-P9""#C&.H'&,5AZEJ%^(]0@N3%
MLM,L[-%E9$8KY8'O][/N!ZTTZC/%K#>9+#/(EU+Y<6W# >3E0#GC)P/?- &B
MWAM'5U:^G;S$D1B53G>X9CT]14USH,$]Q<2/<2K#=+B>)< .=NW.<9'&.AYP
M*P4\2WXMXI7N;:0.ZD^6N6P<97!P,@GH.0".M7?%M[@264LT<,7D+(-ZY\T[
M\$*<]0!G\10!>?P^)MGVJ^N)BH9&+;?F0C!7 ''U'-+%H.V\@NY;QY)H67YB
M@&Y54@*?^^F.?4U7L=8NKC5(X2T+(\TL;PJOSQ*GW7)ST/';^(8JI?>(KVTN
M[G8]M-''++&L80[OEC# YR<\\'B@#?U"P-Y)!-%.T$T!8HX4-P1@C!J/2]*7
M3993'.SQNJ*$*CY=HQU[UB?VK?/K-E ]_;&W$^#*D>%FRF0OWNHS_+TJ>]U>
M]35I+:&\LXXUN%A >,DKF,MDG<.XH N7>@BYGF(NG2":3SFC"@_O NT$$]NA
MQZBKB6!71QI_G$@0^2),#.,8SCZ5S1\474KV826V3[1;J64CE7:-WX^;.,J!
M^/7-,M_$>H+% $FM)$2WC9V<G=(2I)8<Y.",'Z'IV -M=!5;B*3[6VZ-HFQL
M7GRU*C\\FFR>'+86S1PS&)_M'VA'VAMG7Y<'C;\QX]ZS/[6NH6>XF>S-S):0
M.KA"-H>3&W&[G&?;WJJU^M^#<S/$LTL-H6V/QN$[ \9]* -E_# >1Y#>N)"B
MJK", _*5(+?WL%/U-+=>&OM,$EN]Z_DL9&1=@RC29W'/?JV![U+I5]J-QJEQ
M:W/D[;4L)2L97.2/+QR>JY)J@_B*Z+G9):KNE,)B96+VY$@3<_/(P<]NWUH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%%
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MW2_*IZ@<<#VJU10!%%:V\+AXH(D8((P50 A1T7Z>U2T9STHH **** "BBB@
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MKVT-M'+/+!@O,P:0ALY.,#]!5B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I!]XTM(/OGZ4 +1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5C0Z+-$TA&IR_O9S.W[M,ANG!QP,#'YULU@6_
MV<^)Y3;&-XVMY!<,DA)#!EX<?GC\:  >&MD1CAOG4+()H]T:MMDQAB<]=V3D
M>IJ1O#V5FB&HW"P3IB2/"_,^S;NSCTQQTR*D\.W$/]CV4)G1I&C)5=V20#S^
M50^*VM%LD%U<&-GW)$IDV*7(X8G_ &>3_P#7Q0 #0)?-:9M3D,K2^86\M0/]
M7Y9X^@JS'HD"RV;O(SFU@\GTW\8!./0;O^^JPA,IF#->2&X,D:QS9VG[/Y0+
M/@\8SN.<=0*9:RV+R*(;MCITEQND1I2P1?+;!9B>-S+G'TZ$T =%I&D)I:LJ
M3&12H1!L5=JC.!P.3SU-,L-&CM4O4DF,BW9PR@;0!@YX]3DY/>G:=+<1>&X9
MI5:29+?=@]6P.,^_2J&F:1]JT^RO'NI!)+%%)+MP0[?>)_'=^@]* 'VOAQ[8
M0A+X?N6)3$"KQM95SC&3ACSWJLVAWEC)9FTG,I1HT+^4/W:I$Z!B"W/WNU0(
MEM87>L3VH,CZ<J-$GF$\^6<Y]N>:>NN:G*61+JP^2"6<ND9<.$VD8^8 ?>]^
MGX4 7D\-B-?ENFW)Y1C.SHR$G)&><ECQQ38]&8:G;EHW;RW>>:?("2,QSM"Y
MSPP4_AU.35.VUW496C$MQ8LK/$K!8R#^\CW?WNQ_/VIEGK=U':Z>(6M%@^SV
MI:/:<CS'V8!W<8'/>@"_+X=FDB>/[8HW+,H/E=/,<.>_;&*;/X99YIWAN8D$
MDOFIF %@Q8,<MG)!(/'O5(>([NZWI'<VD0$L!#[<C8\C*?XNGRCK@\]!Q4L&
MKW%MIX6!;9###).4PQ$H$C#:G/!X]^HXH TK#1YK2^2Y-TC\S;U\O&=[!N.>
M,$5'J'AY+W4)+HW+H&*'RQTX^5S]63Y<]A2:1K%U>:AY$_V<HPF*^6""-CA>
M<GG.?THUA8&UVP6>5D1HIB^)2@P ,9P1ZF@ DT*=G+I=1*?/DE'[HXPR;<?>
M],<U9TC2Y-/>0O,DBM%%& J$8V+C/7O6'::_>6XMX"Z3Q-.RK-+]YHO,"*Q.
M1ZGGG./QI]KKVH%(H9!;S.P9Y&R$X,A7 ^;J!SWZCZT 68O#MTL*QO>PMLCB
M1?W)Z1OO'\7X5:T30AI5Q))OA88*1E8@K[2<X9N^/PJI>Z?+HVDW%[%=RRSP
MJC(69N=O!')/7)'Y=QFMC5KQK'37N$">8-JJ')P22 .G7KT[^U %6STJZLD-
MI;W2"RWLX!3]XH)R5STQR><9Q^=4[;P_=1?9=]S"QM%2*/"'YHU;/S<_>X'Z
M^M0+XFO3!'+]EM\! TG[PY_UOED =O7J:FT^^EO?$<4K.JQ/#.$C5V_@D5<D
M=,\'^7:@"M>:/=V-FNPI.Q$$06.!C]V7?N(!Z8)S4TGAN\:>&9+F ,LHG8;"
M!O\ -WG !Y&#CGT]S5W7-3FM+J"U2,>5.-KR9(*DD #(^[U.#ZC%9-IKU_;:
M-!&8H9)A#"REI"2P9&/.>I^7]?:@"6[T:YMK-ESYTC0+#$8(SN617+HQ/89(
MSFMF?3"VBK80E,C:27SAB&!)R.02<\CO6%'=RW5]',)I%22\MFV>:3C=%N*_
M2M[6KJYM+6*2U\O<T\4;&0X #. >WO0!F0Z!>H8V:Z@=U,.6*'/[LL?_ &:F
M67A[4+:6.1KJW;9(K\*W.(RA[\=<\=*KV>MW.GP3K)']H0O,T3&4EL^>$ .1
MP/G'.>@J=_$E_%'-+-8PH+:#S)5\[)SO90!@8ZJ#UXYH T/[)G_X1^RTXRQ^
M9;&'<^#AA&P/'UVU0G\/7KK((Y+0>9YV[(;_ ):.&_3%./B.\6[@MY;&-"T@
M23][DKEMH/ XSD=??TS5"SU:_LU%_< 2++'<2RH;@G/EM@;01A>N/P% &B^A
M7S7L\RRVRAY)70E22-\87D=#@@?6J\'AS4(XV3SK95S(0 6;EX@G4^A%6[36
M]0N=0BM/L,$;-N9BTV<*"G(P#V?O5O7]6DTFU26&%9G8M\A8@D*I8XP#Z4 4
M['3Y&UJ)I$8+;P()OE8(\JC"E21\V%8_IZ58OM(FNM6-P##Y+B')(.]#&[-Q
M]=WX55N_$4\<$FRVC#AID4F3^Y'O#=/TIX\07 C+&UC81.D,I\W!#LH88&.G
MS#/X^G(!)H>BS::SM+Y+L(Q$CJS%I%!)!;/3KT'O56/0]06UCC9;-F\N>%U+
M$KMD.[<..HZ8[C'-/L_$5U*T)N+&**&3RLN)R2HD7<.-HZ8YYJ.+Q#>W9MUA
MMH8R]RJ-F0X*%&;(.W_9//3TS0!I:'IDFFQ7"2>4Q>3<CKR2NU1SQU^7-5O#
MVCW6F/<?:FA99HT7Y&)Y7=G@C@<]!46GZU+]EM8XX595@BDF>>XPP5R1D$CY
MCQ[57CUJ?4YK/:DEMBZ",%<D.K1.WH.G'MWYH (?#M\CV_FBUE1$6,KO<!=C
M%E8 <$G/3MQUILOAB[DL8;?R[+*636Y8LW+%E.?N^B_K4ND:U=16>GVLT/G2
MSP1O%(TIS+EL,3QU4')]JW-5NY;*Q,\$*S/O10C/M'S,%ZX/K0!2MM)F33]3
MMF,<+7CR%#$Q(0,N/05331+Q[RWNI+>S39(A>(,<85&7(^7J=_3T44Z?Q)<P
M&<-IRL( RLRS<;U4,1RO3&<']*67Q'<QOY2Z=YDZM)O1)<@*A7)!Q_M#K@<=
M: +&J:0U_J&6BA:VEM)()2WWAG&".*H)X<O6@F\^XA=Y8]Y4@[?..-QQ_=PH
M'XFIO^$H87#6[6D8FRZ*@F)RX;"K]WC<#D>U:6NW%S;:#=3V^U9DB)!W8V^X
M.* ((+-+>RU&;4HD2.[)>6*/+JHV!3VYSC/2LA?#]U/H]HS!99PY:2.9FCWK
MMV+DKR"%QQ[GUJW%J\VGVKH\+W"0S- 7:;<P?;N ^[]WH,GGVK9TRYN+NR2X
MN8$@,@#*JR;_ )2 1S@<T <M)X7U!I7'EVC1LICSYA VY0@X*GGY>Y)SWK7M
M-(N(/$37J)#';;&!"G.[(4# Q\I&WG!P1CBHI?$TB1QS+9!HI\F ^;RP#A#D
M8X^\#WI3XEE!$?\ 9[-*F_SE1]P4*^PD''/0GG'2@#/O?#%W/<7A$5O*))"Z
M2R2OE@SABI7E1C;C./2GW'AV_9)Q'':,)EG549B!%O<,"/E]L$>PK3N_$<$+
M(8HS)$P<;V#)AU4D+@CG..*AD\2M')<#[ Y2#<K/NP!( #MR1COC.<\=* *E
MQX=NIBY:VM&R]PP!;IYBX!^[US5:PM[@>)(S+;*XCN,[!G<A$80N<K]WC(Y
MZ5MV6MS7T]O'!9C#J[2,TA&P*Y0X&W)Y'?%3:OJ4NGW-KMB5H7WM,V[!"JI/
M QS_ /6H IZII-[J%Y>2E857[*8( 6^_DALGCCD8JFVE3+-//J<$$=I(\S2*
MC%]JNJ*. .N5J[#X@NIY(HX]*D$DI.S>^P$;=V<D?4=.H_&FVOB22=8I&T]D
MBD6%]WF D+*VU>/7/;T_*@"YX<LWM=-$DX_TB<[Y6V[2> %R.WR@<?6M6LW2
M-6&IR7*>3Y1@?;@MD]3U&..F?3D<UI4 %%%'6@ HHHH **** "BBB@ HHHH
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M_=C.>,IU_P :>]OJT<U[+&-0<2&=54RX 4J"FWT.<@&@#9&EZ1ID/V@1>2D
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M@8=\;1CTY&3[]ZF30].CN(ITM]KP[=F';' P"1GD@<9-23Z79W%U]IEC)EP
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M7\X^:SL_[UN2Z[6_2@#2B=98DD7[K $?0TZH;:W6V0HC.5XP&;., # _*IJ
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MD6.26 QA6+C[J9P.G4[CD_I6UH=K=V=A'!=,H\M=JJ.>A/.??BM*B@ HHHH
M**** "BBB@ HHHH **0ALC! &>>.M+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (N=HW8SWQ2T44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !35_B^M.IJ]_K0 ZBBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ JM/>I#=1V^"7=2['( 1!U8G\:LUB:K93RWMQY.?],LVM@Q7
M<J,,D9]CN//M0!H#48&G@1&#QW /E2HP*L1R1D=\#/X&K=<M9Z3>026=G-M/
MEWK7C.A9@%PPQN(')+?D#74T %4+_4Q974%M]EGG><,4\K;_  C)')':K]<Y
MXCBEFU2T<6:3QPH_#"3DM@=40XQC]: -JUO[:[@AFBE7;,NY QP2/I4OVB$K
MN$T>W.W.X8SZ5Q L+J)].(5Y?LBQJ6:VE4_*Q.!A#D8.!G'3WJ%M*E$ 3[/(
M\8=AY!CF4;655SO" G&. 1T.,\4 =MJ&H16 B#))++.^R**,99SC/?CH">:+
M34(;E7)#0.DGE,DN 0V <=>>HK$U&?=+IMU:1W$DUD6S'):R@2*5VGG:<'I5
M/5VGU+]X]N^7@DAV-:S$0[L8<'9R1CVH Z_S8\D;UR.HSTIV]=VW<,^F:X)]
M,#M-_HRY=;@9:VERQ<J4;_5]1M-'V6.]O-1:VC>W8RR#[0L$A<Y@";>$SC<2
M?PH [OS8]H;S$P>AS2F2,$@NH*]>>E>?2:8\D+'["L1,4H5/+G?8Y"88'9_L
MYXQ4TMI++<7$WD-MF92RR6\I)^;)P?+..G0@\],4 =G+?11SB% TL@*[E3&4
M#9PQ]N#5CS8\L-ZY7J,]*X&"RDB>VFDLP'C6U#.L$I8&,G=_RSR<C%.EM,K#
M$UHS")@)',$O^DYE5\M\A[ CZMZ4 =ZI# %2"#T(JG=ZG':7<5LT%P[RJ60Q
MIN!QU[_2J/AA)8++[.;;RH59V'#+C+DA<,HXP1TI-;T^ZO-3LYHK=9(;=),_
MZ08F+-C&"!GM0!KVUPES DRAE#C(5QAA]13PZ$9# C..M<M#H%VM[!=&UMDV
MHL;1A\XPI"R9QRRYQ[Y)],5X?#=[#"-UE;2J,)+ TYVS85E\SI\IY!]>OM0!
MV,DB1QM([!40$L3V J.&X69Y%57'ED#+# ;(!R/;FN5F\/Z@ZF VUJZ'SR9/
M,QS(F!@$'C=[^AJPNBW?E7$L=G;P7221RVO(8 A K ^G0_F* .GW#.,C-07]
MY%864UU,'9(5+,$&3@>U<]#X<GMM9@E15>"'R_+D$NTH%&&!7'.3D\''/-)J
M^BZC=:A?SV\41$\+Q*7<9Y50,<9'(.1R/QH ZG</6J%OK%O<7*0(DH9VD4%E
MP,QG#?SKFKOP_J;QLMO:Q)&)WECC$P!3)0C!Q@?=;ISSUY-:]C87L>I02S0(
MJ))<,Q$F<;R",?D: -:VO(KF6XCC#AK>3RWW#'. >/;!%6,CK7-7FAW<^J74
M\ 6"21V9+H-\VTP[ N.OWN?P'>F6VFOIWAO4EO(EB5X22@EW#<$P3P !G ]_
M6@#I\CUJN]XD=O<3O'*J0%LY7EL#.0.XKC7T"]N-)865HD:3H&51(,JXB(#^
MF22/?C/!Z7I]&U"2&4264,R32RLT!E'!9%"OGID$'\^* .A.I0 V0(D_TS_5
MG;P/E+<^G JYD>M8%_I<]S8:5'+9QW MN)H"XP?W93J>",D&LPZ%JRW,+L@F
M*0B)I%FP6!B*GD\_>Q[=#UH ['<!U(I<UQ4/A[44:VW0 QH3Y8218S$V_(=@
M,C)&,[?3WK7U73+FYU:.98$FB*H$=I-IMV5LEO?(P./0=J -[(]:3<.>1Q7'
M?V%?2-;>;9 K$8Q<CS01<,K9,F#UX]>3GVJO-I<]AI;&ZMO*C\N-&Q,,LPFR
MHZ_W#B@#N=P&,D<TN1ZUQTF@7SM"R0L( [M#"LX7[,2P(.>>./X>1G I!H=]
MMGQ:2KYR2+(!*I+ S!EZD@X7/!XYQWH [%G55+,P  R2>U10W*3NZH'VJ%(<
MK\K C/![UR T'579!+:ICR3$0)!MP488.<G[Q' XX'6IXM(U!80ILB(<VYDM
M_,7$H52''7'4@XZ';0!UV117'Q:)J,<PE:"1VC,1A_?@[ )68KR>R%5_ UHZ
MU8WMQ>L\$3/NB58) X'V>0-DL03W&.F>F.] &I;ZE;W-W);0^86CSEBA"G!P
M0#T.#5NLGP[9/96DR36H@D:>1LY!W L2#P3V/\ZUJ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "FKU;ZTZFKU/UH =1110 4444 %%%%
M !1110 4444 %%%% !12$D$ #(/4^E+0 4444 %%%% !1110 5R=E<7DFK7M
MM/J$Y9PS0B(J5D7(QM)'RL!QCW)Y[=96#<CP[;RW+SV]ON=Q'(?*W;VR#C@<
MX."??K0!G+J-Z=-\TW<JR6ED9L,!F217965O7&W''][/I6EIUY<2WT#R3,?M
M#3J\1QB/8V!CT..OUJXL>DW$L5NL-O(8$$L0V A%/0CCV%1?9M,U.*Z%IL#2
MC9)/&F"P/7#8P>G49H R;[5+ZW^TW*3.',D\*Q$96,(A*MC&>V?^!?2I);J[
M^WS:=]MF2*$/(LYQN8A$8*3C&/F)^@K5#Z1YT]T1#O1?+DF*<$=,;L8/3!QZ
M8J-H=%-O;VIMHO+D;S(X?).<]-Q7&1UQDB@"Q;WLG]@IJ$R#?]G\YE)VC.W.
M,GI6.?%%R(5<6,>0LK29E*X";2< KGE6S6[=SV:*+2Y*MYPV^5MW;EZ'@=N?
MI6386GAF^:6"QB@E(7YPH/*GCKW!Q^- $4_B>X@:Z9K&,Q0F4*WG<ML56/&.
M,@G\JFO_ !&]F\B"T#F.4HWSGE0JL2./]KOQQUJ^=%TTDDVB')8]_P"(8/Y@
M 4QO#^DO%Y36:%3UY.6X Y/4\ ?E0!DPWM['?1;)GN"9[M?*=L!]O*C..,"M
M?1]4.J1M*(5CC 3!#Y^8J"5Z#&,XIW]CV<>'MHDBF1FDC?DA'88+8S3(-'2&
M&VC$S Q3M<.4&WS'8DGCTRW2@"36=1;3+-9TB$K,X0*6(SGZ D_@*J:?KXOK
M^*V^S^4LL*RHS/RP*JW QSUQP>U:&H6]I<PA;U R*VX9)!! /3'/3-4;&WT:
MV6SN[50J3*%MW);!RH Z]"0 /7M0!%KUU=17L$44KPP>1+-)(C#=\A7L0<C!
M/'>H7U2YNM2M+8AK4EMQ".&$B-$Y4YQU!7IZXZUK7<-B;V"6Y/[\AHXAN;D'
M[PP.,<#/X55M--T@S/%;AFEM2N?WKYC^4A0#GIM)P.G- %#3O$+IIEMYL;3O
M';0R7$K.%/SG (&.>0<],5-#XG$DZV[6A2=N GF<Y\S81TZC&?I5N?2M(MHD
MEFC6**!0F3(0NT'(!YY /0&FNFAPRB\?R5<SLZMW,FW:V!W..* %TG6'U/E+
M4(%<K)F3YH^,C(QG/M_.F^([BYMH[)K6>6(RW21,(U4EE.<XW \\5)I>GZ8D
M:7.G$LI.0XE9MV 5 Y/(&3@=JEU**PNYK:UO&;S"Y>%5=E)*C.>/2@#+37)[
M%8X[F&XN#/*R0F38C;@<!6 P!G!(/3%2MXE42NBV4[*)#$K@?*T@<)MST')_
M2IKS2M(AA=KLLHE^0O),Y).0>"3G/RC\J1=)T::"6[&'AF7<SB9MG'5QS@'C
M[PYXH ;_ &^RM*DUC)')$\2LI=?XW* _F/R-5(?$%RQ:YEM9=J6\LIA1E(8)
M)MR.^0*O)H6DW,,<J"5T<*P<3O\ O,'<I)SR<\Y-3VNBV-I<>?"LH<;_ +TK
M,,,<L,$XQF@"E-XE2-@J6<TVYFV^5\VY5QN88]"P'YUJ:A>K9:?)>>6TBHN=
MHK+^R>'YH;:SCEC MR5C$4Q4C)(*D@]"001WQ6Q<6L5Q:FVD#",X^XQ4C!R,
M$<CI0!A6>O2/J),@9K><0B,!T(B+;NXZY*TU->EU&>!;420 3-%(/E8-F)F7
M\B!_]>KAT;2(9XH#O660AT0S-ERA)SC/JQ)^M/@\.Z;;LC1"X#(05/VASC *
MCOZ'% %C19I)]#LIY6\R22W1F8 #<2H)K,'BE1#%(VG77[T%U5 '8H, M@>Y
MZ5I(VGZ3:V]@;A($QY<*R2\D = 3S53^Q]'>%( [;;/=TN&!0-]X,0<X..A]
M* $E\0K%F0VDIA<[8&&#YK;MO;IW/TJ.'7\R23M!<^4SQ(5D"KY);C)[XSUS
M2MI>A&%I3/B*Z;,9^TD*K%MV8^?E.1GBIWTG2;6WN(IVVQWB"*3S9C\_7N3U
M.2?6@"./Q)#)<0Q+:W#"7:2RKG:&)"DX['&?I5W5]332K,7,D;2 L%PI ]^_
MTJ&73]+?4(L.(YX47]U'+MRBG*[E'4 ]*ENK:QUJU13+YL:/N#0RXP<$'D>Q
M- $ZWL1TT7[96'RO..1R%QG^59-SXFCM(!-<6-S&I/\ %M'R[=V0<X/T^M:U
MO9PV^GI8J"T*1^7ASN)7&.36<?#.GF 0EKD@*4W>>V=F"-N?0 ]* *M_K[M=
M-!9K*LEO<QQR+\I,BLP&,9R,]B<5M:=>+?V4=RB,@?(*MC*D$@CCW%4O^$=T
M\S><PF>0$%6:4DKA@W_H0!J_9VD-E;B"W#! S-RQ)R22>3[DT 8LOBRUBMYY
MOL\Q6"0QM@KV#$]^#\O0\\CUII\0-:)J$MVIFCCNO+B" #">4K\Y[\GZU:?P
MSIT@;S3<.S'EC,V<888SZ8<BAO#.G/&R,;@[FW$^<V<[-G7W7@T !U^,3,@L
M[@Q+,D)E^7:"^W!ZYQ\P[5HV-V+RR2Z"-&CC< V,X]>*S;C0U339[*R.5NMJ
M3-.Y8A0H7(_V@ /RK4A>W16@B=,0 *R@_<&.,^G% &#J/B7%B39P3"295-NY
M"X92X3<,GMN!P?4>]:RF_BTACD37@1BF\!<GL#@X] <5370=-NK<-%-,\+Y:
M,I+PH+!L*>PR ?PK1<6US'+8O)YA5 )%W?, 1P3CIG!H YNWU;5I](N+F*[M
M-T#.&$D1$@8<+&5!ZD]^>,=>M6+G7;RW$EU)'&L,,OD20XRV?+W%L_4@?3-6
MAX8L0@ FNU;S3*76<ABQSCGVR<?6K2:)8HZ,$<A !M+DJQ"[0Q'<X.,T 066
MI7(>ZBO=CO#;I< QJ1PP;*]3T*FJ"ZOJ#R6MG-Y GO5C='5"1$&#L1C/. AP
M:T%TN&TF@BM;AXR\@9P[EFD15("#/89''UJ1-!L$C9$61>4VMYAS&%.5"GL!
MD_G0!E0:_>3(91Y02UV+.NT_O"9&0[3GC[N1^5;NHWZ:?9_:7CDE7>J8C&3E
MB /U(J :'8 P[8V41;> QP^UMPW>N&)/UJ/7$_M"T?3K2>$7)>-RK2;2H#AL
M\ \\4 1+XGLRT<9AN!*3MDC" M$=VWY@#Z@],],U?TS4%U*W\^.WGB0GY3*
M-WN,$U4/AZR;82TX<9WL)2#+D[CN]>:NVD-OIUO%:)(0N2$#MR3UQ0!1;Q%9
MQK*98IT,1D#@J/EV8SGGON&/K3/^$HL0D3-%< 2R>5]T?*VX*._/WATSQ3UT
M87,NHRZA'&K7@\K$3'[@Z'/][I^0]*9+X:M)MC27-VTB]9#+EF^92,G'8HM
M%[2]2CU.)IH(9TB!PK2*!OP2#CGU%7:KV-G'8V_D1,[)O9QN.2-Q)/ZDU8H
M****  9P-V,]\4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !35[_
M %IU-7^+ZT .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?3CZ4V76-,$TMM+=Q*Z;@ZD],#)'Y<T 8(EU<:?)(L]P3!<"WD<+YA=58[I
MHY.>!QC&#4'VK65F2-IKY\1$;Q;D%_D8J<8('('7G/I6YI^IZ=&K16CP)901
M J5R#]XKTQTR.#W-6TUC3G>)%NX]TW"#D9.2,>QR",'T- &9>23VWAZTE-]=
MB22:#>Y4;\,RAAC;Z$\8JA'=:LMS9K,]]Y>0"WDGYD+N 3@==H7.<=1QUKH-
M3DTW=#'J#J"KB1 6(VD'ACCMG')XS4UO?65^9H;>=)O+^60*>!U&,_@: .;2
M;5UM;@//<L8)Q;;U7=O^<DO@#(&TJ.!Z_6H=/>_>9)BUTL\QA,J&$A9$\O#E
MN.O'KUQZUTVER:=Y3VVFF,)"Q#*G8Y//OR#S]:;_ &YI7[P?;[?]T"7^?H <
M'\C0!SEE)J,*Z3;12W$$:V\&$^S,V\YPZMTV\8Z]N15W4YKN/4KM(IKF)&>U
M56CASP6;?SM.>/RXK1M]<M)!=2O-#Y$+A49"69N,\C&<]>!G@9J?^T-/N9DM
MEN(Y)& =%!Z]QST]#B@"E9W%V?#32R&X>=&=<E<2%0Y .,==N.U0&6Y$QC%Q
M.4V-Y)SRQ#+C/ZCZ>E7]5UB/3YK>!?+>:::.,H6P55FVYZ4R75-*6[CE\X/-
MN$"A6/\ %[="..OM[4 10K,LCD/,\RM( K X4]L';Z8]J1WG \MIKH!<'?Y9
MR?EY&0/7';O^5S^W-+",S7D2A6VG)P<XS^/0_D:;_;^C[B/[1M\CT?WQ0!!8
MSSR:B@,DK 1A64C:/N@[L$>IQ4<N#-)(\DZHMPREU7E!@].,\]./0?4V5URR
MBC=[VZMHOWDBKB3.0IY_''7TJR^IV"2M$]W"KJNY@7 P,9/Z$4 5M.^T27+-
M//.1&BX#+M#Y!YQCCMQGBJ\4JR3R>=+<,S/\JX/[O[W&0../Y"K5CJGVZUNY
MX(U(@D9$PW#X .>G'6FZ?KNGWEG;S&Y@228)F/S 2&89V_7_  H K++>L^_S
MIEB:,)'E#UV_>/'^>>*>7N+?R&2>9E;]YM<;]P)''0$8SW[<FK\VI6<.GO?M
M,AME!.]3D'''%5[+6K6YN+B!Y(HWB<A09 =Z;0V[Z8- $FD2SRV[&>19,-\K
M*<_T'.:OU%;7,%TA>VE250<$J<X/I4M !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !35_B^M.IJ]_K0 ZBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K"DT*R;%M_:$Z[!B*,.F8E+!L $=,J.
MN>E;M<KI,0M["*TN;)I=8A+.TC1'E\G#^81@@\=\\XQ0!OWUBM[#$C3RQM%(
M)%>,@-D CN,=ZSCX9MVC5#=W68TV1N"@*_.'!'R]<CZ5F1SZE));Q_:M16*9
MH_.8P$,CE7WJ/EX4?+[#UJM%>ZNECONKF^C=X;5F+0GY&,FUU'R]<8XY- '5
M_P!F0OICV%PTD\<@(=G/S-GG/'3\.E0/HYFC N+^ZE="IB<[04*G.< 8)]<B
MN?%[JL-S9!Y[YHU?AC"Q,L9D*@L O7;CKCMZ\+!=:NEJTTEU>,T4,5RXDAV9
MVL0\8RH'*]NN<4 :_P#PCMN)V87USYC[6<93YL.7SC;_ 'C4;Z%)]N">?,+1
MXYO-?<F6,D@8KC'3K^=2R6\UOHSWLC.VI"W9?-";F3<<X '4 X_*J5T9KGP1
M.MS#/+.X8!60R,QW\$ #)'IP.* +?_",P-+/)]MN,3')50G&'WCG;D\_I3_[
M%_XF$&07@AF>X\QV&69R24P . V&Y[@5CVWVJU:]:!)HK&2:(/+%;F$HNTAM
MJ'G@[<MCN?2D74=535+:-Y;S84*9,#8=2)-KD!3AOE0G.,>G6@#H-;TF+5H8
MXYYVB2,YX Y/KD]".Q'K4FHV"W;6[)=26T\#%HW3!/(P000<C!_E7(WWV]]*
MACO9M0D>2"*95\@MNDW#>I 7C  (!]370ZY)(E]:-$SKB&<[EBW%3M&.<''T
M[T $GAR-T>+[9.(2QD"G!(D*;2V2.>N<>M*N@+A&COY/E8,"%4@D1>7Z>GZU
M%X9GNW6[2[N)YE"Q2*\L94@LF6 X['M6-%/=PQ1NM[<PAK/;&HAP@;S"#T7Y
M>".>V: -V/PXB-&?MDI6/R< *HR(P0 ?KFDC\-HGV8/>2,EIM$(*+\J*<@$]
M^@Y]OK44]Y>KX1@N!)*ETP3<SK\QYYS@'&?7&.:S'O;^>U*7;W&YH51K9X\A
MHS%DN2!][=GOVQB@#HX]+VZ*=/2X+!L_O&0-D$Y/'0]:HQ^&8X54+?3?*$VY
M .&1RZGZ#)&/2J>G7EZ-2L;<2R1P+%$$B\EBLJ;/F)., AO?C'3FEUJ663Q!
M!'(\B^1-&T,8BW*ZE3N<G'&#QU[>] &C'H.RX-S#?RH\Q)G**,2_-N&/3&3T
M[&I-$T4Z.K)'=O)&_+(R #=_>'IGO6#;ZAJ$2Z6MMYI_T+)MUCV@N$;J,=,@
M#@C'''-26]UJ%U/:0V^JW3I*SNSO;A"2%4[,D=-P8=.^.U &W<Z)%->7=TL\
MD3W,'E?(<;#T+#WP%'X503PJODR1->?(Z2IA(@NWS H..?5<UEP:CJ4HMI+C
M49XT-RHN%6 YB8JP*'*],A1CGKUY%30ZA>0V5A';RF-A"K1((\"XDWD,A&.,
M#'IC.>U &A+X8,T_VF6]#SF0L6:W4KM954C:?]Q2#U&.]6;/0VM-0BG6]=H8
M3*8XB@R/,(+ GOR,].]5- U"]FU,PW=T9EEC=E4QA=A60J!P.XYYJI*]R;N.
MX>\>W+:E)#-A=V8PIV*>.A ''^U0!I:CX=^WZF;PW94$%=IC#%04*D ]NN:M
M3Z7)+HD>GFZ(9 @\S8,-M(."/0XQUKE;#4M1M-)2 W;(@BMR96BQ]G4A]W8Y
M^ZH).?O5U=K VHZ1:&^=VE4*Y=,Q[F'\6.#[T )8:6UEHJ:='=ME/NRJH!'.
M>E5K3PZL&F26+7),<^3,50#+84 KZ8VY[Y)S6)>PVEMK%Q;HRB**"%5\U'8Y
M!;=M8=&VXY^E/N]7U /(\%Y-&Z"1VMO)'[M4= .HR<KDGGO0!L2>'5DE><W;
MBYF#K+)L&&1@H( [<*O-2ZQ:3_9=/@L(R3#<1D,1N"*O<C(S7/7%]=W,ES)%
M=RK)';W8BE\D!L!T*XX[@$?AFM33KC47U.*U:^EGB94N5E,:@-%M(VG Z[N?
MIB@!R^%HXIA+%<J&*C>7A5B6!)!4_P /+'(]/SK3CT]DT-=.,RDB'R1(8Q@C
M&!E3UXK!\1,BZVDJ2":2-44V;,59\MD-&1_%QR.XQFJQU2XN[V2&YG+1QW<+
MQ@K@J!.RGL.-H'7/K0!J0^&7C@V?;1G:JC]T2% D#X&6)QQC!)I+;PU-#=&=
M[Y')D1VS"<ML=F&3NZ_-CTXZ5F_VYJ$MQ<0I?B+,Z*KM$,HID=",8XP-O7)X
M]ZT((=0O;V?2K^\F>.'+2NJ*GF(VWR\$#@Y#YQZ>XH O6&B+9:G/="2-D>1Y
M% A <%SE@7ZD9S@?SJF=)N=0N[\S'[/";DR1;DR6/DB/=G/3[W'TK8M%MK21
MK*.8M*VZ;8[Y;!;D_3)Q7,ZCK]_#J6HV\%PJB)9#$&C!(*B,@8]#N;G//\P#
M5FT!YHP#=K&RPPHK+%]UHVW \GIGM2?\(\SWR7DMS')(0OFEK=3DJQ8;,_=Z
MD=^/?FL'5]2O'TV]LKK40-HN%\T1J/-*A=B8[9R3QZ5OZQ<7$$>E26]RT,;3
M!7 4'>"C$ Y]2 /QH FU+1VO)I'CG"+/ ;>=67=E"2?EYX/)]>O3BK.EV+V%
MM)%),LI>5Y 0FW&XYQU/K7,G7;Y+2-GNV99%B,LBQ - Y)WIC&,C'0\C!]J(
M=:U622V@>]A61XT.X)GS6)8,% !Y7"]Q[T ;.BZ+-IEY<3R7:3"9<$",J>&8
M@D[C_>]*SH-"N;^*Z^T,MM^_G$*M#D[78$D\\\#VZU0L=4NQ):W9U-)2\%J)
MP5&6+2$,.O& >:D@US5KN:&(7]O \TZQN@B+-"2'RIR ,C:O?^8H W)M%N6N
MY;N*]C28SK,G[DE1B/RR"-W.1].:2S\/_9=4^V"XC<%@[;H%W[MFTX;LO .,
M?C2:]/J5I]F-G,Q\T-#A8@W[PJ2C'T&1@_6L:74[Z4PSF=XG>UN/*4H-ZLJK
M[<_,&[=J -R_T6:YU$W$-W''&[PO(C1;B3&V1@Y&,U3@\+&W$0BNHAY+J4(M
MP&*C/#D'YC@]>/I5'3[^XBU:)TOQ-%<201RAL'<3&<D'MSMZ?UJQXEGF%]-:
MO?F**2"-HH\ ?-Y@!.1@GMWH LV'AE[*6!EN8,02*5VVP5F50P 8YY.&Z_I0
M_AJ21'5[R/YHYH\^2>DCAS_%[8J@=>U)7@A%Q;Y$LJM+(I F*R[0@ !^;;Z=
M<BM+69@FMV<6H3-%ILD$FYMY1/-!7 9AC^$M@9YH :WAVX='S>P[G,YSY!P/
M- ''S=JAD\*,YE N80' <,8,N'V@?>)^[QTZ]LXJ.35VM-4L[6SN]UFS*"9C
MEF#NXX8\D<#!'&/7(K+.L7UR$NAJ"^= )2&4 QMB+=\H!^;GU&1G!H Z[3;"
MXMHKL74\<CW,IDS'&4"Y4#H2?2L>?09H+ 1AVN+AE@@BDB0*(O+)*NV3Z]?R
MQ5K7+AKC0;9X[M+:2X*%6<D1DXW;6(Y ."/RK+CUR2 Z?"DQBAD;#K+(&R&D
M93ASR1QP1VZ]J .DN].6;1)-.MV$:F+RT)YQQW]:S+GPW-=>89[Y,RO([E(=
MIRT7E\<GZUEV>N3VT>EVRW481X8_,,AR<LS DDG)Y Z?CU%6[75=8-C87$LD
M4IU"+$8CAQLE(! /)XP'/X4 ;6BZ<^G6\BRM 9)'W-Y,>Q>@'3).>/6M&HX)
MHIT)AE24*2K%"#R.H^M24 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %-7^+ZTZD7O]: %HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** $ P,5'<6T-U&(YT#H&# 'U!R#^8J6B@ J&ZM+
M>[5%N8ED5&#J&Z CO4U% !1110 4444 %%%% !1BBB@ HHHH **** # ]*,4
M44 & >PI, D$@9'2EHH *B6VA2>2=4 DDQN/KCH?K[U+10 8!ZBBBB@ JO)9
M027T5XRMYT2LBG<<8/48Z=A^56** # ]*KV]E!;32S1*WF2G+,S%C]!GH.O
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M** "D7O]:6FK_%]: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !115.XOO(U"UM&A<_:=P60$8! )P>_:@"Y1110 9
MYQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(Q"J68@ <DGM0
M M%9PO;F[;_0;<>2,'SI3M#C_9 Y/UXI[IJ@VE)[1L?>!B89^AW&@"]16:M[
MYTK6.H1/:2O_ *LK+Q*.^UA@Y'IP:=;22VNH&QGE:1)$,D#MRV 0&4GOC(.>
MO/M0!H4444 %%%% !12$@#)( JN^HV,?^LO;9/\ >E4?UH LT4R.6.49CD1P
M.ZL#3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IJ]6^M.IJ]3]: '
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !5*[L7N-2LKH2HJ6I<E"N2Q9<=<\5=HH **** "BBB@ HHHH **** "BBB
M@".X222!TAD\J1E(5]N=I]<5@^5>P7EZPUMT$.PXN$5H]I&<G@8YST/I715F
MM96\^IR&Z1)0-LL2OSM.-I.,^P[4 8L>V^2.]G6Z4RW(AWK<R!'4]&CY&!G'
M4>O7K6U')-I][#:S2R3P7&5CDDQN1@,[2>^0"0?:DUN&:2UMUM8M[I<Q.!G
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !2#O2TU>K?6@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4@.<TM("#G% "T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%,:,M(&WL /X1TI] !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !2#O2TB]^G6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *3+;\8^7'6EICQAV#9(8="* &W3F*UED4@%4)!/:J>EW?VIF(=W
M78#EOJ1_2K\D:2QM'(H9&&"#T(I(42.)51-@ ^[Z4 /HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I%[_6
MEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ H'US12+W^M "T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !10#GI10 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !2+W^M+2+W^M "T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !2"EI%[_ %H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH C@B,2%3(S_,3ENO6GKT/U-+10 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !0!BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ****  ]*1.4!]1FE/2FQ_P"K7Z"@!U%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I38
M_P#5K]!3J1 0H![4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 <]Z*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HZ=:** "BBB@ I%SCFEHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!%!&<L3D
MY'M[4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ I 2>HQ2T#WH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex10_4page002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_4page002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *,\XHHSSB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "D_C/TI:3^,_2@!:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0 C.3G^E+10
MC[MC;,;L<9Z9I1G'/6@G )Y./2B@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3)W8QQCK2TT-F1EPPP!SV-
M.H **** "BBB@ HHHH **** "BBB@ HHHH **** "D'WS]*6D_C/TH 6BBB@
M HHHH ***;(I:-E5BA(P&';WH =1110 4444 %%%-#,9&4H0  0W8]?\_C0
MZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ (R,44'BB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 0,&SCL<&EI!]XG=D>GI2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!2#[Y^E+2?QGZ4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8YS2T44 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !2#[Y^E+2?QGZ4 +1110 4444 %%%%
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MQP0#0 M%%% !1110 4444 %%%% !1110 4444 %%%% !3=PWD;AG'3-.IO\
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M/#MS) 8&O(BL;%H"8>3EP^'.<GD8XQUK0CTA!H3::Y0!E;F--H5B<Y ]CS0
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M&I%2-1J!^5$5SY0^8I(9 >O')Q3-1T"?[%<&&7SY)/.^0(%)\QE)P2>HV\4
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M* "BBB@ HHHH *0??/TI:0??/TH 6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KG/$.KW$+7=G$/*Q;LZ2JV&+ 9P.,?AG/?WKHZ
MR=3714N6;4$A\V2,A\J3\G R<=!VR: ,^7Q+<6ZJDEDID29XY0LA. NWD<=]
MPYZ9[\TNFW-P^M0*\\K(9+Q"K-P0KC;Q[=*U)-&TJY'F264+[LMNV]<@ _H!
M^0J6#2]/MY$E@M8D="Q5E'0MU_.@#.UR^NK'4K>2V7S0+6>1XFDVJP4H<]#S
MR?SJ2RUUKS4A EJPMV8QK*6Q\X4-C'Y_E6C=65K>;#=0I)L.5+#I_P#6X%"V
M%HMX;Q;>,7##!DQSZ4 9^JZ@]EJ&8XWD9;.218Q)@,0R@#&.O/6LZ3Q5,D?F
M"VB*B)V)WD;F4.2HXX/R#@\\].#6_<Z=9W<ADN;>.1RACRP_A/456FT_2+&!
MKJ:VA1(4(+E<X7G/UZG\S0!0G\1SK(T$%B)9_,VHH? 8"-7/..OS 4EKJLNH
MZY9-&1';E9E*"3)8J%Y('H2<?_7K0&A:.]MY0T^W,3E7(V=2!P?RJ.W_ +%?
M55EAAC%X6D56\L@Y4 -C\,"@!-9U2XTV[1A&C6JVTLS\G<2NW ''^U5G3+V:
MYDN8+F-$FMV4$QME6!4,"/SJQ<6EK<R1O<01R-&&"%QG (P?SI;6UM[.,QVL
M*1*3DA1C)H YMIKTZM?1I-=F&&Z0;Q*H2-=JL=P/..3^=3#Q-/\ 9[AVM(Q)
M#,MOM$A.9&; /3[N,'/?.*T5L='NKRY M('GC<&8F/G<1D$^IQBI?[&TS84-
MC 5:,1G*#E1T'TH S4U^ZDR%M84>%5-PKS8*EF9>/7E?KSCK36UV\FEMX[>W
MA7S/)9MSGA9%9B.G!&TUK#2]/#P,+.'=;C$1V#*#VIB:+I:(52PMU5B"0(QS
MCI^5 &38ZW<+;V47V?<US"C0>9*69SN 8$X[ Y^E7-'UF74K@J]KY<3H9(GW
M Y ;!!'KTJ:&32X9TMH(%5K:7RD"Q'$;,I/''''?I5NWL;2UFEFM[>**24YD
M95P6/O0!D7VJ7%IJ-ZL,(D9/LR*'E(7]XS#.,<?U_"M/2KUK_3TN'0(Y+*P4
MY *L5./Q%1O'IES/=/)!')+ 5\XM'SE1N7ZXSD5/IPM/L,3V"*EO*OF(%7:"
M&YSCWSF@##M?$=W=10XLHT>[91;%I1@@AC\V.1@*>W)-+;>))Y8@[6L7WX%X
MD./WCE/3L1FM1M)TM$D7[';+YTF\Y0?,_8_6H;+0;&"U@CN(+>YE@4*)&B Z
M'(X[8)H S+?6YM1O+(,C18N4QY;':Z-'(>?497KT/:MC5[VZLS:I:0Q2-<2^
M5^\<C;\I.>![4Z+1=+AD$D5A;HZD,"$'!&<']3^=6;FUMKG:;F".79RNY<X^
ME &!:>([J>!3);0QR3+ 8CYA*CS-WWN!TVG]*8GB6]>95^QQ*J-''(=Y/S-*
MT1QQTR,UH'^Q8K 3O9QQ13(@*&##;20%!7&1SCZ5,;?21?1VALX?.\K>G[K@
M*K#'.,<$T <ZNL:G#)%?R>7+^XF:5%=@FU9D48'][!(S5I-6N["&1]IEB>[N
M(PTC%B'!.Q![$Y _ 5KWMII%G9SW,]E;B)%+/B$'()R>,=S4%_%96MQ:DATC
M=VE%O#"/WLBC?N/'48_&@"QK<TD&@7,S*"ZQ98!ROUP1S6<^NWL5Y-&\-L8T
MDDB3YR"2L7F G/ ["MYEANK<++&LD<@!V2+G(Z\@U"UCISLSM:VQ)^\3&OIC
M^5 '/+XCO7?S,P*J02%HVC93O#JH!!Y!Y''UJ"?4KJ]@FN2\D+FVQL20J 5G
MVYQG@D5TMS9:=':$RV<)AC1N-BX53][KV]:@TY-,O(93'IR1)N,962 *6'#=
M/3D&@#.N-=U&.ZG1([/RXWF0%F;/[M0V3]0<>U-E\37B_:GCM(=D*'&Z0 [A
M&']<]SV]ZWC86#DDVENQ))/[L=^OYU7E_LJ.[BB-M"TLN8 5B!P N[:3V&.U
M &0=<U(7K1M]E'DK-N49PY5$8<GI][%;&AW\M_IQFG"B5':-P%*\CV/0U8-C
M9,NPVL!'/'ECN,'].*@GN[+2/(MU@=!,Q$<<$)()ZG@?B: ,63Q%?^5;O$EM
M_I6UH]P/[L&58R&YZ_-G\"*VM%O9K_3%GF$8EWNC;/NDJQ7/Z4ZT33[BW,T=
MK&BS,68/$%)8'DD'OFI9)8;*WW0PEEW#Y(5&>2!G'XYH Y(:Q?)<QW;2V\DJ
M6TS.F2!@3*-N,\-CO6QI>MW-[K$ML\42P@R*,,-ZE& Y&<\YST&..N:TTBT^
M;?LBMGPQ#853SG)!_&I]D,1:8(BG'S.  <#WH Y?Q([MJ%R7D4Q6UEYRQ;V7
MYMQYRK#T'X5//K&I1"\>,VKQ6]P(%4(2V-@;/+<GGH/_ *U:%I>Z=J6]S;;0
MT2ONFC $B-T.>XXJ5'L)I[JV:V1?)*&0NB[6)'!]Z *WAZ^GOFO&GN89=LHV
M(BXV*5!]??\ G67J6K2?VJLS3PPK9RS(L3$Y.(B=S 'D$^W3ZUU"B".1M@C5
MVQNQ@$_6@PV\C%S%&S'@L5!/I0!S$/B+47MA,PMR#+);81=Q\W'[O.&. 3Q^
M7K6]JEU-8:-<72JLDT,6[&#@GUQZ=ZSTN=/GUCRDBECCMF8E@$6$R# Y[Y /
M'_UJVC- =P,L?!PPW#@GL: .1O;N;4]1MM/GN[9K=KDQ%D!"S P[O[W4$]CU
MP>M;7B+49M)L;9K;RE\R81&2=L*@VDY)/N .?6M&-;1\+$(3M^8!<<>].G:
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M]I>O/!+>1WZ;F197:5@%0VY5CC=@?/@YK;?7=-M+6+[.KE"(MB)"V KMM!
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MO?GIUSSTJ\OB>RDM?-2&[^8QA!Y7+B3[I'L2".?2G_\ "3:;YD,>Z3=+C P
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MZ* ,[2M)&FPO&+F68E0H9PHVJ,XX4 9YZ]33M)TN/2XY4CE>3S7WG(  . .
M  .F3[DU?HH S;[2C=ZA#>+>SP/#&T:B-4((;&<[E/\ =%4_^$7MUDMVAN[B
M,6Z*J ;3C 8=2"1D,>E;U% &#_PB]NJIY5U<1R*SY= @RKXW+C;@ [0> "#6
MZJA4"C. ,<TM% &5#H4,,+6JW$_V$[L6V0%4-G(R!G')X)J,>'HQ+#,;VZ:6
M':$<[.BA@H^[CC<WYULT4 <W=^'VMK>W6PEF8HT"%BR#:D;9!'&">35M?#T*
M2B2&ZN8B5Q*%9?WIW%MQR.N6/3'ITK7"D#DEB#GFG4 8+^%[=X&A:[N"C1I&
M0P0C:BE1P5QWS]<4?\(M;;YB+NZ E1T(RO ;'?&3C;QFMZB@#';0(BV];NY6
M4E]S@KE@^-P^[C!P#ZTZUT"WM;J.>*:8>7(75/EVC*A<=,XPH%:U% $-Y;B[
MM7@9W0/CYEQD<^_%9</AJTA4*D]Q@%#C*X^0EAVXY8]/Z5M44 8UKX;M+79Y
M4]S^[9&7+C&4! [>AK1L+-+"SCM8G=DC&%+G)Q5BB@#.GT>WN+QKF26;<S1L
M5##;\F<#ITY-0#P[:B.-1-<9AVB%MPS$JG(5>/U.3[UL44 -D19(VC<95A@C
MVK,&@6@MUC$DX9-GE2!\-'L!"@<8X#-UZY.<UJT4 16\:00K!'N(C &6R2?Q
M[FJ3:):O'(ADGR]Q]I#B3#(_3((Z<<8K2HH R#X=L#(&W7&W<KE/..UF"[<G
MU..*:OAJQ7),ET7RA60S'<FP$+CTX8CZ5LT4 9+>'-,?S T<I25-KQ^<VUCM
MV[B,_>QQGK5NPTZ&P\TPM,[3,&=I)"Q)  [^PJW10!7N[*"\,)G3=Y$HE3GH
MPZ?SJHF@Z>D<<:QL$CBDB"AR!M?[W%:=% &6/#^GY4LDKE6#Y>5CN(79R,X/
MR\4#P_IX RLS,""KF=]R@ J #G.,,1CWK4HH HV.DV=A('M5D3$:Q8,K$;5Z
M<$]?>KU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3
M<XD/RD\=:=2#[Y^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %13V\4\;I(@(=2I(X.",<'MUJ6B@"E8Z7;V.2ADE<@+OE;<V!
MT'ZFK?EIAAL7#=>.M.HH ;Y<9Y*+^5)Y4?'[M>.G%/HH 9Y47_/-.N?NBE*(
MS!F521T)'2G44 -V)MV[5QZ8HV)_<7\J=10 T1H,811CIQTH,<9&"BD9ST[T
MZB@!NQ,YVKGZ4I16!#*"&Z@CK2T4 (JJOW5 XQP*6BB@ HHHH **** "BBB@
M HHHH **** "BBB@".";SE9O+D3#%?G7&?<>U2444 %%'3K10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4T??/T%.IH^^?H* '4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%59=2L
M(96BFO((Y%Y97D (_.@"U10"",@T4 %%!( R34<$\5Q'YD+ATR5R/4'!_44
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M8V<\J.K@*Q#2*F5+A=Q7COM'].M0'Q'#(T,<%O<^9*^TAH\%!L+ D=\@?SH
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MDD\JZE:7B,JA8<'\1QWJ73-'FLKQ+B2>)\)(I"H1]^3?Z_A3)M$N9+R65;B
M1M,\JJ8B6&Z+8><_C0!IKJ%DURMLES$9F&X(&&2,9_ES1<7]G;R>7<7$4;XW
M88]O\@_E6-8>&WM+^"=Y;>18@K$F$;PX0)PQZ @9]:GGT$2ZVU^'A*2%&=9(
M=S KQ\I[ C@\4 7FU73@H9KN$*5# [NH.<'\<'\C4<FMZ7&)?]-A)B5F95;)
M  R>/I6<WADBRAACGC=X9RZ^?'O4I@J$(SV4\<]?K2-X:D+'-Y'Y?S\"+'WH
MA'V..,9Z4 :LNK6<-C%=O*!%,RHA]23BH;'7+6YMY7GDB@>)G#IOSM"N4SG
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M^/- &5H^J6T\QU.:"UA,ULDDCI.9&CSC"L,#&<]O2M5-;TUU9ENEPH8G<I&
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M_+ RJA@ 1Z_.<G^5 %@7^DR7B7(8&?"Q+)L;HPW@9QC!'-6K"_M]1A,UJ2R
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M["[FCEN[.&:1>$9XPQ7G/X<BD_LG31"8OL%KY;#:5\I<$9SCIZ\T 5_#9?\
ML*W,I)?YLY;<?O'OWK,E\1W:0).D$#)<;C$I)!CVNJG?^>>W3%=';V\-K$(K
M:)(HQDA47 &?:JYTK3VDFD:RMV:<AI"8P=Y'0F@"#5Q,?#-[YQ"S"TD+&-B
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MRUML )$<9.^(AB,,.W;]:WZ0*JDD  GJ?6EH **** "BC.:* "BBB@ HHHH
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M%:U% !1110 449HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI&>,X8*"<'CCCJ>1Q3EU?3G!*7<1P%)Y[,<+^9XJC%H#09:"X57CN5FAW)D
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MRVUFX:>>XPJ2RK!%\S$QH3(Z;P,]#@'MG(YK<N]/L)O*C/EQ+'(LA1 H#D=
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MMYLD3Q%KEE"E!C+*!@_2J:^'+U?MHC@MT6<AT ?!3$FXQ@X^XP[^I/':M/\
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MBABN6151Q\RB N<C'-2/XFE2WCFDL&B#R 9D;"[2,@YQQZ9.!GO0!5/AW4#
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MVS0D+/;)())),L24W>F"?7OWQBDU+69;;7K=4+"RB817+;&VAGZ$MC QA?\
MON@";4=)NKK1+2S1H#+#LWY&U3@8.W@X_+VXZUG1^&[T+$2EHLR"W!D20[AY
M>02#M[@U;N_$DD%W=PQV7F+;+(S?/@@*F[<1C@'H*1_$D\,LJS6*E+<*9FCD
MSMW*67J!GH/Q/M0!/H>EW>GW):X%ML^S1P9B)RQ0GYB".^:H7?ARZN$*"*S
MS<[26/ D.5_AZBICXCO/+ &G()&!(WRD*5"%\],]B*5_$TR1HOV#=<R.H2)9
M,Y!CW\G'7'% $%QX<O)I9)"MH0TOF&,NX#[D"L"5P>,<>N3G&:EA\.S1*H*6
M;D7AG)P1E=FT#D'G/-#>);EQ(([*-1M.QO.S\WD^:,X'3!Q]:W=/DFFL8)+@
M()60%@IR <4 <S;^%;I/+61K9E\I%+;G)C9$V?*. 0??ID]:UCIEPWAJ/3G$
M'GHB+\I*KE2#D'J#QU]:V** .3;PO=F&13+;2-+#@LX8%7\O9QCC&.^/7UK1
M;0R9[.93&GEQJD\:\++MY3\FYK;HH YFW\/WT"P 2VAP"D@:,L%'F%P5]P3W
M] :M:#HDNER,9'A8+&(D90VYU!R"V3U^GJ:W** .6/AF\:ZFE>>V8/)O&4)P
M!-Y@&,X]1^O>EF\-WICE2*>V'GAEDW(3M!D+C;^9!^@KJ** ,W5K"XNVM9;:
M2)9;=B<2*2K!E*G\>:R;/PO+#-$+F6WFA$:"3*-NRJ;/EYQ@C\>M=110!S\?
MAZ4);B2ZWNC2>9(1\S!DV#'H0NW\JAD\-W4T,1FGM6DC4QE1$0CJ5"Y.#G/
M]NWO7344 8VC://I][/-)+&4==JH@..I.[GH?4#BMFBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ IH^^?H*=2#[Y^E "T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4+C1K"YNC<S0LTK=
M2)& /RE>@..AQ5^B@"B=)LFL'LFC8PNV]@9&RS9SDMG/4"F/H6G2.KO Q979
M\^8W);[P//(..G2M&B@#-_L'3?G(@*EGWY61AL.<_+S\O/IBB/0-+C:,K:C,
M:[1EV.1G///S<DGG-:5% %*RTJSL2YM8V0N@0YD8_*,X R>,9/2HET+35CCC
M$#;8U*@>:QRI.=IYY&>QXK2HH KQV-O%;R01JZQR,S,!(W5CDX.<CGTJK'H.
MFQ>2$@?;  (U,KD(!T !/'05I44 9J:#IB>5MMO]5G;EV/!.2#SR,\X/%"Z#
MIBH46VP-VX8=AM// YX'S'@<<FM*B@#-70=-3R]D#*(U15 E8#"'*]^<&IIM
M*L9_M0EMD<7F//S_ !X&!^57** *@TRS%@;(1'R"<D;CDG.<YSG.1UI(-+L[
M>X\^&':^21\Q(!/4@= 3W/>KE% &/9:##&MV+XK<FX>0G@@!7.2,$G'U'H*L
M1:+I\2X2%AF-HR?,;)4XSDYYZ#GVK0HH S_[%T\>4!"P$2*B@2-RH.0#SR >
MF::V@Z8T*Q&W/EK&T042,!M8Y8=>YK2HH J)IMHD-Q"D;!+@DR_.V6)&#SG/
M2H?[#TW(/V<\8Q^\;LNT=_3BM&B@"E%I5E%:36HB+13#$@=BQ88Q@DG/0 57
M/AS26A\IK8LOS9S*Q)W  Y.<G( _*M6B@#/71=.6;SA;C?N#<L2,A=O3/IQ4
M:>'=)CB$26@"!B<;V[\8Z].!QTK4HH S;W2([[4H;J=@T4431^5@\Y*GD@\C
MY1P12RZ%I<TKRRV:,[[MQR>=V,]^^*T:* *#Z+ITCS.]L&:9=KDL3D<>_'0<
MCT%1GP_I!7:;&/&2W?J2"3^8'Y5IT4 9K:'IAC\O[$K*P*D;CP"=Q[^H!JQ/
MIUG<F(SVZ2>4K(F[H 1@CWZ"K)SD8QUYI: *T%A:06\D$4*B.3AP23NXQR3[
M<57CT+3(E 2U  *G[S=5! [^YK1HH IV^E6%M)&\%LB-$@1,9^4 8&/PX^E$
MFEV,EO-!);(T4[[Y$/(=O4_D*N44 84?AFV%\\\QBD5G9B/) 9@P(VLV>5P<
M8Q6C_96GFXCN#:1>;&@16QR .@_6KE% %"+1=+BC6..Q@5%+$ +T+#!_,<4-
MHNF/$T36,!1]NY2@P=HP/R%7Z* *ATO3RVXV<).<YV#KMV_RX^E26MG;6:;+
M6%8EP!A?;I4]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4@^^?I2TT?ZP_04 .HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,B@ HHH
MH *** 01D$&@ HHI"P! )&3T'K0 M%%% !12;@> 12T %4M0O'AFM;6#'G7+
ME59AD* "6./H,?4BKM4=1M))9K6[@ ::V8G:3C>K###/Y'\* ,V37IGN;@VJ
M;K>WMC/\\9!E ;!VGTP#BMV&19H4E0Y5U# ^QK#?P^T$,BV=Q,WFPFV59"NV
M&,DDXP,G';)K<B1((DA3 5%"J/84 /K/UR\GL-/^TP&/(D13YBDC#,%[$=,Y
MK0!!) (R.M9NNV-QJ%HD-O)LQ(KM\X7.TAASM;N!0!5MO$,2Z8;O4 L:F=H8
MV3I,!_$H/; /Y41^(K9?,=W>5&F$<(B@;./+#\^O!)S5.30-0.[R7C@S-YZ;
M)\B)\$,5!CQSDY!XY[4IT2_\W),9/F>:,W&2#Y?E]X\_=H LS^(8W2WDLED9
M6F19$,+;F1E9@5'OMZU:BU^PE4%&D(/E_P !_C;:/_'@0?0BLI/#^HQJ/+E1
M)$$81_.SMV A3CR\'ACG-*_A^]9T,;1PJH3<JSYWE'+AB3&>=Q)/KF@"_%XE
ML)FB$2W#>:Y5"8B,X(!//8$TQ?%6FR9$7GRMY@15CC+%R02",=C@_E5,^'[U
MH[6)Q$T=LY=%\_ONW=H^/3([$BD@T'4H3"$G4+;R%H5\_(C&" O^KY !/7)]
MZ -%?$NFM \V^0*-FW<A7?OSMQGUP?RHC\2V$TBI")Y"X!5A$<$E2P&?4@'\
MJSH_#U^D*JKHKK'&L;>?S&4SM(_=\\,PYX.:>F@WZSI,7C9A(DAW3YW%5*\_
MN_0G_P"M0!MZ7>?VAIMO>>4T7G1A]C=LBJ=]X@MK59@L<KM'O52%^5G5=Q4'
MUQ_6FZ=::IIVGQ6D2VTHB4*&DG8G X'1!5&YT*_N#*&$"QRLSF-9SM5V7:6'
MR9S@GVYH VM*>\FL%DO&0R2#<NU"N 0."/7K6/::[=R7CPO)#(\=S)#Y*0,&
M<("20V< X'2M*%=7AMDA"6CE%"[WF;)QW.$Q69'HNK1 B.Y0!Y#,X$V,R$YS
MQ'GTXZ4 74\26<ENL\<%VRNZQJ!%R7(SM^HQSZ4?\)/IFZ,!W.]0W"\C.< C
MKG@UF/X?U2%8DLY8HP)TE;$OW2!@L/DZGOG.>:>VBW<( WV\ =1$0MR0)&YP
M3E#\W)Z=?>@"^GB:R>$2"*Y&2H"M'M8Y0N",GT!HD\3Z;'-+"6<O'GH!R00"
M.O') YP.OI6?-X>OYHFB<P;'558&7.552H'^K]#]<\C%/&@7ZM*8I(HUD.X1
MB9BJ,>6(!7O[Y')X% '16LZW-M'.BNJR+N <8(^M2U0T:RDT_3X[>1A\BA0H
M;<J@>AP#SU_E5YF"J68@ #))[4 8EU=:Q'JD5K'): 3B5HPT9. F,9.[OGTX
M]ZCLO$<26\W]I;EDB=_F$>%<"0H-O/T%:-Q9P27L&IO=NGD*0OS+LVMC/4=\
M#O53_A&[5@V^YNG!5@/F4;2S[\@@ Y#<B@#2L+V'4+1;F#.QB1SU!!P?U%9@
MO-3OY[\:=);Q)9R^2JRQEC*P )R<C YQT-:%M#!IEJL;3,06 ,DSY9V/J?4U
M!+IMM)?2LES)$\V'FA1P!)C@$C&1TQD8SB@""?Q):0JS-#<,@W;'5 1)M8*<
M<]B>^*C_ .$HM0DS/:7:&)9"5*KD^60' YZC(_.IG\/6DF\/+.8R6*Q[AMCW
M-N;;QW/_ -;%5K_087@N8[2=OM<J3%5>0 ?O"-QX&<9 /X4 2S>)K. ?OH+E
M&$GENK* 4/RGGG'1@>,GVI)/$UO&9MUG=XA60D[5^;RV ;'S=MP-.G\-6=T@
M,\UR93N+R"3#.3CK@8XVKCCM3I-#2(&6T9GFS)A9WRA\PC?GCVS^% %^RO4O
M5D:.-U6-RFYL88CKC!/&>*S-:US[*UW9VRLMU%;-,LA *CY6/3.3]WKC&:U-
M/M(["P@M(@-L2!?KZFJ=[H-G?74D]PTQ+H5VA\ 97:2/0XXH J-XG@@L6FN;
M6Y5HF"2+A<CY ^>N,8/3K[4L%_>?VG%#),IC>\EB(V<[1'N45-/X;L)]_F-<
M9<DL1,03E A_\= _*I;;2]/BNLPN[302&4@S,Q#,N,D9]!0!:U*]33K&2[DB
MDE6/&5CQN.3CN0.]8UYXD'EW,*VEY%+%&VYU16V,%W$=<9P?7%;=[:17UJUO
M/N\M\9VL0>#GJ/I5*;0+">:6219?WPQ(HE958XP6P#]['&?2@"!_$(2X>W73
M[IW1_+R"F"^P.!][T[U!!XA8W;R-#+)9RK"8W7:!'O7(!YR<GO5Z32=,AG6:
M4NLDDN5+7#C+E-G'/7;Q4<6CZ3#>11(6\R.(%83,Q!53@$J3SC. 30!&WB.,
M11LEC<2-*D+HJE>1*2%ZGCD'-(_B>W1I$:UG\Q)!$$&"Q;YN, \?=)^E2C1-
M)LS%N+H=R+'ON'ZJ24 R>V3@4?V-I<MQ-&7D:XR)#B8[X_F8C!!RHR6_E0!I
M6=RMW:17"(Z+(H8+(NUA[$>M34R"%((5BB!"*,#))_4T^@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ I!]\_2EIH^^?H* '4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<AJ M3X@O\ )M2B
MK 7WOAEY;<5]\ ?I77U!)]C6;$GD"7&_!QNQZT <S+X@NXOMH:X@9K<#R@(R
M/,4O@R?11P?<$],4Z'6KUV6*2\M491N1@F\7.7(PN,<@!>G<^E="DEB[@1O;
MESD !AGCK_.H9KZT@-JL"1RJ\PA!C88CR"?Y#]: .=?7KN9+=5O[9!MM7F=<
M?(SL0X//3@?GBI(+^^AMK7[(\?DW32Q1".'@2B0X)YZ;=Q/T]ZZ,/IXW /;<
M,%;E?O9R ??FE^TV"*@$UNH!^0;E'/(X_6@#)T75+V[U>>WN'@\M-X\L'$B%
M6P"1C@$<\GG/%4M6E\O7KNX$T+R6RVZQ[E!,&]BK/US@!LGZC-=*L]GN2598
M-T_",&'[SZ'O4=Q>Z?#&\DT\&W(5N0?O': ?QH Q]/U&_N]72T:[B$<?FDLL
M8S,JN #[=2..XJ;7-5FL=5LX4FC6*0KYBN!R"X4\D^_;\:V#);1-$I:)&?B,
M9 S["FM/:,'<RP-Y0RQ+#Y1[^G2@#F_#/D#4+3RRNYK!L>I'FGC\*L:OJ=_;
MWU\MO/%LMH(Y!'Y?/S$J23GH.&Z5I6^IQS:5]OBM\#>4";E'1]N<].V:N+/;
M23/"DL32@?,H89].: .4'B"^2:VCEO+,YD4.RD%65GP#GC)Q_=XSUJ2RUR]N
M D4UQ'"7DPTVU2BCR]WRG."">F><=>:Z3S;+=)'YD&8 -ZY'R#KSZ4GF6#1Q
MIOMBDI_=C*X<^WK0!S%GXAU!Y4EN)[=4W1J\7E_WHF;KG/5?3O51=7GO98;E
M[F%)[<N4D* @ P!L$ ]R3[\>M=F]S8JKN\UN!&V')8?*??T-57U*P6^@LAY+
M+)&TN\,NU N",_@>#0!@?VE<VQNI(#!!/<7$8E,AVK&Q@!Y/..1CFMJYU"XB
M\,)?.\:3M%&68#*AF(!QG'KQG'O5Z2ZL<(LD]OB;[N6'S]N/7M2R7=D7E@DN
M("T:[I$9Q\J^I'84 <K'XBOGBBD6ZMSMCW.NP'<?.V8SGT/85:TBZ-[XC2>6
MXC:;[/.OE@ -&!* %/X"NA62R$*2!X!')]QLC#9YX/>HI+ZVC,36YAE,CA3L
MD7(!.-W7D9H R-2U:^MM;D@BG@\E&@ B*?,^\L#SGMC/3O5"V\17T\<?FW5K
M"LY4-(.3;$ACM<=!R%7DYZ^U;\.LV%S?"%"C*59EF)&TE6VD?7-+JU_8:;!)
MY\:/(R-,(0!F39R3SWZ4 81U_4O/N?W]HJQ*5"2 HQ.P,'VD<*3W)QTJ-O$M
MV%#";"^3(V6B4G<HD^\ ?]E>1P<'GD5U7VFQ:/SFE@PY\LL6')_N_7VJ"^NX
M+6X@MH[4SW,ZMLC0 ?*.I)/ '(_.@#&LM6U#4);>VAO((Y&\_<P0.?D*[>AQ
MR#S6GX=N[R]MGGNV/!$>TIM(=1A_PW9'X5+%=VMQ:*LO^A23EXUC9@D@8$@X
M]^.HI]K<Z9:QI:0W< VD* 906+$GKSU)S^M &!<:WJ/]H7T0N[2W$3.D<3 L
M_&-C;=O0],YQR,<U'+KMX;6&1;^**62*X=X]BMLD3;A/?KCW[5U/VJQ,LF)[
M<R(N7^<950>I]LU4EETJ:\M;LWT(=01$%E7:^X@'Z\@?E0!@2:]J8N;D-<V\
M(1MGDL,O&=Z@$C'3!/4\Y&*E&MW@NK2(W:R)]H>*38J[G_>;5X],==O(R#TK
MIXKBUG.8989"V?NL#G&,_ED4U;RR>9HTN(&DC!9E#C*@'!)':@#C1XAU0V(G
MDN;<,VTLL0S)%\K%EPR@9R!\N<\'GI72ZW-Y=I92,T8S=0C]X@YRPZ9Z'O2W
M&KVRO&+=([A)(Y)!(LB[<ICC/3/-6S?V8V+-<0(Y02;&D7('K]/>@#ETUR^1
M?,>]CD5U8L50?NE$X0M@=<*2?PJ0Z]-%,86U!'4& Q3&,+YP:5U;'J H'(^O
M0UU,4MO*2(9(G( R%(. >1^=0F^L%D\LW-N'4E=N\9!';]* .<M=1U&5H634
M/-,EO/.L0C7YBC@*H^HS5.XU>\NM/DAN[^#R)8)6WHF[+!%_=-E0,Y). ,\8
MKI(M;M)&O$1H1); E 95 D7:&W ]AR.:FN]3MK:T9V,32B$S+ )%W,,9X]>A
MYH I:LH;PDG;Y(3DC[OS+SSZ=:H/>ZP%B\BZ:6.::2VBD$:_,>-CGCI]_IP<
M"NAMM0M+FT:X2>(QH/WAW@A"!D@GMBJPGTFYU"WN%O(I)@"L2B;*Y[D+G&>2
M,]: (_$B#^RH5+D.+JWVOMR0?-7G\LFL)M4NLS.MXAG6W*B81KG(GVC/'<8X
MZ=ZZJ/4["5ML=Y;NV<860'G!/\@?RJ(:M:>=)YD]LL"(C+*9EPV[/;MTX]?P
MH RM(U"ZEU98);QIHB\\8^51G8PVG('7!/Y4>(;RXM+Z1[>41L+=,,(PQ&95
M![9/&>*V1JFG'.+VW.U0Y_>#A3C!^G(_.G2ZC8Q6J74MW D$GW)&D 5OH>]
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M6VI IPK#_5NS_KNKJ** .8G\-3M<731-;&-W,D9?<'&X@LN1TQC@CGIZ5?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I 3N(]J6DQ\V
M: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***B
MEN;>!E6:>.-F^Z&8#- $M%%% !1110 444V.6.5=T3JZ@D94YY'44 .K*UC5
MOL,L$$7EF1WCW[VP$1G"D^YYX^A]*U:JWNG6E\%^TPHY5E8,5&?E;<!GTR*
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MUOX?O1!+%<SPNLT0B(R?E522N, <C/6G'0IXU$TEZ%9$(>5I'S(,Y^?GH/\
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M[0I9JRI&B$?)M4!ER /P(X[5=H *0@E2 <''7TI:*  =**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HSSBBDQSGO0 M%%% !1110 4444 %%%%
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MV"[AE<P)(D! $K %.<X(SG/X>] '0:=:?8=/AM/,,@B7:&(QD5DGP\4B6/\
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M)QN]Z %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4^7P[,UO=)',@/G*]LK9 5 V_:2,$?,6Z=L>E+)XBN5CN,6""2V.)4,Q^7+
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M) ()'7VH 6BJ5KJ<%U/)'&DH5,XD9?D<ABI /KD&F0ZO!-=I;)'-N9Y$R5P
M4QGO[C% &A131(AZ.I_&HY;D1R1($=_,;;N7&%X)R?;B@":BF>=$5)$BX'4Y
MZ4V>YAMU5I9 JNP13ZDG % $M%-,L8!)=0%Z\]*3SXO^>J<?[5 #Z*:'0N4#
M*6')&>:JW>HPVDD*N&?S91%E,$(QZ;N>* +E%1-/&%R'5B1D*",M]*IZ;J\.
MHX$,4JYMX[@;@.5?.!UZ\&@#1HJK9:A!>V@N$)C4YRKX!7!(YY]0:G\Z(])$
M]>M #Z*:DD<A81NK%3AL'.#Z4Z@ HHHH **** "BBB@ HHHH **** "BBB@
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M[4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF\O?C[J@%F(]\*0/K5N&XAN(O-AD5TR1N![@X-59XX=5MX+FTG0M%)OAE W
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M@ IH^^?H*=2#[Y^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8'B:*XFN--%JL@D2=F\P1%U3*, 6]LD5EH-0@M]/L[:*[LXX(
M]FU8F;,P/(R" 5(SR?EY/?%=7>7UK8H'NYEC4YQGVY/X#UJ"36M,B+B2\B'E
MJ68YX &,\^V10!RWVC6?*N5!U$%F#H&AD_V\KN XZ+T&.G&.3:N6U@[RAU!+
MG##:J[D\ORCC!QC=OQTYS[5NKKNEMNQ=I\BLS9!& O7MVH&NZ6T!G%XAC!P3
M@^F>F,XQSGTH H:19FY-U%J*W,RJP\IK@,#AHE#8SCON^F33_$:7>+=+(W:*
M(Y2?LX/4)\@./>KPUK3#(Z"\B+(K,W/ "@$\^P(-+_;&GDH/M R^=HVG/&1R
M,<'(/!]* .:9M8^S^7YNH*AE4R2&)F<!HATQ@X#YX'3Z5&\^N&6Y1CJ(<P%0
M4C)^<>7@CC:/XNGJ>3VZ*TURTN5-PLL:VWDK)ELAQEF'(QT...Y.:D.NZ6NT
M-=H"W&"#D?-MY&..>.: ,+?JJ7L$:B_DBCNF!#!AN3>"#NZ$ =CP1GN*T]9!
M;15">:8Q<QF7S,YV>:-V<]L?I6M=7,-I;M/<R".)?O,>@K/O-8L_),<4T+.T
MGE%90P4_,JL.G^T/Q(H R=46_GOQJUM%+ML942.'RF#R)_RT(]CG'3^ 5H64
MADUW5)8$?RO)BW#IF3!./8[2N?PJ/_A(K*WGB@0;+2-I(7<J1M* =!CD5>;5
M-*LBZ>='&.9&VJ<<C<3D#&<<^N.: ,O0)=1:QO5OENU?:K(71LC*#(!/).0>
MG'I5"R;54-M)(^JNRBU\Q75MN3_K>,<X&/\ ]==%+KFGQ7$4'FLTDLHB "'@
ME=P[=,=Z=K6H/I=DMRL22 RI&=[[0-[!0>A[D?AF@#F83J4\JFZCU,*L\;E=
MK\??!Y^NSIQ_,O@&LOY*7$E_\TR+<;49=I^;=@Y.5Z<C Z>];=OK]N%?[?);
MPD.P1HI#(L@ !)!P.F<8]JM'5]/$KQ-<JKQKN8$$8''Z\CCKS0!S3/J\<%F5
M&H9BDD+_ ",2P\X8R!U^3/7C'OTT MS'X0O%MXKJ.YW3F-50B3+2,1@8]Q6I
M'K.FR*[+=+A,;L@C;EBHSD>H(JJGB"U>?=YJ1P1B7S=ZL'&QMI(&,;>N30!D
MW":U!?2BTDNV"INMPR,RL"AX9BV 0WJ,\#%1Q?;()+EX(=4\J1V&65RYS H!
M]?O@_2NDEUK380QDN579C=E3QD;O3TY]J:-5BA662]VP1"7;$_)\Q=N<].._
MMQUH YZ5-4N+:>.9=3,Y@P@!*HR^3SG'\6_/OT[5+ ]\"X$>H+9^?$&^5UD$
M?EX./XL;P,XYKJ+JY@M+5[FXD$<,8W,YZ 52;7-.V#9<J7<LJKM;)(&3D8R.
M"#]#F@# M3K:W=N]S)?MMDA!&SY2IW[MP Z[=F?<U?U5M0_M8K ;H-F(V_E@
MF,KN_>;NW3U]L<U?MM:M&@M?M%Q$LT\:/A,E?FZ<D=\'&<9JU97]KJ$;26<H
ME13@L <>O>@#&MTO;?PI/,S7S7KH20S%G4YQ\H(XX]!63<?VG-8&&ZAU&11N
M$(5'RS"7(W=\;-N-Q]>]=1-K>F03/%+=HKQYW#!XP0#S[$C/IFFOKVEH5#W:
MKNR02K8P#C.<=,]^E &1/;:T(KZ.VDN?W.YX&+DF0.0=O)ZJ P_$5"D-^QE+
M2ZJ EM(T)VL,-G@;<G<>N 22>/:MM_$6E(LC&Y.(V*L1$Y&1G(Z<D;3GTQ3_
M .W-,WE1<AB ""JL0<XQ@@<GYEX'J* .=@&N&YM]ZWB1[OW97>P/[PYW;CP"
MN,;@<#WK6U,7AUR(K%=O"$0PF!L*'W'?O]MNWJ/7'-:ZW4#68NU?,!3S P4_
M=QG..M5%US374,MP2"%(/EMT8$@].A - '+V]OJUM9&"%+\+Y$*GD_(X#[L
M<X^[T([>]203:J!%=W!U"(H4W^8#M5?).\E>GW\?YS6Q_P )#9K)-.D@DMPB
M, (W#DLVT'!&-O3!J;^W]*EA?SY=B;WB(EC(S@X).1TYZF@#FHI=7>$*QU".
M1?*,\66D8+M8%UY!.7 R >@K?=+X6^C^8;II 2+@KU(\MOO8XSG'XU/I5UHH
MNI+/3%BC?+%@D10,5.T\XP2#C\ZMWNI6=@5%U+LW=/E)P..3@<#D<GCF@#+\
M-K?0HR7_ -L9C;0N?/);]YM.\ _7'%9FGVM]#ID43QZD2(I08U4)Y3$Y!5L
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MACTZ ]:=>^(;&T,ZGS7DAZHL;<\J#CCG!8?G0!SQTW6!9KL2_9RP+1RRC!?
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MO-MXT^TKYD=S).K-"&4AR=RE3P>IY^E0R>&"?,_TN,AE5 &@&" 1C< 1D_*
M",$?E55/$=S.8UBN[0&3[-\VW.TN&W#[W8J*KSZO)?K81W-S;J4EMG(V\RMY
MV&(.>,8''O0!UME:BTL(;7>THBC";GY+8&,FLFV\,06KK)'.[2!77<XSP>%X
M_P!E<@?4UF6WB#5;IK=#/90-<2JA4*7:'*N2K=!D%1Q70WMS-)HLUQI4\4LR
M(Q1@-RLR]1P?48H IR^']\'E_:MH6TCMU.SIL;<&Z^HZ5%)X:\R4,]]EM\C8
M:%3\KD$C![Y&0>U9.H:G=ZE87L4FU8 OG*SQD QDJ(^<]2=Q^@[9J>369XKJ
M65C;2S6T%RH94P3M9<< GC'4>U &S9:,UKJ"W/VO>%:9MFS'^L8,><]B*EU'
M3#=W<4\5W);R*C1MM .Y#@GKT.0.:YN\U62.[^W6VH6D\L%M+^]5!B1=\9"]
M>O)Y'O5_Q#/-;:K:WEM-''*MG,4WIN$ARA"#W- %B7PWY@V?:ML<;,80(\E-
MSAVR2>>1Q[>M#>&5>97>[) G>;B,!OF;<0&Z@=CZBL^ZUC5A'(ZW5K$INS;[
MG4!8<+NRS<]3\O3OVJ+_ (2:_2:7YH9-L!.Q5Z,%C.0/O$?,QYQD#V)(!IP^
M&1#'#&M\Y\D;4_=J/EV,@SCJ<.>?I4MMI%WITL7V&ZW(3&LBR*,%54*3ZYP!
M^-8DNHRIJ0OK?4K:4I"P,GE@"1/.7 Z^A(R.XK:UF_O(=2MHK*=-KVTLQCV!
MFD*;2 #[Y(H T=4L!J%J(3*8\.K9VA@<$'!!ZCBLRW\,B"**/[=(XC$2_,B\
MB,L0./\ >-9,&MZG/% &U&T E8GS(UW%<1,Q4Y &0RC\\&DF\1ZC'9LXNHO-
M*QRJ1& !NC9BG/NH]SG% '0:1H[:=-O:]><+ D"J4 VJI)7/<G!INHZ7+<7E
MP8F*QWUN+>9Q@E I8@@'U#L/RK&349FGD>UO+6W:XNE5G6('(: -D\\D$8S5
MK1]:O+S4+..:6-DFMU9EC X?;DY'4=?<=N#0!9N-$E2.Y>*5YKF[@%H7;:JQ
M)S\V .2,^^?85J/8HVEFPC=XT\GRE93RHQC-<W?Z]>0+=QI=1>?"MT50Q\_(
M,ID>XI)-<NXM\3WZ;1*X^TK$#@^6K(F.@R2PSWVXZT 7E\+*L4B+?2C>DB<1
MH H?;G  _P!FK6F6$B:G=7]Q!Y+N!&J[@=V.K\< MA>/]D5DW>O7D:SQK<HL
MR+<':T6"NU R9_/\:;<:QJUK?/")DG*1AXT,?,X*$Y  ['CKVYZB@#H-0L%O
M9H98KAH+BWSM=0#A6&""#ZX'Y50@\/VZ2*+2^E6.!XV\L;6VLB;!DXSTJOX>
MG6:75IENUDWB)S<*@'/EC)Q[8K)TZYDL;!9;>=5EEM3*)/*7]_(&XC/OR>/O
M?-[4 ;D'A:*#9Y=[<#$:J_RKERN=K9QP>>W7'-;%C EG:0V:2E_(C5<MC=@<
M G'TK,T::\O;:\FFO"7$CQ*BHO[H@GGIR?K7.:7=RPFWNH[\O,\%HDNY!F3+
ML&!R.P/7VH Z!O#MO<02*E_.4E692R[#Q(P9L<>HXILGA=)+B6<W]P)) V3M
M3N5;T[%!@?A6=:75Y+!';6MX80+6:0"*)>65R  ,=Q5G2KG47N;"$7<DT$\2
M3!R@X500ZDX_O%.?<T 6IO#ML?,1[^X02OO"Y08;(9B/ER<D9QT&3C%+>^'K
M>\20/>S#SI7D)&PC+)L( (QT'7K[TR[2VEU;43J2JT<4,(C#*6 5BV>!R06X
M/J!6.L!ATN)+J(M']EG2U"JQ'F[_ )"HQ\I(Y'H : .ITJQCLUG>*Z>X^T2!
MV9MOW@H7^$#LH_*K]8^E"2/6+V(#$7DPNX["8[M_Z!#6Q0 444'VH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ I!]\_2EI!]\_2@!:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+W[.+=I+F)9$C^
M?:5#'(YX'K3()+.\M5E5(REPBR%7 R01QD5G^(K"YO&MG@MX[D1"0-%(V!EE
MP&Y&./ZUC2:'.DHEU.&W%I]F\F9@V[&41<XVY.&7^1]: .M$-L'$@CB#\8;:
M,],#]*IW=U8VEQ':FU,CNI;;%$#M7< 6/MDU@_V'>W&GV,H@B-TS>;,VT* ?
ME RI[;5'3D$?6M'5=(GO-5DN(H(@6LGA2<D;E<]/?'4?C0!>OKRRA\B.6$3*
M^XQ[4# ;%)_/ -.L4MR_VT3R.]T@=!*PRB8SM4>G-88T:]-QYL5C'!$Q/[@2
M@!3Y13<,>I/;L*<-!NW:$30P,0+?]Z6R8@@ =!Z@\_\ ?1S0!T<BVYS*8T=P
M/0$GVJ*WDM'CMY0D<3,H,:L &7(Z?_JKG;7PQ-;W"D1PFW4L#&% +*C$Q<^O
MS')] *9#X>NHUM)7LX/.MXK5=^X%E,9^?!QW'% '5L()S\PCD*'O@[3_ $I"
MELS%V6(L1C) R17+>$8G^WO)/;)N\CRUD7.5 8G:^5'S'=SR>E2CPLR:@2JP
M?8C(5\K:/]5N$F/^^QCZ&@#<G>TW&+:J@HQ:90N(\ =3V.#4>G0Z;;V:V,#)
M(ENB9+X)QCY23W-8<'AJ2.U@B73[2-O(N(Y6!')?&WMST_"H_P#A'+L22.FG
MVJH3$YB60+OVJ5*Y Z\[O3(_&@#JGM[9HS$@2,L#@H &'N/>BUA@LH5MHWZ$
MGYFRS$DDD^Y.37.6.@7-K?03_9(5:.=&\Q9,L$$10C)Y/.#SUJ>_T6XN-:>\
MAMH%/G0LLVX;P%SN/3W ]\4 ;,GV"%6+K  \@5N!RQ/&??FG1-%<11R2PB-B
M2%60#(ZBN7_X1V\80L;.UW6XC4AFR+@K)N+GCCC/7GYC4L&AW\;6H>TM'100
M TG_ ![GS2X9<#GC QQT':@#I8XK5&+Q)"K(-I90,CVIL+V4P2YB\D^>ORO@
M9<?UK(\/Z+-817"7<,.9(UB8K(7$V"WS$$<9S[U0B\.W@LXK<VUNI-O'"'##
M_1V1LEUXZGK]10!OWUW8V$;>9&K,B;O+106VD@$X],FHI-*LI;K[0TSA9'5C
M%N&QF7&.V?X1P#VJCKVB7%Y>23VT%O(TEJ82TF 0=PYZ=QQ5.3PY>/,0;> P
M&278GFE1"&8,&&!VQTZ^] &]>7%E:31VXM?-GD!<111J3M7JQS@ #./QI]G-
M8WEO!/%&BYSY8= K*0<' /3D56NK&ZAUN/5+8+/F V\D3,%P-P(8'\\BJ5YI
M%]=W1FFAMW>018<-C[.5<L=N1D\'\3UH W?+M) 5*0L#P1@'WI6-LZ[7,3+'
MS@XPO^%<C;^&;J$(3:6BRHJ8<-W67<3D+Q\IQ^G2FV6C27=J\UA;V\0$TJ_>
MVF5?M&X9XXP!QG/7TH Z_;:;EXAR!A>G0^E/"PLRD*A91\I&,BN1@\-7D?EO
M+:V?F1B)0^_) 64L?X>ZX%:?AJQBA>ZG@_X]PYBM3L*XCSO/7MN8CZ** -*Y
MN+"RMIYV$6VW&75 ,CVQZ\_K1;3P3VZSSV_V8ABH$P4$<]CTP>O%<[<^&KV6
MWDB2&T#JDJ>87.9][ @M\O;D_6M+7])N-1T^WM[:*%6CS@;L*AVD=,$$<\C
MXH V ;<[F!B_O$C'Y_I5&TNK*VNAI\ VAU\Y7+ K)N8YP<Y)S6,V@:FTA55L
MU14E56W'Y]TRR $8X&%((]S1/X?OICYPM;"*3:"JJY_=MYH<X.WVZ^M &_\
M;(!J7V!XBC>5O5B!M89Q@>]3%[1227A!!P3D<$UDZWH\NH7T<J10L# 8B[GY
MHCO5MR\=>#^.*SYO#4SP+LM;;)N97DC$I3S(VSC+*.HW'CIR: .F7[("R+Y.
M4'S*,?*/?TJO]NMI=1%H54XC65)"1M.20 OOP:YS_A'-4$\C*EJ%967/F'#8
M='&1C/.P@Y)ZGZ5/+X?OI9/.6VL(G4*8U5CB-O-WG!VY]?SH Z:7R%3$OEA&
M/\6,$U5O;^SLH//PDF753L(SR0N>O3D5#/#/J^BRI) L$Y+&'=R RM\C= 1T
M!K*/AFY%K<PEX)Q(R&,.,!06#R#H>"PX% &^MQ UPL*(AC\KS!*"NW&<8'.?
MZ5&-2M6U%+;*9>+S(Y=R[6&<8'/-8+^&KTO*T8M$!64* 3@@S"1$(V_=P-I^
MIIUQX?OK@-)]FT^)VC(55<@1L9 _!V^W7U- '2R36T!"R211DD  D#))Q^IJ
M.YO;*WBF:>>("!=T@R,J.W%9&OZ)<ZE=F:".U)%L8E:1B&#EE(/W3TP?SJK=
M>';V=)H]EMD>>\<A8YD,G(5ACL>_/04 ;T%[;LLK2>5"D<OEABZX;@8/Z]*L
MK) TS(CQF51\R@C<!7./H5^SO+Y-@0\SN;=F8H5>,*P)V]<@GISGM4^E:)=6
M6K/<2O$\?SD2!VW'=MR-OW0 1^0% &PUU9+O9KB >6?G)<?*<=_3@'\J7[1:
MEXX_.AW2C<B[AEAZCUKE+S2;FTN!*\,$BRWZ/%&,OSYCL23MRHPW3D YJ5/"
M]TDL>'AV.HWXD=?((=F&P#@_?(YQC&?:@#?;4;;SXQ$\4J,6#R+(N$*C/-5]
M.UN*^WRM#Y$"Q"599)%PRGV!R,=\UGVNA7L<UK+-%8!H!M/EY!D C* DX[Y7
MCMCO3#X>OVL8[<M;1M'9K#O1V&YU<,,X ...>_)H Z!+RR_=+'<0?ON8P''S
M_3UJ,:A"MQ<1SM%%' 5&]I%Y)'IV_&L2#0;^._MKC_1X@LH>0)*[X&XDCYA\
MV<YSP02:GU'1+JZU">=!;&-Y;>10Y((\LDG/'?.* -MKJV6!9VGB$+XVN7&U
ML],&HUU"P;=LN[<[$\PXD'"_WOI[UF?V/<_\(^E@1;&59Q)WV8$F_P!/3CI5
M2Y\.WCSWC0R6X60NT+.6)7?C*D= ,CJ.>!QQ0!OB_L?W(6Z@/G_ZK#CY_IZU
M5CGTB">6\6\@WL=C.T^0N!G R<+TS@>E8T/AS41Y(DF@01RL^^.1RP5I"Y'(
M^;KU."#S3T\.WBS6<I^Q[K7RDP,@2*@<9(QP?FZ?7F@#6O+O3HY/M(DAENHX
M&DC190&=,9]>1Q1%K-O.+$P;)A=2>63&X(C;86P?P4UBIX8OC]G$LUN!'&(V
MVEN1M=3Q@9.&X)^GULP:!=K+#,[6XD62,OL) VK&T>1QU.X_D* -JR^Q?OOL
M4D;DR$RE'W'=[^]6JQ?#VD3Z6KBX>-SL6-60L=RKG!.>G!Z#CK6U0 4C!B/E
M(!R.U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2#[Y^@I:
M0??/TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#.UC4#9Q"*%'>>5'9-A *A1DMSQQD5F?\)*\5EQ:SSR1V^YI=N%\P1AR">G0
MUM7VGVU^%%RC$IG:RN5(R,$9'/(JJ?#VFG@Q2;?+\LKYK8(V[<D9Y;:<9ZXH
M H7WB/RX[NW,$T<T-NTA>-D)7:JD]>/XN_H:O6UY,!JKL?-^S2GRUR!QY:MC
M/U)I)?#NFS%C(DS!E*L//?# @ Y&><X&:NP6,%N)Q&'Q.=S[G+9.,=^G % &
M%9:]<?:XC=QN8[I(" "N(6<-^)!QGOBM'3-;34HII([:9 B"1-XQYBD<$9Q_
MDBG1Z!IT7E[(Y/W90KF5C]S.WJ>V34UII5I9QO';HZJZ[,>8QVKZ+D_*.>@H
M R_^$I46;7#V,J$!&5&=<LK*6!X_W3Q]*?!X@EEOFA-G^[:39$WF#)/E>9R/
MIQ5EO#VFL,&.7A54$3."  5 !STPQ'XT\Z%8;<!9A@@@B=\@A=N<Y_N\'UH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRNUFSG&#G;U''- '3T5R9U:ZB74$9&EA>281NLY#IB(/@<<#&>?4U(E]<+J
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MDNYKC<% \QB<8&">2>M7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV.C6EI'.K(LQG9FD9T7+!CD@X'(YK1HH K)I]DC1LEI IB^X1&/E^GI2'3;
MJ0;*W(+[R/+'+>OUJU10 V2-)8VCD171AAE89!'TJ%+"SC:-H[6%6B&$(0 J
M/;TJQ10!%/;07 47$,<H4Y7>H.#Z\U$--L RL+.W#*, B,<5:HH BM[:"UC\
MNVACB3.=J*%'Z4?9;?:R^1%M8[F&P<GU^M2T4 9,/A^SBN_/8O* [.L<@4JI
M.<]LGJ>I-:1MX3(DAAC+H"JMM&5![#TJ2B@"%;.U1 BVT(49P @QSUH:TMG0
MHUO$58@D%!@XZ5-10!%]FM]V[R8\G/.T=Z?&B1HJ1JJ(HP%48 %.I"P498@
M=S0 CQI(N)$5@>,$9H\M./D7C@<=*J2ZI:1?Q22<9_=1-)QG&?E!]#4<NLV\
M)/FP7H [BTD8'\E- %W[/   (8\#.!M'&>M+Y,62?+3YNORCFH+34;.]S]EN
M8Y2.JAN1]1U%6J &"*,=(U'T%0P6,,-T]PI<NR[5!/"+Z*.PX%6:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IH_UA^@IU(/O
MGZ4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%4]1U2STU5:\E*!N>%+8 ZDX' &1R>* +E% ((!!R#THH ****
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M4 %%%% !1110 4@^^?I2T@^^?I0 M%%% !1110 4444 %%%% !1110 4444
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M %%%% !114-S=0VJJTS, QP-J%OY"@":BJ/]K67]^7_OR_\ A2_VM9_WY?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %(/OGZ4M-'^L/T% #J*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ I/XC]*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "CO110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1GG%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'&?>BB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBCG/3B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "CG)]**3^(T +1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(/OGZ4M(
M#\Q'M0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4@^^?I2T@^^?I0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@^^?I2T@^^?H* %
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "F@_.:=28^8GVH 6BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex10_4page003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_4page003.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *0')(]*6D'WCUH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHH!STH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIXALKR>"&!96>;/8?)@D<\^JGD9'3U% &M169=ZY:6FH&SF64.$+;@O!PI;
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M[_6EIJ]6^M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9M8N].O([E+I8Y+9ID5QN)RFT1D ==WS?E0!NOHFCJPA_P!6\^TQA9V5B4&
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M?I]X&KW]A:?YD4FR0-$$"XE8#Y/NY&><4UO#^G/D&)]I;<%$C (=P;Y>>/F
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M@X9N, \<=<CKWK1K/L]'M[.]:Z1Y7D9-@WD' SGTR>?6M"@ HHHH 0$[B"N
M.A]:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:O\7UIU(O?ZT
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MH **** "BBB@ HHHH **** "BBB@ IJ]6'O3J:O?ZT .HHHH **** "BBB@
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M110 4444 %%%% !1110 4444 %%%% !3%8Y;Y">?:GTB]_K0 M%%% !1110
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ME^60(^#T;!HEBA8*94C(0Y4L!\I]1Z5S6DZ6G]L)CRF6V1&N0JD_Z2JE0=Q
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MP-RRQ@,<= PKG[/P_.DUF;G3K0I%GS-LFX.0FW<01U)P?P[U"WAR\:W@1K2
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M\:+JJ:A/,MK'LEG21L3#D+/O!QCKM]3^F*Z+7+>>[T>XMK9 TLB[0"VWOZT
M6)(+26>.66&%YE^X[*"P^AIC65@QD9[6V)<$.3&OS9Y.?7H*Y>XT/4@(UM+*
M)8X+AY(D\T#:"ZL,<' .#TYR?K3I/#DKP(#IT.]I;AI?W@^8,&V ^N"1],4
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M0@<'/X<5T- !1110 44@!!;+9!/''2EH **** "BBB@ HHHH **** "BBB@
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ML;RQL=LI' D;<,A\XVGVZ=.E;T?B*QEFCC59\2;,.8R%&]=RY/T%1R^)K"&
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MA3[G\*==/H=S<-)>+!)/!'EBR$X'''3G[PX]_>@!VKR3'1HI+.XGW-)%B2%
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M!%&*** # ]*3:/2EHH *,#THHH  ,=**** "BBB@ HHIKNL:%Y&"J.22< 4
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MV>YMC(DJ(IV[5\MFXFZGY2,#V/6E_MZ_="HN[9+B.(%8UC+>?E6^9>^-P^F
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M%%% !1110 4444 %%%% !1110 4B]_K2TB]_K0 M%%% !1110 4444 %%%%
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M6=I&I_VI&TJ0[(U"\[L_,0"5Z=L@?6M&@ HHHH **** "BBB@ HHHH ****
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MWD5O B1SS@PRE_)EV$7#8(?J.,[OIFJ)L=6@@FD^SW+RM)/N$4@4N610K?>
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M'6KTNFZ=JTBWQ=I05VJ4E.WHPSQW^9A_^JF/X;TUT9&28JP"G]\W39LQG/\
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M/DVNV6/ YYYJU)I$,FD1:<7=8XU"Y7!)P.^<YS[T .O=5@LK&*[ECF*RD!4
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MX-%EJNCBSMTM[F..*1,QJ6Q@>_IWZ]Z .?\ [7U-XB8]0=R9 DA6 ?NOWX0
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MG&><C/&: +&HZ!/=ZH;Q+R-0V1M>'?M!1D('S $?-GI4UGH9M]#NM->YW?:
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MCS,FY3D>8FWGZ&@#<6YMFG-NDT9E R4##('TK,.O0K)?Q/:NMQ8KO*9'[Q,
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-7JWUIU-7^+ZT
M.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YR7Q)
M<HTS)IZ^2LIBC=Y@-S"0)C'7N3^%='5-])TZ1Y'>SA+2D%SMY8@YR?Q /X4
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M>]._X264R*PL_P!TT*L!N.XNTA0#ITR/3//3M6BV@Z8TC.;;YF)/$C#!)#'
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M+P(P\_"E5D5<X(_'TZT ;M%4]-O?ML4A:%XI(G\MT?&0< ]N.A!JY0 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %-7J?K3J:O5OK0 ZBBB@ HHHH **** "BBB@ HHHH
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MG^($XZ=*VQ#91Z>+V[>]MTV!F66ZD!7V.&ZU7M;/3[UKE(KB]@=)65Q]J.7
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MXDDA6?S;(![<E9560G:=X5.W\6<_2M&POY[JPEGDM#%-$S+Y9;KCIS[C'44
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MJQNK2*9B;8)NCDV]'RPZ]2N0/<]JOZ)!/#'<K*LL<+2DP1R-ED3 XSD]\]Z
M)YC87-Y#%*$DG57>/(S@?=;GIWQ2-I&GLNUK9"OE"'&3C8.B_2N8ETJ^$$B6
M]I=I)&;KRW\[JS2!D/WLXP.]:6EV^HC7)9KC[8J;W)WNOE,A^Y@=<CIV[]:
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MDD'\2:TZ "@C((SC-%%  .!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %(/O&EIH^\U #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** $9=RE22,C&0<&N2TV[O4@%T?M+K'YQ5IK@".7:Q 7N0<<Y/\
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M&S>[^22-I5$/ED%!L&#GT.3U]O2G7%_=VNM72-=,L+31J69/EACV9W?BW&:
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MQL&4]"#D4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6MJR%%4A&)W-Y^X<;>@4XSVJVWA^_82B!;>&.6&=55'.(R[(0H&.F$Y_WNE
M&U-::;=+%LFC2)3N*PNJK( <X;'49YQ5I_L3,=_V<L>3G&>,<_RKF;S27:[
M$<4%U=28$40+(D10)(<X ![_ % J2Y\-2O=S21V5D8WF9AN<@E/*V $;?[V#
MB@#H3%8AD4QVX9 2@*C*@]2/04QDTQ?+C:.U'F-L1=J\D<X'TQG\*YN3PYJ#
M,X>*"5F@ 60SL/+81;-F,<@\G/N>/6>WT*[MKR"9;*T98IPRKYGW1Y04G[O7
M<,T =1'''%&$B140=%48 IU-B+M$AE0(Y W*#D ^F>].H ***",@@]#0 44
M8&** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IJ]6^M.I%[_6@!:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***JW=_#:N(V62238TFR-=S;1WQ
M^E %JBJ;ZBJR%/LUR2)?*R$X)V[L]>G;/K4UI<Q7ELD\))1_48(/0@^X/% $
MU%%4K_5;33W5;DR L ?DC9NIP.@[DXH NT5#:7,=Y;K/#NV,2!N4J>"0>#SU
M%3$XZT %%1?:$^U" *^XIO#;?EQG'7U]JEH **@6[B:Y6!"S,P8[E4E1M(!!
M/0')Z5/F@ HHJE=ZK9V=PMO</()74NJK$[9 ZG@'I0!<Q\Q.!]:6HK6YAN[=
M+BVD62*095AW%2T %%%(K!AE2"/44 +115"XUG3[6X>">X$<B ,X92 JGN3C
M&.#S[4 7Z*:CK)&KQL&1AD$'((J.ZNH+2%I;B0(B@L<^@&3QWXH FHJO->V\
M%FMW(Q$+;<':23N( XZ]Q4$.M:=<#,-TKY0R*,$%E'4KD<_A0!?HID,JSPI-
M'G9(H9<C'!&:8;J 7@M/,'GE#($Q_"#C/YF@":BJ3:M9*^PRG>2X V-D[/O=
MNU6HIDF17C;(90P['!Z<4 /HHHH **AGN[>W:-9I50R.(U![L>@J:@ HHI&8
M*,L0!0 M%16US#=PB:WD$D9)4,/4$@_J#4M !114:7$,D\D"2*9(L;U'5<]*
M )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FK_%
M]:=35_B^M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BH[B9+>WDGDSLC0NV/0#-9":W<L4B:Q1;B0%XT\\8*!0V<XSGG&,?IS
M0!MT5SB^)6N%8I9ND3959!(N<^3YO3Z<?6IH-<D$,0-JSDF),F0$MO3=GH!G
MUH W:*P+?Q&TRQ+]A99IUC:%#(/F#ACR1TQL;]*C36;NXO!&]M) BS0I\DBD
MY9=Q#>H'MZ4 ='16 _B7;Y1%C*XN%#V^UAF12X3/.,'Y@?QK0M=0>YTMKM+8
MB5-ZF'</O*2",_4&@"_17-OXFCN+2X2**5)A$'7RV!.&C9P1GT"_G39=7OWG
MA2*&11'+"I&]<R[D+$'/3MTH Z:BL^+58Y-"&JB)]AB\W9D9^F>E,M]9CN-#
MGU-(F'D+)N3.>4R" ?3B@#3HKF)I]83P^-5^WC+VK3/&(UPAVY&WC/MS5FX\
M30VL)DN+2X0I(8Y%.W*D 'UP>&''U]* -ZBL.3Q-;PRS":TN4CC$N'PI#&/&
MX#!]QBFS^*+:#<LEK<;T9E95"L<+C<1@\XW"@#>KFM<LYYKK4HD3?)>V:QV^
M6 PREL@$_4'\_2MJ^OUM%@ BDFDN'V1QIC).">Y Z UE6>J7>JZPJVBR0VL<
M22-O13NR6!!YR#QCCN#[4 1+I]S!J*7)M2D*7QF9C*N!'Y.TGKZ]JTM!5_LL
M\S9"7%S)+$#V0G@_CU_&JOVG4M1N]2BLYH8%LW\I T>_S&VALMZ#D"I;GQ#;
M6B2--!/LCWCS% *LR*691SG. >N!P: -BL'Q3>116J0##3>;%*5WJN$60,3D
MD?W32_\ "1JUQ'%'87/WW23=M!3:@;IGG((I4\1PRQ*_V.Z165&+LJXC5SA6
M;YNA_/% &!J]U#<:E-+;WBLDD0\G9=(@0[&!5N_).>#C/7I22&V:[1HI (PE
MN,_;D'.\F7C?UVG'YUU>A7,E[H\%S<;#*^[<57 .&(X'X4SQ'=SZ?HES>6IC
M$L*[AO3<#STX(H Y,R-]EDC6101;/$G^G1_\]<J!\_'R_P L47,I!402ILAN
M'DB_TN,D*75@!E_0-[]N!75VVL6\M\+%HYO-#M$9#& A=5#$#GT.:KZSK$MI
M-+;V]NP:)87,A4%2'DVD 9SG@T <] P@#):S00/Y5TH?[6FTLSAD.-W' (SC
MBF7#QW!<PN([=D<QP_;44HWE@?W^[ >O0GO72R>)],B$7FB5'D+ HRC<F&V'
M(SZ^F:MZMJ]EI"QM=Y_>9(V@=!U/)[9[<T -M-9T\6</VC4+5)-B[PTZ<''/
M.?6LW4-4MEU^SNX)(+B*&"5&*7,0^9BN!\S#^Z:M_P#"1Z>(C+)%,B*7#%E'
MR[, YY[E@!ZY%-C\3Z9(%*),<G#8CR$^;;R0<=2.F>M ',;GLHI/+NHG:Z#/
ML@NT"PN9M^.6'13U'O6GHM_&FNSR76I [FDR3<QF)P6^3 !SD#CMC!ZUT&F:
MBE_#/*UNT*Q2NGSXY"DC/Z5G7GB"W, ^R02><QC,>^+.4=@H<#/(_+M0!HG6
M=)==HU.S.X$8$Z\_K7'0SF.Q6*.<HZP[82+Q?W<V\DLWS'Y2-O7T/'//62W;
M6-E:&\MQ+-,ZQGRH\ $]\'I]*KKXFTAY3%$))9-X55CCW%\[L$8_W3UH T1J
MVFL<#4+4DC.!,O\ C6#/JD":[>W<"I<I+:10IME0 L&D)R2>!AAS5T^(]*VD
MM%."I;(-N>-K;6_(\&@:W9VZ.+E&D832JHBMFX"<G/T'?O0!S,(N;"-;87[2
MO!;!83!<(L?$9#(<G.=W3\#VIK.\MK^^>65HO/5!]H7H\8V\;SQG/K74WFOZ
M=;I<[())7@B,NT1<.  >#_P(4^WU6V\N5Y$9F\XQI$D!#C"AB".Y .<T 8UA
M<Q1W!CDF)M87\]%DG#%CY:KM!+'^(L<>U5X)4FTG2;7<L+V*%Y)//0$D(R[%
MP<G)/7VKHK?7-+N;U+>$.S.P"OY)V$E-X^;']WFC7-1BTZ+;#&C7) 8 QDA4
MW $G'3K0!S4E[<9B:.ZD9A8[67[2%PPB(R#G!.XXQC.<'-1+,\I&ZXD$RK*D
M$OGXVL9%*Y^8_+@=\CC%=8VL:7&C-)\BKYF28B/N-M;MZ\5+#?6%SI\M[ @>
M.+<' CY!7J,>M ',37:B0%YW+(]X%8398 CY,$'(!QQ3?/6-)KD7$HGCLX)M
MWVD[69,[T;YN^?US701:QI4JPK)%L:4(&#0G",_W58XXSV_#UH\0W%E8V3,]
MK%+<!&EA5H=X!4?>..@&1S[T 2Z=>V5M8QQS:C"TOWI-\X)#'DCD],]*K:UJ
M=H1;;+U&@$W^D+!-A]NTXZ'.,XSBG'5M&AE>)XXQ,B[F"P_>;C@'')RPJK?:
MY9I S65JC;460M)"=H&_81]1S^5 &/"WF2,+R:5Y)#;'S$G+;55\G)!P&"]<
M<YR>]217-^TMJ'N;L(JX3#Y.1(=P<Y[IMP3GH<<UU5HVFWEH9XH(O+0LIWQ;
M2I!((((X[U1;5M"5%8P#YRNQ?LIW/NSM(&.0<'F@"7P_)##I433W3^?(H:43
MSEB&Q@_>/'3M4?B.6VGT]"LY<I/$Q6&4AB XSP#SQ3M4>.VBLY+:PM'%S*L6
MV9-N-W0]/TJO'?6_]H?8;FRLX)DG".-FX.C1LRE3CK\AZ^AH QHII[>";RI;
MH>8)"R!R "UQD$#/]TDG')!I;6\OLQ2/<7N8_+4*6.#B8AB1W^3US^)YK=&K
M: 8A*(DVDX_X]SP, [NG3#*<^]58]7L39SF6WM(KJ%Y 5,#%2%DVG!QSQCIT
MS0!T7VNV_P"?F'_OL5S.I73/JDXCNKM8C+!S#DC;AMV,#W&?PJTE[;?;6@GM
M+- MQ)%@1$LRK&'RN!UYI]M>^'[J)9A:Q!B(R0UJ<C?PHZ=\T 7M FEGT6VD
MG9VEVX8N"&R#WSWK1J.""&WC$=O$D2==J* /R%24 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %-7O]:=35[_ %H =1110 4444 %%%%
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MCM2Y\L\ 2-O!P../QJ[<C6HH[Q89;AOLS85\!C*K.I) QR53<..] %D>&\
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MZ=* +6@V<]I:HDEPKQ(NV-48,IYR23@<YR*FU:WMM0LY+&XN3$KXW!&&XY/
MY!ZD5R=EJEQ8:=Y%M<HL>T&-5B'[HF9@1],=SGZ4X7<=]/;W<I032?86<@8P
MPD;=U_SB@#HX='@@OXYC=S/-YC3;6*_,2H4G  [8J2\T>*[O&N7N)T+(BE4(
MQ\CE@>1ZFLOQ#+/:ZU;W%K(D<HM)@A9-WF-NCQ'^.#4NEZI?W&NS6UP8PBLZ
MM#M.Z,#&ULXQ@CW[T 3CPY;JX=;JY5B7\PJRCS S;BIP.F<],'D\U:U33HKQ
MHIWNI;9K<-^\C8#Y2/F!R#QP/RKGM1UW5(;N^1)HH3"758FC+,% !63IT/U[
MXJOJ.J7C1SI)>K(L<5T@!A!28J%*@COPQ_*@#I)-%L&:Z+,RM>JJG#X(VC@K
M[\ _@*KR>&U<EI-3O&8J%9CLYPP;^[QR!TXXK*-R[:[!YTPD>.Z5H(R@&%-N
MW3V+$#ZTMKK=_/;QB\NX(TF=5D<1D^22K$QMD =0!WZ_2@#HK"PAMEN DC2Q
MW#,_S8P Q)P, <9)_.J?_"-Q;(U%[<@PA%C.$RBHVY5^[ZX]S@502YD3P5IC
MPSF!56U#R@#&,J&^E6=(U>ZN]2AB>1'66.1I8@F#;E6 4$^^>_ID<4 :]_9"
M]AB0S/&T4BR*Z@$Y'U&*S[?P[%;R1%;VX9(9 \2$)A0,_+PO/4\GFLV]\0W<
M.I:A!'/"HABE:)73D,@0XQG)SEO\CEPUG4@C,L\%QBX:W!CCX+LBF,GDX&20
M?PH NOX;A,<JO?7/[P2 G"<;WWM_#ZBE/AQ&W[KZY._SL\)_RT #=O;BH/%8
MA$&F"Z-LTGVI%)F.U2,'.?;I6-#KESIVFA89(T"W$W+\QL@=?N$\[<-CUX]!
M0!MOX6C>:5S?W)$L3Q,"$Z,H'7&>-HJRN@K'B5+V;[2)6D\YE4GYE"D8  QA
M1^(K'?Q%?":X036ZIYX196'R1J6?!)_X"!R."?2KNJW-Q<>'["6X*HDT\7VM
MHL[?+SSR<':3CGT- %FV\.P6MQ#)!<2JD,BR!,#DK'Y8!..F/UJ;4]&74)_-
M%S) S1^4^P*=R[@PZ@XY_G6;+<VEA>)!I$T%M#<N?-FV@Q(P3( [9/\ 3UJI
M!X@U*Y9,7-G 79$V-&25S%O)^]ZC]: -.7PRDS2B2_N/+8R%%"H-A=PY.<<_
M,,UH6VG>3826SSO*9<[W( SD8X X'X5@0>(-0FEM7$EKLEAMI#"%.YS(2& .
M>W7\*C@U[5+GR0MQ91F:1>%!=H\I(2K#(P04_G^(!K1^'(U54DNG>,F)I5V
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MJ5_#UQ,98IKJ/R'%RHV(0P$ISUSC(H U3JVEB/S&O[4)N*[C*N,CJ.M7%*L
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M#TGD6,<TL?[DLLP49$D9.[;_ -] ?AFI-)T22QU.:YE,+KE_+<;BY#-NP<G
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M_,_G3XM%TR'9Y5C"OED%<+T(&T?IQ0!1.H:B='TRX18#-</&)>3C!&3CC_\
M54VF:Q+>S1*\"+'<0M- RN2=JD AN.#R*MG2[ V4=FUI$;>,ADC*Y (I]O86
MEK(\EO;I&\GWBHZ\Y_GS0!S2ZQJ27,5[+'&R"WN#)$LI"X65 "..N"16OI^M
M/?:@\ M2D(,BK(6ZE&VD8Q_+-3_V)I9W9L8?FW9^7KN.6_,@5+;Z;96US)<P
M6Z)-)]YQU/3_  % &!/KES<P[6C:V$CAHW23)PDR(RGCOG]35F;Q'+'-=1I9
MK((2 A$F-_[P(><8ZGMG\ZLV'AZT@M6CN42>1W+O)RN3NW=,\<_RJ5_#^D/,
M\S6,9>0DL>>23GU]>: *:^(I!);)+:JAEG:%V,GR@A]O!QU/7G'3'6M#5IFA
MBMROF?-<QH=C[>K <\<CGI1_8NG;]WV9<[B_WCC.=V<9]>?K3TTRV%G!:RJT
MR0,'0NQ)!!R#GVH S-/NKI;;4-3NW8B)YD6'S1L^1V QD#!XQG//6H9/%3I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HIJ-O0-M*Y['K3J "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ I"<#)I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *:O?ZTZFK_ !?6@!U%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444C;N-N.O.: %H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FKU;IUIU(O?ZT +111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%5[>^M;J26.VN(Y'A.V15;)4^] %BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ IDTJ00O+(P5$4LQ/8"GUG>(BR^'[_ &_>
M,+ ?B,4 1V#BST:34+D-YDP:YEXR>1D+^ P /:J*6/VS5)%OLF2>RS(/^>>7
MRH!]L=?45HZ@JE+&S)R))ER/4("__LH'XTMG^\UK4)LY"+'"/; +'_T,4 13
M7KS:5&L#[9[B3[.K9Y!W%6;Z@ G\*ATBY>UD%@X9X%FDBCG:3<=P)8(1[+WS
MVI-,7S[V,$?+;/</T'WFE8#] ?SHM(9+C0Y)8@LDWVF6>/GJPD) _3% &[69
M?;K35;2[3[DS?9YA]<E#^#<?\"J1-2MYC#(DBJISYFYMIC..A'K[&H+F8:G=
M0VUK\T,,PDGEP=HVG(4'N2<=.@!]J -:BBB@ HJI>ZG8V 7[7<QQLWW4SEF^
MBCD_A6-K7B"\AM=MCITJR3@I$\^$Y(X.SENN!R!R1ZT =)02 ,DX%<7>?VII
M.DQ:;!J>^["!<11C(9C@%BV3EFZ=.YZ UM#1]/MK)9=7D:Z,:@R274K.N<<G
M#' ^F* +5QKFDVS;9]1ME8_P^8"?RJ+_ (2'3"H9997#?=*V\A#?0[>:+*^T
MA%D^S1I (W5"/)*'<PX&,=<8XZU6U7Q"UI$);2PDNX@^TON"!CCHF?O'/H*
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M]M(UOYC<SM*&6Q=<98$ [@ PXQUZ4][;4;R*3?974LS*RI+<S)&L1(P&5%R
M1ZXS0!0T1KV9C-;V OHX]PCEDE"*TASYCL.2"3P.#Q]:Z*"UU64J;RZMX$7!
M$5K%T]MS9_0"J]E8:Q;6D-I;R6%E!$H4!$:5OS.!G\*F.CSRL/M6K7THSDA'
M$('_ 'P ?UH U6=8UR[!1ZDXK UF[T;48VMDE-Q>*,Q-:+YDD3=B".G/J0*O
M)X?TI6#/9K.PZ-.QE/YL36A%%%#&(X8TC0=%48 H @TO[6=+MO[1"B[\L>;C
MIN[U:HHH **** "BBB@ HHHH **** "BBB@ HHHH *:O?ZTZFK_%]: '4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?TH T**I?VOI_P#S])^1I/[7T[./M29_&@"]15$ZQIP&3=(!^-']LZ9MR;Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "D'WC2T@^\U "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !2#[QI:0?>- "T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 !^F:*** "BBB@ HHHH **** "BBB@ HHHH **** "D'WFI:
M0?>:@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ YXHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ I!]XTM(/O&@!:*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I ?F-+35R&;/2@!U%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4@SDTM("=Q% "T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %'>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ IJ_>;US3J:O5C[T .HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"FKW^M.I ,,: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "D'WC2T@^\: %HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D ^8FEI >2/2
M@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I!]YJ6FC[S4 .HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "D'WFI::O+-0 ZBBB@ HHHH
M**** "BBB@ HHHH ***.: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *:OWFS3J:OWFH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %-3[S<8YIU(!@D^M "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex10_4page004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_4page004.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *,\XHI/XC]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D'WS]*6D'WS]* %HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BFE 9 _.0".O%.H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH   ,X[T4@SDYQUXI: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ IH^^?H*=31]\_2@!U%%% !1110 444V3?M_=D!LCKZ=Z
M '4444 %%%% !1134<.6 !&TX.10 ZBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ )QUHI&!(&#CGTI: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ..+9+(^6^<],Y J2@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *:/]8?H*=31]\_04 .HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3<-VW/.,
MXH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@! ,,W3GFEHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "FC_6'Z"G4@^^?I0 M%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#1659QZJ;Q99IT:V))V8&=I1<=NN[/?I^FK0 4444  ^M%%% !1110 4444
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MC4O,\,CAR54B38,''&>2,XZ8ZT 1-X7G:.0&[M@SPR192VV %PJEN#UP@_\
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M<?2@#8;29%T&WL(9AYEOY9#$85BA!P?8XJ&QT:XM]66]=X,$RET4'@N0>/\
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MX!P>AVG'//Y5B06>IQW"22P7TMOY>TQF<%A(%_UG!'!Z8'<9]ZKW=CJUQ;+
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M-PT[(LAC\R/C#E&W+].: &Q:]8R@%#-RJ,/W3<AF*K^H--C\1Z;)!),))%5
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MY'/8'-/O/#@O+B7S+LBU=I&\D1C(+IM;YOQS1;^'YX3&_P!O0NB.AQ;*JMN
M&< ]>!]: +$>O6(>W@FF'GS)&WR1MM^?[ISC@$CO2MK^G>7(T<X9D.T#:WS$
MYQCC)'RGD9Z&JB^'95:#%\NR*.!"/)^\(B2/XN,YIMKX:>U\LP7<:/!)F%A
M/NX88?D;CM;&>* -&SU!KC0(]1D,49>#S3G.U>,_7%5H[[19;Z 3?9#J#JA!
M$>6RPR.<9'3C-6K/3GM]#33C<;V6'RO-*8[8SC-4%\/RB:%S>H1&T!/[GDB(
M'ON[YH NZOJ$]A]E,,,<@GF\H[Y-FTD$@]#QQ4=CKMM<:?%<W'^C,\;2%6Y
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MK/D\.W,H97FA&\Y9E!!_U/E\?SJ)_#NH2LTTS632F16\L;PA'E"-LXY[?TH
MZ.*]M)KA[>*YB>:/EHU<%E^H_$4DE]9QRO%)=0K)&N]T+@%5]2/2JFB:?+IR
M3I,8FWR!E9.,C:J\CM]VJ&H:)?W%_=W%O+!&LR8"DD[^%'(QP?E/([8]* -5
M-2@DN0L<L#0>293*)5XYQT]/>C2[]-1AEF15")*T:D,&# =\BL*/PYJ"6\D0
MFME.QA&1N/\ RV\Q0<]NQK:T>SN+2WN%N?)#S3O+B(D@!NW- $YO[()+(;N
M)"<2-Y@PA]_2LO4;W2;F7]XPF%NRB1XY2IC5\8.01E?NYJA%X>U6*9YEDM&D
M1T>,$MM?:9!@C' VOVS@COUIUUI=ZEM=V92%AJ")&IB4C9@ 'C& H X/4\4
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M:/OM0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKG;M;2;7;]-7*>2MJGDB0\!3NWLOOG R.>E=%65>ZG MU);K937DENHED\M5
M/E@YQ]XCG@\#F@#-GUBYM=RPR1;(I/(2&1#OVB/<)"<_B>.GO45EKNH2RQ>9
M<VC+(\:D"(C&^$O_ 'NQ KH_,LG<,_DB5DR=V-VW_"F;=/E78AM\G.-NW(QW
M'TS0!SG_  D.HI;1M)-9,\L,,BE5*A"P8E3EL=%SG([^U2PZ]J%Q/#MELECD
M,49 4L=[QD]=W8XXK:L[?3K2P2!'A>*(*-S[3TZ9/KTJ22"Q.4 @CDQPRA0R
M\=10!3T"_OK])7NQ$HB_=.%0C]Z"=V,GIT_6LJ;Q!J2'Y6LCODG6/<"JXB8C
M!);J1@^V#UK=1K;2K..-#)*#( 3D,Q9V^\?Q-6/*LY%:(1P,J-N9=H(4^N/6
M@#FY/$>HQPS3E;0K^^"+A@5V*"">>_3MSBIIM;U.WNYHG6S98,!RQ*;LJ6!&
M2>.@_ \BK6GC25NYH8E68W69S,ZJ0^6QM![\CI6G+!8R2%Y8H&=5\LEE!(4]
MOH?2@#G!XBU$A4$5N)5WO() 8^%8 K]X\\GIGMZTKZUJK1XWVJ%V3850DJOG
MB,YR?0_SKHA8V)CB MH"D1W1_(,*3W'I3/[-TYD(^QVQ5UP1Y:X(SG'TSS0!
MS[:Q?6ELPM8K4L7NG;<6.?+.21SWS^&:O6VLWMUK7V2*WC\E9"KG!.U0H.[=
MTY)QCM6@+'2Y@V+6U<!F4_(IY/WA_C5*ST/3OMXU"*3S"LK,GRI\K<@C<!N(
M'(QG Q0!0UH3OK%Q(Y#QVJVSQHLC(06D8'IUS@9'? IJMJ/]LM<H\9<WS6^#
M(VW9Y><;>G;KZY]:Z*73[&61Y9K2!W?&YFC!+8Z9JA9C3+\/]DL_+W%G\XP
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M17AC1VP'() )4#K\I8GTKH4TRPCMFMTMHA"Q!*@=2.E2I9VT;1M'"BF)/+3
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M&<]&IX\46H_UMO/%B$S,LB[74#.?EZGE<?B/6K?]AV(AEB19$65E;Y9&!1E
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M **** "D'WS]*6FC_6'Z"@!U%%% !1110 4444 %%%% !1110 4444 %%%%
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MJC)!J[B<N^IK,1,/W;,%SM!3;V W9Q^72@#IDTZT6_-\(SYYS\Q<D#( .!G
MR%'3TJ%++3I;^=HLB5'4S(KL%+8R"RYP3C%8KI?S7>[?JB(9P"%+*!'Y//\
MX_\ UJN\NK?89/\ C^29DM\DH_WO+.X<#(RV 2.^.U &[-I&D6R!IU*)O4)F
M9@$)8$!>>,MC@>U/?0--<DF&3)#@XG?^-MS=^[<U@RRZJUX^?MZHICR-K';@
MQY' (88#\CWSVI]])JV)C"]\DX>42!5)4)N_=E.,9QCIZG- &U+HVEQH\LR-
ML"R%R\SD8;&[.3[ _A2?V'IL\>]EDE\Q6R_GOEPR@')SSP *ALY+D:/J"/\
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M7EO;!OM-M&)"2N5&2.,9SG!^GY8K9K,N]#M+RZDN)VE+R)LX;&T?+G'?^$4
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M >20.,>U:&EZ?]FT=+2X/F.ZGSF)R78]<GO0 HUK364LMTA (' .3D$C [\
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MK?VIH\5[O^V0+)+#O+>8 K(#@'KCJ:HMX<G9;=6N(2+7:(CL.642*_S<]?D
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M('?@#CIQ4VFP2MJ5W>R*ZJZ1PIO&&8)NRQ';)8_E0!=BNK6YDDABFBD>/B1
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M/,&0>"?4>G<^M9-OX@U"YN(A&]GLF=(T7:V<M#Y@.=W8\=/RK:EO[&:ZBM)
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MICDP-^Y<8Y&#C-3CQ1I;,5CDD=MX0!8R2Q+;>,>].'B.P(4XN-IC,CL8CB,
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ME<<\8-9.IIJ^^Z\G[?\ :-\N"C-Y9C*X3;CC=NV^_7-:U[9R#PK<6L/GR2/
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MYDF%WODM82YN(V7+@MN R,8!(Z<54NKC42\RP2:A&#=S',=KC<HC^7G;TW#
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M:H9S/<K(%2,A"@5U)'S=.V>G>NCH **** #-%(I)&2I7GI2T %%%% !1110
M4444 %%%% !1110 4444 %%%% !2#[Y^@I:0??- "T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %8TWB.UBGN$-O=,L!(,BQ_*2"
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M%%% !1110 4444 %-'WS3J:/OF@!U%%% !1110 4444 %%%% !1110 4444
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MOKU]96Z6RO#<R*9BI<[?EC?;M+%NN.<\GV-='<P:79P&9[.W"JP "PJ26)P
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MU;>&;B$8-Y WS;\^0<Y\KRS_ !?0T^T\/W=K/:E;V%HH94E8&$Y)$7EG!W<
MCGOBNBHH P-2TFYN9-1MHBJQ:C&N92N?+*C!!&1U&,?C3[S3KDR37\NVXO#;
MM;P)$NQ4#=SDGOC)]!TK<HH R)M*G-GIT4,L1>T78QD4_,-FTD8[UF'PM<>7
M&GG6[B-(EV,C!7V1E#G![AB?P%=510!@W^@-/:V,4#0$6T30M&Z$1LK 9. >
MVWI[FL^_T"[CLKIE2&5F$_$8.]O,4 <>HQ7744 <9%HNH7\$I(2,M(SF2560
MRL54=, @#:!COU[<Q+I5]?7MU;R0-$LAF 9HR%BW')(/\08J.,]">E=Q10!R
MK>'+Q@QV6(+I@KEB%)=6/4$G.WVZTZ3PY=.ZLPM7423?NV9PH5W# C&.1CIT
M/J*ZBB@#E/\ A'+Q89 B6:L5? #'#$S"09^7T&*T-6TFXO)/,C6W<R6C6SK(
MQ 0G^)>#GZ<?6MNB@#(TG3+BR@OD?R=\\A9) 2Q(V@#=P/3]:I:1H=Y9Z7?V
M=P(&^T1@+B0L"?+"<_*,#Y<]#U]JZ2B@#D7\-7>U0D-IY:%/W E9%?\ =[&R
M0.#W[YJ2?PQ<,X\F:&-0L;#:I!\S:$<YYXV#\SSTKJJ* ,B[TMTO-/O-/6/-
ME&\0A9BJLC #@X."-H[53U72-0U)Q++%9F00,B9<_NV+*1@[>VWKQUZ5T=%
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M4 %5;Z_@L54S;V+9(5%R2 ,DX] *M5BZI;R-J\4O.R6TEME8]$=BI&?KC]*
M- W\(AMIFW".XVA6(^Z6' /IGI]:M5Q_]FW$&FS6HA$$UX(8HH ^[#H?GE]N
MQ_X".YKL* "JE[J5M8/$MP9 9FVILC9\G&<< ]@:MUS_ (D=OM^E@>8JQ3F1
MW3J%V,I_]"'X4 ;=K<P7EM'<6TBR12#*L.A%2YKA)X;:VU2".W#)IL*JC/YA
M4>7M<-N)YZL#QZ9^A$%DM;8S,TV;@++L9D#0HK(I[9W?>_&@#NZ*\_0W$5B(
MVDF&Y+<RIYV6E9=_F 9R.Z>QQ4D3B.Y1Y[B8A3"J,]R/N MOZ$9." <#U^M
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M%M(C92!RQ.WIZMZ< '9@Y&1THJK8W<5PK1QEM\&$D5D*D':#T/L:M4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-'WVIU-'WFH =111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SG_"22K>-
M:/:H)@[1@"0_?#@ =.ZG</H:Z.LMYM'.H!'$9N?.R&VG'F[=OWNF[;QB@#"O
MM4OO[/N8X6:)1;W<OF>=F0,DA48..G]#[<WI-;GCEWS6Y5[=9PR)/E6**K<_
M+Z$?3GK6FVBZ8RJK6J%55U ).,.<MWYR:4Z/IS%B;926W;LL3G< &[]P!0 W
M2=1FOFN4N+80O ZCY7W!@5##L.<'FL_4-5N$U650)%L[1XXW\LKN=WZ9!YV\
MJ./>MJVM+>U+FWC"&3!;DG.  /T I)+&UDNENG@0S+C#]^.GUQDT 9>AWMW-
M<1QW,IE$]FER3@ (Q)&T8YQ]?0TNM:A<++]FL_D,4ENTLF\ @/*!@#'.0#GI
M6G:V-K9M(UO"J-(<L1W_ ,!R>/<U%=Z38WMPL]S#ND4 9W$9P=PR ><$9&:
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M@L3U!.>AP..G% %J\O8[2Q-VZ.P^7:H'S$L0 .?<BL2T\020$QWT,KR/=O$
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MZ312]U=3KJ%S&;HJ750F!MZ8)7(_.HI?#D,GG9O+H&?!?!7EPVY7Z=1P/3
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MXS1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MT??:G4@^^: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-'WS3J0??- "T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112;A
MNVY&>N* %HH!!&00110 4444 %%%!('4XH **0$$X!&:6@ HHHH **,YZ44
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M:?"US&]H\\EA'*\@7G)?!+?,<XR2>GO5X:_??:H((Y[&5<\RY($P\PK\O/)
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M:"1WS(BLIQ\O<'UYJ6WLK6U=GMX(XV90I*C&0.@_"@#/U36)[/48[2WM//\
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MHH **** "D'WC2TU3EV]J '4444 %%%% !1110 4444 %%%% !1110 4444
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M'N3_ "K!L5O(HK6=!J0ECMK<29B<EF\P[P>.0%W<?_6KJGU+3--=;$N(?+
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M ;CBEIH^\U #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ5C !SCFBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M781,$)4!HW;&-W4%/R(IJ^);T6Z&3[,7E-N59>%02*3@Y/\ L]>.M:QT?38
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M3WLLK1VQ62/Y1YK 1GRRFT#&,9).?KQ4L/AUX=3MI4M[<1((R"CE?)9>H"C
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M4R+0;Z*2-VMA(R-"4;S1\BB1RR\^B,%]P*U9/$"QW<D'V&Z;8[1@C;\S*F_
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M6WQ': Q+;!F#')\HDMCY>^:ZJB@#BM,T6XNM+BEA@@B,?"*V07Q.');C(X7
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MN=W9327^FZJ]Q>OY5]*[2-@I*H1D+J5 Y#< 8_/UKM:* ([:&.WMTBA4JBC
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MH0$5,$GC[O&3^5,TDDV5SJ+I)NNW:4*>NP#"#\@#^-4]%TJ":P"S-* CF.:
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MC$ND+&7E(59.-D2D??QWP.@^E49?"]I,T7FRRLD=N\07/WF<Y:0GNV1GZ\T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!0FLIH[XWMC(JLX EB?[LF.AR.A[9YXI5O;H ^;IEQG /[
MMD8?JPJ]10!56>Y=P!:,BDC)D<# [\#-/BBEVYN9 [9! 48"_2IZ* #ITHHH
MH *" P((!!Z@T44 9!T%(6SIU[=V*YR8X6!3_OE@0/PQ3CI5\Q.[7;T _P!U
M(A_[+6K10!E?V('4BYU+49\^L^S_ -  IR>'](3DV$,C?WI1YA/XMDUIT4 -
M1$C7;&JJ/0#%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FC[S4
MZFJ,,WUH =1110 4444 %%%% !1110 4444 %%%% %>Y^V97[)Y '<RY_I43
MKJF/W<EGG'=&Y/Y]*NT4 4 -7#X9K(KZA7!ZCMGZ_I0O]L!/F^PEL]!O (_I
MWJ_10!1/]K%N/L87CLQ/N*3_ (FX<<V17//# D8_3FK]% % _P!L8&!8YSR<
MOTIH&LX!)L1TR!O/?GGZ5HT4 4"=6(P%L@?7<W//ICTSWI0^J9PT-GTZB1NO
M_?-7J* *#-JX0;8K-GX)S(P'TZ'\Z"^K8!6"RR<9!F;C\=O-7Z* *)?5<C$%
MGC)S^^;@=OX:)'U7(\NWLR.^Z9O_ (FKU% %$OJP; M[,KGKY[ X_P"^:17U
M?^*WLNW29OQ_AJ_10!2+ZIQMM[0]<YG;_P"(I#)JN[BUL\8')G;KCG^#UJ]1
M0!0,FKA#MM;)F[ W##/_ (Y2>=K'/^A67_@4W/\ Y#K0HH H+-JQ?#65H%]?
MM+9Z^FSTH\W5@0/L5H1CD_:6Z\?['UJ_10!GFXU4/M_L^V88'S"Y.,_]\4JW
M&J%<M86X.#Q]I/\ \3]:OT4 4/M&J;,G3X<^@N?_ +&D2XU0J=]A #V_TG_[
M'_.*T** ,]KC5-IVZ? 6'8W/_P!C33=ZL /^)7$?I=#_ .)K2HH S1=ZMNP=
M+BQG&1==O7[M/^TZCD8TY,'K_I R/TJ_10!G_:]1'_,,!..TXZ\>WO\ I3Q=
M7O?3SUQQ*IJ[10!GF]O^<:6_7C]\G^-.-U>@@?V<QXSGS5QGTJ]10!GK>W[,
M1_9<B@#.3*O/MUH6]OBP#:7(O!.?-3KCIUK0HH I"ZO=Q!T\XR,$2KTS_DTU
M;R])P=,E'N94_P :OT4 9OV^_&<Z1-[8E3_&GR7MV@!72YWYYVNG_P 55^B@
M#/:^O%)_XE5PW^Z\?/\ X]0+^ZS@Z3=#Z-'_ /%5H44 45OK@@$Z;<C.>I3(
M_P#'J/MUQQG3+KH#UCX_\>J]10!2:]G"@C3;HY7=@&/(/I][K36U"=4#?V7>
M$]P#'_\ %U?HH HB_G+8_LR[ ]28_P#XJ@7]P3C^S+O'KF/_ .*J]10!1%].
M8PYTR[&?X<QY'_CU OYS_P PR\'?GR__ (JKU% &<=2N %/]DWI)'0>7Q_X_
M4@OYB 1IUWSUSL&.,_WOPJ[10!0;4)E!/]EWIXSQY?\ \50^H3*.-+O&^GE_
M_%5?HH H?VA-R/[+O<@9_P"6?_Q5*-0E,8<:;>8(SC" C\-U7J* */\ :$FU
M3_9UYENVU<CZ_-2?VE)WTV] &,_(O_Q57Z* ,_\ M-P0#IM^"1D?NU/?U#<?
MC3QJ#E2?[/O.!D_(OY=:NT4 9PU4D(1I]\ WK%C'..>:%U4LY4:??< GF'&<
M''K6C10!F_VP/FQI^H?+_P!.YY^E._M4;ROV&^P._D]><<?G6A10!GG55! ^
MQ7W(S_J#2_VHK*VRTO-RCHT##_/X5?HH S#K<(8J;/4,@9_X]7_PIW]L6_>"
M\!W;<&V?\^G3WK1HH RSKENN,VNH G_IT?\ PH_MZVP2+:_('7_1)/\ "M2B
M@"."83PK(J.H;LZ[3^52444 %%%% !1110 4444 %%%% !1110 4U<9;ZTZF
MC[S4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "FC[S4ZD'WFH 6BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0?>-+2#J: %HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBD'WC0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4@'S&EI ,$\4 +1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(#\QI:0=30 M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4@ZFEI!]XT +1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%("23[4 +1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-7^+ZTZ
MD7J>* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M0J"02 2.A]*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ I!U/K2TB]_K0 M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 444BDD?, #]: %HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D7O]:6D7O\ 6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ I%[_6EI!W^M "T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110#F@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "@#'I12+W^M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !35[_6G4@&,^YH 6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex10_4page005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_4page005.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *3/S8I:.] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%'2@ HH!R,BB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *3^,_2EI!]\_2@!:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF
M[AY@7N03_*G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%%  **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ IH^^?H*=2#[Y^E "T444 %%%% !1110 44V/?M_>8SD]/3M3J "BBB
M@ HHII<"14.<L"1QZ4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M :6(D5=I((/S>E.I#]\?-CCIZTM !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !112-DJ<'!]:  #: !GCU.:6D1@Z
M!E.01D'UI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I!]\_2EI!]\
M_2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** $Q\V>U+110 4444 %%%% !1110 4444 %%%% !1110
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MBM2_UR* W!MUBG>VA:1D+E6&",C&.F"#FKMA>-=27:/$$-M.8A@YW# .?UH
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M003:D]NWRQ,L9A?8V26W##9''*XH 3Q!9S:IML%7;#L:1W9"06Z*!@CD9)_
M5BWFI7\DEL;E;F$Q01M=>6^/)8-ESM!YW*#]!TKJ=1U.VTV-7NF8*V?NJ3@
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M9X@(+I!)Y>&:,8 ?[I//<@CU_#FD7Q19R*IAM[N0NX6,*@^?.<$<XQ\IZXH
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MB@ HHHH *;N7S"-PSCIFG4G\6,4 +1110 4444 %%%% !1110 4444 %%%%
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M[=E^U1;\(N"'A)P021C/'XU!=7X_L6*T^T06]N$+($08E99L;1UP0H!]><T
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M **** "BBB@ HHHH *:/OGZ4ZFC[Y^E #J*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** &R(DD;)(H9&&"I&015./1]+BQY>GVJ8  V
MQ*,8(/\ , _A5FZ,@M93$I:0(=H!P2<<<UP<S:A;V"VSI>ES,Q 8[#M,0&X9
M8'Y6.<9[T =I_9.F80?8+7$;^8@\I?E;^\/?WIYTW3V\W=96Y\Y@\F8P=[#H
M3ZFN3^PW%Q:S7<"ZB\9EB/+DM)#Y:[MJL<$[AG\Z1M-U1IDWQ:@P$($#"5?E
M4*P*N>NXY!X[D<\9H ZO^R].^0?8;7"+M4>4ORC.<#CUYJP886\S=&A\P8?(
M'S#T/K7)6>DWMO=PR16ES&1)&2[2[L9B*N2"Q_BVYJK;Z+?%(X[FPNV7<3,'
MD0JS>6ZEE (R"2O)Y/>@#M(!:HK6ENL:K$ #&@ "@^U)]DLU 7[/ !T V#ZX
M_K7.Z0)]*N5>YTZ427@@B,F4W;MFUL\Y.",FI_$FF75YJ%K-#"\\:J5 5U7R
MGW AR3VXP<<_G0!HW>IV26#R7<9VA'D,+J"Q5#@G'Y5=9K<;7<Q@M\H+$<^U
M<?-H5Y]B18M-#2FWN8,ET!3>^Y3G/H2/QHN- O&D;R;#_1C+)MA\U5V!PF&[
MXP5.<<\\4 =@C098(T>5^\ 1Q]?R-)Y]JQ_UL)(/]X<=JS?#VF"QM;@2V<<,
MLLSDD8)=2Q(R1]>E9UMX<N(+Q6W1FV#%/*  S&I+1@GU#'GVQ0!LSZI96\CM
M(\8B6,O),'7"XQP><_Q#_)J1=5TYO,(O;?$3!'/F# )Z#/XUS;>';O[#%"EI
M:I*-/E@D96QN<[=O;D?+UJ2[T+4+EY)&M[7:TWF>4)V4,&C",,A>,=O7)Z4
M=+'=VKW!@CN(6F ),:N"W'!..M$MY:P2B*:XACD8;@K. 2/7'X5A:5H=W8:C
M#,R6HC224L48[B&5 .HYY4]3WJ6^T>\GU*XDB,+0W#Q2[G8AHS'_  C@\''X
M9/!H V+>]M+F)Y;>YBEC0X9D<$#C/)'L159M;TE8UD.HVNQFV*?-'+>GZBH(
M-)?_ (1?^R962.0V_E,\73.,9Z"JT&C7G]K0ZA*+5"'R\:$D8$>P$<#GG/X
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MCC947Y!R,9Z]?6NB,<31>4R(8\8V$<8^E0/%8PVZ1M% L.X!%VC&XGC ]<T
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M\<UTZZI8/G9=1-C9T8?Q_=_//%5)M6MKI(X[5[>X25FC978C=\A; XYSQ^%
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MS6UKND?VI]GV[ RLR2,P_P"63*0P'OTQ[BF2>([>.YA@>VN0\BJ[#:#Y88D
MM@^Q/L*$U]6V[K"Z0/$94+;?F4*&]?0T 4;?P_=1O:R3K;W$J1S"5W. 2P55
MP,'L@IHT&^6-5\NS9EBM0"2>6B;)'W>A%64UN6XNH_\ 1KB*/SD2, I\^Z,M
MAN>/P]J?_P ))&80XM9@S$*%P"5<DC:0,\C:QXH H)X7N!(I/V=MDP8NSL3(
MOF!^0<@8QCCKG-:L.F7*>'9M/WPK,ZR!6 RHW$GD$>],U+4;EM$@N;6*6*2>
M6-&# !D!< \'O4 U]K2T(DMYIS"LX9RR@L8FVGIQS0!5'AS4%MY(TDM?W@E4
M[F=L!F5N_4\$<U/<^'[RXCGB^T0*KFXVG82<2\\_0\5'/JNI2WRQ^0(_*NHT
M\M9OO;HV;#''3H:F_P"$I#)OBL)7585DD.[&PLF\ GIT[Y[]* $NO#US<Q2P
M-- (R\DJ':=P9T*D'V&2?R]*?=Z'>W'VG9>Q(+GRED&P\JH(*]>,Y[<U=?4;
MB'3HKJ>U13)*B;%DSM5F !SCKR.*HS>))8U#K8AD5GWGS>0%E\LX&.?44 1R
M>'+V:X622]@X&WY8B-JE&7: &QC!%2Q:#=IMD:Z@\Z,Q-&1&=H**5P1GD$$U
M5GUVXCU#[8(F-L894CC$GWF$J("PQQR3Z\5,-?U%FF0:=$)((FDD5I^202
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MD@G/.#T'Y5'?6&F75\HNSFXE0 )YS*75&W#@'G!.<^]<V=8U=+J%5G,[%'4
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M;=.D:!?KQUJ>@ HHHH 0#:H SQZFEHHH **** "BBB@ HHHH **** "BBB@
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MA_;,9QJ%R+@MN$@"\?($(QC'11^(J6VT2.WO([E;F5BCN^UL<EE"\G&>BB@
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MJ1T]:)?$MJD*R"UNV^65V 0901MM?//8^E2MX?M&8NTMP788=MPRWS;LGCU
M_*H)?#R/>(-[FT*3"4&0[F,C D=/N\'OWH 23Q-9Q7-Q$+>5I(@"=H7+ LJY
MQG/5AC/6G#Q&AP#97"N5?"DKRROL*CGKDC\ZE/AO3VG:4^?EF9MHE( )8-T'
M^TH-*-&C6\@*JAMX96N!N)9_-.<\GMSGZT :PZ44R&(0J55G8%BWSL6/)SCG
MM3Z "BBB@!I8"0*6 )!P,]:=3"6\U1LRN"2V>AX_^O3Z "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX-C.. <4 7=*U Z@MRVS:(9S$N002  <D$ @\TMQJUG;3F&61@RG#$(2 <9
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M#Y1SS3H?#MY"T:QQV@B+QR,K2L2I4L=N2#GANOMTH Z3[1;11/MEB"0@;L,
M%]/I4-GJ=K=6L,X<1"<$HDC ,0/;/M6!:^&KVU$'E+8CRHX04#-MD9&<\_+W
M#YSZ@4Z'PU=I+$\C6[C: R;W"H5=F7:!@$?-CD<8[]* .F@N(+E"]O-'*H."
M48$9_"L?4)M*^VQF:1CYKF.21;ID6(A2?F ;CIBKVC63:?I5O:R"/S(HPK&/
MH2!C-8T7AR[27>TUN0)"ZH06 RCKP3R!E\XY [=: +-\ND6D$S[WEFMX6F$0
MNG+;<=0-U36EG97,]W%]GGC-M*$.;A_FRH;/#?[59<GA>^?C[5;[?(,.-K 8
M,80G [Y4'/7MVK>TZSFMI[N69HR;AU?" \815_\ 9: ,^U&D37=U:.&2:WD*
MF-[EB2H .[&>!\U:.FKIXC=].:-E)PQ1]PS^=4+O0#>3SB295@ED:7Y5^<,T
M?EXSZ8YJUH^G2:?#*)#;F21@28HM@. !SR<G H ;'KEFJ.U[<6\!$SQJ/.#;
MMIZ_XCM6A/<0V]N]Q/(J0H-S.3P!ZUB3:!/)YF+N-?,:<_ZHG_6C'KV_6M=;
M;?IXM+@B0&+RW(&-W&#0!#)K&G1([R7<:K&Q1B3P"!DC\N:K#7[-6D=Y8VA$
MJ1QE"68EAW&.._X"J:>%E2&8"\=I9[;R7=UR"QZOCUP /PJQ-H<\D\DRWD:N
MSPNO[G.#'^/.<T 2VNO63VT#75Q DLR[@L;%EQNVY!QTSWJU%J=E-=_98Y@T
MWS87:>=IP<'H<'BLP>'"(5C-X?EA:+B(#@N'SU]L5#HNFZA;:P\TT12(F0MO
M*E0&8MA,'(Y.3D#\: -JYU*TM;F.WGDVR2?=&TGJ<#Z<U5A\0Z9/&SPS.P 4
MC]TWS9;:-O'/(QQ2:EHXU&^AN1=-&T&W"A0P!#!LC/0G&*KKX:1!%LO9E:!5
M$3;5^4JQ8'IS]X@CTH OZ)?2:CI45W*JJ[E@0H(QAB._/:HHM?T^8@1/(V2P
M&(VY*C)Q^ /Y5/I5FEA9_94G,VUV8EL9!8[NWUK.B\,PQ99+R<2M)YA<!><K
MM/&,9()YZT 5KWQ%<>:YL5'DH81EK=VW>9C!R",=1QWJY9ZR4M9/MC&XG261
M"MO;LOW0"?E))X!'XFE3P[#'"8EO+G!\G)^3GR\;?X?84]M A+F6.ZN8YC,\
MOF(P!&\ ,.G0X'Y4 ,?Q#:6L1:ZE9R9I$4+$5("G!XSSC(&>_I4=SXHMH[>Y
MDAM[AVACD=0R;0^P@-@^V10=#M3=1PPWDT9C,CD)( X#XRO3[OZ]*D_L&Q?S
M+<W,S?)(&3>,JLO7MG^'CZ4 7K^Y:#2IKH%HC'&7)V!BH R>,\_G5*QO;R\U
MFXC!:.WMF"E6C&'R@.<YR#D_3%:$]E'<Z<]E+)(T;Q^6[;OF88P>?>F6>G16
M=Q/-%)*6G(+AFR.  ,>G H J3ZL8+B^=LFWLRD950,L[8/4]  5_,TEGJYGO
M[,#<;?4+<S0@KRA7&0<=B&'Y'UJ6YTE;BYE9G(AG*.X5BK+(F-K*1]!GZ5'9
MZ;;V.H6Z>;Q%"Z6L3,68*2"YR3S_  CV'UH ;K^J2VD;0V:L9U59'< 81-V,
M\]<\BJMSK[W#&.UAN(52XC03F/Y9!Y@1@,CW-:FHZ/9:E(LERC[@A0E)&3<I
MYP<'D9YJ+_A'].\UY/+D!=P^!*P"L"#D#/&2 3CJ1S0!4BUQ[> ^=!-(6DG5
M&D9?F9'("?*.IQQQT]:9+XFEC\XC3)61'\M6#\%PP4C.,=2<>N.U:L>DV4<:
MQB(E5F\]0S%L/G.>3ZDG\:K7&D:.;UFF@ GNSD@,P+$8.< \=!D_3- %0^)9
M(Y)UFTYE6 %&829'F@ [<XZ<XS[=,5;T"XN9TO\ [63YD=VZ ;MP484@ X''
M-22:;I3:A*9;>-KBYBPX;G>HX/'3., ]^E6;*PM=/C=+.(1"1MS8).XX R?R
M% &)/XEN+?S'GL56,F1(BLN2SI)LYXX!)!S]:5M?U'<T:Z=$'BC>20--R=IP
M !COD=:O66A6UO'<K<)'<-<M(9&*8RKMDKC)X_P%3#2]*!\E;.V!$13:%&=A
M/(^A- &2GB.X>VDF6"+_ $>)II@2P)42,N%!'WL*>O? IH\17H5C+!;+N$GE
MX<GE95CY]<[NGM[UJ);:1]L2Q%I#YMLGFH#%PH9CR"?<5,=*TQE*FPM2&SD>
M4O.3D]O6@#FGOYK[=<^;)$_EP95)2%#?:&0D#/<"MNRU&[GU>6QECC7R2Q?
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M!)&TL#20KNAF'S"0X!(!SC^>: +^ER3RV$<URQ+R9< KC"D_*#[XQGWJW0
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M]:4:5I:R1C[/%O#+(N3DDH-H/X XH AUR:ZADT\V1S(]P4V,^U7'EN?F.#W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110 4444 %%%% !1110 4@^^?I2TG\9^E "T444 %%%% !1110 4444
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M@L< FV< ?4D5>HH **** $SR!SS[4M%% !1110 4444 %%%% !1110 4444
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M0 4T??/TIU(/OGZ4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>0ZCYT5W;I-;+.(867) $60QYR0?\*LOK.IV^H0V\EY;MNC60;HR#,K9)*@
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M*CJ0-VU@=I(!P??FK-9FCZ;+I[SF26-UD6, *N,;4"G\\5IT %%%% !1110
M4444 %%%% !112,"<8;'- "T444 %%%% !1110 4444 %(/OGZ"EIH^^?H*
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M@#LPR,V,9Z@K^((Z5T)M;9KD7)@B,^W;YFT;L>F>N*:EC9QH$2U@55)(41C
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MY')XJ]9ZM=W&MVD,M[ (@UQ&P1.)64IM[GG#?H?P -R[TY;K2#IWG.BE F_
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M;A2,2$'>!P/;BN@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/4T .;PY:OJ?VJ0QM'N#!#"NX8  4-UVX'3^G%7)+'2[6%YVLK=5B7>2L0)
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MJ9%D;(V_=VG.5]>/6K2Z'IRNKK"P965P1*WW@, ]>N": -&BF0Q+#"D2;MJ
M ;B2?S-/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!/XNO;I2
MT44 !.,>]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@#HZ*X2P2>_58&6YE^> R"*X!0H,AF)#]6[BK+Z3J:QWBQI=%B^6/G)MG02
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MV"G@')Y/_P"NI)/#-K)(TANKH.TC2$AEZDJ?[OJHI)]%TZ(8N[R41GSB4DD
M!5R&8=,X!&: )+;Q#!=7,5O;VUQ)(Y.<;<* 0"2<X.-P/&>M-EU=[77)K:X1
MVMR(E1E48C9MW7G)SM]*L6>CPVUS'=?:+B:5$9-TC@[@<=>/]D?E3I](MY[I
M[AWEWNR,<-Q\F2O\S0!2M_$]O=/&EK9W,IE8!-NP @J6!R6]%/'6G0^(X;C
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M0 4444 %%%% !1110 4444 %%%% !2?Q'Z4M-'^L/TH =1110 4444 %%%%
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M4 5M.M6LK&*W:5I2@^\V>><]R3CM5FBB@ HHHH **** "BBB@ HHHH ****
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MDDYYYY)//>IKC3IYVBDGU#/E-N0^2O#=C0!G66ORQ:/#]H4-<QS&VE>7,8!
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MXM-0:ZLS&4\H^60<#<"H.5P>F#UH YNT\17U\(DAU"U#3/%%PBLT;,I+<9Z
MXQFED\0:G&UU^_MR(W,;H00UOAPNYOEP 5.<G/J. :Z&QLK&P^=+AI"1L5II
M=V /X16@VQ%9FVJN.2: ..36]1:9%EU*W7+Q1MLC!7#%P6!..R@^G/I2P:YJ
M3FS1KE%#1+E_+SYS;BK8PIY  /;KZ5UHGM\J!+%\PROS#GZ5 M_ ]R(XVC:+
MRFD\Y9%*C! (Z^] ')#5=1FMHC-J4@'^BRO)'&H*%G8.N-O8!3@^OOBNJUMW
M30[YXS\ZV[E<H&R=IQP0<U*VHZ>L>]KVV"?WC*N/YU-+-#%"99942/\ O,P
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MQ:,;]X780 <XZ,1QGI^%;8N-/'S":VX(&=R\$]!4L)@==T!C95)&4P0#W'%
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M\1327$44>GEMP5F;S.%5F*HV<=#C/; /<\5H:+?3ZCI\5Y-!'"LRAXU20O\
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MNMZ3>7VI6]Q;BW*1;#^\)!RL@8] <C H?7OGCM8XI&>18U\P,NX,ZE@=IZ@
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MG-3#1#!'<26M[<?:Y8/*\Z1@3G)(;IUR>W%07&J7:^%;:^8B"YF\K<0O W,
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M;Q#F)48M;JQW*NT,"2<<8R.^*=!X6$)MMMYM%O)O79'@KR#M4[LJO&".1R:
M-%;K3=,GCT]-L+2'<$53C+$XR?<@]?2I;74[6\MY+B!G:.+DMY;#(QG(XYX]
M*J:EH9OK^.[%[)$8RA50@8 JV>,],]_H*73-'_LJQNHHI3,9LL$"A%!QC@=!
MGO[T -_X272S;-<>9+L4*<&%@2"I8,!C., \^U)<^)+.%F6.&YE=9$C.V%L
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M%7'3C')]:?)K]A K?:)&4H&W$(Q7<HRR@@8)'I[&G2Z6XO9[FTNFMS<@"8!
MV<# 8>AQQW[55N/#<4\4L!NI1 [2.J;0=C."&.>_WFZ]S0!.GB'3I)&C5IMX
MW<&%AR!G'3KCD#N*8/$VF&W:822[5 8@Q,#M(+!L$=, \^U1S:$RNUQ'=32.
M)3,(P% 9O+\O'TQ56+PO]JTR"/4+F43B%(WP$P%5"NW&"#]XG/KB@#0D\1:?
M',\3>>2@.2(F(X4-@'O\IS^!JY97\%]O,&XA-N21@?,H8?H16;_8/V9DN(KF
M6>2%A(J2; '(39@G;Q\M6M%M8M,T=%+(%P9'8-E1GGKZ 8 ]@* (+K639:S-
M!<JQMEBB961"=K,S+\QSTR /QJU8:M;W\@2!)02K,=ZXVX8K@^AR#^5,NM*A
MO+P7?G/M=%#HI&V0*VY<]^I[=:KQ:7=B*[F5X[6\NYED9HFW!0N!C)'.<$XP
M.IH UIY$@ADG920BECM&20*QAXHM6MA/%:W,@W.I"A>-J[CSG'0YK8NK>.[M
M);:;/ERH4;!P<'WK+B\-V4;$M-=29))W2GNFP]/;_/2@ N?$,$*NZ0321ABB
MR#&UGV[MO7/3OTS5.Q\03)<S'4(95B<HRGY2(<Q;RO')Z$Y]ZOKX>L%<$>:4
M'/EF0E=VW;NQZXXS4-IHVD+*;>.62:2'8[HT[-_"57(S_=R,4 ,C\2F4PQQZ
M;=>=,^Q$8!<_(7!R3Z _E5[7YY[;0KR>V8K-'&64C&<_C3;;0;"VDADB$VZ!
MMR;IF.."H')Z $@#IR:M%K74(;BWW+*@)BE4'H<<CZ\B@#,/B'9+-#)92K+"
MLA92P/W%#=O4,*ANO$.^X%JD,T;AXR"KJ&8%D[$<K\^,CT/2K\F@Z=+#Y4D<
MARS,S>:P9BPP<MG)R,=?04R?1M(A5KF="B1KDDS/A ,'(YX^ZOY"@"K_ ,),
M4EF2:PD4*76/#!O,99!'VZ#+#]:!XE(GCAEL7B9@V0[8.X;N!D8/"@\X.".*
M=:6>@7ZRR0QEU#/"XE\Q1N<@L,-W)P?K5U=#TU2"+8' QR['/7D\\GYFYZ\T
M )H>IMJMF9VA$15BC*&R00!P> 0>>A%4]0\0O:75S%'9&1+;AY"VT!MFX=L8
MZ#KG)Z5=MY--TV==/@W([D' 5FY(XRW..!QD]JAU*VT;[8)KVVBDN) L)^7<
M<.2HS[=1D^] %%M;OIY(X?LT47SLDH\X\CR?,&&QUY_2H8->O8)5,D<7V)+:
MU=V>0ED#[@6)QST&<^F:V_[%TL];&#[P;[O<# /Y<5%=Z)92(JQ+';9C$+%4
M&6BY^0'L.>U %O3;F2[LHYYD6-I1N50<_*>F??&*S/%<;+IK7:W,\1B**!'(
M5'S2*"3CKQD5L"&!)C.$02;0A?'.T=!GTYIMS;6MV@CNH8IE4[@LBA@#Z\T
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M44  &!@4T??/T%.I!]\_2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M"T]]<2!I \@VJ-_[LQXX'3:34ATF2UT6\M8)I+F66$HGF;1V( X '?J:V**
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M#[Y^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !02%!)( '4FBF3!3"X==R[3D8SD?2@"-KRU18V>
MXB593B,EP-Y]O6IZX^X@C70+"VETZZDF:#RV86[,T*=\>C<<?G756LWGQ9\N
M2,J=I5Q@@_U^M $U1SSQ6T#S3N$C099CT J2H[@Q"!_/9%B*D,7.!CWH J?V
MWIF&/VV+"1B5CGHAZ-]*L37<$-L+B1\1': V"<[B /U(KB[>WD%Q KWML;=&
M-DP-PO-NK;E8\\DXV_C27NH7#:K=M'=MY3,0FV[3:,,F/XQ@</QCOS0!WF:,
MUQMW<.LE\EIJT?EB-I8':]ZNP V9R?NX8^GS#TJ/2KFV?4H&GO91:HKLOFWJ
MG:V5(!"MR.&X.?Z4 =M55]0MDODLR[><_0!"0."0">@X!_*L;7M1LY1;;+N.
M:W5SYT44X5SE2%(Y'0_YXJIX>O+>VNII+ZX4RM%$IE,H8.0.> >O3G% '076
MK6=I=?9IVD6389,")F&T8R<@8P,BK<4L<T*2Q.KQR*&5@>"#R"*Y36[NWNM4
MBN()))(DM)86:"8(VYBA')/3Y3^E9J@?8F225%GCLH4C9,[-RD[E48XRI SB
M@#T#(]:KSWL4%S;P/NWW#%4(4D9 )Y/;@5PRF1;NU:$SB.%PPW/N* L<J<#
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M^0]ZFTR(Q6,>4V,^7*XQM).<8_&@"W1110 4457OKNWL[5YKJYCMXP/]8[
M'\: +%%<J+J[NU22QN]5O86&1(L<4$>/7<R@D?3-.31=6N(@QU![?(R"+N64
M^W0J/TH ZBBN8DBUC1_*VZW%>R2MA+:ZC">8?16'(/US6YIE_'J5DMS$&7)*
MNC=4<'#*?<$$4 6Z*** "BBB@ HHHH **** "BBB@ HHHH *:/OGZ"G4@^^?
MI0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *1@&4JP!!X(/>EHH HII<,/%I+/;+C&R-_E'T!R!4ALMSLSW5
MRRG/R;\ ?D ?UJU10!%#;Q09\M ">K=2?J>]2T44 %%%% "$!@0P!!Z@UC0Z
M;J>F9CTNY@DM,_N[>Y!_=#T5QV'8$?C6U10!EA=>D #/I]OZE5>4_EE:B_L.
M6=BVH:I=W /_ "S0^5'^2\G\ZV:* *]G8VEC%Y=I;QPKZ(N,_7UJQ110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %(/OGZ4M,V_.>3T]: 'T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !2$94@$C/<=J6B@ ' ZYHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "FC[Y^@IU(/OGZ4 +1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(/OGZ4M-'^L/TH
M=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %)WI:,<YH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHI/XNM "T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28^8GVI:
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *._7\**3^(T +1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %'>BDSSB@!:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,?
M,32TG\1^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !2#[Y^E+2#[Y^E "T444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2#[Y^E+2#[Y^
ME "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !2?Q$TM)GYB* %HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "D_B/TI:0#YB?:@!:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I!U/2EIJ]_K0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *:G\7UIU(!C/O0 M%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'IP<4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@
M.21CI2TF/F)]10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex10_4page006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_4page006.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *3/S8I:3'S$^U "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%!.!DT4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %(/OGZ4M)_&?I0 M%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@^^?I2TT?ZP_04 .HHHH **** "BBB@ HHHH **** $"J"2% +<D@=:6BB@
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M??/TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/$6H!+ R&T+720NP56^19&"C//;D]\X/3&:CL_$6H;+5':VE8HCS$_)D,^W
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M,<'J",<TL#ZO]CM5F^VK<"V@$?!P9,_O=_X>O;IS0!NG1-/V%1$Z_O&ERLK
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M/4$<@\G\ZG%C: H1;H-D9B7 Z(<<?3@5+,,IU Y'7ZT^@#/.AZ6<9LX\!/+
MYP%P1C'3H2/Q-/;2;!IEE:V0NJ[0>>F,=/7!(S5VB@"M;:=9VBLMM;1QAE",
M%&,J!@#\J@.B:68C$;" H4"8V_PCD#\,FM"B@"D-)TX1R1BSAV2H(W&W[RCH
M#]*7^RM/W1-]CAS" L?R#Y0#D?KS5RB@"M%I]G#:O:Q6T2P29WQA1M;/7(]Z
MB_L;2\8-A;'Y=O,8/&<X_/FKU% %)='TM9?-&GVOF%MV[RESG.<YQUSS4WV*
MT^RM:_98?L[9W1;!M.>3D=*GHH IMI6FM&8VL+8H2&*^4N"0, _EQ4T5I;0S
M/-%;Q)*X"LZJ 2!T&:FHH S+K0[&X6-%ACB19A,RI&N)",\,,<CDU9?3K!S&
M7LK=C&FQ,Q [5]!Z#VJU10!4;3-/<QE[&V/E "/,2_( <C'''-.73[)3&5M(
M 8F+(1&/D)ZD>F:LT4 0RV=K/()9K:&211@,Z D<YZ_6B&TMK>(Q06\44;=4
M1  ?P%344 106T%LI6WACB5CDA% SV[4OD0A=HB3&W;C:/N^GTJ2B@"&*TMH
M6W16\2-ZJ@!ISV\$D:QR0QLBG(5E! /K4E% #(XHXL^6BIN.3M&,FGT44 %%
M%% !D9QWHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FC[Y^@IU-
M'^L/T% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *CDMX99HY9(E:2+.QB.5SUQ4E% !1110 4444 %%%% !1110
M 5%';013231PQI)*09'50"^.F3WJ6B@ HHHH *B-M URMRT*&=5*K)M&X#TS
MZ5+10 4444 %%%'3K0 44 @]#FB@ HHH) ZF@ HI 03@$4H((R#D4 %%!('4
MXHH **** "BBB@ HHHH ***0NH8*6&X]!GDT +1110 4444 %%%-=TC7<[*H
M]2<4 .HII=!((RZ[R,A<\X]:=0 4444 %%%% !1110 4444 %%%% !12!LL1
M@\=^QI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I!]\_04M-'WS]!
M0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **,T9'K0 44UI$5E4L 6Z#UIV1ZT %%&136=$7+L%&<9)H =6?J((O],=7<
M9G96 <@$&-SR.AY K0S44L$$SHTT4;M&<H64$J?4>E &+ICM!K]U#YTKVYMT
M=7>X,@)W,"3G[IZ<#CBM^H$L[1(W1+:%4<[G 0 ,>N31%=Q37,UNF[? 0'R,
M#D9&/6@">L75RTNN:;9RNZVDRREPK%0[@#:I(]MQQ[5M9QUK(NOL6K7C6,OV
M@^6"20/W9((R,],C(H HW&K'2Q+;V;K,EO$]P3,68N-Y!16SU'3//:FR>([I
M0JJ+4R%7)&3\I681\\]"#^8K1?0K+;'N><K#_JQNSL^G'%4XM.TN:UBOE6[9
M;IE[9;YF&"PQZX.: *DVOW\,HEF\G;#%=!XU4@2-&Z $'/'7ISWJ9==U&25H
MU^Q Q023.PRP8+MQC!P.&'<U9N-,TRP>$N;@&:78I3G#/P<G'&>]3#P[9+"8
MXI)XQL9!M8?*#UQQ[T 9,_B748+1W9+5I B2KM!P5,;.5QGJ,#G/<<=JEFUC
M4)9T*7%I% MZL)PI)*E _)S[XJQ!HNEAO[)+SN8(UD*M@*<Y7/3&>#3[K3-+
MM/(BF><">=50*<CS.H)XXZ=: #1=5N[]V6Y:WB='7*!3\RLI(VG.#GKD=@>!
M5357E_X2#4$MVSLTU9"&N&0(V7Y &1G 'ITJ:"QTE=*_M&![Q+>+=+A&*D%<
M@G:._6KB:-8SH)]\[&5!EG;YB,=": ,:WUZZL[6*-1#Y4%NAD,[DNQ:/=N]2
M,@CIZ\\5'?:]=7>C7$$CVT,AAN!(Q.,[. HPW!.<]3TK>.@62_-NF^52HPW1
M3U XZ57LM&TN\L(I83<&"3YU5I",^Y'K0!1&J3VPE6R-I&7NG!9]S!@(0^>O
M7C%.3Q+<37\<,<EHA948I(>=IBWENN>IQC'O6L=#L#G)E.XYYE/7UJ ^&;#[
M4)S-<[001%YQVAAC!'?MZT 2>']3DO[4_;'C%P'(VJ ,@!3D<G(^8<@]Q4/C
M"WA?0KJZED*26]O(8B&VX8C@_7CBK<,5CI4]M;1HX:X9DBR2VW@L1R>!Q^E7
MW\M_W;[6R,[3W_"@#E;B1-(UAY;&: (4@WH[9.'E(X.>/O9[]*73M8FA&EP1
M^1Y$S,KB,9P3(P&!G(''7GWKIEM[;.5ABZ8X4=/2E$4 <$)'N3IP,KF@#G_%
M-W.Q\FQ.7LP+J4*X'W6!"D'L0&_2H9_$C2ZM!#97MHL<R1-&),$,K;MQZ@Y&
M!@#_ /5T2S(\LP$0!0@%VP P..0?\]*I'3+6749I'^T(H9'92X$4A[$#VP/2
M@#$7Q!J26MC(]U9L+J'SA(R[$9@5'ECKEL;NG/ITH_X2#4I)2B7%G&7N%BVL
MI+PYDVX(XQQ@\\\'MTZMU@V+E$;;\R+@=?:H].F@O;2.]@BV+.H<;EPQ^M '
M+1>)+X6<CRW-O(Q@CD#*F%B!E\MF/7@#YO0?2G1Z]?\ GH'O[-HX_)#E%!\P
M/(RDAL@?= / _2NDM+NVNFN%5-GD2&%MX SC'3VYJ:2XM87CC=T#2-L0>IQG
M'Y"@#"M]2GC\)W-V+U)+F)W!=P/D;>1@C^E5!KE[!-<>9?Q2JBW"IB$9)C"D
M' //4C'H*ZQC&GRG;D]%[DUGV&K6^HRQQ1P2KYMOYX+J,;2<8Z]: ,"'6=5F
MM$>.Y$C-,UKE$4X<X,;D@8QZXXZ5H>("]M>6,ZW*P3+#,HF:,'<V%(7\<=/R
MK8FM[5KR&25\21 F--^!TQG;T)P>M0Z=JD6H))(L,D<*X*R28VN#GD<^W0\\
MCUH S=/U6^GUTV]PR1@=;<J=X78"'''3.1G..W6JE[K&IKJ%W +E+;RG9%3R
M]S;=H*/C'0GCKWQP:Z2[O(;6TGNN)/*0L50@LV!G ]ZC6_27[*8T#K.<,P=?
MW9VYP>>OTH YIM;U+R(O])6.4F42;D!"2JP BX4YXSCNW8U,^L7O[R1KF5&B
MF_?Q&W^6%/,"_>QT*G/Z\"MVYU6UMY[>-F5HYW9#*&&Q"JECN.?0&KCRQ)%Y
MKR(L>,[B0!^= '&-K&H*7N([F61Q#.$C,> P28C=C&<A.?PJ+4=1NKNQ,%U<
M,T>%DADC@R+@B4?[/\(QT SG-=;:ZG;7-W/;@JCQL N67]X"H;<N#R,&H;K6
MK>!K<0)]I28NJM$RD!E4MCKUX- %#7[JX@NWEM9"C#3IGC(A#$."I'.,_A[=
M*FT^\O38ZHHD>ZGMG80%T"E_D!'0 'G(K4M+N.YTZ"^8"-)8EE^8_=!&>31_
M:-CMB;[7!MF.(SY@PY]!ZT <L+_46EAC@OKIK=R"9_)4MN,;%E^[V8+VX+8[
M5)I^HZO<ZI9B:61-R1LT/V<X=2GSMGL0WY8 QS71C4[ ^8!>0?NAF3]X/E&<
M<^G(Q5:37+0SB&UEAG</&'Q*H"J^<-GOTZ>XH RKV]U)=2N$,T\3)-B.)(PR
MF#R^9,[>H;/X@#O4IDU"+P:DXN[MKQUC<N8@74DC(V[>W/:M:WUC3;F-I(KV
M JF[<=X&,'!)]L_TIL>MZ9(LC"\A CE\IB7 ^;_/\J ,#[5J\+3"&6\F<I<*
M@DAX^5EV$?* 3@L?>G+-JDU\D,%U?-:_.T,ABV^;A5(5B5X&[<,\9%=/<W5O
M:Q>9=3)$A. 7.,FHUU.P:Y%NMY 9B,A XR>,_P CF@#,\+37L\$S7D\TN-HQ
M+"8]CX^< GJ,^G'I6[4%I>VMZK-:3QS*AVL4;.#4] !1110 U6W%A@C:<<CK
M3J0-DG';BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "FC[Y^@IU(/
MOGZ4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M5U2*XGTV>*T<I,RX0YQ^&>V>F:M5#=W M;26X92PB0N0",G ]Z .:GTJ^D@8
M)92K$\<GDP_:?F@D)!#DYQZ],X_$U'=Z3JSAH8X7(5)U\Q9PN_>ZLN.>._TJ
M_)XG5+:.86,S!HY9'PR_((SANIR?RJ4:G//K]M!$KI:YF5B=N)&3 ^HP?SH
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M (27#2[]/F4(LI7+ EC&X4\#.!R#GZTQ/$<QD=S9;H=D.S9(IRTCE.N<8Z4
M2Z[8WES<%H83,C0%(P) ODRYX?K^HY&/>IM L9;-+L3VPB>2=F#!@=ZDY'0_
M6H)/$HB@\R2PF##S@R!E)#1C+#KT]_:@>) CR?:K&6".(R!V+ X*IYF !URO
MZ\4 5!H>H+>*"P:T$K(4+DDQ;_,!^N?E^E1V^CZA"8 EJR#]PTO[X$;DE+,<
M9_NX%6F\4LB$MIEP&"NY!(7Y%"DGG&>&_,?C6GI=_+?27@DA\M89C&GS [@
M#GCZT 8@T>^=46XL][B5#-+Y^1* ^[<!GC@GWZ#H*T[:TNE\*FRECD%QY+1[
M5D&[N!AN1TJSKL\MMHMY<6\ACEBB9T; /(&>]8\FLW%G>1O</=M"MIYC1F-,
MR/N51C [EJ *T>BZBI5GM?G7R]C)(%QMF9CD9X.T]N.326FDZJDX,UJ^TW$,
MI_? @;78MC)R>".3S_*M./Q&/,MHY[.:-I3M?/&PY(!P><<=\=15/^W+J:_C
M<">*WF-L8D&P_+(S#)]B ,CK0!I6]E<GPS<63Q".>1)E52P_B+8Y''<5CRZ'
MJ#6ZB*&2.#S%+VJRIN;]V5+9.5ZX./;/6M!/$X*SO)8R1JBDH6=?GQ)Y9SZ8
M..?2E7Q,IEMHS:.OGS&+>SC9D-MRI[\YQG!.#0!/?6EY)IEC$L?G-$Z&XB\S
M_6*%((R<9Y(//7%8MOHFJJUJ#&\7EP(L96< 0,I(.<<G(.>#SWK?U'5Q8ZA;
M6K0%A/GYRP4#V&>"?;-9D'B/[3-;RRQ36T<;2>:-P92!$'';)X/;T/6@"DF@
M7SVZ(]JP(5PV^X!^<QE=PQV+8/KZT^;0[]H1&(&,'GH[P"89?]V%)R<C.X9_
M7K6OH=]=7MW>FY5XTVQ/'&S*=H8$]0/IUK/M/$%Q:VT\=U$\SHTHBE)'[PB8
MQJ" .!RHS]>* '66D7\.I6LT\".89]YF,VXA#%LVC/)P:DU?3KZ;Q%;WEO;"
M2*/RP6\P XRVX<^Q'3KWS@4DGB>:-6,FF2*(XO,E)?&WYF48!&3D@=AP::_B
M*:-FGFLKB,PVTTDD)<!24*],@'H00>/I0!+X9TJZTQR)X516MHD;:^074MDG
M\".?:J%_H%_<0S)';IYNZ8F8N 9PYRH/<;>/^^>.M=!8ZD]Q8W$\]N(9+=W1
MX]X.-O/7@=,5FV_B2>Z:*."P5I'=E;,V H55;/3)X?T_3F@"AK-E)8M*\%I#
M'#+<1E$/^KP$;.X >IX]\4MKHTUQ:18L<1$V_$KC)$;$L3P.H/XUL:3K']K(
MS/9O$NU)8B<D.IZ'H.1W_K699:MJ*2S221B:5O/?R3. JI&^./EZ]L?CQ0!'
M#HNJ13V4GV:/_1L ;90,#<_'3T(Z8[YS@5LZ&;FU@@TRXMF4V]LA,H.5)R1C
M..O&?QHT?5Y=5FG*VGEVL9VK(9,LQPI'RXXX;UJ!O$$@W,EHC1M(T,+&8 LX
M<)AACY1DYSSQ0!2OO#UQ=W5Z1%"@E,K"7(S(&BVJA[\-\W_ 11#I.H-J*74N
MGVH1;E9 C2 D+Y6PGIU! -3_ /"2W E>,Z<N86 G/G?=^?8<?+SU!'3(]*=)
MXEDB27S+)?,@++,BRD[#N"I_#_%NS]* #7-,OKO5K6ZMH(W6#81F3:<AP2.A
M[#^>>U2:)IU[:743W$2*B6OE$J^?FWD_E@U!_P )-=>>L3:9M *B0M+@KF3R
M^!CGJ#@XX--AU^>""*,6CS29E>0-+DJBR%3AL<GZXX'6@":]T>YFU::98XY$
MDDAE65FPT6S[R#CH0/\ QXU:TC3/)\/II]Y;PJ=A214.5;WZ#M5!?$UP/,$]
MC'&<E8L39!(F\KYCC@9(/?C-/'B*Y%XMLU@A="HN"LV0@9RH(..?NYYQUQUH
M JP^&[Q86\YH9'-NPV]!YNTHK?\ ?!Y]Z?#X?NHY@5BMX4\P,#&W*?N3&2!C
MKGG\*TM6UE["9TC@600P?:9BS[<(#@[>#D]3^'O46A->75U>75U*<)-)$D:R
M90@$8XP,8 Z^YS0!030KZ2"V6>RL5\HGS$4\2$1,@8\=22#CL!6A/IMS-X9M
M[&2.-[B-8PW[PCE<<AL=>,CBJ+>)[Y%4MIT+%_,=5CG)^6-MK<E0,_IZU$NK
M:A!<2SD>?++/+##")?DPO/3'!X _$D]* '0Z!J*%&,=H)5V?O0>>(=F,!>F>
M<=*2RT'4X$56BM0%G,H_?,3S#Y9_A]>?PJ<^([UD$D=E#LDG\F+][DD[=_/&
M!QZ$\T)XFN?,5YK&-(/,$9Q+O?)B,F, 8[8Z]Z +TFF7+^%8]-62-+F.!(PW
M)0LH'7V..?8UGRZ%?3"1GBLE-W&4E100(3NW!E./F/4GIR!2R^);J.&+;:V\
MDTR&5%2;@IL#8R1P<DC\,UK:AJ$D*V2VJ(TEX^U6D.%4;"V3CKTH QAX=NU'
MW+0Y,N[$C*6WRB0<@#! &,T0:!J<17?):2',#.W*G<C$G&!Z'&>_M3[?Q!=W
M<R1FWBCA<QQLPD.X%PW(XZ K^(Q4>F:Q?I8Z9 R+(]U;0M$[DEI&X\S)]0.?
M>@ NO#NI26]Q!#):*LPGCRV[A9'WYX[CD4ZZ\.WD^\LUJX\Z0A&+A623!8G!
MSD$=.A&<]:T-?U>;2VMQ"D;;]S,&)S@%>GIUZ_3@YJ@WB*^BDG,L5J8QYRQ;
M6.0R2*@+>WS9/TH UK^PGE:QEMFC,EHQ.V7A7!4J>@X/-94/AF>(1J)8,(Z$
MG:<E1$8SC_OK(JYI%Q-%IFH3SSK-)%/,=Q8[0!T'? JC;>(-1NH[=8X[82/-
M(CY#<JJAN%]><8S0!I>']*ETR*03F NP5<Q _,%& 222<^W08XK7K&\/:M/J
MBR-/$B#8DB;6'1L\$ GH1C)QGT%;- !1110 44U4"EB/XCDTZ@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *:#^\/'84ZD'WS]* %HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BNK>*[MI+>X7=%(NUADC
M(^HJ6J6LO+'I%V]OYGG")O+\M<MNQQ@?6@"!O#VF-&\;12E7#JP,\G(?&[^+
MOBI(M&L(;X7D:2"926SYSD9(P3MSCG'I6$\VH*KQRRZB;43.!*L;"3)12@QM
MR5W%QZ=,\5:T2*^;^TDOS<+<RA68C(4$QK]P_7/2@#4N-'L;J[^URK(9#M.5
MF=1E<D' .,\TQ-!TU'B=(&!B^[^];D;MV#S\PSSSFN>M&U..ULXXFOED6* 0
MJR-M)#8D#Y'IZ]NE7]8FOD\0V_D_;/LZA-XC4E&!W!NG<<=>>F.] %J^ET&[
MN ]W=PL\+!"//( .<@$ X//K4L/A[3(2ICBE&T@J?/?@A=H/7^[Q7.VEA<C[
M"(H[X2BUN%)E5@H<D%0V1P.#3H9-4\F(3-JSV[EAN6,I(DNT8[DE<[N3QDCM
M0!T+>']*>)HS Q7RTC_UKY 7E<'/!&3R.>:D^R:==VQL%^:.W==RI(P*L,,,
MD'.>AY^M95G:W)T/6H<78N'EF*[F.23]W:?IBLZ&+4XYS-IZWR-(0 LJ':P^
MSX!;/?>%')X_.@#H+C1M*AADFG658T5V9C/)\H+!F/7U -.30]+98Y(XF*A5
MVXF?!PV\$\\G)SDUFV7V]O#NH%Y+YY2A,6^(K(&V\A022>1^IQ4$G]HS7A(;
M4ECD=5"[6 "& Y[<?/CGUH V9?#^EW$LDKP.6EW;L3.!\WWL ' SWQ3_ .Q-
M/\[S3$[-N+_-*Y!)7:<@G!^7BN<@75$CM4C_ +0BB2VCV((R2< APQ)X/3&1
MZ8I["^2:VBAN=1-R]K%*$9F(#[_FWYZ#&>#^'.* -P>'=*$8C^SOM",G,SDE
M6 !!.>1@#Z8XJS!IEI!<-<0JXD9MS'S&()QMZ9QT_P :YIQJZP0LDVH!I6F#
M$QERKAQY?RY&%*YYZ>M,_P")M;3A(8K_ &K<N\G!8,#*O3G^Z3[<^O0 ZB^6
MRO<Z;=/N,R$F,.5+*,9Z<XY'YU!)H.FRL&FA>0B+R?GF<_)Z8)]@?KSUK @C
MU6W$J6JWF_\ TO.\$@L74H03_L[L'IFBX&J/++]FDU/[,!(T'#;B?+& V1G&
M_.,^_;% &[_PCNF;XV\F7,>,'SWYP<@MS\QSGD^IJL-)\/P:A%:@!;D[6CC\
M]\C:2PP,\8R2!3]3EO&M[!@+E(G!^T>0#O5BOR\8SC/]*KZ!:W/VVZEU*.<7
M$D<66.=N[9AB#T!SD<>] $E[H>G3 V-LXCN&0MM>1W&PN&;(W=V YZT:7H.G
MF))'<7#12G&R1_+4J?N[2QSAESSGG-9'V:^A$;VZZAYL$<HR58[F\Y2!GN,9
M]JM3MJP6'RFO2WVN7*E"NY-_RY....1D8(SR.* -V_L=/GGCGO1ELA%W2$*3
MS@8S@GDXJ&V\.Z7;2+)% ^\'.6E=L_*$YR>?E&.:J^([6ZU)A;0*46W0SK(R
M$YD'W-N.XY_,5G7&HWTVIP.WVJ"+$'F@9 A8D[D90.2<KR?8B@#H].TFSTP,
M+1'7> I+2,YP.@Y)Z9J-M#TUHV1K;*LC(07;HQW-W]><^M<Z(M82UL)!-J1\
MU7,O!9Q+D;002,+@'KQZ]:%BUIY"EPVHDM<J)-HP@7S.JD$\;?IT]: .BCT/
M38U=5M@0\7E,&8L&7K@Y/K2#0=,6/RQ;?+L*'YVY4]03GG.!^0KGUCUR.SD\
MMKYG:$$[R2>)>0,G[WE^F,_6FQQZN65M^J.J"(Q[P4_Y:'=N /\ <(ZD^_-
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M!_,">4,;O7'K5BXMH+J,1W,,<J @A74$ CO4M% %3^R].W[_ +#;;N.?*7/
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M;SVAD@E@+32('+%P5N%7DYY^]^E;VFZI/<ZY>6DIC\J,$Q!5Z@-@DMGKG/!
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MZDAC^5=!5'3);!E>'38ECCCVDA(MB_,-PQP!T(/XU>H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *:/]8?H*=31]\_04 .HHHH ****
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M/PN-,C>$3K"L>_:=K%<<GOSC\*S[CQ+<6\]S$(K>3RHV93O(!*[,C/\ P/\
M2H-9URYDTJ_M<10SQP7!=Q(1P@'W#USR/RH M6_AZ]AC9#<V[ V\T RK'&]M
MP.223C^M$WAJ>:5=]S#L>%(Y/D;<A0$!DYP#SWSCK4*:O=P/)':1PL9+R2,F
M65F Q$'R/08&,#BK%OXCFN+^WMT@B'FF/<A8[@&C#ELXQ@9QB@!/["U QH6N
M++S0AC;$! *E-N>N=W3VXZ4CZ!=1N)Q+!(8_*DV+$<N4C*E<Y[YH\57=U&TE
MM'.(HFLI9<ABK;E*@8(^O3ZTRY\1WL(,4=M;O/&TN_,@52J8X!)')##_  H
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M& 2>IYJ(>&YTMFB6^7/D01 ^3WB<LIZ]\G(JJ-;EN-3@AN%MW\NZVH5!Z8D
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M/M4*:-JJ9:2)Y9LH/-$PSM\G:PSD'[WY]: .@273]2F</;B22W09$L7(#@'
MS]!210Z5<JJ_9( Q"W'EO$ RD]&(['@UB#1[TS02FU82HL/SB1>%1"&7KSNZ
M>GY5 ^A:AY:%+,>:;.WCD;>A+%&.]23G.1CV]: .GOY;.(V[7<2R%Y5CB.S=
MM8]#[?6GFQL@96:U@S*<R$H/G/OZUS2:-?+-!OL#($DA>)WF4F%5<EE_+'W1
MCMV%:NNV,UW/ PM5NX%21&A+ 88XVOSQQ@CU&>* +5[IMG>I)&0L<KJJF2,
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M.6-+>ZGB*[6^95)H LB]L@L6+J#$IQ'AQAS[>M1WUS9+)'8W,XC>X!V /M)
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MW;_"EM_#=A;/&T3W(,94KF4G&W./_0B*F_L2T$42(TR&)G9760AAO.6&?0T
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M3KH.FPQF!+>0QRP?9F!E9@(QG Y/OP>M-U+3-(C*WEXYMA&$4.)VC4;<A>A
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M%OW#[3E#\O\ >'I^/-2G4]6>X99+UX0TWEX%N,(OD[R1D9^^ .?7UKL,"C%
M'&'6=5G"MYKPDVJ.JK"3ORAW,/E/(;WXQT.:=%?7DE[8_:+NX=5N8V)$048>
M!CCITW<?C^-=CBB@#GM2OK^+5)8HI9$V&(PQ+&")4)PY)QV_3'O3([B^3PI)
M>&ZN);F3!R8QE/F . !T_ X]ZZ2B@#A'DEU&(O=/=-(ME<)CR>K*_P O5.I
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@^\:6FC[Y^E
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#P,\^E2/XCN8Y+Y&BMR+9-\9WD"93@ @G X/WO2@#I:*YJ'Q!>.XBE%G%)&
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MEM:>69T=HS)ORJPLAZKSR0?PJ32],N](OS,UH)&EE,321S.V]68MO*]%Q_\
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M$.D0*=221W-NSJTQD=CDX5LCO]T#\*M3:397%T;F1'\UF1R1(PR4.5XSCC-
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M@'WH S5\2^9+9Q+:$/<J.K_=8[N.!TRO7WXS4JZM>MX>M+Y;:(W$[1KLWG:
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M3"_+S\R]>.#^%2_\)'<K/%#)IX5VD\MQYO3+!01QT^;OC\:U8])TZ)9%2TB
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MT<%E9VL3Q6]O#%'(265% #$]<BL_3DTJZE=;;3$C6!@4D, "MC*@J?;!'K0
M:!J]QJ@D-Q:K"-B21LLBMN5@>P.1C!K8J"VM+6T#BU@BA#MN;8H&X^IQ4] !
M0>G'6BB@!%!"C)R:6@'-% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#[YI:0??/TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*C?PY:R*1+<WCLT;1L[2Y8JVW/;_ &1^5;%% &2V@6K2&3S[I9"[.763!^8
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MY"@'I2T4 & :*** ([B%;B!XF9U##&Y&*L/H11%!%#%'%$@5(E"(/0#M4E%
M";1MVX&/2EP,YHHH 0 #) '/6EHHH ,#TI,#.<<TM% ";1G.!D]Z6BB@".>&
M.X@D@F4-'(I5E]0:BM+&"S+-%YC,P +22,YP.@R2>*LT4 %&*** "BBB@ Q1
M110 8Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M4$@=310 4444 %%%% !12*-J@9)P.I[TM !1110 4444 %%%% !1110 4444
M %%%% !1110 4@^^:6D'WS]* %HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Y1Y=3$DQLKJ22:/46B2.0@JZ"+?L/IDYY^E=769-
M9:7921SR1"-WG!5@3S(W&?J>E #-"N_MPNYU>4IYVU4D/,9V*2N.Q!)%8,VI
MW6GWOE7-U<2):W+_ &D[ACRG_P!63QURP';[IKL(H8XFD:- IE;>^.YP!G\@
M*;):6\AD,D*,9=N_(^]MY&?I0!@Q1WQOK"SEO[B-Y+-Y)<$$[PR^W;<15=!J
M,ND374&JSB=;IX$W@%>)]@)&/3@_6ND:RMGNA=-$#.%*!\G(!ZBHAI-@MNT
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M, @=J .2\4HLU_>"9H)5M]/\^.&5<C<&/H0><"I;K6KZ&&ZF2ZM3'%<F%5"
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M1110 4444 %%%% !1110 4444 %%%% !2#[QI::/OF@!U%%% !1110 4444
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M>4GDX].] &I13(94GA26)@R. RL.X-/H **** "BBB@ HHHH **** "BBB@
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MJ\A\B_V1,5,8&5R0.#GY?H:Z]5"J%4  #  [4 +1110 4444 %%%% !1110
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %(/O&EIJG+-0 ZBBB@
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MR/6B@ HHHH **** "BBB@ HHH/2@#SZ2>]MYM6MH+B4V=TD\L<HE.+?RW8$
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M6UNXV:6T'A^=C]G)O6(<8PK\+R>5)4],]NQI\^H65YXIT.]62)89;6223<0
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MHHH **** "BBB@ HHHH **** "FC[S4ZD'WFH 6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"A?8MKZVO#G8<PR$= &(P3^( _&JN
MK:S8KI=UMF))B8*0C8)P>^,5K311SQ/%*H='&&4]Q7$0R:Y=ZW/IB,TVG6]T
M(Y7D*_+$ K8Z9)[9]/SH VKN_MX);"Y3SY?L^8Y"L#YV%<$]/4*:DO-:M+N!
MK>UDE*RK\\PA?:B'J<XY..@]\U6TC7GU#7+ZPE(CB>,2V;#JR?=/4=<C/T-5
M]$N[Z[TC3+B>_F,MPTH?:J -M#8XQT^6@"2;4HGT[^RRERRLPC$P@?88>N2<
M>@VX[GZU9-RQA,$>IRB'H&^QN9 OINZ?CBG^$M0EO/#ME=7]QON+EG +8&2"
MPP /9:S;G6-0T_Q-+;-*9[2XW0VZE1E)@JL 3W!W4 7KF;3ET_98B3SHF$L;
M>3(2SCU;'.>03[FM"+6K&>W61'F*NH((@<]?PJGX1N[F\T@S7UQYTS32*"0!
M\JL5& /I6!?:A?Z3=Z]]CN&$&GO%-'&P4HWF'<Z>O.3C'2@#H--FM;&UDA:Y
MGD>0YW_9G!X4*.WHH_&HK>ZBL]$FMY)9KF<JY)%O("Y.?4'FLB_UG48D\221
M7DB_8$A>!=J_(64$@\<]:;>WVOVMM:S33W"I->".-0L?F21E">>PY!Q[4 =+
M8ZK:K8VZR><KB)=P^SOP<#VJ5=5LEX#3G)SS!)_A7-ZG?7U@=)0ZE<2K/)(+
MCRT4OM";P,8Z@8J.'5-;?1M+U"WF6Y;RGFF@103-$& Q[. W;N* .DN[^QN(
M2/G+CF,M;R':PY!Z>H%5-*U6("ZDN(KB%II0X3[.YQE%!Z#U!K,NM=N(?"J7
M=C<2SW-PSRQF1,MY2,<\ >@ ^K5U=C=17UC!=P'=%,@=3[$9H PM'N8K:9VN
M7;]W&(8MMNX)0$D$C:,'D#'M4D^LV5KJ-Q<-YVUK9<8@?+%6/&,?[0KH*J7N
MG6]]);R3AB8'WK@XSWP?49 /U H SXM0L$TQ;:87+[H\.?LDGS$]3]WN<U3C
MUN9[:*RV74,BIMEN6M9""!QE1MY)QGGIGO73T4 <Q/+9V,45WI8N?.A(,BM%
M+F=>^[(Y;'()],=ZU4URQD56C-PZL 59;:0@@^A"^]:6*  !@  "@#.;6[%6
M ;[2"?\ IUD_^)K1HQ10 4444 %%%% !1110!S[^'3/<VE],T:7=O<-(6C)P
M\;,6V'/7!((]Q6?'X,==/FMS-")E??;3J#N!#EU+9XXR1P.YKL** .6O/#5U
M)JD$UI<01PV_DE59#N;83G)'7J:JMX6NX(91)=V:HMJ]NC.A_BEWY;/&?ZUU
M\TBPPR2L.$4L?P%9UEIZW2Q7VI+YUPZ[E1CE(@><*.G0XSU- &;9Z(LGAW4=
M*^W1.;J6617C;=MW'(SDFHKSPM<W\*B26VB:2/RIQ$A 'SJ^Y?\ :R#R?7VK
M??2--?&;&W!'0K& 1^(^M5T,NE7<4+R-)93MLC+9+0OV!/<'WZ'USP 8>L:!
M+;Z#J9CB6ZNKJ]6=?+B)8*948KZD +^E/E\(S3+,_P!IC5[@W&]=IVH)=OW?
M<;?U-==10!R.H:"+#3-6G>:-GN98V20P;V0?*N,=R<=1W-/T_P -RJ;&Y@OX
M)$B>X<-L)#K-@^O45TE_!]ILIH00I9>#C.#V./K5/1)D:W\M?E!59D3^ZKC.
M/S#"@#$M/!TEO]D4WB,L(@WX0@DQ,2-O/&<\_C5O0O#4FDWT5RURD@2!X2JH
M1G=(7SU]\5T=% !1103@9- !15:QOK>_B:2V<LJMM.01[CKZ@@CV-6: "BH+
MVZCL[5[B0,P7HJC)8G@ >Y.!5)=6FA;&HV$EJFT$RAPZ+[$CI]>E &I12 A@
M"#D'H:AOKD65C-=,C2"%"Y5>IQZ4 3T5F7M[.VG6]YIP#AW0["/O*>,>QY'T
MJ]:W$5W;1W$#;HY%#*?:@"6BBB@ HHHH **** "@@'K110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !2#[S4M(/O&@!:*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "J46E64)N3%$RFZSYW[QOG/3/
M7KBKM% % :-IXN+:X\@^;:H$A8R-E%].O_ZZ(-'L+9F,$)3=NP [87=R=HSA
M<^V*OT4 9UIH>FV<D3VUN4,.?+'F,53/7 )P,YJ7^R[+S'D,1+M)YA)=B0V"
MN1SP<$CBKE% &?::'IME-'-;6P1XPP0[B=NXY;J>Y%']B::;I[E[57E=@[,[
M%LL.AP3C([>E:%% &:^@:7(UP9+;=]IQYV9&(DQTR,\T^XT?3[J*"*X@,B6_
M,0,C?*?7KU]ZOT4 9RZ%IJM$XMOFB8NC;VRK'J1SU-/M='T^SF\ZUM_*;+'Y
M6; W<GC..:O44 4TTJR1LK#C"L@PQ "L<D8STS4ME96UA;BWLXEBA7HB]!]/
M2IZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AN(C)#,@.-Z%
M1[<4VP<2:?;N.\:_RJQ6?IH\MKJQ; $,F4 X^1N1^N1^% &A69XA8'298 ?W
MT^(X!W,AZ$?3K[8S45I!<K'?6-K/Y"Q3@1.1O*(55B #[D@9_P#K5+]ELM+5
MKZ[F>21!S/,Q8@'L!VZ] * -,# Q14-I=P7MNL]K()(VZ$?R/H?:IJ "L#36
M-OJ2P;6VQR2V^1G&/ED3]">:WZP[Q3;^([3:,K<OO//1E5E/YAE_*@#<HHID
M\R00O+(P544DDT 89U6YO+^W-H'CA@F,=PAV\G<4 /X MQ[>M-O9[R?4XS!.
M5M97-L%'0]V;Z\$?@:@29K30K*>1"MQ=2O<LI&3N8,X7GW*BKUO"8]8LK0ME
M;2T9SD<L[$+GVZ-^= %FTB6WUFYBC 6-H(F"CU&Y>GT"C\*T:HJ3_;SC''V5
M<G'^TU7J *&J?.]E 0")+E2?4;07_FHJU'+!=PMY;QS1G*M@@CT(-4KX?\3C
M3&_VI!_XX?\ "GZ4H'VQE^ZUTY!SZ8!_4&@!NDX@:YL%)V6K@1@CHK ,!]!D
M@>PI^MC=HMX,$CRFR!Z=Z(0!KEU@ 9@B)]SE_P#"C6<'2YE)(#E4X."<L!C]
M: *<.8])DA.2UK=<XYX\P..G^R15NW)M;^2W;_539DAXZ'^)?SY'U/I5:?:E
MQJD) ^>-)@#P#QMY(_W*NZC:M=V>V-@LR$21,>S#D?AV/L30!;HJM87:WEJL
MH&U_NR)W1AP0?H:LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4@^\:6FC[S4 .HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BB@\B@#F+;7;T:@D,X64-<SP;%A
M*'";L$,3AB=N,#U]JU+364O$1X+6X8,D;]%X#,1SSVP2?:HX]!MX72437,QB
MF>X2.20;3(V<DX'^T:=IFEM;VC9_T:::X^T2K"V0#G.W)'3L>G4]* -6LZZ+
M6VKVLX*[+@&!QWSRR_\ LWYT^XNKJ.X:..&V=< KNN-K?EM-4M5;4YK!B+*W
M4Q,LH;[2>"I#?W/:@"[9*1J>HL6)!=, ]OD%-O0)=6L;=QE LDV.?O+M _\
M0C_D5F6%]?M>7KQVEFQEF7:/MA^;$:]/DY__ %TMWJ%]!?6US+:VP1 T,FVZ
M)"%B,%CMX'RX^IH 2ZN_L7B6*."5?*GF07" \AF1E&?Q"5L7VH06+VRW!(^T
M2B)<#H<$\^W'ZU@W+7FNAYK2WMV$ *Q/Y_R^8"K!@=O(!4?K2K<7FKW >>PM
M5$2O$+>2ZY8L &/"GH 1^= '45BZW($U+3Y1D_9BTK@#.%.$)/MAB?P]JH?:
M-<@_=I=:;Y<#X >X)=L?P,2OIWX/3\;?V75;G[5+<6MINNH_*V_:F^1.>/N=
M>2: -ZL7Q*6E@M[**0"2XF5=F/O#G/T P3_P'%)I][K$EOY36=H;B!O*EW7#
M+D@?>^YT/!'UJ1[:_>^2^;3[(W$:;%;[6_ /7C9^ON: 'W<0DU:PMR!Y4<;R
M8_W=H'ZD5/:P3C4;RYG"A7V1Q ')VJ"<G\6-5?*U4WXNS:6>Y8S&%^TMC!()
M/^K]A4_FZQD?Z%98[_Z4W_QN@!UMF75KR8@A8U2%>.N/F)_\>Q^%7JRH;^_E
MNIK=+:R,D.-^+ECMST!^3KWQ4_F:K_SZ6?\ X$M_\10!'K'[N2PNB"5@N1NQ
MZ,I3/_CPJKINI.+",V^GW4Y?,C,H"J2QSP6(SU[4[5XM6N].EB%G:L<!P%N&
M)8J00.4[XQ4"V7B%;86J74$<8X#AR7"^F=G7WP: 'V>I!-2N)[NWF@25DB$C
M%616 ^Z2#QRQ'IGC-7M7#2+9P("?,NDSCT7YS_Z#5"]M]331YK:&QM615!54
MG8LQ!R>JC)/UZU+%'K-Q<1WDT-K$44JD+R,=N3RQP.N,<=N?6@"Q?^5'J5M)
M)MVR1R1-N. 1@-_0_K6D.E8M[9:K?+$D_P!@")*KDC?G'<?B"1^-;5 &9=C^
MSKMM07/V=UQ<JHZ8Z/Q^1]L>E:*NKQB1"&4C((YS3B,]:S&T@I(?L5[<6D+$
MEXH\%22<\9!V_A0!-I-U+>69FF !,CJ,#' 8C\^,5=J."&.WA6*)<(O3G-24
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !31]]J
M=31]YJ '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 444$ C!H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ?XI<22G_@(X'XD_2G)H5FSK)?&6^E7G=<-N /LOW1^5 #GUVPW^7;N]V_\
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MJHN4_P!R[E7^34UWL/#MI%#%#,[SR;45%+O-(>I+>ON333I]]J7.J3^1"?\
MEVMF(R/]M^I^@P/K0!1N$MX)S;Z;J.JRW*GF*WF$NT^C%P0OXFHI8O$D.GRW
M%UK5M:1H,_O(E=@/=@ ,_P# 36Y<7%AHEB $6)!Q'#$O+M_=51U-4X[26]F2
M_P!;*11QG=!:E@5C/]YCT+?H.WK0!6T;4]3M=/5M9M+J2-BSI<*H=@A/&]0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(<'TSC^7%=#10 V//EKE0IP,@=J=110 @(;H0><4M%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !2#[S4M-'WFH =1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %&*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!L>[#;_[QQ]*=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4@^\U+30/F;K^= #J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:
MY*HQ5=S 9 SUH =138G+QJQ7:2.1Z4Z@ HHHH **** "BBB@ HHHH **** "
MBBB@ IH^\U.I!]YJ %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "D'WFI::/O-0 ZBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0?>-+31
M]]J '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !2#[QI::/O-0 ZBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:/O-3J0?>- "T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !2#[S4M(/O&@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ I ?F-+2#[QH 6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0?>-+2#[S4
M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %-7EF^M.IJ_>;ZT .HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "FKW^M.I%[_6@!:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I%Z'ZTM-C.5_$T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "F1',8I],B&(Q^- #Z*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **",]:* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M ID7W!3Z9%]S\30 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *;'POXFG4U.A^IH =1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-3H?J
M:=0!CI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex10_4page007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_4page007.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *3/S$4M(/OGZ4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 444U)%< J<@Y[4 .HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I!]\_2EIH_P!8?I0 ZBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ I%(900,?6EHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BDR=Y&WC&<TM !1110 4444 %%%
M% !1110 4444 %%%% !1110 4T?ZP_2G4T?ZP_04 .HHHH **** "D+ $ D9
M/0>M+2%%+!B!N' - "TBL&&5((]12T@ 484  =A0 M%(P#*5/0\&A%"(%'0#
M H 6BHYD=X\1OL;(.?QJ2@ HHHH **** "BBB@ HHHH **** "B@T4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !2+NVC>03WQ2T#..: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!NP"3?ELD8QN./RIU-RIE(P-P7K['
M_P#53J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IH^^?H*=31_K#]!
M0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I 0P!4@@]"*6D4 * !@#M0 M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ";?G#<YQBEH[
MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !31_K#]!3J0??/T% "T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%!&00>] &  .@H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BDSSCO2T %%%% !1110 444
M4 %%%% !1110 4444 %%%% !31]\_04ZD'WS]* %HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH K7E];V2H;AFS(<*J(79N,G
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MSU%3::)?^$QU"Y-M,L$]O$B2%?E)7<3S^(^M '14444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)CG.3]*6@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 $X!(&30#D D8I",@C.,T(N
MQ H).!C)/- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXCLHIS%/'<1%%W2%D'[KY=V&P3V_#FG#78@P62SNXV*.X#HHR%4-QSW!_0T
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M0Q2R,)U8#]VR85<=>,8QTJ/4]'OKBYN2L D=I)&\[<!OB:,J(N?1L'TXSUH
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MX+(Y93C/3L?Z4]/#TZ07D:RVR_:K0P$)#M526<D@9Z?.??B@#5_M?3BJL+Z
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M "C ]*** # '2C ]*** $P/2J]M8PVLUQ+&7+7#[WW-GG ''IP!5FB@!, =
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M0> /6KLOB-(1#YEI(I>5HW7>I*D.J>O/+#]:C.KSW<J&*&XMD+3(K$QD,4#
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MAK-EJ%S+;VTA9XQNZ<,,D9'XBM"@ HHHH 3(W8[TM%% !1110 4444 %%%%
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MVW)N4':?4>]244 %%%% !11D49&,YXH ** <]*3(]: %/M12,<*<9/TI<B@
MHHHS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 44U H!V8QDYQZ]Z=0 4444 %%%% !1110 4444 %%%% !1110
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M9ZV*B5"_FMYWR@*4Y''/#@]N])?>(#8WYMYH(T19%4R-(>%8$A\;>F1CKUH
MK7V@SW&KO=BULG4SK)EV^8@1E<'Y3W.?PJNOAV^4PEH[60I;+'EIG&QE# 8
MX(.>_3GK4MYXDDDMKB-;2XA*H5+J2"C[0V,E<>H]<CI4NHZ_-_IMI;0LDD*R
M*) XW*5C#;MI'3D8- %:V\.75K<6\D5O:J8W@)97P<+&5;^'OG\:8GAJ\2S
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MCGC'>MAO$=LL8?[/<'@;U"C*$N8P#SR=RD<9Z5L@Y .",^M !1110 4444
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M&;)56] $,9;9<+\L@/S[B23@@ <?I3(-(U'RH8Y[6[<+]F=@;G/SJ[;R#O\
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M[7)=*Y@1O*E#=3G<X)'<]ATK, U)(;>1?MRS?8T7_4O@-YOS [1QQ[9QR,T
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M22,XXXZ<UL4 %%%% !1110 U226R00#QQ3J** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ IH^\U.I!]XT +1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% " 8%
M+2+P",DX/>EH **** "BBB@ HHHH **** "BBB@ HHHH **** "D'WC2TU?O
M-UZT .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **0C/K2T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%%  ,\Y%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4B]6^M+35X9OK0 ZBBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI",D<D
M8/YTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M#[QI:0<DT +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 44US@K][D]A_.G4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  !BBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *:OWFIU-7[S?6@!U%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !12$X(Z\GTI: "BBB@ HHHH ***:X+(0K%"1PP'2@!U%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %-7[S4ZFKU/UH =1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44C8RN3WXYI:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D7O]:6
MD7J1[T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 C9RN/7TI:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI 0PR#D4M !1110
M4444 %%%% !1110 4444 %%%% !1110 4U>I^M.I%ZGZT +1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(O
M4^M+2#[S4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %-7EFIU-7J?K0 ZBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHYSVQ10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%("2 2,&EH **** "BBB@ HHHH **** "BBB@ HHHH **** "FKU
M/UIU(O?ZT +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %-7O]:=2+W^M "T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )CY@>*6DP=^[
M<<8QCM2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !12(I48+%O<TM !1110 4444 %%%% !1110 4444 %
M%%% !1110 4B]_K2TU#][ZT .HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3'S9R>G2EH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1>_UI::G?ZT .HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BB@\#IF@     & **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ IJ_P 7UIU-7O\ 6@!U%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !128^;/%+0 4
M444 %%%% !1110 4444 %%%% !1110 44BMN+#!&TXY'7Z4M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %(O?ZTM(O?ZT +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %-7O]:=35[_6@!U%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4B]_K2T
MU.A^M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHH) &3P* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *:G?ZTZFIT/UH =1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%!SCBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FIT/U-.I
MJ=#]30 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *:G0_4TZD7H?J: %HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,<YHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1.A^II:1.A^I
MH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.OER?_%4 :D]C:W)B,]O%(83F/<H.WZ5B0KJ,6H:BMO8A+F>7(O)B/+$> %
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4450MM6BN;\V:07*L
M%9@[Q%58*0#@_4T 7Z***  #!-%(% )(SD^]+0 4444 %%%% !1110 4444
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MX# GR87R,<;G&0?P'\Q5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "FIT/U-.I%Z''K0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 55AMY%U&XN9"I5E6.,#LHY.?<DG\A5JB@ HH
MHH **0* 20 ">3[TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %4(<-KMT2/F2WB ^A9_\*OU0_U>OG)XGMA@?[C<_P#H8H K7(2X\40V[Q@J
MMJ9&)'7]XNW\B,U/JB"2]TL-C N22",YQ&Y'ZX/X4VW$DGB.[D:%UCB@CB5R
M.'))8X^F11<033Z_:N81Y%O&767C[QR"OKTQ0!)92$ZIJ$+,I*LCC"D84KCD
M]^0:+!UMY&TYLJ80#%D_>C[?D>/R]:=9H_\ :%],Z,NYD1"?XE"@\>V6:I;N
MQM;U EU"L@'0GJO?@]1T% $=[=^6/(MR&NGX11SM_P!H^@'7\*46YA3R+8;-
MY9WDP.I.3^))J+RX[?\ T73XPKN?G<#.W&"=Q_O8/&?Y5=BB2%-D8(&<\DG^
M= #E4(H"C I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1
M.A^II:1.A^IH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D7O]:6D
M7O\ 6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ I%Z'ZFEI%[\=Z %HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D7H?K2T@&,_6@!:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ I%.0?K2TB]#]30 M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4B]#]32TBXQQZF@!:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I%Z'ZFEI%[_6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I$Z'ZFEI%&!^- "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2+]VE/2
MD!RH- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%%  >E(OW1CTI: , #TH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I!TI3TI%^Z* %H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ****  ]*1/N+]*&^Z:%^Z/I0 M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=/TH0Y13[4I&1B@#
M]* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex10_7page001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_7page001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***!GO0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC/:MRB@#D%T34F@:(QN-MO+'^\E4@EF!&STX'4^U78]+U+^R;R$2;!.)B()
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D7O]:6FIW^M
M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I%[_6EI%[_6@!:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ I%[_6EI%[_6@!:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M IJLO/(ZTZD7OP.M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M Z4(HQA0,=..E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4B]_K2
MTB]_K0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY-K2$DC8/?BGWGB&:'58+)8H8_/MEG3SF(;<6"A,>N33[_PM;7]W<S32D)/
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MWZ@@5;M-+@LKR]N;4"-KPAG '&X C/XTFBZ8FCZ:EE'*TJ(6(+  \DGM[DT
M7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3"8\8QTS@^]:>G:DFH+(4@FB*!6Q(!DAAD$8)JA;ZZL=K!YL%U.6B61Y=B#
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MZNY;V[MK$+OMH%8 D#>[9P,]L!?U% $2Z7<?V9]GD6!IA<R31OO8"/<S,#P
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M*\9!'S^7]X>W0X^E2$:I<R>8A:VB9E'EN%) !.[D9ZC'XX]Z &ZCI4MW?2R
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MV[UK444 %%%% !1110 4444 %%%% !1110 4444 %-3H?J:=2+W^M "T444
M%%%% !1110 4444 %%%% !1110 5EW&A6MQ=27#2W 9VW$*_ .PH>/H:U**
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MVB:?-N,D3EF=7W"5PP91M!!SD<<<=:FFT^VG@B@=&\N%E9 KLN"O3H>:M44
M4&T:P995,)VRJRL!(V,,<L!S\N3UQBE.DV19F,;;F=7+>8V0P&T$'/'''%7J
M* *W]GVFV%?(3$"E8_\ 9!&#^=12:1821B-X/D$/D!0[ >7Z<'VJ]10!BZEH
M0N98Y+9TCPS.XD,AW,0!D%6!!P,>E7S80R6L$%SNE\DJ0Q<@EEZ'K5NB@#-_
ML'2]LB_905E7:P+L1C=NXYXYY&.G:I/['L/D_<8\M=JD.V>N>N>3GG/6KU%
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MO5MXHB+5QY+Q2*78#E]PP0,_CVJS+I=W)X=DTYI8WF<GYF)Q@MGD@<G'?'-
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M4=,XZGWK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "D'>EIJ=_K0
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M: $?P]*]JL!NH\0Q-#"WEG.TLI^;GD_*!VI-0TBX%O=S+*CEGFF"+$=QW1;
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M.,<#C%4UT*=0Q%XF]Q.K'R>"LK[SQNZ@]Z/[?<0K(UI@'SDY<C]XG1<%<_,
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MR8RVMTRI&[;E=0P 3!]<X!Z]*MQZE<I>R6T-N9'DN77]Y-PH"*W'' P>GK0
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MCV.R.[660 2!"2RDH?O%>?O8YXYZ\5G6]]=RWUN+F2]15$/F-LD"ABF"C #
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M"2I^E;MM=03O<(B%3 _EON&.2 >/;!%3_NQQ\HQ0!DSZC*;+3)?.$"7>/,F
M!"90D=>!D\<U3L9#J.J63:@R-(;0OY>!@D.,, 1D9P&KHBT?"EEYZ#/6G+M(
M#+@CL10!REQ([ZD(FOF25-4.PNH/EJ8&Q@8I^GZU>75Y9QR7$<9=8FV%/]>"
M/F(X['WXQ74;1UP*,#TZ4 8&HWUY#JTT4%V@V>04MR@S)N8AAGKT&?:J;ZGJ
M"6MO(VI(J7+2J)C$-J,IPHX!SD9/X5TL=K''=RW0+&2555LGC"YQ@=NIJ? ]
M* .7%_J$MT$6_,8>[:':(5RJB+?GGN&&/QJ)-2N7#SI)''-):6K%V4)N8L^X
M;L''3OP":ZVC&: .4@UF]>9=]P\"B)'5)8,M(ICR6X'4-UP>V.]6(=1NCX?O
M)C*S3P[AY@ <,0@.4P!D<_GD5T?&*AN(?.C 4X*G((H Y&'4+RX>1(KI@ 9O
MG6,-O 167G: >2W;D4Z:Y,\UF+@R1[;J%TC5/E="F2V<?WBPZ\8%;Z2NLTDB
M;AM)#1GO[U-]M66 D(>GS \XH YO79)$FN8DDE:.2S7RD"D@G><G&.PP:EN-
M1U".1[<W<L<0GDC%R;?>1\B%,A1TR6Y]@*Z2RC1(0RJPSSR:L4 8^J7<]O':
M!Y)8HI58231Q%BK;?EXP<#.?T%58+C4)[E(FFF24S-'(GE@ 1["5<<=<X]>2
M1715!<2[ 44X?;N ]10!SLMYJ46GPS7$DT8646\[+'O(V[@T@ &<%L?A3)'U
M%V4275Q*BBVR/L^U9-S,')&,CC!Z\5M^7Q]J6)E^4Y0?Q4+=20H9&&Y,9*]U
M.?Y4 <[!=7L^;=FNU5GAR3!]T^:0_5<#C''./4XH_P!*\Q99Y;E9EMY8XI3"
M3M82$ D ?W=OIFNQBD66-70Y##-.H YV/4+L:"3MF%R)#NQEW*>9ABN0"?ER
M1QGI44MQ?%9/)EO2AA9[5VB(+R;C\K#'3& ,XR,UT@AC$GF!1O\ 6GT <G>?
MVC(+I/,O#YGVF/8 =H 3*$$#UZ'-/^UW2WL"1"^\GA2#$YRIB/MQ\V.O.?05
MU-% ')))J82VEWWPV6]H2@0X+%\29&/3J*='/JO[Z25KTLKA9HEA("KYGWD/
M?Y?3M[UU=% ',112OX2U&***Y+O).4$B-O8%R0<$9/!J.Y;4HV> /J'V<3N!
M*B%W *+M/8D;MWXXSQ75T4 <M(NIK#<S*]\S1W**4P<F+:FXJ!C)R&Z'N:25
M=1%M((GU!LP1;'*D/_K3GCUVD>^*ZJB@#(TJXD@F>RN1<LSS2^2T@)^08(RW
MX\5G3V4CZNZM%=JAO_-:1"V-A@9>#V^8XX]:Z;8F\/M&\# ;'.*=0!REFNJ/
M=60NS?KB.(@J/E)&0XDSW_GQBM*=9;/Q$]])#++;RVRQ*T:[C&P8G!'7G(Y]
MJV:* .<N([UKEC#!/#DQ-;!3\J?.=X;'&2.3GUXYJF]G?M%(5_M'S#%<,!YC
MCYQ)F+OZ9_K77T4 <DJW<UU<R6IO6GBNG&/,.S9Y0^7GC.2,>A]J;;6VH3LL
M<\-^D/G;L;RORF C'WL_?Q^-=7%!#"7,,2(9&W/M7&X^I]ZDH YJPBN6O[6-
MYG+26\;W:-(=T3ICMVW;N?7;72TQ(8DE>5(T623&]@N"V.F3WI] !1110 44
M44 %%%% !1110 4444 %%%% !2+W^M+2+W^M "T444 %%%% !1110 4444 %
M%%% !1110 5S>H1Z@=:+Q071A#@%D;AD,;#CD8^;'&.O.:Z2B@#E+:UO[>"%
M6MKR2() UPAER7(5@V,MZ["1WQ5E;6Y_X0Z:U6TE$S>8%B)&[!<D<YQT/K71
M44 <[JEI>:A<S74-O)$L5E+"@W /*[XQC!X QW/6HIK"^:.\G2&Y\TSH53S1
MEXL)N"@DKG*GK_6NGHH YF&RO$FA5[2\DA*J8F:=0T#"0L=^#T((Z9X&*AAT
MV^2V:!;.5 (G2$JZCRY=Y(?KT(V^_!XYKK** ,K2+%X+J\N)TD$CRD(S/D%,
M#H,X R#6,NEZE';G[-;S1R/%+Y@,H^8^<K*.I )3>!VYKKJ* .6BTB[=W,<5
MU#_HS^0TTPS'*6)&=IQW/3(Q^5-CTJ9TMGETVY$:S[Y8'G5C_JV7(P0,9([Y
M/7%=710!S.FV3IJ4-NTRR%(D:[3?N,;H?D!^H;\=E7-0M+J75]XMFEC9(_*E
M$@7R&5B6R,YP1CIG.,&MA4169E50S?>(')^M.H YB+1;J>U,,R&!_LVR1RP(
MDF#9608/L>OKBB[TR^E^RR2VSR&57:=(I@OER,5(.3V &,CFNGHH Y0Z5>Q^
M:\-FWF2+=*V91\P9@4&<_7_ZV::NCW<J%+BQ<QAIV52ZCAE!48!P.<_0_G76
MT4 8VAV<]I<7C3VH1IBC^;E<L?+52#COE3^=9,>D:@Y9);(B-V@+#S%QE926
M/7)RIZGD_I77T4 <C/I.H&SE@^PB9&C=(%,B_N#YC,#UZ%2HXZ;:T?$EE=WL
M<8M;?S"(I!]\ J^!MZ\=1U'/TSFMVB@#B2#=ZE>1&'S)6,T:*KINW% ,-ELX
M!!QQW%:!T69+^!H[7]SMC96$VWR7#%F)'?.>W7OQ72!%#%@H#'J<<FG4 87A
M_3KFR64W%OY<IC6-W\[<)2,_,!VZ]3SS[5F1:+J'DRI+:;=ZQ%0CHP#J'!X/
M##D=>2.<YKL** ,B]L99[+38VMHY'@D1I ,84!2#C-9KZ-?FQGC$*B<VDT#N
M''^D,Q^5C^IYZ9-=310!STFG7C7TD[6RR0&Y$AB9A\Z^4$SZ9!'0^M5W\-W+
MVL,(=59[?RIWSDJ5.Z/'K@\9]*ZFB@#G5TJ\%]9W'E)YJX:=L@H22Q; Z@@G
M@C\:VK"/R;**/[.MOM'^J4Y"_C5BB@ HHHH **** "FR.L:%W. .M.J&[_X]
MW/! &2,=10!5_>7A9>3$PR#Z'K359XY&B3Y&7 4YR&^O%,M9HK:)O+P+=_F5
M@>%)//?W_2K$2+';M)+*H!SM;/0>N?UH F BF<!R#*@YVDC'_P!:E^S1^=YN
M#G&,9XJO8NQD*R#YU7K5Z@ HHI'=8T+L<!1DT +56\C=V7:2H]143WDBR;B
M(#R".O\ G-2PW!9S', ,_</]X4 )9W2R)M8;2.,&I;B$2(2,[@.W>H9H&!W\
MG;TP>H]Z2.\81\H21D$=",4 11L;:0,@9UDDP5 'RY_P.:TJRR99YUE@49)
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MV]GM*9BG/[PJRYR .#@_A\IJJ=?NA:R?:)K='6:.)MPVJ%;)$N3_  MP!Z4
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M>[UV&6>65I_LLBRQM'M$3;U^7I_,GI[T\7E]).ZO-(IWSI/'L \I!G8P./\
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MN&YD::R\M#&&(!#?D#R/\BJ]RFHK+) K:B+7S9%22,%G!*J5//49W\].F>*
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M8<$#IUSGVQ@U2@AU&& %4OW+INE5G8D@3<A<GAMF>F.U &A=:=I5W9R-;K'
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MN\^YXK2K/N=)AN3>&66;_2E0$ @>65Y!7C.<\\YH CAUVUGFCAC28R2$C:5
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M(OE?V:XN&#-&N_AU"@Y!QZG&"*K#5+B6]\N.S^<R^3N,P&YA&'Y&#QCBM1M
MTPVPM_LPV*VY?G;*G&.#G.,<8Z8JN--@CNB?LZK(LAF5E) )QMZ9_NX% &?:
M:AYT\#VEE(4>*)Y<.!Y>\9'UQ_\ JHB\07DMM$L=LB&8P,A>3?\ *[[2#Q[?
MK6G8Z?I;&%ULUBF@7RT&3P!T'OCMZ4R\TBR@C7R[0/%L$6S<1A0=PQ]#^5 "
M:S=+ID0*PK(NQI&7=TVXZ  GOUZ<=>:J&_,%Q(+JV1[:*211('^8E4W_ '<=
M,9'7K6I_9]AJ=NAN81.$5E7=QA3U'';I^56!I=DI!%NG#%_Q(VD_EQ0!3TNY
MGFU2_P#/*A1%"Z(LA95R&^F.GZ56C\0SRE4BM(S(TD2C,I"X<-SG;SC;VR#V
MK5L],LK%G:TMUC+@*V.X&<#]3446C:9;L'ALXT9<$$#IC./RR: *<.NSR&VW
M6L:_:D_=?O"<N&"LO3H!SGN :LZI>.LPLX88I7:%IB)'V@@$# _.JMLD<=TD
MR@K;0+NCMQ'CRV;<"V>_<8^M:4MK8ZCY4TT,4YC.8V89VT <\VM-:VTLPMD>
MV$=P8E8XYB)X88[[3^=237\\MY!#Y%K%(MSL;#E_E,1<<X&#6M>:=:@2R?9T
M*R@K* F=P;KQ[]ZK1Z;:/.D4UO$YWK)NQU*C"GZX)'TH R1JUV+.*]>V@5IH
MA* C[F=/ESGCCECS]/6IKJ_NA;7=Q:B"-8S(N2QW;T('*^^"?;CK6\^D:=)#
M'#)90M'$I5%*#"@]0*=_9=AOE?[' &F79(=@^<>AH S9M;E@G>-TA.R9XB<D
M XA\S.>WI4<.I2WMY:>8/+,5Z8B$) 8& MR/Q[^E:QTO3VE$C64!< #)C'0#
M _3BB+3+"!E,-G A1MR[4 P<8S^7% %*_P!6FMKJ=(HT9+81&13]YP[8^7Z8
M_'I2V>HW;:;>7UU%#Y</F;%B)R=A8'.?H*T9+6WEF6:2"-Y$^Z[*"1WZTZ*"
M&",QPQ(B$DE5&!D]: ,"?5+YFCB#P)EK>3S54E2DC$%>O7(Z]P>U5K?5[G3+
M:176.2(FX>,EB6&V<+\Q/;Y\^P%=&-/LA"81:0B-B&*;!@D=.*46%F.EI .&
M'^K'0]?S[T 95MJ.IS7\-KBS&=S.P8DE59?0G!*MZGFI+[59X;N=(EC*6S0A
MT8'=()&QD'MCZ<\UI165I R-#:PQF,%4*Q@%0>H'I3GMH))DFDAC:1/NN5&1
M^- '(27-TGAVZMI&B:"2VNF0J3OC*,>ISSU_2M&YU-K":\V&&/=>!"^UFQ^Y
M##Y<\G@#BMP65H/,Q:P_O?\ 6?NQ\WU]:K7^CVUZJ ?N2C[R8XT.XX(Y#*0>
M#0!EKK5[]JM()6MT>4() !]QF5CW//('3/X55M-4EBM[>Z>6&6=[&'=+C[I:
M0*=W/0;L_@:Z.VTRSMHHT2"-C'C:S(,]<^G')/2I5M+500MM" 5*G"#D'DCZ
M4 <_<:OJ*R2P1RVJM$9AYC(2) B(P(&?]H@^X-=#:3?:+2&? 'F(K8'N,T"U
MMPJJ+>+:N0!L&!GK4BJJ*%4!5 P !P* %HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "@44 8H **** "BBB@ HHHH **** "BBB@ HHHH *PKZ[
MFM=2OFM_)$@2U&7!Y#2.N#SVK=J)[:WD8M)!$S-C)9 2<=* .;GUO4X()7=[
M1F5+@+A#C=$V,GGN.W:K*ZI?"]^Q2R6X)=L7*H=G"!@N,_>Y]>@K3O-+M;NS
MFM_+6(2JREXU4,-W7&1WJP+6 0B(PQE <[=@QGUQ0!S;^(KQ(!.\2 &V,BHH
MW9<1ERIYR/7IC'O1/J\\MN]O<7=B$FCE*S1MN5@%7"G.!N.XGZ"NE%O")#((
M8PY&-VT9Q]:3[+;B-8Q;Q;%.0NP8!^E &'<$G1-$:.6-&WP[7<9 RA'K20ZI
MJ1:W60QG[27AC=(SM+J_WOH4#-^'N*WVAB>+RFC1H^FTJ,?E4(LHQ?"Z+R':
MFQ(L_(GN!Z]J *.K:A/;77D1RQP_Z,\RO(N0S+CY?UR:H)J^I-,9-T.!+&IM
M2G[S#1ACSGJ"?3H#72/'')CS$5L'(R,XJO!8Q075Q<@L\D[!CNQ\N !@<9Q@
M4 <];:SJ-W':^5>6(:Y=5^0%S&2C$AAQR"HXZU%=:W<RBZB6]C0*-P90 5VS
M!6XSG&/7WKK1%&.D:#G/3OZT>3%S^Z3YLY^4<YZT <['?F.]GAAG@ACFN6+7
M"H,9\I",]LG)Y]%J.VUN_EEADFEAC4M;AX=G/[P<\GGW'%=,8HR"#&A!.<$4
MIC0G)12?I0!BZOJ=U:W<\<+(IB@26-&7_7DL05'Y#IW84ND0Q2WFISS.DTB7
M#1[B%RJ[5R,CMQ^E;116(+*"1T)'2@(HSA0,]>.M ')66KO;KIEK%<Q+$8X5
M*G'1@PR/7D#VJQ#J6JFZCMG9BQ=K9W\L8$H;(8<=/+!/Y5TGEH,?(O'3BEVC
MK@=<T ,@FBN(_,A=73)&1Z@X/Z@U)2*H484 #VI: "BBB@ HHHH **** "BB
MB@ Z4BL&&0:25-\97.,UGQ&>WE2 ] ,YQUZT 6KXR"W)B&3G)'J*CBDB2V>0
MJW#'(P3SZ"I0\=S&R-D$$9 [>A%17PE6)3;Y&TY(&.10!!M++YI/^C $$-D?
MB*FMY9A-L8!D8\8SD#WILMRALQ^[.T\,!VJQ:1F.'!)))SS0!/1110 456NI
MWB_U0#,O+*>X]J=:W4=U'N0@-W7/2@!)KGRYDC"D@\DXX%2%4G16(R.H]J66
M))5VN,C.:< %4 # % %"2TD W8WLO"$'&1]/TIN;N5%90=V[E3T(J\)D,ICS
MAO3UJ2@"*WA$*$#J3DU+110 53FNV$ZI&IYR >Q-274P0!#D;^-WI4$#J+D)
M.?F'S1Y]Z ));7>ZSQJ(YL<XZGVS590\!::*)_,8 .F1^=:E,DC5^O4=#0 R
M*5+B/!QR.5)!JEY4D4ZPE69<Y5MW(ZTLJR6;&2- 5/+D?X5H(=ZJQ&"?6@!P
MZ4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %(,=J6@#% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%(Q(4E0"<<#- "T5FZ%J;ZK
M8-<R0B%EFDBV!MV-K%>OX4:/J4FHM>K+ L+6MRT& V[. #G.!ZT :5%%8^J:
MG=VVLV.GVL<#?:TD;,F1@H <<>N: -BBL"R\66$^GQ7%R'MY&21FCVEMOEG#
M\CKBFWGBF",7@MD)^S0Q2^9(C!"'/'09Z4 =#165+XBTN&6:.2Y :%6+_*<?
M* 6 ]2-P_.K]K<QW< FBW;22/F4@\''2@":BH+ZY^R6<DP7>RCY5S]YCP!^)
MQ5&WUN!M*M;R<,KS_*8U&2) #N7\-K?E0!JT56O+Z&S@6:4.5;H%7)Z$_P @
M:2?4+>"SCNW+M%(4"E$+$[B O ]R* +5%92>(-/8,6,L85'<F2,J/D.&'/<$
MC\Z0>(]/*;E,S8WY"QEL;<%NGL0: -:BL2XUY-]O]E21E-P(I5,+;BIC9@5'
MO@5,OB'3G:!4D=C-M"@+R"Q( (Z@Y!% &G)(L:%W. *C98[J#G(##@]Q52+4
M;;4-->Z3?' %W%YHRHVXSD9[8-9$^K26D4YM8I-R^65C=.0'.%;KR/ZCM0!I
MRV\T6YB2"@'ER _H?\]ZM6USYRA)UVR>GK51M1DB%I;7$?G2W,A0LJ[0!M9@
M<9/88_.J%GJUK):PW%X7298XW)$>T,6;:-N>V>* -Q+*))FD!8[NJYX_*K-9
M=YJF?#UQJ5B0#'&S+YBGJO4$9]JK6NN$7%U'=%'CA6(HZ(4+,Y(VA2>>0.>G
M- &[167-K]G!&SRK*NQF60%0"A&,YYQ_$.F<TL>MVTLC1QQ7!82F%?DP'<$Y
M )/;:30!/J$;E1-$V&3]:I#<A2^B#[3G*9XST_F!4VG337^@0SR\SR1[NF/F
MSQTK(&IW\%IJMPCPLMDY(B>(Y=0B,<L#P?FQTH W6OU-L)$ZMP#C.#[BK2.D
MT>5.0?0XKEUU"*"662*&XD\R58UA6,9R8]^.O/U]:MV>O6Z2/ $F:-251MHY
M;?MV]>NX@<XH UX;8HW[QO,VGY2W)%6:R'UP17#":UFBA2)G=G !!#[<8SSG
MM]13I-=B23ROLETTPD,1B55+9V;_ %P<CWH U:;*S+&S(NY@.!ZU4OM2BLI[
M>%U9GN&VKR .W<D<\].O6LBQUZ2,.+I9I6!F(.U0&5)=O&#V!'7\Z -2%99;
MGS 1Y3\E3G*GT^M32V^ !&J[<D\C.,@]JR)]7:9&FLG:)3;73$$*?GC( .>?
M>M62]%O96TTJLYE:-#CU8@9_,T 1VMQ)$Z07!R2#AN15\$,,@Y%8<^JPW#P0
M+&8I9G= S%1@JY4XYY/&<#G%2:)J9OV*(DBA560.R$*ZMG'/KQ^M &R0",$9
MHKFQK<J6-ZDPG#I]K:.=0G2-R, >H&.H[5J6NI+-J#V.PAXT#%F(!;@<@=QS
MU]0: -"BL,ZM+::I>I<1RR6JW$<8D&W$6Y%P,=3\Q_6C_A(Q]F^T&RF2)@I2
M20%4(8$@DD<=!GMR.: -RBL_2[Z:\DO!+$L:PRA$VMDD%%;G_OJLZYUZ>?3)
MIK*UE0%5:*9P0""VWC(Z]#WZT =#17.)=WEOJIMYII9"CJD2>8,2%@S88[>@
M Z]?E'J:EE\03,CBVL"SI#)(V^0*$*$JP/KR* -ZBLBTUAY+VWLYX%226(/N
M+_>^7)VC'.._.123:M/!JL]LT$;(/)6+#X)9RW7C@?*?R]Z -BBL^/5/,TNY
MNQ"0]MY@>,M_$F<C/X=:I?\ "03!EBDT\K<2%/*02Y#!E9@2<<'Y&XP>U &[
M17.7FN7[Z?J#06 @:VMC(7>491BF[& #G'/Y5-!J3V>^+RGEC2Y\AG>8LRNR
MA@.1RN2!GK0!NT5SI\0WJV<5P=-CQ+;O<*/M'\"JA/\ #U^8_E6GIU_+>/<Q
MS6ZPO"RX ?<&#*&!Z#!YH OT5RK:MJ$20W\D:2%(KII(EE*IMC=0#TZXR*U;
M75I;G46A2U_T=9'B,N\<,H]/?G\O>@#5HK!U*^GENDCM\)';WT44C;R"20&Z
M#J/F _\ U5%+KMY);0&**&-Y5B;)8D#,RHP_(T ='17/#5)[>::VM[?SKAYY
M=JM+D':JG )QC.X<=N:N6&K276I-:RP+$-F]/F)+#Y>0>AY)!P>,>] &K111
M0 4444 %%%% !1110 4444 %%%% !111F@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHK-N-5:*[FCCMQ)%;[?/??@KD$Y QST'?O0!I45AOKTRJG^A*7D$
M+(/.X*R-M&3MX()Z?K49\0W*P22/IZ K'*P GSEHV"L/N].>#_*@#H**PVUV
MXAF<75BB1Q2-&[)-O.1'Y@(&T9XX^M#ZY<HN/L4;.RPNF)OE*R-MY..H- &Y
M17/'4+R6YMKB*#]]Y-TIMO-.QVC=5'.._.#CO6CI]_\ VE9O<1(/**C8=Q^8
M[<GMQ@G'X4 :%%<U;ZY<06MN%M5>%+:WE=WG)?#L5_N\D8S[U->:I+/832+"
MH@^<*RS[7!20+CIWY/X8[T ;](V2IVD ]B1FN=U#598YDO0O^C6SSJR+)\SE
M$;.1TZCC\^]2MK&HAHHOL, DED*J6FX(V%P> ?0C\/?@ GT_1IM/MD@AOV"B
MY:=_W8^<,22I]LFI]*TTZ?)>.;@RFZF,S97&TD 8'MP*@TB_N;^YED<QK T$
M4D2 <J6!)R>]4[?7+P6)>1(99HX)+EQRN55R-H]\ \_3UH Z.N=UVUU";6K6
M[L[2=S;1N$>.2,#YQ@Y#'/85?O;F=KC3TBD6.&YW>8"#N(V$@ YXK*TS6KR+
M2[*&:*-YI(;?8_F9SO4\MG'/R'OWH SIM#NC9V]O!I%Y"L$<T99;F%F<2#YB
M<GK22Z-J$T-Q%_9MVJSV\5O)B>'GR^A'-=.^I3)86DDD*)<7,HA*[MRHQSGD
M=>AK.EN+G4[NVA9EA4?:%=5+<O&P7<""..] &:NF:E%+=M%I,^V[8NR-- 1N
M( ;KDD''3IS6WX;T^YLK:-9A-;1QHT:VK2*Z\MNW CIUP!V K,L;U[&&*^FS
M+)+8B5V,C!<[E'()('WN3[5H7&LWD-P+1(;>6X57D)$@5652OJ>#AL]\?C0!
MJ7EDMX\'FL#%$^\QE00YQ@9SZ9S6?)X>C:&X@2<K!/*93%Y:E4)&#M&..>?K
M3]:U:73UC,21OF-I&!)R0"OY?>Z_3@YJK)KUU \TD\,)@0SJ-C'=^[&<GV(H
M TK_ $P7EK! ;B1!"P.<!MW!'.1@]<_6AM,W:7;6)N'Q 8CYFT9;801GC'51
M5739I5N]4>:6.0KY;#:2% V9[DXJD/$-X;*28119C8;FVD@(8]^[;G. 2,]\
M<XH NR>'XI5*RW,K*?.R  /]80QYQV(&*<^B&5%^TZA<3.$D0NP4$AU"]  !
MC%.U;4I;)+=X]GEN-TDA4L%''. <XYZ\XXXK/FUF]N+>1HA!%$TPC5BV74B8
M(<C/H?;% %M=*BEN#)'>2K+&T;CY5X*H5SC'<,:1]&%K(L]K=7$0"_OPI'[W
M!+9/&<Y)Z8]*K:VLRR64(E46\C/O"@YDQ&Q[$?YQ44'B"[,4*A(#YJVS(W.
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M-]>E '1ZAIT6H%1-)($ P44C#<@\\>W6JEQX=LIH?+#2J0) #NZ;V#G_ ,>
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MPPQP*5C& 6+'G.2:DP/2BB@ P/2C ]*** # HP*** # ]*,444 &!Z48HHH
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M&WDNM/G@A=4D=2%9AD T 03:WIT/WKE&'EO)E3GA,;ORS4HU.QVJ6NH4++N
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MB43.R<Y*QL=N#M.<#CGBENM'%U]MWW#K]I:-UVJ,QLF""/7D XK+U/2K][N
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MR#T[]#4]M+$T8"#;_L^E6* ,^"Y='\N8J#G..^/;\:MRQ"0;T^5R.&_QJMJ
M(VK&=LCY(/?BIK$N;90Y)()&2,4 1V]H8Y2QPJ\':.A/K5RBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *1>_UI:08YQ0 M%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M""[8:'<-P.,\#N>G% $MQOO9?)P-G4,.0,&M"*,11+&.BC%9]K>:?:VY#WL
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MI4$ C(Z'D]>F,=Z9<:Z([HQ)$X2*Y$$K-&W="WR^O.!^- &S16<=<TX>3_I
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MMS'.>.>U#Z2YU!KE;HA&G6?R_+!Y";>OY5J44 8L&@-!/%+'>N,($E'E@^8
MQ8=?NGYB.*N76GM)?I?6T_D7 3RV)7<KKG."..AZ&KU% &3-H@F>0R74C+.B
MK.I4'S-K%A].I'TI/[#&[/VI_O3G[@_Y:\G\JUZ* ,&STB4SW:7#R) +A)(O
MNY?;$BALCIRO3CH*?9^'A:R1NM]*Q1T?[B#)5"O.!W!K;HH Q+72GCU"U$D9
M:*QC(CG9QF4MV*CTQ_*M'3XKF*%UNYC*YD9E)QPI/ X Z"K5% !1110 4444
M %%%% !1110 4 8HHH **** "BBB@ HHHH *1>_UI:1>_P!: %HHHH ****
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M%<E::W>RVDET+GSDM98VE5$!9XF49Z#J"3T]".:GEU2\M]4M;6:Z&2T:RJ4
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MI#*".AYJ."YBG:58FW&%]C\8PV <?J*Y@QZL7N6$=[YR;L ,!&\9(P%.?O
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M**** # ]*,444 %&!Z444 &**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D7O]:6D7O\
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M/:@!A>6)RR+^\.-R'..O7]*J07MR_B]K9Y7%L; 3")@!M;?CZ]/6MG:DH5R
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MU-74[I)/*A<*(Y7A\@I\RQB,E7]>P]N<4 :R:1:)(LBK)N683@ER?G";,_\
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M8T1-B(JKZ 8%((HP !&@ QCY1QCI3Z* $5%7.U0,G)P.M+110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH * <T4U.A^IH =1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%07#EEVQ.-P/S#C./2@!6NHE5FR2%.#
M@=*D7:V)%.<C@U6^S,VV0,5; RO8_6HRTEO\Z*0N,>7CI_GUH ,O#<EISD%C
MLP.@H#//<[9%SM8%2.,8-6QY<R\@-CUI8XDB7:@('N2?YT /HHHH SM'U*34
M?MOFPK$UK=-!@-NSM .<X'K6?;:M?_V[<VM[;+$D:+(FR3=\K$@ C PW&?PJ
MW;:/+:"Z^SW[H;F[^TL1&..F5^A Q5=-.^P:E<74]_<W"W ),;*NU3QSP,G
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MY])$MS<31W<\/VI564)MY ! P2,CK36T. ,GDRRQ1QK"JQK@@")LKU% #?\
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M#FG)86,-RL\=I;I.%V*XC 8*!T!],=J +-%%% !1110 4444 %%%% !1110
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MIPYAD5]C%&VG.&'4?6L#Q%<74DA_L_<QTX"XDVN!EL\*>>FT-^8K>>2&WR.
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M9=:>TN QA*1;&6,G:SLR_,?J!^=-M]9C"Q1S%Y9I9)%4+'M("OMZ$]LC/YT
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M6@6U,D7V>V=Y))LOB0[?3DCK[U)<:I-<6/G"'; [*8W2?:QQ(%((QGW_ $H
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M HHHH **** "BBB@ HHHH **** "C-%% !1110 4444 %%%% !1110 4444
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M)J+2$D$J81&P.P[D!*X+9P<8[8S6C93W4>FZPT#3S7D4DK1I(O.<90#CZ<4
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MZRY(&3UVY^O%:^L0W,TL>V&X: VSJ!$^&27C:3@_7GM0!:D&EQW2VC6T1D<
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M2*'RV#*%>3YD!3&-VWD9_''>I[G3HH+"^EOK>.*XN)%,#QC>PDVH!CC^^F:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD).?)$BDG=SR<5N2P03@>=%'(!G&]0<9&*CFLH9(7C0"%F!Q)&H#*<8R..M
M%'3M2N;G39[R6+!C3'E[<'S%!WC_ +ZX_"LV;5KR2%/],A2,_9IC,BX"AWPR
MG)Z<?E716<<4-N(87W",E22<DGN3[YH2*U99(DCB*AL.H48SP>1Z\@T <K%J
MMQID,_DO \+27;(FTY4K+]XD'D88G&.U7[34=0NK^VMUO;!T?S'+P@N&52G
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M]JB +"S!R"Y(SC'<=?6IK[7;.UBE,3I/)'"T^Q7'*@X//X'\JM#4;$P^<+N
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MLR/Q';M/"T@:*VEB9PSHP8$.%Y&.!SUH S[K3;T6]Q!#I[Y>XF?>CISN!*D
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MO<?9=.:6.(R*K&0+N9.HZ=^<?3WJY::D;O3YKV!%>)5W1,&XD 4$]N.<C\*
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M6\D(O#M>*2,8B4;0[[CTJ2WUF<0&2ZLI&R5\O[,/-)5ESD@$X&01FH(=3O\
M>;?= \[O<,I92%"QL!MZ]3D<_6@"Y86DAU:ZOYX#"Q A7+ [P#]_ Z9&/? I
MEQH9FU![O[7(I9MP78IP-A0C)&<<YQZY]:JW.N33Z=%+:6\]N[F!_,FB)3:[
MH" <\G#?H:!J%Y%=2P6J0,\EW(A:1F(XB5P1Z?2@"P- "M&\=Y*DL2Q+&X5>
M-@9?3G(9@:F72=FC'3_M4F2Q<2[1D'?NZ8QUK-C\0W9MD>6"!6G2WDBPQPHE
M)&&)QR,>W6K%]<74^BVTT@BCN?M40(20E ?,"]1U'M0!/+H:3;EGN9'1Y'=E
M( SO381GZ$U-'8RV^G3Q-<S7<C1E5,FT'I@#C _&LLZ]?>:;<16HFB\PN6;:
MCA7P=I)XX^N#5O7-7ETYH_)$390R,K=<!E'J,=3Z\XXH 9#H9FL[=KFXGCO(
MXXPLB[=T14'@<$'J<^N:M?V.NVZ!NIV:YA6%V."0!NY''7YC6/?:O(MPE^KQ
M,L#7,8A!(;* C+<\CY<]. :MRZIJ"W26J-:[FN%B\THVTAHF<<;NH*^O0B@"
MX-%B\PLT\I#/'(Z<8=T VMT_V5_*A-'CCM[2(7,P%H'"M\N3N!'/';-8XUZ]
MC$UQ/+;J3'"%C((52TA1GSG[O&?ICGO3-1U2XN-,N;:YN+*-EA+EU)*RC>1\
MISP0 ,]>2* -<^'X"8R+JY!01@$%>B*0.W^T?Z8I8M!@B15%S<';Y/4KSY?W
M>WYT:KJ,UM,L-N\,9-M),&E4D,5Q\O4>N:-*O;V]NYVE,*01A1Y84[U+(C<G
M/;+#I0 @\/6XMQ +F[VHX: ^8,P8.0%X_#G/'%6I=-BELX[=Y9B8W$BR[OG#
M YSGI^F*PCK6IB!Y3<V0"PS2C]T?^6;[<?>[COVJ>;7+N/?+&L<H6::(P!?F
M4(C,K9SWVC_OH?B :<6F6\,\,JRR!X6=NH^9G.6)X[TL]A%-?-/]JFCE:/RB
MJ.!\N<^F?QK BNHY-0DF%U:W.^XM22 ."01QSU_I20RK%?K=!H;FY^V7,:DJ
M-_"L0 1] * -N70K.2!85,L42P/ %1L?*V-WODXZU(^E6LUVMWOEW;0KA9"%
ME Z;@.#C-8EKKT\T,+3WUJ()V4-,@SY&5)*MD8!R  #R,\]JT_#%Q ^C6L$<
ML;R)%DA?3)&<>G!H DBT&TAA2))+G;&ZLF9B2@7.%'HO)&*4:%9"+R@9@B@*
M@$A_=J&#;5]!D#\A6G10!%<VZW$0C9G4 @@HV#Q59M*M&TZ*Q"NL,.TQE7(9
M2.A!ZYJ]10!DMX>T]H!"?/V#?G]^V6W-N.3GGGFIAHUGYWFE9"?-:7!D)7<P
M(/'3D,?S-:%% &6N@6"P>2//V$%<&9C\I&-O)^[CM4\.FQI'=Q2,SQ7).4).
M%4C&!SQQZ5=HH S8M#L8F#()MP;=DS.3G;MSR?3BD&@:<)(G6*13$$"XE8 [
M/NY&>2,=ZTZ* "BBB@ HHHH **** "BBB@ HHHH **** "BB@'- !1110 44
M44 %%%% !1110 4444 %%%% !52[L$N;B&Y622&XA!"R1XSM.,@Y!!' _*K=
M% &;)HT$K[I)9F+Q^7+EA^]7.<-Q[GICJ:7^QX?,WB><'?(^,CJXP>U:-% &
M+::,8[J42O)]F5HC&N\'?L4 %N,Y!'KV%26_A^UMV1HY[G*;,;I,\)NVC_QX
MUK44 9,.DF.[M4*HUM:;I(G9LR%VSD=, #/\O2KFH6$>H0^3,\BIR&"$?,""
M"#D=.:M44 5I+&)Y;63+K]E),8!X^[MY]>#5)_#]D[S,6N/WJR*5$IP!(06
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M# _+ JU10!4;2[!EVM:1$;&3D=58Y8?B>3ZU+!:V]NTA@B1#(07*C[V!@9_
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MBB@ HHHH **** "@8[44"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'VB2:YD:XG5$,N!\BJ=P51V&>:6311)'(/M4B2-<_:4=5&4;&,8/!&,CGUH
M<NNV,D:R0-),KC(V1D\E2P7V.!_G(IL.O6KVL,TJR1[TC=P5R(M_"[C[FEBT
M8Q733"^N"LFTRQ_+B1@,9Z9'&.!QP*AA\/1Q6_D-=S.C1I'*"%^=4/R]N../
M<4 2'Q!998!;@X9D'[HC<5W9 SU(VGCZ>M7;N]CM?+5E=WDSM1!DG R3^%49
M]!CGL6LWN9#&\DCME5/WR3QQP03P>U6[NP%Q);S)-)#-;YV.N#P1@@YZ]OQ
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M;^<DYQC.?H* *":A=SW,9DV[?M[11^7*0,>62-W'S#_/:F2ZQ-<Z?)F'8\#
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MN]659Y(HXQ$Z^6!]]ED*D@Y_V<]*+G5-0BOYTC%LT,-Q'#MP=Y#JISU[%OQ
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MZ< L;R,)HFPB%C@.I/ ]@:TJ*  <BBBB@ HHHH **** "BBB@ HHHH ****
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M 9T&CV\%K<VT;R>5<+M(+9V\8./2FG1U:.WCDNIW6!@4W8XPK+V'HWZ5IT4
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M4 %%%% !1110 4B=#]32TB]#]30 M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4B].F.:6D7ISZT +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex10_7page002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_7page002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *,YHI!CG% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+<$G.Z0+D>W %6** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *1>_UI:1>_UH 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*1>_UI:1>_UH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *:O?ZTZD7O\ 6@!:*** "BBB@ HHHH ****
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M1-PDEW<JW'IM_,^E3Z(;F26\EN;F9P)WC2-U 55!X(X!/UH UJ*** "BBB@
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M+(K'J?0&J.K65Q-J$EQ#;2L4BA\IE<+\PD)/?T/?WH W/)BR3Y:9Z=!2A$#
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MC&.W'3- %NBBB@ HHHH **** "BBB@ HHHH **** "D7O]:6D7O]: %HHHH
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M$!!SD;0V?UK)D\/W4DEPS7L7[Z.>,9A.0)#G^]V]L5JV=I);SW<KRJ_VB0.
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M2<>PSCIFKEU82W&FQ6PG598FC82;,C*D'[N?;UJE)H,LEM) ;Q<.ERA/E?\
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MY4:AIB7[$O-(@:"2 A<?=?&3R.O J.+1XH[@2>=*R";S_+.,>9C!/3WSCUH
MDN]5MK29HY=YV!3(P'$88X!/XU5NM?AAM9)8X)7=8Y9 G SY;!6&<^I'X58N
M])ANKB25I)%$R*DR+C$@4Y&>/<].U5Y/#UO(\I:YN-LB2ILR,*)"&;''J,T
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M1)3)N+ .5.>..U:#Z992,S/;JS-()23GEP, _7'%1F'3-+V3MY5OM4QJS/@
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M0!D7&KSR6E_$\066V24RA)"I  !4@]MP.?P/I3-2U>58KVW:,H$@+QL'96<
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MBNFAMHX \MVZ,9&8XQ&&]?PP.*UDL;%)_,2V@$H._<$&[)[T\6=J)?-%O$)
MQ?=M&=Q&"<^M &%#X@NI(TE9;6..=U2,E\F,EMIWC/T].>*'UB\AN96EFM6
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M+*D!++^[4KQC.W=G]!T-=']JMR$(GCP_W?F'S=N*/M5N02)XB VTG>.OI]:
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MGKFKEOK,$_EX41Y=XY5E=5:)D&2",\_AVYJ==3L&VE;R [SM7$@Y/''ZC\Z
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M)K=M=4\S3+F]E0[('D&U%.2%)'0\YXI\.KVDGDAG9'E"\,A&TL,A2<8!/H:
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M?[W.*?=:]%;7%Q"UO*QAC=^"/FV $]^.O'T- $/]D70\V9?LHN3="X7KAAM
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M2#8QY!/KB@#2@T.&!0([JY!$7E Y7.-V[T]3^5)!H%K;2H\$UQ'M7:ZJX D
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MQGFLH:U<))(LUPJQ^<JM.J@I&A+X/J#D*I#=#S4?VV2+4FE65"TT%LDUPJ8
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M7BUF^BL_-GO/,+V\4IPBJ4)DVL!VSCU[T =+!86UO.9H8RCF-8N&. J] !G
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M!;WJ>TMQ:VRQ!BY&2S$8+,3DG\22:FHH **** "BBB@ HHHH **** "BBB@
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M<%^P- $AYXJO#:B%B <Q]0#ZYJ#=,[^8K,"#@@]/K4]I,)4)#;AG@]Z '7,
MGCV&HK:9EE\ET*J/ND]ZMU1NK<;E/10>#TVF@"]14-JTK1GSEVD' /J/6IJ
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M@G(H ;#K<*;$N2[2.TF"D+ !5?:<]<8R,G\:?%K]A,K>0SR," $5<ELJ6X_
M&ECT=$F#O<2.-LRE2  1(P8]O:HAH1$,*C4[OS8&_<RG82BX(VXQ@\'N,]*
M'Q:Y#++*HAFPKK''\O,A*;^!]/7TJ2WUJTN;F*"!9G:10^1&<*#N')[<J1]:
MC_L2,7'GI=3APZR+D@X8)L)Z<Y7BIK#2H;"X:6*1SNC"$''/S,Q/U)=J );N
M_BM)HHY5<F;=M('&5!8CZX!_*J8UB.X:R:U<B.X9>6C)#!E8@9SP>,__ *ZN
M7]C#?PI'-N 217!4X.1_0C(/L35>/1K>)8UA=T6.Y:Y &.6.>/IS0!#I&H75
MW):B<Q[9;8R-M7'S!@/7I@U:U'5(-.95FCF<LC/^[C+<+C/\Z;8Z5'920ND\
MC^5$8@&QR"V<\#K4E[IZWDBNTKIMC>/"XZ. ">1[4 1-K-J)-BB1@6\M7"_*
M7V[MN?7'X5/IMV;[3X+IHFB\U ^UL9&:JPZ)!#(F)9&C603>6<8,FW&[I^/U
MJY86@LK-+999)%084OC('8<"@"@/$=BQ(C69^5"[4SNW-M&/Q]:<=?M! DOE
MSD,K,R[.4 ;:<C_>XXI(]"CB18UN[KRHY%>.,L"$ ;<%''3/KS6??Z#=?:(/
MLC,Z1!RKLR?*SON.05.1G&,<T :;:Y:))-'()4,4;2'*]0I .!UZD?6F2>(+
M6)6WQ3AU+@Q[1N^0 L>O/WAT]:K7?AYC#<20W$CSS)(I5F"J1(06'0GMQG..
M.U)9:#+Y49GN9H'A9O*,;+N"MC<"0H!S@=L\=: -:]N/+TN>YB<KMA9U;;NQ
MQG.._P!*JIK4 N4MGCF+DQJTFS" N,COWJ]/;)/926K,P22,QD@\X(QWJE_8
MT/F;C<3Y+Q/U7K'T[?G0!<O+M+.$2.CL"<87^I/ 'UJ@OB"V=H@D-PR2K$P<
M*-H$A(7//J,5<O[*.]CC2221/+D$BE#@Y%4X]!MHH@BS7!VK$H)8'_5L67MZ
MDT 3V6J1WLBI'#*I^<-NQ\A5MI!Y]>E+J.J0Z<T8G20A_P")0,#D#N??H/>F
MZ7:20O<W5S'''<73AG6-BP   ')^F?QJ/6-*@OP)I9)U9$*?NGQD;@W\U% %
M6_UPK')Y-K-(H;:KCA6(D"$9SZGOC.*8M^\<\J2(_%T(%8J L9**P!PV2.>O
MOBGQ:5;.TT32W'DW!+H!)\J,6W$J.QSSS_6KKZ1:-:W4$ID>.Y8/)N;G( &<
M_P# 10!0;79,O(D3N"D!2%E"\22%=V<]_2K-M>I-?B&.!T=9&C=6QE< '=UZ
M'(_.H6T^WNKJ99FFC>1$0,C8X1BRD>A!JWI]H\=U/>7(B$D@6-"C%OD7."2>
MYSS]!0!+?7<L%W9P11[A<.RLV1\@"DY_2LW3->,FF0M<03-/Y$4C,0H#[\C=
MUX&0>N*UKNRCNWA>1I%:!]ZE&V\X(P?;!JD= L D2!ID\M(XT(E.0$)*_B,F
M@!]AJIO[P)%"1";=)@Q(SEF88Q_P&FZK=K#=1QQPR27'EE_W>"0N0#P>O7]*
MDLM(M+*='@>7?''Y>#(3\N21D=\9.*??:7;7\\<TIE62-2@:.0IE202IQU'
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M)^[@XQTH KKKZM$'%L1NAAE&7 P)"PY],;:=INHM?ZBLB%U@DLUD$;8^5MS
M_P J>OA[3D!"I,,A0")WRNTDK@YXQD]*E@LM.THHZL(0J>6IDE.-N<XY/J:
M$U'51922*(&E\F'SY2#C:F<<>IX/'M3]/U![Z:=1;-''"Y02%@=Q'MUZ8-.N
M;&ROI=T@#NJ[&VN1E3SM;!Y'L:EMK6&U\WR01YKF1LL3R?KTH GHHHH ****
M "BBB@ HHHH **** "BBB@ I%[_6EIJ]_K0 ZBBB@ HHHH **** "BBB@ HH
MHH **** "L>XUBX@OI8OLBM;PRQQ/()?F^<#!"X]3ZUL5GQ:6@U*XO)B)#*R
M,B\X0JN.F<$_A0!G)K][+#!)'IRXNBGD%IL [@2,\$]AGZ^U33:Y-%;RW)MD
M,*,T0_>\^8'"X(QT)).?0>]31VFB132>6ELCPMY[[6QL(S\Q]!U]NM3C2]-E
M::?[) YNEQ(VW.\'_'B@#.DU&^^T*?L9%RD,Y6+SOE?:5(X ZD$8],T\Z[)(
ML1LX%F\\D0G=C=A-Q_7C\_2M*WTZRMVC:W@1#$"J$=@>O\A^5)+IEC-;);2V
MD3PQG<B%>%/J/S- &5+J4]W<V111%&MVL<@$G))B+$<<$<C\LU<NM4DBNYXX
MXD:.V"F8E\-A@3D#OT'US5AM+T_[0MPUI!YJ$%7VC@@8!_ 5))8VDMTMU);1
M-.@PLA4;@/K0!D2:[=(B;;:)VECAECQ(<;7<+@G'49'UIEQ<7=^UO#+B%2TZ
M2B*1ARF0"",'WK7&EV"H4%I%M)!QM]#D?D>14)ATGR&O"D'EQ&0F3LI)P_/U
M'- &9:ZD]LL1<,[O:6@#/(<$NS+DCMSU/>KMI?7DVL?9YO)5$A9F5#G+;R <
M_0 X]ZGEL=*ALY))K:W6W$(5RZC;Y:\@'V%.M[;31<*MO! );1=J[5 ,8;GC
MZT 5H]6EDND01*(99Y+=3GYE9 >2/0[3^GKQ3A:6/PJ]_.\DDTL:R/B5E[]O
M3KVK<%E:B=IQ;QB5\[FV\G(P?T I!86BV7V,6T?V;&/*V_+C.>E &/<:U>J]
MRBP0*JM-'&^XL=R)N!(QTZ]Z<NL7@E,*P)+Y(032%PO+)N!Z^N!T]?2M7^S[
M+=N^RPYW,V=@ZL,$_B.*B_LO2X=DALK93$A16,8R%YX_G^M &8FN7S>4ILXO
M,:%+AE$@QL8XZG'(Y]>WK2C5KV:]B@7RH3]H"NK*22A#D$'."#M'(]ZOO#I$
MEM:7+P6S0Q[1;N8QA<X"[?3M4W]EZ?MV_8X-NX-C8.HY'Y9/YT 5=7U*YL)0
MD4*2>9$QB!SEI!C"?B"?R-9]UJMQ- U[:[0#:3R0.2<?*%ZKT/.?\FN@D\AY
MXXY-C2KF1 >HQP2/SQ^-,-C9L$!MH3L0HOR#A3U ]C0!BI>W=MJLA)26.0VR
M/EB,%\C*CH.<&K=Q(]QXD2QED=+=;7S556*^8V[!Y'/ QQ[U=73-/0 +96X
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M&'0G(YZYZ5/:/;:EY,KA6+KY@..2"!CZ<&IM0%A#:/9.AC6Y1E*P1Y.W@$X
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MHHH **** "BBB@ I%[_6EI%[_6@!:*** "BBB@ HHHH **** "BBB@ HHHH
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M@C_@7Z4 85O)JC7%O%,]\J!1Y;")B6*R-D.> ,KMY(Z=.:T-%>]:*\#^<[
MQ/+N&XG/&UNA'&<<>E:']J:?EQ]L@)C.' <?*<D<_B#^1IPU"R+[!=0EMF_
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M;N#^-;:ZSIKQ"5+R-D)QN!R.WZ?,.?<4EQK-C;I(S2ES&0I5%).2VWCUYXH
MR$CO5>)&CU.2!P3"=P5D;?G#\\+C@9SQFH4M;Z&WF@B@O$"K.(2K'B;>2K=>
MA!&">.M=)%?VLUQ]GCF4RX)V]"<8S^61GTS3H;VVGG>"*4-(F=P'L<'ZX/%
M%'28)A=7LUPUQO\ -*J'8["NU>5'U!K"DFU*W69I(+P+)Y05&;EV$K;E!SU*
MXY ' Z5TB:QILDCHEY$6C#%AG&-IPWY5#=7^F71AM)T6X6>4Q[&B+!6 W?,"
M../7UH QK2"\N@A@DO0\5O-S([*%FW HIR><#(]Q2"WOWMXFV:NL+/B>,NOF
M*VS&5_V<_KS6W%JND6\*QPSPQ1@A555P.02,#'< XQUQ39=<MR66V(<B..4.
MP(0J[8'S8/H: *^F17L>L%IA<-&8B&:4_=;Y!U'#9P3P!CGUJLMI<1:E<;K:
MY^RM<N[^6Q^?<B[2,'. =V?<CTK4O=7AAM[DV[++/ C.4.0#M.#SCG!]*MW5
MY;V:![F4("">A/ &2?H* ,NX@OF\.V<,_GR78,/FF)\-PR[B2#Z9S6>;74_(
MFB$=WPDBVC;^8W\QBI;GD;2G7/ -;YU2Q$A0W"Y )Z'!P,G!Z$@=A5:?7K,6
M;3VDGGG?&@"JW5R #TZ<T 48+6XAU$ 6LX3[<\CNI^5T:)AZ_P!XC\:K0VDL
M-O8P1;H;F1Y8I(6DP?+<D[P,]0 .?K6G9:M-*T:W2P1,9I8WPS=$[C(_/-2G
M4]->\@:-3)/(WDJXB.Y05W<G&0"!GWH ;J]JS7&FRQ6SS""9L[2,JIC89Y/3
M)%8D>GZG;6D<<4-X(Q!;^<B2 L2N\.%W'&>4XZ$"NHEU"UAN!!)+MD)"]#@$
M] 3T!/:J46J3S17MQ&D:P0"0*9 RG<O'/'3@].E $-Y9W+^%TMHH[B24-&0L
MKJTF!(#R>F<#_P#756.POUNKV=(YS!-/"[+(P$D@7(89';&W ]CZUKIJ]F9%
M@>8>>< J%;J5W8SCTZ52CU^V=(+DN\2S[=J2*1\I. >G&<XR>M %"6SU5'A*
MP7#HLN]<2@E$\[=M.2/X/KZ<8IZZ?>0VT;M:W$^]YA/%YV2<LWED9;& #T]Q
MZ5JCQ!I1B:7[6-BYR=K=NO;MCGTI;C7+.**21#)*(V53LC8C)8+P<8/)[4 9
M;074>BZ7#/;,# L7GQ;@=P"X(Z]C@]><4W3X)8]3L9;B!F,<-PNXL&9-SJR*
M><G"@BMJ_OK& &.])'[IIL>6S?*N,G@=1D>]4;F\M&N8764LJ!F.8VW'";_E
M.,="/_UT 5UBNUU;4)H+.25)EC$>&4*2 <YR>!D^E01Z+>VMHMF$>95M[6,N
MC[<E)"7QR#T/Z5IVVN6[7020&*.5(6C^1LY?( ;CCD #/K5FXOI#J:Z?:JAE
M\KSI&<\*N<#@=23_ "H Q9='O5N;I+=)EPC"UF\\!57R]H4C[V01_7K3I=,N
MI7BFM]/^S2$2J-T@8PLR !^N ,KT'U[UK+JB0*$U$K%/D!@@+*H+%5)..,X[
MXJNWB73HYG2220! Y)$+G[APW1><=\4 9EQI5Y*J%K5DB)@62+S.I4G>W!Z$
M$#U.*M:-:O!K4S1PA+<QL 6P2,%0NTYS@@9(/0XQUK1_MO3S<&W,K[@X0DQ-
MMR5# ;L8Y!'>J$VHZ>SK<12S ^8J$+"V26!9>,=Q0!5N=#NYIKMK:/[-</),
MRW.X<JZ$*.#G[Q!Z=JA33)X/LDTMCY82Z,CJ\B,8QY;+D=!U*\#TSUK6@U^U
M\L',C_NQ)_JVR1NV\<<G/&.M.U:>>.UFO+4*SQQEO+ESMX&>GJ?6@#+?1;V2
MVC!MURL<*2J)!B=ED#%\Y] >O/S5<M-(FMM;WBW!MHWW0R"7'EKLV[-O4_GC
MG/6K%IJWG+"WR01QH_VJ.0?-"R <9STYSGN,5))KEN&1(XYFD:2-"A3:P#YP
MV#VX- %"^TJ\FU6YE\A9D<;H9#+@1_)M*%<9()R>N.?:L^ZM)M)L5+0PQJYM
M@ [C874'=N^N.YYXK?.O60 )$HRLI *\_NSAACUJ,ZNP<PJOF2.\RJP3 38.
M^3SU'2@#&L].NI4L9[*T40Q"+),BY)61BW3.00<C'7G.>*K:7&]^ES'#!$\[
M0C8WF*< 2;@'[ACGN.U;]IXBMGT^&282>>R1;D\LKN9U)&W..,AORJ;^VXDE
MN5FMYD$,BH#@?,2F_P!>./6@#+NM+GMI+J^-NF/,G=FC;YRC1X&..N>U3^$2
M'AN6:&$2-LW/"RLC$+MP,>FW)'O5]==LGN$A43'?Y>'\L[?G&5Y]ZJSZS(UP
MWV?*P&*-XW:/._=(%R.>F/IUS0!0;0+QK508+<RQVB1(2WW760G(./0]:T/$
MFG7>H0HMI'&Q\J1"6?:5+ 8/(/I]>G/6K*:[9-)(K>:@C$A+O&0O[LX;GOBI
M+?5([B*Y:.&8/;#YD8 $DKN '..A'YT 8_\ 9303-?7]O;)$)99+AL[OW1CQ
MZ<\CI^-:7AZV:#3U=V+E@%1B,$Q+PF??;@_4FJUKKKM=K]IBD6*:"!U 0'RS
M(6'S$'H2!5ZPUBUO[IX+?>2J[@V.&&<9!^OK0!H4444 %%%% !1110 4444
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ML:T,$,2-*HA1D5E?YBK=5)]/\*G73[5+@7"1!)5A\D,O&$]*QH-0FBE2UMY
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MTXSVK.T.21[ZZ,\LS/)%%(H=2!@H,XXXYSQ6<;[5(U9X[F>;S!."IC'[L+,
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MY:LJ@$)_='M45U%80SI>7,,0F)$2RE,M\QP!G\:JZS)/)8V\EJEP=[C/E9R
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MB@ HHHH **** "FKW^M.I%[_ %H 6BBB@ HHHH **** "BBB@ HHHH ****
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M<2-)Y3$$Q@DD+QQW/'N: -*BBB@ HHHH **** "BBB@ HHHH **** "D7O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH LT5''<0REQ#*DC)PP5@2/K69%KR&))[BUF@@>8P^8Q4A7W%><'@$C&?<4
M:]%4Y]4L+=&:2ZA^1E1@'!(). #^-%WJ4%O%(R,LTD>"T2.-V"0,XS[T 7**
MS[75%GG6*2%X2[.B;B#N*GGI[<_GZ5:>[MHY3%)<1)(!N*LX! ]<4 34562_
MLI8GEBNX'1#AF60$ GH"?Q%-TR]&HV*72J%#E@ &W=&(Z_A0!;HHHH ****
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MUI++Q!8SV0FN)XHG !D7=G;EMHY^O% &6UC<S*NVWU)(V2=@CS %&(7:/E8
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M?J*ET;3I[6TGCF@BMY)$5,QS-)N(7&[D#';BI_[;M3<M L=PSJQ3B(X+!-^
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M\9[5KVLPN;6*<))'YB!MDB[67(S@CL: ):*** "BBB@ HHHH **** "BBB@
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M@ZC+ +F+*75KY,;#[N6&3UY'-)_PD-XQBB#V*2X=B9"563;(4(7G.<#/?J*
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MHH **** "BBB@ I%[_6EI%Z'ZF@!:*** "BBB@ HHHH **** "BBB@ HHHH
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MTL,#W4Z#)6*3[/O\XK*00V  ,H%]!R30!T#6ME:3R:A*0C#)9WD.U<@ D G
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MQ#M$3*=SE2#E2.0#Q\OMVZU7DT>^DANHFCM&)9VBE+'>VYP^T\< 8QGGH.*
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MIY[F0W%PHN0%F16 #*!C&<9'7L: *-MX@62/[4\<YC>"W=851<J9&8<'//(
M]L>]3#Q%;!F$EO<H%4[F,?"L%W%3@]>WIGBK$FBVKN2IDC7;$H1" H$;%EQQ
MZFFR:':2RW+.\_EW.?,A$F$W$8+ >N/\: (Y=;,5RJS6<T40CE>5WQ\H3;[\
MCYNU)+K\<3&-K*Z,^X+Y0"ECN4LI^]CG:1UZBI#H=LZ(LTUS-A75B\F3(K
MAN.GRCICI3DT>W$B2--,\L;J^]F&3M!"@\=,$_G0 NHZLMAY8>UGE+Q/*1&%
M^4+C.<D>M0/X@ACBE=[6X4QOM*G:,@IN!SG'(_'/%7+RPAOF#O)(N(WB^0@<
M-C/;V%5I-"M))-SS7&XE3Q)CHFSL/0T .AUF*:Y\A8)@Q\LIG WJX)##GH,'
M/TJ&YU66RU:YCECFEMDCB;**N(MQ8$GD$C@=,U+8Z:8;Y7D"%+2'R+=MQ9RI
MQDL3W^7C\:GN-,@N+HSR&3YU570'Y7"DE<_B: &6&K17\[1PP3A I9963Y&
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M% !1110 4444 %(._P!:6D7O]: %HHHH **** "BBB@ HHHH **** "BBB@
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M 0\&%\#//.14XU>[CNU@N9;8#[2(F<+@!6A,@ZGL1CWJ]'+IDTRP+;QEW:1
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MC3HY-/M)K@+/%'(Y\V8-+ST R03QP!0!SEM-=3R6[S&\<17*LH:.08W0D#/
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M5%FDMYE#M<;V:4,-ID#1\;CVSTZ5OT4 <]?6%P;Z\N8+%BWF6\B,K*#($;+
M<^GKBH#9:@\$N+&12T%XBKYB9!=\H.OI^5=110!E:Q:R76FV\:VIF=9HG*$K
ME0&!/4XZ UE7&EZC):7,:02"8Q7",ZR*!.6_U>.>,<=<8QBNJHH Y[^S9X=0
M58[-VA(1XI/. \A\L7SSGG/;.>AXJ3P[975K"YNH)8YC&J.6E5A(RY^8!?7U
M//KTK=HH Y"TTJ_D>-;JQE$?F0NZF5<<!PW1N>J]>33O[-U$6T<<U@TV%B$1
M\U<P[),D<GTQR,].:ZVB@##UVQN;N\MV2"2> 1LC*DHC*.2I#9/T/3FH&TJ4
M.<:?&1_: F)^3YDQU_/M71T4 <FNFZA!"SO:L\L;CS2TXVW2A\X [''][Z=*
MD\A[7=?#3<QM:+&JB52R$.QVY/4_,.G'&/2NDGB$R;3R/0U2A+VLI1P?*!."
M* *&J:=<2M;R1JGFQML^;D-&R[6_$9!_"JFFZ;/MLPT:N\,S)(3P1$L;1IUZ
M]B1[FNF5TF4HX&>X_J*B^QK]H$N>F>>_:@#F;70+M((BUDL<L,-LJ 2+\K)(
M2Y&#U()_,UKZO8W%SJ=I-#;AQ$5RSE2F-P+9!Y! &016S10!R46D:HD?EK:Q
M*L,$<8S(,3;9=Q''0%>.:DN=$N)D+QV,<1$&(8_-SY3^9NZ^OTZ=*ZG..M-#
MJ3C(ZXH P?$NE2:@R,D$<BBVF3+'[KL!M_45GKIMU!.)UL0]MYB2/"K ^8?+
M*MD'C<&YYZ^N:ZRX0O P498#*CW'(JI;2HL3[E;<?F93Z\"@#F9;"^BL8HO(
M2Z^2%49W&8"LFX]><8P,CGY:U(]-F>6V<V\;B*^FE)W+PC!L$?F./:KBH<M(
M SJ0,QMVJW:%E 5?FCY.[@8H P;71[Z)K59K6":-84C^:3'DNKEMPQU!XZ>F
M#Q446BZDLK2/:P$ PL(_-&"4=R>W<-U.3Q76T4 <U)HUVWF;X(I4;[4HC+#
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M@ HHH)P* "JMQ#@^9&=I'7'>D2Y87$B2J0!]T]C5A'25..1T(- $5M/'. <
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MYA+[-X#>AXH JV<R'+E,.3M?U!_PI'D>:3,9+JS[=N,8QU_&GWEJ68SPJID
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M-#$18);B!K=8O,D"D,X8C/7KV]ZG;2M0DGN76/3L7"%)0LLOEOQL.1G&<9%
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M!KLQBD\RU#RIYSE4?_EG&^W/(Z^W\J+:\:_U&0I#-]G1MC$X*ME58#;UZ/\
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M\N)"&&]QP,=1C/UK8UJ1HM,=UW9#I]URA^^.XJM-I^A+<V]M-!!YJJ%B4CG
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MP!SZ=7'T'M6_HDZA9[=IE(%S*L"LW)0'G'J 21^%6HS9M=W-HD*"38LDP\O
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M7.%+KV(ST[]13=)U"[_M"%;NXG:*47 (DC"JI67"<X&#M/XUN6TD$T*QJJ@
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M_6KV@:?<K=1W&H0W"RQ6L*JSRY!<*5?@'GJ.O\ZZ.B@ HHHH **** "BBB@
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MS;W%XJ,-J_.#;J=V?J/YTNFZE,ITF*.:/R)(HPT<*J,$[LY7'W>/X3QCD<T
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MI+=8AAB:.-5^5B2P?'')Q@@9ZXH WFGB6=(&D42NI94SR0,9/ZBGLP52S$
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MJ)"F3L3&3C/;(IMWK2,UL+$F19)XE>0+E0K\XSGK@@T\Z&HF,\=W,DIDD?<
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M,"#6K<6L5S;>1-N*\'(8@Y!!!R.^0*ISZ%I]Q$L<L<A # D2L"P;!;<0><D
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M7UJ_-X=L&CD6*,H)"&P'8!2#GY>?EY],5'!86JEUF@RS&0X#L,B0_/QGOUH
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M$6\N#MR"PX)^O&* *4>N7;2_-:0B-FD1,39)*IO&>,8[=:A'B&[D C@M$DN
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M_E6CX?MHOM-S<6\B26:2,+4J.!N(9QGN-W'X8K>H "C   ]!0 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M145E!/'7YLXZ#GF@#:%[:EXT%Q$6D *#>,L#W'KT--_M"R\HR_:X?+!P6WC
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MRLY&=Y+:%F< ,2@)8#IGUQ2M9VK&(M;PDP\1DH/D^GI0!C^%;QI[06Y=0($
MV-DNV<G=G/3M^!^E49)93H-Y?-*XU..Y8(-QR&#X5 /0C''?.:Z>*UMHF#Q0
M1(RKM!5 "!UQ]*BNA8VS"[N(XU?<J^9Y>6R3@<@9ZG% &'?ZMJL<-SL>VP'G
MB0(AWJ50LK<G!Z8(Q[^U/74'@NF=9+>5Y4MD,X!P-S.,D;O4<>YK7M--@MI)
MY"%DDG=G9V10<'^'('2HHY-+,GV>.&,%V,&WR< E1G:>.@% &3/KFHJ)65K5
M1;Q2R/E"?,\N3;Q\W&1]<'UK6UF9C:K:0E_-NSL'ED;E7&689]!^I%7#:6I
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M"D$'CIBI],TN6TU2WN%L8XXS'('S+N:(LP;KCG)STX&:Z"B@ H[T44 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %(O3ICFEI!^- "T444 %%%%
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MX@,J"4C<$W#<1ZXK.UBZ27P\]U;NK)(JLA*A@P)&."*CTI(WU?4W,OF,LRE
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MY+8Q&>ZOY 5AFD 0@KMF ;&U1_#GCVS6YK63#82J+C8ERI;9NS@J0,@<]2*
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M:@#J:*** "BBB@ HHHH **** "BBB@ HHHH *0=_K2TB]#]: %HHHH ****
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M[A5QO4X/?#=,YW<]* -R[O+:P: 21N6F;RXQ'&6R<9QQ[ _E38;^SG1?(5G
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MG K E\/7#0S(C6^98)TYSA&D?=QQT%:E]9SSS6L\)C+P;@8Y"=K!ACKCJ/\
M&@!EWK5M;R>7&5E</"'^; 59&"AL]\9S5G^T;'RXW^U0[)?N-O&&YQQ^-8ZZ
M!=1"**.:!HE2W#;U.28GW?D1Q36\.W!N1+NLW5VDWI+&6"JTA<%?<9QZ=* -
MBP?3WEN&L9(G=WWS;'W?-TR?^^<?A53_ (2"R^T1 NBV[K)^^=MN&1E7&/?=
M^E6M*LFLK5XY/++M+(Y9!U#.S#/TW5F/H5VXD5I[<J8[F-/D.0)6!!//48H
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M2!W!C!VR, <8^N*RH=5OOLR7J7:7=N)55A$F3AEP!G Y#D?@>:ZC@>E( H'
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M,X.<4Y]5$LMLMH01)<&&42(0RGRRXX_ ?@: ,FWTF^6\M6N+165%CVM'+L6
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MZ1=S7:71N 5,=R\:J0 0HQCI]: -"BBB@ HHHH **** "BBB@ HHHH ****
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M[2.:%%M&N=KJH+$$?*P/3OT]: ((_#MZEM!Q9_:+=HP&#O\ OE0$?,>J\-G
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MIT4 93:#;,)U,USY<K%P@D^6-R0VY>.#D9I;72I+2Z22*\G>,N\DHD8'S"5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *1>GXFEHZ=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ***AGNK:V:-;B>*)I#M0.X&X^@SUH FHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@'-%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %87B7[+(@MYK6:1IUVM+';/+Y: Y.-H.">WY]JW:* $0[D4D$9&<'J*6BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "D7I^)I::G*_C0 ZBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *:G3\33J1.GXT +1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %(G3\:6D7I^- "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex10_7page003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_7page003.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *,\XHI ,,3ZT +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %(/O&EI!]XT +1110 4444 %%%1/<V\<J
MQ23Q)(WW49P"?H* ):*** "BHOM5ON=//BW1C+C>,J/?TJ6@ HILLL<,9DFD
M6-!U9C@#\:;#/#<)O@ECE7.,HP89_"@"2BBDW+O*;AN SC/.* %HHH)P,F@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4@^\:6FK]YJ '4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !31]YJ=35^\U #J*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ I!]XBEI!]YJ %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ]_B3[_^K^;Z_)S6[10!ACPZPD$BZQ?APNT,/+R!Z9V=*:/#6U0JZM?!5;<
M!%@'U^YUK>HH PO^$:'R?\36^^0Y7B/Y3ZCY.*/^$<._>-7OPV<Y_=YSZ_=K
M=HH PW\/2/(DC:SJ#.GW6/EDCZ'92IX>>,GR]9U%,G)VL@S_ ..UMT4 82^&
M]DQF35;]96ZN/+R?QVTG_",@*RC5K\!CN8#R^3Z_<ZUO44 8#^%U=&1M5O\
M# @\IR#U_AHA\+1P6ZP1:G?I$H4!0R8XP!_#VP*WZ* ,'_A&5_Z"E]C_ +9_
M_$TH\-D.'&M:H& V@B5<@>GW>E;M% &%_P (T?,\S^V=3W_WO,7/Y[:7_A'"
M&+#6=3#-U(D7)^ORUN44 <[+X1@F6-9-3U K%)YB+O0!6P1D#;[FI/\ A&?N
M?\3C5/D^[^]7Y?I\M;U% &#_ ,(P-C)_:^I[&.2OF+@_^.T^#P[Y-TMQ_:^I
MNP(R'E!# '.T\=*VZ* $1%1 B*%51@ # %+110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(/O&EIJ
M_>:@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4$A022 !U-%,FB2>%X91N1U*L/4'K0!GZ5JW]I7M_$L)2.U=55CU?*AL
M_3D4NF:F]]?ZA;26_E?8Y%CSNW;LKG/ZU5LO#D>G7-S/IUR\!N)HW9<;@$4
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M=R[1F/S5QD@C YP0JG'5?:M]K^S1T1[F%6D * N/FSTQ]:KZCJL%COC/SSK
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MX;_6A^/XNP_"NAFUNQC0,LIDS(B812?O-M!^F0>?:K-W>VUFJM<RA V2.">
M,D\=A0!S<MM<R7%X+X3VEM)%*OGO* J-O!1L[O3IP/2M[1UF^P)-<KMGG_>2
M+_=)[?@*9-JFE2N]M--'(RD[HRI;E1NZ8ZXYJW!=P7 !@D#C8L@(!^ZW0_I0
M!R[:9J AF^Q1W,4P$WF9DP)09,J%R2 =N>>,9K=T>&2&Q<&.XCW.S*D[*64'
MMQP!G/%,CUNWE$<JD) 1*7,@96 0X) QR*DBUO39I4BBNE9W8*HVGJ1D=N_;
MUH YK[/>1*OVRUN8XY9K<%?,'S-N8,.&R<C')ZT]M/G^TM:;+DS&V=K<"4_N
M?WIV$G/8$>O3%=+#=V&HR&.-HYFAP^"O3KAAD>QY%9_]N60O$N&C$<16:-YG
MC8."C 8Z9V\D^V* *T>F3Q%)Y;>:53<R?:(VDW%TRVP@$XP"V<?X5):Z1>(U
MGYWS"2$)=[FR048,G/<_PD]ZTY]:TZ!I%EN54QJS-\I(P "><<D @XI/[;TW
M>B_:0#(VU<J1SD@9XXR0<9ZT 8<&FZG''(9+66257'G9F7;<KYF>!ZX_O?3I
M6SH=O);V$L<EL;?=/*RQD@X5F)'0D=Z;<Z[;+9R36S-*RLB8\MN-Y 4XQTYS
M[TRWUZV%F9;]_*9))(V^1@#L."P!&<?RH QAI0M=,!NR;$):B-FEE!#S@@H1
MR>F"/<'%=+ID,B6"FY0+--F25>P9N2/PZ?A20:A8W\[V\3B5XCE@8S@$8[D8
MSR*DNK^VM"1<2%"(VE/RD_*N,G@=LB@#F?['NOLRHFFO&8+>5(]DBK\Y<%3U
M]!GFM#2["ZAUB:>YAEW;Y2)O,7:R,V57 Y) P.>F.*T6U>P5Y%:8CR_O'8V,
M\<9QR?F7CWJ>SNX+Z 3VS[TR5Z$$$'!!!Z'- $]%%% !1110 4444 %%%% !
M1110 4444 %-7^+ZTZFKW^M #J*** "BBB@ HHHH **** "BBB@ HHHH *S)
M[.YBUEM1LUCD\V%898Y'*_=)*D'!_O'BM.LG6M3>U@G2V#F:)4=V4 A%9L9.
M3['IGI0!!<Z5>7$TID,)%QY19@2#"4;/R\<_IS5<^'YBCCR+3<R72YSWD8%?
MX>V*N)K"P2-'*)I7>Z>)!A5QC' YYX/U//%%YJ[/:NUHDT8##;,5!1P) K >
MGXT 4+?3GN[V["Q0(T5TCF7OD0J"!QR"<@\],TMIH-Z)X7NH[1ECECD8;RV=
ML;(<#;@=0>,5IMKELA),4Q0^:$=0")&CSN4 '.?E...<5$?$5MY<;+;W$A=6
M<+$ _P H(&>#SU[>] %.RTTI>V-J<B6UA N=BG8Z@YC 8@9((S^=:^HVL]Q<
M6,D(B*V\QD<.Q&1L9<#@_P![]*?=WRVSQQK#)-+*K,J)C.%QD\D>H_.H+#6(
MM0N/+MH)FCV*_G' 7#*".^><^G:@#/30;B*UA6-+8M]D>VE0D[26Q\P..>E.
M&A3"X#D6\@6>&0,Y^8JD>TYXZYYJR^OP13NDUM<1Q)(\1F(4KN5=W8YZ ]J:
M/$"ML":=>LSOL4; -WREN"2!T!H =_9D_P#PCC6 \H3 ';@G9G=D#..G3M4)
MTJ[>Y265+5@+S[0PW'!'DE,=/4YI1XEBV,YL+L*$:3=\F-BMM9OO=O\ ]5/@
MU.;[>ML$>0/=21LS;1L"KNP,'D<]: * \.WBVT21FV1XH(EX9L.R.6P< '!!
MZUJ'3I/^$?FL46".61'PJ9V!B2>IYZGK2W.K?9=1FMY8&,:11,K*1EF=V4+C
MZBI8[[[5:71C#PS0%D8, 2K 9^AZ@T 4H=*N_M:/.8=HN1=;U)R#LVE!QTSW
M].U.U?3+N[GG>W:#;-;"$^82""&)!X!]?TJ*U\0@6<(N;:X%P\<152%_>[P>
M1@G^ZW^%3ZCJ3)H<>H)YEL#+"7$J895,BJP([<$T 0MH\[WYN&BM2#>>?R3G
M;Y03'3KGFJUGH-Y:R0/(+218XHLY+$HT8Q\HZ'/Z<]:O76O+:HKO8W)4PM/E
M2G"*1D_>]P<5(^M1K,46VF=3(\2,N,/(JDE1S_LGD\9% "W$-WJ.@^7*D<5T
MZJQ4D[0P(./7'%9\V@W5QYFYK>,RRS,TB$Y >/8.WKS^%6X/$-O<2".*"8LT
M<<BCY?F#Y]^HQS^%3:5JZ:G]VWF@)A291)M^9'S@\$^AH 72+.>TAE,\=LLT
MA!/DEL,0,9)//^%4HM(O)+.SLKIX%@MIEF8QL29"K;E'(&!G'KTIMIKDT,#K
M=6MS.PDG"2($_>;&;Y0,]=H[XSBM6UODNH9)HE)B0 JP(._Y0>/SQ0!FV^BS
M;U^T"  0S)N0DE2[[@1D=J@BT._A2&518_:(2%*X;9*NPKDGJ#@]/J.]6XO$
M"2J/*LYI',HCV*RGDIN!SG';'UI\&NQS^4%MI09HHY(PQ&6#, 1UZKGF@"N-
M(O8KD2QM;%8Y4E5.5#$1^61CL,<CK4NE:.]C=^;((6 BVJ1G*G>[$#C@?/@?
M2K5_JB64C1^3)*R0F>0)CY4!QGGJ?;V-9KZQ=R7B^5 YCCNC$$0KF9?)+@Y/
M3L: +&JZ+)>W+RPS"(21#=QSYB',;?0$G/T%,ET:XWOY+0[3# @+$Y)1RQ)X
M[YJ2/Q##,T0@M;B171&)5?N;EW#/;Z_45+!J_G:-)J;6<\<:Q>:J,5W.NW=D
M8./SH EL[.6WCO0YC)GF:1,$\ @#!_*LJ'0KN 6K1M;A[:*!0 3B1DW YXXR
M&Z]B*M-X@1&\I[*X6<L D1P2P*E@<@GLI_&D_P"$@!260V%RD<.P.SX&TL$/
M(SD8#\\<8- #]/TNXLKR.4/$4*2"5>?E+/N 7VY(IDNE7C7[,LEN;9KGSSN4
M[Q\FTCT_&I$UR)MK"!S'OCC=U8$*S@%1[CD<CU%2:7JXU"0I]EE@/E+*N\J=
MRDD=B>XH SH-#OE$(GDM7$8MUP W(C+'/U.:G.CW'V_S\6Q07+S!3GH8@@'3
MVS4LVO1Q*TGV>5HCYHC8$?.T>=P]ONG'TJ=M4\O2_MT]M+%D@+&<%CDX7IGK
MD4 <[#9WEIJ=M;&+S5@2 $"-]KLBXWAMI'&>A(Z5NZMIMQ>S![>2) UM+ ^\
M$_?Q@C'TJ&3Q T?WM-N1M1W;.%PJL 3SR>H(XI/[1NI;M%9/+'VQX4",,. A
M/S9&1TSQ0!#/H-T\OG1O;;ED1EC<,48",H0<?7CZ5M6T#6UA' @CW1IM 5=J
MCZ#L*S+/799+:U-Q:[9KBW69 K\,20"H^FX?G6M<S"WMI)RI<1H6VKU.!G%
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M1110 4444 %%%% !1110 4444 %%%% !6=J&C6U_*\DDD\;2((Y/+?:'4$D
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M$\-7$B/!:"9'@>&214"@;-LF/US^E1:](PU*>)[H@$6KQ(X!53YQ!(^F!WH
MUSHEDR%6\YMT9B8F9B2I()R<]>!S4@TBT%P)P)=XD\T?O&P&V[<XSCH36!)K
M%^)%M_ML,95Y5$KIQ*R28"X /.WL,$YXK;UJXF@M8'BN5MM\Z([LH. 3CO0
MVWT@6]W;A!']DM5)@4[FD#D$'YB>F.@_PJ464$6GW,%Y+O@G+F3S'. &Z@$G
M('/K],=*Q$U74/-AADO(TSDQR&/BY D(.!CJ5 Z$?>STIIFN+NWL);K4=RR7
MS(%5$ PID'H<]%H VHM$L4;S$\XDDMDSN<DKM)Z^E+::<8;U96\KRK>+R;8
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M&;3WF_=HL.9$)@*R$\Y/==O(STP: .M\N/:1L7#=1CK42M;S3O$44R0XX*]
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M+JYOY)K>&)E>*($LV"=DFXKTZ,.*EBTZX&EZE#&1 ]VSM"F>(LJ!V]P3QZT
M6AJ437CVT<4CE'5&88VC<I.>O3C'UJWYL6"3(F <'YAP:YZ#2[S[;]H:QMH!
MYT3A4DSC:C*3T'J/PJ&#1K^*-/\ 18)8E8C[/-(.5*X/S <X[9YP30!T,-['
M++<QD&/[.X1BQ !RH/'YBIC+&'52Z;F^Z,C)K!_LJ\2Y$WDQ/&DZOY6[AU\G
M8>O0@\C-0IH5ZGE1QLJ?NC&TF_< ,/@ $9!4M@$8XS0!TJ2)("4=6 .,@YIO
MVB IO$T>SD;MPQQ63IFFSP:?=1R6\$4TT83"RLZL0NT$DXP.G [5GV^A79F5
MKJUMG42&3!DW9S#L(^Z.X'^10!T_G19(\U,C (W#C/2E:2-65&=0S?=!/)KG
M=-L_^)G;PY&^VMHUO% )4R*!Y?S$<]2?P%6M1TNYN;RX9"ACN!"-S$YB*,2<
M#WS^= %J+5H)IYU09AM]WF3;AM4C&<\Y[_H:(=7MKB5DA(;]W')&Q8 2!]V
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M:U7[-(#<;1@L,J6)&/P(P3[CK0!LT5S\6LR!+>ZNT= \$C>4A!4D.J@9ZYY
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MH YF6WNI;RZN&L=4_?Q3Q8%B/E$A!'\>.,?CFNALM;>VLH+=M%UAC%&J%A;
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MU S&X<'_ %G3C&*=/IT\R,/L.I@NMR'/V13S,>2/WG&.*[:]N_LMGYX0/DJ
M-V!R0.OX]JQ9=1N[Z6W> &&,VCW&WS"#N5E&#\O3J/QH ?::S-:V<$!T35I#
M$BH6$"C.!C.-]5]:OI]6TFYT\:/JL/VA"A<P(V!]-XJ;3M4GA6TBN%DF>[6-
MF;S-VPLA/'' RO?UXSBGV>LW!MXDBLI;C;:+<,QE&X@[@!TY.5_6@##N[.2^
M%TUUI>K---:K:QND"*(U!!Z%SDY )YIR1WJ3VL_]D7RM;+*"([2-0Y< $X\S
MCH#W[UUVF7PU"T\\!5^9E(5B<8/?(!!]B*J:IK$NGW$J+9&:.&#[1(XD (7)
M!P,<GC- ''?V5>"SCMQI^IX2VBM\FUCR=D@<'_6]^E32Z=/*NHQMI&I[+QG=
M6^S1&2-FQGYO,Y7(SC ^M=3'K-Q).(A8@%YW@B+3<,4W9)XX&%_6H#XC<QO,
ME@S110K-*?, 90696 &.2"A^M %?P_%J'VR^EDAN+:2YE29VFMU52  I48<\
MD#K73,"5(4@''&:PSJD\\D+O;-#$EZ8=R3?>*[P<C'(^4<?X4U=<N[G[,]M:
M!(II(RKN_P!Y&STXZC ]N>M %F+2)8].L+3[2A-I(K[O*/S@9XQGCKUJO!X>
MDAFCD%W$WR[) UN#D;V<%<GY3\Q&>>W% \0S,'$=B'8-&%'FXSO8KUQC@CMD
M59M=5GFOC936JQ3JP++YF?W>W.\''/S?+^!H U:S=4TLZC-&WG^6@BDAD7;D
MLC@9P<\'Y1SS4>J:I+I]\-R(UJEI+._)W$J5 QQ_M4S^V+LN8/L %P0[HC3
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MTWY/3H: +YT2//$\H&Z8CITEZCIV/2HXM 6+>J7URJ2QA)%4J-S!-F[.,@X
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MNUO(W>>0[!QP, [0/3&<T ;+:#IK0^4T+%!&(P#*W"@[ACGJ#SGK5ZWMHK:
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MR6\EBEN$FDG9+Q!!"Z;5'"MG.,^OM3VOKR2XM4@N;E8GB1T9[<LTC;CO4X
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M]5O["TOR$@^QQ^6C[U'/!Z=>O3C'I6--+JT%S<PQ3W3RP*WE*8"PF41<'?\
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MSL9OWWV6%C)'LW&,9*>GT]J$TZUCNH[B.)4:-"B!5  !.37.O%J3W+&7^TU
MB5HS"P"[?+P0<_Q;LGZXK2T:YEMQ#97<<QDE:0I(<X(7')#$E<^G_P!:@#:H
MHHH **** "BBB@ HHHH **** "BBB@ I%X)%+2+U;ZT +1110 4444 %%%%
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MP/X8Q0!N)=0/.;=94,RKN9 P) X_Q'YUGO>V=AJ/V"WCVRSAKAR.F<C.3ZD
MG_@)I;/3[J'5I+MWC6.0-O1&)#GC!P1\IP,''7BLVXTN:XN&N5D1;M;H2@EG
MV #Y0"O3[N1T[DT :<FJP1R;&NX00-S*S %0!D_I5B/4[)]N;F$%F*+^\')'
M&/SKF7M;BZU2]@>!E25IE4M$X6+>FTON*[6SC^]W_"IIM+D^V13%;,P^5''(
MK1L53:20R^_U]!0!T;ZC9)NWW4(V,%;+C@DX'Z\40ZC93G$-W"YV;_E<'Y?7
MZ5@66A2^3Y3&S)CDB991&=TJ+('^8_ACCOS4TWAR66%XC<1J'%R"50C_ %K!
MA^6.?6@#5?5M.1-[WL"KSR7 Z8S_ #'YTR;5[>,S;?F6WD5)C_<W <^_45GM
MH$\B?.UE&[13(PAAVKEU50W7D_+^M%SIEVEK=VRLCK?&-?E0Y0[55B3G&,+0
M!KWR69A$M\L9CA82!I.B$=#31JE@;<SK=PF)6*E@X(!'.*HZPE]/X?U.*2)'
MD(80B-2=Z]N.<GM[U#<:%/<S&[+VAF9]QCEA+QE2@7!&0<\9S^% &DVK:>K,
MINXMR8R-W/.,<?B/SIT=]8B18XYH@TOS@ _>R,Y^I'-9W]A.+>XB+PL)9UD'
MRE-H"*N 5/RD%001TI(="G1426[653)%-(Y3#ET4#@YZ$J/UH MV^HZ/''+)
M;W-NJLX>0JPP6<X!/UJ;^U+#RHY?M46R0X5MW!YQ_/BLM?#TJPVZ"YCS%'$A
M.S[WER;_ %[]*63P_(;KSDEMF#-)N6:WWX5GW\9/!!S[>U &C;ZE&]C-=W.V
M".&21&);( 5BN<_A45Q=:-?6^^X>VN(D<CY@&PP&3^E5M1L)X?#6I6T'[Z27
MS60*O/SL3C'?K3O['F:];4%FB6X<ME3&=I4H%QUSGY0<_A0 ZXU% \UIY-N;
M<)#L+/\ )(DC%<8 ]CCUJ674[.VA,-K)!NB*H$8E5 W!3@@'IG'UXXJL- =(
M_+BN%"+%;QKN3G]TQ;)Y[YI1HMTL,L O(S%OW0@P\J/,#D,<\],#I^- %Y]6
ML(Y'C>Y0,@)(^F <>N,CIZU9@GCN(A+$VY22,XQR#@]?>L0>'Y%>Y EM7BE=
MG4/; M\QRRLV>1U]#T]*N:9:7MC(ML\HEM%C8AFY8,6) R220 <<^@Y- $!\
M1VBS1%_W=LXF!D<%2&C95Z8Z<DY]JT!?V37HMA,AN#D!?7C)&?ISBLUM#G8N
M/M4>TK<(H\H\"4@\\]013]/T1[*_,_G0O'G> 8!O#%<'#YSCOC]: -FBBB@
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M>G0U8FT*TE0;IIW<QO&7>4DR*P .?7H,?2J\.EJ+L(_F!T=)4^;@%4* G\*
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MBR,8/^>:#KUZ;:"1/LY:XCAD7*G$>^14*GGK\W7V/%=!]DM@VX6\6<AL[!U
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M68"6(;5#?,CCC ILE]%:VSW<J>9;@$L0N6!SZ<<4 4[[$#6RRF+:RSE6D'W
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M/(N$E82 "9F/[LKS_ACI6T==TM693=KE6V'@_>^;CZ_*WY4L6MZ;,K-%=*X
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M-T3+D.<*>>Q(QFC^W[' )\[&UF/[HG:%)!)QTP0?TH RI/#\EQ" ]A!%NCN
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M[P]J3ZC+J0>YCD,<X"*A!\M3&AQ[\D\^N:JV>N75OI\0N+1IF$#3"0R<NBL
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M6UO/.TL[O:1#87R"[2%<Y_']*T%UN<3P13V/DM*2/GDX)!(P#C&< '!(.#0
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M#T$;*R7=V&R^YA( 75FW%3QTS^/)JS:Z3#:W*SI-,S+YO#$8_>,&;MZBK]%
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M+8QGZXXIIT?32RM]@M]RQ^4#Y8R%QC'TQ5TD $GH*J/<EG CSL()\Q1GGTH
ME2TMD@>!((Q%)G>FWAL\'/K5 6UM!.LEM91J8/D("8. , CCGO\ A5^W,A0F
M4YYX/J*D9%<@L 2IR* (GM+::9+B6WC,R@ ,R@L.<XS]:KS6=I;R27,=K$KS
M<2NJ %OJ>]778(A8YP/2F1R+,F"!D]LYH SX]+MYDFAG@@D@D?>X* [SZGCD
M\5:?2]/D #V5NP"! #&#\H.0/H#5E$5%VH,"G4 51IE@J[5LK<#&,",?WMW\
M^?K2OI]C)CS+2!L/Y@W1@_-Z_7WJS56\6<[6B8;5Y*XSD]10 X6%F+O[6+2
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M^[$#NKHXP1N4'!XS0!MP:C&R2FY1K3RI/+(G*C)V@\$$@CG^=2M>VB2>6]U
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M% &E%XJLI=,O+P0W*FS;;)"R@.>,C SC!'?/:M&UU.VN+:UE:1(6ND5XXY'
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M-D$+G!Z=<'%$VDP37_VQI9UDW*V%?"Y4$ XQZ,10!4TB^NKF6U$\JLLMJTC
M*!E@X&?R-6KZ744G*VEN)(]BD-N ^;> 1S_LY(^E.L]+ALWB:*29O*B,2AF!
M&"<^G6KU &-I]W?:C:+?Q311Q/,<1,G_ "S#D')_O8!-.;Q!;+!YIAGVM&LT
M>%&9$9@H8<^XX.#S5F'2H(&8123)"SF0PAODW$Y/;/7G&<5!_8-H(# 'FV!%
MC3YA^[0,&"CCID#\A0 P>((=Q5[2Z0J9%.X+]Y!N*_>ZX&1V]Z!XAA\HLUK<
MHP"L%<*,JP)#9S@#Y2.2#GCO2W.C1212O#)*TI>21=S#&]TV\\=,40Z'$]I
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MBBB@ HHHH **** "BBB@ HHHH **** "@9[T4@SN.: %HHHH **** "BBB@
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M<& '^UQZ<'O6[<-!!!+-(@*QJ7;"Y.!R?Y4Z)XY4290!O4$$CG!H R]&U07
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MMF5\V=HP$0D,2.%ZD_I4D)A$2"-E*D97GJ* .66;4KK<L,H$YMY'*[%S!(K
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M3/"5C,3B4+Y+*Q+9YSR".F<XP:L'7-/"@F23)?RPOE,6W;=V,8S]T@U'>:W
MD$+VC>:96AQA21M=@ 21TX)QGTH R8]*OK>#$=B_SQ0B1?,4Y99"3_%@_*1U
MXP,>U,BT*ZGLI8[JT;>MD8HM\BD>9EP.A]&%=+-J%M#=);2.1*^T#Y3C)SC)
M[9P:IZ;J=Q=3VB2I&%FMY)#MSP5=5_+YJ ,]8;NRO&U$6#+&D1S&SIQA!@*0
M>,D8P>.,U-XGG_T>P 0$RR$F.1E4$>6V<[B!D9!QGK5^YUJRMTF+.S&-7.%0
MG<4&6 /0D?X^E5DU>WFOVM;V,*I\HPAHR>6!/)Z Y''2@#.ATV26UDN8+*1R
M8H5AWR+E@,!^-V,\?0U6.G2M)]AFM':<VTPB_>K^[_>?(_!&,;NPXQTK?;Q#
MI:9'GDXP %1CG.<8P.<[3^5.U?4(;&TEN$0-<K;O(@\LDX SSCD#.* ,G^R+
MM9))#:R-([W =TE56=&7Y<'/&3^1YK0T8W-F8["XM<;M[B1=HP,C&Y5. 3D]
M..*MKJUIYBQO+M8G;D@[=VW<5STSCFDCUBRDD1$:3<YPH,;#/REAV[@$_A0!
MCS:1>?:9Y;6 PRR2S@3>8.%9,*>O3=SC\:#I-P98YUTY51)87%N77A@K!F'.
M/XA[G;6F?$&FC9F63YU1@?*8\/\ =SQWQBE?7]-2))7G*JY8?,A!&UMIR.HP
M>* ,6/1;OR&$]BSRAX_-;SP1<!9-V0/7&>N/2GMHMXL<L:6V4D1Q; ./]$8N
M2&Z^X^[G[N*U)?$%BD,[Q^;(T,<C[1&PW;#A@"1S@X_.K5OJ4%Q<&W3?YJC+
M H< X!QGUPPH QI-+OF>7]R3+NF+3!P/.1E(5.N>"1UX&VH)-(OWT]H7LMTX
M?>)=R$2?(0 X)Z#.WCT!%;AUFR#["[@[WCY0CYD&6'Y57L]=@>29+IQ&R-(5
M.Q@NQ>>2>^#DB@"27S-2TO4+,VX5@K0KD@JYV]?S/Z5E#2;LW?FOIYQL4Q;;
M@)Y.$VE#CU.>G'S>U:7]O6T\B0V>^21RRD[#A"%W<_F/UI-/\06D^FQ3W#^7
M*8XF==A&6<9&W/49S^5 %+3-)N;2^M9GLT98VD4,=@=%8)ACCC/RD<>WO3[S
M3[]]6$JVB2J+I94G+@%$V;2OJ.<GCUK2M=:L;R6..VD>0R*&4B-L8.<9../N
MG\J8^OZ?&9 \D@\OS,DQ-C*9+ '') !.* ,.VTF_B\N2XL4VQ3Q2[#(I'",K
M8_$@Y/)^M+IT%U:N9+BQ!2X\J(;)5RK;F!;CDX!SD\G'-:MQJT)>8NY%NB*<
M-"V[)<K^(/M]:J6^M06\J1@.(!'([.R%?+"-@Y!^OZ>] $>JV%Z=6MYH[9&C
MB,3>=O X5CN'/(X/;KSG.!6/#% ^DVEW]F1486\3X<?OF,R8_( CGIFNEE\0
M6<VG7$EJ?-F1'Q&%+<JH)R/3E?SJ:2%!:)=NA9$A\TH@')QG H S;?09%NED
M:TC$ 6<QPEAB)F:-D''3E">.A-,L=(U&-HS+:Q(%NHIL!UX CVMC'OC\/>MB
MVUFWF10\<J2[(W*%#_&<#![\YJ-/$6FLI8R2(NW<"\3*&&[;P2.>2!^- &(V
MA:A]@:WCLXMK?=#NN]28R.N"&P3C)&<5:GTK4)H9@\(+.8V7$@.TK'MY!X(S
MU'H:T?\ A(].*.ZM(52.20D)V0@-^(R*?_;MD;A;=1,SNVU=L9(/W><CM\XY
M^M %>1;J\L9[=D6VE@'E"92<$E.J_0G]*R8["Z5;>[BTVW26&3:\:2</F,H6
MSC@<CCVK0?7O] ;?!)<,+43%XUV!LMM  )R.E">(+&SGN8[IF5T#%MHS]U=Q
M&/7;0!DPZ9<_88U,4:D68MY'9E93B(J".X.X]N,9[U=M-.NYYD=X(U+30S!U
M<'R B@-'[@X/3CYC^-VVN$O9YI(!-\AV/$Z%<="#@CI@TRTU;[+JLME,K&-F
MC\M@A^4N"<,>G4<4 9I\+W'V<J+:V\S[,54\#]X),J?P'0]JL3:#=R?:M]M"
M\CERDS3ME@S!MI7H", 9]A6J/$%DPR%G)W(H C))W@E>!ZX-1WNN)_9IGL5=
MI"JOAD^X"VWYN>.A_*@"Q>V)-O9Q64,<:07"2%!\H"C.<?G66-'O(X[0)%$'
MMY9&W9!7:TNXC:1Z8/'((K2.N6BS")UE5B\D>&4#YD7<>_IR*HR:_P"9,?(,
MT86:.)A) 2 2P&,\<D$?2@"A%I5Y)+;[(H!Y4Q;<&#*4,H8[E(X. ,8Y!%7Y
M;2\OM)B=85C=95D-N[$@A7Z9QG! !Z5);:_ 7WR6LD,;)/))(<?*(F"Y/-2M
MXCL@N5CN7.YEVI'N/RJ&/3V- &1)IMR@DB00H\\5TFPL1Y7FD%<<<].<=S4[
MZ)>*_F6\-L8PZ/Y'F%%?]UL;D#@Y_.MN?R;FQ%TC*JF/>LA'12,Y_*LBTULS
M-:+ P >X"S97JK1LP(.?]F@"YH^D?8I[F2:"!2P18FC))51&JE<GGJO\JSKO
M1=3DB,<*6H >8J3(02&D#C/R^V"/I]*U+?Q!97.! LSLVWRP%_U@()&WG'12
M><5&/$$>^3?:7(C7R@AV?,QDZ KG(H SKK2+BWM[FY,,.=MV7,1.]A)RN,#.
M1TINCVUQ<E7$4#.ES'-),&.U@$*X7Y!R !^?6M@Z[;!0S0W"JVX E!RZC+)U
MZC!_$&HSK27$2F!;B B:$'S(@<JYX/7@'IGMZ4 41H%VL($<=M')''Y8*L1Y
MN9 V6X]![\DU;T_2;FVU62>986C\R1XY?,<OASDKMZ#ZCK@<5?L]1CO)BD44
MP3:661E^1P#@X.?4=Z9?:K!9/(LB2OY48EE* 'RT)QD\^QZ>AH S)M$NY&>,
M^2R+---'(S'<WF*PVD8X W>_ %79=-?_ (1\6%O'!'+L4$9PFX8R<X]O2IK7
M5([JXN(HX)PL!(:0J-I(P< YYX(JDOB..1;66.W?[/,S;I&9?E54+$\'_.#0
M!"^A7+O*<6R>:]P2P8YQ(N!VYYZ_2F2:/JDUU%/(;0;6#E0[8_U3(1TYZ]3^
ME77\01(OS6ESYA\HK& N660X4]<=>/:A?$-L6;=;W"A0VX[,X88RIYX.3CZ@
MT 8U[IM[IMO;O$L*LBVZ*T:NP5HPV6(53P<XZ&K,&D7-UIR(D44""S:V4,S$
MD[P02"H."%] >>E:-IJ;HNK3WV](K.7(4@95/+5CTZ]31+KJQ3" V=P;@NJ>
M6-N?F5F4YSC'RD?A0!7;1+F6<S-Y,7FRNTBQL?E!B\L8XY/?M4^E:9<6EE,D
MZ6BSO&(]T((#X& 6)_EVJR-4B:QM;F..1C=$+'&< Y()P>PP ?RJ!=<C."UM
M.B!HTE+  QL^-H(S[C/U% %%- N51 /LP98;:/(SUB<L3T[YIL.@7ZR;I);9
MAF'(&[_EFY;@=!G/0<"K+>)55&<Z?=!51I"3L^ZK;6/7M3Y/$ C:3=8SA%:5
M%<E<,Z DCKW"DB@")-%O%5%#P?+'<IW_ .6K[AV[4B:%<"Z61C:.ICC#>9&6
M971<#;['].:GEUJ4WD,$%KNW2HKLS 85D+9'Y4Q?$7F0I)!I]S(LVWR2  )
MP..3@=OU% $-OH5Y (MD\($<C$(V7"*T84@$\GD< ]!Q3;30M0MWCD,]NSI+
M')T8@X0H>I]#D?E5[6=1FM[.9+:-_M(M7GX(_=@#KSP3G^1JL-:-HD\DXDD
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M?ER,Q'K_ !$@?6JNHZS=7&GZG$RPI''#/&663#AT4\@9SV)Z<#'6@#0N=/\
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M.TLN<9Z_A3HK:"!Y'AB1&E;=(57!8],GUKFV74XK?"S7SRM:I) 6!.9LG<K
M#@?=X/8FFF34GFN6L9[J2:.>X38P_=A0AVXXQG?MQ^- &\-'TP2-)_9]J68Y
M),2G)SGT]>::NFQ"\CFA94@0E_(2-0K2'.7)ZD\FL:S2\N+RU5I]36W?>S%H
MV3! 3"DG)QD-U]3CBH[&&\B@T^&)[E/-5K:9)'8%"#N\P9]@PSZD4 =-<VMO
M=*JW,*2A3N7<,X/K566'25OHHYH+;[2P54#1@G"Y*CIQC!(^AQTJMK;70G18
M_M(A-O)M: $D2\;<X_'KQZTFEQR?VO</=13B8V\(9CN\LMAMVWMQG]?K0!9:
MTT9[J"!K:S,R;Y8D\M<CD;F''J1GWJ[#!#;H4@BCB4L6*HH )/)/'>N0-M="
M-1$E_'-"E[^\57)+%U* $YX./QQ6G8OJ$FM[KG[4BALJOED1&,H.IS@$-VQG
M/M0!:GM- M'43P6$3(-PW(H*@'.?89IUWHMA=V0BMX+>$$*%98%(*AMVW&.5
MSVJO;AK/5M4%Y;S2K=NKQ.D9<,NP+LXZ8(/7UJJPU!9RL:74921U*J&*"#RS
MMQCC.<=.<^U &K8Z+9VD.PP02-\W/DJ  P (4 < XZ5833[&-4"6< $;;TQ&
M/E;&,CT..]<W"FI+LD\W4F*QVCE75L%BQ$HQC^[C(ID,MZ]KY]O)J,RE7$@(
M;_GJ NWC^[NSMYQ[XH ZFULK2S\S[);0P>8=S^6@7<??%,>QL%B(:TMPFTJ0
M8EQM)R1TZ$\US&=6:U+?\3%9(H9"H"L-S"7Y>N<_*>F>16K:V\[:K=P/++):
MH3*I,A/+KC81GH,,<>XH =_9\-Q?RL;"V"SQD/*(QEEXX)QR/8^E/.C6UM&H
MM;6&,1G>/+0+\V-I. .N#UK"O9[Z'4+I(/MOE[)4# -MSY8V8/0?-GWSGGH*
MLB6[@<^;]ODM#-&SGYMY4Q=L<XWXR!TH T-*BTG[/YD%C:HC;65DA W $D'I
MV/Y5>FTO3[FW>*2T@9)%93^['1CDXX[GGZUC^'B&M[.QD@EAF@@#D2(1E22,
M9]1@53N9;ZVAG607\:PQ3KYF6P3YP\O![G:?Z4 =5<65I=*HNK:&8("%\Q V
M,]>M+#:6T#EX+>*-FZE$ )YSV]ZYQH[Y7D&[4&L2)?*(W^8K[4VY[XSYG7C]
M*D@CU*/4EEF-VV+I P!)388!N..F-^?I0!T)B@9VS'&6.UFRHR<="?ICBJ5Y
MI=K).]R+:'>Z%93L ,B^A..?QK$U;[;%JMY-!%<_O8X.8R?F57;>%Y^]M(]^
MM,$%]-'>>6VI'98DP!W*LTA,G! Z'!7&?;N* .BT]H7!D$,:3[0KE4VD@#@>
MN!3+>QTFXMQ-!8VI23G/D 9Y/M]:PX[6]M;]98_MQC%S%C<Q(V,GSG'IGMV[
M8J*.+4IK574WHEBML@*YYD$I.#ZG;CZB@#6>.W10+N".2!?]6&0,J#&,X/0X
M_2G:?96$US<.;6%IHI-KN8N22O3)'/RD5BW=MJ-Q+?Q&VO&A=7(!)P2)01@Y
M[KTP!QQS5[R[T74C>1<K9F[5F0$[O+\E0,8.<!\Y H WQ:6PX%O".%'W!VZ?
MEVJO8Z5:6=H+=88W&,,S(,N,DC/'/6N?2#5O*621;UI$2W9,2'G]Z=P(SR=A
M&?6M#7DO6F<P+.5-LP@,1QLFSD$_IUXX/K0!<N7TI+F2.6WB>:0 /B#=NQR
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M0O,Q<%G01A2,@\G=@G'7!ZU<TS3[MK^)K[[3Y21,8\RG _>-M#8/)"D=?Z4
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M<NK*?7L>IX[8JP=)NHII!%8QR6IFD*P,X  9% 8=N"&X_P!J@#:M]0@N%A9
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M-78-%L;=P\:2%@YDRTK'YBNTGD]Q4O\ 9MK]@CL0C""+;L <Y7:<C!SG@@4
M9W_"0-N,2V$[W";O,B7DC:P'!'!ZY[5;U'5#93PQ" R&5&?.\+M *@]?][/X
M42:)I\C1,\+%XRQ#;V!;<<MN.>03U!J&]A;^T(KQHQ^Y5DY)X4XSQT/0'\*
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M6CS$_O#\Z '450OM8L[!;AKIG5+>(2N^PD8)( ![G(Z?2GV6HPW@D*)+'Y1
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MVNJQ37D=M.LK'**TGE[5&Y-PR<\4XZW'#>;BK)9&W5XSM'[QF?:,<]\]\=:
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M)]3P/RJ[10!3N=-@N+@SN7R54,F[Y7VDE<CV)_QINEVDENLT]RL(NKE]\OE
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M@/E,63,8.TGJ1[U(EK;QB4)#&HF):3"CYR>I/K4U% %9=/LE:)EM85,0Q'A
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M'BN?-\F]D4-<G:UBV&$V#SSVQ5>ZLC+ L(&H-Y<-Q -]L[E%DX R3GY0 .:
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M%NP62YABC8 ['<#=SQU-78;FWF.V":.0@9PC \=.WT/Y4 2T4R*6.92T4BN
MQ4E3G!'!%)/*L,32-C ]3B@"2FR+OC9/[PQ6<\TV3,AD=64@QJ!E??/^>M6+
M&(JTCEV.X]#VH K(3!(@;8)!G&#P1GI5^.XCD)7.&7[P/&*2XMHYUPXY'0U4
M>TD+KA22N-K!AQCUXH L7%Q&8F$<B,W?!SBH=-B*EI4;]TWW1FE2Q+,6<E"1
MCY2.GY5=4*@"K@ #@4 +13$ECD=T1PS1D!P/X3C/\J?0 444@(89!!% "T44
M4 %%%% !14<,\4ZLT+APK%21V(."*DH **** "BDR 0,\FEH **** "BBB@
MHHS2*RNH92"I&01WH 6BJBZG9-(L8G&]I#$!@_? SM^N*>M[;M*(PY+;F7[I
MP"O7G&* +%%117,,LTD4;AGC"E@.V>E)<W4-K$TD[A549/<XSCI^- $U%%%
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M^''FMO!X]&S^M;%U>PVT,SLP9HD9R@(W$ 9Z4Z.ZMY(O-65-O<[AP?0^] &
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M2XRAF@DD>4.9X]S8!<Q[.>.A!J]+;12Y)1<L,'CK502FRFVRN C9*Y'&/Z4
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MH>U2T4 5O[/LMFS[)!MP5QY8Q@\D?C4=KIL%NT[%$=IG+$[ , @#;].*NT4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %-7O]:=2+W^M "T444 %%%% !1110 4444 %%%%
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M.O'2KYT_3!.C^1&)%"[<<?=Z<>HJO=V%I=W+7"+%/+%MW*.H(.X9Y]\_C[T
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M&2H>(C<G&<9'(Y%36SVTHD>V,;8<HY4?Q+P0?I0!@P:U>"*)KAX&\](V#*A
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M&8E:,D#T^\H&3_>K6CU:PG,7E,TGFRM$A$;$,RYW<X]CS[4MQJEG!YXF$F(
M3)^Z)   )/3I@B@#%.I3QRK=RJ@F%KM=@.B>=M\S'ICYJT_#SH\5Z4G$P-TQ
M$@ &X$+SQQ^-6GU"UCLY[J4M'% #YA=2,< _R(JVI5E#+@@C((H 6BBB@ HH
MHH **** "BBB@ HHHH **** "D7O]:6D&><^M "T444 %%%% !1110 4444
M%%%% !1110 5@Z\9%U&%H@\CBTG*1D HS H0#QU/]*WJ8TD:DAW4$#)R>@H
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MBBB@ H'THHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9(F>_7)#>N$&<=J -B7Q5I<?VK,CL+4$R;5SP&VG'T/%:EE=)>6XGC21%)(
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MW _&G:?J0O[,W2VT\4>W<N\#+C&>,$_2B32K>2Z><M(#(ZR.@;Y6=1A6QZC
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MJ6I26M[%:F+$4P \XD@!B<8X'!],XSVK4JI=6MDTGVFZ1,J -S-@=>/;J>*
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M110 4444 %%%% !1110 4@.<TM% !1110 4444 %%%% !1110 4444 %%%%
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MR>F* .66QNVT>.W-G=@)8JK(3UD5QT&>O!JS-!?RW#0"UN_*>:0Y+_*$: @
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M*Z1@J2(KC<<$ C(S^=5KK5H;5[A7CE;R$1V*@<AR0,<^QS6'!HE[;Q0I%9Q
M"&W64>8!EU#!F[@GE>H/3Z5(FEZB-->!K9?,-G!"/WH.61CGGZ&@#?FO8X+R
M"VD# S*S*W&T;<9S^=3[TW!=R[CR!GFLO6+!KRXM)#:1W4<0D#1N1U8#!Y^E
M4;#1;NVU"#[1&EPD0C9;@S,"A6/81M[]SU[T ;=[>Q68B\P%C+*D8"XR"QP#
M],FIO.B"L3(F%X8[AQ]:P]0TV]EU)GC@AEC:XAF65GPT80C*@8/H3^)JA'H-
M]':Q_P"C0F>%D$G^DO\ Z4J[AG/\/WL]^: .K\V+(!D3)Z?,*/.BPI\Q,/\
M=.X<_2N8_P"$>DW<6-MM#6^T&0MM5&)89(STX]Z#H-V9%#VT$L&9%$?GL@B!
ME+JPV]>,<>PH Z$WL7]H)9 $NT;29!&!@@$'OGYA5&]L])U:1I+B9B;=C$Q2
MX:,*>N#@C-0Z9I][;ZA"\]O %BCE1IE?+2;F5@2,>Q[TU],NQ?O*+:WDA%P\
MFPOCS Z8R1C@@_S- $=YH.C6B1N\5VRR2+'E;N3C<< GYNE3CP]HH"<RG?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***AGNK:V*"XGBB,AVIO8#<?09H FHHHH **** "BBB@ HHHH ****
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MK@,JH8PSHK(<NBX)(]>M &O138G\R%'QC<H-.H **** "BBB@ HHHH ****
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MM!AD:5GFDS+*)7VX&2'#*?P  _"K$6E1Q7(N5FD\T!P6PHR&()R ,?PBK]%
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M5:=% &=+H]O)/),VXL[E\$\!L ?TJ"TT38SS74I:=F.&1B,*552/_'0:V**
M*IL@UI#;&60+$ ,AL%@!C!IHTV$65O:AGVV^S80V#\N,<_A5RB@"C;Z7!;SI
M-&S[E1ER3DG<P8D^Y(IMSI:R^9(LLAF:-XU+L2%#8S@?@*T** &QKLC5/[H
MIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4B=#]32TB=/Q- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !34Z'ZFG4B=#]30 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4B=/Q
M-+2*,#GUH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex10_7page004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_7page004.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH * <T4B]_K0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4B]_K2TU.A^IH =1110 4444 %%%53J5B+S
M[(;N$7&=OEEQNSC.,>O(H M4449'K0 454AU2PG#&&\AD"L%.UP<$G _,U;S
M0 45#=7=O9HKW4R1*QV@NV,GT_2G03Q7,*RP2+)&W1E.0: )***8DL;R/&C@
MM&0& /(R,\T /HHIDLL<,32RN$11DL3@"@!]%58]1L9;DVT=W"TX)!C#C=D=
M>*EN+B"UB,MS,D48.-SL * ):*B^T0;HU\U,R@F,;A\PQGCUJ ZKIRP&=KZW
M$0;87\P8#=<9]: +E%4SJNGB<0&\A\TD +O&3G&/SR*'U73HT=WOK95C;8Q,
M@PK>A]^#^5 %RBJT6H64TD<<5W"[R+O15<$L/4?D:>]W;1W"V[W$2S,,K&6
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M %%%% !1110 4444 %%%% !1110 4U.A^IIU-3H?J: '4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !34Z'Z
MFG4B=#]30 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4U.A^IIU-3H?J: '4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3$93GY@>?6GT
MU!QT[F@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4456U&S@O[&2VNMWD.!O"L5R <XR/I0!9S17-:2VF:/H@BF)MX[L2
MW(CRQ(C^O7A=M.\'((DU*.(QR6QNB\,L1.Q@P!PHYQCI0!T=&1ZT5QVOEX];
MFN(V@ND_=12VDIVRKSPT1_X%R.^* .QHKCFU?7+N?5(K.2WBEMFD6.!E)?Y<
M%3C'1AGGW&*=>:YJ:6FG3PND":@697N%PL8"9520/XCS^E '7T9%<D-6U0S:
MS*;N%(-/ 95,)8MF//;!P&]L\5G2:G<ZB]A)<3+$UMJC()2HRJ>42">W?Z=*
M .]+ =2!2Y!Z&O.=4O[J]L9)+V)%FET=F/RX.[S!C'UX.*M+=W*WS)%<>1"=
M71'=%'S)Y0(S^(Q^% '>45S=AJ=]#<7XU>;;!I[MYDHCXD1MIC(P,\#.?PKI
M 00".AH :9$ )+J O4YZ4JL&4,I!!Y!'>N3NC!NU 13I$6U6%7V;>1B/KD>N
M?UK;U25=,TD&!A BO&@( PH+ ?0=>O:@#2HKD4UJ]>%93>PKY<4;2+M'S'S2
MAY[9 K8TZ>]DU*>VN&8K;,Q+[0!(K8*8^@R#[B@#6HK"UV\NK>[6."]2WW6T
MDJJR [W4K@<^N[&*JQZCJ#2RRRW8C@%TL#J$'[D%5.<_4[>?6@#IZ175P2C!
M@#C@YYKG8;W4W:V#R,4NM\2.L8P&5^'Z?Q("?3CWJ ZA-;KB&=%7[7,'6-5#
M-^\ ! QANO(X)SF@#J597&48,,XR#FEKE%U*XAAD2*580/M+QL(QB619#A>G
M<<\<G-6;34;QM7B26Y4QO<O"8M@^7$8;KUR&XH Z*F/+'&RJ\B*SG"@L 6/M
M6;J]W+;W-O'YWV:"19"T^!PP *KSQSR?PJGIC/>:RLE\3YOV&&0PD#"ON8G'
M&0>A_&@#?=TC4O(ZHHZEC@"@NBLJLRAF^Z">3]*YGQ*Q%Q>QO.^UK#*1D94M
MO.3T^GZ4HOIEU!4FN4E\B>9%E,8SCR0W;T)(XZXH Z>C(SC(R>U97A^ZFNK.
M1KB0R2))M+@@J?E'W2,9'/H.N.U9M_=2KJ4>LHP^RVTPMB YY0\.=N.N[!^B
M^] '3T5RMSK,YU2\@2_$8B$FU<+@@1@KMR,DYSFE%_J*7-K$]\?WT,<T;&'(
ME)8[DX'88].N>: .IHKDH=4U":%6:],<K2Q1RQ>3S"Q?##)'I]>F<TG]IZE#
M 76ZDG=HIN/*&4"2A0P ')*DGWQP* .NHKDIM0O_ "7D@U*22-()9HV6#'F8
M9=HY'/4CMFM?0W+3:@KRRNXN2V''"@@8P<4 :F]/,\O<-^,[<\X]:=7.^?<0
M_:9,LK/J'ESR 9,<>/EQ[8V_]]$TNFSW]SJ44<UW*L:([X\L 2J)"%)..,K@
MT =#16-XEN[BUMH_LKR([[\%%SDA"1G@]^V.:I07M]->1N;F<1R7"1^7Y8 "
MM#DGIGAJ .FHK)T1[R3S?MDCL8&,&3C$A#'Y^/4$?K5/4KF\76KB&VO)5:-+
M=XH H*MN=@V>,XP/7B@#HJ9+-% F^:147(7+' R3@#\37+3W^I_9F:.682^2
MYG3R^8G#@+MXZ$;O7(&:DG2>UO+M&N;N5R+9E=DW!AO^;HN/R^M '445REQ=
MZF+:X>.6Y$PAG\U/+^XX/[O;QW_'(K8T:28O>Q332S"*8"-Y%P2I53V SSF@
M"^\\4<B1O(BO(2$4GEB!GC\*DKE7A=M4DB:2\0_V@S>8 3M4PGH2" .U,M[S
M4Y9;87$]U&?(B8!;8D2'!#[CT4Y]?08H ZVBN2\W4DMK$/=WX^T6X;S!#O99
MOE^4@8P.#UXY-6%DOY&=9FN0<3BX3:< 9^0J1[8Z=<F@#?MKRVNM_P!FGCEV
M'#;&!QWIQFB%PL!=1*REU3/) (!/ZC\ZP]+1HKC1T0.&%BPG#9R/N8SGWSC\
M:GUB2=+P>2\T:FTE&](RX5MR8/'?&[]: -DG R:C@GBN84F@</&XRK#H1531
M9)GTM&N%=7#.#O8L2-QP02,XQTSVKG(/[3M=/1+87F#;HSJ8V^3$F&"CCG;G
MC.30!UWGQ?:?LWF+YVS?LSSMSC/YT17$4S2+$X8Q-L<#^$XSC]17,L-03,L(
MNY9!9N%D>,JV#(#CGOMS@'G@9K2\/C]YJ+JERL<EP&0SJP8C8H_BYZ@T :D%
MQ%<!S"X<(Y1L=F'45)7,QVUS_:,J)+>1&2[E,@!*QB(J?F!Z9SC!ZUHZ!]J>
MU9[QV9T/D [R0^PE2_U8Y/Y4 :M%<OJ4NHC4[H0+?! '5=BL5.8LJ1CC[P],
MYSSR!6AH7VA);F.=[ITVQLAG!ZE?F )'KV[4 ;%%%% !1110 4444 %%%% !
M1110 4444 %-3H?J:=2)T/U- "T444 %%%% !1110 4444 %%%% !1110 44
M5S5_97TNKR2QVDACW$!U=<,IB([G/WL<<#OSV -X741O3: GS5C$AXXP3CK^
M%$=W%(Y0[D;S&C =2"Q')(]1[US3Z%(L,2QVCB1[,(KB3_53?WB<]NN1GH?6
MII=,NC*TGV,R'SIPN67(5U&&Z],B@#IJ9'+'*"8W5@"5)![C@BN6FTB[BBLT
MM;)\QQQ.S"09$@92P.3QD#J.O\W?V3<IYT?V#,)^T*BJRC#N^Y']N.,]10!U
M5&:QM'TU[>^N[BZC)F9E"2[L[AY:!CC/&64FL^[TB_E@G18B9OWX:0.!YP?[
M@ZYXXZ]-O% '4T9'K65>V,B:(+>PA&0RN82V-XWAG7/OR/QK-DTJ[8.([3RA
M(@\@"0'[*^\L3^.1T_NXH Z?-,$L;2/$&!=0"R^@.<?R-<M?:5?R1SP169*^
M7=*CB11N,C!DQSQBM33M.6RUFXDALUC@EA3#@C(8%B1Z]Q[<4 :Q"8Y X'Y5
M7L+R*\B+P1R)'@%2R8# C((]161'IERMWOD@W%'G:1]P(N$;.U>O;(Z]-M3)
M874?A."RAA5+B..,-%D /M(++D<?, 1GWH V\CUK)N]"@N[I[A[R_1G.=L=T
MR*.,< 'BLV;2KJ2*18['RUEA98$$@)M9"Q.[.>.H^[TVTY]%:2\,LMDS[KF1
MG)9<,A3 XST+8.* +7_",VV?^0CJO_@?)_C3)/#UA"JF34]44%@HSJ$O4\ =
M:S;33I)KQX6@9;V!;7,V\?NBH^;OGD#MUSS3X]$O%4-+8++-%,A9FF!$^'SN
M /3@D\\]J -+_A&;7_H(:M_X'R_XTP^'K$3+$=2U02."RK_:$N2!C)Z^XJB=
M&O6682V9>4R#,HG&)5\T-TXP< ]?PJYI^ES6VJ03?8D6*-[A5.5_=HS!E(]L
M C'O0 J>'[5YY8OMFLKY>/F:^E"MGT.>:<_ART2-G^WZNVT$X%_*2?IS4=U"
M;S4+Z6S1)_+-LP 8<LCN6&>QQ45GHTIGDDO+!>$F,8#@@,TCL /^ M0!=TS1
M+2WDCNXI]0+.NXQW%T[ Y&/F4GKBKW]HQF[:V6*5F1U1F"Y RI;.?3CKZU@M
MI&HLL1AB\J86HB9G92 1&0""/F!R<>A'/6I(--N_MJS+IJVJ&YCDVHZG:!&R
MD_F10!T4DT46WS'5=[;5SW/I203">+>8WC^8KMD&#P2/Z9%<W%I-X(;9I=-@
M\ZWECWGS<^=MW OST^]GU/X"E?2;QH)(_LN5DCG2)=X'D.TC,KYSZ$<CD;:
M.G^7IQ52RBM;1I;>&5GD!\R3S)"[?-G&2?I@>PK)M-*G@U6.Z-MAOM,C/+N&
M2A3 []VYQ3]1TVYDU.::"UC>-_)=CN ,FQCE/RP>>.!0!HWJPVS/JDGF,;>%
MAM3GY>">/7@?E5M)$>-7!&& /-9<&GS+H5Y:;0C3B;RXR>(PV<+^&>U9<NB7
M(C$MO9*L>]"]GY@7?A64MD9&?F!]]M '33S>2J'RW?<X3Y!G&3U/M3RR#DE?
MSK+GL91I=A;QPAF@EB8C?G:%(SR>O'%9EMX>=D:&:V2))H)4D=2"=QDW(??
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MV45X;5W<2*X1CY3;0Q&0"V,<]JOUC#3I[C5;UIB8[9I8I%&T'>5 [YX&1Z4
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MAVE@NXKGUQ3=/TUK.Y>>2\EN':%(?G51@*6(Z#K\QICZ/&T[OY[B-I3.(\#
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MN* ,+0S&+O3@A4_N+D#!["5<4XW-Q9ZQ>FW>$J]Y&K0%?G?,:Y(.>W7IV-=
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M0'!_7BHI-4L8C*)+J-?*!+Y/0 X/Y'B@#*BM[V+PGY-O%<1SJY.S(\PIYI)
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MWDVD$!B=W&1POH<Y&*G.KJVE0WT4)/G$*$<[=IYX/7N,< T 5#HMV+>>W%S
M8R7:$F+Y@6;<0QSTSZ8[>E1OX>ED:Y#S6VV8NZR"']XKL.1DG[N>W7'%6K37
M5NKFTB6 HMS$LBEVP>03@<<XQSSGGI2?VK<K?36[01L3<^1  Y&?W>\ECCC@
M'U_K0!);:=<[+\7LT3&] !,*E=OR!>Y/I59M$N7$;23P&1/(4D(0&6-MW3/4
M_I5S^UD.CC4%B8#=L*,<;6W[#D^@.>?2J8U:>259DMI#MAG(B60;9"C*.#CO
MS@^] %[4;&2ZDM6A=$$!<D,"<Y0KV^M41HDZQH/.A&T6P.(S_P LCGU[U*^O
M*8XVM[<S><0(MI)W'9O/0'MQ]?2I;O5F@M[5DM)&GN5)6$YR,+N(. >>U &5
M8Z/=W.EVKEDMYHH=B*T9!^^K'=T/\(Z>I-3MX?N6MWA-S!@PSQ#$9P!(X;U[
M8Q4-]>ZC+-=2PYA6%8=B>;@_/D'<-IYY_#%6(=9:VC=&@FFCCD:(3,W_ "T#
MA=I.!QDXSSP,F@"6?0WEU%YQ)!Y4H7>K0Y=&48RC9XSGT-2Z7IMU:71EN;B&
M0+;I H2,J<*3@GD^M$.H7DFK16DEM'$ACD9_WFXY5E (XZ$'/.#S4<6K7)NI
MK<P1-(;AXH0)"!M5 Q)./?\ 6@"%]!NI(7B:ZAP898D_='@.P8$\]L4DOA^9
MTNHQ-;;9F=D<P9D7>V6!;/(SG'3MZ5;DU226TTZXM(AMNY51A(<%002>G?BJ
M-CKDL%B@NX6=F'[MR^3(3+L&>..67UXH M2:([ZE+<*]OY<V&8-#N=&"[?E;
M/ Q[?SJK<:5-#8>6ZF>=H8[:%H$QY93)61LGL<'V]ZNW=]*=$EN7AEMY$;!4
M. W# 9!QT/TZ56O->N88;LK:*IB2<QN9,AFC&>1CH1_GO0!I6\4\%W'"@4VJ
M08+$?,7SZYYXSGBLJY\/74\]Q)]LA'FK*@S$<A78,/XL<8QP!Z]:M'6)_M+0
MI9&01$+*ZOPK%-W<=.@]>>E5TUR[N!;K':)$\C0L=TF?DD!/8=?E- #YM$NV
MFFF@NX4>4RJ0T1*['"@_Q#D;!S[GBK,EE+"NFR+^]:S^1PHQN4KM) _(TW4]
M6FLKHQ1VGG*D0E9O, ."VTX&.M03>('@@=Y+0;XGD615DS]S'3C)X/< >IH
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M'XTR31]/FA$4MLKJ'\P%B2V[&,YSGIQ].* (-1U::U-NL%JDCS0O+AI=NT*
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M=9L&?8)6S\F,QL 0QPI!QR"1UZ5%)K5M'.6:91;)#([G8^X%'"MQCH#G/^%
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M(7&&!8D'CV(J-?$>F%8R977?@@-&0<$X!P>Q)ZT7&MVYAF%L[+(D9=7:(LI
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M]]<SP) PD2 )N;!RCLQ[''WN#S5:RT;4+?8LD=I(AP&WNS;-LC.K+QSG/3U
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MB@"Y1110 4444 %%%% !1110 4444 %%%% !2+T_&EI%Z?C0 M%%% !1110
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MY(_&HK/21:WB7(FW$+(&&W&XN^XGVY%9QU2ZOH;25H&MXWGMWC991^\5FY!
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MZO;_ 'W2R_-&T<8(^56C1N/;)- &U1110 4444 %%%% !1110 4444 %%%%
M!2+T_&EIJ=/Q- #J*** "BBB@ HHHH **** "BBB@ HHHH *IRZ793+<K+#O
M%T0906/S$=/IT'2KE<]>7M\+Z\BB:<3Q$F"$1925/+R#G'][/?L!WH TAHNG
MJ\#BW^: 84EFR><\\_-SSSFA-&T^,,(X-H9Q)@.V P.1CGCGG XK'-S?221I
M!=W/V>26(>;Y8W#<K;UY';"_0G'M5<7>IK;K_IETS211MN,(RI$H4X&WNN2?
MSH VK/1(4MIH[P"9I6EW<M@+(Q8@ GCKCCTJ[)96\EO% Z$QQ,K(-QX*].<U
MSAFU-4F5+J[E?_28TW1@?=&4;A>OZ&I!>7=U<A8[B\BA:XC7<(2/E,1)^\O3
M<!S0!KMINEO>SEH8FGGC_>H3]Y3\N2O3G&,U7@\/VL;W"RHLD+RK)&N6RA";
M>3G)R,_G68+W4!#%+^_9_LD?FE8?F_UN'(X^]MR<?I2W-[=Q/#Y$M](@=2I:
M!AN4R@'@#G"GOCL>IH U_P"RM(CN($\B)91'Y<:[CDJHQTSSC/X5+_8]AE28
M Q4DY9BV<@ YR>> .OH*P(9;V&!4M1<O<(;S D0G+[B4Y(^G?!J=I;R2XCCA
MN;U;5Y5 <QG?S&Y8<C@9"_B<4 :4FCZ1;V866".."([]Q8C;VZYSC'&*230[
M>6)HB=L8C6&)5R/+0$' YZY Y]A4$L]S+X.$S^;]I-N"?W?S%L?W<?TI]A-<
MMKMQ'(TSPE6*D@A5P5&T@C&>N"#R,T 7KV&SE,$=WMW%_P!U\Q5MV#T(YZ9J
M*6PTR-XUDCC0R%$1=VW<4Y4 9[8S6/J4MW)J2A4N3<0W1,2B-C'L\IMISC'W
MCZTVUEN+C[#)*]U*/M2$B2V9#&?+<-UYQG'/3GB@#>DMK'5$BG=4G1=WEL&X
MP>#TIDNC:=-&4DM593M[G(V_=P<\8K)A_M#[/8O"\Y6=7MY 5*^6=Q(DQ@8X
M!_,5#<7&I8OML]ZDT;NH1+9BNW>-C!L$'Y?3GDYZ4 =))9VTMF;.2%&MRNWR
M\<8JA_8^BR.]K]GB9P-SIN).&XR>>^T?E6?*^H0ZF;=+F[?8%: F$LLPP=P9
MAA1R>_8#%3:"[RZG+*ZW>YK2(.9XV7YP6W 9 '?MQ0!H2:)IDH<26D9WN)#U
M^\!C/MQ5F:T@GA2*2,;$(*@$C&!CM[5@3SZD7FV-=+,LDRNJH2HCVDH5XP3]
MWISDFKVA/=!YX[F2XD&R-U:9".2OS <#OV[4 6_[(T[STF^R1"2/&T@=,# _
M3BJUO;Z%',MO;_95EBDR$5^5?!&,9]">/>JNA7=Y+J<Z7 NO+:(,OFQL &#L
M#R1CIMX'%4-1AGENK[R(KAO^)C!*D7V=@LFT1Y._' R#SGM0!TW]GVAL?L/D
M+]FQCR^<8J%K'3/M0C:*/SI"TP4DY/&UFQ]#C\:QKJXOUN9(%:^0B6?YUA9U
M"%,H1Q@X/3'TJ.2;4/LLC*MZLHM+G9M1W^<,-A!(SSS@'G% &[#HVG0.&BM(
MU8$,",]0"N?R)%3K96RV/V(0K]FV%/+[;3VKG;B748RT(EO_ +/YQ!E$#NZY
MC4K@  D;MW3@' /%++)J?GS+YEW\T8 ?RGPC90$$#@@\\J<C+>E &Z;;3[%F
MO'2.':.9&/"\ =^G %1"VTB_N_M*I;3SH5)92"01T)JI.T\_@Z<203^>]NZ^
M60SN3R!VR?RJKJ?GS7B7=C!=*;:TE6218RK.2!M501DD$$]#0!LQ:/IL((BL
MX4!D$GRKCYAT/ZTKP6%K#'&\<4<;3!D!''F$YR/?/-8*2ZCY$<L<EP7%R\'E
MRADW(_W6PW)VG'X9K5UR!SI4,2&9MD\!+("S[0ZY/KT!YH LR:3I\LTLTEG"
MTDR[9&*\L/?\J<UA92W27+VT33QC:KE<D#TKG)Y-2M[9L&_DWQR" A6+<2 K
MNQT.TGKU%:^BJ8H[Z-DN%87,C9DW<@G(VD]1C'2@!9]'TF"$R"WBMU5T=F10
M,[6RH_.K3PV.JV\<DD<5S%G<A89&>E<S$;VZLI$N4U @R6LBADD##YAOY_ D
M]O0=*4K=P1^0G]I10FXN [Q([L&+9C([D8)YZ9ZT =(NEV";=EI$-K*PPO0J
M,*?P'%1-9Z0D]K"UO;^8I;R!M!(QR<?SJ+1H[@S7<MS+=$^:55)>%"\'('US
MS6.;6;>L02_0QW%TQD4.3@ABN&_$=/IZT =%_9.GE"GV.+:>VWV(_D2/Q-33
MVMO/"L,\*/$I!"L,@$=*P+1M2DU6%K@WJ<1LH5#Y;*4^8-V!#9/(STQ5N^:Y
M_MM4*WGE;8S"8,[-P8[P_;!&WKVZ<T 6K>RTJZMA)!;020LK1@[<@J6^8?3(
MJU#:V\%J+:&"-( ,"-5 7'TKF(UU!;'9''>1GRI#;A%9<2^:Q&X>A!7KQC-.
MG;54ENC$+R1"RLQ 8$+YGS*JG@\9P5ZCWH W5T72U7:NGVP7(;'ECJ!@?H34
M=S8:1;VS?:+2W$3*L9'E@Y Z#'?%0!;T>&W%NUR\^"4,O$A7=T]CC@9YZ52:
M">6>WD=;QK=+\-%N+[EC\K!SWQO]?Y4 ;2-82PQ62+$T4L.](MORF,8'3ICD
M5*+*U'EXMXAY3;D^4?*?45DZ[;R/?1RQBZ %I,B-;E@1(2A4$CZ'KQQS6=)=
M7\=P4?[<^V9F>2,-MV&#''8_.#QV/UH U;Q+6ZU-+>\@CD?#!"R G:<;@.O&
M"*?=Z=87-SY;V<)(YRT8.3C&?R&*R%74C;-M2[9A#<!) T@\QMB[#ACE22#C
MWZ=:AE%]$S@'46A692Q#,9-IBP=I/. _4#IZ4 ;+VD<$[R0PK%."N3& "ZC@
M=NPXQ5FQL[24/<O80)+)E6;RQN<'KGZXKGC'?O<-&3J#?N!&SY8M&=B_,,?*
MV23D8SG)%;$2:@?#,T<2.EX%<)ECEN3@C<<C(Z9/% &BNGV21K&EI J*K*%$
M8P W4?0U,L,2E"L:#8NU<#[HXX'MP/RKG'@O9KM=HOULVG.T>:ZL%\GG/.<;
M\?C[5?VW4GA>))?M*7)A17*Y,@;C)]_>@"^MC9J25M802_F$A!RW][Z^]0HD
M>G":ZNKAY#+(!O8#Y06PJC Z M^M8)75 D?^C7F6,)^20X&V8[CRV1E,'![<
M=J6>UU":TECEM[TSB4"1O-^1U\Y6!49ZA1[8H Z.YMK60-+<6\<F%Y+(&. <
MX_/FJ]M>:9>QI:0&)T>/>D13 9..0".1R*9IL=Q%I]S$Z2[UEE$8D<L2N25Y
M)Y&,5C:;IE\LFG@QSJ8+%X)6EV@(2%X3'.<CKZ"@#I6L[5L[K:$Y;<<H.3Z_
M6FHMK+<RE8E\Z,A7<I@GC(&>XYKF/(U.:&0/;7D9,4(&6W!G56#9 ;."<#CV
M-6WL[Z695EAN%C:YB9PDQ 5/)PV"#G&[C]: -]+6VCE,J01+(227" $YZ\_@
M*5K>W:3S&AC+_P!XJ,_G7,V]EJ?G68N(KW8D<8!29?D9').XDDX(V],Y'%1&
MQU'^SFC6WN20^Z/>1N?Y",2#=SR<;ACG![4 =%?R:?:LDUY$A:5A&K"$NS'!
MP. 3ZTMF^G7 9+5(LPMAD\O:4)'<$9&15?6(+B6&P:*!I##<QRR*I&0 #GJ>
M:SKBQOIKZ[O_ +$ZB=H8Q"'7<47=EB,X/+=,]OPH Z$VUN5*&&(J1M(VC!'I
M]*BD2TCN(T:W4O,"H81Y& .A/;BL#3[>=KFQ@DDVS^0@O86D#,OED%&X/?I[
MCZ5J:S;7,\UL;>-W55E#D,!C*$#OZT :21QI'Y<:*J?W5&!0D429V1HN>N !
MFLG0;.XLY)5EBE2-H(?OR;LN 0W<\]*IW.DZ@EVYM-JP),3&-W)648D^FTY8
M4 :,D=G=(9HS*D=K(V^.)<"0IV(QD@'H*O/-']D:9U8Q[-Y4KSC&>E<VND7D
M,TABM6PSW()$H^XR_)@9Z9_6I18WWFMYE@SMY:F*7SE'ECRMI0\\\Y]N<]J
M-^W,$T,,\*+M9 R';@@$9_"GND4G^L5&QZC.*Q_#]A/8RNKV[PQM;PCEPV9
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M$2_. 0 VX$$#J#W]J)- M9'#O-=%@%RWFG+$-N!/X_YZ4 5TULE8;FY62WC
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MJ4MQ:QS*$^V0I*F$XCQ_K ?P(Q]?:GZEJ=S!K"6D4MO"NQ'7S<YERV&"X')
M].Y%:D=G''>RW>^5Y)   S95!Z*.V<<U.54D$J"1T..E '%W=SG3BCSQ)!):
MWH\I0 KNK]AZXYJY-K-Y [6QN;8 3"/[0PVJ@,0< ]>YQ^'K73>5&1CRUQ]*
M7RH\$;%P>O% &1HUW>WEW<&>XA:*':NR./&241LY/.,ENW>LXZU?QK+(UU"Z
M*UPC!8AF+RY"JL>>_O\ XUU(55R5 &>N*KV=C#9PO''E@[L[%\$DLQ8_J30!
M@V>J7U]<QP17T(&)]Q50S'8ZX]N5;TIVFW]\;?346<SK=6Z 2; =DBX+[C_N
MY_$5T@15.0H!]A4"6427K70+ERFP*6.U1WP.@)H RM<U>2POH8DGC0'RRRL!
MR"^T\_3T_&BTOGB\.W=P;LRRP/,&=P"5(<\8X]JW"BL<LH)]Q1M4 C:,'J,4
M <F=;OY(7,5[ &BCN6/RAMVS:5YX'1NPK4MKN]DU3[.S[HI%6X1PHP(]N"N?
M7=C\#6OL0=%'Y5#;V<5O/-,C2,\QRV]RV!Z =A["@#!U:Y,6H7\<MP"H6V=(
MI%!4#S,$@?ES2-J5^UTZ)J,"(9IH@#$#M"+N!Z]>U=,54G) S1M'H* .;LM6
MN;_4(X99H41U0F KDRHT>2PX_O9&<XXQBK$-W<1^&Q+%*BNLK1H\AP&42%1R
M0<$J!@GUK:>-71E.1N&,@X./K1'#'%"L4:*L: !5 X % ',PZM>RNACO5)"P
M,()(E#R;F*MT]AG(X_"F0ZY=M$99[J-(RZK.%3+6OS$$GC [#G/KTKI8[2..
M[EN5+%Y552"> %SC _$U-M!SP.>M ')W]TSVVH!KM&8Z=GSEC",_S,._8\?G
MQUI6O_L#W*V\L*0FYC62<*J[5:('<2%(Y;C)'>NKV@]A1M&,8% ')76H2S_9
MH;RZ D2:U956/:)P67+C(SC/Y8]ZT-8U66RU6"%)MB'RBRE1@JS[6.<'.!],
M?C6]@'M00#U% &-H-[/>"Y6XFWLFTATP4P<XQP"#Z@\CWK"BN[BUL6:"4B4P
MRNKE%+2R"1OW9X]\XZG<:[7@>U0W<+31J$?:RL&SB@#F"5:\D/E NNIYV>_V
M<C]3Q2?:+UK)I+>1G1;9)Y4$:_(^3N3IZ CU!QZUN122(\DB'[OWXR/Y4^:]
M66S+JC;"/F]1R.* ,%-1U017"&8P^6RF)I0 &1V78"=IP<;ATX.,UMZ1=&Z2
M-VFD+-;QL8G497);YL@8.<?I[U=MX5CC48;.,'<<DU-B@ HHJK=RL"$1]I&&
M;CM0!:JO=P><@'8'G'!JO(DD>V4+A#C*8Z'C%/CNQ'#YLC;HFQM(.2* )4ME
M-M&C\LH&&/6HG@D1BZL X^Z>QJZ"",CI2%0PPP!'O0!#!<!V\MR!(!R*GIBP
MQI(751N/4XI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !34^[^)IU-3[OXT .HHHH ****
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M(@5I",%R!R<#UJ6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHIKR(GWF
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M** "BBB@ HHHH **** "BBB@ HHHH *1>GXTM(G3\30 M%%% !1110 4444
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MWDOL(#8X)[51M8Q+,V\!'CQC&,D8J_(@DC9&Z,,&LX"2.<E\"5"=N"?F']:
M'W-NT.Z:/+#9M**,9/K3TNAL3S!E&P#['WJ:"Y6;Y2-KXR5/I5>X@^SMYMNI
M.\@%,$C\ * +!MD(^4X'\(ZA?I2I;*I5G.YQ_%C&:6W(,("DX''-2T %%%([
M;4+ $X&<#O0 M,EC$B%6'T]JK+=A8A*02IY([K[U;5E894@CVH SUFAC<0W
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MC'X#_&MRB@#';P];-$L;SSL%5U&2,@LX?/3J& (^E22:)#(PE-Q.MQO+-,I
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M2V3]: +M%4O[(T__ )]D_6J]UI5H@#I:KM7G S\WM0!JU2U!EP$D.$(Y.,U
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M_>5QSQ[5?50JA1T%,@A6&/:HJ2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "D3I^-+2)]V@!:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J.>>.WC\R9B%SC(!/\JDHH I?VM9?\]7_[
M]-_A1_:UE_SU;_OVW^%7:* *7]K67_/5_P#OTW^%']K67_/1_P#OTW^%7:*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IJ?=IU-3[M #J*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.=IDCS!$LCY^ZS[?
MUP:DHH I&?4>UC#_ .!'_P!C1Y^I?\^$/_@3_P#8U=HH I>?J7_/A#_X$_\
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M]ZVJH)[FXDCD-P"CH J[9,(> .J_G6RM_9M</ +B/S(]NY=W][I4Z.CC*,&
M)&0>XH =1110 4444 %%%% !1110 4444 %%%% !34^[3J1/NB@!:*** "BB
MB@ HHHH **** "BBB@ HHHH *YJ]:>WUF[9!=>7(T!D9-Q"Q\AMO8'..G.,F
MNEJE)J*B\DM(()+B6)0TH3 "9Z Y(Y.#Q0!F2SZA%H!D!F8K<X+;"9/(\S&<
M#!)V^G..>M4T?4%D+FYU!UC6 IF$@/F5@V1C^X1_,UT"ZE;O:B52/,,/G"!F
M DQC."/6JQUN!+1[F9!'&L,<@)D7DOG"XSD?C_2@#*@66.=LB]2VDNI_,=0^
MX$_<([XZ].,XS2+_ &QY$]Q,]Z9XX8"T2*0IS_K-HQR<>G>M^WU"&2/]^\4,
MH!9HS*K$*/XN.V,'Z&G?VGI_'^G6WS' _>KR<XQU]: .>GDOO.@6*34EMG#&
M%S$S-NW9PPX(&.!N[9S5W6&O_MDRP>>&$2&T,8)4R;CN#8XZ;>O;-:2:E;A9
M6N)(H%CE,8+RKAL?CQ].M7.M &1I,4V+R:YFNR3+(@1P<!0Q(*C'H>M9-L-2
M\JVD=M0$D<=IO3:P!))$F1CGCKZ=:ZVB@#C[=;^*."W4:C%"I<;DC9CYGF9Y
M)/0C')R.M/(N(TLFN[K4D-Q=2I(J[LA0)"N !G'3GV%=;44MO#-)%)(@9XB2
MA_NDC&?RH X]5U:6.=VDO&N(8(O+3L_7>1V+8[9ZU/:6\L>J6\A2^EC:.8*T
MBLNPED(# G@8!QN]/I71K;^3(\Y9L+DA1]*9:J#<&4R9##E2>AZT <TL$GVP
MKMO0!>S.TJ;ONE&V[6].@XIQ-_<P,9!=K*]O;!OW3L-P#%U8+@CG ..>E= D
M?G74B+@P/DY X!Z8J]#$D,8CC&%% &5.+JXTFRM?(:-K@*LP<%_+7&6#'WQM
M_&LDR7NF:4FGM%</]GN_*C\M6'G0X) !&3P/3^[Z&NNJ"[L[:]C$=W;QS(IW
M 2*& /KS0!S$46I3V\CVL]ZTL5BOE,Q95><&0,"&[].#[>E)(FH&-/+;5UM9
M6?/R_O8W(7;P>=OWN3D9]JZV.-(HUCB1411@*HP!4-Y.T$88*2/XB!G ^E '
M,2K=-? .^H!9)I5XD905V KC'8MT(^E"+J\B S?VD)?LZ&,(,*3Y.&#>AWY/
MKG&*W=.1HY624E@?FC))X]1@],5I4 <F+6[ 7SHK^:-)+:7!9BQ."'QSV)&1
M4^L6MVVJL;2&5T>)E9<$("4?Y@0<'DX((],5TM% '(K%J-O;"*."^92L.,EC
MAC&P;C(XSMX&,'!J2.*_EMQ)-;3ER;%CN3D['!?\1S7544 86MP7,EU.UO%,
MQ:PD1'CX^?<"!GUJB5OFUZ0R"[WJQ,?3R3&4  /N#VZYYKJZHZC;R.IE@;$F
M,=<#% &"MK>-<7GG+J17]YY?DN%C9&(V%2.<CCZ<YSW41:FD"1W<%[-AI4N&
M@?!9B!L=.1\N.W8^O6N@M[A0NTY^7@^U6?,3;NW#'KF@#E)?M<%W*S07!'VS
M<RH>75H N>V1N Y_&F0PZJT$+>3<NQLMCAV(*OY/56!YRW&#SGG-;=U(TEQ]
MT/%)M";>N>>:TXD$<21CHJ@"@#"CL;S[9!M\P030I)+N<_)(G;KW)&?]T^M4
MK.SOMD)N8;]I!/#YXE=67*YRR8[9P<_3TKK** ,/0H&%S.1-YMM [);N)"VX
M,0QSZ[?NCZ&LVZL;V>)U,-Z"%NRNV1E^8L#%T/UQ75PPQ6\0B@C2.->BH, ?
MA3Z ,/5;:::33[D6LDKI'(K;<94LG<9]164MCJ-O!$D5O>F ) 9HUD!9B%8-
MC<<<'9QTXKL:* ,&\L&DT>Q@D2]9H2")4D!GA(4@-GH3V/7KWJD]EJ(BCFDM
M))KLV<L1>,A.=^1G!&"1Z=\]*ZNB@#C5T[4RNY+299@ES'$[,H\O?M9#]XX'
M!'?!K1@MKI-"O1#;7:RR?,L,TB[LX (&TX XZ9YYZ9KH:* ...FW\D+B2UNP
MR0W/E?O OSF0-'P&QP,_3%78[6];6+>2>RE)CNFD-QO!7RS&0!USQD#&/YUT
ME% &-!8RR:Y>W3_:(DWHT?S#9)B/:<CZG]!659Z?J44*O-:7,CAT%RC3)B<#
M=RH&.Y!YP3C':NNHH Y"#2[]6@5[.=807**LR PMYK,"3SP05Z<\$=Z;/HU[
M_9,4<-E)]H=)?,)E!*M_ >3C\1R/U'8T4 8L5K>O;ZP$5H)[GF%V(X;RE7/!
M[,*I1V%R3%*^E-' 2WG6OFJV6* !QSCC&/7G-=/10!RL>F:E T,;VYG.^VD>
M7S!P5&'Z\D^_>DM]$DMK>SD73?,N!'*DW[P!@2."&S[8X]JZNB@#GX+"\3PW
M?V@M_P![*&6)3M5F!4 %L':#]/3-1R:7?RW#[5,4OGO*MT&'"-&0$/?@XXZ<
M UTE% ')3Z5?S6"QKIJ0NPVR*LP.3Y97<,\8/';-+-I.H,KNMDA+3QSR()5!
ME'E[&7..Q^;G@XKK** .5.D7J&*);&.1%EMI(W,V3"J,I*9/)Z$Y'7)JWJ^F
M7%W>3M';*\<B0#)8#)27<W_CM;]% &)!I\T6BW5G]DA97G<I Q&QHV?./;@G
MZ5G/HE_]A:V@C+6_G-Y4<\NYHD,97AB#D9/N<&NLHH YBRT:ZBNH+F2TB69;
ME)&<."0GD!&&<?WAG%7IK?45O]0DMX(6%TB1QLTG"X!!)&/?I6S10!R[^'KJ
M!$CM?+=(8;9!ND*>:8V<D$CIPPP>>E4+FW-IJ$-JUK!L"Q-Y D8L2LC. A93
MNZ\]/PKMZ* ,/2]*N;:ZMY)O+'V=)4,BL29MS @D8]O?DU+86=]IXEM8DA>!
MYWE25G.5#,6(*XY(R<<^E:]% ',-X?O);/R',*O':2VX<,3YQ8@AFXXQC/?D
MFGMHUW<7S7%U:VA#3M+LW[L PA,<KZUTE% '*7.GS6E@8[H1B22.!('CR["X
M0?+QCID=2:W+43VUQ#9B(-#Y)>2;D$R9YXQCG)/6K]% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNG":&U5[B0S6K!DFP,YP0<C&.035)-.MK1BUO.[R&,1E"0-QW,V[..N6;VH
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MP,^U $]%5KR^@LXW>5B2D;2[%Y8JO4@5.DBM&'!&",T .HHR ,FDW+_>'YT
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M-!O) *%@,'GZ$?C6?-H]TH98+#=;^:&>#S57S 8MI/<9!YYK3L->MIDLHIW
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M226+H;>,2SHSX*J6901QSPI/..*FTY[FYU2]DFD*I;S>6B+)E2-BGD8]\YH
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M[HV"7<B2?:?M,;[0=K;=N"#U&,_G3CHVZ3,ERSQN(_,4J,N4.1SV&>V*U:*
M,S1[1HGNKR6 P273[C$6W; !CMQR<GCUJ&30O,GN)_M1264@ADC P0^Y21_$
M1@#Z5LT4 <[_ &+<I?I$D\C0217 EF95SF1U8CC'HW.*L-X>79=0Q7LT=O<!
MOW052%)7:2#C/OCIFMJB@#*O=#BO[CS+F5B-A3Y5"M@J5(W>ASG'J!3?[$EQ
M$YU.X,\091*53[I !&,8[ YZYK7HH R+#0EL98VBO)]@2-7CPN'**%!SC(X
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M"@V@@YST]*TX],TZ>VF46R&*XP'&3AMO /MT'3T%6/*BN-LJ$J1Z<?4$58
M  & * *"Z/IX5!]GSL7;G<<L,YPW/S<\\YJ4:=:"<S",AVE$I.\\L!MSC..E
M6J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I![4M(O3F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "HI[=9@#]UQT;TJ6B@!J+M4#.3Z^M.HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHH!S0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%%  :!R!0>E(OW10 M%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4B]*4]*11A0/:@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ /2D7[H^E*>E(.5'TH 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ H) Y) HI" PPP!'7F@!:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH #T-(O"CZ4IH'04 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $;[I^E"_='TH;[IH'W10 M%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex10_7page005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_7page005.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***..U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %(O?ZTM-7^+ZT .HHHH **** "BBJ=SJMA:7 M[
MF[BBE(!VNV."2!_(_E0!<HHS1F@ HJG_ &K8>;+$+J(O"&+J&Z;?O?EWJV""
M,@]: %HJ*YN(;6!I[B18XEQEF. .U-M;RVO(S):S)*@.TE3GF@">BC(IGG1^
M=Y.]?,V[MN><=,T /HHR** "BJ)UC31*D;7L >0!E!<#(/3\ZN22QQ1M)*ZH
MBC+,3@ 4 .HJNM]:/;I<+<1F*1@BN&&"Q. /KGBFG4;%3,&NX08!F0;Q\GU]
M* +5%4)-:TN((9+Z "0%D^<?, <''XU*=3L5D>-KN$/&N]U+C*CU/YC\Z +5
M%4UU;3F5&6^MR'?8I$@Y;T^O(J:YN[:T"&YGCB#G:N]@,F@":BH!>VC3R0+<
MQ&6,9=-XRH]Z9#J-C/#)-#=PR1Q#+LK@A1UY]* +5%('4IO!&TC.?:JLFJ6$
M44,LEY B3C=&Q< ./4>HH MT5574K%KPV8NX3<#@Q[QNZ9Z?3FI+:[MKL.;6
M>.8(=K;&!P: )J*IQ:KITR2O%>V[K"-TA$@^0>I]!2?VOIH2)_M]MMF)$9\P
M8<]./6@"[14,=W;2SO!%/$\L?WT5@2OU%-^W68NOLOVJ'[1_SRWC=TSTH L4
M5136-,D5F2_MV"KN8B08 SC)_,5(FHV4D8D2ZA9&D$88.,%CT'UH M45 U[:
MK.T#7,0E1=[(7&0OJ1Z4V+4+*>'SH;J&2+<$WJX(W$@ 9]>10!9HI@EC,QA#
MKY@7<5SR!ZTP7=N8UD$\91G\L-N&"V<8^N>* )J*KF_LQ<_9C=0^?C/E[QN]
M>E)::C97K$6EU%,0,G8P.!0!9HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D7O]:6D7O]: %HHH
MH **** "L34;6]>]OOL]HDT=W:I"&=P%4@OG(ZX^8=*VZ* .7?1]27?'$7\P
M!P;@SX\Q-F%3'8YQSVQGO3GT_451Q:VC1)*I14-QDQ?,#D\^F>!FNFHH Y>;
M2]2:2Y6*$QAQ.<F8,C,X;!0'E"203R!UJH+:ZNK^2VB6X$H\SS91*ZAAYJ$=
M<8PH8#]*[.B@#$GT^Y_L26T179A<[X@)!N""4,,$], <5!<:;=W<8&R\39'-
MM\RY&2Y"[.5/3(/TKHJ* .9NM+U607*I*XC #1!9<,Q9E,BYS[,!_O5$FDZD
M!&\D<\D8&'B,X#LF]CLR#CN#C..,9KJZ* .1M['4CJ/E%+CS(O)993.2L2;V
M)4\_,=ORYP<UH>'=/O[)IS>O*Q9%!WR!@[C.6'IGCK^7%;U% '+II>H)8SV8
MM%;[59QP%S(NV-@&!)[G&[M6I>6<LNE7$$41\PN& =\^9@@_AG&*U** .8N-
M&U&Y=+I?+B_TM9Q;2+NV'>N6R&QG"D_B?6HQHU\OG1O!++&-Y/[\ R$RJXV'
M^'@'/3)Q]:ZNB@#F4T_4DG2:5+U_W;(/*G3>H,A*ABQYPI'Y5);Z??Q:S/=B
M%^?-<;I%V'<J[0!U#949/3K7144 <U<:/<I9I#%!YSS6CP2N6 V2.06<YZC.
M>G/ JQJUA?SVDL+ 71E5U1XPL;Q XP"2>0>_\JW:* .8O=)OKN9U6V2(""1"
MV\>7(6P>@Y!.,$GMZU>DM9=1@O!=:7'"'A"*KE69V&2,D$C .,?C6S10!DW.
MGWUQ9BW6[C2(HBM&T1).,9!8,,@]*SK#3]1T^TA$EC'=NUC';,BLH$97/!R>
M5.><9Z=*Z>B@#EAI6H#4BRPLJ?:DF7$B^2%$2J?E^]G@X_"IM!TO4K-,%S;@
M+$K>;B4OM!!"X/"],9YZ\5T=% ''VVBZAY CFMIRJ6S1,KSI\V64XC(Z< ]?
M:K#Z?JA9)42Y$R[EA<W(/E*7! DY^88'OZ>]=110!S6FZ9J=M<L(V\G:K@RR
M[9%<L^X;5!R!C.<XYQUQ5FVM;N"4VKZ<DJF[>X^TLR[0"Q;.,[MPSCICWK<H
MH Y2VTO4/[%%B\5ZD@2-<O+$44JZDE<'/0$C/I5O4=%N[SR[47+M%%&[K/,
MS&4\+TQ]T9.?<5T%% ')S:3J5U,S/ T:R!I9%\Q,%S#L(##D<^V.,^U7$TVX
MGL@)[>3,5W%+;I/('>-04W'<"1V;'/3\JZ"B@#&NM,G;4;R:R*6[7-LJ&;&2
M6#'WS]VJMMHL\>EVL,UM 9K:^\R,(,!$\[<2,D_P_P"%='10!A16MW$S6IT]
M)5-T\WVAF7;@DD'&<[N<=,>]6M TZ;3M-@BGN9I7$2*4<J1&0.0,#I^=:=%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %-7^+ZTZFK_%]: '4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !35[_6G4B]_K0 M
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M50@_=D3@=?<,>O QGM5J#4]0EMK>593)YLDUL0J@[7W'RV/'3 Y[=* .GHK
MTS4;J?69K:6=/W3R(T!7YMH(VOTX!'/4YSVJ*?4[G^UKJ"2\2UCA8C:5RVS8
M"'''KGG..V,T =)17)'6KY+1/M,XMYO.$4[, !#\F5;.#PQP?;./>IH]3O)F
MFB-X4NHT.(5@_P!8OEY#C/(^;/\ +% '3T5R@U1[JZMG^VR"!;B+<448.Z)N
M.G/S<?6DM]9O717GN@JM(J7"B+YK7YCG/&/0<Y]: .J1T==R,K+G&0<T!T9F
M574E?O 'I]:YZU+'P=?_ &69RX^U%)$&&)WN01Q_2J\-TT=^TUM=YBDF@1\J
M#Y@9/O$X]ATQTH ZI'610R,&4]"#D&FM/"C['E16/\)8 US-AJ$ZMID22CRG
M10\<:@')+<[<?=X['C'?-.\0+%)K'EF2VC9K"129H]XY9<=QSUH Z>BN3@O[
M^.RMD!E@D2VMS##(-QF).&!.,Y_+'6FMJ]ZTEPB7;KRNTF/E3YVUAC''RGU/
MK0!UC2(A4.ZJ6.%!.,GT%.KEI)I6U:TM[FYE>6WO455* !T\H_/P.Y)]NU7-
M7O;N&\FCAD:-EB1[9 N1.Q8AE/'IM_/- &SY\/G&'S8_- W%-PR!ZXHCGAE.
M(I8W(_NL#65HT:?:]2E=VD<7+ ,X'"[5Z''3C'X5CVZ+)I6E0V<9^W)=!PRJ
M08TWDL6.. 5R,=\B@#KXY8Y4WQ.KKDC*G(R#@C\Q3JY>WGOI'BBMKB12/M,F
MP1*!(5E^4'CC(S]>M1V^HWGV>*2:]N6AD=1*XM2K0'8W'0Y^8#MQ^/ !UE%<
MI%<745Y*LMQ=8EEB\R0QX*QF(?,!@A<OQ[<TZ*YU.8.9+Z6'R[0R ^2"'.YU
M#$8STVM@?_6H ZDD 9)P*CAN(+@$P31R@==C!L?E61;RM=>&KO[<MPW$J.%.
M68<CY#@9'IQ66LM_:13[)%E56A1KZ&W.YH_FX*#J1QDCL>U '7TQYHDDCC>1
M5>0D(I/+8&3CUXKG(4U2\,T<>J72NEJK1L81&'<EQD@@^B'&?YXITUSJ$D5I
M=QQRB6?S72!TSL_=':#QQE@/SH Z2BN4EOKS[/%)#=WJV\C@2RO:DM$=AXP
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M !1110 4444 %%%% !1110 4444 %%%% !1110 @50Q8* 3U.*6BB@ HHHH
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M&7,ABP3CYQU7Z^U %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 5Q],_F*ZL8Z#M0!A^(_L5C##J#VD<MRLR1Q9[EF _'CG\*U4^R&<PH(?.C
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MVM)&XDN727Y@7553=]3NYS4"ZS:O(D<?B&_<M<&VW"T3 DX^4DQX[TY-2M9
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M2&3I@XJ2=B(S@[<C[W]VFVIF,9$_4'@^M "6T1 $DBXD(QUZ"IZ** "BBB@
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M]<D\'BGG0+Y)$9;:?>FKF42!ER+? [9QU"\8[5US:OIZ7#0/=1K*JEF5CC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHJ%[E%+!0SE>NWM0!7OF<.$*%D8<X].]%T$CCC@52.^X=L5:C9)@)%!].15
M6>1DNP)%!C)&#GH./ZT -FC<.(W/!P5?W'8U/:323!@Z$ 9YJ"5I+F7RB"@!
M&"IZCK_2KX  P !0 M%%% !1110 4444 %-DC212KJ"#ZTZB@   &!THHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *1.GXFEI%Z'ZF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -.BH+61F#*[!B#\K#N*GH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I$Z'ZFEI%Z'ZT +1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4V1BD98#)'04ZB@"O:W(E4!ROF8R0IR*+B)B,H 5Q@K_A56X5%F+VQ
M4MR'4'''?BK$5R"JD%3%W.>5H 9!*8"(WR4'&\GBIYH5G56STY!I9(TN(< \
M-R"*A@$T<WE-DJ!P>V* '?9-TRRNY) Y&.#5GI110 4UW"+EJ=4%X%-NV\X
MQD^E $X.1FJUU;-*5>)PK YYY'_ZZK+)+$X1G/E]5DSU]OI5R&</E7&UP>F<
MY^E $'DRNP<%DP>4/(/XYJ4F*)'#?\"[U8JL+4B8R>82#CY30!':*WFY5@4Q
MP/3V_2KM,BB6)2%'4Y)]:?0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !2)T_&EI$Z?B: %HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *CN-_E'RR QX&:DJ.>/S82@8C/0B@""U42,[2 ;UX_0=J6:#RXV:
M$\D')S4"LRSL$+*\8 ((^^*E2]$T3%5*L,Y'% $-M,R!&C8R1/C"X^89K2%5
MK-(_*61$V\<<=!5F@ HHJ"ZE,<9"'YR"1^% $^:CGC\V%D]15(*Q7[0B%>Y4
M]_\ //YT^.Y*C>22G.0?X3_A0!+!;(+=HG&Y"< 'TJ*6U(P=Q 7[K*<$>Q]J
MN1R+(@93D&G=>M %6"Y8-Y<^-V< _P!*M5'Y,9D$A7+#I[5)0 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%-DD6, N< G H CGF*Y2+:9<9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR<_X]:M6\"P1A%)/N:9;6JP%B._&.U6* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1<XY]:6D'%
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M0!.+>%ER@PK#H.E(EFBL2QW\Y&0..,8I+!T:$[&S@_,,_=/<59H ***"<#-
M!39(UE0HZAE/4$52CO';+F-QQG8W!':KD4R3+NC8$?RH S6<61(F)>)CPO!
MXZ=/:K%S]FVQ@;%D8?NSCD5)>KB,N%+<<@#DU5A0LZQ2D/N)*MZ@'/!_$4 .
M6"5XQ(@"2C[Q  W5)%;DSAF#IMY..CU= P,"B@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %(O3\:6D7I^- "T444 %%%% !1110
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M.WD%R-VX%<?O!CYAZ'BKU !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M+T_&EI%Z?C0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?6K\,8BB6,$G:,9-1VL"P1 +N&1T/:IZ "BBB@ HHHH **** "BBB@ HHHH
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MW$I0 *0"3U-1VMXLO[N7Y)0<;3W^E6) C(1)C:>N:SY%1IRH(#@\9XR/K^=
M$M] ?FN(HA)(%QMZ9&>:B68VJJ45FC)&Y2W*9^M3VMUN4)*1Y@X;'8T^:#=F
M2+&\CD'HW^?6@ :&"YCR,$$YR.<&GQ6\<2@#+;> 6ZBH;:!XIVPY\OJ03DYJ
MW0 4444 07=P((\X))].U0V]L&+ER60MNVMS@^E,O;=U=ID#2;AM*GD8^E$5
MX(8AF-BOM_"?2@"U/<+"R*027.!4GRR(#U!Z53B1II<DJ\9.2WMZ#]*O  #
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I$Z?C2TB=/QH 6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M Z></"P@8E@?3WYIEA&"6G"[0PP![>M/%GND5W;!4Y.WC-6J "BBB@ HHHH
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M3>C;<GYQV858HH 15"J%4  = *6BB@ JA?;C.!&/W@4;?S_GP?RJ_5._MS(
M\9PX[Y(P* +$ VPH" #CG'3-252M+DE1'(/G YP.*MAT*[@P(]<T 4[NXDBN
M%5E(B;@,.Q[5=1@Z!AT(S6;>RM).BKAH&&TXZDG_ "/SJ_ GEPHN",#H: )*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "FI]W\:=2)]W\: %HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *A>ZAC8[G4!>&.>A]ZFJC-:M$[2P?=(^:,#K]*
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M9&/+XP*LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ /2D7[H^E+2)]V@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *@N[A+=/F8*3W/;W_6IZS9Q*MT0RB:-W7Y",_YZ
M4 *K3QO^]==YSL;H&].,U:M[@2Y1QMD'5?ZU#.RR7"0LG/(7CD<#D>G>H98]
MD[1G!EQNB?HQ]J )IK1Q*TMNP4MU!SS4EI:);Y8* S=<5);F0PJ9AA\<U+0
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M<!CVH 2UMDM8RL>>3DY.:FHHH ***1F"C+$"@!367;_N9_,RQ5V^?'(4X/\
M6KJW<+2-&&^=>J]ZJM;IO-Q9[6#\.G8_YXH OLJ2(58!E/K64\'+VLA?;U0C
M.3QZU)YKPD>22T1/(SG9TX%36<4@D9V8F/.5R<DGUH L6T<D<*K*^YA^E2T4
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U/N_C3
MJ1/NT +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M +'*?W;%2G9P>1[8JW'$$YZMZFG(P= R]",BEH **** "BBB@ HHHH ****
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !2+TI::GW: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %17%NDZ@-P0<@CM4M% #8TV+R06[G'6G444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4B]*
M6D7 '% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !2*,"EI <CF@!:*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI!T% "T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!2+]T4M(!@8H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *!S12+R : %HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*1?NCZ4IZ4B_=
M'TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH #T-(OW1]*4]*1?NCZ4 +1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%5;W4+6P\O[5+L,AVH I)
M)^@H M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%%  >E(IRH)]*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "L;7;1KN:$06]Q]JC^:&YC?:L9R,AN>1QR,'
M-;-%  .E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4#ISUHH'09H **** "BBB@ HHHH **** "BH+Z8V]C<3KMS%&S
MC=TX&>:K17LS7L<4L*A94+1E6R<#&2?;D?Y- &A16?)?31W\<!B4K*^U &YV
MXR7^F<"I)[QHM2M;01Y$Z.V_/3;CC]: +E%99U.1=/2X:(!C="W*Y_Z:^7G^
MM54\0.VFVER;-P]S,L>W.=@8\,?:@#>HKGY?$++9"5(E\YKI(50G^%G !_[Y
MR:UK*Z:X>Z5E"^1.8QCN-JG/ZT 6J,C..]9(U9UN+V&6$[H7 B _C7"Y_$$_
MRI9=:MH!/))%.$B#'=M&' X.WGF@#5HJO970O(/-6*2,9*[9  002#_*L^#5
M3-JS6QN84VNR^28R7;'?=G';.,4 ;%%91UZT*ED65QN"#:OWF()VCW&.:>NL
MPN^V&&>7""1BJC" DCG)_P!D_E0!I45EW&LQQS)%##)*S>62%QPK[L'_ ,=-
M/35X&MQ-LD"MMV@@9(./FZ]!GGZ4 :-%4=-U./48W:.&6/9C(D !.1D$8)JK
M?:M-!?W$$4:%;>V-P^>K =A0!L45E?VS&%+>5*Y&254#@  D\GIR/SIB^((&
MAW_9;D,Q4)&0NY]V<$?-CG![T ;%%9SZJT98&PN21MPH"Y;/X]N]-_MJ'RV?
MR)\(%+_*/D) (!YZ\B@#3HK,N]3==/CN88]C/-&FU\'AG"GH<=ZEN]0%M?)!
ML9]T+287&3AE'<C^]0!>HK''B&W,'G"VN2@5&. IP&) [^HJS_:/F:6UY#$X
M()&Q^#P<'IF@"_16<-3A2%S-(OG1Y#( >" #C\B/SI-)U$W=OYEP(HF(0X#Y
MSN4-_7\10!I45D3:I<K/=1);_P"JFBB# YX?'S8]!FK>F7@O89)-N&CE>(G^
M]M.,T 7**H7^J)93I"T$LK-$\OR;?E5<9)R1_>%4KS73Y4GV2WD;8Q4L<8^[
MNXY]Q0!N45EZ5J$UY9RR2!0R 8Q[HK?UK+@\0W,_FJB9G6.)XX0A(DW1JVW=
MC Y)% '445E?VTBSO#);R!EW!3N7$C#^$<\'ZXJ)O$42P[FM+@2@.SP_+N0*
M2"3SC&1Z]Z -JC(K.U*\N(;:VFM(BZNX\SCE$VDY_,"EN-1^SVEM*(9)VG(5
M53 ))!/?CM0!H45CV>JM>ZIY"*R1"W\P@X^]N*E?P*U!)J=W!'=^<^V6)'G1
M"@YC5L#G/>@#?HH'2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH #TI%^Z/I2GI2+]T?2@!:*** "BBB@ HHHH **** (;R
M$W%E/ I :6-D!/09&*K6FEQVTDTGFRM), I.\X4 8 'IWJ_10!2738UN9)Q+
M.7?CF4X QC@5*]G&]Q;SL6+VZLJ$GU !SZ]*L44 9?\ 9<G]GI;^<NX70N"V
M./\ 6^81_2ECT*PC965&W*B)G>>0I!''U K3HH S/["L!M 1]JA>-YYVL&!/
MN".OIQ5A;:2"29K4Q*)G\QMX)RV ">OH!5NB@"C)I-I,_F31 R^8)2RD@[L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH #T-(OW1]*4]#2+]T?2@!:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T
M-"_='TH/(- X44 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex10_8page001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_8page001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD8D*2!D]A0 M%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !2#[S4M-7JQ]Z '4444 %%%% !1110 44
M44 %%%% !1110 4444 0P2RR33I) 8UC8!&)SO& <C\\5*&4L5!!(ZCTI:8D
M:J[OM4,YY('7TH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !35X9OK3J0?>- "T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!11D49'K0 4444 %%&1ZT4 %%&:,T %%%(S*HRQ H 6BJTE[ @X8L?0"IH94
MFA26,Y1QD&@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-7^+ZTZFK_%
M]: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1103@$]:
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MH **** "BBB@ HHHH **** "BBB@ HHHH *JZD\Z6;"U0O*_RKCL3W_"K5%
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MHHH **** "BBB@ HHHH ***,\XH **** "BBB@ HHHH **** "BBB@ HHHH
M*1>_UI::O?ZT .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>M6Y]:ODDT0*4'VRSEFF^3^)8PPQZ#)JY'X:M_/,EY>7=Z!$\*+.X(57X;H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF=@Q0NI W ?+P#T'I0!U-11W,$DFR.:-GY^4,">.O\Q^=<S)HVO>6Q6_9Y'
M#!IV"Y'EXZ#@</G&.M:4]B]OJ=M)IUJ@*K([L3A23M&"?4XS^% &S1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444P2QD,1(I"G#
M'/3ZT /HH!R,B@D $DX H **9YL00.9$VGH<\&G;UW;=PW8SC/.* %HIB2QR
M9\MU;'7:<T^@ HHHH **** "BBCI0 4444 %%%% !102!U-&<]* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I%[_6EI%[_ %H
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M%5Q_O5OOJMG&TP=Y!Y!Q(?*<@'CC./<?G2_VC;#(_>;AG*;#N&,9)'IR/SH
MY]M>U1)?,2U$RLJK@ JF=TF6!..NU14__"0WWF2@6181O(J@(<OA,@ ?7C/Z
M>FVE_ ]QY*"1FP&R$.-I!(.?3@BH/[8MC;F6%)90LBQE53D;B /YT 44N[W4
M8;%'9K1YS+N9/4 [?\<9[54-_JFGZA/$_P!HO((A&@/DG Z GA<ELY/!(Y[8
MKH'N ;NVB,)Q(K,&8<J0.GUY-1R:K;1J699=O\)V_?YQQZ\F@#G(=5UURX^R
M3$J_FX\IA_P#)X(^G3%2QZ]KK+$3IIR\<K-_H\@ (#[?<<JHQ[\5T]O.EQ&7
M0,,,596Z@CJ*@U"]>T\I(H?.EF9E1-V,X5FZ_P# <?C0!BVUUJ^JW#VEQ%-8
MQ-"KK,L3*P;"G&>1U+#&<\5<M;^866H)"'GN(&F:-3D[OG?:/S!&/04L>O*+
MPVMY;/;.%4_,<Y)8*,>HY'/:HAXFL][I%$W^LC"$@@.K^7ELX[>8./:@"A_:
M.N+&\<4,I+"1_,:U?CEB,#/'"CY3ZBI+S4-=>VNXTMROS,D;);ONQAL$?7"\
M]L\U?7Q1I31>8DLC+L=SB,\!0"?T8?G4C^(M/5F0><S#& L1.XDJ,#U.77\Z
M *EU)J]OJ<SVR22Q.R!04+ 8 XZ\ DG+>U2SW&M+8P/!&C3M'(\B^6>"!E5Z
M^O'OCM4\&IW"W'EW]J(,PO*N'R<)MS[?Q?I3%\2Z>RY43'@]$SSR-O7J=IH
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MMYXD=$<0V^UT(Y9@P/ R.#ZG\>U3Q>(DDF,*VLQ83>2&.%#$;LD$GMM/'TH
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M0V*O<E9W"LRD@+M+$9/J6 P/?TH 738=0AN[A98SNFC7?-GY1($&2/7D@?\
M 355M,UPJ@2Z9"L1&3<LWSX;)Z<Y)4CTQQ5J*Z=#.9;J3&QC+W,3;\  =L@G
M\A1)-,-/BF^U*-I9MAEY8=EW#.2/Y^M %:32-8S(L=_-L8N1F=LC[^SG\4S]
M.]$FE:R.(KMBJAPA,[97.[K_ 'NJ]>F.*Z-&W(K8*Y&<'J*SKB6^FU*2WM)4
MB6$1NV]<[@=V<?D/R- &4VDZK#<AXKER'98BWF%F$>YR<D^@;CWJW=Z5?2ZI
M/-%.4MY]@(20H1@KGIZ@$>WXFJ-KXBU1+43W=@KJ\;RJ1\AVKM'3YL\L.>.,
MG%/_ .$HNS"LBZ8I&"6_?YQ@9.,*<\ _I0 Y-)USRLM?8F6) &\UB&8!,@KT
M R'YZG=4UGI6JQ7,$UQ?M+Y;#(WL 0,CIT)VX_'-4W\574,4P-BLKQ;>3)LS
MN8CGC"@ =SSZ5?M-1O=4><0M':+;R8;_ ):%E(!'., XSW- $=KI6JQWXFFN
M T7VDR!!.Y 4Y['KVXS@&HKS1K^Z:Z1&"H[RYW2L ^[!4X'I@#/8 \=*U],N
MGO\ 2(I/,"7#1*7(7[K%0>GXUC1ZSJEJH>XC^UJUNKA578P?$AP!CI\@'6@"
M670]2DDWIJ$D9)F/RSMA2Q.SC!SA<#''2I+'1[ZU:9VG\QY+8Q*TDS/M;<Q'
M89'S?48I6U'4Y_[--M"J&;>TRY#*%5E&<_0GIGG%5T\27[!?^)8,M$DG^MP/
MF(QVR1SR0.M #5T'5=L.^\5GC5\,9GRA(< #CG[X^;KQ2CP_J M"D=ZT;%\[
M4G<87<Y(!(/.64YQSMI9/$%^B[VLT7 8[0Q((Z=2!SP>/I4L'B&XDNC$UEL0
M3K%N+\X)89VXS_"/P/M0 JZ=JMM>?:HY!,$DD=8VN&^8,. > .#^0]3S4E_I
MFH7-[(T=P$MW*GB1@PY3(XZ<*>_>EGUJY35IK&&T#[&0+(20.<9SQ[U6&NWT
MNFQW@LS&PGVM$#N++Y9;'MS@>O% $:Z#J".TAG61I%,1;>=RJRQJ6]R C'GU
M%3'2-32=S!<(L+2'"&5^$)0_3C:0!Z&FGQ#>>6S?9HOE3(Y;]X?,*?+\O3C.
M3ZBDB\07YE1'L5/FRJ -VW8I1#SGJ?F./H: $CT+4(7A9+I@L<B2.J3,-Y5$
M!Z@C'R'CON[5>U"QOK]+>3*Q'R762+S6 5V P>/O8P1SQS5%-<O_ .S;B]>#
M)2;Y85!^[Y(;:3C.=W!XZU=EU&]^PP2^4D<AN3#+U8 #<,CCU _.@"K!IFHV
M-Q (6:6,22.Z^:=K9<E>O3[YR.^T4^]TB_GO9;B*5/\ 6;HPTS\9C9>W3D@X
M'OS4=EKNH&:SM9[(,SE5EEWX!RJG(R!S\W(]J)M9O+8/)Q/(TK*;<H5\D#<1
MR 22=H ]S0!$?#^J&-@+XI(X7<ZSL&.TO@9(/]Y><=JV+-9K*PF=X)'8S2.L
M28+$%CC'0>]9TOB&[&[RK#=LW;MS$8V^82.G7$8_[Z%36.K7DMY':SPQ[I7D
MPRY&U49@201_N?7=0!'JDMQ?Q(B:9?+MW;@=JY!4CJ&SWIGG77G@G3KWR]ZN
MW[M0V0NWCG'I^M/&K7]SJD5K%$(HQ<8=N3E!OX.5X/R _0CFM_('<4 <]I]S
M=6KYDTN^;$,<*[$7D+GDY;J<]*AO_M%WJ"W(L-050J#88UZAN<_-W4XJTE_)
M'),XN'ERI*X4%5RV!D'!7\\8!-!U>[\E90L8"QRNZE#EMCA0!@\9!]Z **)>
MQM/FPOW\U''1%!W-GG!!R!WR:FC\V..!?[)N9/*E9PK0H!@@^AQG/L*WKN;9
M93/&XWK&Q7'KBLQ[QQ$P6X+QK)#M=N"V2"PR/0<_F* +<.I222*ATV^3) W,
MBX'O]ZM"LJ34K@:EY*1J8=ZJ"<#<" 20=WOTP>E0QZM<O(R?NBWE(Y7:08BS
M;2&YYQU[?A0!MT56L;AIX2SE258KN48#X[BK- !1110 4444 %%%% !1110
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M:B%])O)<$D$&%>IS_P ]* '/X?TY4"2S7.PMD*URP!)]LTJZ/IF[>LUQN"[
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M1P,_0T 2V]SK4VF%Y(5BNFN$4#RS\B$KN.#C.,MS[5EB^UBYNI-.1S#+%Y9
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M8=AV<@_0TD.N:G(J/]C(60*S J=R;A'P..Q<GGTH DD;Q!LE$7F(%/R[E0G
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MU);R7:3>62PF5D50GR@C'<\Y'X]>*L6,>LK>CSR5MMT@VY4X!+$-GKG[OYT
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M110 4444 %%%% !1110 4444 %(O?ZTM-3O]: '4444 %%%% !1110 4444
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M-#\S;F^0<G&,_7%5+F]TF!F\\P;D+ _)DCIGM[C\Z *=[K[6%Z\=Q "OV=)
MBN-P8^83]1\@Z5#+XEQ<@Q(K6X<IG(^;YG7.[IC*@Y]*T3JNDO<*K30M+D(&
M*YZ@$#/T8?F/6HQJFB*H'F0A6B+@&,@%!GV]C]: ,^S\222+$+BW5VD.2R,
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M* "BBB@ HHHH **** "BBB@ HHHH *1>_P!:6FH.OUH =1110 4444 %%%%
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MRRI'#L!\PDYPG\.,=58Y[YH L#0-/!A81L&A;<K;CGHH_DB_E45OHFD2*WD
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MZ_**;)X:N'8@SJ5Q@,TC%@ \A49^C@?A0!J^3J^/^0A:?^ K?_%TOD:L<?\
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M (2#33:272S.\<<GE';&Q.[&> !D\<YH U**RY?$&G1&0-)*2AQ\L3'=USC
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MO*_WNOL>.OM0WB> ' M+@@??/R_*1R0?F[ '\J -VBL1?$D#;2+6YV,Y&XJ
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M%%% !1110 4444 %(O?ZTM(O?ZT +1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%4]3NGM8%,31K([8&_IT)]1SQZB@"Y535;-[_39K2.58C*-
MNYDW8_#(JG'J"-?V9EF13+;%BF2N&^4^N.YZ\\&JB:Q=R9 N+=6(B.#$?E+.
M593S_#0!?;23)J=MJ$MRQF@R,*H"E<,,8YQ][]!5C5+(:CITUH9#'Y@ W 9Q
M@Y_I62^N3[8BKPXPVXD<.0Q7'7CH#WZ^U.350^J0B2\14$TBF, @*H!P2V<'
M/!H 8OA6-M0%W/<^;_JP8_+ 4A,$=_;]:FTSP^+#4))A)NC^SB*/UW?Q-CW"
MH/PJ36-7CMX$^R7<&]B>^[@#VSS]:KW.N1K-Y3W2!7..G&TQD_>' .X>O>@
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M$LC(>&:*$D?CLIE]/?W=A/;+I%PIEC9,F6+C(Q_>K-:QO0LBQ:3(J.^\H#$
M?F<C^+_:'_?- &E_9*&>6,ZA*6D 9QY4/S#/&?DYZ4'0HVC1&O'*1GY1Y,.%
MSZ?)Q5: :C#<0S?V0[LL*0LS21[OESR/F[Y-5H[+48[.>%=-D8RQ>66:2/G_
M &C\W7_&@#9&FSEBPU2Y)(VD^7%R/3[GN:@;0 \?EM>R&/.[:8(<9]?N4ZWN
MK^"%8X]"9 /X4EC"CZ<UJQLS1JSH48C)4G./:@#-;29S,DW]J7/F1J54[(N
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MAN+61KEE5MD)# EF"@9)'/S#KBM@6UM"EP7"^7.^^0/]TD@ ]?I4:VVF0O\
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M?32W5JNQ!#<VYE!R=P(V\>F/FJ2TGN'NI89_*/EHI)CSU.>.?8#\Z +E%%%
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M444 %%%% !1110 4444 %%%% !2+W^M+2+W^M "T444 %%%% !1110 4444
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MV5IV&'V*#YB2WR#DGK3[QKU=GV*.W<G[WG.5Q], U6\S7/\ GVT__O\ O_\
M$4 3'2M..<V4!W *<H.0,8'Z#\JD2QM(UE5+>)5F.9 %&&^M5"^N9X@T\?\
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M-K#(ZLCR.Q4J54!2.,<YW#'2KMOIMG:NK6\(C*C:,$XQ].]%MIEE:$&W@5,
MJ,>AQD?^.C\J *$/B6T8,TT<L0VJR97.X$(<>QRX&*FN-;@B:R,:-*EXNY".
M#CY>W?[V?H#4W]CZ?Y8C^S+M'3DY'0<'_@*_D*L):PILPG,:&-2220IQD9_
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MO.(P01VQ\_3':JHU;7EF\LV\K[+AW)$! >+<55,XZ\$Y],>M3KK>LRH,:?\
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M-1KJ^O.VU;  E.-UNX&?[V<^_P!WJ*6ZN]8?^S)&6>$'S/M(BA8@E2 N1@D
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MGJ<?A7244 8VG:&=/O#/#<Y+\29CY<9)Y.>O3FMFBB@ HHHH **** "BBB@
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MV-M/#,$DRX1R&(#8QQ[#KZT )>^&[T"62SN )678I!.5_>LWK_=<C\!5N_\
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M1110 4444 %07TT5M8SS3KNBC0LRXSD8Z5/D>M07MLMW936SD@2H5R.V1UH
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M .@YJ1=3A=XD2.9C("1MC)Q@X.?3!ZT 7:*** "BBB@ HHHH **** "BBB@
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MWK1CL]D)W.6$G[K&?G4+GGY<J6/U%4[>7Q#%"6022NT2AO-3&&"<D?CQTYH
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M3&)V^4J201\GN?SJVS:HRD&WL^?^F[?_ !%7J* ,^(:G#"D4=M9!44*H\]^
M/^ 576SU(7!F\NV)+[PK7#%5;&,@;/2MBB@#&OK+4;X*D\=GM7.,2-GD8/\
M#3!IE^&0_P"BX!0X,CD?*"!V]#6Y10!D6MA?VTID1[8G8(P&9R H.0!],TL]
MA?SSB9WM0P&WY0XR/0\UK44 8W]EWA#!I+8@[^"'XWMN/?U_*F)I.H+'(GVJ
M B27S22'SD8QSN_V16Y10!D?V??F0NTMH27WG*.<G;M_O>E1?V3?"/8)[; Q
MMR)#MQTQ\W'6MRB@#'&GZBK1,MQ;!H@0IVR'J<G/S<TUM,U!_/\ ,N+5O/&'
M^23!'TW\5M44 8-QH^H7$<J-=6J^86)98Y >0 ?X^G XZ5=6#5U4*+RR( P/
M]';_ .+K1HH PUTC45A\L7EJ!O,@/E2$JQST/F9'4_F:6/2=1CDBD2]M@8DV
M+B&0<$@G/[SG)'>MNB@"E:Q:DDP-U=VTL6/NI 4.?KN-7:** "BBB@ HHHH
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M%!8I*D2CRQSF0_+T]OF/;C;4/]L:C]HAF:(^2"ZR(L+_ "C>@!)/7@EAC^E
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M/)B_YYI^7MC^5/HH CCMX8G9XXU5G.6('4X _D!4E%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 444@H 6BBB@ HHHH **** "BBB@ HHHH ****
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MTD:YW.HV]>>E<Y>:%<QW_G:2D,"I 43+]\DX'RY7))R0?PJ#^P=7DGD:2XC
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M9!Z&B@ HHHH **** "BBB@ HHHH **** "BBB@ H%%(O?/K0 M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 445%/<P6P0SRI&)'"+N.,L>@H EH
MJD-7TUFC47L!,A*H-X^8CKBFMK6F*@8WL6"I;@YX!QG\Z +^!5?4;@VFG7-R
MJ[FBB9P/4@9J!-9T^218UN4W-(8U!XRP(''YBBXU331%(L]Q'L (<'_@6?\
MT%OR- &5;Z[<27(MWV,Z7 1BA!W*6V\C^$C(/T!KI.U84>KZ-YT4.-CI)A<K
MT(W@$G_@+=:NPZWIL\D,<5RK-,2$&#S_ (=.] &'#XEU&%;87EC&SW<A$(0[
M21P,XYSR<9R/I3G\63O&);33?,B92REY-I(^?'&/]@_F*V9]7TV!W2:7:\)
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M/?Y7[U+%9:E9PZI=,!Y\MO\ N_+.3O 8\#ZD5&-<U*%&5[42-Y[!7)V@IOD
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M: ):*K2:A9Q0F9[J$1A"Y;>/NCDGZ4YKRU4$FXBXP#\XXST_.@"?%( % "@
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MCY%YZ;L@'KBFMXJD0%3IK&1!\X\T  Y?IQS_ *LG\:)/%H#3I%I\C-$[+@R
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M!Z#G'X9JL=(O_L9!),TEU)++M<+N#(RCZC)''M1/KVIXVPV"!G$OEL6)^Z6
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M_P"$?\QHY)KC]XKLS$*#NRRD=>A 11GZU9.BVK6EC:NH:&SZ*0,/\I7G\\T
M6'U&S1&;[3$V QVJX).!DX Y.*<;^S5<O=0K\VSF0##?W?K[5CW?AI9(76"7
M#%6 ! P2=_).,C[YZ=<"I+;PW!;R^<DS^9YID)(!SG.1SGU- &M:W=O>0I-;
M3)(CJ&!4]CTJ:J6G63V*F+S \:HJ1_* 0 ,<^M7: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHINS][OW-TQMSQ]<>M #J***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4U.A^IIU(O3\: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "JNHZ?#J5L(+AI @</\C8R1TS[5:H) &2<"@"."!8$959VW,6)=BQR:AU);
M9K"47BLT!'SJJDD\^@YJRK*RAE(*D9!'>H;R W5I+ DS1&0;=Z=1ZXH RKRT
MT.]%OYX#?;75H2K,NXA#C!'3Y<U-<Z-I,4$T\\&$56>1MS=/F8]_]IOSI_\
M9)*6J?:W"VLBN@"*!PNW'3IU_.KUU MU:36[DA949&(Z@$8H QI+/P] PGD9
M(W5A*29V# N5 )YZ$A>O'%/TR\T&V5S97,*( JEFE.WDL0,D]<[CZU$?"UNT
MCRR7<SRN%&]E3(*E<'IC^!?RIZ^%[$*0TDC J5'08!#CT])#^0H UX+JVN'D
M2">*5HCAPC E3Z'TZ5"-3M?-F1I-@A;:SN,+G&2 3U..:IZ+HCZ7+<,UZTJR
MRM(%V;<9).#USU_G1<Z%:7TDT[W$Q:88W(P&!R,#CT8CG/6@"5=>TYFV^>H(
MD,;<CY<!CD^WRGFIAJVG-C;>0G(!X;U.!^M4F\-6#AP\DS*Y)QO&!D,#CC_:
M/Z5&F@Z9.I=)Y"J_N25*J 0^>P'.X=?RZT :2ZI8/,(4NHFD+[ H;)+>E1#6
M[ &<2SK&T#E&5NO!(SCTX--L](LK.Y6>)W+KE5W/G:.?E'L,G\ZJW=CHMQ<2
M1SR_O0Y)!;HS'/?C.6''O0!=;6M/#%5N%9\LH4=R.H_I]:+/6K"\2(Q3KNDV
MX4]<D9 J!-+TJ3RIU(.S<RMN[,<G\,TEII.G6MS#/!+G[.C'YGW'Y@H!)/8*
MN!0!--K=E';/,)"VU2P7!&[&>GUVFH_^$AL 07D*H5!W%3U^;(QU& I/TJ-M
M)T9&7S)#\Y(P9S\Y;/7GGJ<4R+3]#E9H48EX92I+2-NWC).">O#$'VXH N?V
MW8"4Q&5E<,5(,;#&!DGITP.O2ELM9L;Z1([61I&="^-IX .#GTYJC]B\/I+Y
M>Y"99LLOFD@O@L,\^F:MQV^F6EU$ID998%VQ^;*QQNSTR<$\4 +:ZW9W3QI'
MYH>09 :,CUXSTS\I./:H8O$$#VK3/&8V )$9.6],''0YX(/2A(]&MK]44JLZ
ML5P7.%;&>YQG#\?7 IB6FAR0FX"@[$,KDNQ8+CJPSD\+W]* &CQ38@!YM\<>
MQ225.0QYQC'ISFK#>(=.7=ND8!#)D[3C]W]ZJWEZ##8?:A&4C4;@275QP>><
M-T!_ >E2;-"FF>.0Q,7?/SR961G&..<$XX]J )K3Q!IUY=16T,I,LJEE4CTS
M_@:+O7K*TN9;>7S3+'MRJ+G.<?XU&T>B2KN6XB!9>72;DA.3DYYQG\C5K['I
MMRQO5ABF:09\Q>=W0=?P'Y4 00ZW'=7$\=I"\JQ0F16''F$$C:/Q%5V\20II
MSS-&/M"H6\H'(R YP3@'/R'/'!XJ,7WA^&*:6.)/GC5)0L?)4H6 /M@&E:3P
M[YR1/;VQ01L!(0I4*>2,^^\_7)H E'B2V%T89(Y!DA5 7+9R5.1[$=JD/B*R
M6-&9)EWC(! !/S[,=>N3^'?%07,^@6K1(\4)P(W4JO"JQ(5L^F<_G4Z0Z"_F
MA([5O*3]YA0=JD[OYG- #/\ A(K>:WNVM8I3);VYF =< X4''UY% \2VOS V
M]R62-G<! =NTL,'GU0_I2BY\/QEB'M%+P?-@ ;H^F#^73VI&N?#Q8.QM22#\
MVS. V2><?4G\: (I_$BHR;;2;"3&.7('9'+;3G&04JY#K4%Q;W,L$,TGV=26
M50"2<GY<>O&<>A%59[C0'G<2PV\@?+R/L!^8$+@CJ6^>GKJ&BB"=DD$D=TS,
MXV,0QV#CICE=N!W[4 -D\1QM'$;:$R.[+\N1R"4!P<X_Y:#%10>)XY&D_P!'
MD9!\VX#&Q-@8%LGCO[59M7T.\9HH88"XB5F0PX^7 P#D=@5X[<4UM0T$F-V6
M++(70F _=P1UQQD(?P% $9\3P",,+6X)(PJXY9M^PJ/7!Z_A3Y=;EDM9FMK<
MQS))$@64<X<CYB./4CKU%$MYH$ </%$,JRD"V)W /@K]WGYNU.;5M,BMKF2T
MC61HI$1XTC(^8MM!.!ZC&?:@"'_A)T\M7-G* \>\?,N>5+COW Z^O%..O32V
MERT5JL4T.T@2N"#EV4]QD@HW&1GCUJ9=7T<[-I&>(Q^Y;A3C';[O(YZ<BHTU
MW298%:5)(Q+%YFUX&R5W8[#GD_K0!6G\4(((FMQ&[EEW9;:"IQSS]W.>])!X
MI+L5^RE\J\BD,%PN"5'/?C!^HK0LM6TJ_>5+<H62,2/NC(^4J#GD>A%0#6K*
M>4K%:-)&D#S.S1$$8QQ@CJ0<T 5Y/%D:+G[.A^5''[W&X%"YQD<]" .I/I5U
MM7D;1[R]BAC$L =DC9\Y"D@$^F2I_*H1XATZ))FGB:$1;3@Q_>!"GCW&X<4L
M^MVEIJ)46K,KP+-),@R=A#D9&.@VG\6'K0!7G\2S6OF>9:1R G,3+, K#C.2
M1QUZ]_:K%UJNH0ZE(D-LDMO' DC G:06W8^;/J .G?K3V\1::F]"LFZ/AD$>
M2."<$#TP?RI5\06;2$;' +*F2I!#$L.0>@^7]: *<OB:XC\X#3@QBD=3^^ R
M%5R3T_V#C/J*0>([A)\36BJ-P1E#]&S(#CC+?<';O6C9:Y9WTT44"N3,&*L0
M " ,_CP>WXU"/$=EYCH89UVY^9E !QN[Y[[&Z^GTH CL/$7VF:W2>&.%9D+!
MA*&YW;0./PZ_2DN]7N[/5+B,Q)) &18P6QV!(''+'=P/:EEUVRN+"XD@A,CP
M0M<"-P.J@,._J1^(-2'Q'9I(B212H6X).WY2&(.1G(Q@G/3 H AN]6U :;'<
M)%#$TL<S*,EB"JDH.G4XJ2SUF[N-12TDLU3.X,Y?C(+C(SR1\H_[ZJQ:ZW!>
M2RQ0PS QQ>8&=<*> <9]<,.M5+7Q/!)#;^=;3B6109 J A/E4Y.#T^8?UH K
MP^(=098XS91O*5 )W%1N+8Z=<#H?<5:76[I+W9<VT:6ZN5>0$Y _><]/^F?_
M (\*DM?$-O<SP1K:7*>;CYI% "YSC//?':F2>(+-P4>VE9"P1R0,+DN.>?5#
M^8H ;KNKWEG,8+* .3 T@<H3M(#'\?N]/<4W4=2U"&X_T;8ZJBRJNP_,NR0G
MGZA?TI8_$:W!MDM[2=&FD4-YJ@;5)QGKSGMC/O4]EK8N;X6C6S@[W3S!C;D%
M@!UST0T -@U:[EAU*1K14-JI:)><MUX/UP#^-5IM8U9+F:%;6',;;5)5N?E)
M)]Q3CXD:&X;[3:,L # E&#$%6D'//<)4LOB)8[*"Y%A.WG%LID J%(!/./7B
M@"A<ZWJWV8I%;L9',HRL# H,97G.,\CMS6EJ&K3Q"U-E$9EDF\N0^63C#!3R
M.F.?RJ ^*(O/C@2U9II%&$#CAMX3:3TZG]*CA\3C?Y#6<CS>9(F$Z?*V,_J/
MU- #8]5U>62UBFMQ%OD3>R0N=P.PD?[.-QR3Z'I4VI:Q?VMS-$D("JP"N878
M8)0 \=3\S\#TID'B<LT:S617>P!VR [ 1'^?,@J9/$,<VCQZ@+0X>3:BLX .
M 6SGMP#0!#'JFLR-M^RI&S!,[H7Q'DJ,DYPW4G Z8YI;K4]4V6:QV[JUQ:EY
M=L1/EOL)X.?[P P1WIZ:S<M%YYBC\J2Z$,>YMNU2F03[Y[>]1V'B9IVLX);-
MOM$P7?M;@9"'(_[[!_ T /6]U6*"T58FD:224.7C8G DPHR/N_*2<GTK2T4W
M+:/:/>LS7+Q*TFY<$,1DC';'2KU% !10#GI10 4444 %%%% !1110 4444 %
M%%% !2#\:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J&K6
M<EY# (2-T4RR8+E<@9!Z?7I5^L[6X+JYM8HK*1XY#,NYU8C"]^A!Q0!EV>AZ
MG;2V2_;6-O;[08Q,1_"@/4'(R'XXZ]J230-0^T2&&\:.-C.RA9F'+[B"1@YQ
MNQC(Z9IS?\)'&\(!,B[W#MM7H& 4_BN3]?RIJQ^(BR;Y9'7[V<("#A<<#&>6
M;@_W1^(!(N@7:70E6]<!75@#,Y& 4P,$X_A?_OJK-E87\6EW&GR2JI\LB*8,
M6;)SU/4XXYX[UG9\3F-V9)@WDC8BF(Y;C.22,'.[G!&".XJ:_M-8%\]W9"3?
M)$B8#I\I ;(Y[;MN>Y[4 !T"_+O)'>I ^P>7L+L%8;>"">5&T_\ ?1IK>&)V
M>93?,8F?*[F;(&U@!P>Q8?E4MU'J\>C1();AKR6X;<8RF57YL 'H!PM(L&OO
M,J3R,L:OEWC=1N')X'7T% #/^$;NFEF>74 V]MR83&QOFP>#R>1^53VNA3VL
MVZ.XB">5)&,1=V8L"<GMGMU_E4L8-?D@M9GFFPQ5V5W7(!"9W<=.'P.V1^!%
MI_B$IB2[F4?9S& &&=W/S$YX/0\9^M #E\+2K!M-\ X1E$B(5V@^9G SP/G'
M_?-7%T+_ (ET%NDL!\NY:XP8LQG<6.-N>@W<<]0*KZCINL7<0C68*&L_*<"8
MXWE6#<8YR2F#VP:L:AI^H%XTT^4QPQP>6@$Q3:?H!SD8&>W6@"NOA?YPSW*D
MJQ*[8\8/'S'G[W')IJ^%  V;E&RZMAH<ABI4C=SR3L&3WR::VD:VZY^WR*RH
M0H%PV >=N>.>=N3WP?6DCT[7)2DB7+1+]H#,LD[D[0Q)XZ<C V]/SH E7PO&
M=J/=!D55!'EC)QMXSG[OR]/4DU/#X=CBCNHUE4I<0"$KLX[X)Y],#C'2JR:+
MJL;QNEX=X$6]FG<[B-^[/'(^88'3BEATG5X521[QF:(AEC%PY!P4R"3UR%?K
MP-WXT /3PY;6TJRM<[I-\9#.!EF7MUQZXXR,U+<^'+6::2=YBF]S(Q"C@YSP
M>W(Y]127^DW-_=K<$K&KI%N E8,I1F)QC_>Z^WO44.BZC]CU"&ZO/.-Q#L3=
M(2H./0CCKCOGTH D;PW9S0LJ2*(W48VHO!"%,C\#GZ_6K&H:';7UT]Q/*^3'
MLQ@8'##/U^:LQ?#^I*J(EU&D2QNNQ)&7EF8XZ8[KSCMTJ]9:3>Q&]-S=>:UQ
M%L!W':#C'W<<?G0!))I%K>3RW N"Z3<X7:0#@#(./]D?K3K/1X;22<Q7,N98
M@A4[2%QG#8QR?KZ5FIX:N8BXBO6"%'"@,5VL5(SQUY/MT%6H-#DA-R5E4B>W
M:$9+9'S,1SZ8;]* $/AFS9"AO+C:%*L 4QDAN?N\8#G Z=.*5?#=D9(9Q<3.
M4?S-Q*D-D[CVQR?3\*KQ^'KU&'^EP &19)"J8+$*@(]A\I_[ZI(_#5S&@47<
M>U4C4)AMN%VY4C/*G;_X\: 'P:!I4D44:WT\HF5Y%)D7,BLJJ3G&2/N_CC-;
M&GV4=A#Y4<SN@Z;MO'))/ '7-9KZ S6EA$)U5[.'RU<+C)W(<CGCA"/QJLOA
M8B&2*2Z4[]^UMISE@O)YZX4Y]=QH MQZ#I3R3")GWC<CX?.W=AL?@.GH#3?[
M TNZ5V661\LV2&!P0W/!&."OZ5%;>'&AN(7:Z!,)5DX/RD; <<]PA'_ JNV.
MCM::B]T)U8,) 5V<_-(7'.>V<<4 5)/[$9()C?*(DB1%PXPP&2AQCV;]:99V
M^@K]LM[6\'SPA9L.!M4#&=V/ZXI;3PU]@D1[.]"RA%4!XP5X4ACC/?=GZ_6K
M?]B(-.N;,2[DEMUA&Y0<;00"?6@"H/#UA+#((+B14X5 &XC*DY/UZC-2QZ;H
MTL C5WVR,[9,I!;'RO\ AUS]:@/A.-F9FN "RL,+'PN69L 9QCYL8/7%6&\.
MQO9P0O.I:%9%W>4,$.P;&.PR!QZ9'>@"=-&TR.19E'+N6!\PX9B0Q/7J2H-,
M&C:,=CX4A,;3YQQPJJ._HJT3:#'+96EKYQ46S%@RH >0<X[#J?P_.J5KX96-
MBAN@FV4.%C11N4;,9&..4- &A;6>E6K&XBF0%X\%S-G*\#.<^PYJG+INAI=I
M;%S&T<>]P93M9&W*,DG&27;!ZTT>$[46;127$A)Q^\/48<OU],FIKS1K*[ S
M=!&54@R I' 88P<\X<_I0 Y[#0894\UX_,#A!OG).XDMSSU)R>:GBCT>*-EC
MF@"3MYN/.R&(;=D<^N3Q5/\ X1ZT@DW?:VC=Y,QYVY'+''N?F-59/#$2W80W
MY,1A.]7;Y^KY;_Q_K]>N: --=-T2)+=AY05B/))F.'Z8 YY'RCCIP*J7MEX?
M-J&\Z-1N6(/'+N.=P(4 YSR1^!JVVC07-A91)<OY5NPD1D(P_.X9[$5"/#%L
MHB$=Q,@C '&WY@-O!R/5%- $^GPZ7;220129FV;)!*_S.% !)'3ICD"DA.A6
M\8:&:V"R(ZC$N[>O&X=>> /RJ5='A6_>[$L@9U<,HP =WX9J >'+0.C>9+@;
M=RY&&V@8SQV*YXH 4VVAM;Q.QB$<R[D=I""0 "2#G/ 4?E2SWFD1W-S#*4,A
MMP) 2/WB#?\ *.>2,/\ G4DVBPSVUO!+-*RP1M'G@%P5VG)QZ>E5I?#4#(^R
MYF\QU()?!!)W\D #IO:@"5FT-I'W/;[Y)-K#?U<@C&,]<9'YU%Y_A^58KAO)
MVW"^<K'(#!#U/T+?K4\.@6L$RRPO(CK(9 5P#DYR,XR0<GK^%.?1+=[>&$S3
M@0*50AAD D$=NQ48^E #8AHML;.>/R$W\6S9XY&./S _'%5H[S0KF5X/)A9"
MVS<5!5SQT_[^G\S5R;0[*:&TA<2;+5@R -U((.3Z\@563PW;+,I\V0QJO )^
M8-\F#GV$:X&* &BXT&!V"&+;<1")AM.SRPI?&<8 PQ-!N?#C^9,WV8D95R5R
M?FW9'_H6?QJ;_A'-/Q@"4#:$XD/W0A3'Y$T^7P_ITS9DB9CO+_?/4DD_^A&@
M!D-]HWVT"W\HW$S^0=B<D@'@^WR$9]JA%QH,5S#;I;P* [[&6+"JX*J1TZY(
M'X5=71K))DF1&62-MRL'.<Y8_P#L[?G2#1-/\R1S$S-(Q9B7/)RK?S1?RH K
MP7NA+&&MA  "-H6/'.0!V]7&/]ZH(]0T21I919)E(?M<K"$$@C'MRPW5<'A_
M35" 12?(P8?O6YQMQGGD#8OY5)%HMA#YOEQN!+&8F4R,1M/7 SQG% %"*_T"
M(L3!# UN^%S#@@GNO'\NG>KMQ>Z9921F0(C2*TJ.(^#@$DY ZXR:671+"9%6
M2)FVG(;>V<YSG.:?<Z18W<J27$/F,D9C!+'[I!']30!4CU/2"9V:+R]K?.7@
M*[CLWGJ/3-*E]IAN%LHK= $+AE,6T1X )X([YJ>30["5"DD<C!NN96R>"O7/
MH2*?!I%C;S/-#"4=RQ)#GJ>N.>.M %)=8TA2)WB5$*ADE\D\@@MSQQT)YHGU
M;34@MKP0+)%+*Z!Q'DH55B3C&?X35D:#INT#[.< $?ZQN<YSGGG.3U]:EDTJ
MSEMH[>6-WCC8LH,C9R00><Y/!(Q[T 5(]2T=H9Q"J,L+"-UCBSRQP  !SR/T
MJG8:MHT5I%!;P8:3RW>$*6VEMN"<]<96M8:38B&2(0D1RMO90[8!SG(YXYYX
MI%T73T7:MN OR\!CCY<;3UZ_*.?:@"JNOZ3-&3&6E0$D[8B<;=IST_VE_.F'
M6]++*QA(V-SNA(92 >@QS]TCCTJ_'I%A%&8T@ 0@KMW$@ XR!SP/E'Y4/I-@
M[$O;(23G]6/_ +,WYT 53XDTT.(]\OF%-X3RSGKC&/7/:K]A<_;+&&YV%/-0
M-M/:H3H^GDL3;CYAA@&(!YW=,]<G.:MP0QV\*0P($C0851T H ?1110 4444
M %%%% !1110 4444 %%%% !0/>B@'- !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %4-7NY[.""2!5.Z=$?<#]TG!_&K]% '--K=_+I:W:1+$PF
M QM+ @Q[L'C/#?*<=Q5JTU>^GCU%GLMAME)C3^)B,\$=>< _C6W@>E07LWV:
MTEF#1KL&2TAPH^N* .4N-1UTP%[>1P^UW#>0<-@SD *1D9"IU]OQOQ:EK"N]
MN+4,8I/+#NC9<!6.3S_%M&#VW=ZG?691!I[XMA+<NJO"6);G&<>F 2>?;UK6
MNYC;6<]P$+F*-GVCJV!G% './JNORV9:*T57,38(@?.XA\8!/&"JY!SUK9EN
M)Y=%GDMM_P!I$+;3Y14E]N1A3[UD'Q5]GC47"P7#M'YI:VD^4##$+@G)/RG)
M[9%,O/%4H:."&W$,^XB02,"1C/ &>>!^% #;6^\11R>3+;M(?."%VA)#*!&,
MC!&W.6.3GD$4NG:AXCS%#>6P"B ;I/L[;B_?@''MV]:8GBR=)"9K:)0N5YE"
MY/R<D_PC#9_$5I:;X@^V7@BFMOL\;IE'=N2?D^4CL?G'ZT 5KFYU>VUJZD@A
MN;BW)4*/+.U!@ @#^+GG=GN0>U4TN/$K&0-;2'$@E&5(P>/ESGE>O';'O6MJ
MVKR:?J0C)1HO(:3RQRQ(W$YYR!@=<'O[5G3^);EYYTMT7:R_N2#N(P7RV,<@
M[!^8H !?^)S'_P >_P WDLW$.,.&.!SZC\NO-+/>>*<S>7;!0) % 0'"_-@^
M_P#!GKWZ5,GBB5E#&S1=SN@!F&?E7(!'8^N>E'_"33R,B0VB,SK'MRQ&"Q09
M/'W?GQGU% %B0ZO'KB>5&[6CRCS#V"^6HSR>!G/ JGJ<OB1Y[Z*VAD%N?EB*
MA,XPW(R?7;G/OBK>L:I>07B65JJ"0K$X;KG,@5@1V&#U[\^E4;O7]2EC*0VS
M0MY<;EE4G!(4E>1_M?H: '2_\)$/NHW[G(C8!26RC')&<'&5'/<$TVY;Q-()
MT$4GE.H 5/++ %>S''.>O'KC%6+[6=0M[TK';ETACR1M.7R%^8\8P,G\C4*Z
MSJD=QY[6C21F(,8T&>2(P-I[_,Q_#/I0!-=1:Y$]N;4W!7[+&DBHR'# _-C=
M_%@]>G!]JGNTUXVME]E=!,T6+C.-JR  Y]P2"O'KFDMM5U.XO?L[6L<8$XC9
MB&.%PY)_\=&/][\X9[[5TU5E0;HH9R&41-\T9"8Y[GEN?8T 116WB&X2,7<T
MN$*'!$:D_O,DG&>0HX_E1I5EJT,4NG/,RQPV0VD8!\UUP1G'8JQS_M5*NH:Q
M?Z43%#]GNOM 0 +C QSG(/0]_P"5/DU'689HU-K&X8N"1$W\)VCG/?DCCV]Z
M *2:=XAAAD:">0-, 74NA.0L0R#ZG$G?'2KU_#K[QZ>+.0"1$'GLS* 6XSD?
MGTJ#^T=>8Q^9;J,MG*1, ,*#SU./FQQ_=--;6-;,<I6T*[8U*[K=]S'Y<X X
M[MQD=!F@ CL->BF$J2RL3&@99+@,"07SGCN&4Y]L4^STS73J$,E].CPQ/$V/
M,).0I#'\<^U2:C>ZO;W<QMD=HV6,QCR"X7Y7R.#W8*#Z9J34YM0BOXY;43O_
M */S$JDH&Y.<]">V.O3WH IKI6O!Q)YR!_,Y83$-LWEL9QZ'&.E*UAKZ:0(&
MN7DNGN,[EF(PNPC[V,@;N<?RIGVC6Y9Y3Y$ZK*RG;L(V@-V.>. ,CW-/CU'Q
M T2F2#:Q5^!"QVMM!&>.F[(XSVZ\T .DT76"WG"\\R4F3(\TK\I="%4@?*,*
M?SJ<:-J#Z1J,%Q?.]U<Q!(W\P[5Q&!^'S;B?7-59;WQ-Y<QCM55ODV!ER0,#
M)X&"<]0,U->MK4=_*]HDA66%.J@JIP<XR>N<<4 .33-9"7P^V!#/&5B_?,VU
ML\'D<8'''7K5230M>>/:-2(^0+CSVS]X'.['IQT[=\FK,T_B%6F5(I"JN0&6
M-"<?-C'/(.$SGID_A+:-KQOT:Y_U'F890B\#<XZ]>@0_C0! ^CZUY<H2]7S'
M8_,T[\J4*],8!!(/'7VJ)?#5\'<_:RF]FW%9WRP+.PY[?>' ]*EO5UQIY9;=
M96DCD<1Y"!0A9<;?7Y0>O>G%O$4DPC"ND9$>Z3$?!RFX@?B_7/2@!ECIVJ2?
MVQ;WQD_TB)HX9&ERO.X<*#QU!I$\.7B\K<JA9][HLC8)^3'7_=;GKS4]V_B!
MEM1!$REK;]^04^63:>W7(..^*6&#6&U:T-R)&@A9B7R@!XD4%NY.-G3B@".7
M0;V:UTY'N8C/:L=TQ))P3R!ZG'<]^1BH4\.ZJT\,T]]$74@,P+YV@)QUYSL.
M<_WC3X['7+:SCBMI9%VE=P'ED\ABQYQD[B._3-7+9-;%E?B>1C<,Q\CA!@9_
MA.?3U[T 9@\+:BEO)#%JI7?&B#.2$P .![8X_I5C_A';TS0R'46"I<-*RACS
MG;W[_=/X-BGQ6.K*+FY9G^TM'&D9+)NVAR6'H&VX]LU473-<^R?9G:3RUC38
MBLG4.K$[L_>X;MB@#JX?,$*"=D:7:-Y48!/? ]*?7,/8:[)%NEG?S5.$967*
MCRL>W);.35R]@UF26V:WE*;8AO D& _.[/'S=L>AH VR0.M%<]<:9J<MDD3S
M/*ZR2_>EZHT;*,^N"W3VIUM8:Q%J-OONF-G$3\N[)(.>&Z9ZC'7&* -_(HKF
MSI.HI#MM5B@FW,9)DE(:8\[6;CIDY(]\4ITO6MS'[?*=XP?WQXSNSCCC^']:
M .CHKFUTO6UEBQ?R>4LBLP,I+, ?7TQCCZTJ:5K*&/%Z[#&7W7#</@<].0,?
M=Z'- '1T5S T?66C0/?S*54 A;E_5L\X]U_*EDT?6I!/OU"3+2%T*SNH^Z^!
M@=,$IQT.V@#I20!DD49&,Y%89TFY.EFV*02.+SS]LDA*.OF;^>#CKT]JIC0-
M24>7YT)@54*1B5P P=&QC'  # $>HXH ZFD+ #)( KGH](U5=+GMY+KS)6FW
M@F=P&7&.H&5]<#-3_P!CSG2[N"6?S9YW#!G=L<8('MR#T]: -F.1)5W1NK+D
MC(.>0<']:031&8PB5#*!DIN&0/7%<TWA[4 I6&\V(9&D*"5AR7D.0<''#KVZ
MK4^I:'>7-Q?26\L2?:@N&+-N7  Z8QGC.?I0!O&:,3"(NOF%2P7/) [_ *T&
M:)91$TJ"1AD(6&3^%<[<Z#>JAF@N3]I)?Y]QS\SKZ]@H-6[_ $(7<YE24H4M
MQ%"<G*L-PW'UX:@#9R/44N1ZUR[^&KIHMJSP*?**8(+*I\S>  ?X1TQWXSTJ
M4>'KD2.?M*ONG:7<Q/0Y[8X.#C.<_P J .@65'9E5@2APPST.,_R--N+F"UB
M\VXFCBCR!N=@!D^YKGH_#5ROV?==0_NF!XCQMQMY7'?Y<9]&-6;?09;:S6&*
MX3<LJ2C<I*[@H!R,]SDT ;?F)M#;UP<8.>N>E.SGI7-#PLZON^TQ';Y>T&'
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M6L6MIKF*V8PI.D8*Q'<Y?:0V,9_Y:?SH ;/KZQ:;;7GV1V>>0QK'NY'WN_\
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MP"HW'D^Q.3^- !9ZV+V^@M[>UD1'1G<R  @ *1C![AQ3?^$DLPCN\,R!!DY
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M#V//2@#:(!Z@&EK.;6K2.\:UF9DD\T1K\I()(3DD# Y=1S6C0 4444 %%%%
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M()HI%ND0)*)2%0C) 0=<_P"P?P8U-8>'C:3QR><I,:.@^7D;D0$@]CE,_B:
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MI?L>AF*5_-0K#^[E8W+?+ST8[NN>F>F>.M $4'B*UN+AEF@*1+@Q.<DNQ)&
M,=?UZU8NM9L=.EN%>-U,95I2J@9+#@^_ JL/[ +H/,@B,$WFKO<?,54G=D]@
M&)S4EQ+X=NVDGN)K68C;N8R;@.H'?_>_6@!6\36"M*'2X41;\L8^#MW=/KL;
M'^Z:<^O6,4,$PAD'VLG;\H!+#C!Y^@SS3#<>'O-$7^CNS.R$8R ?G)S^;_F:
MNI:Z=-;PS)!&\<8W1DKG'?O]* *<FL[(;"Z6SVI>*"[.V"@XVC@').XXZ#WY
MJ&;Q/$)!Y4#M$8R2YQ\K?)MSST^<#BF+J>D26R3+IH:.U=(X=T:C8S*&^4G
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M?L:N1Z^DMT%6VE2-+=Y7W@!@0$;;C/7#4P^)H=A(M)MZC+*2N5S]WOSGVZ4
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M'].^>*S^)KL/($L4D"S-'E7.%P7&"2."=G3_ &A2RZYJ,2^:ULA#JI1.<?\
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M)%J2F6).#]SC],_K5FP.DJRQ6'V8,T>0L>.5Z_U'YUG_ /"/Z7,LCM-(59Y
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M5]!54ZI8"*27[5'Y<94,V>!NQC\\C\ZCCUG39 ICNXV5V*!AG&<9Z].A'YT
M7MH]!33%&9%D**70$*V.1GK_ "K/M=>T^ZE$:3!6:0H@88WX .1[<]ZD76=/
M>3RH[@/)YGEA54DD^W'3@\].#Z4 7(XHXEVQHJKDM@#').2?S-/P/2L[^V[
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MELD?04IUNU6)'9)AN9E*[.4VL%)/L"1^= &E16:VM6RZ?%>^5.8Y20JA/F(
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M=G/WOF^;&>/3 ZU"VG^)'1F:\?S@9!&P90HW+@'&.0"!Z5(NG>('A^>_E1R
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MO7S,Y .<?NS@BI$\66[D8M)\&8Q;B H)&>1GW&/RIT6H:(JW#/9I$8&:-O\
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MP!'X<B@#5P/2BJ]M?6MVQ6WF60@;N/3)'\P:L4 %%%% !1110 4444 %%%%
M!1110 4444 %(!@4M H **** "BBB@ HHHH **** "BBB@ HHHH **** "C'
M.:** "BBJ6L7<MEITEQ#Y>]"N/,( Y(![CMGC- %VHKLD6LN!(?D/^K +=.V
M>]<]+XK3;&L/DF0%2Y=P@*G;SSRH.[C-+'XI^=T: ,QW.H9PF%"D@<_3!],B
M@ >?6#H4*6L=PUP/FD=UPP7)POS8R> "<>_>ND<E49@"2!G [US3^+HU21EM
MXFVJC#]_@$,A;KMXZ8 ZD^G%6;KQ UKIKWLEL@47#0HID.6"DC/3@_*>* ,^
M&?Q%Y)BN8)E:5V8LH#X#*,+U&,'//..*?#<>)EMX_P!RI:.,!E9,[F^8?>S[
M*<X[U)>>([E89DBMXHGR1$[29!Y8>GWLH<#]:<VO7,-PQ\I98I69H@202HR!
MMXYY4L?9A0! ;OQ4$4QV@?>#C>JJ5[<C/^T#]$/K0K^)H)'C2%FAP[!CM))+
ML>YZXQCMTJW?ZEJ<4.F21Q*K3_-,B*6'5?E]>A/Y56GUW5&MALLRDKPB10JD
ML"02.HQV"G/<T 5(;WQ#',UE%%+YBQ%P&13N)<D_-]W(7WQGBKR#Q2QBD9E7
M&W<FU!N_U><\G'63OV%+%K>J3R,J64<9)C53(&XW;<DCJ0-Q]/N^_#VU;5/L
M<%PD W&21'C\EN<*2N.^"0!GO^E $=JOB=]OVEBA5R6 $?S#*#'!/&-Y['I4
M^B+K=N\<>H+--&(55F=TX<'!/')R.><=NM2#4M0&FP3M #(T_EN%A?E,D;@I
MY';K5$:KK4SQ_N'B0L 1]F92PWQ^N<<,WY&@"YJEKJ+:J;FP5\_9]@9G&U2,
MG@9ZDD#D$>XQ51K#6IY+@R[@LZD$%UQC+X!QWP4Z>AJ/^T]9C=KV:!@JQQIY
M+1LBEV=UXR?79UYP>@S5J\N]:@OIQ A:)0P'[EF4ML0C&.>NZ@!(H/$ 3]Y,
MY?S'W8V  %>-O)R >F<>],:T\1%' NF7,:* I5L?=W')(^;AOSZU%=WFOW$,
MZI;20E2?+V1,&/R/U['G;TZ'BKMS=ZO;W<-K;VAFA9$!F(/RYX.>>QY/M0!+
M>6^KR+8"UG"O&A\]V.-S8'4#\:HKI>M>=O$Y19%C5SY^7X?).[ S\I('UJ*.
M?7DVR%96,(#%'A.&!C7(SGD[@WT_&M'5KG68)I381(\0"A<QEN2&R>.3R%&,
M=Z *HT[7Q\XO?WJQ *6E)5B-O!7'J&R?>F2Z-K;(&^WYFP$>19"K%1D#!QQ_
M"Q]\TLFIZT+];=(069GP#$0&0,@SG/ PS<]R*/M/B&;3V62)XIVB<@Q1?Q <
M YZ>QH AN],UN.:25'>4S2*&,4[!MH,AQR!M^\HP...:NV6EZQ#=0R7%Z)56
M9G?,S8(*@<+CU!.,X&:6_DU=+B1K$3E7CC*@QJ=IP^>N.<[,^U.U*#5)KY?)
MDF2-EA/R;=J,),N>>?N_A0!7CT*_B??#<"-EW*")G^9292 ?Q=?I@U-IVDZA
M;W"S74ZS.557/G/V=S^/# <^E-MI?$3I=&=%63R,Q*%7;OP.ASZ[NOM^)G7F
MN-L;3"([1OD6/(7*Y;C^+[_'3&.] $NK:;?7=[(UI((0RQXDW$'Y=_''NRGT
MZU#/HMU<6<:%E4I-++L9B,YF$BC(]AC\:A^SZ]<3Q//O!1%&0R!<YC).!SGA
M^O'3%%G#X@C:'<TQ7>AD9RA+?)&&S[?ZSISG% %[4=)NI[V2ZM;A8G= F"3@
M@*PY'U8'\*K1Z'?FSNK>>[63SH40,S$_,._L,5/%'K*:1*CR.]T70AQL#;2%
MWX_AR#NQGVJO;Z=JJPSSSR2FYDG@8['0$HJIN'IUW<=/SH :^@:B6)^WY#1X
M #-A#NSMYZKVYJ]I>D36-RLSW!DPA0@L3QM0 <^ZD_C6?;6.O0_8X5N&$,;J
MSYVL<87*]N/O>I^M6AI-^M_/=1731F6?[H;CRP.^<CK@< <4 4;#P]?FSQ-.
MUO/R&;.[<3M#'@XZ;A^1J8^%G*RJMYC=(SH<$X)#;2>>HR.?]D40V'B"2*,7
M%_*KC&_:4&>1GL>V<?6F#3_$"AG295DD4E_F &[8HSQWR"/QS]0"Y>Z UWJ,
MUS)<)Y4H0&/R^H#(<$]_NG\ZBO= DNH(VCND>2*U$*DKR2%89!SQG<,]>@J:
MVM-62*X2>=I-UKL1F89$F,=!56WTO5D5GM9OLZ-M:./. N5 .X8[8H 8GAAS
M=_\ 'RD<:1$ QIAD)+Y"\_*,,/K4\7AR!0R&>%IOD('D_*FV0O@+G@'<.,TP
M:7J\<@DAF(+J%</.2>O7..?_ *]-AT/5!,TDEQAG8>8XE)9A^[S@XR,A6X[9
MH >/#*QA6N+Q62'!0F+&P*5(.<]?EZ^]/7PUY4T+1S(5$JO(=FTLH0#;GN"4
M0_G5:TL]9F^W6M[YA+6GE)(TIV,VQ1G\\\CWS4LVE:S)"\7G@(\3+CSV)4_O
M,#..?OIS_LT 6-0\.17MY-.957SF#,/*!(PFWKZXZ'MS2WFA6\M\UY+.%8-Y
M@+*/EQL[_1/UI]_8:C/+"]M<&#9$%QYK$!L\D_WN,]:JVVCZ@@E:>19&EMI(
M<-.S!"<8ZCGG/TS0!%'X725Y ;O,:H$1D7#?Q C/H-V,9[<G-6;?P]$B@P7*
MX5D9?W0;!4CN3G'R],^M0'0M1VNJ7948?8$F90"?,(X'NR'\*CE\/ZD1+Y5U
ML,I!<I.R$X+\9P<??4]/X: -&ZT:"YU1[B:Z)+!#Y) ( #*1Q[E/Y^E,MO#L
M-J93]I=E>W:$Y X!503G_@ ^G-1?V'=,M_YLRNTY4QL96R=LC. 3_".0O'I4
ML>CW9L]1AGN1(;I-J NQ&?FY/IG(&!_=H C?PS8W,9$<Q"AVSM P3EL@^OWB
M*>^A012//-?3_/*&^8@=<@+GT^;%5YM O'$BPW)B$C%W196 8EG/!YQC<.<=
M15J[T>ZN-2:X%T=A10%+'Y<%2>._3.?6@!K>&[;R91+=S$L%)D8J"-I!!X'^
MR*F.D6OFV\?GD&.%4$?'S!#D'IVS^M9Z^'+PVOD372RYBEC8NS'EAC<!QSZ@
M^IJ6;0+A\.MP@D.[>C,Q5@60A>N< *1^- %NSTFSTZX=4F;S+F/RP&QDX4 D
M<9["H)]&TE81;M,L(2-8C@J#G(<$^_R9IMMHU[:71NH[B*9O-)"$$!0V >_8
M?GBI[K0TNM1>XDD)5V!903C'ELA&,XS\V<]L4 1IHNFQRK&MQB1.0H901M\L
M] /]A?SJ.TT/3;B(/;7IG1"J@J49?E7!&,8)(QD]>!3&\,22+F6^8R[2ID"#
M+;LAR??! 'T'6K5[I-W>6,,+W4$3Q3"3='#@8 P.I.#[B@!7TM;6PNX1>%8)
M$.-X&(W)Z\8XZ<?XTV"PLTU,^3=DS1R^;)&QZ#YC@>G,F>]59?#)) 2ZC56?
M>RNA8%N,L/FZ\"K-UX>BGOI;II$"RN&D&S[P!C."<_\ 3,_]]4 6&TBU)NW\
MZ15N4=)0&&,,2?TR?SJ*;0M/EFDG9W&0^1N! +%B3@C_ &C45MX?\K1;JQ6X
M5Q<OO\PJ3Z=1GD\?0^E10>'G-P9+B6 [9=^%CP7ZX+<XZ\CCB@"[-8Z=-'9/
M)*[(H6./YS\XX(!]>5!J"WT+2&C!C)8)OB))'NI'3MR,]:JCPM$81']LP6PK
M.JX+%<8[_P"R>/<U*?# >XEFEG5O.W;UV'NY; YQCGH0: +T^CZ?,D22%L12
M&91O[DYR?Q%0)HFCHRQERS(#@-+R%VA,?0 #\0.]-U'03=7;3)*J(X1"BC;A
M1PW/^Z6& !U]A5:?PU'/&\B7J!)F+ A/EPSJX .[)&1Z\Y[8% &A_8FF?:%<
MY,BR&098'DX[?\!'Y4^+1;$6IAC:8QEU8,)22"HP,'T &*I#PS LB2B5?-0@
MAMG/!3N3G^ CK_$:OZ193Z?!]GDF22% !'A<$<DXZGCD ?2@"33],@L)IY(1
MCS=H Q]U54 #^9_&KM-21'0.C!E(R"#D&A'61%>-@R,,@@Y!'K0 ZBBB@ HH
MHH **** "BBB@ HHHH **** "D&1UI:* "BBB@ HHHH **** "BBB@ HHHH
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MY]Z ((?%<4K0K]CES*V/E(8 84YR/]\<>QI5\2-Y?GM;QB(Q1R9\X$C<Q'.
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MMF7RC\HA_A'.,8_2IAH.F*"NTA3+YA4-CYLDXXY[FFG1M)A@"O\ +'E8QF3
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M%,N]8T9Q-#>QHL$JC<S(068EU8$8R" AYJT=9TL'&"3N8C$1.2I"DCCKDXH
M98:Z;R]BMOLC)YD7FY+= <X[>U4+'Q-+]CC^U0J\S1JY8.  6VD9&.% <#/L
M:T?[;M&!GAA=TA&9G\L@Q+@GTY.1C'O3KC6-.M1%YRE!-"9!^[_A )Q^0- %
M >*&!5I+9%5IDC51(2V&4$GICJ3W&<4[3O$S7UQ;1BS55G8_,)<X7 QVZ\\C
M^=3CQ)I3G"[V;:"%$1SR0 /K\P_.F:5J&E1LEM96KQ))*%C.WAB4#9R?8@4
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M?V*[0L6,B+M$8'R[023W&<GZ8J</J\-CIB0QR%O*7SL@,=V5&&)/ P6.>O%
M$<6CZH\Y-S=,8O-#;%N&QMP_'0?WE'H<4:;HNI07T,MU<1M#"ZLJ"1FZ(Z\
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M (+*V.OJO7WJ ^$8Q:"(W:C QQ%A3P!T!]L]>IS4CZ;K:0CR;IFEW1DL\[<
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M6JK:S6EKNAOWPTI^51C &?<]AQ3/^$CL&EBCBB=XY(]^[9PN=FW(]#Y@Y[4
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M'<%$841\]\YQT[9I/^)^9DYE \]MW^JV[=PQ[[=N??-5/[<U*5)=EO(A=8Y
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M,Z\_[:_]\BNBHH YP>&I/M,<S7$>$=V"A6 &XYX(;.?7/;BIUT>Z;1)=*>6
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MJ%S;VL&(QCRY&@) XR>^&_2KFCWMW>/<BZA6,1,$&.YZ_P#H)7\<UIT@ &<
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MW );S8U;)7&<CTJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %,FD,4+2"-Y-HSM09)^E/H) Y- &8=7D'32M0/_ %_P#BJ!JS
MD<Z5J _[9K_\56CYB?WU_.C>G]]?SH H?VG.5!32+\_A&/YM0=3N-N1I%\?^
M_?\ \75_>G]]?SHWI_?7\Z "-B\:LR,A(R5;&1['%.H!SR** "BBB@ HHHH
M**** "BBB@ HHHH **** "D&<<TM(#D4 +1110 4444 %%%% !1110 4444
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M/FV],^U.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M"<#-4X]4LWCMF,RQFY7=&K\$BKAY&*Q/^$<A/V8/>W3+;$&('9@ <@?=H M)
MKFGR"7RIO,\N#SSM4\ISR/RJ/^WK4012.K(\S )&64L03C/!( ^I[46^A06Z
M/&D\Y22%H6!*\@DGTXQN.,<<]*0:!!F,M<W#; H/W!N"G(!PH[D_G0 ^WU_3
MIXO,,QC&Y5(=2,$@'\L'KTIT6IV5QJ$ELF&90%+[>"26&W/_  $^U5F\-615
M5,L^$(*@[3CY0IZCN%'Y<8JS::1#:3&2&>XY(^4L, 98[>G3+&@#+F?1C?7'
M^A%)-.3<-N%4X(.-H/7)&,CGMFK O[:TMKBVETKR1&BRO$3&$8,2,Y)QU!ZX
MJP^A6S7INO,DW,^YE."#\P;'YJIYSTQ3_P"QT$MS(MW=*URP9L,.,>G'3VH
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MRZG$MM<,TDJM"\K94$@*6'/ ')Q7144 ,AB$,$<2DE44*,G)XI]%% !1110
M4444 %%%% !1110 4444 %%%% !2*<BEIJ?=H =1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-3[M.IJ?=H
M =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 !Z4V/[M.I$^[0 M%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex10_8page002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_8page002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***0?>:@!:*** "BBB@ HHHH **** "BBB@ HHHH ***CG\[RO]'V"3(^
M_G&,C/3VS0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4B]_K2TU>_UH =1
M110 4444 %%%% !1110 4444 %%%% !1110!!9W4=Y!YT08#<RD,,$%25(_,
M&IP0>E   P!BH[>".VB\J(87);&<\DY/ZF@"2BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "FKW^M.I%ZGZT +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPA#.&)'FEI(V)($8^8]Q@/C'/(S5N.#7$T5XY))GNO,C.=Z!RFU2X4_=!SN
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MA3CER1TYR9&Z^M+8:1J-NM^9[MI)+B':C^:<*VW'3'&#WS^%02Z)JWE&&&]
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MGTP.E5[GPQ=S07$8O$_?LY8N&/WC)@]>H#KC_=J?4/#DUU>37,=T$9P%&<X
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M8SGB@!5L_$;0',\JE4;:IE4DG*9R1[>81Z9'3M;N$U<Q:7!&TWF^63.05 #
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MPW(/,\E85D*JAEW1B3&,;<]1P.E*+?0%U..^AU"&.2W!+*DZX/;YN^.?Y>E
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M.M57E\.6I6U6&$K(N%" $-N#''X@M^=-TX^'4MY&2YC>/4OF:.5@0?XB,?\
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MSUH Q=*UXWFH+:36Z[SO7S58=5P2,=A@^O:J\/B6YC$#WEJGEW4VR%E)7(W
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M% !1110 4444 %%%% !1110 4444 %%%% !5+4M-CU$1"5F C;. !S[&KM%
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MES$"]RMQEHR2,%CC[V/XB <=*Z6B@".!9$@19G$D@4!F P"?7%2444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@P"?K
M2TB]3]: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJE_J-M
MI_D_:F91,X12%)&3P,^G6@"W16&OB:UDD=8HY&'F(D9VM\X;;\W3@?..>]-M
M?%-K.(]\,R%DS@(3DX0X7CYO]8* -ZJ>KS/!I=Q)%MWA,+N&0">,G\ZKV^OV
M-U)+';&61XTWX$9&?E#8!]<,O'O38-5L=53[))%*/-AWLCH0,8!*Y]0&'YT
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MNW^MV]I=O ]N["+B5\# &QGX]3\OM54^*8EWO]BF*%4:+@#=D@$'GKSGZ=Z
M)(O$32:&VHM#!&5F6(AIQM&[;R6 XQNZ8[5#;^)Y[FY2%+%4+E/ORX(W ')&
M,XYX.*M76N6*V$]S<6TOE6TY1E(4-N7G(!;VR._M4=WXG@B6X2&UG-Q&65 R
M@!B-_P V<_=_=M[^U %0>)KR> $6BQ%BH!60L03L.,%?1ZGM?$<S0W'GPP-+
M;VGGL(Y,Y/<$8^7\??KBK>HZ_!I\QBEM;F0AE7,:@@DC/'.3@#TJNWBBT43.
MUE=".,-E]JX;&[@?-WVMCZ=LT 2:9KDU^UQ^XB6."'S/,5RP?YG V\<KA,Y]
MZS$\37<ZPW:(%B 8M&#E6P).=V,@?*#^%7)O$WSP+;6<JJR[G,P"X&"=H&<Y
MX],>]6+'Q);7TULD5K<(MP[(KR*%' SGKSD'M[^E %4>)+HM"BV.\S?=="2F
M"Q53G'0X)^E./B.86=A/]F4M=3>4R@D[?F"G![]2??%">)G%\T4UDR0@NNX,
MO!5RH)R1P<?A]*6W\2F\@N9(+-D$%JT^78?>5F4K@?[O6@ L?$%W<75K;RV0
M5K@C!4D@#:KG/'HWYBFP:M?ZAJ<$"(($2<^;MSR '^4Y'!X!/U%6!K"?V8NJ
M3V#&6.62%54J6P&()!)[[<_A4)\60*ZH]G,KG>64E25V@MV/=1G]* &'5]1B
MN"S1+,JS2Q-&BG( <!3]<&A_$-XFEV]R;>'SY9'7RP2=V%)  '.3C'XU/-XB
M$4EG+]G8VMRK_-D9'SJJMUZ'/ZBJI\664D$=TUFYD4,8QP3U921WQD ?\"%
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MV.H /O5VV\3K/'=L]E)&;9 Q4GJ> 1TXP3UJ:SUR:]CN&@LP/)@+EC*""X+
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MN"QN&-NPV@8X'7IZ\ _A4][=ZNFJDV,+-;.B-EXRPZ,2!SP3P*Z"B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *:A^]QCFG4U>_P!: '4444 %%%%
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MC=H!L\SO]WUI\VK6$#%9KE4(3S#D'[OK0!=Q1@>E48=7L[BZCM[>3S6D4O\
M+_",9Y_.F3:W81QAUF$F=O"<G!V\_P#CR_G0!HX'I1@>E9,'B&QN&VQ%RVY
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M/WG&[&>CCFE_X1_4Q(62==QC0.QN'_>$(BD=.,[2-PYPU %O_A%+17+I(P?
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MQ[T 7%\+V2/$ZW$X:)E8?=.<=L$>PI/[#L#;SZ<+Z?\ TG#$!ER%3 P..F"
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MV-@*._S;3G/0G-6-1\1?8M0:S6W6601*X'F8R2P&.GOUYZ57;Q85E"/9[?\
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M^G'7K6I10 4444 %%%% !1110 4444 %%%% !1110 4444 %(O?ZTM(O?ZT
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MY SC[K(/^ U+_8-RVCVMJ\L8GMYFD#;B0N0R\' Y&[(X[4 %]X<L#;-YM[+
M@5MSY3H=Y;J".CM^57;S1;:\N3/)+("8PF 1C 5USTZXD/Z5G-X;N)-/MH6G
MC$L,DC##-M4,I "GKQD'\Z3_ (1:0B5OM8663?\ ,,\;O,SW]'7_ +YH N?\
M(W9 $I-.I\XS!@PR&W*W&1TR@X]S4 \.Z=9_9MUS*-C[(@P0Y^[A3\O/W!SU
MXZU)'I5Y_8ESIDC0A2FR)@S<YY.?0<X ]!55_"]Q(FV2[@=0/NM <$Y!/ /J
M./2@"W::1 ;2:S2_FD@1U"8*[HG5MWIC.3TQC  Q3(M#TRWF,@O)?W/EJR,Z
MX##9M)XZG8O^35"W\,7$TCO/<A)!O10WS,%(*A\@\9ZD>P]*O1^&HTM[R+%H
M!<^6<+!A5*'(&,\C@<?6@!;[PS:W-O(L<[I(S%@Q.0">QQ@XQ[U:328S8VEO
M/<LS6Z%-T8"A@1@C'/' _*J8\-$6=Y;BXB'VHKG]P"#AB26!/+'.,\=!52Z\
M+>3;L\-RHF?8GF8"M_RS4G)_V5;C_:H U(])TZPODO?,82,=@S@[BQ..V1RV
M."*K?V+H]O*=\[C[/%&[;F& B-E23CMLQUZ"K-YHT4\KM$\:R"W2*(%<E K$
M]?0\#\*R;/PF%LXUO7@AEV-&-BYX(D!Y/KYF<>PH VXM*L3=BX1V:1"K_?Z?
M?(X_[:-^E-L=+TZSF6>WE)*[E3,F0HX^4>PQ45CI$NG7%Q*L\'DSH/,41[ "
MJX!')_P&![U0L/"4<=K:B>2(L@4R*L0VY 3.WTSLY/?)H T)=&TS;()96VR-
M_%+T.6X'_?QOSI?[&TUHYK3SI#]HD,CJ)SENQ'7I[5GMX-MWMV0WDC%F#;FY
M[$'H0>01W_A%68]#$5Y'=V%U$LP9W)V#YQ(Y8D^O!./H.: 'S:)I'F2"65@P
M/F,#.1M!SQUX7YCQ[TR32=%:Z%NSMYDL9<J)#@@$')_,4M[X?MK[5I;F2YW.
M40-"0#@;E/(]#Y>/SI+?PS%:-)+#,6<V[1*&4#JBKR>N/D'';F@!C:9H**DG
MGD[BBQE9B<!?E &#TYYJQ=QZ9)'#87UQ)(Z(V9&)&05<-DCCH&^F*@A\*VX@
MVSR[R=F[]VH PP;  '?&#35\+6,D1C%Y,Y5?+9@P+%@6.3[_ #_RH M+#H4%
M[]J2>&.8*9&/GX!#$_,1GD98X^M(NFZ$HR#%BUVESYQ^48&-W/3"J<'CBJ \
M) SNIN +<QJJE2=X(V?AU3GUXK0@T&WM[:ZA,[^7=*J%< *N!C@>IXH 8MEH
M!$06:+$16--MP1R5 "G!YR%''M216WAL21I%);9<[4C6?AB'SPN<$AO\*0>&
M+03/(L\HWS"8CCCEC@'' ^<T0>%[*"VDA6:8[HQ&K_+N3!!# XZC _(4 -DC
M\-PP&?SH2EJ/,XN"=I/(/7J<<4^W_L**^5$6.WGB E WE<^8<^O/)J.X\-Z=
M!%-,;B6"/!;(VX0;2#C(Z8)J34M&M&62ZDN7C_<B,;L;0=I56/&<C=ZT 1:L
MFBW.VVD=T:;?-Y\*[@F&!9B2"H&5'7TI3)H=JK0,XEE@AW[C)EY-I.<'/+9C
MY^E$^EZ9<6-H)+YOLZ0B./!7Y@PV!LXSR6'?!.*E?PU:R*RR7=RP=6#\K\V=
M_/3MO/Z4 /== DNC,[VIF\[!S)_RTXXQGK\@X_V?:F2-X:=Y)I)K,M(OG.WF
M_>7/4\],CZ4P:+IT:S2)<N%AE\QR A*D9)!.W.,.?P/O2P:!IL>U%N96$:B3
MRRR].0&QCICCTP* +$::18S).DZ1!HR54RG;M;G(!Z?=^G6H!<^'H$B2 VK)
M.&0;&!&W&&)YZ8CP?I5F\TRSU?R[AIY-CQX'EL &!!P>G^T?SJ"ZT+3LL\\\
MRI(=C+O #9W =O\ ;/YT 1N_AJ))+@?96,<)E)0[FV ]?S%+]J\.L9FE^S1F
M$A&+D#@\C\#5J#1+*&WN(@SE;F+RI#\HXRQ[ #/S&HKC0+&Y_P!=+*Q."3E>
M2.^,8/\ ]>@!+AM!M+P_:%@BE$8F+L.,%@ <_4"BXO?#QA2WN)[0QH2JHY&
M<8('X-C\:?>:3IVH2!))26B14*JPX&=RY&/\@U&VG:4DC!YBIM@'<E@ H9E8
M9XQUC% !+/H4,,EU''!((C'O,8'&\K@G_P =/X4YKGP]^[8M:'RH@$X!VH<
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M9J>72;3[-#:272_Z.#*X8#YE+;B2.@&0:J_\([,MO91Q-"LENSEI"S,0&;)
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M>(K[<RFP"XG:, YS@ X)QTY Y]ZB_P"$FU(Q[UTTM^X63.T\DL!QZ@ G\NM
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M1G/K3TU2Q=F4W,2,"0 S@;L#)(]1CO0!8-O 0H,,9"@!?E'&.F*B?3[-]O\
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MHQ6&GB.(V"WDENZH95C('S$97=G '.*G/B'3 [IY[90 G]VV#D$C!QSD ]*
M-7%%91\06!L)[R!I)XX)5B<(ASDD 8'<<@U%'XFL/)+W!>)ED,978QQRP!SC
MI\IYH V514SM4+DY.!U/K2UEW7B#3;6YEMYI6$D.-^$) R!CG'/5?Q(J/_A(
M;;[<D/ER"-PV)&0C+!@N ,<@YZ^U &Q16./$5D\L:QEF1F578@C86 QU^H^E
M2VFO:?>22)%(V8X_,;<A'RX!/Y9'YT :=%8Y\1V"H'=;A04WC="PXP2!TZD
MD#TI%\2V+2;=DX4E0&\LX).[(]L;&S]* -FBL=/$-K)(^Q)/+CB>1RR%67;M
MXVD=PX-(/$VFG^*7!3<#Y3<G^[]?:@#9HK)_MZWCT^&\N8I469F "H6*A2<D
MXZ<#-,'B6PR01.&V;MOEG=G<%VX]=Q H V:*Q#XITX(S_O3A%<#;RP;' YZ\
MCKBG?\)/INV1MTI\ML,!&21P2>!Z;6S]* -@HI8.5!8# ..12UC#Q-IN\(S2
MJQ1G*M&<KMW9!'7/RM^7N*DBU^TD:XW+-&EO$)'9T(Q\S*5QUSE3Q0!JT5F6
M&K"_U"2"&%UBCB#EW4J=Q9E*X([;36G0 4444 %%%% !1110 4444 %%%% !
M1110 4B]_K2TB]_K0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 445@^*+/4+R%$L#*0T<J.J.%!)7Y2<^X_6@#>K/UNSGU'3GMK:6-"[ ,77.
M5[@>A(XS6?:PZ\FIQB:1S:A77<=ASR^"W(.<;.@JI;V.LP1VR6MO+;MN N'\
M]7$K KESDDX(W],'D>E &DVDW,VJ6MW--"%@ZB-6!;&[:.N,#=5[5;(ZAI[V
MRNJ,65E9EW#*L&&1D9'%8,5CXD 'F7DIRR _.G PI8].N=U+%9^)%VA[EW&\
M$DR+D?,,YXY&T'CU- #CX8EEO))[N[A=)"I>-(F4'!0D?>Z?(<#MN/6HD\&@
M0K$]YN08;&T_>VH">O?:?^^JMPV.L/HMQ:74QDFG9%W.X.U"JA^1_P "Q54Z
M9X@6U6-+IPT91!MEQN10P)^I.PT /'A(^8=UX/+QC;Y9SCCY<Y^[@#C'7FK%
MUX:^U:=;V+7CQQ0&1D\M<'<V=O7LH)X_E4,%GX@%_')++F$798IYQQY?3ZGU
MQTS2/8>('GG;[257SM\068XVYZ'/;':@!LOA1)KR.87R^:DCR2_N\[BV.>O!
MX[YXI^C^&%L;F*;[>)O*62,A8]IRQ)/.3C&?K[T^UTS4X].U!)7/VNXQME6<
M[FP,=<?*/;WJF^B:Z+.=;>X6.6;YL"=P%?(Y!Z^OU[T :&HZ-:7]O;0B](^R
M95&=]YW$X!;)YY'0]>E5W\)+(LBR7TA#9"X0#:/GP.#S]\T^+1+LP7"3LN9I
M(VRKD'B9G/(Z<-5=-%UY6W?;@&$*IGSG.6PJDD'CIO/UQ0!9MO"\=K#=*EVR
M_:+<0$A -O\ M<YYJ*'PC9^2-EV[N,J), ]-W'N,GD>U.CT/4!:ZC%-<-*9G
M#0AIVP<,2,\97C:.">E,G\/ZCM/V:[:,-/YQ47##DLQ]#ZKQCM0!;G\/6;Z1
M:Z9/<'RXI69"0 69@_'X;B>/2LVY\*!KI9+6]B9UN/.F64>I+<@=>2>#5_7M
M(O+J1[NTE8RH@$:"0CHK@X'3)++S[5GKX;O;BRRS&%V5E:*65CN&20#@XZXZ
M=!QVH M2^'K2$1P7&IS*TA*0\J&Z?=''/ _6GQ^$[9(XX_M4A$:J$.Q<@JH7
M.<<_=4X/'%37NEW6J00/-LMYHEF10&)P&X4Y]<"JLOAJYDDFQ=;8V+; '?/1
M]I//5=R@8[+0!)+X5L%MV4W,B<<R';G[I![8[DXK2%@)-)-HM[(\3JH21@KG
M;@<<C!!QW]:HR>'W?2ULG=)%6X\T!RV I!!&>N>2:KKX8G#(ZWI615 +J3U#
M#G&?[O% $[>'+19(]M_.C<>6"4/("Y(R.3\@S22>&=.38[7+HH0QC?L((VD#
MJ.H&?ZTQ/#4HTVVM_M2F2!Y&63;TW(5R/0Y.:ED\.B718[!WB)CF,B_*=J@D
M\ 9SP#0 )X<LGC!2^N"'5,,&3D!"N>G.58\_3TJW+I=FFEF S-%$DAF$H(!1
MMQ;/(QP3WK-'A9B1(;E1,,9D"G)QQZ^F1^)J6UT.>'1+C2)7M_L[QD(^TGYR
MQ)^4GI]WCZT 6FT.S.FO9+-(L1=7+ C<NT #DC_9'/6H!H6FV\H)NY4>1F"
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M\H-I)B-B?]22S,'9<@ <_=)S4AU[1U=55&)+JJXA(!)XX)_+]*!9>'I2X62
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M7275JL1-P(B<;MQ5N.GW1E 2.G3UK0@UG1)I%,(4OD1J?((/WE  ..F77\Z
M%B\00R:5<7GEKOA)!B$F2.< DXXZ]>1[FJTOBJ.)6!@B:1!EPLX*J/DYSCI\
M_&!SBF)KND01F5+-Q-(B"5(X2<!E9QT'(Z\@=ZL'7](6$L\+G '"0%@WLIQS
MC&/;% %<^*7A5Q/:PLZ"0XCGY.W?CC'_ $SY/;(I9/%$T7RR:<@<OM4?:.#R
MX/)7CE#CUR.E6Y=5L19W-U;6HD\B98F&P L68 X[GK^-*NN:;(DA$4A\N-I'
M!BY  !Z>OS8^N: ([/7S+?1PW5O#;K*K%',V2</M QMXR?4]QC-,U+Q&;*ZN
M85@@(@<)F6?822N[/W3A>P/<\4RXU^U+X_LZ61(RI;,8RIW,,8]04S4\?B+3
MKJ8QP0S3OO5!MC!R3GW[;3F@"N_B.Z:50EI!&AE"YEF(RN2IS\O!R!CK4;>*
MY8Y%CDLH0S0K*3]H.U-S*!N)3@88'//0U?N==M;2[D@N+:4$3+$I50=^5#9_
M#=44?B73I'B3R)E,TBQ*&503G&TXSD@Y'2@"HGBFY1]DUK;,6G9%V3G)7> ,
M#;R<')Z<<^U3VWB.>6WN7GM(8GAMTGVB8MD,,X/R\<&A?%%I(HE2RN#'Y+2D
ME5#  (1QGH0XYJ;4]?@LHI/*MWDD%N90>-GW68 G/HIZ4 41XKN&A$O]GQA#
M&C;_ #3@$A"<_+]T!R<^U2C6+Y+32715GDNHCN#?*I;<@!R!Q]XU+=:])9SB
M*>R)V;/-*8Z&-V.T9[;/RJ=->@N+74);>&0FR1F^=<!\;NA^JG]* ,Z3Q!J$
MT.ZWM1$ZQER6RRDF)G4=.>@Z?2F2^+;N-9R+"-O*95#>< IR&.>>@.!@^]74
M\1%809].G5QGA0 #RV,;L'E59N0./K2#Q1;I+)'+;3':&8%%XVC)&<]"=IH
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MO)$]N6>*-""\#L[9*YZ<'JPQQTJU_:NN"XV?90RB8KQ;OAERO )/& 2<GKC
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M10 4444 %%%% !1110 4444 %%%% !1110 4U!U^M.IJ]_K0 ZBBB@ HHHH
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M7-1$UNVJ6K102J58BV=2'W[5SDG&1CCDY]JFO[S5+;5'2TMWDB=UP3"SC'R
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MT^Z73KS3VF6*!U98)022NYF.#D] "H_.L^3PK*ZS!9X8S,,,%5BNW" #!/\
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M%%% !2+W^M+2+W^M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4$XSP 3ZC//6M.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D7O]:6D7O\ 6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "JFK+$VEW GD,<>PDN!G;COBK=5-5A,^F3QAT0[<AG^Z".>?;B@#
M,M8].L]:AMX;F7S,.5B)+*&?DX/;[C<?6MN618HGD?=M4$G:"3^0Y-<_;Z$E
MIJEO*+M6WS>;M.%8X#GC'WC^\Y/H*Z)V5$+.P50,DGH* ,+2H=#FN/,L2X=
M5V/O3/8G:V,^F<>U,AT?PY;"((\:@ABH-P<.-N3GGD8Y^AJ2QT:T;4!J$%Z)
MU5F.U=I&XY[CGHW3\:K)X5M'1;1M0E?R$*%5VA@C($ ..V%_$B@"Q<6V@P:0
MEO*P>UF<RIB5F,C $\'.3P#WIJZ;X<NW!1XW:[)95%P?FZ[L 'W;./4U9_L&
M+^S;>S^T./(=G\P 9.X,#_Z$:B70[&/5H95N&6=,R"/"X(!ZXQVW=1ZT 1(/
M#TTDA8&--VPF4LD<I))X)X;DM^M21Q^&U5X4FM?E#!QYV2!@@YY]'/YTZ3PY
M')$(3?W0@7(2,;/D4YW*#MS@Y^HQ3(]#TR:69(IY&:-@DH!'!PW!X])#^E
MH\-"S>-9[7[.2H;]]QG<6'?KDDU+;VF@2F9K=;=C;@)*5;[@7& ?IL'_ 'S3
M9/#-BXQYLZD[N0PZ,7+#I_TT8?E5@:-:K#<P"20+<J5D^89VEF8C_P ?(^E
M&?%_PC$D*W!6WC\V,/A_E;:/EY'UXHF@\.RWZ737:!L",HK@*^_<1GOSN/?'
MY5/+H&E[GB9I%-R05&[."IW<9SWR>::_AW3HG+O<2J2T?\2C[O"@<<<^GX4
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M110 4444 %%%% !1110 4444 %(O?ZTM(O?ZT +1110 4444 %%%% !1110
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MRQWDC0B-PA,@#;B&P3^:]N,59T^WU.SU7?="2XCFS$K^;G8H=V!8>NT@9]:
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MOY+Q1()9)/,.&XW;@W3ZC_QX^M36FC6]K-%*LDSM%]TN0>/FP.G;>?TK2HH
MQF\-6!='!D#*C1Y^4Y!W>H/]XU"/"MHPD$\TT@)'E\C]V $'XD[!G/Y5OT4
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MZ@*<$YZ&@!]%1O/%&K,TB@(,MSTID=Y;R0I*LR;)$\Q23C*^M $]%1_:(?\
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MMBR%USM[\COVH >GAJP@4+]IG$C[@'+@$L5QGZ@;L?4U"^@Z6I2P^VS1R,N
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M@XYS22>)[V.41-IT>[RI')\[ RN_ &1D_=&<#C-7X_$5G-:RSQ03N$E$2C:
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MQ-JMU"GD68+2*WW8F.S]WN&>?7\QZ5+'K6KQ@'[,TQD;(S XX('3CC'7GKG
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MH*+GPE;R,[+<"!79B0D8'42 =^WF?I0!I6EAIEA.)8Y?WJJ1NDFR<84=SVV
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M))[$<GI[TP>);611BRNRCEU7Y!AMJYXYYST Z^U,6[\/22,@AMCAEC3Y/OG
M( XZ?,/;D46UYH$T'GR6]O"0-Y#H,C<I)/X@'\J "#Q):C8B6TGEG8%";<(I
M" 9YQU<#C-61KL1TB34#:7"K&P4QG;NY .>N,88'K20S:%(&:&* K;)YI80\
M1@<9SC@X'3KQ2-J.A- 87,)B?YF1HCC@'J".#A3U]* ,^3Q):2V<T>J:>9$$
MK*5PC*Z!W ;!//\ JSG_  JU;ZX\5M,TEJ'6)Q&D<&%..?[QQT%+-?\ AY8V
M-Q#$JJ%8A[<\;LL.,=>23]2:=/JFCP)*L<*LZESM$1 8HN2<XQQG&?>@"/\
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M** "BBB@ HHHH **** "BBB@ HHHH *:O?ZTZD7H?K0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445C^(A=E+06@NMOFGS/LYPWW&QGVW8]O
M6@#8K-\064FH:3+:PQI([D8#$#'/7D$?I6,MWXCWD20.#$Z 8CR'.Q@?^ [M
MISVS[8&OH=U?3VVW489%E&3O*;01D@#ZX'I0!4?3M1FETWSHK/;:%=[AB';
M'0[3@9R<9&>*T=;LY-0T>ZLXB@>9-HWG _&LO3A>0Z],;GSV,L16(-]T .Y/
M\U_.JEJ?$HD1RLB^;)NE+JG'RH, 9Z9WX[\#\0!L_AK59(WBCN88H)8I UM'
M(RQ(S;^BX^8?,/3I4K:-K2WPD-\[1RW8+!)6(2$98C!/&<*.,]3VID$NNW4A
MMYA-^[V^8#L&/NG.1@Y//'3%6M%&O)=6L=\9C D 60R!#N?!R20<]<8]NO-
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M#QGKMQ@>N>0* .JHKEX-1UP/Y*P]6;#2P,< L<,2"!CMCKQFK$NHZR/L2I;
M&4$2GR6/(8#U^48RW.?2@#H**Y9AK$5M8P+=2,[P1EF,+'Y_,3<6.?[I/'UJ
MSI&H:S=7SQW]H(8O)#+^[8?-M7OTZEACKP* .@HKD[:3Q):Z1 [$RSM$)'1U
M+L"=@P3@<C+-C!Z8J6.\\0R20M(B+&P'F((#_P!,\\D@C.]^W&SZT =/17)P
MWOB&%((?(=D5HE9VB).-HSGU.0<GWJQ]JUM["&?9*)Q+*#&(AAQM.S(XP,T
M=)17.7AU6;18F*7+W*SDA8QY;2*"<;L'Y>WZ<5!=3Z\\H>.WG5H6PF$4ASB0
M<\_=^YS0!U5%<@DWB2WBECC@D*J"T? 8L=^<9/MG\.U6OM?B%KB,+;NL?G.&
MWJOW?EV].W+#/J,^U '2T5SD%SKXT=9)X'>[64[D55#,NP].@^]C\*KW8\12
MV_WYU;S#\L2H/EQ(!^&=AH ZNBN:DM=1%M8F*.X,D=RS.F\!2"W5CN!Z<CK[
MBH/^*@FFCED@F1Q^[Q^[V[2(]Q;GH2'P1STH ZRBN/M4\2P11P;)=D:0JH7R
M^@ R,D_7/!]JE4>*-Z;=^,2_?\ODX;;G'09VXQGIS0!U=%84*ZR=)LA,TYG\
MX^=L\L/LRVW.<C^[G%588/$LB@3321=S@QD[OESV^[RY'?B@#I\XZT YY%<F
M(==N+I[>8RO%%Y62Q4*V"I/U/'THBM/$<4+1J[@(L0C5"F, #<,D\=^U '6$
MX&329&<9&:Y[4[379[FYB@D4V<@(4%@#RN<?F,?1CZ4EKIVIPW22AI05F.0T
MBE6C+YQ] ">/6@#HP0>AH) ZG%<O>Z=J\>H7MQ8>8!*,QA)0!D%3R">_//48
MJ?5+/6+B\F,18V_R,J"50#@H<#(X;(8YH Z ,I;:&&?2E) &3Q7%7MAKEM'+
M<P[UGE('F(?,9<K$.<#)^X1P/YU8>QU^X24RF0H[-Y:&5?NE6QD'_@/'N: .
MMHKF'L?$3^;_ *2Z#+%=LJ\G#XQQP.4&/8U9U:QU-[V::QDD EA1<+-LP06Z
M9SCJ#GV- &]14=NLBV\:S,&D"@.WJ<<FI* "BBB@ HHHH **** "BBB@ HHH
MH **** "D7OCUI::O?ZT .HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "H+J\MK)%>[N(X59MJEV R?05/6/XAM+6Z%H+R]%K&LI'4 R;E9=H)^M
M %DZUI@8J;^WR"P(\P<;>OY8/Y55U/5=(:"6*[,<JHX782/F;../<&F_V'IT
MIC<3R-$-V8PXVR99CSQZNU5I]+T.VM8Y)KYXXP1!YAE'SD')!..22N3]#0!:
MA.@[3>XL@;>39YBXPAZ ?7&*EN]3TB>W\JYD@G@EX8-AEP,G)![?*:KC1-)C
ML/LOG$132JZ'<N=PY7!QS^.:?)HFFI;SNS.J'#NZGD;%(!&!QC)/'>@"M!=>
M&;B%I)+2S4^7AE,"L=H;:!P.?X>/<5+)?>&HXE=DM"D*K(I$&X*"!C&!UQCZ
M#%.M= TN"430R.22I)9P<D,&!)QGL*CCT;1[BP#)<SFVDC1E!E.!@ !L'O@
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MZ2<]!^532>(;N&9(Y+&+!V[BLQ./]7GC;_TT'Y&K$?B*RDDB06]P#*P )0<
ME0&//0[U]^:;<>);"WDFCD@N"T;E!B,?.03G;SVQ_*@"IK.OW,5W<V5J CPX
M/F#D] <8(_VNM-OM?O([/R(D47#6BR"0GYMQ0MN"XQM!&/J:LWGB>VBMKF2"
MUFDDB#[ 5 #E=^3UZ#RVIR^)+>-&-S;R J'RR8*_*6 &21R0I]J (;K6+ZQO
M9XRT4B11\"5@FYO+#<' 'J:GO];FABMO)A7-S"'!)(.3@?*,<XSDYQQ4TVO6
MT-C!=R6MQLF1Y NU<JJC)SSZ=,9J'_A)[7RFE-E>;452WR+D%FVA<;LY[^F*
M ,NU\17[6\5Q(-RPV^Z3'W92$5CSC@Y)!]P:>?%%]+&?*M8T81[R3N/E_/CY
MOP!X[5:D\36S(\<ME*ZR*-HVKC:P7 8$Y!)<#&#4RZO:Z?:VL<>G21>?&)/+
MC"80L< 'GN3VS[T 5(?$-^J^6UNDCX8@DL,\MSP,;> ,]:L1:]=N;L?959X+
M;S510QRP)!&?Y"I&UXVFFV5Q?VK[[B%I6V  )A=V.3U/;FFS^(P1(MG9R2/%
M(JL25 YEV8'/?#8_#- %9O$=^QWPV(:(B0#Y7W<>9M.,=,(/?FHDU[5(P%6W
M$VY68.R,-Q+MC'?  '&.XY]="7Q-;Q_9MMI</Y]N;@A5!*#G@^_!%5KCQ052
M1K:%7#$&%B1@KG!8\\YXQCUH GU2YU.*\AMXID4LD1R(B07\P!^?3!''6H=/
MU?49K^-)876*9F8YB9BG[M& SQ@9)]3GBIK?Q-'<21JEC, \NP,Q  7Y!NY_
MWQQ[&G6/B1+NZLX!92I]J7>K;@P5<$@G'?CIVH SX-3U5=.:/_29YY-P24V[
M<GCD?*,#!XR.H(YI@U778[=9C:R%PBIEH' /!)8KU!R OZUH1:])>ZA;VUI"
MJ*TGSL[ DIAL8 /!RIX]*/\ A()HVG62S,WE-(H9& W$%\* ><X0T 0?VSK'
MVAD%DS(+@(/]'?E?F&,YQV4[O0]*0W>MW.F6MPT;QS),S21K#(N\"-F4$=0-
MV!Z$X^E3IXG261(X+7S'<#:!* #G9CMP/WGZ4EOXJ2XP8[0LGF%'99. ,H 1
MD#.=X_6@!G]H:\9GA$"@Y5=YMGVKG;\W7G.YN >-O-/_ +1UH:'-,]J1>*ZA
M%6!CD,H/W<YX)()]NE.M/$R3WD4$MNL2/#YSR><&5 =V,GI_#SZ9JWK-_=6E
MS9Q6J*XE+&3*;CM4 G'(Q]>?I0!DW6H>(&@G5;=DW;E1EMV+)UYZ\YX^G6GW
MD^LOBSA29$-O&#)Y+$AB5S\P/7!/ICK4C>)Y)DD-C:Q.(R,N\V%QE!V'^W^E
M,3Q//%B&:S\R4S; RR8!4LX!Z=?DZ?K0!''J7B #RQ"'VPM\YMG!,@+#Z<8'
M?GKW%6M8.L"YMXK:20J4CWM'$=I?S4R3@\#;NXSTS4DFMS'2Q=1Q1I(;A8Q'
MOW?*6P">F":T-&FGN='M+B[*F:6)7?;TR1F@"AHM]K%S?.FH6JPPB(%?D8$M
MA<\GCJ3QG/%;E%% !1110 4444 %%%% !1110 4444 %%%% !34[_6G4B=#]
M30 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F:UIT^H"V^SS)
M"T,H?>0<CZ8([9&#D<UIUD>(+2ZNTM1:1>8T<P<@OM7H>O?\N>E &6?";%PK
M3VR)L,:HD."5W[NN>>.OO5Q-"DCM(X[&>VB"7<ES&1%E=KJPQ@$<C?U]A55M
M/UY[BWE=COA8J'$PY7Y>2,=#@\5#;Z3XA@M?*2X*JD")'&DF " G&>W1AQZT
M 3Q^$C',76YB**8]@,(S\@QDX/)Y.#VJUI.BSZ;:36!FA,$L;#< P9G(QG!)
M[#MU)JM_9_B$W"M]L8()G;_6Y^4E2,CH0.1_^NE.EZR^C112W#&]25F$GF<J
M#&1PW^\: '1>%A%,LJ31$[][AX0P<[G.2,]0'P#VP*C_ .$1.2?MBD"-5"F$
M$$CR^O/(/ECCW-6M3T_5KB!/LMTT4J0(I"S, 6W?/^..A-4DL-?BU 'SY)08
M<_/<-L9@8^#QA3C=TSGVH >?"D?ER^5<H\P0(C.@^0A5'4=/N_K2P>&@=,AL
M;NXACDC,I_=_-E'4J<Y[\YS4?]A:N;>4"ZV3%5P1.V"<C?G ') Z]>:D70M2
MF6[6[G#&:T:!7,S/\Q"\XP !D=NM %NU\-V]KJ4-[%,Q,6?E(XY+GC'3_6&J
M_P#PBJ2FX::\D1IKAY?W0 X+NP!R.?O_ *5-I^FZE;SW,L\P*R0E519F?YL#
M'!X&.1D=>IK.AT#63:VY:\,4@1MR?:'.TE5'7!SR&_.@"W;>'; 7;H\X>:-F
MD,60VU&=2HYZ<1@?G4R>%[-'+>?*V=G!"D#;M]N^P54;PW?"5V@NPNYEY,CY
M "(,Y[D%6X/7=3IO#5S) B+=%7$9!;S7Y8K)D]?[S(?^ T 7XM AAL6M([J9
M5+1NK87*L@ !Z<YVCK2)X<L5L/L67:'S4D(;!SM4* >.G%5[W0;VZU-K@7:K
M T:(4!8$X*DYQ_NG\ZC@T*\5;N W+JIMQ%"Y8D;B!N/7./E7WY- #X_#VF6<
MWS73[I2!M8KDDJ1Z9YY/UJ_::4;3?%'>2&V=&'ED#(9CR<X^OYFLK_A%YFD5
MY9X6)50V-W&UW8 <YQA\?A3K7PU/'J EN;_[0GF+(RL3S@-QCZD?E0!=_P"$
M=L]RD33!1C<H(PX  &>/]D'BHI/#FF1QK-<23$01@;F?^%01S@>F/^^5]*CU
M+P]+>W5PXN85$SAUW1LS8"%<'YAP#\P]Z@G\)RRK*!>1MYI8L)(V8$DR8)&[
MJ XQ_NT 6H-*TEXXXX[MG4-MC4R#@@J<#\8L_@:5O"NG-:FV>6X*,NUAO S]
M[MC'\9Z<#CTJLWA60M*?MB;I V)/+.]<F3CKT_>?I3SX6+*,W,0;#K\L) "M
MYGR@!L@?O!QG^&@"Y)X=T^0DEYE+#!*R8R,N<?3YV_2J\N@Z=<V]S;V\K!M^
M'W$D9P#@]#C&.A[]:KS^&;B>:V1[B()!:"+S?*&YFRW0 _*.1ZYZ5)+X45[G
M?'<1QQ9&(Q#G: $'RG/'W.?8XH LMHU@8K.VN[AY#'$8XT\S:&PI!( [@,:5
M?#NF*!N>9@P8?-,?F+%B2?4_.WYTVY\.1SV-E;))'']EB:+<(0<AEVDCG@YP
M:C;PR&MK6(W,8:"1W;;  OS-N.U<_*>, \XYH D7P[I'+1LX7S&.%EX#$$'\
M>32PZ'HT#QLCD%64(#.<%UVXXSC/R+GZ4IT!/[,LK-)4!M7#[C""'."#QV)R
M>>QJO:>%8[?RB]P',1&W$0'0IC\<1\GN23[4 :'V;2Y+J>Z\U'>XC\ESYV05
M&<@#/'0]/0U271O#QCCB5DQ\OEXNFW<[B,'=GG<WUJ,>%5\D1->' B,1"PJH
M(VLJDX[@.?J:D?PM:F99%D*E9?,P%XZ(,<?[@Q]30 \V>@R2QQ^>CF1I&11<
ML0>A8#G@=#@5'+:>'K&(3.5"$G!$K.%& ?4X4 +[#(]:GM?#\5K<0312X,0P
MP\M?G&P*?I]T'BJZ>$;-%D43SXD&T\CIG_ *OT04 .VZ!>S7-Z75F@/FR-YK
M 8"J=V <%<!>V#@>E.,GA^_NIKN22W,L!3?(TFW  ^5NO3YS@_X4^+P["C3,
M\\CM/#)$Y( R'5 3P/\ 8'YFHG\*VTB8>XFSG)(VC/"#T_V!^9H 6Y30M-=8
MY4=1Y7F94.RJB[3DD< ?(OUQ3EA\.#RW6>U_=,NW%QT.T;1UYX13@^F:FNM!
MANDMTDGE"6\1C4*%'52N<XST/3IP*CM_#D$5\+Q[FXED#A_G(QD*P].GS&@"
MJQ\/)&&@W 7]J5$L:LX$1VJ2>H7^')/XT\?\(PKH!+;9$;@.)3T!^;)!ZC?]
M?F.*M-H$#P6T3W-QB"$P<%1YB$@X;C_9'3%5QX4LA$4,]PVYF9F8J22VSV_Z
M9K^M $LMCH-K8I<NB);MY:I(LC8P<*@!!Z<_3GFHH!X;?;(#;A_,:/#R_,')
MQC&>O _"K::,ITQK"6X=H@Z-%M 4Q;"I7'&.JYZ5%+X:LI9(W=Y=T;!A]T]#
MGN* *\=SX?M[IH!;)"8YC%N,>%WX#D9]M@_(4QI?#,);S98)7NIA)DG+99B!
MSU !W#\ZT)M#MIKAYWFN!(YSD.!@888!QTPQ%,@\.V4$>V-Y\Y0AMPR-KLX[
M>K&@"&>;0?-EMKJS141CEI(/D+9R<'IGYS^9I)9O#UXKVS/ I=]BD  EB,Y4
M_P# ^O\ M>]6;G0+2YDE>5Y_WK;MH<84\9(&/]D=<TR/PW812PR*9B82-FY@
M0,!1W'?8OY4 1S76C:;''83;&2(F)RXSY8968Y)[$ \#U]*@NKS0() B6,,[
M >6VV(94;AP<]LMG\*OW6@65W=2W$QE+RKM8!\#&TK_)C42^&=.61Y )MSMN
M/S^^?YT 12/X;@OGD?[,LULNPKLR$Y X&.O0<?2I5O- +QJHMMT&5CQ%]SD*
M0IQQRP''K4TFA6;S239F61VW K(1L)(8[?3)&:8?#M@=F?/(1RZJ93@9(8CZ
M;@#^% $-SJ>C"*SEDAC>W<O%'*8>(P%.>HR!@?3'M2I<Z$+FWA@MH6=F\M-E
MO]SECZ<#*-^(JW<Z-975I!:RK)Y4"[4"N1QMVD''7()'XTV'0K*"X,\0F$GF
M"0'S#P1NX^GSMQ[T 5;;4M*G"/):)$8',<.Z-25((4XQDKR0,<=:KQ:WHLT,
M$DEHJ((_,.Z')B(V!1C'_33@CCK6@= L&8,PF9A)YFXS,23QP3GIP./:F+X:
MTI8]BQ2 8P#YK9 RIP#GMM&* &1ZGH)?$8B^=P,B$X)8!LYQZ8)/TS2VVHZ+
M)-&MO$!)\\B_Z,R[,#))X^7((Z]<BI?^$?TXR!VCD8AE;#2L1E1@<9YQ4MKH
M]E:;C#&P+(4)9V8D''<GV'Y4 4DUW0PCSQA@%'F%A;.#SCGISPP_ U.-3TF6
MWGE^4Q1(9)"8CP,L/3U!I\F@Z9)&$>WRH  &]N@"CU_V%_*G0:-9PPW4(CW1
M76 ZGT"A0/R% %&+7='-R%V*H;8(W\HY8Y(Z8R " .:?%K&FR"0P6KLB6QN0
MWDE0RCTR/8$5:&B6 ='$<F].C^:^[KGKGD<TL.BZ? 08H2N$9,;V(VGJ.O3C
M\* (K;4--N9?)C@(D5"VTP$=@2 <8)^8<>]5KCQ/IJQB6 &XVJ[':.0 F_\
M48_R*T;32K*SF\ZWAVR;=N2Q/& .Y]%'Y"HTT'2TW;+1!O&&P3R,,/\ V=OS
MH SE\160#J;1E*RE&7RCDIW;IST&1VI]QK^F(\0CB#H9"KLT9 "JK$L..<$8
MX]:T!HVG#&+8<9QEB>O7O3/[!TK+'[&GS=>3Z$?R)H ?I;6]U;27$=L(O,E8
M$%<$[6*@D'O\HJ\JA5"J  . !4-G:064 @M4V1@DXR3R3D]:GH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "FIT/U-.I$Z'ZF@!:*** "BBB@ HHHH
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M5?OQ[CP<YP']L5UPD0MM#J6],\TZ@#DK;_A)5\K:)@"5#&383D!!\V?X?O\
MW>>E6K+_ (2 7=E]K:62,MF<$1J%R@XR!D@-GIU]>*Z.B@#FROB-[^Y57>.
M2?N2?+((Q)[9QGR^O-)%'X@_LZR#M*UPLQ,P)C7*]LD$C\JZ6B@#CX++Q%)+
M ]VUQA5&5WQD A\C/O@]1Z5&NE>(#_I0++<%%5MTBEB "#@]C@GOC)Z]Z[2B
M@#FM/MM:34H+F^1IBD.P%I%4#=Y>>!GYLJY/8\5TM%% !1110 4444 %%%%
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ME!M').,>G)_.@#534+-TA?[1&OG1^8@9@"RXSG!]J?%=VTQ80SQ2%0&(5P<
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M(=RA0,(WR<],G[@_6I9]"M[BRBMC(RI%;F!2@ QRI!'XJ* +,FKZ;&I9[V#
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M46X5T$CQLWEG#,6Y/^USTZ5= \1K<,&DF9!.H&$BP8\L"<Y]-IZ9R/?CIJ*
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MB9BFQBQ4;N"H/ ZX8BHKK1M&2Y\JXNC'+.S,$,@!;<7Z#_MHWY"@!&B\+/
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M -O6PBN;WSY1$"&A4H=_W\=._P#J_P!:-7DUA]=$-D;E;<P _NU&"V3GYB,
MXQCGKB@#I: <]*Y<VWB0@9EEX1<XD3D<9'3[_7GI3H+'7(+73HH79!'%B4>8
MOWMV3NXYXSC'>@#ILC.,\T5R<VF:^TQ9+B4E(@$=I03SL+@ 8YX?G..1C%6C
M8ZV=+N ;F5KMVC"9E "J%7=C'0D[L\\\4 =%0#GD5S$NG^()(WW7)8R( ZB;
M: <8X.#CDD^^*M7=AJA2W2TE*".V\O"S% KXY)X^;M@]NM &[35D1L[74XX.
M#7-+INOA"1=L'(8 &X8@+\V!TZ_=&[K53_A'=4",!Y8W @ 3'J1U;CYN1W]:
M .RI"ZAPA8!B"0,\D#_]8KFVTK6V\[_3'&69DQ<MR</M/3Y1DI\HR.*GOK/4
M=0>PN406\D1<.//*E074@\?>X7H>.: -[-%8&GZ;J<=_;7%[(LGE;D)$[GY=
MB#.,8))4DCWZU7FT;6&>4I>';(^[!N'!4Y?Y@?8%/EZ'% '2O+'&C/(ZJB@D
ML3@ #K3L@]ZYF?0+R33%M4:)71[@ F5L%9%8 ].N6''2I[?1KZ#589A<$V\>
M["F9LJ"6.,$'/WE[_P (H W\CUIHD0NR!U+* 2,\C/2N4D\/ZK##F&Y:5A;E
M,?:&7YSG)Z<@D@YR",5*WA_4C) ZW,4>QD+8=S@!B< GK@''- '49'K1D>M<
MHWAS4692+I% A:/Y9G&20PWG.<DY!(R.@ZTZ?PQ=986UX41I-Y3S6'&7QSSC
M 9?^^10!U!=00"P!;@#/6H[BYAMH_,N)%C3<%RQ[DX _.L*U\/SV][!</,DO
MERF0ABW4F3D>^'4?\!ITOA^2?4Y+B:2-HC,LH7!R<,#SSC@# ^M &V+B%I?*
M612^"< ^AP?U-%Q<0VT8DGD5%+!<GU)P!^9K!;PY)]M:>.2)#Y[RHR@@@,RD
MY]\ C\JDM?#QBT=+&>5)&282*X!^7 QD>_>@#9DNH(I4BDD57D.%![U+D>HK
MF8?#4ZV@A-W&K9;)C4@*2H QD_4_4T[_ (1>7=$%O_+B7.Z*-"J'+'@#/ VL
MR_B#VH Z&*>*>)989%=&&58'((J0$'I7+7GAB;[/*]O-&]P^ <KC<N4)4YSD
M?(>#_>K8T.P?3[!8I%B1MJY6,' PH7KWZ=: -&BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ IJ=#]33J:G0_4T .HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBF33Q0('GE2-2<9=@!G\: 'T56EU"SBC=VN8L)PP#C.?3
MZ\=*(]0LY(ED6YB"D9Y<#'&>?R/Y&@"S15=;^R<$K=P$*<$B0<'./YFG"[MC
M DXN(O*D^X^X8;OP?PH FHJC/JUC"&_TB.1U )1&!;!('3\:2UUG3[JVCG2Y
M10ZAMKL PR,X(]<4 6$L[:-T=(45HRQ4@=-QR?SJ>J2ZMIS9VWL!QU^<<=/\
M1^=3+>VK69O%G0VX4MYF?EQZYH R#XA@CNGBN(@5::2.-E(Z(!G=D^N?;I4V
ME:S'J5X4CCVQM$77(Y!5RK9(X],8JJESX>E+7<D<,C/(S,9 K>6#D%N>BG83
MQ[U:M[C0[.\D%O-!%(1L*+PHPY' Z9W'F@"/4=4OK2_EB2"W>)!$PPQWLKOM
MQC@9R#W[BI=.U^#49WB@MYQLB$A=E^7D*=N?7##]:6?5M$)\V66%PR_ZSRRP
MPH#CG'8$$5)8S:3+?O'91P_:8D*L4BP0H;&-V/4=/:@"A#XB>.."2\CB872"
M2,0."8URHPV3R<L.GOQ3D\41/L_T*X'F!3'DI\^=F .?1P>:2#4M" +2VL4$
MB.\F#;YPP?9N! P23CISS23:YHD-Q"GE(8RFYI! <1XV;1TZ\KP.1@4 *?%$
M0(5K*96!!8,Z<*<?-UYZ]!S2OXCW:3<7,-MMG4HL4<ASOW@%2<?7)'L:G?4M
M&610\8RLJQJWV9MH?.  VW'!XSVID?B#0T\H+((_,;";H&3L,'D<###GIS0!
M6;Q1#^[GBLGE$C+&KJ>>5#,.G;<OUY]*EL?$\5Y=0P"!5\R5H]WF9&0H88XY
MR#[=#S4O]LZ>=-GOIH"+6*;:#Y)RW ^;:1D=:4:_HZRQJ&VEY3$C>20"W .#
MCU(&?>@"M_PE&Z2X1+,-Y$WED^;Q@!B3T_V#Q^M(-?EE2]E001K"T2H6.\1[
MG92SXQC &<=O6K=AK6EW\\<5LI+RAF&8\?=X.321ZW:"\NK66)HWCDV<)Q(/
MEYS_ ,"% %5?$,GFM:B*"\8+CS$DV+(25'"_-A?GZY/(-1P^*;B?:D6FH)"%
M;!N.-K;,<[>O[P?D:MIXCTLL@6.8;@N&\@@<X(YZ?Q+^=)_PE.D_N\B4,ZEP
MIBP0, @D>XQB@"O'XGFF.V*RB+F-"%,_(8E!S\O"_/U_V3Q4EQX@F TZ6&WR
MDT8EN %9M@;Y0,@<?-GD]E-:-CJMM?/<)#'(CP!=RR+M/(R..M4?^$DB^R,Z
M6LID$6[A?DSY?F8W>@!&>.] %1_%-U&&\RPB!6W6;_7=VV\=,X^;KZBK-WK=
MU&ME-;VX875N)/*<D;22O< ] 33SXHL?,V"&8GS#$& 7!8<<<YZD=J9:>)X;
MA(VDM)D\PH ."4W!",_BXZ9H K-XGO$D5'LX58IO*AV)(X(QQS@'GZ&G_P#"
M1WR/()-/#"(!I!'N+8(7D#'(^?C_ '35Z/6K-]/EU3[)*OE%8V#*N\ [2#G.
M,88'KQ4$WBFV2!WAM9F<(_#;5 =5R4)SUH K#Q#JOF3P_P!G1++"0,,YQPK,
M>@S_  \?6F2^)-4B;8=/5G1)"VT-AF4,0%_(=N_:KQ\36X,H%C>,8CM.%7!(
M!+ '=CC:?Z9J2T\0V]U>1VXMYHBV\,TFT!2O;.>3WXH SYM;U>&20/!'E5 "
MB)B&(D*L1^&.,]ZNWVI7+2V\NE_O4E1@-R$H#N R<<^O>B?6Y(9KAF@C:&*7
MR%17Q([_ "X/. %^;J342^*+<21QQV4PA;8 ^5 &0G;/;S$_7TH CDU74FF$
MGD,%A?F-87^[@\D]&]0!TJ"35M5N&B(AEBP%;:L+C()3DD\=R,=>#5J/Q2KQ
M%S8R1Y4%-\B#=DIC)SQQ(I/XU:TW75OKHQ&W,2>5YBNS@Y^521CMC>/UH RS
MXBU.*?3X;J"&-KIEW$Q, @(CXZ\'+D9]<=*FU'6=5@N+U+.W$PA(5 +=VP?E
MZD'G.X].FVF1^)1+%YTU@LDD?F2#'!2, ,IY&<D,!QW!JS;^(DGG-NEN(I7@
M>8?-G!7CD8_R* *=U?ZVTAD6%Q&Z3IA(V&P!@$..[$]^, D]J9>:]J]F,31Q
M1*\BB-Y(6  S("#D\GY%/_ OI2P>*[B6WCB\A&N60MNSM'#,.G_ <=>]2OXG
MF:X"FTB\L G:7RQ(5^/;E",T 6)[[6?[3GMX(3Y(=%60P' '!)!S@_7M56+5
M?$!%N9+1@7=MX%L^%&!U[\$GIU [U?T[Q U]J?V+[,L;!&+DR]&!(P!CD<=?
MTK.MO%%S$IANDAEG*>9N\S:B990 QVX  8<\]#0!<^VZA=:&2EO*;^WD3>A3
M9N.0?R(QGZU6^W^(E*;;>208DY-OMW?*Q&1V.0!UYJ.77]0AFE=3#(B$G8>%
MQO<?>'LHYJ7_ (2BYC+QO:Q/(B,Q)F"C.XC'/4<=1U]* (K8Z] C21K<%F+N
M?-3.[]Y*0N,_+D;.GM5C3]4U.[TO490"]Q%+MB1$&0,_0Y_G4VJZQ.EE9WFG
ME)$)9ID0\G;&6V\CCD>@-5D\4714M]A@";>&6?<-QSSP/N\$D_I0 Y+OQ&$6
M26%_GB3>BP@F-L1[B.>3\TG'M4JOK5O;6$44<KEH )"54E'!&=W/<>E02^*;
MI#.%LX"(E1MPGZYVDD*0&(PQQ@<X]:L:AK]U;ZH]C;6L4C;1M9V8 $E!SQ_M
M_I0!4;_A(UB5R9FE"[6=$3=S@C"GY?O''TS278\1W-O=P[;A0S;5VF//W7^Z
M<#Y<[/4^]6M,URXO=0=I%6*!;4R^7SD'Y#ELCCJ>_2J(\67MQ;*UO:1AW1SW
M.PA21D=>W3W'J,@$LIUZQLY9$,H12X5 %8@%\ALD$YQQW'M5LR:Q+8Z7);/<
M,Q -P65%)Y'WE(]-W3%5_P#A)KPSLGV2-$6X2+<6R2I+ L #GH 1['OBI=;U
MN[C80Z?"6CGMC(DXZ_=8\?3 [=^U $;)XE1@/-N)%\I,[?*!W$@MR1U'S#I@
MC'?FKFDRZNMRT6I),RRHFU\)M0A#NZ>XZGUZ<55BU[5'N&C.G\";R@=AXYZG
MVP&/;M^,$/B'5I0LQM=B,I7!@<@$.HW8'/1NGM0 KVWB./3C';371E5%5=[1
M?>!?+$XY'W?3@U+'::V=5^ULTJA)6 RR?/&9$.TCG "[L=^/?%+%K^HJT4EW
M:".!I%60B%R57RU8M[#+$<],=ZMZIJE[ R2640>!HD<L878C<X&<#G@'..M
M%22V\0R7UQY<TD4!FW1Y=3P ^!TZ$[./_P!=01VOB81Q!II"1&ZN=R9).['&
M>H.WO^7=TVIZS>H;98&MBZH2ZPR H"8\G/'7<_ Y&.:NVNMSR:3/(T3F]A4O
MY0@?[NXA>#@G./8^U $R#4;K2$@<36UPKQI(^\%F4;=Q!Q]169]E\2YB(D8,
M)07)E!';.!_=ZX'./3N'KK6M&-9'L@JL%! @=BAQ&6;'4CYFXZ_+3SJ&K0:7
M9L(V)^R1M,[0.[!R0"=H.3@$G'6@"O#IWB..(R0RJDLDA>59) VXA4 Y [D-
M^&*D%GK\,VTW#LCS!%.\M\G)+$]C\H'I\U-EO=9OA]F>&2 .T6_9$ZE%)CS\
MV1UW/G'(VU8U&\U9=<\JU1Q"@VK^Y8H=VSYF.<'&6X[8]Z +^A?;X[7[-J$;
M>9$H_>LV[>23_(8_/VK4KE5O]<FN9/W#IY<K1HQA8*RED&2,\X&XYS4-UX@U
MBUMWDG@$7[J/#20E5#DIGDG'=N/;\P#L**Q- O\ 4;VXG^VQJ(=JM"PC90V2
M>YX.1@_C6W0 4444 %%%% !1110 4444 %%%% !1110 4B=#]32TB=#]30 M
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FZWIKZG;P0I*(PDP=
MF(!XVL. >,\UI5GZW9W5[9I%9RB.195?)<J, \YQU^G% %"#PS;6LTDINY65
ME"@/C"@!P,>_SFFIX2LD,7^D3$1 !0<<C=G!]>"P^C&J;^'M2N[=DGG.&65-
MDDS=!\L? R.BJ2<]SQ4K>&[YY)R]ZV'D9U(F?N'QQ@8P6'<]* )5\*0I*"+F
M63=(\DC2$%B2H &,8(!53SGD5:30 VEOIUU=RS0!E,1X#(!U&?<Y_ XJ&TT:
M_M-26XCNHS&JLFURS?*92P STPIQ]<>E;] &"OA2S1HREQ=!(X]@0L"/O%L\
MC.<FF#P?I@MXH"]P4A4A/G QG&3T]1G\370T4 87_"+VJW*S)-,3YWFMO(/9
ML*..F2#SG[HJ>WT*.'3Y[![F>2VD0(JL0"G).00,9R?3' XK6HH R8_#UDB,
MKF64.07WMG<?FZ_]]FH_^$7TS;M*R%?)\D@MDD>N>N>_7K6P)(RY0.I8=1GD
M?YR/SI%FB9E59$+,NY0#U'J/;D4 97_",Z6KH\<!4QEBHW';ENN1_3TXI;/P
M_;V4EM+#+*)(8UC9MW^L4#N/<\G_ .N:U?,0/L+KN],\TX$'."#B@#*_X1W2
MS*93 Q8^LC?WMWKZTK>'M+8L3 ^64JV)G&0<9[^PY]JT@Z,S*K*67[P!Y'UI
MQ( R3@4 9AT#324/D/\ (^]!YKX5LYR!G'6F6_AS38884,3.T2[=[2-EN .>
M>F%''2M5'610Z,&4C((.012Y'K0!G_V)IWV%K,P,8&<.5,C$Y&!G.<]A2_V+
MIP$8%N!Y;EUP[#DG)[\Y('%79)$BC:21PJ*,L2> *%D1D#JP*D9!]10!F_\
M"/Z<JQB*)XC&<J5D;U!/4]\8^E2RZ-ITLLLLEJC/+]]LGGI[^P_*KQ90"2P
M'4TBR(ZAE964C((/!% %(Z/I_E>6MLJJ.F.W3I_WROY4R'0=,A@CB%JI$:;,
MDG+#&.?7I6CN'J*C:Y@2&28RIY<6=Y!SMQUS0!7&E62W@NEA EY)()YX(Y_
MG\Z<-,L53:+6,+M*XQV*A2/R 'X5-'=02J6252 2.O<'!_6E:>%7"-*@8] 6
M&3WH S[7P_IMM,\RP;W9]X+G.TYSQ^/\A4Z:1IJ%"ME!F,@H=F=I  &/P4?D
M*GDN[>+R]\JCS#A.<YIZS1.P5)$8D;@ P.1ZT 0MI]D\#0/:Q-$Q!9"HP<
M<?0"HTTC3U)8VL3L69LLH)!;K^G'TJ[10!432]/C8LEE I(P2$'(QC^7%-ET
MG3I2&>SAW @[@N#P0>H^@J[10!5ETZQFE>6:S@DD==K,T8)8>A_(4_[':_\
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M,JJB[44*!V H 6C SG'-%% !1110 8&<XYHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *1>_UI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@!J)L9SO9MQS@GIQT'M3J** "BBB@#F)- 9K>9UN$,FV
M:( GY/F=L,?]H*["NF1E= R,&4C((.0:Y=]'U25)(XY%CA9I&:-F/+^8Q!^A
M5@?JHK:T2&2WTJ*.9"C98["?N@L2!^ (% %"_P##<%_=W%Q]I=7E<%@.0,!,
M#'U0'\326WAF.WOH[H74A\LKM3'R@*, ?S_.F3:)?F]GGANMBO<&5565D&#L
M!R!WPK>O6JZZ%K+01Q2WBX  9A/)N/4=?Q!SQS0!?;PS9-&%)8$F4LPZL7!'
M7VW'%5QX4C:XD,MR[1R1E6VJH))#@]N!A^,>G-5SX>U5I)P;\B%G9HU%Q)E>
M' YZ]TXR>AJ<:'J/]H17'VPK&D[.ZK._[P%@1D$$#@8P,"@"Q#X:MH8=BRON
M!1@V!U5V?]2QS4]GHL,&CS:>[_+,S;F7J 3\HY]%P/PJB^C7ESJ]W-+*5M7D
M "><X+K^[)X!P!\K?F:@C\,71=O/O3(/,9_]8PSDKSQC!P#Z]>M %K_A&]/E
MG=FN[B1UE+D%U.UCVZ>AQ]#]*FMO#UM:R1R07=PCQC&Y=@+#(/.%YZ51'AN]
M66/R[R-(U(!7#'Y04(QSU_=X_$TDOA:;RF$%TJ%HPISN(S\G/)]5)QWSS0!U
M-%0VBS1VZI<.CN,C*+@8SQQ]*E9E12S$ #DD]J %HH!!&12;ANVY&<9Q0 M%
M%% !13%FB<J%D0E@2 #U X/\Z?0 4444 %%%-61&9E5U+(<, >AQGF@!U%->
M1(QF1U4'U-".LD:O&P96&5(Z$4 .HJ)+FW>=X$GC::/[\88%E^H[4W[;:^:\
M7GQ^9&I9USRH&,Y_,?G0!/14<%Q#<(7@D5U!*DCU'6I* "BH9[JWMEW3S)&,
M9^8]N!_45-D>M !15>VOK2[>1+:XCD:)MKA3]T_Y!JQD>HH **0NJXW,!DX&
M3UJ*XN[>VMI+F>9$AB&7<GA: )J*C-Q"I ,J G& 6'.>E(MS Y4)-&Q<D+AA
MR1UQ0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %(IR/QI::BX'4]?6@!U%%%
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M3^4&,B*T0WDK&2&W\GV..0.1]>M #[3PU>QQA+J],F%(_P!:W<ID\ 8X5O\
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MC7%B;R)Y)I0XD:/<#C&<@GJ<=?4YI+3PW+;QR*;W+2VSP.P4Y)*H >O;:?\
MOJ@#:EO+>%I!)*%,4?FO[+SS^AIT5S!,F^.567GG/H<']:YQO"LS8/VN)/D9
M3LB(VY+<+SP/FY'/>JK>&KV749BLUO);2;AO= VW+EB,?I[=>M '6&[MQ+Y7
MG)O&<C=TQC/\Q^=2AU)(##(&2,]JYE/"KJC9N('=@NXO"2'P(QAAGYA^[/\
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M[P3&3SGKT]7_ !W>] "1>*+>6YA@2TN"TC[#@#Y#\H.?H6&?QJ2^\1QV5W+
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M **** "BBB@ HHHH **** "D7O\ 6EI%SCGUH 6BBB@ HHHH **** "BBB@
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MOY5#;Z%80SWLGVH-!=0B%T#8^0*$&6SV"\8QU/6@"TGB'3O*#32F)\9,>-Y
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M[J/E_>#<!]8SQ2R:MH$K>7,L;%@SX>W/(&23R/\ 9/UQ3FU;1%4R2!5V\DM
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M#,1CVRY_.F:;X>-@\ZM>J[3VPBY7YN% )Y)!'X=ZKP>%Q!:L'O+:1#$REI(
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M;G:S-DKU]1T]JCCC\.%]R/:EF;RO]9U8<XZ]>!^5,A\,P_?N+F1I1*S@J%P
M6<XP5_VSFGKH&GS,2DTO[LA#@KP0",9QD=><=: )H$T.X\V"W>"3[9EF19,[
M\$Y(&?7/2JL;>&YP)V^SHZ 2D.V&3!X)Y]7_ %JQI^AV5A=1O!,^^%3\N$&0
MV?O8 )_^M38O#]@(B(9Y<'[K*P.TC;C'';8* 'AM!2W: 26PBF(C*[N&(X ^
MO'Z5"3X9:'86LS'LW8SQMX7/\JGCT&UCNEN//G9UD\P!F&-V"#V[Y)J.30+#
M[0CB:2.4HL:D;<_+@@@D9S\HXZ>U $/VG08;:%O*55U%501YY93P"1GI[T7
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M7.D:1#&\DUU-&+LYW C<3M.><9Y!;.?7M4]UX<L9[66)970ON(8G."0XZ?\
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M:>Y6!83&L+E#O!.Y3)SCN/D'TI\?BH/C%K@>=Y>YGQQR,].N1CTY&36\+.U
M %M",#:/D' ]/UI?LEMN+?9XMQ;<3L')QC/UQ0!SR^+-R!OLB']UN.)>C9(Q
MR.G')'Y'K3]3\130Z9#+##''-<02."SY"LHZ8 YSSUQT]>*WA9VHVXMXAM4J
MN$' /8>U.6WA1558HP$&U0%'RCT% '-W/B2;>+588UE;AMKE]I#[2/N@$8!Y
MS^ J1_$,MI%:))#"WF6JS.QD*G)#=%"G(^7GTS71>6@.0BY^E-$$0F,P0>85
M"$^PS@?J: ,?2M>DU&XBA-GY9>-I"P?<H4$KG./[P/X<U#I?B&>YFM[>XA@W
MNO[QHY2=IVL<X(^Z-N"<\$XK>6WA6<S+&HD*A"P] 2<?F33PJ@Y  /TH Y2#
MQ)<) T4S1RSL"%D3 4MQ]W&0P&0<\>A J/\ X2F]2$3&WBD8 (560;">N[<0
M/I]:Z_:HZ ?E1M7^Z/RH YE_%,ZR2 6L+!7D4*)<L=JY'0=3[9QWJYIVK7E_
M),H@@5(XBP=7+;VW,!MXY7Y>OO6T%4= /RI<#TH Y*V\0:FEOY\L44X>!6(!
M*[)-O(Z=.I//%6;CQ%=0I8D6:,;B!G=0V[80K'@C@C(Q^-=)BB@#EF\1ZE%'
M)YEA"&5BH8,Q7C=G/RYYP /K3IO$EZLABCL$\P$Y#EAM&'(SQUP@_.NGHH Y
MM];U"'2WN/)AEF%S(@7#851DJ#@=2  /J*>MYJ4=IYKR9+W\D9W)]R,%@ ,#
MV&#[UT-% '+6^O:FG]GP2VBR&5E663!'!6,Y]C\Y]?N_EU-%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4B].?6EI%Z?C0 M%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 52UB*YGT]DLR1+N4X#["5!&0&[9&:NT4 <?
M_P (_JTD44$TS&&-8 $%PP4;=F<>^0W/?-.;0]:,"(MR%E0@K)Y[$*/*9,!<
M87D]1]:ZZHKKSOLLOV4*9]A\O<<#=CC- '-_V)K/E_\ '])YFPIS<O@CYL]N
M#]T9QD8J>VTW5"MZC3O'A$^S!Y6=5? 8Y/4C( SC.,U3G&L?V EL8;TWT3LP
MD5RV_P"9P 2"O8#J"!D<5UK9*$#@D4 <S'H&HAX)+FX2X>*0-EI&&0&3'/KA
M6/U-16OAB^AM8(3=KA(E1@LCCG,9;![ [#^=5G@\0-;KC[;&1&L#KN5B[!)
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MT5:U71KV:^>XLI"I,21Y,[(3@/W'H2I]\4 ._P"$;D+9:]55,QD9$BPN"4;
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MN-7T^V94DNHM[XVJ&!+9( P/Q%5=+\/6NFD>7([XB,7S =#CG/KQ4$'AZV8
M"]EE,9",2J]04('3C&P?G0!=CU[39/* N 'FV[(V&&.2!T_&K,>H64KQI%=P
M.TN=@60'=CKCZ5D0^&K)L&.ZD?80K$;3RI''3@\?J:?I6@V5K+%+:7<KBV9T
MQ\O)Z$$@9XQT]J -(:II[,JB]MR6?RU'F#EO0>_(_.F1ZO82"9A<QB.&01,Y
M8;2Q . >_6J/_",6F23<W+9<M\Q4X)96XX_V!2KX?M8K+[%]LGP\JR*25W#:
M  %X] .>OO0!?.K:<"1]MM\ABI'F#J!DC\J8-8T_SGB:YC1D;;\S#!/&<?3-
M9T.BZ4+Z:W^U-)-Y;[H2R@JCX'8 ]N">::VBZ5&&S=SJ.+:3YP=VX*-IX[X4
M_6@#9@U"SN75+>YCD9E+@*V20"1G\P1^%1_VMI_E^9]KBV8SNW#'?_ _E5>R
MT.WLIX98YI2T4;(HPB@@G/.U1FJL_A>V:W=([J=6*N!DKMRP89P .FX\#% %
MV?7M-AMGF%U&^V-I J,"S!<YP/\ @)_*G)K6GLN6N40@$E689 !(S^AK.E\/
MV9E\FYO)B)86!7< 7/S;F)QVW\?UJ1?#VF&5VCE<.048AQD$Y;KC((W4 6HM
M=L)(8I7E\M90[)N[A&VD_G3KO6K*UM$N3(9(Y(WDC*#.X*I8\_05!)HMB;6"
M'[1*HAW[6$@R26#$GCJ& /U%.?3+&YT^*V$\HCB61=P?!8$%6SGKU/XT 6(-
M7L+B6&**Y1I)E+(HYSC/^!_(^E5X/$6FS1>8TK1 ] XY(VAL\9[$4T:9I5M>
M#4FD"R0J6+LXP%)8Y/I]YJ1=.TB>Q\B-@((T>V.&Q_$,Y]3E.M $_P#;^E^:
MD7VM=\@!4;3WQ[<=1]*;'K^G- )))C'PNY2I.W<NX#CCIR?3O5,6.AP?9_WY
M8R.8XRK9W-@*>@_V1FB71]%,Z([OYFP,G[SH%&./P?\ 6@#9M+R"]B:2V?>B
MN4)P1R#@]>M3UE:9;65NWVJUNW,4XW[&?@E\'<?<@#]?6M(31'@2)SGOZ=:
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M:A;7]9\Z=8].9E21E4F%U)48P>ISD_+^.>@-3-XG59LQ6.R%R6>1F&3AV0G
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MRP _4BK55M16W>S<7<HBA!5F8L!C# CD^X% &4&\,&%6!L3&5* \$;57!'T
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M** "BBB@ HHHH **** "BBB@ HHHH *1>GXTM(O0_4T +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %,FE\F(OL=\?PH,D_A3ZIZQYPT>[^S;_.
M\EMFS[V<<8H ;_:7_3E>_P#?FF_VH_.W3;\X_P"F8&?S-<W,-<#D 7K(\\S@
M@'Y%#X"_0@ CZFKMQ!>V3^;:)=RLMXWREW?<GDMCJ3QO(YH TCJ]T"=NAZ@1
MZ_NA_P"STG]KWG_0!U'\XO\ XNLW36U*U:.WOXKF0PK(ADB8R;MVQE.<#I\P
MZ<8K2\-K<1Z>\5TDP9),+)+N#2C ^;!)(^F>U &I&Q>-6*E"P!*GJ/:G444
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M*;E]R(23C!.2.O&?8T ;$*E(44N[D#&Y^I^M/IL:".-4!)"@#)ZTZ@ HHHH
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M@P,G)_H!DGV!JA::";2Y,\5](&94#GRDW-M"C[V,\A>GO5O4]*MM45%NRY1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *:GW>X^M.I$Z?B: %HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex10_8page003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_8page003.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH * <]**11@?C0 M%%% !1110 4444 %%%% !1110 4444 %%%-<2;DV%0-
MWSY[C!Z?CB@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2!@S,
M>5.#2T@4 D@<GK0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4B]#]32TB=#]30 M%%% !1110 4444 %%%% !1110 4444 %([!$9SG"C
M)Q2T4 -219(ED4_*PW GCBG4V2-)8GBD4,CJ58'N#3@   .@H **** "BB@@
MD$ X/K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^J@J3[YYJ>+0[B,7H:6-FNH2F\%E(.]V]^,-^E;U% ',R>&[PV\JQ7D:2S(
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MW[N1GTP.O:J+>&9&;=]K7=YXF+%,DX;=USD'MQUKHZ* ,*R\/R6UY;SM=;A
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MJ]NY+BK1U*P"[C>6^,;L^8.F<9_.HI+K3+AP)Y+<R0EF42$;EVD@D9Z=#S0
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MX%: T?3 ,?V?:X_ZY+_A2_V3IO\ SX6O_?I?\* *5O<W8E;S)I9%621&Q$
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M5!=1C4!*(F^5 47+$D\MC@8 [>HK;HHH **** "BBB@ HHHH **** "BBB@
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M0=W)[?QM@^]7I;RT,-O>-<%(R-R_-C<#QDCN.168GA>-40"ZS(@ R8P00 F
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MD58\^$$@RID8R-W3/2@"2BHWGA0D/*BD=<L!C_.1^=127]I'*(WGC5BI?D\
M#')]/O#\Z +-%027EM$,O/&/F5/O?Q,< ?C44.J64T22I<)L=2X)., 8SGT^
M\/SH N457:]MUN_LK28EV!R,' !SC)Z#H:C?4[1&F4RC=#C>![^GKUH N45
M+VU) %S#DDJ/G')'4?6ECN[:5@L=Q$Y*[@%<'(]?I0!-151=3L6E:-;J(E8_
M,)WC&WGG/_ 343ZS9+)*@D+>5$TI*C(*J%)(/?[PH T**@BO;68QB.XB9I!E
M '&6^E0QZM8R77V=+A#)\PZXR5.&'U% %VBJIU&S A/VF(K,2(V# AB!D\_@
M:/[2L NXWMN!C=DR#IZT 6J*@BO;29E6&YB=FSM"N#G'7\J:-0LBP47<&2^P
M#S!RWI]: +-%4TU2R<3L+F,) P5W+#:"0#U_&GMJ%DN[==P#:VQLR#AO3ZT
M6:*SI=<TZ*X>%[A<Q@%V!RJYW<$^ORFI4U6P=0WVJ)<AB-S@9 )!/TX/- %R
MBH(;VUG?9#<12-MWX5@?EZ9^E5SK%CYJQI.LFZ-Y-R$$!4QG/YB@"_15"WUG
M3[@RA+F,>4 6W,!P0"#]/F%7D=9$5XV#*PR"#D$4 +1110 4444 %%%% !11
M10 4444 %%%% !1110 4B=/Q-+2)]W\: %HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBL+5WU9=0<6'F>6\"QC"Y",Q;Y_P  !Q[B@#=K'UJS
MO;B\LI;4*Z1-EE8C .Y?F(]E# >Y%4(;W7@XC>"78#""QAY.1\^.WIR?TJ."
MZ\2&-(RK B&,%WAY+%E#-Z<?-Q^- &G8VEXNNW%[+'Y4,T2@J7!.X8].O?\
MI5C5]/\ M\=N BL8YD8[C_#GYA^54-2GU:W-TME'*[DH4<IN4+C#8 [Y[8J'
M[5XA,[C[,^P3(%&T?,/FSSV7[I]>W6@ M=-URW^R1K=D0Q.I=<@G&$X[<</^
M=3WVGZH][*]I<,D4DR/]\G@*!@#H.1GWIOG:X/#RN4;[;Y@#84;@O?C'/Y=*
M8LOB(W3"1&$0<["B+SZ;LG@=<XYP%]30 R32-99%Q?R!_+PQ\XXW?.?3U,?X
M U<@BU1%O;>1LM*)'AG,A.PG&T8]CGIV [FLPR^(YBML3,LIB)8A$ &=PY/K
MQQC\:L75OJYDM[FW^T[EM41_N%MQSNX/&<A<^V: %_LK5RR[;EHTV;2/M+,0
M/3D=<\[NO:HI="U.>2,S7"R"/ 4M*QP,^F.3COUJX\&L2:/<^;-*+LR@H(MH
MVJ&'"GW&>M5%MM?@C>.&2789"Z?<)4DOP<_P_<SWYXH 6+1-5B5!'=;,$;CY
M[$Y'&[/<=?E/'-6;32]3@N+9WO&=$?=(&G<@Y4 C'?G)'84V!-?^WQ>:[BV$
MSER=AW+V!'8>G4\<]>((U\0W#3-'+*B"239OV#)&\*.GW?N>_6@"6YT;5)KB
MYD6_,:R/NC59G^3Y7 _5ER.G%.CT6^)O3-=_-<-'ATD8-M60L>?X<J<8'%1"
MUU^2(1O(YC8;L2,N\8)P"1QDY!X_N^],>SU_YGCD<28*[]RAFQO*^H R5R/0
M?A0!*VC:JC22+J$KGS"Z@S-C'S8&,>A'?MFHH=#U41Q,^I21$1L-HF8[&9<9
M.<[N>>O7I4Z6VNK,&>=W4S(Q 90-NY\CV&TH>_(I7T_4[G4!]JD+6JW DVEA
M@@$E<#'8;<Y[T 1?V!=^?YD=T(W"@IB5VPP!'.3R,X/YBK>GZ/<V=W/(]])(
MDD6Q26Y!P!G'KD$]>]0W&FZ@=3DN+=W7$A9&,G&#Y61C_@+?I49TS6)]+2.Y
MN=UTEPLH;=@#:O'3/&[G'UH CC\-W@:)FO%)3<"0SG .S.,GOL.0?[QJ$^'M
M46ZBC2X'DI"5#Y^4$[L\?B!TQW[8J>'2];@D7R[@*)9GEG(D/5D X'^]G\A2
M?V9KP)9+L1L\B.Y$A;=M4#&#TY&3]: %'AFX#EOMV69$5V.[YR%4$$9Z';]>
M33F\-W#0LIO=SLFS)W8QA>,9Z C_ !S5UK._2QLBK">YAG\V3S)",Y5@1G';
M<./:J,6G^(5,'F7:N5G+2-YS#*_*, 8QR QP>F: )M0\/S7TA9[I<-"(S\AY
MX((ZXVG.<8Z@5)=Z/*]^T\5S%;JQ0J@0_,RE2-WS8/W".,'!]J9IVGZQ'=Q-
M>71,(B*L%E)YRW/(Y.,<U7_L769.+J_\S:24*R,I!VE<_HI_%J &IX9VIEK]
M%^ZID1,,6&P<G/JG'IN-/'A9Q;^2+J+'ELG,1/5]V>6]>W?OD<4K:+J,@>.:
M56C=P^1,R[3YFX\ 8)([]L5:FT_4V@TQ([E=]N5,[M(P+8(SCUR,CGUH 9!X
M="7HGFN%E42B3;Y>-Y&XC=SR06X]  *2[T**^UB:>2ZC97VAX-@S@;3@\\].
MX[TFGZ3JEO=K)->LZ_9@AS*S?/CDX(Y^;G.1UJ.RT*_2Y2:>94R^Z0),[%N%
M'4@$_=H E@\.^0;AGN8Y/.A\LEX<YZ$ECGGI[8J-?#WG1X.I"95^]N3=EQM!
MSSR/D Q]:BCT'4S9&"XN1,6B="7N'(#%0-W09R>QZ9XJU9Z7>PZ@6:79"5DD
MVJQ*B0LV/KPW/T% $4?A5$F@D^UDF$@@%3C[JCC!&/N_D<5'_P (G$T/DM=J
MP$80KY6 1O+ '#9P,D=?J32_V#J1C11=+&1"4)$\AYPPSSZEE)]-O%30Z#.E
MR':8,,C)\U]VU7=E'TPR_P#?- #X=$M+ 7S3W("7J&-BW&,YXR3@]3C^M+;:
M!#$\K-<AC/"T>40*<%5!.1U^Z,>F:HKX;U%X(XY[R,E03PS$(2#T_/OTQ4\G
MAZZ=.+E!*IDV2Y;=AEQGKP1P..PH 8_A>T0P1->LGRLB(%&&)W$\$G/4\>U6
MX-#M9$FDCG4_:(GB=XT"@Y"KV]-E,LM#N(-0M;F2X5E@R0I8L1D," >!CYL]
M.U0KH=Y!<1E+@"-Y_P!X(\@>7DLQ.3U)VCCTH <N@6(<1-<QDD%GC$:@':X;
M@=@">GN*6WT"PMBMZ]V)(5V2[I,%<*N,YZ8[TK^'Y3J$EU'-&F93(I .[EXV
M.?P1A^-2VFBRPVEW!+)#*L\:* 0>H7!).<_X4 )=:38W5Q_:,EWNAF9&4?*4
M)W1X(/?.Q1^-0+X:LY=Z)>R%H@L;;0N58!#R<9Z(O'O39/#M[*-LM]'*-J$A
MU;EAY><\]/D_6B/PU<1RH_V[..3P>NQ5SUY^[^1H T$T.WCLVMXW*YFCEW;1
MU3;@?3Y<537PU8@^3'=2*Z1;2%VY )7YNG7]V.?:H1X8NA (OMR#Y"#A#S^]
MW@#T&,CC\N*M7GA][H(#=;0D*1C.3RJN,]?5P?PH GU#1HKN7SI;F1 L13Y5
M7/U)QD\\XZ9JG%H-C+(C+?22&1/,'"Y8<_-P.GS5/>Z&]SJHNTO6C0X)BQP2
M,9_/:GY'UJM#X8>%(D2YC*1X_=M&2AX4'(SZ@GZF@!]MX<M#'&UO>3-$DA8#
M@AB"HP>.<;,59M- @M)XY4N9G9$V8?:>/F]N/O?H*9%H!BLKZV2YV?:EQE5/
M!RQSC/<,!^%5I/#.8=@O I"CY=IVY# DD9SC"J,=L4 3GP[9Q11J;N965?+2
M3<H89W@ <?\ 30X'L*;!HNGQS/;K>2M)+;RPE=PSM.P,>G4?+^=(OAQ#,DR3
MQN49&^9=V2I7KSZ C\:?-X=62]>Y$R(3(9$Q'RI)C)YSU_=X_P"!4 20:'9V
MES%=-<.74@9?: S9(';@_,1QBGR:#:2N[/+(0SLV,CY<MN(!QGK4$&A);:.;
M.2>)@)DEWNA(RI7J">^WG&.M0Q^%HA;R0M<ARRR*&*$D%MHW')^]A>O&<T 6
M_P"P;7^STLS/)L4MDC:"P92I!X]#]:B?1]/MMJS3N6ED51\JY9_G/0#_ &F/
MX9H3PXD5U#-%+'&(Y1)M$?7#,?7&<,%SZ#BG1Z!''J*74DR/BX\U5,>"3B3J
M<\GY^OHM !:66FVMWYT%VVZ%"[*I&-N-G.!SC8>/4&F3:-IMH)+NZNY0I?<S
MNPX)*X[>H %1OX823S"MRBL2^UEBY4,SDC.?]O\ 059CT8K9WENEQ$3//YF?
M*X0\'GG)/?.1B@"--*L8+)8EO9<3R(T4GRD@JHV@<8Z#N*$T33Y_-Q<RO\S)
MR1\G#J0..WF-S]*@E\/"0N7U&)]O)\V(-@G&2W//()[4X>%U\U)!=EBB.JET
MW$$AAGKC^+G.<XH F?P]8.),W$OSCCYE^0'?C''J['G-)+HFGQW"++<2@SLX
M"9&'8ASGIQ@,_M5:3PJDJ"+[8I55"LOE_>.XD9^;H-QP!BK5]X>%W<K*;D*%
MC"8V9/"LO7/3Y^1WQ0!:MM,M;>Y:9)V)=&7;D $,Q;L,GD\9Z?C3+/1K.U^[
M,\A:,Q$NPY4A1V [(*JIX<,.6CN8U?"D-Y ^5A(7&.>%R<;?UID?A>VW1R+<
M;F"J%<(,D#R^<_\ ;/\ \>- %A_#]D\!5KB4GC]YN&<@(,]/^F:_K6EI\<,5
MA!';.)(50!&&,,,<'CC\JQK?PM#"L.9@S1,"#LZ_,A[D\X3''J:U],LQI^G0
M688,L"! 0NW('3CUH M4444 %%%% !1110 4444 %%%% !1110 4444 %(G3
M\32TB]/QH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q-9UB>
MTNUM+6.,RL(V4L_WLR!2,8XX/7^=;=9.IZLEE=^2;5Y2HC8D8Z,Q''O\N: ,
MF\\4S-!*+6)$D6%9!DEBN5!P1C_:%7;W7)(#+$8HCM5,EY2GWAG)XX7MGUXJ
M9=:L[B.[%C;O/);Q[PNW ?CH#_\ 6J*;Q% ELK)"))B4!5#E3EHP<$XS_K!C
M(% $7_"073.JI9K$ID0;I7/"EE!SQQ]X8IG_  D-W+'"HM5B>54? 8LRAN<X
MQTQP3ZFK$'B6UENO*,4GSN%CVKDXVH>1VY?'X5(OB2T95*V]R2RAE7:N3G/'
MWNHP<^GUXH 9>ZY/::A-#]D#PPX+,I)?;A2S;<=,,<<]0:BM]>U">Z%M]@2.
M0R*AWO\ =R,DD=<>E6FUL2Z>;RT@D9!.D0W #S 7"G;S[]\5&OB>T<@16UT^
M50@A!C+%0%R3U^<?K0!%)JNHQZJ$$2M"LSQNH!SMW1A3TZ_,32'5=2N_#KW4
M$ M[SS8U5/O]67(([=2/:GKXGAD9?*M+@AF**"H!<Y4#&3C&6]>U2W'B6T@%
MN3%*PN(#.N,9 VEL$9XX4_C0!2AU[4?M"L]H[0W$Z"-3&08XSM&3[\[OT[5&
M-?U81^<;-6W(F$V$!3E]QSW'RJ/Q!K0B\0)<WUM:PPNC/(4E\S'RX\S@8/)R
MGY5#?>)TC::WMX7-S&^TA@,<$@]^WR_]]K0!,-1O#;6]S.AB1KMT94C+'RQO
M SQW(!S[BJ<.O:JX@,FFE2[D.!&QVC"]2.A!;WSCM5H>)(W+*EE<,R@9'&-Q
M(&W/3OUH7Q/;GK;3J#(8T)7[[!L$#\,GZ T ,L-:OYKN);FQ>.!H@S.(F^\3
MCCKQG_&K.NI>?(UI<7,8\N3<D2J<D(2.H)SG'2H[7Q!]MA9H+61"(&FR_0 =
M..],CU^22PNIUMANMXO,&Y\!\$@GCIR* *\FJZY#Y<8LA(5C8L_DOAR <?3H
MO7KFDNKS79+E[?[/A89%8&.-U\W"DXW9Q@D>O'0YJ1_$KV_F)-:^8PD(0H_#
M#=(/3_IGCWR.E3:MK%S8W4D<42NK0#RL@\2DMC=C^'"D_@: (&U/7/L\DD=H
M#L Q_H[@ME@,A2<\#/'?%2WMW?W-C9RVB.9HW)G1%8 LL;-M['&\*/TIB>)L
ML8_(C++)'&6\P@9;/;&<Y7&!GKUIMIXFDG5$6R1I62(G$N!N?9D=,X&_KST(
MH N:=<ZI<R2_:%$<:P_(3"4+L689P3QP!Q[UEVUUX@AMFE\IYG:-,K)"RD-L
M7<0/KNX Y-7[[7C8/<HZ1RR).$2/?M(0QALG\<C/KBHF\4!9)0+9'6.8QY67
MDX!Z#&2<C&.GO0 3ZEJX:RCAC4S26_F2)Y+8W9QWQM'UIKZEK @>X:-HHP5"
MJUN2QW2!>F>N">/I5D:S+-IMK>I!%'YT_E-NDR%7GD$>X'%5K3Q!=%K*VNK-
M6EF*AY!( IRJ'(R!D_/T]CUH 07WB QR%K?:PB! \KO\F,=>3\^1VP/QDBO-
M=:X EMRL?VE5*JG(CW,,YZ=-I[]Z27Q)/%<7$!T]MT)8%BQ"<$Y.<<  QG_@
M1]#4%YXDO?[/N)(;6-2$94DWDC?M8@CY>0=HQZY% %C4?[7NKV6VC61+;S$Y
M4 93<G1NO(WY'M3)$UD:OYB&4Q),PP<;3&S1<?@-Y]>#5_49+RUC-XMP!"JQ
M@ILR<EP&/Y']*I?\)%.;B15M4\I9UC#;\L5)(SM'/8$>Q]J (X5U9]&N[:Y2
MY#)'$(F0C<3@;AG()Y')SG!XYI)FUQU6+[/.D<?EN=C*S<%#@$GYB/GZ]>.M
M \378QC3@Q\II,*_4@MP/7[HY'K5I;K4'TJZU3S-O^CNT<"@-M8#@@\YZ'\Z
M *4/_"10ODQOM<.[JFTY?;T!/3G&.W6E+^)C#@+)O,8R<1_*=YY]R1MST'!J
MW-KEQ%8RS_9@[)<2180,1PK%?KDA1^-0_P!OW_GA%L X\UU) ."%"D 'U(/I
MVQCO0!?NYM1N-+5].&RY#[&#J!GJI;![ _-[@>]9Q@\1!Y+A"!-+%@QY0JI^
M<C'N,J/0U)%J&I/I+7 !,[705<1G 4XZ C.,TD^J:D]M:)"O[V>W5V=8F)5\
MC(([#K0 DD7B,P(ZSOOW*"H6/.W;R?3.[&>>F<4_RO$0N8\R_NEE*G:$.Y 1
MACG'4%LXZ8%5KC5]7D'DI;.AVH6=(SP=Z @$YR"">W:K<M[J<#:<RQ22;[<>
M:AC)RYQGD?=(Y//I0 DEGK3V]D4N7$WD8N),ID,2I.!C'8CI3M3LM2NGM?+>
M11Y:B4HZ@*X="3@]3@-4,^HZP^@I(+?R[J8LIV1,VWY21QU!SQGI_*E35-::
M0 V:*IG*Y9'X4'H?<CG/2@"2T@UUO.%])E6M=BJNW&_:.<CD'.[VY%4?[+UZ
M*-#'(YDC@-NA$P^Z"I#'/?[P_ >M3G5->6 R&TC)*C $+97.TY(SS@%N.^*>
MEYK%Q=',9C"6CD!(FP9-J%3D]>2P ZC% "2VNO--YHD8-A@,.H R%Z#I_"<>
MYJS%9ZH;&X6XG>21D01J64=,$].Y^M.TR\U&:Z:.YCS$L((;R60EL+SD\<Y;
MCMCFJ/\ :/B)82[6T;$@8Q PV_<))&3G&YAC_9_"@!\]OXA>2Y>*0J)'#1+O
M7"#' _ED?SZ5+%:ZW]NC,D[" 3LQ^922N1@$=AC(X^M0R:CKY>016JX&""T#
M8^XS$=><D*,\=>E2:C+K(O";4L54I(B>42N-DFY2<\_,%^G% !/IFI?VL]U;
MR,%$I=-TF1@B,8QV'RM3H[/6_P"RW5KO_3#("&)&T C!Q[#)8#U%2P7.J7$&
MHK<)]F(#"!DC9F7E@#C&&X /![U1>[UDV8ACM[E#L#!RA9A@COQD]>.N* 'O
M9>(VC_X^@)"C<JXP"0_&,=<E.?;\[5EIEV-4N9+US+ \)A4F3)*YXX[<=?>J
MD-YKHN828,1RRKYC/$W"X4< 9VY^8\\ \9H;4/$ C^6UW.8\\PL #YF"?7&W
MD#KP<T 37&EWT#7,6E_NHI3&0PDY !.X<],YZTUK+7"[E;CJY*LTO'*8!('H
M>W3U]:43Z[<6NHI-$D3B#]QY:MG?MZY(&>3]:9)=^(A*8TACVA" _E-\S;F&
M<=!P <9[T 3VNDW4^4U9VEMRF%B,Q.#NSR1C)]ZEEL;[^V%N(6 @+@LN\@$;
M0,D#J>..U4GN/$!EDS"N8I&$>U&Y&' )Z Y^4XR>M;.F37,MN%O(V69>&;;@
M-R>1SZ ?G0!E/8ZXP.VYVMO(4^9\N,$!B,?0XZ46FF:J+RRDNI3)' ^[#2D[
M>''3N?F7DG/%=#10!AQZ9>)<7DJN5,T+I&4DQL)D=@<=,X8<X[55.D:NBS-%
M.%:90'43/C($8!!SG/ROWYXS7344 8$.CWGV74DF>,R7<!C!S_$=W)X_VJ6Q
MT_5HK^"2>Y)MTS^[$I; ^;@D_>ZKSUX_/>HH YJWTC5XKE)6N2 9=\N)R2W"
MC/(Z<-\O3YJ2+1M7:-/M%_*6# MB=AGYDW8QZJ'X[%N/;IJ* .;32M9#.9;Q
MWRJ* )V4$#;D=.#D-R/6IFTF\6WL$BD >"U$$FV5DSRA.,>H5AGJ,UO44 8D
MNF:B\5BHO'#0QA9")6&X[ESGU^4,,GUJH=*UWR9@;TM(T:JA\Y@ 1MYX[\$^
M^>:Z:B@#+TNSOK>YEDN[@R+(#QO+ '<2, ]."*U*** "BBB@ HHHH **** "
MBBB@ HHHH **** "D3I^)I:1.GXF@!:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ JO-96T\PFFA5Y   Q'8'(JQ3!-$9FA#CS%4,R]P#G!_0_E0
M! NFV2+(J6Z*LB[7 X!%4;R#1;6X@MIK. R7(V*NQ>5!7U[ [??IZ5K[EZ[A
M^=9]W9V6J/'+)(V8&*_*V.C D'_@2#\J &11Z4^IO9QVL?GP(LA(CX .!C/K
MA5X],4R]MM)L402:>D@ERH5(@QX!8_RS4]OI=C;7YO8Q_I!CV.Y;ENG)]^.M
M27UK;WHC$LS(8V.TI)M.2""/R- $"WND?9T"2V_ENX=5&.6W'! ]<@_E5>*]
MT!D\X"U1D1"0%!91P0./3CI[5)!I&F6TWGQOCNH,GRJ/FZ#TRYJE+X?TZ_L%
MBM9W0*Q4,23G:0",<=U'Y4 6[F\TBTF0_9D+-LEW)#V=@ W3KG!]>*?)?:*8
M97"P2BU@+D+%DB/'0<=,'H/6GM:V$I@EDNE=HD"!A( &VD') XX(J&#2M'M(
MI0DB+%+#Y3@R\%, >OIB@!XU'1A<KM\H7 8*N(3O!;)P.,^N?QS4EGJ&E7\[
M);-')(5+',9&1\O.2/=3^51P:=I45PDD4H+F3*@S9W. 0>_)P3FEMK72+27?
M%+$&3]US+G!(5=IYZX5>* (4U+3I;NW2UM5D,F_+B+&Q5 ;TYSN4CUS3+;6]
M.EE)6V\MFV2*6BVEMP'.<=1O^M3V4&D6LDK6\BYM00[M*2$# #&2>,!!QVJ)
M;/085C7SXAY85E)N.0/E"GKTX6@"<ZE91V=O<6UONBN9/+4A @YSR<XX./QX
MJ-M<TY9(U1=T<@.]A&?E'7D8Z<T];;1VM8[<3(T1F.!YY.]SU!Y^;KT-016O
MAZ681H8C)Y[*$,I!+@\J!GD#TZ4 $7B#2I(3YB 2+&)'C";MHS]/]H?G4S:_
MI6X;I/O2+$#Y9Y)&1^&#^M1-;>'@DL9D@"H0LB^>0%/;(SP?E^O%1E_#T-V(
MPT:M$-QD$Q CVG8%)SQSQB@"S=:WIUK<2Q2QOOA8;@L6XG@G(Q]#4$VN01QW
MDMM:%Q;1;@=FW>=Q7 ..F13Y6\.K<2R32VHDD;#EI>I(QZ^A_6IQ%HT*J1Y"
MB\ V_-Q(,Y&/Q/ZT -@UBSN9DA\F1IG(7'E<'K\V?[ORGGVJ"_U^WM9GABAW
MRQN0X.!_"QR/^^33H;C0;5HIK1H6>:;:AC;)+,0#WZ?,/SISKH!G</\ 9C*\
MNULGDN<C'ZG\S0 ^ZUVQM)I8)(Y<QG'"<,?EX!/^\OYU'_PD%NTJ^7!*\9R
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MYJ.+POO\U[B6-6D>0@1ITSO ;.?O?/U]@*GU(:Q%)<+8)*YD:,K)E"%4##
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M X![< ]:I)INOP1I';W.V/S0Y&0Q&68D#IQ]W]: -&'1(X;2[MENI,W"XW
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MIS\V03CIR* *]O8Z[;'RHYV2%@#\H0D$L"Q)/?ENQJ::#Q )%,-TQ!$GW@F
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M>Q0O9!49%E5S%@AF. -N,@_*2>F,4'3=$ !9U8/N7!G)WGG/&>3\Y_.K,?\
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M_P!7D_6K&GZ##;0W<#2>9%/&(5QU"A<'Z$MN/XU6CT[6'TZ[@EG(::V*(-^
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M+69?+6ZX.UD3^$+M((QG."23UZU:&DHME=6C3PK$\@<'8,AR^[+>O51]![T
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M.5QQC@#^2C\J:-&TT+M^QQ'Y=N2.<9SU^O- $ URTDBNW@ADD^S#+?)C=SC
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MV94J;6###!'ECD=<5(]O!)MWPQMMQMRH.,=,4 94>N :@;.2%FS,8]ZC 7G
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MKJWM[6TB<N&DRL&-F%SZ?>XZ=>E.M]8T;9%<+&8BR1D,;9AL##Y03C X]^*
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M.P<CM3DLK6.X\]((UEY^95QG/4_7CK0!/BBBB@ HHHH **** "BBB@ HHHH
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MY4*=BKNQCYONGCCZTK?\)$4 B66%5M %7$;$R#J2<]?TQ[U*R^(6F)'F*GF
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M!?#S6UW9-!)!)#;2 L'^7:V(P2 .YV9^IH T[G2+"ZGEEFF<EWSM\SA7 "Y
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M^4\9ZCC^0I]O;>'983Y4L?E@,,-,1PI8$\GMN;FKNIV5KJ+PVL]PR3(&= C
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M9;M%DA8MYH2$A<D95,DCL<R8X]Z>=?T^X6,_99I#A9(QL4DG)Z<]1@Y]/K0
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MH"N 2Q<[.J@?[?;TH =]H\2"'YH)-Y5"2JID'!SP>"2=N?8FK,1UXV]T9/\
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M%8DPXP,#;GT^\OYBI6?11=0*7A,K*8HR&&!L&-OL?G/'O44;Z!<P%F>%8YD
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M GG& <$9'7I49U/00OF^7'@R#YOLQY8 8.<>XP?RH @B\26L*L(]/DC 5I)
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M.,^YYK;HH R[?1(88KE#+(YN8C'(Q !Y+$D8&!RYI]II$=O++(TTDID0J=P
MQGEN@[GFM&B@##?PQ:R0"-YYB5VX<8!! 0 ]/^F:G\ZG?0K=E55FEC A2(A
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MX&!S]T9)SUXK?HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYMQ?;C'Y'\: .BHK&?6\VHN5B\J+[1'$6E('#$9/MC/>H&\4PK+M-NP7[0(
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M <_I0!T]%<]?:KJL-Q.D%KN5)-J#[/(V1L)SN'!R1CCIWH.JZNMR$-F"ID4
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M@DDYR&/)/4<FGPVOB))HW,I"L093\C%L*@Y' [-T[T =-17-+#XB,*@R29V
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M2ZM$G6\?S'=P^_>2#E1GCMR#6E0 4444 %%%% !1110 4444 %%%% !1110
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MB7?]Z3C!#$@?@S&E71=)E4NF0+E"O#<L.I]Z +$+:2T$T\,4/EV[LTC"+A6
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MC\XG<V%&3P.#\QQVS0!H06%TNJB]GNTE41>6J>5C;ZD'/<CT["G:SI@U6U2
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M.IP#_P"@BJ\_AVTC)GEO98XXPS+D@*F7WYP>.N*K1>&[^-8U6]*1QR[]D<K
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MY^49 ; /;*C\J)[/15CFDE*NA;;(/,+ ;V;J,\#,C?G4#>%XFSOO9C]\X"J
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MMJ G[Q]!4F1ZBN?_ .$=?R^;K][V<@L0/*V <GUR?Q-(OAM\'?= D[< *0%
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M&06]M+"50."L1SDQ.=O/7!V^GTK4U'4-1M;@BWMEFB$8XVL6+%7/;M\HX]Z
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M** "BBB@ HHHH *1.GXTM(O3\: %HHHH **** "BBB@ HHHH **** "BBB@
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MEC&67TZ?XBI))XHHVDDD144;B2> /6@"N=*TYAAK&V(XX,2]NG;MDU8^SP[
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MI0!?72+.SU"&Z,H0?,JJ[?>=L8/ID ,!_O&H1X>TZ>-HTGE<1@Q,%<8'#<$
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M\32Q/%*699%D5P!&,97"[3GIG/7G%2,OB5'6.,R.BQR#>3'R?FV?C]VNFHH
MYIT\0RR[B)XXR0VU6CRO[WH.N?D/.>..^:J3IXCM+'<K2GA$V !]H CY  )S
MGS*["B@#F;^PU:\4O;/(JW%JD4@D?:1P23@=&S@?\"]J5;37O-(+L(O-7"^8
M,;?F#<]0,;3CU'XUTM% ',6]CKK!$EN)XT"1*0)%/ *;N>N>'[<@U8O;+5FG
MNEM&\M);@2B19.<>6JXP>GS#/H:WZ* .:FL==,DABF;:7E*[Y>Q'R\>H/ [
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MCYLXV]?UH ;_ &UJ+7,4:V85&GV,S1O@#*\9]<$GTXQ[U)>ZGJD=]+#;VZ%
M5"%HG. 60;B<X(^9N!_=IR:ZT>F6=U=0?-<$A@AX4C.!^>!]345QXE!65+2
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M9[[0W- %-/#$GF SW:RKB)2"IY52A*]>00AZ^I]Z:/"S* #=Q^9^\P[(22&
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M'GS+J%=K;3ND P?3Z\&@"0PQ$J3&A*G(..E-%O ""(8\@8SM%0#5+$EQ]JB
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M@?AVY'O5F/0]6C&(YPH.T'_2'R""WS9QSU!V].M %^^T!;V:=GNB$FE$ICV
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M%M?+,SO_ !8)X&.#DCGTZC@5 VDZO-=222,H68?O!YN01ER%QCME>?:NHHH
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M8W$8R#G-->X\/&3R_(@D+,(CB#(YSC)QT^7K5A/#FF1VSVZPL(WQD;SV)/\
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M 3DR# Z!>W.21].:Z#RH]V[RUR.^/\^M*$4<A0/PH PGU^:**TD>&#;<6RR
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M+#\25Y^M01Z)JT<@(O$V P[5$K@?+D-Q[@]/;M0!TH((R#D4U71F958%E.&
M/2N:M?#VH0B.)[UA D4<>Q)V &TKGC'< \Y[XJQJ6CWT[W0M;A(HYY$DX<JW
M"!=N<'T!S0!OTV21(]ID<+N8*,GJ3T%<])HFIL7VWBIF21@2[$@,N/3KGGV]
MZFL]%FC\UKET<F(K$H=BL3;F/&?JO/7B@#;,B*ZHS .^=HSR<=:=6%-HUW+;
M:<INE$MIG>1G$F<=?RS]0/I44?AR96B5KO=&A&X$MG&%W8.>"Q4Y_P!XT =
M\L<;(KN%:1MJ G[QP3@?@#^5(TL:2)&S@/)G:">6QR<5S@\-7C1,)M4=W)+*
MV#\I*,IQS_M#\CZU'<>&KOR2T5PC2*A51@YYR" 2>F#T_I0!U5&17.Z3HEY8
M3QW*O'O,:1LC$G8HVY[X/W>/0D_B77AIIGD=+E%,KEGW1[@V2^,C(Z!^/H*
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M)/%:(UQ+FV79NP"7&Y6P<^Z+0!:EU.RBC1VN8B))!$FU@=S$@8'XD4\7UHQ
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M)SQ^A_*JS>'[(ER&F4L205D(*YSG'_?3?G0?#NGX4 2*JMN #?[6[^= $_\
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MWQR1MR!SD>H]* (%U+7EE,ALG*RM&%B:/(0?,&Y'?@'GU%(^H^( K2);C)7
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MM/,9E?S<1-C(. >O&>N/3O3K*^U5]1AM;N*)=X,A94*_*O7@DX.63'T:J_\
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MUV\_6G6GAJV@BN46=W%Q!Y#%AR!M"G';^'TJL="U9UG$FHR$N201.P&=K@<
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MZ4 3453_ +5L=CO]ICPF>_WN >/7@CI3X-0L[F01P7,;N4\P!6!^7)&?S!H
MLT52_M6R,Z11SI(71WW(P( 7&23GW'YTVWUG3YX!-]ICC4C.)' ., ^ON/SH
M OT55&I6)B\W[5$$,AB#,P +#.1^AJ./5[*6X$4<Z,"@?>&&WDD =>O!_*@"
M]153^TK'C%U$<MM&&SD^GZBD74[7[/;32R"(7*AHPYQVS_6@"Y155]2LHTB=
M[A LHRA)^\*B_MG3MI8W2 !0W.1D'H1Z_A0!?HK/36M.=MOVE0=Y09XR1C].
M1S[TS^V[4V[7"AS$LZP[@O7<%(('7'S"@#3HJA)J]FML\\3^<$3?M3KC.._
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MVJI'XJC?3I9A;3/<(-P1(9"K+D@-G;TX/Y&J!\2ZC*=T=M,@=05!MW.&_=\
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M@CD\!L$GI@CCM0 L7AS4HUN NI0!IHO*W^2Y*K@ 8^?V_4^M-_X1:[W?\A"
M1X ,?V=MIPV[IO[]/H!44C>(IY9,V-PJ2@$@O& ,-D=&R#T]NM/BO/%16+=8
M-O\ ,.\;H]NW XZYZDX^G.: )O\ A&KK#_Z=;;F5US]E)(W #/+]0%P#3D\-
MW2R"0W\#%6+A3;G 8D$G[^>H]>^.E1P7WB."XC>YL))83&H*;XP2Y('4?4^V
M*+J7Q+]HG:VLY0KLI0>=$0OR].>V1SWYXH DD\.7DEE#:'4H5B@;<FVUP1^.
M[_/?-0KX7NXKB%X]0A"JP+XML9Q@C/S<\JI/TI]Y)XI-P7MK=1&9%P@E0@*
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M4?\ :B,)Y!)\T.58AMV&YY!Z'VQ3AH%Y!IUU#%?AY)T"Y,7)PH &<YQP?SH
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MHJK:>#S':(L^HL)1&4^2*,*#\O;'/W #ZT :4F@:1*\;K$L809VHV PXZ^W
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M/*F1\\C:P.>G^(_.I*PM*T6TM+Z1[>[F?R@J[#,25;ON'N G_?(K=H ****
M"BBB@ HHHH **** "BBB@ HHHH *1/N_C2TB?=H 6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH S_$'_ " ;W_KBW\J6_P!4M=.,2W.XF0$C:,X
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M@,8TZ[C+_,""A(;=GJ7X &,#OS4DUYKTGV60:5>><BL&421JC'LQP_MT/J:
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M1HA)O5> "K,!USDA30!J45F7FK?9GMT^SR;I@K'.,("RKS[_ #=JHKXIB?\
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M^P)93(@5<;#AL'KR?F'Y5-%HTJZ7<6\LX#/.&!?YAY:L-JMSR"JX/U- #O\
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M ]JG&I6QU(6 8^?@G&/0*3_Z$* +E%%% !1110 4444 %%%% !1110 4444
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M>1QUZU5A\70RPJPM_G8,53S ,XWYQD#^Y^M #[+4=9:\M8+J%/W_ "6\LKL
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MKO;Z;33WU#6)M/\ /-N\3QW"?=@?[N,L"N<M@\9'![4 5X;37F&^$M% RO\
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M],<TR#6-&:-8VCBCS(T.P1Y *G9@D# Z@?\  @.] $4WB.0*RP6_F2).$/(
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MT[7*H@CBM9'"#(61P1CDC..WYTT>(+Z60)'8R\(DA.PKN) RO.?6NGP/2C%
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MVF<_902I0[<8.XY]<YVCKWK>HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "D48%+2+G'/K0 M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!%=W$=G:37,N?+A0NV!DX R:HZQI7]K+:D3^4(9%D_U88G!!X/;I3_$/_(N
MZG_UZ2_^@&KT?^K7Z4 <^/"RA-IN(O\ 5^7D6XS]>O4_Q>OM39?"D!MG1KI5
M9B"7,0P/E9<8ST^<D#M@5TE9VNV5Q?V AM3$)!(K R?=&/P.?RH RV\+6KS.
M9;O+3%B%*C^ZX! ]1O\ T%3IX:ACNX+E[C<+>1Y%!0#AF#<D'D@KU-1+I&L>
M?IY:>P(LE"[_ "VW-A<#/?OV(_&K=[9ZU=VDMN;RP195*DBW?.#U_C]* (/^
M$9MFN9;A;B0"5BX7@J/F##'_ (]_WT:?;:/:6%Y:%KG]ZORQ A06"JPQQUX;
M]*SFT'7;:(/;:G$YACQ&BHXSM^Z,;\>E376@:Q<0P?\ $U@6:"(HKB)P3DJ3
MD[^^W'XT 7)/#=I+YHDED(DW#& -H8L2!Q_MFD70+66RAMQ=2E(7DRR;06+9
M# G'UJG#X>UJ/S-VMJ?,@\H_NF)!P!D'=[=?<TP>&M5'R+K$<:-N+!(6X)W]
M,M_TT/Y"@"[=:%8F%([R[D+28C5V*AF.U@!P/]H_E3O^$:M 0PN)UVCC;M #
M8QNP!U_3VJL?#VI-96]O)JZ'R&9E;[/R"0PX.[MNX^E1MX4NG9\ZK\C;00(.
MH!4X//(^7]3ZT 6)]"TJR$%Q<W+((I 5>5EY/''([[1[\59NM'L)=2^U2SRK
M<3D!?F'&W#8''^Q_.J"^&+Y++[.FL$?O!(&\@95@H&0<Y!X_4TR3PI>2,V_5
MR1NW*3;K\OWO?K\YY^GI0!<M]!TV5%FCN9Y"BA$DWC*;&&,<=B@'X?6IY="T
MZ4YD+%MQ();)R2Q/7_?;\ZR6\'7),I_MEQYBD<P+QEMWXC/;IU]:E'A21V63
M^UY&S*901!'QD@Y!QUR!SZ<4 :B:-8)'<*'?;<X4_O.F&+ +Z<L34;Z=I<$$
MD+RE5O6$7,F<GD[!Z=3Q[U3;PIF"UA74YPEOT'DQ>H.1\O#9 YY[^M/?PWML
M8(&U>Y2.!MRXCB #8(!^YUR<T 36VG:.TKR6\YW"0\K.05*EL@<],LV?K4\-
MII0MI;6.1#&Y2-@)><A1M .>N,&LM_!RN /[5N@NUA]R/G<NTDG;SP33G\(!
MY8Y&U6Z)1U?[D8R5 '.%_P!E?RH O_V9I'$')\S<_$K<X&ULG/\ M<_6FKIV
MA*XE0PJ<F7*S8!R>3UZ$@?E4'_",*(88%U6\2..-HMBB,;E;&1]WC.!SUJM'
MX1BVM$FL79(0 X$>1\Y<'[OKF@"W=Z1HT\>Q9DB;<D>5ER1C&%P3_LCWXJ6U
MBTF"&ZM6G!V#R[GS92,Y R3S@9SU'4FJZ^&;>WF-U+J%S\DGF98H HPW4A?5
MV.31=^$[:Z:1_MUZCR-NWJXR#E3UQ_L"@"U]GT,2A5DB$@?<H%P00QYXYXSG
MI3+^RT:^<M+-$DTS)\ZR#+$;2  <CG"]NF*K'P=9'R"+R]'E/NXD W?=X/'^
MPI_"B#PWIQ=HOMMU+)"R[AYHRH^0J#@<<(M $UF-#;RXTE1WA?8LK2_-(=JD
MG(/S<;<]N*=*^AV5HDX$;1A-Z;6+$JI'(YZ# _*H5\(V"LC?:KWY#G'G<$8
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MK@_38V1U]O8_D?2HT\+:&@D T^/$B[6R2>,8]>*0^%=",?EG3HBOXY_/.?\
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M3JBOIUL1&,+^[' QBB31=*ESYFG6K9ZYB'KG^9- &?<^*K-(YA"KM+&&(#8
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M$$0D&77+\ X'/7D5&WC?35C+!26 !QYB\^V<^Q_(>HKHA:VX+$01 L "=@Y
M[4GV2V"!!;Q;1T&P8% &$?&.G@.S% HW%?WR$MM]LY&>U1#QG: R&18\*<!5
MF4Y +9.<_P"STZ\BNC-M 3DPQDYS]T=?6@6MN 0((@"VX_(.N<Y^N>: ,S3/
M$EAJ-T]LDB)*&PBEP2XR1D8_W3^&*V*:L:*<JB@^PIU !1110 4444 %%%%
M!1110 4444 %%%% !0*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$U>&=G.HVY5MXV^6Y7#9[;\=:K1^&M7B@V1ZE;QMY80[$?# !0!][_9Z^YH
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M@G\:?+X:NI;V6=M4!WNC;# N.-W4#J?FX/J* .DR/44QIXD<(TBACC SZ_\
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M;XMX H"PQ@8(P%'>GB-%)(103[4 <ROC.U+(K0/N;J%R>" 1CCGKS_6G0^*
M]BLY,)9KI8_EW,H0D#(8#GJ:Z01H,81>.G'2E"*%VA0%';% '+6OBQA':)<V
MY:25@KLH;T7D#;U^;I['FI9O%1CN @LI&1I'4, X)"G;GE<9SSC/2NDP/04
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MEIXK1E3S8-@3:<3>_/\ #Q[=<5->V7B"YN3CR$C0HT1%P<JP5@3]WU(KI:*
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MYCA:&Y!/E'"R%LEQU_P% %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM*,/,C,S(,L9"I^7:-P'\)RB\CT%.DL=&AFM';"M(X\EQ(0"0"0,YY'/3O0
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M%%% !1110 4444 %9FN::VIV\4:2+&T;,P)]3&RC]6S^%:=9/B"SNKR.U%H
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M48P=Y.< @?H30WAW3&7:T#$;MV-Y'=CZ_P"T: &O=:'Y<%R\<.W<1$Y@/!7
M)'' &!STXJ.XU'0X5GD:)&<;VD46YW$J/F)X]&ZG^][U:FT>UF2UB;>(;<,
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MLK^*:X+O<0-%&#*S*F=W'/U SUXI+!];>XC^V12K&9'#*2GW-H()('.&W#
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M9"-K(W^LX)!4KG\5%11:'I-O(Q21U)9@P\\C=N !4\\_=''M54^$QY31K=@
MHJ<Q;LX4KDY/7!XQC! /-2S^%HI1($N6C\Q][$(,D[G/)]?GZ^U #S::+=I$
M[3LZ^4T )D8 A0P);W +<GUJ>_L=+GF-Q=2(': J3YNW*#//7MD\U3?PJCB7
M-T5\QB?EC"_Q%N<'GDXSZ"I;GPW'<);)]H*);PF( +G.59>Y_P!KOGH* $M]
M)T<QJK7'GDM(@)G/S$EB1UY(#D9Z\T\:=IINHYX+L(8U=@%E[%P[<YZ9&/Q/
MK4:>&D$J.TZX23?A(@O=6/T^9>OH<>]+)X7MGC1!*RA$1 0 #\H(_7J: +;V
MNE-<&[9T+NRMGS?EW#:00,XSPOZ56NH]&N)H)[K.Z\^9068 A5YR.F,<'/!X
MJ(>&$\R0"7RX]B"/:,E6'WF&>A("#O\ =J_JNCPZF(A([((@0NWW(/\ [**
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M@3ZGG/:@#;HH&>]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5#=74=I&'E$I!./W<32'\E!-344 4?[6MO[EW_P" DO\ \31_
M:MM_<N__  $E_P#B:O9%&10!1&JVQ_Y9W?\ X"2__$T)JEN[!1'= LP S:R
M<GUV\5>R*,CUH **** "BBB@ HHHH **** "BBB@ HHHH **** "D3[M+2+T
M[?A0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#<R2Q1AH+<S
MMG&T,%_')J:J6J12S6\:P@EA,C'!QP#S0!&;S4<X&E'\;A:476ID?\@U ?\
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M%'Z 51F\,VS7=K/;2R0>1CA23G&P#G/H@'?C- !;^)K:2*W9X)U:127 C/R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 !Z4B_='TI3TI%^Z/I0 M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 'H:1/N+]*4]*1/NCZ4 +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex10_8page004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_8page004.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***1>_P!: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **9$\CAC)
M'L(8@#.<CL?QI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !35[_ %IU-7O]: '4
M444 %%%% !1110 4444 %%%% !1110 4444 %%1PPB%656=MS%OF.<9.<#VH
MA654(F<.VXD$#'&>!^5 $E%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-7^+ZTZFKW
M^M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  9[T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %(O?ZTM-7^+ZT .HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D7O\ 6EIJ]_K0 ZBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"<$#!.3^5
M+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%(,Y.>G:EH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "D7O]:6FK_%]: '4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3$9?F^8=?6G
MTU0.>.] #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ IJ]_K3J:G?ZT .HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FKW^M.I%[_6@!:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ I%[_6EI%[_6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ IJD\\'K3J1>_P!: %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA-INI.\I&K%-VS!&3\H49.,\9(/YTTV4\KR)%KC9=R @)R"!G .<].3_ $H
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M>1K:*Q+E9'ADPW^QN;G/7C%1VFJZ5!*EP;*59'B:X9MV2"0JD#/7A>OMQG-
M$R1:%)EOMIB:24@J[*"6\W<, ^K(<>PJQ#9Z%;H0MTBAK?R_]8!\C]#^.T_7
M%-D;25MQ=Q6K#RY0A)9EV!L*6X[8-4EO-!:9HDLMT06--Y8] 3QC.<C^M $T
MEGH,:2W+:DQ*KEF5U[*HX &.FWC'I2WEAH#3RP27ACFD1@S!E&T*HW#..NT@
MXZ]Z0S^'BDI>T;#XE;)P6+ -Z]?F Q]:DO;K2-GF&RDE:[9AR"-X!5&(/;CI
M]* %ABTF4!)+]PT=RVUF.S<6R H)Z\="/2HPFDBSC@?5V9()%\MT< J'X7<>
MA!8$Y]1[5'->:,R/'%9&:-58EB3@E$+ 9SSP*DCF\.2PRYC<C]V) 0YY)8 9
M[G+-GZT .DTC0]CN]_A68KD2K@%0I(QC''EY/XT^*QT2&>.0:F,HN]4-P-H7
M.0<>F6'Z57DOM )AM8[69XP74;<J%# YZD<8Y^F,4Q9=#N8H;:.WE22:6,/$
MI88(()R>G&_GZT 6+?3=+MF>!-6*B2W,48$BADR<%ACC.2!TZ_6HXK71I967
M^TIB0[#<S*J9R!@$  \CCVZ4+/X=96F<2Q?9W:5MY;@[@#WYZCCT-"2^'@#&
MT,Z*A:/#!S_M$\9_"@!Z:1IT,<<<NL,)XV7>PD49=>3QVY8>_2G2:9I5N!,=
M3D7RMV=DH)/S GCZ@#C_  IOG>');B28F59))-SN?,7!!4@D]@#M([?K37AT
M2&U2=;2;[.)0$D5F!RJMGC.[@ @CO0!K:6;>QMQ:-J,<P4@1[G&['3GGDE@?
MY=JN/>6ZHS>:C;5WX4Y)'L._0UC6EOH-S*(X%??N<CEUYX+?^A=/K5=_^$85
M8EQ@01;8PBN/E)*\ #DY)_/- '0V]Y;73.()D<H<'!]@?ZBIZR](@TS<\^GH
M58 (^=P(R <$'OC;6I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %(O?ZTM(O?ZT +1110 4444 %%%% !1110 4444 %%%% !1
M110 444$X]: "BBB@ HHHH **** "BBB@ HHHH *IZM<"UTZ68VQNMN,0@9+
MY('3!]:N56U![J.U+64:R39& ?3/)ZCMGO0!B_V@LET/^)+)QYJ$[3DIC/ Q
M@Y( ID>M(S(JZ'()&3>%V\MPN<<<_> S[58%WXCX)T^W/7(W8[^N[_/MV1I_
M$0F3%C:DG<-X'09&/XOJ<4 1MK#[3G0I&P-P &<G;N./E]0!]?I4CZC(;9)(
M]);/G;#$4]4W9Z<?,0"<'O1]J\1F+_CQA#$'."/E/R]/FYZG^7N9K)M;CD"7
M$:2QG'SLPR#L]O\ :'ZT 5GUF1]J_P!B2M(QQM*GCU).WCM2-JD\JQP#1G42
MR1@EE)7:_+'IV'Z_K.ESX@*<V< 8;#@X&?[W\7^?>D,WB,PLOV:W#E,!EQPV
M#S@MZX'Z\]* "._G:"61])9=ABVY4_,"<$XQG*\U"FMS0VA:]TAX72-2[8PA
M8N%V@X_&I;63Q$.)88MHY)?&YOF' PW'!/TP.N:)FU^0RKY**%D C*E?G7=@
MD@GCY1G\?:@!DVLW$2NIT60 )N0$'#?-C'3KU..>U.FU>[4,(]'DR&(!8'N6
M .-O3Y>?K4ADUY+6W MXI) K>:3C)((V_P 6,D9_^M4;_P#"121W#8B0O$ZH
MJXRK8?:PYQ_<ZT 1QZI=*C,VA.9!SA5(X&>^WV&/7/:I9=4NE655T5\+(8U)
M!PP!X;&W..I_#O4>/$8A 7!,>67=M)?AL*QSC^[G'YFK$+:\;B*2:.%4!VNB
MD8(.<GKV^7\S0!&=4NHX(2='>4E8F*IQM+!B>".Q&/QIIU&=7-PND.)R/+=,
M'YMNYAAL=,Y X')JQ;2:\;=WN(+<2Y0(@/7GYB>?3I]/PJ&*;Q$Z*LUM$C.,
M,R8RAP>1\QSCC_"@ 34+N>6"&/2_*5U1G9U)"@M@CH.W\^14<NKWH ":,5W!
MV0G)&%/!.!QGT^G6@R>(+:"YD,:NJ%C&"N]B.0HPI^A/?K2D>(1<3R0X*/M*
M+)MVC" \#.1E@0<GO0!&NM7B1JLFB2'C+LJ, ,;><;<]^,9Z?E.^I7;W3K%8
M%(HQ+EFC9BQ4?* ,=SSWS]:)&\13!@J0P_,NPC![*3GGIG=QS_6FW7]MRNYA
M60;6 \M&50<QC.&/HQ..OO0!!_;&I!!G3&!SDL86 9/F/ Z@_*!^/2IQ?/-<
M6[QZ2X*N$D\R(@IN89(/?H"?PJ.&W\1"X0O.Q0%.3LY/\6?;&>!WQVJS ==C
ML8HVCB:=9XU9B1S'A=Y^N=PH B?5[MK>25=&D!\MBA(9B7W;0-NW."#G/I^=
M*VJW,>4&BR2$$H<*1NP%Y''3GUZ#\*F$OB#D&"W/S#D>G/\ M=N*1'UXD%TA
M4 (6&W.>!N PWUYQ^?6@"*;59]ORZ2X;@+F-C@90$'Y>/O'\JC?5+IF5ET=L
M;6W@QMG(V_[/3D]NU*O_  DH#2,(S)M4A.-NX@ CKD@<MVJ>Y_M]I9?*$(CW
M QXZ\ \'GN0OYF@!D.J,]TA_LB>)[I1N=E/&%) /'L?S'K2#59F@$DNB3;N!
MMQD_=;VX.1C'^T.>:E UZ.=L>1)$#D KC/!&!SQT'YFGB76O,\Z2&%(E&3$.
M6/RGN#US@?A0 U-0GDDCSHTFQCM+'^'J3QCIT_$]J@;5;KR8VCT63&[E,$G'
MS9QQU^4?G4MI-X@FFMFF@MXHF4&7(Y'/(^]P<8_6D23Q"7820VX7<<%1GC<.
M?O>F?_K4 -&HSR6TLJ:+(C^6TB[T/S'(&#QG)!_0TD-_.TQBFT9LJ=N\*<$9
M7;CC_:Y],4[SO$;1L_V:V0X&$SDYYS_%^5.:?Q OF8MH&^=MF,?=[?Q>GZGM
MUH ;%J+3C>NC3I(T>X%X^^20IX_&FVVHE8I#<Z<J3*@E5%7!=<_,1QG(ZX]Q
M4\[:VMQ*UNB,C'Y ^,+^[^H/W_K2R2:UYLBI;P[ [!7X^9<<'&>N2/R/3B@"
MLM]*RL'T0^4^%52G3H"&XQU)_ 4P:O=K$9;G1G<@YC"J1@;<D<CKD'TS_.R)
M->CCXABE8NY .!A<-M!.[UV\C_Z]#2:\R$F"(-D, C =-N5.<]<GGV^E "B^
MS??9/[)8!G"L[#"\H23TYX&/>JK:G&L0)T,J70'#)@8!X!..V<^U6K6ZULRJ
MMU8+Y;!OF4J"/E!&1N/?(^OMS4)G\1O9\VD4<K)CY2,JW'/WL>O'\^E "3ZA
M%Y<LO]DNP6Y,,@:'EUV_>&<<=.O&!49UF"6X*VFF[I1,$9RF<$, 2<>Q;OVJ
MT;C7#<,JV47EB0@%L8V[L _>STYZ>OMF+S-=99%2QB@)8LK*5Y[X//4\?K[4
M 5YM61K>5K?0G9]O(>+J"S=L<\KG\14J:C:N[M'HK[LD*_E#YSR2!WS@-G_Z
M].-QXB,B2&S"HK'*?)\RXZGYO4],]JDM+K6/[2MTO;;:CQN66/! .1@D^V?7
MG)]* (;G4;%K*/[1I;F.6-R55.1A@I'KWS[TB:M;+$()]-_B8L!& F[<H/7O
M\_.>^171X'I1@>E '+KJ^D&.1AI3*\94[5C7.3CN#VP ?PI9]1L4F1O[+C$(
M),DCQ@G;@OD#Z@'_ .O73!5&<*!DY/%#(KJ590RGJ"* (+."&&$&&W6#S,,R
M  8. .<>W%6*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ I%[_6EIJ=#]: '4444 %%%% !1110 4444 %%%% !1110 4444
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M_,JJ6C(W9&1BI?[<L"(PDI=Y(Q(J*IR5(X-9\-];S1S2RZ.S,'C*#RERP;:
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MO/=+;3@JJ^ 6Y#_,O.1T&,GI_*GQV_B**U,8NK9Y/+C578]""-S?=],__6I
M-?W2)YT3_N7*, ,&3C Z=N?TH 7^T]5DM[IAIWE,D3M#G+%G'08Q^-1_VEK
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MBI*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCMC@?R'Y"K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB].,]S[>XJ9]4GC5731Y6R9 V!@C:6QVYSC]:W:* .:N+T_8UM)/#[O %YC
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MK-T]S#;75DRM*=H;[O(!).#VX/>MRL6R?6A+"MW K(" [DKG&#D\>^!^%;5
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4B]#]:
M6D7O]: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *SM4AU!V#Z?*D9$3K\Y. Q*X.,'/0_G6C10!ABW\0[C
MF\M@"QP=N2%RN.W7 ;\ZEF@UPS2M%=6X0EMBE>G3;GCZ_P#UZOZ@URME*;(
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M7(3']L2;OF&[+<$MZ;L=./\ )SGWFEK;6MRMKK)B*N&9?,*A01CG!R/4>X%
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MB"JX 7/ JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %(G0_4TM(G0_6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "LS5=,GOI%:&^DMP$*LJYPV3UZ^F?T]
M*TZ* .?'AN4'(U*5<DD@+U&<COVR1^-6O[&8[Y#=O]H:V6!9@,,,');.><G'
MY5K44 <U_P ([?)B%-5E\ED*GJ-OR!1@9YYYZU=31&^WO=37DDN2Q1#G"94C
MCGW/Z4_6-2NK&YMEM[8SI(&+A5)8X(Z8^M6].GDN-.AFE \QE^; P"?4#TH
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M+ Y(  ...IP?SK6M%D2UB29P\JH [9SEL<UC'P]-]O6?^T9VC#F0@L00=V[
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MDA#_ -AVCJJ@1N@'0(K(.5!&=P %3/K%@L\:_P!EV"GSEC7S&"L.HW#Y>F%
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M8R-P7;T^\,Y(Z8'6NKP/2B@"KIMQ+=:=!<7$:QR2H'*C/&>1UJU110 4444
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MC@R%*@^6. >,?2@#,3Q78LN3#<+\I;!49XW>_P#L_J/6AO%5HD;L;:Z/EYW
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M&2I(^;'!!'X5;TW6+?49I8H4E5HQGYUZC)7(_%2/6K"V-FL;QK:PJD@PZA
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *:G0X]33J:G0_4T .HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=2TF\NM1%S;WI@
M P3E1@@C&<<[LY]0*VJP-1U^>QU2:V^Q-+%'&K!E."68A0/3DD"@#4A2ZMK1
M58BYE#'<Q;;QDFD$]^0";&,?]M__ *U8T_B2[C-PBZ>[2)*R1D*Q4A<<DX]S
M3H/$LY;;+IL^&*E6 Q@,X4 CJ2.^* -83Z@<YL8QQ_SW_P#K4HFU _\ +G"/
MK.?_ (FLI/$DK8!TNXW8#$<]"I;CCGICZUT(H ;$7:,&50K]P#D#\<"G444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1U;34U.W2*1RNQBPX
M!!RI7D'V)_'%)8:<;!)2D\DSOT,K$@<?7_.:9K=SJ%M! VF0K+(TP5PRD@+@
MD].G0#/O68=9UES%/#I9>%T)**>00^WK[CD<4 6[G1WN'=Y;>Q=W?>S-OSG@
M>OH!^50P>'O(+L(K9R[L_P S/\NX8('/ XZ57BU;Q!'+")=(>5"YC<@A<#<N
M'_[Y)X'I2_V[KNW<N@NQ*,2"^,,$! Z=SD4 76T=WMQ#);V+(I)5-K[1GKQF
MI[;1[=(P);>!2K!E,.Y<$ #U]JL:9<7-S:^9=P""7<04&2!^8&:MT 4ETFP%
MP;C[.IE\PR[CD_,1C/\ +\AZ5/;6EO:@BWA2/("_*.PZ"IJ* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "D7O]:6D7O]: %HHHH **** "BBB@ HHHH
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M[6\)#_*?LSG( [<>HQ^M;=% &3;:K())!=6UT%ZH5MG/&2!T'H!6L#D T44
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M8MP .IS7.+>%85LX&AF5%VF."5I.<Y[1G_"LK6%NK;0'7^SY%\XK"NYPN2[
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M< CV8C\JE_LNTQC$N/\ KN_^- #ULXE.5DG_ !G<_P S1]ABW%M\^3_TW?\
MQJ,:59CHD@_[;/\ XU9AB2",1QYVCIEBWZF@!R($0("2!QR23^9IU%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2)T/U-+2)T/U- "T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5V
ML;1G9VMHBS\L2@Y^M6*P;S4M62YN$MK!GC$BK$V#]T'YR?Z=/6@#9%M;C&((
M^.GRCC_.34<EC#(Y9VGY.<+.ZC\@:QTU?6/*#G2RV3)U# C!.T8QGD8_7VSH
M6-_<RM.U];BUACR0SG&1D\DGVQ^O;!H F_L^#^]<?^!$G_Q5(-,MA_%<?^!,
MG_Q512ZM9B:()?6Y0Y#D2*<>G>HX[^W'E,=3B=0[;LS)TYQG'7M0!>AM(H'W
M1F7.,?-*S?H34]8]WJ\*W<2PW<'EG!?]XOJ/Z9IJ:S&/*:2YMVZ[]LBCC'IG
MU]Z -JBL==73S8&DN[=58-N0,/;;SGV-.75&,B?O(77^)5(SSCOGC )/X4 :
MU%48M7LI(/-,RQCKAS@X[<>]55U8@1*I#?/^\+LN<9P<<]L_H: -BBLA-49\
M*SI&V03R#@8YXSZYYI(]7.8O.*HKDG)(Y7'7.?K^5 &Q16/'J#^7$/M(D&_#
MR;<9'J/;]:D354B\E)B\C2.5+*G" #.3C/\ DT :E%9]Q?0/&-DDP&1RB'(_
M,8IMIJ"*FVY=@3\P+<DYS\O'<=/RH TJ*R#JR!GWR. '^7]TW"C )/UYI4N1
M%$4^T2.PE!W,"3C@8XSUP: -:BL^VO8(T*N\Y^? +JQ)ST_"M"@ HHHH 0@$
M@D D4N!6=JK:JLL)TV.-T4,T@8CYST"C\R<^WO5"!O$<8=VACD.T85V7)^9C
MV/7!7VX_&@#:FM8)RIEC#%>G)&*B_LVR#;O(7-4[636VO(UNH8E@R=S*!V]M
MW?\ I[\&K7"2-!%%-(CI.K, K@,H/S#('/% %L:98#I;1_C2KIMBF-EK$,>B
MURK6E\B1&.XD4%<LNZ3 ;+$H..G*_P#?)J6.WO$M;R-Y909+98U<^8<M@<@[
M?E[COV/K0!V%&:XZUAU_RFAM+H(NW,:,"-F6#9R5Y.,C'3GBM.ZTW4Y[. -<
MAKGS'65MV!Y3D],#J!M_*@#>S17+OIGB*29K@W,*R*Q\L"0\+@@#[N,Y/4U8
MBM]:FM;A;B7=)&\(CR=@?:59SD#OR/PH Z"BLJS355O9&NBK02#Y5# ^7U/H
M,]A69;:9KMM:01V\R1NI;SLN")#L !SC/4'KZT =11D5SIM/$3%P;M47JF'!
M/W3@'Y?[V,^O/2J\FD:XWVAO.CWSD!RLI!(VXR#MXY ./KS0!U5&:PXK;67T
MZ]M+B51+)&PAF#Y"':!C@ ]<GV%1PZ9J,5_;W$?E0Q0L?W D9@5;AN3] 0,=
M?2@#H,CUHR/6N2FT'5&DE9&7YYF=6,Q)7T/3KR/H%QWIZZ#?.SJ\4*1M&4'[
MTM@&0-C&/X5SB@#JJ*;%&(HDC7[J  <YIU !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !34Z'ZFG4B=#]30 M%%%
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2)T/U-+2)T/U-
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1.A^II:0?UH
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K(G\16$$D\;L^Z&58CA<@DD#/T!)!^AK7K(NFTL32?:+(,T;;B
M?)SDYSD#J?O$Y^M !'XDTUHC(\K(!NX*G^'K^F#^(J]:WUO=LZP,6*?>^4CN
M1_-36=YFC2*H6R1T#; 1;Y +<'M] :M6JV3R3PP0^1)N(?8I0M@]<C&>OZT
M3W5T8)DC"!BT;N"6Q]W''Z]:C6_),&82!+(4Z].O/TXJ0V,#'+AV.TKEG8\'
MJ.OM0MA K!E$BX)(Q(V.?QH 9/?>5=^0L>["AG8MMP"3T]>AJO#KMK/(B(DN
M6P"2 -IR1@\^JFKK6D3G+>83C'^L;_&H_P"SK;<&VR9'_35N?KSS^- %2WUM
M)(K5I()%,\8D.W!"]1C\ZNP7L<UM).JNJQYW CG@9[4U-.MHSE5DZ <RL< =
M,<\5(+2(# ,@'IYC?XT 4+37$N+GR&M)T<OMX&X#A3DD=/O?I5RYO!;W-O$P
M!$Q8$Y^[A2V<?A2FP@/_ #U'.>)6']:0V%N6W'S2V"N3,YP#^- #;34%N[)[
MF-&79G*/P00,_P!:IV6OI<O%&]M*C2$#@%@N0",GZG%7TL8$5E7S &.2/-;_
M !I5LX5((#C'3]XWT]: *D>K#9;F:W=#,#G&"%(<+C\R*GLM1@O(5<;HF+%-
MDG!R!DC\JD6R@0Y DX&.9&/\S1]C@W X?(S@[V[_ (T 0ZA?O:30QQQ"0R9)
MRV,#('\V%,@U3SY8D6(J'?:22#C]V']??%6390$Y(?.,?ZQO\:!90*  K<=,
MN3_6@"E'K.4L_-M)@UUV0;A'T')[<D?K5RYN&BFBC3RRSGE2<'&>2/\ /I3O
ML<&,;3US]X_XTHM(0JKM)"],L30!GP:I=2M%NM<!A\_7()VG:/<!CG_=-:U0
M-:0-C*=\Y!.:DCB2($(",^^: 'T444 9FK:Q'IDT*/$\@=6=RO\  H'7\20/
MQK/'BI%,OG6<H$: G80><GCK[#\_3FM6_O/LLT0**Z/D,,C=U &!]33(=0CF
MD6,Q\,<9QP2<'&?8=?I0!!;^(+:YO5M8X9MS-C+ #N1Z^V?H15S5+U[&R>>.
M(RE>P!XXSDX^E6@BC&%''2HOLD&<[3GK]X_Y[T 4+B^NQ</';B%E1U^9L],D
M$=>O2K-I>O<7$D;0LBJ,@D8[]*G6T@7I&/\ /_ZJ#:P'_EF* *#ZN8?M!DA9
M_*E*@1J3E0 <_P ZNW4[1VS21<OMRH()R<9QQ3_LT/7RUI!:0!=OEC&<X[4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^E.HH 3:HZ*/RH  Z "EHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<QS1"3]_&1CDIC!&,XP>: .HHJO87MOJ-G'=VDF^*0<'&/8@CL<U8H ****
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M'PW';3)-#>/O5@3O0%3A=HXX[9_.M33+&/3K);6)RZ(3C/;)Z#V% %NBBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ I$Z'ZFEI%Z?B: %HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,T=>E%% !1110 4444 '7I
M1D'C-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2)T/U-+2+T_&@!:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ IJ=/Q-.I%X'XF@!:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BD^;?C VXZYYS2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(G0_4TM &* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *1>G;K2TB]/Q- "T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !2+T_&EI%Z?B: %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D7I^-+2+T_&@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ I$Z?C2TB?=_$T +1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-3[M.I$Z?
MC0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex10_8page005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10_8page005.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  T)"@L*" T+"@L.#@T/$R 5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!# 0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P  1" /B P # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***100.?6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BHXWD:65
M7B**C (Q/WQ@'/YG'X5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444T??- #J
M*** "BBB@ HHHH **** "BBB@ HHHH **9(LI9?+=57^+(SFGT %%10Q-$9,
MR,X=RPW?P^WTI81,/,\\H?G.S:,?+VS[T 24444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4@^^:6D'WS]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "D'WC2T@^\: %HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FC[S4ZFK]
MYJ '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !31]YJ=2#[S4 +1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 44C,J*6<@*!DD]J6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I@9=[?,/S
MI]- ^9N* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !35Y9OK3J:OWFH =1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(/O-2T@^\U "T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12 Y ."/8TM !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %(/O-2TT?>:@!U%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U#RW'>G4B]_K0 M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4U.K?6G4U,?-]: '4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !35_B^M.IJ_Q?6@!U%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",VU2<$X[ <TM%% !1
M110 4444 %%%% !12!@>A!I: "BC(I REBH(R.HH 6BDWJ&"EAN(R!WI001D
M=* "BFB6,@$.I!. <]32JRNH96#*1D$'@T +12%U#!2P!/09ZT*RL,J01ZB@
M!:*0.I<H&&X#)&>1_G%(74.J%@&;.!GKB@!U%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSTP  ?QH U**Q(]=G>-&;3+@,P *A2=I/KQTZ4R'7+V9XE;2YH0TFUV8$@
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M 5D7FHWMOJS0QVCSV_EH0$0YW$MD[NG  X]ZUZKM?6JW9M6GC$X7>4)P<>M
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M3<49.2,-UK%QIC-YBS7LID_N+(V<9]![G\ZFMYEA"M;P:E(N3F-DP.>_S8H
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M=W<T<KE+EPYC/W5;&"1]:N5F#1V'35-1_P"_J_\ Q-+_ &2^,?VIJ'U\Q?\
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MXU9M(KF)6%U="<D\$1A,4 6**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2^8F<;US]: '44FY?[P_.ER#T- !11D>M&10 4449H **** "BC-% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(O?ZTM
M(O?ZT +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCXQ_9EKCT\H5HT4 9W]@:/\ ] RT_P"_0H_L#1_^@9:?]^A6C10!G?V!H_\
MT#+3_OT*7^PM(R3_ &;:Y/7]V.:T** ,_P#L/2?^@=;?]^Q1_8>DEMW]G6V<
M8_U8K0HH H-HFEL,&PMR/]P58L[*VL8C%:1"-"=Q )ZU/10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %-3O]:=34& ?J: '444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %5M26X?3;A+-BEPT9$;#'#8X/-6:@OHY);&>.!BLK1L$(;&&QQS]:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ I$Z'ZFEIJ=#]30 ZBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JKJ=J;[3YK56"&1< D9 JU4=Q
M/%;6\D\[A(HU+.QZ #J: ,9]%O\ GR=6DC4L"$ )55W X SQP,?C5S3K&738
MI%\UK@-]U>F.2?7'>I6U6Q638;A,_)WX^8D#^52F]M <&YA';[X]0/YD?F*
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M "BBB@ HHHH **** "FIT/U-.IJ=#]30 ZBBB@ HHHH **** "BBB@ HHHH
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M'ZFG4B]#]30 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4=Q!'<1&*494D'&?0@C]14E% &4WAW2V+9MOO,
M7/)ZDD_U-2+H>GB42^42X# $L>,[L_\ H1K1HH STT33TC=!"2KXSER> 2P
M].233K;2+.T8&W1TPV[B1NO7U^OYFKU% $/V<[BWGS<G.-W _2FFUS_R\3CZ
M/5BB@"J++'_+S<]/^>E/AMO*8-YT[^SOD5/10 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !2)T/U-+2)T/U- "T444 %%%% !1110 4444 %%%% !1110
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MB1UJ+^R]>>1))-33<N_&T8ZYQV]Q^7XT )8W'B&.\B-_"6@8[2%"G!(ZG'(
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ML_Y/ =*USRE3^UV+ C<W3/S$MV]#@>F!0=%U4QRQ_P!IC8[LW(/?<?ZC]?;
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M0 4444 %(G3\32TBC Y]: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "D&>]+2+W^M "T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2)T
M_$TM(G0_4T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %(G0_4TM-3H?J: '4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2)T_$TM(O3\
M: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "D7IQZTM-0Y7/O0 ZBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HI&#$?*V#GTS2T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-087ICFG4
MB?=_&@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ I$Z?C2TU/N_C0 ZBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *,444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U/N_C3J:GW?QH =
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %(GW:6FI]W\: '4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !2)]W\:4TB?=% "T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M2)]VEIJ?=H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 !Z4B?='TI::ARHH =1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 C L,!BO/44M%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >
ME-3[HIU-3[HH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 !Z4B?<'TI3TI$^XOTH 6BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TI%^Z
M/I2GI2)]Q?I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 'I2+]T?2E/2D7[H^E "T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E(GW%
M^E*>E(OW!]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ****  ]*1?N#Z4IZ4B\*/I0 M%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !12.@< -G@@]<4<\=Z %HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ /2D7[@^E*>E(O"@>U "T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%%  >E(OW1]*",@BD51M'7IZT .
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ****  ]*0?=%*>E(OW1]* %HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*11A0/04IZ4B_='TH 6B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIB[\L3&?<ZC(P"-R[1_=R7^IS72UG6]LUQ<Q7MP(2P7Y&171L=@>>1[$5HT
M%%%% !1110 4444 %%%% !1110 4444 %%%5KB]AMIECF)&Z-Y,XSPN,_P Q
M0!9HK+?7[ )(Z.TBI$TI*KQ@;<\GO\XJ)O$EDDZQ%922JDE1NP6SQQU/';-
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MB-XDMX[MX)894"NR;SC!(W?S*X_$>M:ME<K>64%TJE5FC5PIZC(S0!-1110
M4444 %%%% !1110 4444 %%%% %35=/CU339[&9W2.9=I*'D5470;?[#'9R3
MW$D$:JH1B"ORCCC'M6G-&)HFC+.H88RK$$?0BN:O;RULK]K9SJ+;6";A<MC)
MVX[_ .T* -E=,5%58[R[55& !(,?RI\5AY;(WVR[?:<X:3(/L>*YYM2@6!I'
M74!E%**MVQ+DA3CKQ]\#\ZO07-M)-:M&UXT4TI19#<.4R.1GGOZ&@#?HHHH
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M@!:*** "BBB@ JK>:?:WK1M<Q;S&"%Y(X.,]/H/RJU10!031=.12J6P 9-A
M8\K@#'7IA1^5(-$TT.7^RJ7.,L22>F.N<]S6A10!0CT73HBACME4H<K@GCK_
M (G\Z271=/FFDE>W&Z5663!QO!ZY_,_F:T** */]D67F(_E'*+M&6)XVE<<^
MQ/YT@T73@ /LJ<;?7MC'\A^0]*OT4 5I-/LY8$@DMT:)'WJI'&[.<_F:B72-
M/63S/LL9;*G+<\J,#K[5>HH KRV%I-@2V\;!6W#*]#N#9^N0#^%31QI%&L<2
MA$0850, "G44 %%%% !1110 4=*** ,A_$FF(,O(X&QG!*$9"[L_^@D_A4RZ
MU9O>+:Q&21R[1Y5,J"H!.3]&%-.@::TWFO"SN2Q):1CG((.>?0FG0Z'I\"JL
M<&$7.$R<<C!R._% "#7=/:!IEE8HLIA)V'A@,G\ .<T^/5[22P:]5G\E6"G*
MD$$D8X_$'\:3^Q-/"%!"0K') =N3@#U]!BDCT6SB62-0_E.%!C+DK\IX/Z ?
M0"@!?[;TW[-YXNHRFS?P><?3\:676M-BB=S=Q-L4N55@20#C@?6HO^$>TORO
M+^SG;C ^<\#!'K[G\>:4Z!IK%R8#ESEOWC#/.?6@!TVMV4,CH[2%D4,<(3UV
M_J RD^QJ"^U+2(+B7[3$'DC4,[>3N[J>OME3^%6)-%L)2Y:%LNFQB)&&1@#L
M>N%49Z\4DFA:;)OS;XWKM8*Q48XSP#CG H BN[W2["14EM\$+O0I#D'&!QCN
M./P%,AN=)^UPF"Q'F-+Y22+ !M8+GKV^4_EFK+Z+I\C9:$@;0H"N0!R3Q@]<
MDY/>I8M-M895DC0AE<R#+$@';MZ?04 6Z*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ /0T@^Z/I0WW30OW1]* %HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M  ]#0.@I#T-"_='TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BB@Y'09H **:&8]4Q^-*"3U&* %HH!.3Q
M29;^[W]: %HI 21R,&ABP!VKD]N<4 +1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 C?=- ^Z/I0>AH'W10 M%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=/TI1T%(>AI1T% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 !Z4#I2'H:4=!0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%%  >AH'2@]#0.E !1110 4444 %%%
M% !1110 4444 %%%% !1110 4'..,9HHH **** "BBB@!&=4QN.,G'2EHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 1ONF@?=%!Z&E'04 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 C?=/TI1T%(_W#]*4=* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 1ONGZ4HZ4C?=/TI1T% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 (YPAX)^E*.@I&^Z?I2CI0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>25
<FILENAME>modd-20190630.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 73903 06302019 S1A.xfr; Date: 2019%2D09%2D09T13:17:07Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:MODD="http://modular-medical.com/20190630">
    <link:schemaRef xlink:href="modd-20190630.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_ComputerEquipmentMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_ComputerEquipmentMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_BuildingAndBuildingImprovementsMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_BuildingAndBuildingImprovementsMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_LeaseholdImprovementsMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_LeaseholdImprovementsMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2018-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2018-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MODD:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MODD:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MODD:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MODD:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_BuildingAndBuildingImprovementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_BuildingAndBuildingImprovementsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_TechnologyEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_TechnologyEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_Consultants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MODD:Consultants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_Consultants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MODD:Consultants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_Consultants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MODD:Consultants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_Consultants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MODD:Consultants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-03-31" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2018-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2018-03-31" unitRef="Shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-04-01to2019-03-31_us-gaap_ComputerEquipmentMember_us-gaap_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-04-01to2019-03-31_us-gaap_ComputerEquipmentMember_us-gaap_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-04-01to2019-03-31_us-gaap_BuildingAndBuildingImprovementsMember_us-gaap_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-04-01to2019-03-31_us-gaap_BuildingAndBuildingImprovementsMember_us-gaap_MaximumMember">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-04-01to2019-03-31_us-gaap_LeaseholdImprovementsMember_us-gaap_MinimumMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-04-01to2019-03-31_us-gaap_LeaseholdImprovementsMember_us-gaap_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-04-01to2019-03-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-04-01to2019-03-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-04-01to2019-03-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-04-01to2019-03-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2019-06-30_us-gaap_BuildingAndBuildingImprovementsMember_srt_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2019-06-30_us-gaap_BuildingAndBuildingImprovementsMember_srt_MaximumMember">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2019-06-30_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2019-06-30_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2019-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2019-06-30_us-gaap_ComputerSoftwareIntangibleAssetMember_srt_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2019-06-30_us-gaap_TechnologyEquipmentMember_srt_MinimumMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2019-06-30_us-gaap_TechnologyEquipmentMember_srt_MaximumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2019-06-30_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2019-06-30_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">6553768</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">4296676</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">392007</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">5706628</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">4053771</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">15590</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">16804</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">9500</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">6569358</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">4313480</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">5716128</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">180</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">213</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">172</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">75948</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">13259</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">75961</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositsAssets contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">7500</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">7500</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">7500</us-gaap:DepositsAssets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">83628</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">20972</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">83633</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">6652986</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">4334452</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">5799761</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">178929</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">14955</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">253474</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">516</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">178929</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">15471</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">253474</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2018-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Liabilities contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">178929</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">15471</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">253474</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">17840</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">15983</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">17870</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">9684578</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">5011661</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">9898776</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">-3248161</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">-708663</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">-4370359</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">6474057</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">4318981</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">362632</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">15983</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">17840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5011661</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9684578</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-708663</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-3248161</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-03-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7582</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">404467</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-49417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31_custom_CommonStockIssuableMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_custom_CommonStockIssuableMember" unitRef="USD" decimals="0">19800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-03-31_custom_CommonStockIssuableMember" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">5546287</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">6652986</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">4334452</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">5799761</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2018-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2018-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">17840261</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-03-31" unitRef="Shares" decimals="INF">15983273</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">17870261</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">17840261</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2018-03-31" unitRef="Shares" decimals="INF">15983273</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">17870261</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ProfessionalFees contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">260396</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">232961</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">287831</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">41710</us-gaap:ProfessionalFees>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">1882345</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">332642</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">703783</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">135789</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:Depreciation contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">14468</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">1861</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">6714</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">1395</us-gaap:Depreciation>
    <us-gaap:OperatingExpenses contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">2577299</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">666164</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">1138240</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">255190</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-2577299</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">-666164</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-1138240</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">-255190</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">39390</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">8518</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">16042</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">5624</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-2537909</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">-657646</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-1122198</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">-249566</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">1589</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-2539498</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">-659246</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-04-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2539498</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-04-01to2018-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-659246</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-1122198</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">-249566</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-04-01to2019-03-31" unitRef="USDPShares" decimals="INF">-.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-04-01to2018-03-31" unitRef="USDPShares" decimals="INF">-.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-04-01to2019-06-30" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-04-01to2018-06-30" unitRef="USDPShares" decimals="INF">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2018-04-01to2019-03-31" unitRef="Shares" decimals="INF">16589633</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2017-04-01to2018-03-31" unitRef="Shares" decimals="INF">13336309</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2019-04-01to2019-06-30" unitRef="Shares" decimals="INF">17847740</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2018-04-01to2018-06-30" unitRef="Shares" decimals="INF">15983273</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2018-04-01to2019-03-31" unitRef="Shares" decimals="INF">16589633</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2017-04-01to2018-03-31" unitRef="Shares" decimals="INF">13336309</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2019-04-01to2019-06-30" unitRef="Shares" decimals="INF">17847740</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2018-04-01to2018-06-30" unitRef="Shares" decimals="INF">15983273</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-03-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">15983273</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">17840261</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-03-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7582060</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2017-04-01to2018-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1168182</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">-116277</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2017-04-01to2018-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1168</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2017-04-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-117445</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-04-01to2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1856988</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-04-01to2018-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7233031</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">4142666</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">4731872</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-04-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1857</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-04-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4140809</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-04-01to2018-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7233</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-04-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4724639</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DepreciationAndAmortization contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">14468</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">1861</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">6714</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">1395</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-1214</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">23998</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-6090</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">-10248</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-1807934</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">-791131</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-840421</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">-236219</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">77124</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">15119</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">6719</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">6170</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">213</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-77124</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">-15332</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-6719</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">-6170</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">4142666</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">4731872</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">516</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">20740</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">516</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">4142150</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">4711132</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">-516</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">2257092</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">3904669</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-847140</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">-242905</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:InterestPaidNet contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">0</us-gaap:InterestPaidNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-03-31_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">15103</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-03-31_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">20565</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-03-31_us-gaap_OfficeEquipmentMember" unitRef="USD" decimals="0">49724</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-03-31_us-gaap_OfficeEquipmentMember" unitRef="USD" decimals="0">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-03-31_us-gaap_MachineryAndEquipmentMember" unitRef="USD" decimals="0">21937</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-03-31_us-gaap_MachineryAndEquipmentMember" unitRef="USD" decimals="0">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-06-30_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">25028</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-06-30_us-gaap_OfficeEquipmentMember" unitRef="USD" decimals="0">49724</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-06-30_us-gaap_MachineryAndEquipmentMember" unitRef="USD" decimals="0">24194</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">16278</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">1844</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">22985</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:CashUninsuredAmount contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">6269116</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">3933002</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">5421940</us-gaap:CashUninsuredAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">817000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">182500</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">1098000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">817000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">182500</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">1098000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">-19800</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">0</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">0</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">420090</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">98700</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">139912</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">76296</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">19800</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-04-01to2019-03-31_custom_CommonStockIssuableMember" unitRef="USD" decimals="0">19800</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensation contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">532108</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-04-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">532108</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">194428</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-04-01to2019-03-31_custom_Consultants1Member" unitRef="USD" decimals="0">466197</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-04-01to2019-03-31_custom_Consultants2Member" unitRef="USD" decimals="0">23150</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-04-01to2019-03-31_srt_ChiefExecutiveOfficerMember" unitRef="USD" decimals="0">42761</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeTaxesPaidNet contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">1589</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">19800</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Modular Medical, Inc. (the &amp;#8220;Company&amp;#8221;)&#13;was organized under the laws of the State of Nevada on October 22, 1998, to engage in any lawful purpose. The Company has at the&#13;present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements&#13;of the Company and other relevant factors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Quasuras, Inc. (&amp;#8220;Quasuras&amp;#8221;) was&#13;incorporated in Delaware on April 20, 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Quasuras has developed a hardware technology&#13;allowing people with diabetes to receive their daily insulin in two ways, through a continuous &amp;#8220;basal&amp;#8221; delivery allowing&#13;a small amount of insulin to be in the blood at all times and a &amp;#8220;bolus&amp;#8221; delivery to address meal time glucose input&#13;and to address when the blood glucose level becomes too high. By addressing the time and effort required to effectively treat their&#13;condition, Quasuras believes it can address the less technically savvy, less motivated part of the market.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Reorganization&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2017, pursuant to a Reorganization&#13;and Share Exchange Agreement, by and among the Company and Quasuras, the Company acquired one hundred percent (100%) of the issued&#13;and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary&#13;of the Company. Since the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was&#13;accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the Reorganization,&#13;at their historical carrying amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the reorganization, the Company&#13;changed the fiscal year end from June 30 to March 31, to coincide with the year end for Quasuras.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements of the&#13;Company have been prepared in accordance with accounting principles generally accepted in the United States of America. The following&#13;summarizes the more significant of such policies:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the consolidated financial&#13;statements in conformity with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates&#13;and assumptions that affect reported amounts and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements include&#13;the accounts of Modular Medical, Inc. and its wholly-owned subsidiary Quasuras, Inc., and are collectively referred to as the &amp;#8220;Company&amp;#8221;.&#13;All material intercompany accounts, transactions and profits were eliminated in consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the accompanying financial&#13;statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets&#13;and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the&#13;reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Reportable Segment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has one reportable segment. The&#13;Company&amp;#8217;s activities are interrelated and each activity is dependent upon and supportive of the other. Accordingly, all significant&#13;operating decisions are based on analysis of financial products provided as a single global business.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Professional Fees&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses the cost of legal, accounting,&#13;audit, tax and other professional services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses the cost of research and&#13;development as incurred. Research and development costs charged to operations were approximately $ 1,882,345 and $332,642 for the&#13;fiscal year ended March 31, 2019 and 2018, respectively.&amp;#9; &amp;#9; &amp;#9;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;General and Administration&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;General and administrative expense consists&#13;primarily of payroll and benefit related costs, rent, office expenses, equipment supplied and meetings and travel.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company utilizes Financial Accounting Standards&#13;Board (FASB) Accounting Standards Codification (ASC) Topic 740, Income Taxes, which requires recognition of deferred tax assets&#13;and liabilities for the expected future tax consequences of events that were included in the consolidated financial statements&#13;or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences&#13;between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws&#13;and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances&#13;are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for uncertain tax positions&#13;in accordance with FASB ASC Topic 740. When tax returns are filed, it is likely that some positions taken would be sustained upon&#13;examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount&#13;of the position that would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements&#13;in the period during which, based on all available evidence, management believes it is more likely than not that the position will&#13;be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not&#13;offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured&#13;as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable&#13;taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described&#13;above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any&#13;associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized&#13;tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in&#13;the consolidated statements of income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2019 and 2018, the Company had&#13;not taken any significant uncertain tax positions on its tax returns for periods ended March 31, 2019 and prior years or in computing&#13;its tax provision for 2019. Management has considered its tax positions and believes that all of the positions taken by the Company&#13;in its Federal and State tax returns are more likely than not to be sustained upon examination. The Company is subject to examination&#13;by U.S. Federal and State tax authorities for the period ended March 31, 2016 to the present, generally for three years after they&#13;are filed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject&#13;the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company maintains cash balances&#13;at financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to&#13;limits of approximately $250,000. The Company has not experienced any losses with regard to its bank accounts and believes it is&#13;not exposed to any risk of loss on its cash bank accounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is subject to risks from, among&#13;other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements,&#13;rapidly changing customer requirements, limited operating history and the volatility of public markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain conditions may exist as of the date&#13;the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when&#13;one or more future events occur or fail to occur. The Company&amp;#8217;s management and legal counsel assess such contingent liabilities,&#13;and such assessment inherently involves judgment. In assessing loss contingencies related to legal proceedings that are pending&#13;against the Company or unasserted claims that may result in such proceedings, the Company&amp;#8217;s legal counsel evaluates the perceived&#13;merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected&#13;to be sought.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the assessment of a contingency indicates&#13;it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability&#13;would be accrued in the Company&amp;#8217;s consolidated financial statements. If the assessment indicates that a potential material&#13;loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent&#13;liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies&#13;considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would&#13;be disclosed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents include cash in hand&#13;and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months&#13;or less. At March 31, 2019 and March 31, 2018, the Company had $6,553,768 and $4,296,676, respectively, in cash. Deposits at the&#13;bank are insured up to $250,000 by the Federal Deposit Insurance Corporation. The Company&amp;#8217;s uninsured portion of the balances&#13;held at the bank aggregated to approximately $6,269,116 &amp;#160;and $3,933,002, respectively. No reserve has been made in the financial&#13;statements for any possible loss due to any financial institution failure.&amp;#160;The Company has not experienced any losses in such&#13;accounts and believes we are not exposed to any significant risk on cash and cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Property, Plant &amp;#38; Equipment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment is stated at cost and&#13;depreciated using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. The estimated&#13;useful lives of our property and equipment are generally as follows: computer equipment &amp;#38; software developed or acquired for&#13;internal use, three to ten years; office equipment, two to three years; buildings and improvements, five to fifteen years; leasehold&#13;improvements, two to ten years; and machinery and equipment, one to five years.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;As of March 31, 2019 and March 31, 2018, property, plant and equipment&#13;amounted to:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Computer equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,565&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,103&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;49,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,937&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(16,278&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,844&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,948&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,259&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Depreciation expenses for the year ended March 31, 2019 and 2018&#13;was $14,435 &amp;#160;and $1,844, respectively.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Fair Value of Financial Instrument&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For certain of the Company&amp;#8217;s financial&#13;instruments, including cash and equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair&#13;values due to their short maturities. ASC Topic 820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; requires disclosure&#13;of the fair value of financial instruments held by the Company. ASC Topic 825, &amp;#8220;Financial Instruments,&amp;#8221; defines fair&#13;value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements&#13;for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities&#13;each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between&#13;the origination of such instruments and their expected realization and their current market rate of interest. The three levels&#13;of valuation hierarchy are defined as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 inputs to the valuation methodology&#13;are quoted prices for identical assets or liabilities in active markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 inputs to the valuation methodology&#13;include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability,&#13;either directly or indirectly, for substantially the full term of the financial instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 inputs to the valuation methodology&#13;are unobservable and significant to the fair value measurement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to their short-term nature, the carrying&#13;values of cash and equivalents, accounts receivable, accounts payable, and accrued expenses, approximate fair value. Based on borrowing&#13;rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair&#13;value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Earnings Per Share (&amp;#8220;EPS&amp;#8221;)&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number&#13;of outstanding common shares during the period. Diluted earnings per share are computed by dividing net income by the weighted&#13;average number of shares outstanding during the period increased to include the number of additional shares of common stock&#13;that would have been outstanding if the potentially dilutive securities had been issued. During the fiscal years ended March&#13;31, 2019 and 2018 we incurred losses. Therefore, the effects of any common stock equivalent were antidilutive during those&#13;periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets for the computation&#13;of basic and diluted earnings per share for the fiscal years ended March 31, 2019 and 2018:&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 76%; padding-bottom: 2.5pt; padding-left: 34.6pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,539,498&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(659,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Basic and Diluted:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted average number of shares used in computing basic and diluted net loss per share:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-align: right; text-indent: -8.65pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,589,633&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,336,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,589,633&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,336,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 3pt"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 3pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the FASB issued ASU 2014-09,&amp;#160;&lt;i&gt;Revenue&#13;from Contracts with Customers&lt;/i&gt;, issued as a new Topic, ASC Topic 606. The new revenue recognition standard supersedes all existing&#13;revenue recognition guidance. Under this ASU, an entity should recognize revenue when it transfers promised goods or services to&#13;customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or&#13;services. ASU 2015-14, issued in August 2015, deferred the effective date of ASU 2014-09 to the first quarter of 2018, with early&#13;adoption permitted in the first quarter of 2018. The company has adopted the new standard utilizing the modified retrospective&#13;approach. The adoption of this new accounting guidance does not have material effects on results of operations, cash flows and&#13;financial position for the forceable future because the company does not have revenues.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2016, The FASB issued ASU No. 2016-01,&lt;i&gt;&amp;#160;Financial&#13;Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825)&lt;/i&gt;. ASU No. 2016-01 revises&#13;the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes&#13;for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments&#13;to be recognized in net income. For non-public companies, ASU 2016-01 is effective for fiscal years beginning after December 15,&#13;2018, and interim periods within fiscal years beginning after December 15, 2019. We are currently evaluating the impact of the&#13;adoption of ASU 2016-01 will have on our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2016, the FASB issued ASU No. 2016-15,&#13;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This update addresses a diversity&#13;in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic&#13;230, Statement of Cash Flows, and other Topics. The amendments in this Update are effective for public business entities for fiscal&#13;years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including&#13;adoption in an interim period. We adopted this ASU in 2016 and the implementation did not have a material impact on our financial&#13;position or statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2018, the FASB issued guidance that&#13;eases certain documentation and assessment requirements of hedge effectiveness and modifies the accounting for components excluded&#13;from the assessment. Some of the modifications include the ineffectiveness of derivative gain/loss in highly effective cash flow&#13;hedge to be recorded in other comprehensive income, the change in fair value of derivative to be recorded in the same income statement&#13;line as hedged item, and additional disclosures required on the cumulative basis adjustment in fair value hedges and the effect&#13;of hedging on financial statement lines for components excluded from the assessment. The amendment also simplifies the application&#13;of hedge accounting in certain situations to permit new hedging strategies to be eligible for hedge accounting. The guidance is&#13;effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2018,&#13;our fiscal 2020. Early adoption is permitted and the modified retrospective transition method should be applied. We do not expect&#13;the adoption of this guidance to have a material impact on our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, FASB issued ASU No. 2016-02,&#13;Leases (&amp;#8220;Topic 842&amp;#8221;). Topic 842 requires an entity to recognize right-of -use assets and lease liability on its balance&#13;sheet and disclosure key information about leasing arrangements. For public companies, Topic 842 is effective for annual reporting&#13;periods beginning after December 15, 2018, including interim periods within that reporting period, with early adoption permitted.&#13;We have evaluated this ASU and believe this guidance will not have a material impact on our financial position and statement of&#13;operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other recent accounting pronouncements issued&#13;by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities&#13;and Exchange Commission did not or are not believed by management to have a material impact on the Company&amp;#8217;s present or future&#13;consolidated financial statements.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Reclassification&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior year amounts have been reclassified&#13;for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations&#13;or cash flow.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Modular Medical, Inc. (the &amp;#8220;Company&amp;#8221;)&#13;was organized under the laws of the State of Nevada on October 22, 1998, to engage in any lawful purpose. The Company has at the&#13;present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements&#13;of the Company and other relevant factors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Quasuras, Inc. (&amp;#8220;Quasuras&amp;#8221;) was&#13;incorporated in Delaware on April 20, 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Quasuras has developed a hardware technology&#13;allowing people with insulin dependent diabetes to receive their daily insulin in two ways, through a continuous &amp;#8220;basal&amp;#8221;&#13;delivery allowing a small amount of insulin to be in the blood at all times and a &amp;#8220;bolus&amp;#8221; delivery to address meal&#13;time glucose input and to address when the blood glucose level becomes too high. By addressing the time and effort required to&#13;effectively treat their condition, Quasuras believes it can address the less technically savvy, less motivated part of the market.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Reorganization&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2017, pursuant to a Reorganization&#13;and Share Exchange Agreement, by and among the Company and Quasuras, the Company acquired one hundred percent (100%) of the issued&#13;and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary&#13;of the Company. Since the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was&#13;accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the Reorganization,&#13;at their historical carrying amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the reorganization, the Company&#13;changed the fiscal year end from June 30 to March 31, to coincide with the year end for Quasuras.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements of the&#13;Company have been prepared in accordance with accounting principles generally accepted in the United States of America. The following&#13;summarizes the more significant of such policies:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the consolidated financial&#13;statements in conformity with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates&#13;and assumptions that affect reported amounts and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements include&#13;the accounts of Modular Medical, Inc. and its wholly-owned subsidiary Quasuras, Inc., and are collectively referred to as the &amp;#8220;Company&amp;#8221;.&#13;All material intercompany accounts, transactions and profits were eliminated in consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the accompanying financial&#13;statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets&#13;and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the&#13;reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Reportable Segment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has one reportable segment. The&#13;Company&amp;#8217;s activities are interrelated and each activity is dependent upon and supportive of the other. Accordingly, all significant&#13;operating decisions are based on analysis of financial products provided as a single global business.&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Professional Fees&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses the cost of legal, accounting,&#13;audit, tax and other professional services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses the cost of research and&#13;development as incurred. Research and development costs charged to operations were approximately $703,783 and $135,789 for the&#13;fiscal quarter ended June 30, 2019 and 2018, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;General and Administration&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;General and administrative expense consists&#13;primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and meetings and travel.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company utilizes Financial Accounting Standards&#13;Board (FASB) Accounting Standards Codification (ASC) Topic 740, Income Taxes, which requires recognition of deferred tax assets&#13;and liabilities for the expected future tax consequences of events that were included in the consolidated financial statements&#13;or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences&#13;between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws&#13;and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances&#13;are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for uncertain tax positions&#13;in accordance with FASB ASC Topic 740. When tax returns are filed, it is likely that some positions taken would be sustained upon&#13;examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount&#13;of the position that would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements&#13;in the period during which, based on all available evidence, management believes it is more likely than not that the position will&#13;be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not&#13;offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured&#13;as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable&#13;taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described&#13;above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any&#13;associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized&#13;tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in&#13;the consolidated statements of income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At June 30, 2019 and 2018, the Company had not&#13;taken any significant uncertain tax positions on its tax returns for periods ended June 30, 2019 and prior years or in computing&#13;its tax provision for 2019. Management has considered its tax positions and believes that all of the positions taken by the Company&#13;in its Federal and State tax returns are more likely than not to be sustained upon examination. The Company is subject to examination&#13;by U.S. Federal and State tax authorities for the period ended March 31, 2017 to the present, generally for three years after they&#13;are filed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject&#13;the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company maintains cash balances&#13;at financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to&#13;limits of approximately $250,000. The Company has not experienced any losses with regard to its bank accounts and believes it is&#13;not exposed to any risk of loss on its cash bank accounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is subject to risks from, among&#13;other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements,&#13;rapidly changing customer requirements, limited operating history and the volatility of public markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain conditions may exist as of the date&#13;the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when&#13;one or more future events occur or fail to occur. The Company&amp;#8217;s management and legal counsel assess such contingent liabilities,&#13;and such assessment inherently involves judgment. In assessing loss contingencies related to legal proceedings that are pending&#13;against the Company or unasserted claims that may result in such proceedings, the Company&amp;#8217;s legal counsel evaluates the perceived&#13;merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected&#13;to be sought.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the assessment of a contingency indicates&#13;it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability&#13;would be accrued in the Company&amp;#8217;s consolidated financial statements. If the assessment indicates that a potential material&#13;loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent&#13;liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies&#13;considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would&#13;be disclosed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents include cash in hand&#13;and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months&#13;or less. At June 30, 2019 and March 31, 2019, the Company had $5,706,628 and $6,553,768, respectively, in cash. Deposits at the&#13;bank are insured up to $250,000 by the Federal Deposit Insurance Corporation. The Company&amp;#8217;s uninsured portion of the balances&#13;held at the bank aggregated to approximately $5,421,940 and $6,269,116 respectively. No reserve has been made in the financial&#13;statements for any possible loss due to any financial institution failure.&amp;#160;The Company has not experienced any losses in such&#13;accounts and believes we are not exposed to any significant risk on cash and cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Property, Plant &amp;#38; Equipment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment is stated at cost and&#13;depreciated using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. The estimated&#13;useful lives of our property and equipment are generally as follows: computer equipment&amp;#38; software developed or acquired for&#13;internal use, three to ten years; office equipment, two to three years; buildings and improvements, five to fifteen years; leasehold&#13;improvements, two to ten years; and machinery and equipment, one to five years.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;As of June 30, 2019 and March 31, 2019, property, plant and equipment&#13;amounted to:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;(UNAUDITED)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Computer equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,565&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;49,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;49,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,194&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,937&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(22,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(16,278&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,961&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,948&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Depreciation expenses for the quarter ended June 30, 2019 and March&#13;31, 2019 was $6,707 and $1,387 respectively.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Fair Value of Financial Instrument&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For certain of the Company&amp;#8217;s financial&#13;instruments, including cash and equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair&#13;values due to their short maturities. ASC Topic 820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; requires disclosure&#13;of the fair value of financial instruments held by the Company. ASC Topic 825, &amp;#8220;Financial Instruments,&amp;#8221; defines fair&#13;value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements&#13;for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities&#13;each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between&#13;the origination of such instruments and their expected realization and their current market rate of interest. The three levels&#13;of valuation hierarchy are defined as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 inputs to the valuation methodology&#13;are quoted prices for identical assets or liabilities in active markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 inputs to the valuation methodology&#13;include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability,&#13;either directly or indirectly, for substantially the full term of the financial instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 inputs to the valuation methodology&#13;are unobservable and significant to the fair value measurement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to their short-term nature, the carrying&#13;values of cash and equivalents, accounts receivable, accounts payable, and accrued expenses, approximate fair value. Based on borrowing&#13;rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair&#13;value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Earnings Per Share (&amp;#8220;EPS&amp;#8221;)&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic earnings per share are computed by dividing&#13;earnings available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted&#13;earnings per share are computed by dividing net income by the weighted average number of shares outstanding during the period increased&#13;to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities&#13;had been issued. During the fiscal quarter ended June 30, 2019 and 2018 we incurred losses. Therefore, the effects of any common&#13;stock equivalent were anti-dilutive during those periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets for the computation&#13;of basic and diluted earnings per share for the fiscal quarters ended June 30, 2019 and June 30, 2018:&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;(UNAUDITED)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;(UNAUDITED)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="width: 76%; padding-bottom: 2.5pt; padding-left: 17.3pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,122,198&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(249,566&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Basic and Diluted:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted average number of shares used in computing basic and diluted net loss &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;per share:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,847,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,983,273&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,847,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,983,273&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify"&gt;In May 2014, the FASB issued ASU 2014-09,&amp;#160;&lt;i&gt;Revenue&#13;from Contracts with Customers&lt;/i&gt;, issued as a new Topic, ASC Topic 606. The new revenue recognition standard supersedes all existing&#13;revenue recognition guidance. Under this ASU, an entity should recognize revenue when it transfers promised goods or services to&#13;customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or&#13;services. ASU 2015-14, issued in August 2015, deferred the effective date of ASU 2014-09 to the first quarter of 2018, with early&#13;adoption permitted in the first quarter of 2018. The company has adopted the new standard utilizing the modified retrospective&#13;approach. The adoption of this new accounting guidance does not have material effects on results of operations, cash flows and&#13;financial position for the forceable future because the company does not have revenues.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2016, The FASB issued ASU No. 2016-01,&lt;i&gt;&amp;#160;Financial&#13;Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825)&lt;/i&gt;. ASU No. 2016-01 revises&#13;the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes&#13;for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments&#13;to be recognized in net income. For non-public companies, ASU 2016-01 is effective for fiscal years beginning after December 15,&#13;2018, and interim periods within fiscal years beginning after December 15, 2019. We are currently evaluating the impact of the&#13;adoption of ASU 2016-01 will have on our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2016, the FASB issued ASU No. 2016-15,&#13;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This update addresses a diversity&#13;in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic&#13;230, Statement of Cash Flows, and other Topics. The amendments in this Update are effective for public business entities for fiscal&#13;years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including&#13;adoption in an interim period. We adopted this ASU in 2016 and the implementation did not have a material impact on our financial&#13;position or statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2018, the FASB issued guidance that&#13;eases certain documentation and assessment requirements of hedge effectiveness and modifies the accounting for components excluded&#13;from the assessment. Some of the modifications include the ineffectiveness of derivative gain/loss in highly effective cash flow&#13;hedge to be recorded in other comprehensive income, the change in fair value of derivative to be recorded in the same income statement&#13;line as hedged item, and additional disclosures required on the cumulative basis adjustment in fair value hedges and the effect&#13;of hedging on financial statement lines for components excluded from the assessment. The amendment also simplifies the application&#13;of hedge accounting in certain situations to permit new hedging strategies to be eligible for hedge accounting. The guidance is&#13;effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2018,&#13;our fiscal 2020. Early adoption is permitted, and the modified retrospective transition method should be applied. We do not expect&#13;the adoption of this guidance to have a material impact on our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, FASB issued ASU No. 2016-02,&#13;Leases (&amp;#8220;Topic 842&amp;#8221;). Topic 842 requires an entity to recognize right-of -use assets and lease liability on its balance&#13;sheet and disclosure key information about leasing arrangements. For public companies, Topic 842 is effective for annual reporting&#13;periods beginning after December 15, 2018, including interim periods within that reporting period, with early adoption permitted.&#13;We have evaluated this ASU and believe this guidance will not have a material impact on our financial position and statement of&#13;operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other recent accounting pronouncements issued&#13;by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities&#13;and Exchange Commission did not or are not believed by management to have a material impact on the Company&amp;#8217;s present or future&#13;consolidated financial statements.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Reclassification&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior year amounts have been reclassified&#13;for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations&#13;or cash flow.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <MODD:ReorganizationAndPrivatePlacementDisclosureTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On April 26, 2017, Modular Medical, Inc.&#13;issued 2,900,000 shares (the &amp;#8220;Control Block&amp;#8221;), of new, restricted common stock, par value, $0.001, per share, for a&#13;purchase price of $375,000, resulting in a change in control of Modular Medical, Inc.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On July 24, 2017, pursuant to a Reorganization&#13;and Share Exchange Agreement, by and among, Modular Medical, Inc., 3 Quasuras Shareholders and Quasuras (the &amp;#8220;Acquisition&#13;Agreement&amp;#8221;), the Company acquired all 4,400,000 shares of Quasuras&amp;#8217; common stock which represented one hundred percent&#13;(100%) of the issued and outstanding shares of Quasuras for 7,582,060 shares of our common stock, resulting in Quasuras becoming&#13;our wholly-owned subsidiary (the &amp;#8220;Acquisition&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Simultaneously with the closing of the&#13;Acquisition and as a condition thereto, we sold (the &amp;#8220;2017 Private Placement&amp;#8221;), in a private placement an aggregate&#13;of 7,233,031 for cash and 568,182 from reissuance of previously canceled shares of our common stock pursuant to one or more exemptions&#13;from the registration requirements of the Securities Act, at a purchase price of $0.66 per share resulting in net proceeds to us&#13;of approximately $4,731,872. Simultaneously with the Acquisition and Private Placement, the Company cancelled all 2,900,000 Control&#13;Block shares it had issued in the Control Block Acquisition (the &amp;#8220;Share Cancellation&amp;#8221;). In connection with the Private&#13;Placement, we paid $41,928 as compensation in connection with sales of our shares therein.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Following the Acquisition, the 2017 Private&#13;Placement and the Share Cancellation, we had issued and outstanding 15,983,273 shares of our common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The cash received in the private placement&#13;was recorded as the cash received in reorganization in the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Simultaneously with&#13;and as a condition to the closing of the Acquisition and the Private Placement, pursuant to an Intellectual Property Transfer&#13;Agreement, dated as of July 24, 2018, by and among us, Quasuras and Mr. DiPerna (the &amp;#8220;IP Transfer Agreement&amp;#8221;), Mr.&#13;DiPerna transferred to us all intellectual property rights owned directly and/or indirectly by him related to our proposed business.&#13;Separately, we agreed to pay Mr. DiPerna as part of his compensation for services to be performed for us pursuant to a Royalty&#13;Agreement (the &amp;#8220;Royalty Agreement&amp;#8221;) certain fees based upon future sales, if any, of our proposed product subject&#13;to a maximum $10,000,000 &amp;#8220;cap&amp;#8221; on the aggregate amount of fees that Mr. DiPerna could earn from such arrangement.&lt;/p&gt;</MODD:ReorganizationAndPrivatePlacementDisclosureTextBlock>
    <MODD:ReorganizationAndPrivatePlacementDisclosureTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On April 26, 2017, Modular Medical, Inc.&#13;issued 2,900,000 shares (the &amp;#8220;Control Block&amp;#8221;), of new, restricted common stock, par value, $0.001, per share, for a&#13;purchase price of $375,000, resulting in a change in control of Modular Medical, Inc.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On July 24, 2017, pursuant to a Reorganization&#13;and Share Exchange Agreement, by and among, Modular Medical, Inc., 3 Quasuras Shareholders and Quasuras (the &amp;#8220;Acquisition&#13;Agreement&amp;#8221;), the Company acquired all 4,400,000 shares of Quasuras&amp;#8217; common stock which represented one hundred percent&#13;(100%) of the issued and outstanding shares of Quasuras for 7,582,060 shares of our common stock, resulting in Quasuras becoming&#13;our wholly-owned subsidiary (the &amp;#8220;Acquisition&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Simultaneously with the closing of the&#13;Acquisition and as a condition thereto, we sold (the &amp;#8220;2017 Private Placement&amp;#8221;), in a private placement an aggregate&#13;of 7,233,031 for cash and 568,182 from reissuance of previously canceled shares of our common stock pursuant to one or more exemptions&#13;from the registration requirements of the Securities Act, at a purchase price of $0.66 per share resulting in net proceeds to us&#13;of approximately $4,731,872. Simultaneously with the Acquisition and Private Placement, the Company cancelled all 2,900,000 Control&#13;Block shares it had issued in the Control Block Acquisition (the &amp;#8220;Share Cancellation&amp;#8221;). In connection with the 2017&#13;Private Placement, we paid $41,928 as compensation in connection with sales of our shares therein.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Following the Acquisition, the 2017 Private&#13;Placement and the Share Cancellation, we had issued and outstanding 15,983,273 shares of our common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;The cash received in the private placement&#13;was recorded as the cash received in reorganization in the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;Simultaneously with and as a condition&#13;to the closing of the Acquisition and the 2017 Private Placement, pursuant to an Intellectual Property Transfer Agreement, dated&#13;as of July 24, 2018, by and among us, Quasuras and Mr. DiPerna (the &amp;#8220;IP Transfer Agreement&amp;#8221;), Mr. DiPerna transferred&#13;to us all intellectual property rights owned directly and/or indirectly by him related to our proposed business. Separately, we&#13;agreed to pay Mr. DiPerna as part of his compensation for services to be performed for us pursuant to a Royalty Agreement (the&#13;&amp;#8220;Royalty Agreement&amp;#8221;) certain fees based upon future sales, if any, of our proposed product subject to a maximum $10,000,000&#13;&amp;#8220;cap&amp;#8221; on the aggregate amount of fees that Mr. DiPerna could earn from such arrangement.&lt;/p&gt;</MODD:ReorganizationAndPrivatePlacementDisclosureTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2019, and 2018, accrued expenses&#13;amounted to $178,929 and $14,955, respectively. Accrued expenses comprised of accrued legal and professional, consultant services&#13;and year end employee bonuses as of March 31, 2019 and March 31, 2018.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June 30, 2019 and March 31, 2019, accrued&#13;expenses amounted to $253,474 and $178,929 respectively. Accrued expenses comprised of accrued legal and professional, consultant&#13;services as of June 30, 2019 and March 31, 2019.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Payable to related party comprises of the amounts&#13;paid by the major shareholder on behalf of the Company. The payable is unsecured, non-interest bearing and due on demand. As of&#13;March 31, 2019 and 2018, respectively, the payable to related party amounted to $0 and $516.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Payable to related party comprises of the amounts&#13;paid by the major shareholder on behalf of the Company. The payable is unsecured, non-interest bearing and due on demand. As of&#13;June 30, 2019 and March 31, 2019, respectively, there were no amounts payable to related party.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Common stock&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2017, pursuant to a Reorganization&#13;and Share Exchange Agreement by and among, the Company and Quasuras Inc., the Company acquired one hundred percent (100%) of the&#13;issued and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary&#13;of the Company. The historical equity for Quasuras was restated pursuant to the reorganization.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has 5,000,000 shares of preferred&#13;stock authorized. The par value of the shares is $0.001. As of March 31, 2019, none of the shares of preferred stock of the Company&#13;were issued.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2017 Equity Incentive Plan&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;On October 19, 2017, the board of directors&#13;approved the 2017 Equity Incentive Plan (the &amp;#8220;EIP&amp;#8221;) that reserves 3,000,000 shares of common stock of the Company to&#13;be issued. Under the Company&amp;#8217;s EIP, eligible employees, directors and consultants may be granted options to purchase shares&#13;of common stock of the Company. The EIP is administered by the Company&amp;#8217;s board of directors or, in the alternative, a committee&#13;designated by the board of directors, and has the sole power to adminster the EIP. The board of directors determines whether the&#13;EIP will allow for the issuance of shares of common stock or an option to purchase shares of common stock and whether such options&#13;are designated as either incentive or non-qualified stock options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the EIP, the exercise or purchase price&#13;shall be calculated as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 1%; font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;(i)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;In the case of an incentive stock option, (A) granted to employees, directors and consultants who, at the time of the grant of such incentive stock option own stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company, the per share exercise price shall be not less than one hundred ten percent (110%) of the fair market value per share on the date of grant; or (B) granted to employees, directors and consultants other than to employees, directors and consultants described in the preceding clause, the per share exercise price shall be not less than one hundred percent (100%) of the fair market value per share on the date of grant;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%"&gt;&lt;font style="font-size: 8pt"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 96%; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;In the case of a non-qualified stock option, the per share exercise price shall be not less than one hundred percent (100%) of the fair market value per share on the date of grant unless otherwise determined by the board of directors; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%"&gt;&lt;font style="font-size: 8pt"&gt;(iii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 96%; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;In the case of other grants, such price as is determined by the board of directors.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The board of directors is responsible for determining&#13;the consideration to be paid for the shares of common stock to be issued upon exercise or purchase. The EIP generally doesn&amp;#8217;t&#13;allow for the transfer of the options, and the board of directors may amend, suspend or terminate the EIP at any time.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"&gt;On August 15, September 15, and October&#13;15, 2018, the Company granted a total of 54,039 options to the chief executive officer of the Company in lieu of salary. The options&#13;expire 10 years from the respective grant dates and vested immediately upon grant. The fair value of these options was determined&#13;to be $24,840 and was included in general and administrative and research and development expenses for the year ended March 31,&#13;2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"&gt;On November 15&lt;sup&gt;th&lt;/sup&gt; and December&#13;15&lt;sup&gt;th&lt;/sup&gt; 2018, the Company granted 10,648 options to the officer of the Company in lieu of salary. The options expire on&#13;November 14&lt;sup&gt;th&lt;/sup&gt;, and December 14&lt;sup&gt;th&lt;/sup&gt;, 2028 and vest immediately. The fair value of these options determined to&#13;be $17,921 and was included in general and administrative and research and development expenses for the year ended March 31, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"&gt;The following assumptions were used&#13;in the fair value method calculations:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Volatility: 71% &amp;#8211; 112%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Risk free rate of return: 2.73% &amp;#8211; 3.01%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Expected term: 5 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"&gt;During the fiscal year ended March 31,&#13;2019, the Company granted options to purchase 1,529,208 shares of common stock to certain employees and consultants. The fair value&#13;of the options granted was $1,021,733, and the Company has been recording stock-based compensation expense for each grant over&#13;the respective vesting periods. For the year ended March 31, 2019, the Company recorded stock-based compensation expense of $532,108,&#13;which is less than the total fair value. This difference of $489,625 represents stock-based compensation expense that will be recognized&#13;subsequent to March 31, 2019, so long as the option grants remain outstanding and vesting continues. The table below provides a&#13;reconciliation of total fair value of the options granted and related expense recognized by the Company during fiscal 2019.&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Grantees&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Option&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Vesting &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Periods&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total Fair &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Value of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019 Stock-Based &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Compensation &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Expense&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Unrecognized &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;expense at &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 28%"&gt;&lt;font style="font-size: 8pt"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,280,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 22%"&gt;&lt;font style="font-size: 8pt"&gt;July 25, 2018 to July 24, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;682,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;466,197&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;216,043&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;185,221&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;January&amp;#160;&amp;#160;16, 2019 to January 15, 2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;336,732&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,150&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;313,582&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Chief Executive Officer&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;64,687&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;*&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,761&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,761&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,529,908&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,021,733&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;532,108&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;489,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;* Options were fully vested as of the grant date, as disclosed above.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"&gt;The following assumptions were used&#13;in the fair value method calculation for the consultant options:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Volatility: 104% &amp;#8211; 110%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Risk free rate of return: 2.54% &amp;#8211; 2.82%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Expected term: 5.27 &amp;#8211; 5.88 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The following is a rollforward of the options outstanding and exercisable&#13;for the year ended March 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Average&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Exercise&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Average&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Remaining&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding and exercisable &amp;#8211; March 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 64%; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;918,020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding and exercisable &amp;#8211; March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;918,020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;The fair values of options at the grant&#13;date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of&#13;options as well as average volatility of three comparable organizations.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Common stock&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2017, pursuant to a Reorganization&#13;and Share Exchange Agreement, by and among, the Company and Quasuras Inc., the Company acquired one hundred percent (100%) of the&#13;issued and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary&#13;of the Company. The historical equity for Quasuras was restated pursuant to the reorganization.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has 50,000,000 shares of common&#13;stock authorized. The par value of the shares is $0.001. In April 2019 the Company issued 30,000 shares for services bringing the&#13;outstanding balance to 17,870,261 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has 5,000,000 shares of preferred&#13;stock authorized. The par value of the shares is $0.001. As of June 30, 2019, none of the shares of preferred stock of the Company&#13;were issued.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 19, 2017, the Board of Directors&#13;approved the 2017 Equity Incentive Plan (&amp;#8220;EIP&amp;#8221;) that reserves 3,000,000 shares of common stock of the Company to be&#13;issued. Under the Company&amp;#8217;s EIP, eligible employees, directors and consultants are granted options to purchase shares of&#13;common stock of the Company. The EIP is administered by the Company&amp;#8217;s Board of Directors or, in the alternative, if necessary,&#13;a committee designated by the Board of Directors, and has the sole power over the exercise of the EIP. The Board of Directors determines&#13;whether the EIP will allow for the issuance of shares of common stock or an option to purchase shares of common stock, such option&#13;designated as either an incentive stock option or a non-qualified stock option.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The exercise or purchase price shall be calculated&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 3%; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;(i)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;In the case of an incentive stock option, (A) granted to employees, directors and consultants who, at the time of the grant of such incentive stock option own stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company, the per share exercise price shall be not less than one hundred ten percent (110%) of the fair market value per share on the date of grant; or (B) granted to employees, directors and consultants other than to employees, directors and consultants described in the preceding clause, the per share exercise price shall be not less than one hundred percent (100%) of the fair market value per share on the date of grant;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 3%; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;In the case of a non-qualified stock option, the per share exercise price shall be not less than one hundred percent (100%) of the fair market value per share on the date of grant unless otherwise determined by the Board of Directors; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 3%; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;(iii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;In the case of other grants, such price as is determined by the Board of Directors. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Board of Directors are responsible for determining&#13;the consideration to be paid for the shares of common stock to be issued upon exercise or purchase. The EIP generally doesn&amp;#8217;t&#13;allow for the transfer of the options, and the Board of Directors may amend, suspend or terminate the EIP at any time.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 15, 2019, the Company granted 4,778&#13;options to a consultant, these options are fully vested on the grant date. The 4,778 options will expire on April 14, 2029. The&#13;fair value of the options 4,778 shares is determined to be $8,173, was accrued in professional expenses for the quarter ended June&#13;30, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following assumptions were used in the fair&#13;value method calculation:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Volatility: 101.85%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Risk free rate of return: 2.41%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expected term: 5 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"&gt;On April 15&lt;sup&gt;th&lt;/sup&gt; and May&#13;15&lt;sup&gt;th&lt;/sup&gt; 2019, the Company granted 8,908 options to a consultant, these options will be fully vested on the grant date.&#13;The 8,908 options will expire on April 14&lt;sup&gt;th&lt;/sup&gt; and May 14&lt;sup&gt;th&lt;/sup&gt;, 2029. The fair value of the options 8,908 shares&#13;is determined to be $15,000 was accrued in consulting expenses for the fiscal quarter ended June 30, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"&gt;The following assumptions were used&#13;in the fair value method calculation:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Volatility: 97 &amp;#8211; 102% &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Risk free rate of return: 2.15 &amp;#8211; 2.37%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Expected term: 5 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"&gt;On April 15&lt;sup&gt;th&lt;/sup&gt;, 2019, the&#13;Company granted 9,000 options to an employee, these options will be fully vested three years from the date granted. The 9,000 options&#13;will expire on April 14&lt;sup&gt;th&lt;/sup&gt;, 2029. The fair value of the options 9,000 shares is determined to be $16,258. During the&#13;quarter ended June 30, 2019, $447 was accrued monthly in general and administrative expenses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify"&gt;The following assumptions were used&#13;in the fair value method calculation:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Volatility: 101.85% &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Risk free rate of return: 2.41%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Expected term: 6.0 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 25, 2018, the Company granted 1,280,000&#13;options to certain consultants, these options are fully vested one year from the date granted. The 1,280,000 options will expire&#13;on August 31, 2019. The fair value of the options 1,280,000 shares is determined to be $682,240, was accrued monthly in research&#13;and development expenses for the fiscal quarter ended June 30, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following assumptions were used in the fair&#13;value method calculation:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Volatility: 110%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Risk free rate of return: 2.82%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Expected term: 5.27 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 16, 2019, the Company granted 185,221&#13;options to certain consultants, these options will be fully vested three years from the date granted. The 185,221 options will&#13;expire on January 15, 2029. The fair value of the options 185,221 shares is determined to be $336,732, was accrued monthly in general&#13;and administrative expenses for the fiscal quarter ended June 30, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following assumptions were used in the fair&#13;value method calculation:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Volatility: 104%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Risk free rate of return: 2.54%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Expected term: 5.88 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The relative fair value of each of the granted&#13;options set forth above has been calculated using the Black-Scholes-Merton pricing model, which, for each such option, is based&#13;on the granted strike price, the three month average trading volatility of three comparable companies (e.g., PODD, TNDM, VLRX),&#13;the five year, risk-free treasury bond interest rate on the applicable grant date and a weighted average term using the simplified&#13;method calculation. It outlines calculation methods for sbc.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The following is a rollforward of the options outstanding and exercisable&#13;for the fiscal quarter ended June 30, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Weighted &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Average&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Average &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Remaining&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 64%; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding and exercisable &amp;#8211; March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;918,020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;280,352&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.74&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding and exercisable &amp;#8211; June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,198,372&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Based on the available information and other&#13;factors, management believes it is more likely than not that the net deferred tax assets at, March 31, 2019 and 2018, will not&#13;be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets at, March&#13;31, 2019 and 2018. At March 31, 2019 and 2018, the Company had federal net operating loss carry-forwards of approximately $817,000&#13;and &amp;#160;$182,500, respectively, expiring beginning in 2037.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Deferred tax assets consist of the following components:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 51.9pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 76%; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Net loss carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;817,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;182,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(817,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(182,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Based on the available information and other&#13;factors, management believes it is more likely than not that the net deferred tax assets at, June 30, 2019 and March 31, 2019,&#13;will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets&#13;at June 30, 2019 and March 31, 2019. At June 30, 2019 and March 31, 2019, the Company had federal net operating loss carryforwards&#13;of approximately $1,098,000 and $817,000 respectively, expiring beginning in 2037.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Deferred tax assets consist of the following components:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 51.9pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 76%; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Net loss carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,098,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;817,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,098,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(817,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <MODD:RoyaltyAgreementDisclosureTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 12, 2017, the Company entered into a&#13;royalty agreement with the founder and major shareholder. Pursuant to the agreement, the founder and major shareholder is assigning&#13;and transferring all of his rights in the intellectual property in return for royalty payments. The Company shall pay royalty to&#13;the founder on any sales of the royalty product sold or otherwise commercialized by the Company, equal to (a) US $0.75 on each&#13;sale of a royalty product, or (b) five percent (5%) of the gross sale price of the royalty product, whichever is less. The royalty&#13;payments shall cease and this agreement shall terminate, at such time as the total sum of royalty payments actually paid to the&#13;founder, pursuant to this agreement, reaches $10,000,000. The Company shall have the option to terminate this agreement at any&#13;time upon payment, to the founder, of the difference between total royalty payments actually made to him to date and the sum of&#13;$10,000,000. All payments of the royalties, if due, for the preceding quarter, shall be made by the Company within thirty days&#13;after the calendar quarter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</MODD:RoyaltyAgreementDisclosureTextBlock>
    <MODD:RoyaltyAgreementDisclosureTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 12, 2017, the Company entered into a&#13;royalty agreement with the founder and major shareholder. Pursuant to the agreement, the founder and major shareholder is assigning&#13;and transferring all of his rights in the intellectual property in return for royalty payments. The Company shall pay royalty to&#13;the founder on any sales of the royalty product sold or otherwise commercialized by the Company, equal to (a) US $0.75 on each&#13;sale of a royalty product, or (b) five percent (5%) of the gross sale price of the royalty product, whichever is less. The royalty&#13;payments shall cease, and this agreement shall terminate, at such time as the total sum of royalty payments actually paid to the&#13;founder, pursuant to this agreement, reaches $10,000,000. The Company shall have the option to terminate this agreement at any&#13;time upon payment, to the founder, of the difference between total royalty payments actually made to him to date and the sum of&#13;$10,000,000. All payments of the royalties, if due, for the preceding quarter, shall be made by the Company within thirty days&#13;after the calendar quarter.&lt;/p&gt;</MODD:RoyaltyAgreementDisclosureTextBlock>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 21, 2017, the Company entered into&#13;a sublease agreement to rent office space. The term of the lease commences on September 1, 2017 and expires on December 14, 2019.&#13;The monthly rent for the lease is $3,000. For the remaining lease term, the rent balance is $27,000, $3,000 payable monthly. The&#13;Company paid a deposit of $7,500 upon execution of the lease which has been recorded as a security deposit in the accompanying&#13;consolidated financial statements.&amp;#160;&lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <MODD:ReorganizationPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2017, pursuant to a Reorganization&#13;and Share Exchange Agreement, by and among the Company and Quasuras, the Company acquired one hundred percent (100%) of the issued&#13;and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary&#13;of the Company. Since the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was&#13;accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the Reorganization,&#13;at their historical carrying amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the reorganization, the Company&#13;changed the fiscal year end from June 30 to March 31, to coincide with the year end for Quasuras.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements of the&#13;Company have been prepared in accordance with accounting principles generally accepted in the United States of America. The following&#13;summarizes the more significant of such policies:&lt;/p&gt;</MODD:ReorganizationPolicyTextBlock>
    <MODD:ReorganizationPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2017, pursuant to a Reorganization&#13;and Share Exchange Agreement, by and among the Company and Quasuras, the Company acquired one hundred percent (100%) of the issued&#13;and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary&#13;of the Company. Since the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was&#13;accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the Reorganization,&#13;at their historical carrying amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the reorganization, the Company&#13;changed the fiscal year end from June 30 to March 31, to coincide with the year end for Quasuras.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements of the&#13;Company have been prepared in accordance with accounting principles generally accepted in the United States of America. The following&#13;summarizes the more significant of such policies:&lt;/p&gt;</MODD:ReorganizationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the consolidated financial&#13;statements in conformity with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates&#13;and assumptions that affect reported amounts and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the consolidated financial&#13;statements in conformity with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates&#13;and assumptions that affect reported amounts and related disclosures.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements include&#13;the accounts of Modular Medical, Inc. and its wholly-owned subsidiary Quasuras, Inc., and are collectively referred to as the &amp;#8220;Company&amp;#8221;.&#13;All material intercompany accounts, transactions and profits were eliminated in consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements include&#13;the accounts of Modular Medical, Inc. and its wholly-owned subsidiary Quasuras, Inc., and are collectively referred to as the &amp;#8220;Company&amp;#8221;.&#13;All material intercompany accounts, transactions and profits were eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the accompanying financial&#13;statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets&#13;and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the&#13;reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:UseOfEstimates contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the accompanying financial&#13;statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets&#13;and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the&#13;reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has one reportable segment. The&#13;Company&amp;#8217;s activities are interrelated and each activity is dependent upon and supportive of the other. Accordingly, all significant&#13;operating decisions are based on analysis of financial products provided as a single global business.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has one reportable segment. The&#13;Company&amp;#8217;s activities are interrelated and each activity is dependent upon and supportive of the other. Accordingly, all significant&#13;operating decisions are based on analysis of financial products provided as a single global business.&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <MODD:ProfessionalFeesPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses the cost of legal, accounting,&#13;audit, tax and other professional services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</MODD:ProfessionalFeesPolicyTextBlock>
    <MODD:ProfessionalFeesPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses the cost of legal, accounting,&#13;audit, tax and other professional services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</MODD:ProfessionalFeesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses the cost of research and&#13;development as incurred. Research and development costs charged to operations were approximately $ 1,882,345 and $332,642 for the&#13;fiscal year ended March 31, 2019 and 2018, respectively.&amp;#9; &amp;#9; &amp;#9;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses the cost of research and&#13;development as incurred. Research and development costs charged to operations were approximately $703,783 and $135,789 for the&#13;fiscal quarter ended June 30, 2019 and 2018, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;General and administrative expense consists&#13;primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and meetings and travel.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;General and administrative expense consists&#13;primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and meetings and travel.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company utilizes Financial Accounting Standards&#13;Board (FASB) Accounting Standards Codification (ASC) Topic 740, Income Taxes, which requires recognition of deferred tax assets&#13;and liabilities for the expected future tax consequences of events that were included in the consolidated financial statements&#13;or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences&#13;between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws&#13;and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances&#13;are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for uncertain tax positions&#13;in accordance with FASB ASC Topic 740. When tax returns are filed, it is likely that some positions taken would be sustained upon&#13;examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount&#13;of the position that would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements&#13;in the period during which, based on all available evidence, management believes it is more likely than not that the position will&#13;be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not&#13;offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured&#13;as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable&#13;taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described&#13;above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any&#13;associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized&#13;tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in&#13;the consolidated statements of income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2019 and 2018, the Company had&#13;not taken any significant uncertain tax positions on its tax returns for periods ended March 31, 2019 and prior years or in computing&#13;its tax provision for 2019. Management has considered its tax positions and believes that all of the positions taken by the Company&#13;in its Federal and State tax returns are more likely than not to be sustained upon examination. The Company is subject to examination&#13;by U.S. Federal and State tax authorities for the period ended March 31, 2016 to the present, generally for three years after they&#13;are filed.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company utilizes Financial Accounting Standards&#13;Board (FASB) Accounting Standards Codification (ASC) Topic 740, Income Taxes, which requires recognition of deferred tax assets&#13;and liabilities for the expected future tax consequences of events that were included in the consolidated financial statements&#13;or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences&#13;between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws&#13;and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances&#13;are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for uncertain tax positions&#13;in accordance with FASB ASC Topic 740. When tax returns are filed, it is likely that some positions taken would be sustained upon&#13;examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount&#13;of the position that would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements&#13;in the period during which, based on all available evidence, management believes it is more likely than not that the position will&#13;be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not&#13;offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured&#13;as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable&#13;taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described&#13;above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any&#13;associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized&#13;tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in&#13;the consolidated statements of income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At June 30, 2019 and 2018, the Company had not&#13;taken any significant uncertain tax positions on its tax returns for periods ended June 30, 2019 and prior years or in computing&#13;its tax provision for 2019. Management has considered its tax positions and believes that all of the positions taken by the Company&#13;in its Federal and State tax returns are more likely than not to be sustained upon examination. The Company is subject to examination&#13;by U.S. Federal and State tax authorities for the period ended March 31, 2017 to the present, generally for three years after they&#13;are filed.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject&#13;the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company maintains cash balances&#13;at financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to&#13;limits of approximately $250,000. The Company has not experienced any losses with regard to its bank accounts and believes it is&#13;not exposed to any risk of loss on its cash bank accounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject&#13;the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company maintains cash balances&#13;at financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to&#13;limits of approximately $250,000. The Company has not experienced any losses with regard to its bank accounts and believes it is&#13;not exposed to any risk of loss on its cash bank accounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <MODD:RisksAndUncertaintiesPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is subject to risks from, among&#13;other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements,&#13;rapidly changing customer requirements, limited operating history and the volatility of public markets.&lt;/p&gt;</MODD:RisksAndUncertaintiesPolicyTextBlock>
    <MODD:RisksAndUncertaintiesPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is subject to risks from, among&#13;other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements,&#13;rapidly changing customer requirements, limited operating history and the volatility of public markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</MODD:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain conditions may exist as of the date&#13;the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when&#13;one or more future events occur or fail to occur. The Company&amp;#8217;s management and legal counsel assess such contingent liabilities,&#13;and such assessment inherently involves judgment. In assessing loss contingencies related to legal proceedings that are pending&#13;against the Company or unasserted claims that may result in such proceedings, the Company&amp;#8217;s legal counsel evaluates the perceived&#13;merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected&#13;to be sought.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the assessment of a contingency indicates&#13;it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability&#13;would be accrued in the Company&amp;#8217;s consolidated financial statements. If the assessment indicates that a potential material&#13;loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent&#13;liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies&#13;considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would&#13;be disclosed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain conditions may exist as of the date&#13;the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when&#13;one or more future events occur or fail to occur. The Company&amp;#8217;s management and legal counsel assess such contingent liabilities,&#13;and such assessment inherently involves judgment. In assessing loss contingencies related to legal proceedings that are pending&#13;against the Company or unasserted claims that may result in such proceedings, the Company&amp;#8217;s legal counsel evaluates the perceived&#13;merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected&#13;to be sought.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the assessment of a contingency indicates&#13;it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability&#13;would be accrued in the Company&amp;#8217;s consolidated financial statements. If the assessment indicates that a potential material&#13;loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent&#13;liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies&#13;considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would&#13;be disclosed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents include cash in hand&#13;and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months&#13;or less. At March 31, 2019 and March 31, 2018, the Company had $6,553,768 and $4,296,676, respectively, in cash. Deposits at the&#13;bank are insured up to $250,000 by the Federal Deposit Insurance Corporation. The Company&amp;#8217;s uninsured portion of the balances&#13;held at the bank aggregated to approximately $6,269,116 &amp;#160;and $3,933,002, respectively. No reserve has been made in the financial&#13;statements for any possible loss due to any financial institution failure.&amp;#160;The Company has not experienced any losses in such&#13;accounts and believes we are not exposed to any significant risk on cash and cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents include cash in hand&#13;and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months&#13;or less. At June 30, 2019 and March 31, 2019, the Company had $5,706,628 and $6,553,768, respectively, in cash. Deposits at the&#13;bank are insured up to $250,000 by the Federal Deposit Insurance Corporation. The Company&amp;#8217;s uninsured portion of the balances&#13;held at the bank aggregated to approximately $5,421,940 and $6,269,116 respectively. No reserve has been made in the financial&#13;statements for any possible loss due to any financial institution failure.&amp;#160;The Company has not experienced any losses in such&#13;accounts and believes we are not exposed to any significant risk on cash and cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For certain of the Company&amp;#8217;s financial&#13;instruments, including cash and equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair&#13;values due to their short maturities. ASC Topic 820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; requires disclosure&#13;of the fair value of financial instruments held by the Company. ASC Topic 825, &amp;#8220;Financial Instruments,&amp;#8221; defines fair&#13;value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements&#13;for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities&#13;each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between&#13;the origination of such instruments and their expected realization and their current market rate of interest. The three levels&#13;of valuation hierarchy are defined as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 inputs to the valuation methodology&#13;are quoted prices for identical assets or liabilities in active markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 inputs to the valuation methodology&#13;include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability,&#13;either directly or indirectly, for substantially the full term of the financial instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 inputs to the valuation methodology&#13;are unobservable and significant to the fair value measurement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to their short-term nature, the carrying&#13;values of cash and equivalents, accounts receivable, accounts payable, and accrued expenses, approximate fair value. Based on borrowing&#13;rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair&#13;value.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For certain of the Company&amp;#8217;s financial&#13;instruments, including cash and equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair&#13;values due to their short maturities. ASC Topic 820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; requires disclosure&#13;of the fair value of financial instruments held by the Company. ASC Topic 825, &amp;#8220;Financial Instruments,&amp;#8221; defines fair&#13;value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements&#13;for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities&#13;each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between&#13;the origination of such instruments and their expected realization and their current market rate of interest. The three levels&#13;of valuation hierarchy are defined as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 inputs to the valuation methodology&#13;are quoted prices for identical assets or liabilities in active markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 inputs to the valuation methodology&#13;include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability,&#13;either directly or indirectly, for substantially the full term of the financial instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 inputs to the valuation methodology&#13;are unobservable and significant to the fair value measurement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to their short-term nature, the carrying&#13;values of cash and equivalents, accounts receivable, accounts payable, and accrued expenses, approximate fair value. Based on borrowing&#13;rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair&#13;value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number&#13;of outstanding common shares during the period. Diluted earnings per share are computed by dividing net income by the weighted&#13;average number of shares outstanding during the period increased to include the number of additional shares of common stock&#13;that would have been outstanding if the potentially dilutive securities had been issued. During the fiscal years ended March&#13;31, 2019 and 2018 we incurred losses. Therefore, the effects of any common stock equivalent were antidilutive during those&#13;periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets for the computation&#13;of basic and diluted earnings per share for the fiscal years ended March 31, 2019 and 2018:&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 76%; padding-bottom: 2.5pt; padding-left: 34.6pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,539,498&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(659,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Basic and Diluted:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted average number of shares used in computing basic and diluted net loss per share:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-align: right; text-indent: -8.65pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,589,633&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,336,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,589,633&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,336,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic earnings per share are computed by dividing&#13;earnings available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted&#13;earnings per share are computed by dividing net income by the weighted average number of shares outstanding during the period increased&#13;to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities&#13;had been issued. During the fiscal quarter ended June 30, 2019 and 2018 we incurred losses. Therefore, the effects of any common&#13;stock equivalent were anti-dilutive during those periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets for the computation&#13;of basic and diluted earnings per share for the fiscal quarters ended June 30, 2019 and June 30, 2018:&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;(UNAUDITED)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;(UNAUDITED)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="width: 76%; padding-bottom: 2.5pt; padding-left: 17.3pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,122,198&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(249,566&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Basic and Diluted:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted average number of shares used in computing basic and diluted net loss &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;per share:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,847,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,983,273&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,847,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,983,273&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the FASB issued ASU 2014-09,&amp;#160;&lt;i&gt;Revenue&#13;from Contracts with Customers&lt;/i&gt;, issued as a new Topic, ASC Topic 606. The new revenue recognition standard supersedes all existing&#13;revenue recognition guidance. Under this ASU, an entity should recognize revenue when it transfers promised goods or services to&#13;customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or&#13;services. ASU 2015-14, issued in August 2015, deferred the effective date of ASU 2014-09 to the first quarter of 2018, with early&#13;adoption permitted in the first quarter of 2018. The company has adopted the new standard utilizing the modified retrospective&#13;approach. The adoption of this new accounting guidance does not have material effects on results of operations, cash flows and&#13;financial position for the forceable future because the company does not have revenues.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2016, The FASB issued ASU No. 2016-01,&lt;i&gt;&amp;#160;Financial&#13;Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825)&lt;/i&gt;. ASU No. 2016-01 revises&#13;the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes&#13;for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments&#13;to be recognized in net income. For non-public companies, ASU 2016-01 is effective for fiscal years beginning after December 15,&#13;2018, and interim periods within fiscal years beginning after December 15, 2019. We are currently evaluating the impact of the&#13;adoption of ASU 2016-01 will have on our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2016, the FASB issued ASU No. 2016-15,&#13;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This update addresses a diversity&#13;in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic&#13;230, Statement of Cash Flows, and other Topics. The amendments in this Update are effective for public business entities for fiscal&#13;years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including&#13;adoption in an interim period. We adopted this ASU in 2016 and the implementation did not have a material impact on our financial&#13;position or statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2018, the FASB issued guidance that&#13;eases certain documentation and assessment requirements of hedge effectiveness and modifies the accounting for components excluded&#13;from the assessment. Some of the modifications include the ineffectiveness of derivative gain/loss in highly effective cash flow&#13;hedge to be recorded in other comprehensive income, the change in fair value of derivative to be recorded in the same income statement&#13;line as hedged item, and additional disclosures required on the cumulative basis adjustment in fair value hedges and the effect&#13;of hedging on financial statement lines for components excluded from the assessment. The amendment also simplifies the application&#13;of hedge accounting in certain situations to permit new hedging strategies to be eligible for hedge accounting. The guidance is&#13;effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2018,&#13;our fiscal 2020. Early adoption is permitted and the modified retrospective transition method should be applied. We do not expect&#13;the adoption of this guidance to have a material impact on our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, FASB issued ASU No. 2016-02,&#13;Leases (&amp;#8220;Topic 842&amp;#8221;). Topic 842 requires an entity to recognize right-of -use assets and lease liability on its balance&#13;sheet and disclosure key information about leasing arrangements. For public companies, Topic 842 is effective for annual reporting&#13;periods beginning after December 15, 2018, including interim periods within that reporting period, with early adoption permitted.&#13;We have evaluated this ASU and believe this guidance will not have a material impact on our financial position and statement of&#13;operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other recent accounting pronouncements issued&#13;by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities&#13;and Exchange Commission did not or are not believed by management to have a material impact on the Company&amp;#8217;s present or future&#13;consolidated financial statements.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify"&gt;In May 2014, the FASB issued ASU 2014-09,&amp;#160;&lt;i&gt;Revenue&#13;from Contracts with Customers&lt;/i&gt;, issued as a new Topic, ASC Topic 606. The new revenue recognition standard supersedes all existing&#13;revenue recognition guidance. Under this ASU, an entity should recognize revenue when it transfers promised goods or services to&#13;customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or&#13;services. ASU 2015-14, issued in August 2015, deferred the effective date of ASU 2014-09 to the first quarter of 2018, with early&#13;adoption permitted in the first quarter of 2018. The company has adopted the new standard utilizing the modified retrospective&#13;approach. The adoption of this new accounting guidance does not have material effects on results of operations, cash flows and&#13;financial position for the forceable future because the company does not have revenues.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2016, The FASB issued ASU No. 2016-01,&lt;i&gt;&amp;#160;Financial&#13;Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825)&lt;/i&gt;. ASU No. 2016-01 revises&#13;the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes&#13;for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments&#13;to be recognized in net income. For non-public companies, ASU 2016-01 is effective for fiscal years beginning after December 15,&#13;2018, and interim periods within fiscal years beginning after December 15, 2019. We are currently evaluating the impact of the&#13;adoption of ASU 2016-01 will have on our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2016, the FASB issued ASU No. 2016-15,&#13;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This update addresses a diversity&#13;in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic&#13;230, Statement of Cash Flows, and other Topics. The amendments in this Update are effective for public business entities for fiscal&#13;years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including&#13;adoption in an interim period. We adopted this ASU in 2016 and the implementation did not have a material impact on our financial&#13;position or statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2018, the FASB issued guidance that&#13;eases certain documentation and assessment requirements of hedge effectiveness and modifies the accounting for components excluded&#13;from the assessment. Some of the modifications include the ineffectiveness of derivative gain/loss in highly effective cash flow&#13;hedge to be recorded in other comprehensive income, the change in fair value of derivative to be recorded in the same income statement&#13;line as hedged item, and additional disclosures required on the cumulative basis adjustment in fair value hedges and the effect&#13;of hedging on financial statement lines for components excluded from the assessment. The amendment also simplifies the application&#13;of hedge accounting in certain situations to permit new hedging strategies to be eligible for hedge accounting. The guidance is&#13;effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2018,&#13;our fiscal 2020. Early adoption is permitted, and the modified retrospective transition method should be applied. We do not expect&#13;the adoption of this guidance to have a material impact on our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, FASB issued ASU No. 2016-02,&#13;Leases (&amp;#8220;Topic 842&amp;#8221;). Topic 842 requires an entity to recognize right-of -use assets and lease liability on its balance&#13;sheet and disclosure key information about leasing arrangements. For public companies, Topic 842 is effective for annual reporting&#13;periods beginning after December 15, 2018, including interim periods within that reporting period, with early adoption permitted.&#13;We have evaluated this ASU and believe this guidance will not have a material impact on our financial position and statement of&#13;operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other recent accounting pronouncements issued&#13;by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities&#13;and Exchange Commission did not or are not believed by management to have a material impact on the Company&amp;#8217;s present or future&#13;consolidated financial statements.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:Reclassifications contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior year amounts have been reclassified&#13;for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations&#13;or cash flow.&lt;/p&gt;</us-gaap:Reclassifications>
    <us-gaap:Reclassifications contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior year amounts have been reclassified&#13;for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations&#13;or cash flow.&lt;/p&gt;</us-gaap:Reclassifications>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2018-04-01to2019-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 76%; padding-bottom: 2.5pt; padding-left: 34.6pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,539,498&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(659,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Basic and Diluted:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted average number of shares used in computing basic and diluted net loss per share:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-align: right; text-indent: -8.65pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,589,633&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,336,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,589,633&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,336,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2019-04-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;(UNAUDITED)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;(UNAUDITED)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="width: 76%; padding-bottom: 2.5pt; padding-left: 17.3pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,122,198&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(249,566&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Basic and Diluted:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(0.02&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted average number of shares used in computing basic and diluted net loss &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;per share:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Basic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,847,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,983,273&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,847,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,983,273&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2018-04-01to2019-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Average&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Exercise&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Average&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Remaining&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding and exercisable &amp;#8211; March 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 64%; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;918,020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding and exercisable &amp;#8211; March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;918,020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2019-04-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Weighted &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Average&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Average &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Remaining&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;Life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 64%; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding and exercisable &amp;#8211; March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;918,020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;280,352&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.74&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding and exercisable &amp;#8211; June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,198,372&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;0.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2018-04-01to2019-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 76%; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Net loss carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;817,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;182,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(817,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(182,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2019-04-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 76%; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Net loss carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,098,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;817,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt"&gt;&lt;font style="font-size: 8pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,098,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(817,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">817000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">182500</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">1098000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">918020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-03-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">1198372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2018-04-01to2019-03-31" unitRef="Shares" decimals="INF">918020</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2019-04-01to2019-06-30" unitRef="Shares" decimals="INF">280352</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2018-04-01to2019-03-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2019-04-01to2019-06-30" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2018-04-01to2019-03-31" unitRef="USDPShares" decimals="INF">.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2019-04-01to2019-06-30" unitRef="USDPShares" decimals="INF">0.74</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2018-04-01to2019-03-31" unitRef="USDPShares" decimals="INF">.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2019-04-01to2019-06-30" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-03-31" unitRef="USDPShares" decimals="INF">.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-03-31" unitRef="USDPShares" decimals="INF">.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-06-30" unitRef="USDPShares" decimals="INF">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2018-04-01to2019-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment is stated at cost and&#13;depreciated using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. The estimated&#13;useful lives of our property and equipment are generally as follows: computer equipment &amp;#38; software developed or acquired for&#13;internal use, three to ten years; office equipment, two to three years; buildings and improvements, five to fifteen years; leasehold&#13;improvements, two to ten years; and machinery and equipment, one to five years.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;As of March 31, 2019 and March 31, 2018, property, plant and equipment&#13;amounted to:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Computer equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,565&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,103&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;49,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,937&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(16,278&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,844&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,948&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,259&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Depreciation expenses for the year ended March 31, 2019 and 2018&#13;was $14,435 &amp;#160;and $1,844, respectively.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2019-04-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment is stated at cost and&#13;depreciated using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. The estimated&#13;useful lives of our property and equipment are generally as follows: computer equipment&amp;#38; software developed or acquired for&#13;internal use, three to ten years; office equipment, two to three years; buildings and improvements, five to fifteen years; leasehold&#13;improvements, two to ten years; and machinery and equipment, one to five years.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;As of June 30, 2019 and March 31, 2019, property, plant and equipment&#13;amounted to:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;(UNAUDITED)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Computer equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,565&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;49,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;49,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,194&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,937&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(22,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(16,278&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,961&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,948&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Depreciation expenses for the quarter ended June 30, 2019 and March&#13;31, 2019 was $6,707 and $1,387 respectively.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2018-04-01to2019-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;March 31,&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Computer equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,565&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,103&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;49,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,937&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(16,278&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1,844&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,948&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,259&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2019-04-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;(UNAUDITED)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 76%"&gt;&lt;font style="font-size: 8pt"&gt;Computer equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,565&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;49,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;49,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,194&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,937&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(22,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(16,278&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,961&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,948&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">163974</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2017-04-01to2018-03-31" unitRef="USD" decimals="0">-109748</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">74545</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="0">1704</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2018-04-01to2019-03-31">P9Y5M5D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2019-04-01to2019-06-30">P5Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-04-01to2019-06-30">P9Y5M5D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <dei:EntityRegistrantName contextRef="From2019-04-01to2019-06-30">Modular Medical, Inc.</dei:EntityRegistrantName>
    <dei:DocumentType contextRef="From2019-04-01to2019-06-30">S-1/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2019-04-01to2019-06-30">2019-06-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2019-04-01to2019-06-30">true</dei:AmendmentFlag>
    <dei:AmendmentDescription contextRef="From2019-04-01to2019-06-30">To update financials.</dei:AmendmentDescription>
    <dei:EntityCentralIndexKey contextRef="From2019-04-01to2019-06-30">0001074871</dei:EntityCentralIndexKey>
    <dei:EntityFilerCategory contextRef="From2019-04-01to2019-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2019-04-01to2019-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-04-01to2019-06-30">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2018-04-01to2019-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Grantees&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Option&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Vesting &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Periods&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total Fair &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Value of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2019 Stock-Based &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Compensation &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Expense&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Unrecognized &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;expense at &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap; width: 28%"&gt;&lt;font style="font-size: 8pt"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,280,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 22%"&gt;&lt;font style="font-size: 8pt"&gt;July 25, 2018 to July 24, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;682,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;466,197&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;216,043&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;185,221&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;January&amp;#160;&amp;#160;16, 2019 to January 15, 2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;336,732&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,150&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;313,582&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEECC"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Chief Executive Officer&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;64,687&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;*&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,761&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,761&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,529,908&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,021,733&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;532,108&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;489,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;* Options were fully vested as of the grant date, as disclosed above.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2018-04-01to2019-03-31" unitRef="Shares" decimals="INF">1529908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2018-04-01to2019-03-31_custom_Consultants1Member" unitRef="Shares" decimals="INF">1280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2018-04-01to2019-03-31_custom_Consultants2Member" unitRef="Shares" decimals="INF">185221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2018-04-01to2019-03-31_srt_ChiefExecutiveOfficerMember" unitRef="Shares" decimals="INF">64687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <MODD:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod contextRef="From2018-04-01to2019-03-31_custom_Consultants1Member">July 25, 2018 to July 24, 2019</MODD:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <MODD:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod contextRef="From2018-04-01to2019-03-31_custom_Consultants2Member">January  16, 2019 to January 15, 2022&#9; </MODD:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <MODD:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod contextRef="From2018-04-01to2019-03-31_srt_ChiefExecutiveOfficerMember">Options were fully vested as of the grant date, as disclosed above.</MODD:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">1021733</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2018-04-01to2019-03-31_custom_Consultants1Member" unitRef="USD" decimals="0">682240</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2018-04-01to2019-03-31_custom_Consultants2Member" unitRef="USD" decimals="0">336732</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2018-04-01to2019-03-31_srt_ChiefExecutiveOfficerMember" unitRef="USD" decimals="0">42761</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">489625</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2019-03-31_custom_Consultants1Member" unitRef="USD" decimals="0">216043</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2019-03-31_custom_Consultants2Member" unitRef="USD" decimals="0">313582</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2019-03-31_srt_ChiefExecutiveOfficerMember" unitRef="USD" decimals="0">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>26
<FILENAME>modd-20190630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 73903 06302019 S1A.xfr; Date: 2019%2D09%2D09T13:17:07Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6kps7xRiXgen8uKYXQsSaSNKaPtxZp8iZlBuWpybVl63yYuF6h6ESRypv0mwXUE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:MODD="http://modular-medical.com/20190630" elementFormDefault="qualified" targetNamespace="http://modular-medical.com/20190630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://modular-medical.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementOfStockholdersEquity" id="StatementOfStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ReorganizationAndPrivatePlacement" id="ReorganizationAndPrivatePlacement">
	  <link:definition>00000008 - Disclosure - REORGANIZATION AND PRIVATE PLACEMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/AccruedExpenses" id="AccruedExpenses">
	  <link:definition>00000009 - Disclosure - ACCRUED EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PayableToRelatedParty" id="PayableToRelatedParty">
	  <link:definition>00000010 - Disclosure - PAYABLE TO RELATED PARTY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000011 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000012 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RoyaltyAgreement" id="RoyaltyAgreement">
	  <link:definition>00000013 - Disclosure - ROYALTY AGREEMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/LeaseAgreement" id="LeaseAgreement">
	  <link:definition>00000014 - Disclosure - LEASE AGREEMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="OrganizationAndSummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000017 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000018 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1">
	  <link:definition>00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/AccruedExpensesDetailsNarrative" id="AccruedExpensesDetailsNarrative">
	  <link:definition>00000022 - Disclosure - ACCRUED EXPENSES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PayableToRelatedPartyDetailsNarrative" id="PayableToRelatedPartyDetailsNarrative">
	  <link:definition>00000023 - Disclosure - PAYABLE TO RELATED PARTY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000024 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
	  <link:definition>00000025 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000026 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000027 - Disclosure - INCOME TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000028 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <element id="MODD_ReorganizationAndPrivatePlacementDisclosureTextBlock" name="ReorganizationAndPrivatePlacementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_RoyaltyAgreementDisclosureTextBlock" name="RoyaltyAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_ReorganizationPolicyTextBlock" name="ReorganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_ProfessionalFeesPolicyTextBlock" name="ProfessionalFeesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_LegalAndProfessionalChargeMember" name="LegalAndProfessionalChargeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_CommonStockIssuableMember" name="CommonStockIssuableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_Consultants1Member" name="Consultants1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_Consultants2Member" name="Consultants2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_ReorganizationAndPrivatePlacementAbstract" name="ReorganizationAndPrivatePlacementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MODD_RoyaltyAgreementAbstract" name="RoyaltyAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>27
<FILENAME>modd-20190630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 73903 06302019 S1A.xfr; Date: 2019%2D09%2D09T13:17:07Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/DocumentAndEntityInformation" xlink:href="modd-20190630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20190630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20190630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20190630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementOfStockholdersEquity" xlink:href="modd-20190630.xsd#StatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20190630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ReorganizationAndPrivatePlacement" xlink:href="modd-20190630.xsd#ReorganizationAndPrivatePlacement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/AccruedExpenses" xlink:href="modd-20190630.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PayableToRelatedParty" xlink:href="modd-20190630.xsd#PayableToRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquity" xlink:href="modd-20190630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20190630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20190630.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeaseAgreement" xlink:href="modd-20190630.xsd#LeaseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityTables" xlink:href="modd-20190630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesTables" xlink:href="modd-20190630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/AccruedExpensesDetailsNarrative" xlink:href="modd-20190630.xsd#AccruedExpensesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PayableToRelatedPartyDetailsNarrative" xlink:href="modd-20190630.xsd#PayableToRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetails" xlink:href="modd-20190630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetails1" xlink:href="modd-20190630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:href="modd-20190630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails" xlink:href="modd-20190630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:href="modd-20190630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ReorganizationAndPrivatePlacement" xlink:title="00000008 - Disclosure - REORGANIZATION AND PRIVATE PLACEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/AccruedExpenses" xlink:title="00000009 - Disclosure - ACCRUED EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PayableToRelatedParty" xlink:title="00000010 - Disclosure - PAYABLE TO RELATED PARTY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquity" xlink:title="00000011 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000013 - Disclosure - ROYALTY AGREEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeaseAgreement" xlink:title="00000014 - Disclosure - LEASE AGREEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityTables" xlink:title="00000017 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesTables" xlink:title="00000018 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/AccruedExpensesDetailsNarrative" xlink:title="00000022 - Disclosure - ACCRUED EXPENSES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PayableToRelatedPartyDetailsNarrative" xlink:title="00000023 - Disclosure - PAYABLE TO RELATED PARTY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetails" xlink:title="00000024 - Disclosure - STOCKHOLDERS' EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetails1" xlink:title="00000025 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000026 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails" xlink:title="00000027 - Disclosure - INCOME TAXES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000028 - Disclosure - INCOME TAXES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>28
<FILENAME>modd-20190630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 73903 06302019 S1A.xfr; Date: 2019%2D09%2D09T13:17:07Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/DocumentAndEntityInformation" xlink:href="modd-20190630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20190630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20190630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20190630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementOfStockholdersEquity" xlink:href="modd-20190630.xsd#StatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20190630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ReorganizationAndPrivatePlacement" xlink:href="modd-20190630.xsd#ReorganizationAndPrivatePlacement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/AccruedExpenses" xlink:href="modd-20190630.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PayableToRelatedParty" xlink:href="modd-20190630.xsd#PayableToRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquity" xlink:href="modd-20190630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20190630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20190630.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeaseAgreement" xlink:href="modd-20190630.xsd#LeaseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityTables" xlink:href="modd-20190630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesTables" xlink:href="modd-20190630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/AccruedExpensesDetailsNarrative" xlink:href="modd-20190630.xsd#AccruedExpensesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PayableToRelatedPartyDetailsNarrative" xlink:href="modd-20190630.xsd#PayableToRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetails" xlink:href="modd-20190630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetails1" xlink:href="modd-20190630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:href="modd-20190630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails" xlink:href="modd-20190630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:href="modd-20190630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_CommonStockIssuableMember" xlink:label="loc_MODDCommonStockIssuableMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MODDCommonStockIssuableMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ReorganizationAndPrivatePlacement" xlink:title="00000008 - Disclosure - REORGANIZATION AND PRIVATE PLACEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/AccruedExpenses" xlink:title="00000009 - Disclosure - ACCRUED EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PayableToRelatedParty" xlink:title="00000010 - Disclosure - PAYABLE TO RELATED PARTY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquity" xlink:title="00000011 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000013 - Disclosure - ROYALTY AGREEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeaseAgreement" xlink:title="00000014 - Disclosure - LEASE AGREEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityTables" xlink:title="00000017 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesTables" xlink:title="00000018 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="loc_us-gaapTechnologyEquipmentMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapTechnologyEquipmentMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaapBuildingAndBuildingImprovementsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingAndBuildingImprovementsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_280" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_280" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation_280" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/AccruedExpensesDetailsNarrative" xlink:title="00000022 - Disclosure - ACCRUED EXPENSES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PayableToRelatedPartyDetailsNarrative" xlink:title="00000023 - Disclosure - PAYABLE TO RELATED PARTY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetails" xlink:title="00000024 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_Consultants1Member" xlink:label="loc_MODDConsultants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MODDConsultants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_Consultants2Member" xlink:label="loc_MODDConsultants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MODDConsultants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="loc_MODDShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MODDShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetails1" xlink:title="00000025 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000026 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails" xlink:title="00000027 - Disclosure - INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000028 - Disclosure - INCOME TAXES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>29
<FILENAME>modd-20190630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 73903 06302019 S1A.xfr; Date: 2019%2D09%2D09T13:17:07Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment and software</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US">Buildings and improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_CommonStockIssuableMember" xlink:label="MODD_CommonStockIssuableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_CommonStockIssuableMember" xlink:to="MODD_CommonStockIssuableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_CommonStockIssuableMember_lbl" xml:lang="en-US">Common Stock Issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Computer software developed or acquired for internal use</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TechnologyEquipmentMember_lbl" xml:lang="en-US">Computer equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_Consultants1Member" xlink:label="MODD_Consultants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_Consultants1Member" xlink:to="MODD_Consultants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_Consultants1Member_lbl" xml:lang="en-US">Consultants</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_Consultants2Member" xlink:label="MODD_Consultants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_Consultants2Member" xlink:to="MODD_Consultants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MODD_Consultants2Member_lbl" xml:lang="en-US">Consultants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_DocumentAndEntityInformationAbstract" xlink:label="MODD_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_DocumentAndEntityInformationAbstract" xlink:to="MODD_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Payable to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" xml:lang="en-US">Common stock issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administration expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss From Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expenses):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss Before Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares used in computing basic and diluted net loss per share:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Reverse capitalization, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Reverse capitalization, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued for cash, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issuable for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss for the fiscal year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Shares for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xml:lang="en-US">Increase/Decrease in current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Decrease in current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment to related party, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents, at the beginning of the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents, at the end of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid during the year for income tax payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the year for interest payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_ReorganizationAndPrivatePlacementAbstract" xlink:label="MODD_ReorganizationAndPrivatePlacementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_ReorganizationAndPrivatePlacementAbstract" xlink:to="MODD_ReorganizationAndPrivatePlacementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_ReorganizationAndPrivatePlacementAbstract_lbl" xml:lang="en-US">Reorganization And Private Placement</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_ReorganizationAndPrivatePlacementDisclosureTextBlock" xlink:label="MODD_ReorganizationAndPrivatePlacementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_ReorganizationAndPrivatePlacementDisclosureTextBlock" xlink:to="MODD_ReorganizationAndPrivatePlacementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_ReorganizationAndPrivatePlacementDisclosureTextBlock_lbl" xml:lang="en-US">REORGANIZATION AND PRIVATE PLACEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">PAYABLE TO RELATED PARTY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_RoyaltyAgreementAbstract" xlink:label="MODD_RoyaltyAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_RoyaltyAgreementAbstract" xlink:to="MODD_RoyaltyAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_RoyaltyAgreementAbstract_lbl" xml:lang="en-US">Royalty Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_RoyaltyAgreementDisclosureTextBlock" xlink:label="MODD_RoyaltyAgreementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_RoyaltyAgreementDisclosureTextBlock" xlink:to="MODD_RoyaltyAgreementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US">ROYALTY AGREEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASE AGREEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_ReorganizationPolicyTextBlock" xlink:label="MODD_ReorganizationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_ReorganizationPolicyTextBlock" xlink:to="MODD_ReorganizationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_ReorganizationPolicyTextBlock_lbl" xml:lang="en-US">Reorganization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Reportable Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_ProfessionalFeesPolicyTextBlock" xlink:label="MODD_ProfessionalFeesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_ProfessionalFeesPolicyTextBlock" xlink:to="MODD_ProfessionalFeesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_ProfessionalFeesPolicyTextBlock_lbl" xml:lang="en-US">Professional Fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_RisksAndUncertaintiesPolicyTextBlock" xlink:label="MODD_RisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_RisksAndUncertaintiesPolicyTextBlock" xlink:to="MODD_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant &amp; Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instrument</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share ("EPS")</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Reclassifications" xlink:label="us-gaap_Reclassifications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Reclassifications" xlink:to="us-gaap_Reclassifications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Reclassifications_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Summary of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_2_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Uninsured cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option shares</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:to="MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US">Vesting periods</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">Total fair value of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding and exercisable, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding and exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price outstanding and exercisable, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average exercise price vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price outstanding and exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Average remaining life outstanding and exercisable, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Average remaining life outstanding and exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry-forwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MODD_Consultants2Member" xlink:to="MODD_Consultants2Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MODD_Consultants2Member_2_lbl" xml:lang="en-US">Consultants2Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_2_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_2_lbl" xml:lang="en-US">Common Stock, Value, Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_2_lbl" xml:lang="en-US">Common Stock, Share Subscribed but Unissued, Subscriptions Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Repayments of Related Party Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>30
<FILENAME>modd-20190630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 73903 06302019 S1A.xfr; Date: 2019%2D09%2D09T13:17:07Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/DocumentAndEntityInformation" xlink:href="modd-20190630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20190630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20190630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20190630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementOfStockholdersEquity" xlink:href="modd-20190630.xsd#StatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20190630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ReorganizationAndPrivatePlacement" xlink:href="modd-20190630.xsd#ReorganizationAndPrivatePlacement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/AccruedExpenses" xlink:href="modd-20190630.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PayableToRelatedParty" xlink:href="modd-20190630.xsd#PayableToRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquity" xlink:href="modd-20190630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20190630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20190630.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeaseAgreement" xlink:href="modd-20190630.xsd#LeaseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityTables" xlink:href="modd-20190630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesTables" xlink:href="modd-20190630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="modd-20190630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/AccruedExpensesDetailsNarrative" xlink:href="modd-20190630.xsd#AccruedExpensesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PayableToRelatedPartyDetailsNarrative" xlink:href="modd-20190630.xsd#PayableToRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetails" xlink:href="modd-20190630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetails1" xlink:href="modd-20190630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:href="modd-20190630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails" xlink:href="modd-20190630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:href="modd-20190630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_DocumentAndEntityInformationAbstract" xlink:label="loc_MODDDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MODDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MODDDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MODDDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MODDDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MODDDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MODDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MODDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MODDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MODDDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_CommonStockIssuableMember" xlink:label="loc_MODDCommonStockIssuableMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_MODDCommonStockIssuableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilitiesAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ReorganizationAndPrivatePlacement" xlink:title="00000008 - Disclosure - REORGANIZATION AND PRIVATE PLACEMENT">
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_ReorganizationAndPrivatePlacementAbstract" xlink:label="loc_MODDReorganizationAndPrivatePlacementAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_ReorganizationAndPrivatePlacementDisclosureTextBlock" xlink:label="loc_MODDReorganizationAndPrivatePlacementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MODDReorganizationAndPrivatePlacementAbstract" xlink:to="loc_MODDReorganizationAndPrivatePlacementDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/AccruedExpenses" xlink:title="00000009 - Disclosure - ACCRUED EXPENSES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PayableToRelatedParty" xlink:title="00000010 - Disclosure - PAYABLE TO RELATED PARTY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquity" xlink:title="00000011 - Disclosure - STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000013 - Disclosure - ROYALTY AGREEMENT">
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_RoyaltyAgreementAbstract" xlink:label="loc_MODDRoyaltyAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_RoyaltyAgreementDisclosureTextBlock" xlink:label="loc_MODDRoyaltyAgreementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MODDRoyaltyAgreementAbstract" xlink:to="loc_MODDRoyaltyAgreementDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeaseAgreement" xlink:title="00000014 - Disclosure - LEASE AGREEMENT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_ReorganizationPolicyTextBlock" xlink:label="loc_MODDReorganizationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_MODDReorganizationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_ProfessionalFeesPolicyTextBlock" xlink:label="loc_MODDProfessionalFeesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_MODDProfessionalFeesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_MODDRisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_MODDRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Reclassifications" xlink:label="loc_us-gaapReclassifications" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapReclassifications" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityTables" xlink:title="00000017 - Disclosure - STOCKHOLDERS' EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesTables" xlink:title="00000018 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="loc_us-gaapTechnologyEquipmentMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapTechnologyEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaapBuildingAndBuildingImprovementsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingAndBuildingImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/AccruedExpensesDetailsNarrative" xlink:title="00000022 - Disclosure - ACCRUED EXPENSES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PayableToRelatedPartyDetailsNarrative" xlink:title="00000023 - Disclosure - PAYABLE TO RELATED PARTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetails" xlink:title="00000024 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_Consultants1Member" xlink:label="loc_MODDConsultants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MODDConsultants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_Consultants2Member" xlink:label="loc_MODDConsultants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MODDConsultants2Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20190630.xsd#MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="loc_MODDShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MODDShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetails1" xlink:title="00000025 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000026 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails" xlink:title="00000027 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000028 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6767467808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional expenses</a></td>
<td class="nump">$ 287,831<span></span>
</td>
<td class="nump">$ 41,710<span></span>
</td>
<td class="nump">$ 260,396<span></span>
</td>
<td class="nump">$ 232,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">703,783<span></span>
</td>
<td class="nump">135,789<span></span>
</td>
<td class="nump">1,882,345<span></span>
</td>
<td class="nump">332,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administration expenses</a></td>
<td class="nump">139,912<span></span>
</td>
<td class="nump">76,296<span></span>
</td>
<td class="nump">420,090<span></span>
</td>
<td class="nump">98,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">6,714<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
<td class="nump">14,468<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">1,138,240<span></span>
</td>
<td class="nump">255,190<span></span>
</td>
<td class="nump">2,577,299<span></span>
</td>
<td class="nump">666,164<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss From Operations</a></td>
<td class="num">(1,138,240)<span></span>
</td>
<td class="num">(255,190)<span></span>
</td>
<td class="num">(2,577,299)<span></span>
</td>
<td class="num">(666,164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">16,042<span></span>
</td>
<td class="nump">5,624<span></span>
</td>
<td class="nump">39,390<span></span>
</td>
<td class="nump">8,518<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss Before Income Taxes</a></td>
<td class="num">(1,122,198)<span></span>
</td>
<td class="num">(249,566)<span></span>
</td>
<td class="num">(2,537,909)<span></span>
</td>
<td class="num">(657,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for Income Taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (1,122,198)<span></span>
</td>
<td class="num">$ (249,566)<span></span>
</td>
<td class="num">$ (2,539,498)<span></span>
</td>
<td class="num">$ (659,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (.15)<span></span>
</td>
<td class="num">$ (.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares used in computing basic and diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">17,847,740<span></span>
</td>
<td class="nump">15,983,273<span></span>
</td>
<td class="nump">16,589,633<span></span>
</td>
<td class="nump">13,336,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">17,847,740<span></span>
</td>
<td class="nump">15,983,273<span></span>
</td>
<td class="nump">16,589,633<span></span>
</td>
<td class="nump">13,336,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637345&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6630875360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REORGANIZATION AND PRIVATE PLACEMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MODD_ReorganizationAndPrivatePlacementAbstract', window );"><strong>Reorganization And Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MODD_ReorganizationAndPrivatePlacementDisclosureTextBlock', window );">REORGANIZATION AND PRIVATE PLACEMENT</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On April 26, 2017, Modular Medical, Inc.
issued 2,900,000 shares (the &#8220;Control Block&#8221;), of new, restricted common stock, par value, $0.001, per share, for a
purchase price of $375,000, resulting in a change in control of Modular Medical, Inc.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 24, 2017, pursuant to a Reorganization
and Share Exchange Agreement, by and among, Modular Medical, Inc., 3 Quasuras Shareholders and Quasuras (the &#8220;Acquisition
Agreement&#8221;), the Company acquired all 4,400,000 shares of Quasuras&#8217; common stock which represented one hundred percent
(100%) of the issued and outstanding shares of Quasuras for 7,582,060 shares of our common stock, resulting in Quasuras becoming
our wholly-owned subsidiary (the &#8220;Acquisition&#8221;).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Simultaneously with the closing of the
Acquisition and as a condition thereto, we sold (the &#8220;2017 Private Placement&#8221;), in a private placement an aggregate
of 7,233,031 for cash and 568,182 from reissuance of previously canceled shares of our common stock pursuant to one or more exemptions
from the registration requirements of the Securities Act, at a purchase price of $0.66 per share resulting in net proceeds to us
of approximately $4,731,872. Simultaneously with the Acquisition and Private Placement, the Company cancelled all 2,900,000 Control
Block shares it had issued in the Control Block Acquisition (the &#8220;Share Cancellation&#8221;). In connection with the 2017
Private Placement, we paid $41,928 as compensation in connection with sales of our shares therein.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Following the Acquisition, the 2017 Private
Placement and the Share Cancellation, we had issued and outstanding 15,983,273 shares of our common stock.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The cash received in the private placement
was recorded as the cash received in reorganization in the accompanying consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Simultaneously with and as a condition
to the closing of the Acquisition and the 2017 Private Placement, pursuant to an Intellectual Property Transfer Agreement, dated
as of July 24, 2018, by and among us, Quasuras and Mr. DiPerna (the &#8220;IP Transfer Agreement&#8221;), Mr. DiPerna transferred
to us all intellectual property rights owned directly and/or indirectly by him related to our proposed business. Separately, we
agreed to pay Mr. DiPerna as part of his compensation for services to be performed for us pursuant to a Royalty Agreement (the
&#8220;Royalty Agreement&#8221;) certain fees based upon future sales, if any, of our proposed product subject to a maximum $10,000,000
&#8220;cap&#8221; on the aggregate amount of fees that Mr. DiPerna could earn from such arrangement.</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On April 26, 2017, Modular Medical, Inc.
issued 2,900,000 shares (the &#8220;Control Block&#8221;), of new, restricted common stock, par value, $0.001, per share, for a
purchase price of $375,000, resulting in a change in control of Modular Medical, Inc.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 24, 2017, pursuant to a Reorganization
and Share Exchange Agreement, by and among, Modular Medical, Inc., 3 Quasuras Shareholders and Quasuras (the &#8220;Acquisition
Agreement&#8221;), the Company acquired all 4,400,000 shares of Quasuras&#8217; common stock which represented one hundred percent
(100%) of the issued and outstanding shares of Quasuras for 7,582,060 shares of our common stock, resulting in Quasuras becoming
our wholly-owned subsidiary (the &#8220;Acquisition&#8221;).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Simultaneously with the closing of the
Acquisition and as a condition thereto, we sold (the &#8220;2017 Private Placement&#8221;), in a private placement an aggregate
of 7,233,031 for cash and 568,182 from reissuance of previously canceled shares of our common stock pursuant to one or more exemptions
from the registration requirements of the Securities Act, at a purchase price of $0.66 per share resulting in net proceeds to us
of approximately $4,731,872. Simultaneously with the Acquisition and Private Placement, the Company cancelled all 2,900,000 Control
Block shares it had issued in the Control Block Acquisition (the &#8220;Share Cancellation&#8221;). In connection with the Private
Placement, we paid $41,928 as compensation in connection with sales of our shares therein.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Following the Acquisition, the 2017 Private
Placement and the Share Cancellation, we had issued and outstanding 15,983,273 shares of our common stock.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The cash received in the private placement
was recorded as the cash received in reorganization in the accompanying consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Simultaneously with
and as a condition to the closing of the Acquisition and the Private Placement, pursuant to an Intellectual Property Transfer
Agreement, dated as of July 24, 2018, by and among us, Quasuras and Mr. DiPerna (the &#8220;IP Transfer Agreement&#8221;), Mr.
DiPerna transferred to us all intellectual property rights owned directly and/or indirectly by him related to our proposed business.
Separately, we agreed to pay Mr. DiPerna as part of his compensation for services to be performed for us pursuant to a Royalty
Agreement (the &#8220;Royalty Agreement&#8221;) certain fees based upon future sales, if any, of our proposed product subject
to a maximum $10,000,000 &#8220;cap&#8221; on the aggregate amount of fees that Mr. DiPerna could earn from such arrangement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MODD_ReorganizationAndPrivatePlacementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MODD_ReorganizationAndPrivatePlacementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MODD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MODD_ReorganizationAndPrivatePlacementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MODD_ReorganizationAndPrivatePlacementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MODD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6757025632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 253,474<span></span>
</td>
<td class="nump">$ 178,929<span></span>
</td>
<td class="nump">$ 14,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6759056352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">17,870,261<span></span>
</td>
<td class="nump">17,840,261<span></span>
</td>
<td class="nump">15,983,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">17,870,261<span></span>
</td>
<td class="nump">17,840,261<span></span>
</td>
<td class="nump">15,983,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6617394384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PAYABLE TO RELATED PARTY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">PAYABLE TO RELATED PARTY</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Payable to related party comprises of the amounts
paid by the major shareholder on behalf of the Company. The payable is unsecured, non-interest bearing and due on demand. As of
June 30, 2019 and March 31, 2019, respectively, there were no amounts payable to related party.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Payable to related party comprises of the amounts
paid by the major shareholder on behalf of the Company. The payable is unsecured, non-interest bearing and due on demand. As of
March 31, 2019 and 2018, respectively, the payable to related party amounted to $0 and $516.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6629973104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASE AGREEMENT</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 21, 2017, the Company entered into
a sublease agreement to rent office space. The term of the lease commences on September 1, 2017 and expires on December 14, 2019.
The monthly rent for the lease is $3,000. For the remaining lease term, the rent balance is $27,000, $3,000 payable monthly. The
Company paid a deposit of $7,500 upon execution of the lease which has been recorded as a security deposit in the accompanying
consolidated financial statements.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6770779376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of deferred tax assets</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31, 2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 76%; padding-left: 8.65pt"><font style="font-size: 8pt">Net loss carryforward</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">1,098,000</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">817,000</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt"><font style="font-size: 8pt">Valuation allowance</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(1,098,000</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(817,000</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><font style="font-size: 8pt">Total deferred tax assets</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">March 31,</font><br />
<font style="font-size: 8pt">2019</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">March 31,</font><br />
<font style="font-size: 8pt">2018</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 76%; padding-left: 8.65pt"><font style="font-size: 8pt">Net loss carryforward</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">817,000</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">182,500</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt"><font style="font-size: 8pt">Valuation allowance</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(817,000</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(182,500</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><font style="font-size: 8pt">Total deferred tax assets</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758415792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">$ (22,985)<span></span>
</td>
<td class="num">$ (16,278)<span></span>
</td>
<td class="num">$ (1,844)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">75,961<span></span>
</td>
<td class="nump">75,948<span></span>
</td>
<td class="nump">13,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">25,028<span></span>
</td>
<td class="nump">20,565<span></span>
</td>
<td class="nump">15,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">49,724<span></span>
</td>
<td class="nump">49,724<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 24,194<span></span>
</td>
<td class="nump">$ 21,937<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6607622720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Common stock</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2017, pursuant to a Reorganization
and Share Exchange Agreement, by and among, the Company and Quasuras Inc., the Company acquired one hundred percent (100%) of the
issued and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary
of the Company. The historical equity for Quasuras was restated pursuant to the reorganization.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has 50,000,000 shares of common
stock authorized. The par value of the shares is $0.001. In April 2019 the Company issued 30,000 shares for services bringing the
outstanding balance to 17,870,261 shares of common stock.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preferred Stock</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has 5,000,000 shares of preferred
stock authorized. The par value of the shares is $0.001. As of June 30, 2019, none of the shares of preferred stock of the Company
were issued.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Stock Options</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 19, 2017, the Board of Directors
approved the 2017 Equity Incentive Plan (&#8220;EIP&#8221;) that reserves 3,000,000 shares of common stock of the Company to be
issued. Under the Company&#8217;s EIP, eligible employees, directors and consultants are granted options to purchase shares of
common stock of the Company. The EIP is administered by the Company&#8217;s Board of Directors or, in the alternative, if necessary,
a committee designated by the Board of Directors, and has the sole power over the exercise of the EIP. The Board of Directors determines
whether the EIP will allow for the issuance of shares of common stock or an option to purchase shares of common stock, such option
designated as either an incentive stock option or a non-qualified stock option.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The exercise or purchase price shall be calculated
as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 3%; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">(i)</font></td>
    <td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">In the case of an incentive stock option, (A) granted to employees, directors and consultants who, at the time of the grant of such incentive stock option own stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company, the per share exercise price shall be not less than one hundred ten percent (110%) of the fair market value per share on the date of grant; or (B) granted to employees, directors and consultants other than to employees, directors and consultants described in the preceding clause, the per share exercise price shall be not less than one hundred percent (100%) of the fair market value per share on the date of grant;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 3%; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">(ii)</font></td>
    <td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">In the case of a non-qualified stock option, the per share exercise price shall be not less than one hundred percent (100%) of the fair market value per share on the date of grant unless otherwise determined by the Board of Directors; and</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 3%; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">(iii)</font></td>
    <td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">In the case of other grants, such price as is determined by the Board of Directors. </font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors are responsible for determining
the consideration to be paid for the shares of common stock to be issued upon exercise or purchase. The EIP generally doesn&#8217;t
allow for the transfer of the options, and the Board of Directors may amend, suspend or terminate the EIP at any time.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 15, 2019, the Company granted 4,778
options to a consultant, these options are fully vested on the grant date. The 4,778 options will expire on April 14, 2029. The
fair value of the options 4,778 shares is determined to be $8,173, was accrued in professional expenses for the quarter ended June
30, 2019.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following assumptions were used in the fair
value method calculation:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font-size: 8pt">&#183;</font></td>
    <td style="text-align: justify"><font style="font-size: 8pt">Volatility: 101.85%</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 8pt">&#183;</font></td>
    <td style="text-align: justify"><font style="font-size: 8pt">Risk free rate of return: 2.41%</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 8pt">&#183;</font></td>
    <td style="text-align: justify"><font style="font-size: 8pt">Expected term: 5 years</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">On April 15<sup>th</sup> and May
15<sup>th</sup> 2019, the Company granted 8,908 options to a consultant, these options will be fully vested on the grant date.
The 8,908 options will expire on April 14<sup>th</sup> and May 14<sup>th</sup>, 2029. The fair value of the options 8,908 shares
is determined to be $15,000 was accrued in consulting expenses for the fiscal quarter ended June 30, 2019.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">The following assumptions were used
in the fair value method calculation:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Volatility: 97 &#8211; 102% </font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Risk free rate of return: 2.15 &#8211; 2.37%</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Expected term: 5 years</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">On April 15<sup>th</sup>, 2019, the
Company granted 9,000 options to an employee, these options will be fully vested three years from the date granted. The 9,000 options
will expire on April 14<sup>th</sup>, 2029. The fair value of the options 9,000 shares is determined to be $16,258. During the
quarter ended June 30, 2019, $447 was accrued monthly in general and administrative expenses.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">The following assumptions were used
in the fair value method calculation:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Volatility: 101.85% </font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Risk free rate of return: 2.41%</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Expected term: 6.0 years</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 25, 2018, the Company granted 1,280,000
options to certain consultants, these options are fully vested one year from the date granted. The 1,280,000 options will expire
on August 31, 2019. The fair value of the options 1,280,000 shares is determined to be $682,240, was accrued monthly in research
and development expenses for the fiscal quarter ended June 30, 2019.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following assumptions were used in the fair
value method calculation:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Volatility: 110%</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Risk free rate of return: 2.82%</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Expected term: 5.27 years</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 16, 2019, the Company granted 185,221
options to certain consultants, these options will be fully vested three years from the date granted. The 185,221 options will
expire on January 15, 2029. The fair value of the options 185,221 shares is determined to be $336,732, was accrued monthly in general
and administrative expenses for the fiscal quarter ended June 30, 2019.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following assumptions were used in the fair
value method calculation:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Volatility: 104%</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Risk free rate of return: 2.54%</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Expected term: 5.88 years</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The relative fair value of each of the granted
options set forth above has been calculated using the Black-Scholes-Merton pricing model, which, for each such option, is based
on the granted strike price, the three month average trading volatility of three comparable companies (e.g., PODD, TNDM, VLRX),
the five year, risk-free treasury bond interest rate on the applicable grant date and a weighted average term using the simplified
method calculation. It outlines calculation methods for sbc.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The following is a rollforward of the options outstanding and exercisable
for the fiscal quarter ended June 30, 2019:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Options</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Weighted </font><br />
<font style="font-size: 8pt">Average</font><br />
<font style="font-size: 8pt">Exercise Price</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Average </font><br />
<font style="font-size: 8pt">Remaining</font><br />
<font style="font-size: 8pt">Life</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 64%; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Outstanding and exercisable &#8211; March 31, 2019</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">918,020</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">0.68</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">9.43</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Vested</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">280,352</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">0.74</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Expired</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Outstanding and exercisable &#8211; June 30, 2019</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">1,198,372</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">0.69</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">5.13</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Common stock</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2017, pursuant to a Reorganization
and Share Exchange Agreement by and among, the Company and Quasuras Inc., the Company acquired one hundred percent (100%) of the
issued and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary
of the Company. The historical equity for Quasuras was restated pursuant to the reorganization.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preferred Stock</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has 5,000,000 shares of preferred
stock authorized. The par value of the shares is $0.001. As of March 31, 2019, none of the shares of preferred stock of the Company
were issued.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>2017 Equity Incentive Plan</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 19, 2017, the board of directors
approved the 2017 Equity Incentive Plan (the &#8220;EIP&#8221;) that reserves 3,000,000 shares of common stock of the Company to
be issued. Under the Company&#8217;s EIP, eligible employees, directors and consultants may be granted options to purchase shares
of common stock of the Company. The EIP is administered by the Company&#8217;s board of directors or, in the alternative, a committee
designated by the board of directors, and has the sole power to adminster the EIP. The board of directors determines whether the
EIP will allow for the issuance of shares of common stock or an option to purchase shares of common stock and whether such options
are designated as either incentive or non-qualified stock options.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the EIP, the exercise or purchase price
shall be calculated as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 1%; font: 12pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 3%; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">(i)</font></td>
    <td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">In the case of an incentive stock option, (A) granted to employees, directors and consultants who, at the time of the grant of such incentive stock option own stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company, the per share exercise price shall be not less than one hundred ten percent (110%) of the fair market value per share on the date of grant; or (B) granted to employees, directors and consultants other than to employees, directors and consultants described in the preceding clause, the per share exercise price shall be not less than one hundred percent (100%) of the fair market value per share on the date of grant;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 3%"><font style="font-size: 8pt">(ii)</font></td>
    <td style="width: 96%; text-align: justify"><font style="font-size: 8pt">In the case of a non-qualified stock option, the per share exercise price shall be not less than one hundred percent (100%) of the fair market value per share on the date of grant unless otherwise determined by the board of directors; and</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 3%"><font style="font-size: 8pt">(iii)</font></td>
    <td style="width: 96%; text-align: justify"><font style="font-size: 8pt">In the case of other grants, such price as is determined by the board of directors.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The board of directors is responsible for determining
the consideration to be paid for the shares of common stock to be issued upon exercise or purchase. The EIP generally doesn&#8217;t
allow for the transfer of the options, and the board of directors may amend, suspend or terminate the EIP at any time.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">On August 15, September 15, and October
15, 2018, the Company granted a total of 54,039 options to the chief executive officer of the Company in lieu of salary. The options
expire 10 years from the respective grant dates and vested immediately upon grant. The fair value of these options was determined
to be $24,840 and was included in general and administrative and research and development expenses for the year ended March 31,
2019.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">On November 15<sup>th</sup> and December
15<sup>th</sup> 2018, the Company granted 10,648 options to the officer of the Company in lieu of salary. The options expire on
November 14<sup>th</sup>, and December 14<sup>th</sup>, 2028 and vest immediately. The fair value of these options determined to
be $17,921 and was included in general and administrative and research and development expenses for the year ended March 31, 2019.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">The following assumptions were used
in the fair value method calculations:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Volatility: 71% &#8211; 112%</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Risk free rate of return: 2.73% &#8211; 3.01%</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Expected term: 5 years</font></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the fiscal year ended March 31,
2019, the Company granted options to purchase 1,529,208 shares of common stock to certain employees and consultants. The fair value
of the options granted was $1,021,733, and the Company has been recording stock-based compensation expense for each grant over
the respective vesting periods. For the year ended March 31, 2019, the Company recorded stock-based compensation expense of $532,108,
which is less than the total fair value. This difference of $489,625 represents stock-based compensation expense that will be recognized
subsequent to March 31, 2019, so long as the option grants remain outstanding and vesting continues. The table below provides a
reconciliation of total fair value of the options granted and related expense recognized by the Company during fiscal 2019.</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: black 1pt solid"><font style="font-size: 8pt"><b>Grantees</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Option</b></font><br />
<font style="font-size: 8pt"><b>Shares</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Vesting </b></font><br />
<font style="font-size: 8pt"><b>Periods</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total Fair </b></font><br />
<font style="font-size: 8pt"><b>Value of</b></font><br />
<font style="font-size: 8pt"><b>Options</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2019 Stock-Based </b></font><br />
<font style="font-size: 8pt"><b>Compensation </b></font><br />
<font style="font-size: 8pt"><b>Expense</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Unrecognized </b></font><br />
<font style="font-size: 8pt"><b>expense at </b></font><br />
<font style="font-size: 8pt"><b>March 31, 2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 28%"><font style="font-size: 8pt">Consultants</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">1,280,000</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 22%"><font style="font-size: 8pt">July 25, 2018 to July 24, 2019</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">682,240</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">466,197</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">216,043</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Consultants</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">185,221</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">January&#160;&#160;16, 2019 to January 15, 2022</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">336,732</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">23,150</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">313,582</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Chief Executive Officer</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">64,687</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">*</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">42,761</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">42,761</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Total</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">1,529,908</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">1,021,733</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">532,108</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">489,625</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">* Options were fully vested as of the grant date, as disclosed above.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">The following assumptions were used
in the fair value method calculation for the consultant options:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Volatility: 104% &#8211; 110%</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Risk free rate of return: 2.54% &#8211; 2.82%</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 8pt">&#183;</font></td>
    <td><font style="font-size: 8pt">Expected term: 5.27 &#8211; 5.88 years</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The following is a rollforward of the options outstanding and exercisable
for the year ended March 31, 2019:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt; text-align: center; text-indent: -8.65pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Options</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Weighted</font><br />
<font style="font-size: 8pt">Average</font><br />
<font style="font-size: 8pt">Exercise</font><br />
<font style="font-size: 8pt">Price</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Average</font><br />
<font style="font-size: 8pt">Remaining</font><br />
<font style="font-size: 8pt">Life</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Outstanding and exercisable &#8211; March 31, 2018</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 64%; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Vested</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">918,020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Expired</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Outstanding and exercisable &#8211; March 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">918,020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">0.68</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">9.43</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify">The fair values of options at the grant
date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of
options as well as average volatility of three comparable organizations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6757010400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MODD_ReorganizationPolicyTextBlock', window );">Reorganization</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2017, pursuant to a Reorganization
and Share Exchange Agreement, by and among the Company and Quasuras, the Company acquired one hundred percent (100%) of the issued
and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary
of the Company. Since the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was
accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the Reorganization,
at their historical carrying amounts.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the reorganization, the Company
changed the fiscal year end from June 30 to March 31, to coincide with the year end for Quasuras.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements of the
Company have been prepared in accordance with accounting principles generally accepted in the United States of America. The following
summarizes the more significant of such policies:</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2017, pursuant to a Reorganization
and Share Exchange Agreement, by and among the Company and Quasuras, the Company acquired one hundred percent (100%) of the issued
and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary
of the Company. Since the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was
accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the Reorganization,
at their historical carrying amounts.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the reorganization, the Company
changed the fiscal year end from June 30 to March 31, to coincide with the year end for Quasuras.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements of the
Company have been prepared in accordance with accounting principles generally accepted in the United States of America. The following
summarizes the more significant of such policies:</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the consolidated financial
statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates
and assumptions that affect reported amounts and related disclosures.</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the consolidated financial
statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates
and assumptions that affect reported amounts and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include
the accounts of Modular Medical, Inc. and its wholly-owned subsidiary Quasuras, Inc., and are collectively referred to as the &#8220;Company&#8221;.
All material intercompany accounts, transactions and profits were eliminated in consolidation.</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include
the accounts of Modular Medical, Inc. and its wholly-owned subsidiary Quasuras, Inc., and are collectively referred to as the &#8220;Company&#8221;.
All material intercompany accounts, transactions and profits were eliminated in consolidation.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the accompanying financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the accompanying financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segment</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has one reportable segment. The
Company&#8217;s activities are interrelated and each activity is dependent upon and supportive of the other. Accordingly, all significant
operating decisions are based on analysis of financial products provided as a single global business.<b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has one reportable segment. The
Company&#8217;s activities are interrelated and each activity is dependent upon and supportive of the other. Accordingly, all significant
operating decisions are based on analysis of financial products provided as a single global business.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MODD_ProfessionalFeesPolicyTextBlock', window );">Professional Fees</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses the cost of legal, accounting,
audit, tax and other professional services.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses the cost of legal, accounting,
audit, tax and other professional services.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses the cost of research and
development as incurred. Research and development costs charged to operations were approximately $703,783 and $135,789 for the
fiscal quarter ended June 30, 2019 and 2018, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses the cost of research and
development as incurred. Research and development costs charged to operations were approximately $ 1,882,345 and $332,642 for the
fiscal year ended March 31, 2019 and 2018, respectively.&#9; &#9; &#9;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administration</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expense consists
primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and meetings and travel.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expense consists
primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and meetings and travel.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilizes Financial Accounting Standards
Board (FASB) Accounting Standards Codification (ASC) Topic 740, Income Taxes, which requires recognition of deferred tax assets
and liabilities for the expected future tax consequences of events that were included in the consolidated financial statements
or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences
between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws
and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances
are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for uncertain tax positions
in accordance with FASB ASC Topic 740. When tax returns are filed, it is likely that some positions taken would be sustained upon
examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount
of the position that would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements
in the period during which, based on all available evidence, management believes it is more likely than not that the position will
be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not
offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured
as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable
taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described
above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any
associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in
the consolidated statements of income.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2019 and 2018, the Company had not
taken any significant uncertain tax positions on its tax returns for periods ended June 30, 2019 and prior years or in computing
its tax provision for 2019. Management has considered its tax positions and believes that all of the positions taken by the Company
in its Federal and State tax returns are more likely than not to be sustained upon examination. The Company is subject to examination
by U.S. Federal and State tax authorities for the period ended March 31, 2017 to the present, generally for three years after they
are filed.</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilizes Financial Accounting Standards
Board (FASB) Accounting Standards Codification (ASC) Topic 740, Income Taxes, which requires recognition of deferred tax assets
and liabilities for the expected future tax consequences of events that were included in the consolidated financial statements
or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences
between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws
and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances
are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for uncertain tax positions
in accordance with FASB ASC Topic 740. When tax returns are filed, it is likely that some positions taken would be sustained upon
examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount
of the position that would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements
in the period during which, based on all available evidence, management believes it is more likely than not that the position will
be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not
offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured
as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable
taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described
above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any
associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in
the consolidated statements of income.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2019 and 2018, the Company had
not taken any significant uncertain tax positions on its tax returns for periods ended March 31, 2019 and prior years or in computing
its tax provision for 2019. Management has considered its tax positions and believes that all of the positions taken by the Company
in its Federal and State tax returns are more likely than not to be sustained upon examination. The Company is subject to examination
by U.S. Federal and State tax authorities for the period ended March 31, 2016 to the present, generally for three years after they
are filed.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company maintains cash balances
at financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to
limits of approximately $250,000. The Company has not experienced any losses with regard to its bank accounts and believes it is
not exposed to any risk of loss on its cash bank accounts.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company maintains cash balances
at financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to
limits of approximately $250,000. The Company has not experienced any losses with regard to its bank accounts and believes it is
not exposed to any risk of loss on its cash bank accounts.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MODD_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to risks from, among
other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements,
rapidly changing customer requirements, limited operating history and the volatility of public markets.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to risks from, among
other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements,
rapidly changing customer requirements, limited operating history and the volatility of public markets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain conditions may exist as of the date
the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when
one or more future events occur or fail to occur. The Company&#8217;s management and legal counsel assess such contingent liabilities,
and such assessment inherently involves judgment. In assessing loss contingencies related to legal proceedings that are pending
against the Company or unasserted claims that may result in such proceedings, the Company&#8217;s legal counsel evaluates the perceived
merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected
to be sought.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the assessment of a contingency indicates
it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability
would be accrued in the Company&#8217;s consolidated financial statements. If the assessment indicates that a potential material
loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent
liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies
considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would
be disclosed.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain conditions may exist as of the date
the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when
one or more future events occur or fail to occur. The Company&#8217;s management and legal counsel assess such contingent liabilities,
and such assessment inherently involves judgment. In assessing loss contingencies related to legal proceedings that are pending
against the Company or unasserted claims that may result in such proceedings, the Company&#8217;s legal counsel evaluates the perceived
merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected
to be sought.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the assessment of a contingency indicates
it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability
would be accrued in the Company&#8217;s consolidated financial statements. If the assessment indicates that a potential material
loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent
liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies
considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would
be disclosed.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents include cash in hand
and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months
or less. At June 30, 2019 and March 31, 2019, the Company had $5,706,628 and $6,553,768, respectively, in cash. Deposits at the
bank are insured up to $250,000 by the Federal Deposit Insurance Corporation. The Company&#8217;s uninsured portion of the balances
held at the bank aggregated to approximately $5,421,940 and $6,269,116 respectively. No reserve has been made in the financial
statements for any possible loss due to any financial institution failure.&#160;The Company has not experienced any losses in such
accounts and believes we are not exposed to any significant risk on cash and cash equivalents.</p>

<p style="margin: 0">&#160;&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents include cash in hand
and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months
or less. At March 31, 2019 and March 31, 2018, the Company had $6,553,768 and $4,296,676, respectively, in cash. Deposits at the
bank are insured up to $250,000 by the Federal Deposit Insurance Corporation. The Company&#8217;s uninsured portion of the balances
held at the bank aggregated to approximately $6,269,116 &#160;and $3,933,002, respectively. No reserve has been made in the financial
statements for any possible loss due to any financial institution failure.&#160;The Company has not experienced any losses in such
accounts and believes we are not exposed to any significant risk on cash and cash equivalents.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant &amp; Equipment</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment is stated at cost and
depreciated using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. The estimated
useful lives of our property and equipment are generally as follows: computer equipment&#38; software developed or acquired for
internal use, three to ten years; office equipment, two to three years; buildings and improvements, five to fifteen years; leasehold
improvements, two to ten years; and machinery and equipment, one to five years.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2019 and March 31, 2019, property, plant and equipment
amounted to:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2019</b></font><br />
<font style="font-size: 8pt"><b>(UNAUDITED)</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31, 2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 76%"><font style="font-size: 8pt">Computer equipment and software</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">25,028</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">20,565</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Office equipment</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">49,724</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">49,724</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Machinery and equipment</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">24,194</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">21,937</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">Less: accumulated depreciation</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(22,985</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(16,278</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">75,961</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">75,948</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Depreciation expenses for the quarter ended June 30, 2019 and March
31, 2019 was $6,707 and $1,387 respectively.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment is stated at cost and
depreciated using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. The estimated
useful lives of our property and equipment are generally as follows: computer equipment &#38; software developed or acquired for
internal use, three to ten years; office equipment, two to three years; buildings and improvements, five to fifteen years; leasehold
improvements, two to ten years; and machinery and equipment, one to five years.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">As of March 31, 2019 and March 31, 2018, property, plant and equipment
amounted to:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">March 31,</font><br />
<font style="font-size: 8pt">2019</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">March 31,</font><br />
<font style="font-size: 8pt">2018</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="width: 76%"><font style="font-size: 8pt">Computer equipment and software</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">20,565</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">15,103</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 8pt">Office equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">49,724</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td><font style="font-size: 8pt">Machinery and equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">21,937</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">Less: accumulated depreciation</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(16,278</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(1,844</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">75,948</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">13,259</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Depreciation expenses for the year ended March 31, 2019 and 2018
was $14,435 &#160;and $1,844, respectively.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instrument</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For certain of the Company&#8217;s financial
instruments, including cash and equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair
values due to their short maturities. ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; requires disclosure
of the fair value of financial instruments held by the Company. ASC Topic 825, &#8220;Financial Instruments,&#8221; defines fair
value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements
for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities
each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between
the origination of such instruments and their expected realization and their current market rate of interest. The three levels
of valuation hierarchy are defined as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 inputs to the valuation methodology
are quoted prices for identical assets or liabilities in active markets.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 inputs to the valuation methodology
include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability,
either directly or indirectly, for substantially the full term of the financial instrument.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 inputs to the valuation methodology
are unobservable and significant to the fair value measurement.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to their short-term nature, the carrying
values of cash and equivalents, accounts receivable, accounts payable, and accrued expenses, approximate fair value. Based on borrowing
rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair
value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For certain of the Company&#8217;s financial
instruments, including cash and equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair
values due to their short maturities. ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; requires disclosure
of the fair value of financial instruments held by the Company. ASC Topic 825, &#8220;Financial Instruments,&#8221; defines fair
value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements
for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities
each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between
the origination of such instruments and their expected realization and their current market rate of interest. The three levels
of valuation hierarchy are defined as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 inputs to the valuation methodology
are quoted prices for identical assets or liabilities in active markets.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 inputs to the valuation methodology
include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability,
either directly or indirectly, for substantially the full term of the financial instrument.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 inputs to the valuation methodology
are unobservable and significant to the fair value measurement.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to their short-term nature, the carrying
values of cash and equivalents, accounts receivable, accounts payable, and accrued expenses, approximate fair value. Based on borrowing
rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair
value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share ("EPS")</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings per share are computed by dividing
earnings available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted
earnings per share are computed by dividing net income by the weighted average number of shares outstanding during the period increased
to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities
had been issued. During the fiscal quarter ended June 30, 2019 and 2018 we incurred losses. Therefore, the effects of any common
stock equivalent were anti-dilutive during those periods.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets for the computation
of basic and diluted earnings per share for the fiscal quarters ended June 30, 2019 and June 30, 2018:<b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2019</b></font><br />
<font style="font-size: 8pt"><b>(UNAUDITED)</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2018</b></font><br />
<font style="font-size: 8pt"><b>(UNAUDITED)</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="width: 76%; padding-bottom: 2.5pt; padding-left: 17.3pt"><font style="font-size: 8pt"><b>Net Loss</b></font></td>
    <td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(1,122,198</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(249,566</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 8pt"><b>Net Loss Per Share</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-bottom: 2.5pt; padding-left: 8.65pt"><font style="font-size: 8pt"><b>Basic and Diluted:</b></font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.06</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.02</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Weighted average number of shares used in computing basic and diluted net loss </b></font><br />
<font style="font-size: 8pt"><b>per share:</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-bottom: 2.5pt; padding-left: 8.65pt"><font style="font-size: 8pt">Basic</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">17,847,740</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">15,983,273</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 8.65pt"><font style="font-size: 8pt">Diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">17,847,740</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">15,983,273</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number
of outstanding common shares during the period. Diluted earnings per share are computed by dividing net income by the weighted
average number of shares outstanding during the period increased to include the number of additional shares of common stock
that would have been outstanding if the potentially dilutive securities had been issued. During the fiscal years ended March
31, 2019 and 2018 we incurred losses. Therefore, the effects of any common stock equivalent were antidilutive during those
periods.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets for the computation
of basic and diluted earnings per share for the fiscal years ended March 31, 2019 and 2018:<b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31,</b></font><br />
<font style="font-size: 8pt"><b>2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31,</b></font><br />
<font style="font-size: 8pt"><b>2018</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 76%; padding-bottom: 2.5pt; padding-left: 34.6pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Net Loss</b></font></td>
    <td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(2,539,498</font></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(659,246</font></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Net Loss Per Share</b></font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Basic and Diluted:</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.15</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.05</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Weighted average number of shares used in computing basic and diluted net loss per share:</b></font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-align: right; text-indent: -8.65pt">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"><font style="font-size: 8pt">Basic</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">16,589,633</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">13,336,309</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"><font style="font-size: 8pt">Diluted</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">16,589,633</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">13,336,309</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify">In May 2014, the FASB issued ASU 2014-09,&#160;<i>Revenue
from Contracts with Customers</i>, issued as a new Topic, ASC Topic 606. The new revenue recognition standard supersedes all existing
revenue recognition guidance. Under this ASU, an entity should recognize revenue when it transfers promised goods or services to
customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or
services. ASU 2015-14, issued in August 2015, deferred the effective date of ASU 2014-09 to the first quarter of 2018, with early
adoption permitted in the first quarter of 2018. The company has adopted the new standard utilizing the modified retrospective
approach. The adoption of this new accounting guidance does not have material effects on results of operations, cash flows and
financial position for the forceable future because the company does not have revenues.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2016, The FASB issued ASU No. 2016-01,<i>&#160;Financial
Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825)</i>. ASU No. 2016-01 revises
the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes
for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments
to be recognized in net income. For non-public companies, ASU 2016-01 is effective for fiscal years beginning after December 15,
2018, and interim periods within fiscal years beginning after December 15, 2019. We are currently evaluating the impact of the
adoption of ASU 2016-01 will have on our consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU No. 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This update addresses a diversity
in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic
230, Statement of Cash Flows, and other Topics. The amendments in this Update are effective for public business entities for fiscal
years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including
adoption in an interim period. We adopted this ASU in 2016 and the implementation did not have a material impact on our financial
position or statement of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued guidance that
eases certain documentation and assessment requirements of hedge effectiveness and modifies the accounting for components excluded
from the assessment. Some of the modifications include the ineffectiveness of derivative gain/loss in highly effective cash flow
hedge to be recorded in other comprehensive income, the change in fair value of derivative to be recorded in the same income statement
line as hedged item, and additional disclosures required on the cumulative basis adjustment in fair value hedges and the effect
of hedging on financial statement lines for components excluded from the assessment. The amendment also simplifies the application
of hedge accounting in certain situations to permit new hedging strategies to be eligible for hedge accounting. The guidance is
effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2018,
our fiscal 2020. Early adoption is permitted, and the modified retrospective transition method should be applied. We do not expect
the adoption of this guidance to have a material impact on our consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, FASB issued ASU No. 2016-02,
Leases (&#8220;Topic 842&#8221;). Topic 842 requires an entity to recognize right-of -use assets and lease liability on its balance
sheet and disclosure key information about leasing arrangements. For public companies, Topic 842 is effective for annual reporting
periods beginning after December 15, 2018, including interim periods within that reporting period, with early adoption permitted.
We have evaluated this ASU and believe this guidance will not have a material impact on our financial position and statement of
operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other recent accounting pronouncements issued
by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities
and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future
consolidated financial statements.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU 2014-09,&#160;<i>Revenue
from Contracts with Customers</i>, issued as a new Topic, ASC Topic 606. The new revenue recognition standard supersedes all existing
revenue recognition guidance. Under this ASU, an entity should recognize revenue when it transfers promised goods or services to
customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or
services. ASU 2015-14, issued in August 2015, deferred the effective date of ASU 2014-09 to the first quarter of 2018, with early
adoption permitted in the first quarter of 2018. The company has adopted the new standard utilizing the modified retrospective
approach. The adoption of this new accounting guidance does not have material effects on results of operations, cash flows and
financial position for the forceable future because the company does not have revenues.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2016, The FASB issued ASU No. 2016-01,<i>&#160;Financial
Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825)</i>. ASU No. 2016-01 revises
the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes
for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments
to be recognized in net income. For non-public companies, ASU 2016-01 is effective for fiscal years beginning after December 15,
2018, and interim periods within fiscal years beginning after December 15, 2019. We are currently evaluating the impact of the
adoption of ASU 2016-01 will have on our consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU No. 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This update addresses a diversity
in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic
230, Statement of Cash Flows, and other Topics. The amendments in this Update are effective for public business entities for fiscal
years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including
adoption in an interim period. We adopted this ASU in 2016 and the implementation did not have a material impact on our financial
position or statement of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued guidance that
eases certain documentation and assessment requirements of hedge effectiveness and modifies the accounting for components excluded
from the assessment. Some of the modifications include the ineffectiveness of derivative gain/loss in highly effective cash flow
hedge to be recorded in other comprehensive income, the change in fair value of derivative to be recorded in the same income statement
line as hedged item, and additional disclosures required on the cumulative basis adjustment in fair value hedges and the effect
of hedging on financial statement lines for components excluded from the assessment. The amendment also simplifies the application
of hedge accounting in certain situations to permit new hedging strategies to be eligible for hedge accounting. The guidance is
effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2018,
our fiscal 2020. Early adoption is permitted and the modified retrospective transition method should be applied. We do not expect
the adoption of this guidance to have a material impact on our consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, FASB issued ASU No. 2016-02,
Leases (&#8220;Topic 842&#8221;). Topic 842 requires an entity to recognize right-of -use assets and lease liability on its balance
sheet and disclosure key information about leasing arrangements. For public companies, Topic 842 is effective for annual reporting
periods beginning after December 15, 2018, including interim periods within that reporting period, with early adoption permitted.
We have evaluated this ASU and believe this guidance will not have a material impact on our financial position and statement of
operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other recent accounting pronouncements issued
by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities
and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future
consolidated financial statements.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Reclassifications', window );">Reclassification</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior year amounts have been reclassified
for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations
or cash flow.</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior year amounts have been reclassified
for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations
or cash flow.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MODD_ProfessionalFeesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MODD_ProfessionalFeesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MODD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MODD_ReorganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MODD_ReorganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MODD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MODD_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MODD_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MODD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Reclassifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Reclassifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6633006656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2019 and March 31, 2019, accrued
expenses amounted to $253,474 and $178,929 respectively. Accrued expenses comprised of accrued legal and professional, consultant
services as of June 30, 2019 and March 31, 2019.</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2019, and 2018, accrued expenses
amounted to $178,929 and $14,955, respectively. Accrued expenses comprised of accrued legal and professional, consultant services
and year end employee bonuses as of March 31, 2019 and March 31, 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>44
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"["KO.V+W]Q\870=7 KW^AO@!02P,$%     @ :8LI3YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MV#2]#XVFGT)S)Y\?;@^E/_;#K0GW[?6[Q?6A;\[3-YGD]F%H\S]02P,$%
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M-C/0SAU"69SPA,X=E' ";V<>*(T9JVY>"H!J0:KQVC)BD#HA,*-[L&L^O&0
MU0S<89Z ]GF=2! .$[J+NV;$ZP%002 =":@B3*5.4I423O\#><V*5P]@Y -_
MX0!M^:0H*02L4T*:L;W&ZP(PPF Q'7>_*U%(1P<7 (6EQBEM':Y<QA^MW&<&
M-DVD<H#;W JHNAEEE= CGQC BQPP*D="4?F"5"DY4B>25R_)J!>JWI6DTA2^
MFZ2$L9J4O#1)1IIP_4NJ.UHK(QU.8'QQ#&O/]K]GU=O^4$]>RR:<Z+ISU[8L
M&Q^<BB_!W<YGF_,@]]NFO;7AONK/U/V@*8_#_P7Q^4^+Q7]02P,$%     @
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M<O?2M+?6WU?]65S_T)2GX9PQNAQV+O\'4$L#!!0    ( &F+*4\QG#:FR0$
M &T$   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULC53M;ML@%'T5Q .4
M!#OM%MF6FDS3)FU2U&G;;V)?VZA\>(#C[NT'V/'<U)KV)\#U.8=S@)MLT.;9
MM@ .O4BA;(Y;Y[H](;9L03)[ISM0_DNMC63.+TU#;&> 59$D!:&;S3V1C"M<
M9+%V,D6F>R>X@I-!MI>2F=\'$'K(\19?"T^\:5THD"+K6 /?P'WO3L:OR*Q2
M<0G*<JV0@3K'C]O],0WX"/C!8;"+.0I)SEH_A\7G*L>;8 @$E"XH,#]<X A"
M!"%OX]>DB><M W$YOZI_C-E]EC.S<-3B)Z]<F^-W&%50LUZX)SU\@BG/#J,I
M_!>X@/#PX,3O46IAXR\J>^NTG%2\%<E>QI&K. Z3_I6V3J 3@?XO(9D(R0V!
MC,YBU _,L2(S>D!FO*R.A3>QW2?^,,M0C&<7O_FTUE<OQ9:F&;D$H0ES&#%T
MB7F-.+Y%[-[/$.(-S"[HFHL#?<.G-SNL(.CZ#LEJSB3RDU<Y=^L"Z:I &@72
M?Q[4&N;^)L@:YN'&"%G<G@33Q(=N4:E[%9ML49U[Z9'&V_\+'QOQ*S,-5Q:=
MM?-O*-YTK;4#;V5SYU]WZWM_7@BH79@^^+D9.V!<.-U-S4WF?YCB#U!+ P04
M    " !IBRE/0-$L,,T!  !M!   &    'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;'U4[6[<(!!\%<0#!!M?FNO)MI2[JDJE5CJE:O*;L]<?"A@'\#E]^P(F
MCG-Q\\>PR\PR ZS34:HGW0 8]")XIS/<&-/O"-%% X+I*]E#9U<JJ00S-E0U
MT;T"5GJ2X(1&T1<B6-OA//6YH\I3.1C>=G!42 ]",/5W#UR.&8[Q:^*^K1OC
M$B1/>U;#;S!_^J.R$9FKE*V 3K>R0PJJ#-_&N\/&X3W@H851+^;(.3E)^>2"
M'V6&(R<(.!3&56!V.,,!.'>%K(SG4!//6SKB<OY:_;OW;KV<F(:#Y(]M:9H,
M;S$JH6(#-_=RO(/@YQJC8/XGG(%;N%-B]R@DU_Z+BD$;*4(5*T6PEVEL.S^.
MTTIR$VCK!!H(="9LHT\)22 D%P0R*?-6OS'#\E3)$:GILGKFWD2\2^QA%B[I
MS\ZO6;?:9L]Y3+<I.;M" ;.?,'2)>8\X?$1<?YTAQ J85= U%7OZ@4\O=EA!
MT/4=DE6?B><G[WS^1^)FM<#&%]A\>E KF"2Z,+*&B2^$D,7M"5"U?^@:%7+H
M?),MLG,OW5)_^V_PJ1%_,56WG48G:>P;\C==26G 2HFN[.MN;._/ 8?*N.F-
MG:NI Z; R#XT-YG_,/D_4$L#!!0    ( &F+*4^:\*'!S $  &T$   8
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M'FBX_?_PJ1%_,-WPSJ"SLNX-A9NNE;+@2DENW.MN7>\O@8#:^NF]F^NI Z;
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MZ?TE8%!K.[TU<SEWP!QH,?CF)LL?IO@'4$L#!!0    ( &F+*4^MF%$/M0$
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M*P5"M%0@-%(K#/:\)\:!!*T6"-%R@=!LQ QNCRP"$@DU@Z"4FKD/]<W@5LM
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M+0L&E;;3.S.7TU6<%EKT\RN#EZ<N^P-02P,$%     @ :8LI3YT\2N7; 0
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M[!OR-UU*:<!:"6[LZZYM[\\!A]*XZ9V=J[$#QL#(;FIN,O]ALK]02P,$%
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MKHLP"6^!Q_)XTC80+><M._(?7/]L'Z2918/*OJQYHTK1!)(?%N%],ML6%N\
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M!/0T.U0D<I2?X)Y!0--@B<,%II?8^()0D<A\9_Q&=!\,IHX [+@#.X*Y(U/
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M8WU?#X="PT.K3N.!5W ]=5O^#U!+ P04    " !IBRE/7[-#7\@!  !0!
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R-5.UNFS 4?17D!ZC#U])$
M@-0FJC9IDZ).:W\[< FH_F"V$[JWGVT<2AFK^@?[7I]S?,^U3=8+^:(: !V\
M,LI5CAJMNRW&JFR $74C.N!FI1:2$6U"><*JDT J1V(41ZO5%\Q(RU&1N=Q!
M%IDX:]IR.,A G1DC\L\]4-'G*$37Q&-[:K1-X"+KR E^@O[5':2)\*A2M0RX
M:@4/)-0YN@NW^]CB'>"IA5Y-YH%U<A3BQ0;?JARM;$% H=16@9CA CN@U J9
M,GY[331N:8G3^57]P7DW7HY$P4[0Y[;238YN45!!3<Y4/XK^*W@_*0J\^>]P
M 6K@MA*S1RFH<M^@/"LMF%<QI3#R.HPM=V,_K"1K3ULF1)X0C80P^9 0>T+\
M64+B"<F,@ <KKC=[HDF12=$'<CC=CMA+%&X3T_W2)EVSW9IICS+92Q&E<88O
M5LAC[@=,-,6\1^P6$#/(?@'RM@\V-8Z%1HN%1HX?3_AA_!^!>%$@=@+).Z?)
MS.F 21V&7[N1K&>PW;^P<'V[B38SRPNP9).FLZ+QY*CL6_M!Y*GE*C@*;4[=
MG4TMA :CN+HQ8HUYWF- H=9VNC9S.5SR(="B\^\7CS^1XB]02P,$%     @
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MW4FIA(X\O-,Q'_1E:!P48J?:UUB_U_V-H!\H>1QN.\%XY5K\ U!+ P04
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M@7"&6)PQC#W9I5X;SI42/89;#1N&M=W# :19WE'_601YD06Y!JP 5?^LH:H
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M3X^TC?XA%V<O!Y<[<)&AK/3FH L?T-[$[XT'/HG63CVB4HWR6N9_O1&SIV7
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M'5:MC!;X'Q,W0J9A I)7VM&4,;14IH)'CR3!>EY(=9FR@T*B.'QKRJ>I*T8
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M(.ODMZU<3:=,=#/AJ&%PAWHX\, 5Z+F[\LJ[RI5M@<KBKXQA4CY*BR0+F/T
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M!WU.=3L'$W78@4/]@;>/"#(8]>'!>.B=4%OVN89S];];35PF\STDV/Y@C!@
M<Q^J4:>W)8W[M8$T:=VV@$K#L/KX:T"MY;CV[('5T._T_.CBTXFZF?YYG>A'
MS9]?6HKC?P'?KE";<TW%*:(:9.MGK'=)]Q'.'2G/GIH HX._O(:J[,C5]8L@
MC\B;P&/XAC?58=\S\+5_?26>V;01O238$E#(4=LVS,IA1_S>S]W$S],$CK%A
M?)R_5?OJ]OI8O=FK8<:T13ZL5W!<*\:V%5VIIMX_9 #<VA8K F_U>8O ^TM
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MR&[609L7N!5SP*7:LO5VT?NR:F>J=WF^^N[_ U!+ P04    " !IBRE/(^A
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MFW$I';%W6"3.J2X04>DUX/8@AYR5A$E2(OTF>45+S5&B*UQA5A!D0/H I']
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M+-95-=1Y"1MSW%["-&UL;[<N?P)02P,$%     @ :8LI3W<"Y'%A 0  ^1$
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\78/6Z#0!"&X:M8',#+
MC/\CVU4:MTDNL,)C0.9/NQO%OGT(3;!D[Z2POC0@!)IYJT? ]DTJ&\JV\479
M^<FEKAJ_2XH0NA=C?%9(;?VT[:3I[YQ:5]O07[K<=#8[VUP,I^G2N/&,9+\=
MSYP<CKO$'8Z43#ZLRR7L$G.IS%?KSKX0"=X,)YKV"_I'KIW\97U[.I69O+;9
M9RU-N%/QNR Q]X,X'L3PH%D\: 8/FL>#YO"@13QH 0]:QH.6\*!5/&@%#UK'
M@];PH$T\: ,/HE21,<4G:5CCM2:%:\)[30K8A!>;%+();S8I:!->;5+8)KS;
MI,!->+E)H9OP=I."-^'U9D5OQNO-BM[\#^_:VLLV7F]6]&:\WJSHS7B]6=&;
M\7JSHC?C]69%;\;KS8K>C->;1WK[PCHYO@=7-KE_=LG-\(=?VR.X?;A6\OR,
M8>K#_2.E0[]%S'!\NLW#U)\(<_.G9_\-4$L#!!0    ( &F+*4\8HYZ=@@$
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MBWU]TOVZFGX#4$L! A0#%     @ :8LI3Q\CSP/     $P(   L
M     ( !     %]R96QS+RYR96QS4$L! A0#%     @ :8LI3R?HAPZ"
ML0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " !IBRE/L5K-4.\    K @  $0              @ &9 0  9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " !IBRE/F5R<(Q &  "<)P  $P
M        @ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &F+
M*4^%Q^P&( (  .@&   8              "  ?@(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " !IBRE/U]X':>T#   D$@  &
M        @ %."P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ :8LI3\\,ODEA @  . D  !@              ( !<0\  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &F+*4^^Z#GRVP,  -00   8
M              "  0@2  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " !IBRE/3@<[ ]@#  # $   &               @ $9%@  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ :8LI3P.8AFI^!
M^!0  !@              ( !)QH  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( &F+*4\QG#:FR0$  &T$   8              "  =L>
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !IBRE/0-$L
M,,T!  !M!   &               @ ':(   >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ :8LI3YKPH<', 0  ;00  !@
M ( !W2(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &F+
M*4_L57M7S $  &T$   9              "  =\D  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ :8LI3V#9FSK, 0  :@0  !D
M         ( !XB8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " !IBRE/LYU98,P!  !M!   &0              @ 'E*   >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &F+*4_=S^2PS $  &T$
M   9              "  >@J  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ :8LI3ZV840^U 0  U ,  !D              ( !ZRP
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !IBRE/@\.1
M*OL"  "W#0  &0              @ '7+@  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( &F+*4\MM @.WP$  /8$   9
M  "  0DR  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M:8LI3YT\2N7; 0  T00  !D              ( !'S0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " !IBRE/KV%FB-$!  !M!   &0
M            @ $Q-@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( &F+*4]BC---0P(  )4'   9              "  3DX  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ :8LI3R&0%%2< @
MN @  !D              ( !LSH  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " !IBRE/J^+,/><#  "!$P  &0              @ &&
M/0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &F+*4]?
MLT-?R $  % $   9              "  :1!  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ :8LI3^LV:\2^ 0  0P0  !D
M     ( !HT,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &F+*4^M:W_WR0$  %($   9              "
M :)0  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ :8LI
M3]LQV&=!2@  5((! !0              ( !HE(  'AL+W-H87)E9%-T<FEN
M9W,N>&UL4$L! A0#%     @ :8LI3R/H0#P] @  @ H   T
M ( !%9T  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !IBRE/Q(!(J@,#  !A
M$P  #P              @ %]GP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ :8LI3W<"Y'%A 0  ^1$  !H              ( !K:(  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ :8LI3QBCGIV" 0  PA(
M !,              ( !1J0  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ "4 )0#U"0  ^:4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6767500352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MODD_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Modular Medical, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">To update financials.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MODD_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MODD_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MODD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6767452800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Common Stock Issuable</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,582,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, amount at Mar. 31, 2017</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,582<span></span>
</td>
<td class="nump">$ 404,467<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (49,417)<span></span>
</td>
<td class="nump">$ 362,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Reverse capitalization, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,168,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Reverse capitalization, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,168<span></span>
</td>
<td class="num">(117,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,233,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued for cash, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,233<span></span>
</td>
<td class="nump">4,724,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,731,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(659,246)<span></span>
</td>
<td class="num">(659,246)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,983,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, amount at Mar. 31, 2018</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,983<span></span>
</td>
<td class="nump">5,011,661<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(708,663)<span></span>
</td>
<td class="nump">4,318,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,856,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued for cash, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,857<span></span>
</td>
<td class="nump">4,140,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,142,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issuable for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,539,498)<span></span>
</td>
<td class="num">(2,539,498)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,840,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, amount at Mar. 31, 2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,840<span></span>
</td>
<td class="nump">$ 9,684,578<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
<td class="num">$ (3,248,161)<span></span>
</td>
<td class="nump">6,474,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,122,198)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, amount at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,546,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6616982880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PAYABLE TO RELATED PARTY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Payable to related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6712611872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net loss carryforward</a></td>
<td class="nump">$ 1,098,000<span></span>
</td>
<td class="nump">$ 817,000<span></span>
</td>
<td class="nump">$ 182,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,098,000)<span></span>
</td>
<td class="num">(817,000)<span></span>
</td>
<td class="num">(182,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>49
<FILENAME>0001019056-19-000521-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001019056-19-000521-xbrl.zip
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M=*L_;"WD#*R$JN(Z*)EVDV6LLR;[[4$QJGK5K/L"<]L,JE:_F/IS5.BWS^&
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M9JQ@]<GK!7MC?:'7,K%]++"W4"=. .I-B;O?,BO)U0AUL6Y\'02]"M+B?+4
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MWLH: FRKA:T788%!/,5DJ#DLV4,?T$V(W74QYU9$=Y04+)M$JBYTG (<J%9
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M)'>[H<X2;%I"9I ^AHK-/XVK>.K90D<@79"6FT]L#>G$A^5GL2EVY,4F 5&
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MT7W R:4($)/RH"N] E O<]5><0&W'IYLW!X)SR;93CS$T#)U)<J 7 O0L.E
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MLAH C\Z'<*S\N^KYL96%4=6DV9V._HTS:<N"83:<,U\WH-48]C9*W-YZ$^K
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MIW/'<\((,?S,Q+/-TS<$P-R:SX LZ5!V_.)F^R)P,!(+] %$N;!? ]_E#S_
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M /E):]"[)'76JV-5NN0^23-#<]0;FL->^RCHNE"D]\WQJ&M:P[(I9TU-ECP
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MRBQE6D# A9214 %8\J[S7YE0.?>GSLRA,3]1X,OQT!P$G#I@3Y[XV@E -*$
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M6-4$M@.P$E]3YKR]\R(G>OV-/3K8!-.+/MKSPE,Q?_[@3\&P#XP/;(H:O6F
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M8[VNQMU. J73[8^L2\?=/H*J73_R_OK3]X? ==[B_\(__Q]02P,$%     @
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MHY$H3D5@:N6DY([X@Y!@0BB'I4XY-3X5P!TNV'M+:I#0 Z.R? B77?R\J\O
M0MSOZ&M;R#^HDV+0[>AD)F&_DZO-A9:#.@Q#9U>'5T?;=_*W-5>R[&YRN:"\
MN%V0?,_>0+@"QP/*D9^[T2"[X!)?S6D'5B1*PB*^*2F?(IH4M:K4U+,ILQ>6
M[F+$(@R[&9'R[6&$])I-D15L'9-X4!;<VQH@O;2S)@R1_D+&,G$Y2UN4A:A]
MK,E?N-G?G$C6'O9L<==HFU19YNS$C")7+D6NJ/4W&K.?(7M;L9)\T=X?G8E@
MG^^4M<N,Z1=E(67G?&&4[YXJ*5.<)O!M?88D5[>B,D_<^/ICXX'.13DW(%-^
MX\+JJ!1YL,5AT&)>QW7%=M!UB=-03-7BSF #IG GL ?1F\8.:7(Q*W[SQ!?G
M&CR587#B"4H(3_C,8)(/!?4=#<+)=2D6YP")U.W,<1V9EUN1O@NG5O"(]K%G
M&T#+$[T'1WHT&!(F[@)C]Y8D1T?RKFPF>P_.]!WVC<'@>(#7.X7UC\^=M1YM
M2?L>W#+'F)(;J!;L9N")+?=X$H"%G3^*2&]F"Y(>GD5W*U\QM:./+X1%?VN)
M;$Z]/ZS(G8,44S!.0<H! M0F(^Q&D^(B2YMC<3?VGGC/A*9>;T&W+]YVX$$.
M'< 7P,,+_&AKS& L%,:L.B$C> ?6^RQTH;[F3,V:7=#SGNRMKK6W^G[LE5V=
MUD"F^ </J0?;T>+D*?7I'Q_,&TN=K)\[,+P_9S,53\ZWM?W_H"M7Y;A6AL>_
M 5!+ P04    " !IBRE/D2@ +) *  "!=@  %0   &UO9&0M,C Q.3 V,S!?
M8V%L+GAM;.U=7W/B.!)_OZK[#EJVKG;O@0!A)K/)3F[+ 9)S'0$6R-[,OFPI
MMB"J-18K&P+[Z:]E#,'_Y8!M;=5-U23!4;?ZU]UJM5JR\OFGS<)":\(=RNS;
M6NNB64/$-IA)[?EM[6E2UR8=7:\AQ\6VB2UFD]N:S6H__>OO?T/P[_,W]3JZ
MI\0R;U"7&77=GK$?T0 OR UZ(#;AV&7\1_0+ME;PY.<ONNW",\.E:P)/=[W>
MH \7EU<8U>L23"=LQ0URX/BI?=ULH^95NWG9;%VC24N[V,R@PRYVX;?BV3\N
MN\W=EVFK?=/Z=-/\]*MD5RYV5\ZAJ^;FAV:SU83_._+/%K5_OQ%?GK%#$*C1
M=FXV#KVMO;CN\J;1>'U]O7AM7S ^;UP"5>/+8W]BO) %KE-;J-,@M3V5X!)'
MU[J^OFYXO]TWC;3</'-KWT>[L1?GP!E^2U/:'TGBT!O'$Z_/#.QZWI#9#4IL
M(3[5]\WJXE&]=5EOMRXVCEG;*]_3(&<6&9,9$M^?QOJAUP4S5Q;F]04QJ8&M
M"X,M&J)- ^RT6A#;U6RS9[O4W0JC\84G,^#PF+YP,KNM 0NS+IQ .(CH^5L9
M6G>[!"=WZ&)I@5X:IPE[ARVAW\D+(:Z3)5ULX^+$&6$.JG@AKFB32[98RK,*
M*@8?$99RAK/A4L01L%"F M.IBA%P.)NXS/C]A5DFQ+/>'ROP*FDYTX@+TV<'
M.R_W%GO-I<X(T5G%&_(YMNF?GKU@;$Y6BP7F6] .G=MT!FUAR!H&6\&8M><C
M9E&#DDSQ3V)Z5GACPH*RC#A=@VY'%C8\!6=!D69P5K%!.WQ%S-YF26PG6]\)
MS<\JT@AO\;-%IFQ,+,!O0B3*'FZI1&<>9OE#02GC7X><;D&F>)-MQIBFYQT,
M;(LM=ZO-.9'S_83V9Q6J3R!/D18IOG7U$;'0R%AHA'R71%,QJHL!&V1=<(R0
MPY%%5U2\D),ND:!Z-^D2%U.K&#\)\58&;*M(M"WEX XP%\G^FA0).]))D<E6
M7F"2Y,4G8WD%S\6DX$ L&2DR"<L1,W.,9U.6(ZBT+\AS*&JRD_2 9(J"!9-6
MI01IFJ@@A@$RB3#9A\\!"K)QB6T2<\]'B'J>LAT\%JR:NW\M5$=[JN,?L6VB
M'0L4X%$T@OCR7$#D2Y#S4#6!GSL,NH%X;(J?')A.3!'BD,\)^:Q\N?>26\P(
M2&N)@BSC08O[PGI5UQEVGKW2Z\JISS%>-H0G-(CE.OLGGF_4FRV_ ONM__@W
MS7% @,Z*\Z-UC(6?B>5U^YO?+M2L49W H@P%'B2^B0"QQI8H3VEN!YQ["U.V
M5ZQ/!B))'@9XY$L:-Q#C$*!N:X<HBKD1\*!H.=QOT7!$OB'8U"GXR)Y^QMDB
M3=^^;ME[H!S;!:2HH5="YR^N)WV%=ARZ+X1+>E]<6SD+759JH62,RIEC)^6
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MB5' ;!F;1%M6/<:E#9($4CEK:*9)!6YLC3 U=;N#E]3%*36G1(*JE\;2MLF
MK)R)QF+WRR9F#W,;)@P'\N+58N7E6ETRHP9-R2YE:.4,]Z%ZP\DK0CD;'L6#
MR0OF9+)Z=@Q.GXEYMW*?;.HXL-+Q'RZ],]]C8A"Z%DLAJ0#Y#JYR=O]8O=W/
MH;P8CZ@KLP 1YWARY%G9E%4G+K+8DM<O:A?2WHDOZZAT$LS/C3#*/GPN\[!
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M1_9"_@#L2.(2SF"KP9+OCOX HDB6DY3E5H,L^RK_ )I(+A0_CY07CR2N^ \
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MY6,F>OB5+C"<W=9(%7J=]A?:EVC+/_#(NNLE&0^.82U-8I?&^\#> 9/:=[R
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MKUF:Q(D3LD--+:JBHM4WT20F-+&MI *:<B).4]Y%!TT8Y"O-#+4,\XPT>YH
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M@*Y*'503!^-AFC%J$POQW%,E'1@48[.[;+0[6_,F0>WZR2'$H:ZM-.,[(\/
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M[0%4!1UTP#E#B5U-_D^OTC//M%Y.)P^9:4U.;#(=SC[20&GP\_D6+J*=$]#
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MWNE5E*$XK,W&SZX69ZFX(C[CC$.WD8-="K#KSMH:5O5NIMJ]T[,S9(GO.Z@
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M5*,[+KL61KGP&,)L&@J#9LQC0GX@N7_$*Z\]*EO-T^!J; 8KS<9'-K^W*^-
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MO4>4TLITGU\>;!010&GJR %Y]UW%'&#UZ3[_W(=(F4FH('K\W@N\;]6Q_VG
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MZF6TN*<AK&190=U[LGQKR;Y*RE=QWUTC.::74$POE8,T3,'TDHNI&><9H//
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M948\J0FPTGS'[U;I7]@_V&D2_<W_ U!+ 0(4 Q0    ( &F+*4^3O&2Y'9H
M (Z*!@ 1              "  0    !M;V1D+3(P,3DP-C,P+GAM;%!+ 0(4
M Q0    ( &F+*4\WG2T&'P@  +5$   1              "  4R:  !M;V1D
M+3(P,3DP-C,P+GAS9%!+ 0(4 Q0    ( &F+*4^1*  LD H  (%V   5
M          "  9JB  !M;V1D+3(P,3DP-C,P7V-A;"YX;6Q02P$"% ,4
M" !IBRE/N),DQF$,   YG0  %0              @ %=K0  ;6]D9"TR,#$Y
M,#8S,%]D968N>&UL4$L! A0#%     @ :8LI3ZB-NJD!)0  K P" !4
M         ( !\;D  &UO9&0M,C Q.3 V,S!?;&%B+GAM;%!+ 0(4 Q0    (
M &F+*4\N!*I8'!P  "7% 0 5              "  27?  !M;V1D+3(P,3DP
A-C,P7W!R92YX;6Q02P4&      8 !@"* 0  =/L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6630192896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ROYALTY AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MODD_RoyaltyAgreementAbstract', window );"><strong>Royalty Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MODD_RoyaltyAgreementDisclosureTextBlock', window );">ROYALTY AGREEMENT</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 12, 2017, the Company entered into a
royalty agreement with the founder and major shareholder. Pursuant to the agreement, the founder and major shareholder is assigning
and transferring all of his rights in the intellectual property in return for royalty payments. The Company shall pay royalty to
the founder on any sales of the royalty product sold or otherwise commercialized by the Company, equal to (a) US $0.75 on each
sale of a royalty product, or (b) five percent (5%) of the gross sale price of the royalty product, whichever is less. The royalty
payments shall cease, and this agreement shall terminate, at such time as the total sum of royalty payments actually paid to the
founder, pursuant to this agreement, reaches $10,000,000. The Company shall have the option to terminate this agreement at any
time upon payment, to the founder, of the difference between total royalty payments actually made to him to date and the sum of
$10,000,000. All payments of the royalties, if due, for the preceding quarter, shall be made by the Company within thirty days
after the calendar quarter.</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 12, 2017, the Company entered into a
royalty agreement with the founder and major shareholder. Pursuant to the agreement, the founder and major shareholder is assigning
and transferring all of his rights in the intellectual property in return for royalty payments. The Company shall pay royalty to
the founder on any sales of the royalty product sold or otherwise commercialized by the Company, equal to (a) US $0.75 on each
sale of a royalty product, or (b) five percent (5%) of the gross sale price of the royalty product, whichever is less. The royalty
payments shall cease and this agreement shall terminate, at such time as the total sum of royalty payments actually paid to the
founder, pursuant to this agreement, reaches $10,000,000. The Company shall have the option to terminate this agreement at any
time upon payment, to the founder, of the difference between total royalty payments actually made to him to date and the sum of
$10,000,000. All payments of the royalties, if due, for the preceding quarter, shall be made by the Company within thirty days
after the calendar quarter.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MODD_RoyaltyAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MODD_RoyaltyAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MODD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MODD_RoyaltyAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MODD_RoyaltyAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MODD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6752697968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: black 1pt solid"><font style="font-size: 8pt"><b>Grantees</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Option</b></font><br />
<font style="font-size: 8pt"><b>Shares</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Vesting </b></font><br />
<font style="font-size: 8pt"><b>Periods</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total Fair </b></font><br />
<font style="font-size: 8pt"><b>Value of</b></font><br />
<font style="font-size: 8pt"><b>Options</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2019 Stock-Based </b></font><br />
<font style="font-size: 8pt"><b>Compensation </b></font><br />
<font style="font-size: 8pt"><b>Expense</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Unrecognized </b></font><br />
<font style="font-size: 8pt"><b>expense at </b></font><br />
<font style="font-size: 8pt"><b>March 31, 2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 28%"><font style="font-size: 8pt">Consultants</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">1,280,000</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 22%"><font style="font-size: 8pt">July 25, 2018 to July 24, 2019</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">682,240</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">466,197</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">216,043</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Consultants</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">185,221</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">January&#160;&#160;16, 2019 to January 15, 2022</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">336,732</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">23,150</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">313,582</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Chief Executive Officer</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">64,687</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">*</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">42,761</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">42,761</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Total</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">1,529,908</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">1,021,733</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">532,108</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">489,625</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">* Options were fully vested as of the grant date, as disclosed above.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Options</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Weighted </font><br />
<font style="font-size: 8pt">Average</font><br />
<font style="font-size: 8pt">Exercise Price</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Average </font><br />
<font style="font-size: 8pt">Remaining</font><br />
<font style="font-size: 8pt">Life</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 64%; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Outstanding and exercisable &#8211; March 31, 2019</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">918,020</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">0.68</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">9.43</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Vested</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">280,352</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">0.74</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Expired</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Outstanding and exercisable &#8211; June 30, 2019</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">1,198,372</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">0.69</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">5.13</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt; text-align: center; text-indent: -8.65pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Options</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Weighted</font><br />
<font style="font-size: 8pt">Average</font><br />
<font style="font-size: 8pt">Exercise</font><br />
<font style="font-size: 8pt">Price</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">Average</font><br />
<font style="font-size: 8pt">Remaining</font><br />
<font style="font-size: 8pt">Life</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Outstanding and exercisable &#8211; March 31, 2018</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 64%; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Vested</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">918,020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Expired</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt">Outstanding and exercisable &#8211; March 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">918,020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">0.68</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">9.43</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6770841440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">$ 703,783<span></span>
</td>
<td class="nump">$ 135,789<span></span>
</td>
<td class="nump">$ 1,882,345<span></span>
</td>
<td class="nump">$ 332,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">5,706,628<span></span>
</td>
<td class="nump">4,053,771<span></span>
</td>
<td class="nump">6,553,768<span></span>
</td>
<td class="nump">4,296,676<span></span>
</td>
<td class="nump">$ 392,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Uninsured cash and cash equivalents</a></td>
<td class="nump">5,421,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,269,116<span></span>
</td>
<td class="nump">3,933,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 6,714<span></span>
</td>
<td class="nump">$ 1,395<span></span>
</td>
<td class="nump">$ 14,468<span></span>
</td>
<td class="nump">$ 1,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software developed or acquired for internal use | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software developed or acquired for internal use | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember', window );">Computer equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember', window );">Computer equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6759213392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding and exercisable, beginning</a></td>
<td class="nump">918,020<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested</a></td>
<td class="nump">280,352<span></span>
</td>
<td class="nump">918,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding and exercisable, ending</a></td>
<td class="nump">1,198,372<span></span>
</td>
<td class="nump">918,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding and exercisable, beginning</a></td>
<td class="nump">$ .68<span></span>
</td>
<td class="nump">$ .00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price vested</a></td>
<td class="nump">0.74<span></span>
</td>
<td class="nump">.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price expired</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding and exercisable, ending</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ .68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Average remaining life outstanding and exercisable, beginning</a></td>
<td class="text">9 years 5 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Average remaining life outstanding and exercisable, ending</a></td>
<td class="text">5 years 1 month 17 days<span></span>
</td>
<td class="text">9 years 5 months 5 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6770087920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">17,870,261<span></span>
</td>
<td class="nump">17,840,261<span></span>
</td>
<td class="nump">15,983,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">17,870,261<span></span>
</td>
<td class="nump">17,840,261<span></span>
</td>
<td class="nump">15,983,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6636474400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Modular Medical, Inc. (the &#8220;Company&#8221;)
was organized under the laws of the State of Nevada on October 22, 1998, to engage in any lawful purpose. The Company has at the
present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements
of the Company and other relevant factors.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Quasuras, Inc. (&#8220;Quasuras&#8221;) was
incorporated in Delaware on April 20, 2015.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Quasuras has developed a hardware technology
allowing people with insulin dependent diabetes to receive their daily insulin in two ways, through a continuous &#8220;basal&#8221;
delivery allowing a small amount of insulin to be in the blood at all times and a &#8220;bolus&#8221; delivery to address meal
time glucose input and to address when the blood glucose level becomes too high. By addressing the time and effort required to
effectively treat their condition, Quasuras believes it can address the less technically savvy, less motivated part of the market.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reorganization</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2017, pursuant to a Reorganization
and Share Exchange Agreement, by and among the Company and Quasuras, the Company acquired one hundred percent (100%) of the issued
and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary
of the Company. Since the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was
accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the Reorganization,
at their historical carrying amounts.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the reorganization, the Company
changed the fiscal year end from June 30 to March 31, to coincide with the year end for Quasuras.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements of the
Company have been prepared in accordance with accounting principles generally accepted in the United States of America. The following
summarizes the more significant of such policies:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Basis of Presentation</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the consolidated financial
statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates
and assumptions that affect reported amounts and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Principles of Consolidation</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include
the accounts of Modular Medical, Inc. and its wholly-owned subsidiary Quasuras, Inc., and are collectively referred to as the &#8220;Company&#8221;.
All material intercompany accounts, transactions and profits were eliminated in consolidation.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the accompanying financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Reportable Segment</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has one reportable segment. The
Company&#8217;s activities are interrelated and each activity is dependent upon and supportive of the other. Accordingly, all significant
operating decisions are based on analysis of financial products provided as a single global business.<b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Professional Fees</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses the cost of legal, accounting,
audit, tax and other professional services.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Research and Development</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses the cost of research and
development as incurred. Research and development costs charged to operations were approximately $703,783 and $135,789 for the
fiscal quarter ended June 30, 2019 and 2018, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>General and Administration</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expense consists
primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and meetings and travel.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Income Taxes</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilizes Financial Accounting Standards
Board (FASB) Accounting Standards Codification (ASC) Topic 740, Income Taxes, which requires recognition of deferred tax assets
and liabilities for the expected future tax consequences of events that were included in the consolidated financial statements
or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences
between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws
and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances
are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for uncertain tax positions
in accordance with FASB ASC Topic 740. When tax returns are filed, it is likely that some positions taken would be sustained upon
examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount
of the position that would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements
in the period during which, based on all available evidence, management believes it is more likely than not that the position will
be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not
offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured
as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable
taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described
above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any
associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in
the consolidated statements of income.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2019 and 2018, the Company had not
taken any significant uncertain tax positions on its tax returns for periods ended June 30, 2019 and prior years or in computing
its tax provision for 2019. Management has considered its tax positions and believes that all of the positions taken by the Company
in its Federal and State tax returns are more likely than not to be sustained upon examination. The Company is subject to examination
by U.S. Federal and State tax authorities for the period ended March 31, 2017 to the present, generally for three years after they
are filed.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentration of Credit Risk</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company maintains cash balances
at financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to
limits of approximately $250,000. The Company has not experienced any losses with regard to its bank accounts and believes it is
not exposed to any risk of loss on its cash bank accounts.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks and Uncertainties</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to risks from, among
other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements,
rapidly changing customer requirements, limited operating history and the volatility of public markets.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Contingencies</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain conditions may exist as of the date
the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when
one or more future events occur or fail to occur. The Company&#8217;s management and legal counsel assess such contingent liabilities,
and such assessment inherently involves judgment. In assessing loss contingencies related to legal proceedings that are pending
against the Company or unasserted claims that may result in such proceedings, the Company&#8217;s legal counsel evaluates the perceived
merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected
to be sought.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the assessment of a contingency indicates
it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability
would be accrued in the Company&#8217;s consolidated financial statements. If the assessment indicates that a potential material
loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent
liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies
considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would
be disclosed.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Cash and Cash Equivalents</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents include cash in hand
and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months
or less. At June 30, 2019 and March 31, 2019, the Company had $5,706,628 and $6,553,768, respectively, in cash. Deposits at the
bank are insured up to $250,000 by the Federal Deposit Insurance Corporation. The Company&#8217;s uninsured portion of the balances
held at the bank aggregated to approximately $5,421,940 and $6,269,116 respectively. No reserve has been made in the financial
statements for any possible loss due to any financial institution failure.&#160;The Company has not experienced any losses in such
accounts and believes we are not exposed to any significant risk on cash and cash equivalents.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Property, Plant &#38; Equipment</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment is stated at cost and
depreciated using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. The estimated
useful lives of our property and equipment are generally as follows: computer equipment&#38; software developed or acquired for
internal use, three to ten years; office equipment, two to three years; buildings and improvements, five to fifteen years; leasehold
improvements, two to ten years; and machinery and equipment, one to five years.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2019 and March 31, 2019, property, plant and equipment
amounted to:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2019</b></font><br />
<font style="font-size: 8pt"><b>(UNAUDITED)</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31, 2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 76%"><font style="font-size: 8pt">Computer equipment and software</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">25,028</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">20,565</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Office equipment</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">49,724</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">49,724</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Machinery and equipment</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">24,194</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">21,937</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">Less: accumulated depreciation</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(22,985</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(16,278</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">75,961</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">75,948</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Depreciation expenses for the quarter ended June 30, 2019 and March
31, 2019 was $6,707 and $1,387 respectively.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Fair Value of Financial Instrument</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For certain of the Company&#8217;s financial
instruments, including cash and equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair
values due to their short maturities. ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; requires disclosure
of the fair value of financial instruments held by the Company. ASC Topic 825, &#8220;Financial Instruments,&#8221; defines fair
value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements
for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities
each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between
the origination of such instruments and their expected realization and their current market rate of interest. The three levels
of valuation hierarchy are defined as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 inputs to the valuation methodology
are quoted prices for identical assets or liabilities in active markets.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 inputs to the valuation methodology
include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability,
either directly or indirectly, for substantially the full term of the financial instrument.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 inputs to the valuation methodology
are unobservable and significant to the fair value measurement.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to their short-term nature, the carrying
values of cash and equivalents, accounts receivable, accounts payable, and accrued expenses, approximate fair value. Based on borrowing
rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair
value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Earnings Per Share (&#8220;EPS&#8221;)</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings per share are computed by dividing
earnings available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted
earnings per share are computed by dividing net income by the weighted average number of shares outstanding during the period increased
to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities
had been issued. During the fiscal quarter ended June 30, 2019 and 2018 we incurred losses. Therefore, the effects of any common
stock equivalent were anti-dilutive during those periods.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets for the computation
of basic and diluted earnings per share for the fiscal quarters ended June 30, 2019 and June 30, 2018:<b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2019</b></font><br />
<font style="font-size: 8pt"><b>(UNAUDITED)</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2018</b></font><br />
<font style="font-size: 8pt"><b>(UNAUDITED)</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="width: 76%; padding-bottom: 2.5pt; padding-left: 17.3pt"><font style="font-size: 8pt"><b>Net Loss</b></font></td>
    <td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(1,122,198</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(249,566</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 8pt"><b>Net Loss Per Share</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-bottom: 2.5pt; padding-left: 8.65pt"><font style="font-size: 8pt"><b>Basic and Diluted:</b></font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.06</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.02</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Weighted average number of shares used in computing basic and diluted net loss </b></font><br />
<font style="font-size: 8pt"><b>per share:</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-bottom: 2.5pt; padding-left: 8.65pt"><font style="font-size: 8pt">Basic</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">17,847,740</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">15,983,273</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 8.65pt"><font style="font-size: 8pt">Diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">17,847,740</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">15,983,273</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify">In May 2014, the FASB issued ASU 2014-09,&#160;<i>Revenue
from Contracts with Customers</i>, issued as a new Topic, ASC Topic 606. The new revenue recognition standard supersedes all existing
revenue recognition guidance. Under this ASU, an entity should recognize revenue when it transfers promised goods or services to
customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or
services. ASU 2015-14, issued in August 2015, deferred the effective date of ASU 2014-09 to the first quarter of 2018, with early
adoption permitted in the first quarter of 2018. The company has adopted the new standard utilizing the modified retrospective
approach. The adoption of this new accounting guidance does not have material effects on results of operations, cash flows and
financial position for the forceable future because the company does not have revenues.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2016, The FASB issued ASU No. 2016-01,<i>&#160;Financial
Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825)</i>. ASU No. 2016-01 revises
the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes
for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments
to be recognized in net income. For non-public companies, ASU 2016-01 is effective for fiscal years beginning after December 15,
2018, and interim periods within fiscal years beginning after December 15, 2019. We are currently evaluating the impact of the
adoption of ASU 2016-01 will have on our consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU No. 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This update addresses a diversity
in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic
230, Statement of Cash Flows, and other Topics. The amendments in this Update are effective for public business entities for fiscal
years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including
adoption in an interim period. We adopted this ASU in 2016 and the implementation did not have a material impact on our financial
position or statement of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued guidance that
eases certain documentation and assessment requirements of hedge effectiveness and modifies the accounting for components excluded
from the assessment. Some of the modifications include the ineffectiveness of derivative gain/loss in highly effective cash flow
hedge to be recorded in other comprehensive income, the change in fair value of derivative to be recorded in the same income statement
line as hedged item, and additional disclosures required on the cumulative basis adjustment in fair value hedges and the effect
of hedging on financial statement lines for components excluded from the assessment. The amendment also simplifies the application
of hedge accounting in certain situations to permit new hedging strategies to be eligible for hedge accounting. The guidance is
effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2018,
our fiscal 2020. Early adoption is permitted, and the modified retrospective transition method should be applied. We do not expect
the adoption of this guidance to have a material impact on our consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, FASB issued ASU No. 2016-02,
Leases (&#8220;Topic 842&#8221;). Topic 842 requires an entity to recognize right-of -use assets and lease liability on its balance
sheet and disclosure key information about leasing arrangements. For public companies, Topic 842 is effective for annual reporting
periods beginning after December 15, 2018, including interim periods within that reporting period, with early adoption permitted.
We have evaluated this ASU and believe this guidance will not have a material impact on our financial position and statement of
operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other recent accounting pronouncements issued
by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities
and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future
consolidated financial statements.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Reclassification</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior year amounts have been reclassified
for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations
or cash flow.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Modular Medical, Inc. (the &#8220;Company&#8221;)
was organized under the laws of the State of Nevada on October 22, 1998, to engage in any lawful purpose. The Company has at the
present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements
of the Company and other relevant factors.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Quasuras, Inc. (&#8220;Quasuras&#8221;) was
incorporated in Delaware on April 20, 2015.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Quasuras has developed a hardware technology
allowing people with diabetes to receive their daily insulin in two ways, through a continuous &#8220;basal&#8221; delivery allowing
a small amount of insulin to be in the blood at all times and a &#8220;bolus&#8221; delivery to address meal time glucose input
and to address when the blood glucose level becomes too high. By addressing the time and effort required to effectively treat their
condition, Quasuras believes it can address the less technically savvy, less motivated part of the market.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reorganization</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2017, pursuant to a Reorganization
and Share Exchange Agreement, by and among the Company and Quasuras, the Company acquired one hundred percent (100%) of the issued
and outstanding shares of Quasuras for 7,582,060 shares of the Company, resulting in Quasuras becoming a wholly-owned subsidiary
of the Company. Since the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was
accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the Reorganization,
at their historical carrying amounts.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the reorganization, the Company
changed the fiscal year end from June 30 to March 31, to coincide with the year end for Quasuras.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements of the
Company have been prepared in accordance with accounting principles generally accepted in the United States of America. The following
summarizes the more significant of such policies:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Basis of Presentation</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the consolidated financial
statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates
and assumptions that affect reported amounts and related disclosures.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Principles of Consolidation</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include
the accounts of Modular Medical, Inc. and its wholly-owned subsidiary Quasuras, Inc., and are collectively referred to as the &#8220;Company&#8221;.
All material intercompany accounts, transactions and profits were eliminated in consolidation.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the accompanying financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Reportable Segment</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has one reportable segment. The
Company&#8217;s activities are interrelated and each activity is dependent upon and supportive of the other. Accordingly, all significant
operating decisions are based on analysis of financial products provided as a single global business.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Professional Fees</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses the cost of legal, accounting,
audit, tax and other professional services.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Research and Development</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses the cost of research and
development as incurred. Research and development costs charged to operations were approximately $ 1,882,345 and $332,642 for the
fiscal year ended March 31, 2019 and 2018, respectively.&#9; &#9; &#9;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>General and Administration</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expense consists
primarily of payroll and benefit related costs, rent, office expenses, equipment supplied and meetings and travel.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Income Taxes</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilizes Financial Accounting Standards
Board (FASB) Accounting Standards Codification (ASC) Topic 740, Income Taxes, which requires recognition of deferred tax assets
and liabilities for the expected future tax consequences of events that were included in the consolidated financial statements
or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences
between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws
and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances
are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for uncertain tax positions
in accordance with FASB ASC Topic 740. When tax returns are filed, it is likely that some positions taken would be sustained upon
examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount
of the position that would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements
in the period during which, based on all available evidence, management believes it is more likely than not that the position will
be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not
offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured
as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable
taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described
above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any
associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in
the consolidated statements of income.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2019 and 2018, the Company had
not taken any significant uncertain tax positions on its tax returns for periods ended March 31, 2019 and prior years or in computing
its tax provision for 2019. Management has considered its tax positions and believes that all of the positions taken by the Company
in its Federal and State tax returns are more likely than not to be sustained upon examination. The Company is subject to examination
by U.S. Federal and State tax authorities for the period ended March 31, 2016 to the present, generally for three years after they
are filed.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentration of Credit Risk</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company maintains cash balances
at financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to
limits of approximately $250,000. The Company has not experienced any losses with regard to its bank accounts and believes it is
not exposed to any risk of loss on its cash bank accounts.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks and Uncertainties</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to risks from, among
other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements,
rapidly changing customer requirements, limited operating history and the volatility of public markets.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Contingencies</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain conditions may exist as of the date
the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when
one or more future events occur or fail to occur. The Company&#8217;s management and legal counsel assess such contingent liabilities,
and such assessment inherently involves judgment. In assessing loss contingencies related to legal proceedings that are pending
against the Company or unasserted claims that may result in such proceedings, the Company&#8217;s legal counsel evaluates the perceived
merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected
to be sought.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the assessment of a contingency indicates
it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability
would be accrued in the Company&#8217;s consolidated financial statements. If the assessment indicates that a potential material
loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent
liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies
considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would
be disclosed.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Cash and Cash Equivalents</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents include cash in hand
and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months
or less. At March 31, 2019 and March 31, 2018, the Company had $6,553,768 and $4,296,676, respectively, in cash. Deposits at the
bank are insured up to $250,000 by the Federal Deposit Insurance Corporation. The Company&#8217;s uninsured portion of the balances
held at the bank aggregated to approximately $6,269,116 &#160;and $3,933,002, respectively. No reserve has been made in the financial
statements for any possible loss due to any financial institution failure.&#160;The Company has not experienced any losses in such
accounts and believes we are not exposed to any significant risk on cash and cash equivalents.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Property, Plant &#38; Equipment</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment is stated at cost and
depreciated using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. The estimated
useful lives of our property and equipment are generally as follows: computer equipment &#38; software developed or acquired for
internal use, three to ten years; office equipment, two to three years; buildings and improvements, five to fifteen years; leasehold
improvements, two to ten years; and machinery and equipment, one to five years.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">As of March 31, 2019 and March 31, 2018, property, plant and equipment
amounted to:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">March 31,</font><br />
<font style="font-size: 8pt">2019</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">March 31,</font><br />
<font style="font-size: 8pt">2018</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="width: 76%"><font style="font-size: 8pt">Computer equipment and software</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">20,565</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">15,103</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 8pt">Office equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">49,724</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td><font style="font-size: 8pt">Machinery and equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">21,937</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">Less: accumulated depreciation</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(16,278</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(1,844</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">75,948</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">13,259</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Depreciation expenses for the year ended March 31, 2019 and 2018
was $14,435 &#160;and $1,844, respectively.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Fair Value of Financial Instrument</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For certain of the Company&#8217;s financial
instruments, including cash and equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair
values due to their short maturities. ASC Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; requires disclosure
of the fair value of financial instruments held by the Company. ASC Topic 825, &#8220;Financial Instruments,&#8221; defines fair
value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements
for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities
each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between
the origination of such instruments and their expected realization and their current market rate of interest. The three levels
of valuation hierarchy are defined as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 inputs to the valuation methodology
are quoted prices for identical assets or liabilities in active markets.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 inputs to the valuation methodology
include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability,
either directly or indirectly, for substantially the full term of the financial instrument.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 inputs to the valuation methodology
are unobservable and significant to the fair value measurement.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to their short-term nature, the carrying
values of cash and equivalents, accounts receivable, accounts payable, and accrued expenses, approximate fair value. Based on borrowing
rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair
value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Earnings Per Share (&#8220;EPS&#8221;)</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number
of outstanding common shares during the period. Diluted earnings per share are computed by dividing net income by the weighted
average number of shares outstanding during the period increased to include the number of additional shares of common stock
that would have been outstanding if the potentially dilutive securities had been issued. During the fiscal years ended March
31, 2019 and 2018 we incurred losses. Therefore, the effects of any common stock equivalent were antidilutive during those
periods.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets for the computation
of basic and diluted earnings per share for the fiscal years ended March 31, 2019 and 2018:<b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31,</b></font><br />
<font style="font-size: 8pt"><b>2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31,</b></font><br />
<font style="font-size: 8pt"><b>2018</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 76%; padding-bottom: 2.5pt; padding-left: 34.6pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Net Loss</b></font></td>
    <td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(2,539,498</font></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(659,246</font></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Net Loss Per Share</b></font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Basic and Diluted:</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.15</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.05</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Weighted average number of shares used in computing basic and diluted net loss per share:</b></font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-align: right; text-indent: -8.65pt">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"><font style="font-size: 8pt">Basic</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">16,589,633</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">13,336,309</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"><font style="font-size: 8pt">Diluted</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">16,589,633</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">13,336,309</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 3pt"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 3pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU 2014-09,&#160;<i>Revenue
from Contracts with Customers</i>, issued as a new Topic, ASC Topic 606. The new revenue recognition standard supersedes all existing
revenue recognition guidance. Under this ASU, an entity should recognize revenue when it transfers promised goods or services to
customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or
services. ASU 2015-14, issued in August 2015, deferred the effective date of ASU 2014-09 to the first quarter of 2018, with early
adoption permitted in the first quarter of 2018. The company has adopted the new standard utilizing the modified retrospective
approach. The adoption of this new accounting guidance does not have material effects on results of operations, cash flows and
financial position for the forceable future because the company does not have revenues.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2016, The FASB issued ASU No. 2016-01,<i>&#160;Financial
Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities (Topic 825)</i>. ASU No. 2016-01 revises
the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes
for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments
to be recognized in net income. For non-public companies, ASU 2016-01 is effective for fiscal years beginning after December 15,
2018, and interim periods within fiscal years beginning after December 15, 2019. We are currently evaluating the impact of the
adoption of ASU 2016-01 will have on our consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU No. 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This update addresses a diversity
in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic
230, Statement of Cash Flows, and other Topics. The amendments in this Update are effective for public business entities for fiscal
years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including
adoption in an interim period. We adopted this ASU in 2016 and the implementation did not have a material impact on our financial
position or statement of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued guidance that
eases certain documentation and assessment requirements of hedge effectiveness and modifies the accounting for components excluded
from the assessment. Some of the modifications include the ineffectiveness of derivative gain/loss in highly effective cash flow
hedge to be recorded in other comprehensive income, the change in fair value of derivative to be recorded in the same income statement
line as hedged item, and additional disclosures required on the cumulative basis adjustment in fair value hedges and the effect
of hedging on financial statement lines for components excluded from the assessment. The amendment also simplifies the application
of hedge accounting in certain situations to permit new hedging strategies to be eligible for hedge accounting. The guidance is
effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2018,
our fiscal 2020. Early adoption is permitted and the modified retrospective transition method should be applied. We do not expect
the adoption of this guidance to have a material impact on our consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, FASB issued ASU No. 2016-02,
Leases (&#8220;Topic 842&#8221;). Topic 842 requires an entity to recognize right-of -use assets and lease liability on its balance
sheet and disclosure key information about leasing arrangements. For public companies, Topic 842 is effective for annual reporting
periods beginning after December 15, 2018, including interim periods within that reporting period, with early adoption permitted.
We have evaluated this ASU and believe this guidance will not have a material impact on our financial position and statement of
operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other recent accounting pronouncements issued
by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities
and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future
consolidated financial statements.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Reclassification</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior year amounts have been reclassified
for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations
or cash flow.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6617316272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 1,098,000<span></span>
</td>
<td class="nump">$ 817,000<span></span>
</td>
<td class="nump">$ 182,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6767471744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (1,122,198)<span></span>
</td>
<td class="num">$ (249,566)<span></span>
</td>
<td class="num">$ (2,539,498)<span></span>
</td>
<td class="num">$ (659,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (.15)<span></span>
</td>
<td class="num">$ (.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares used in computing basic and diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">17,847,740<span></span>
</td>
<td class="nump">15,983,273<span></span>
</td>
<td class="nump">16,589,633<span></span>
</td>
<td class="nump">13,336,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">17,847,740<span></span>
</td>
<td class="nump">15,983,273<span></span>
</td>
<td class="nump">16,589,633<span></span>
</td>
<td class="nump">13,336,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6756996720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,529,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Total fair value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,021,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 194,428<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">532,108<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MODD_Consultants1Member', window );">Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">July 25, 2018 to July 24, 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Total fair value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 682,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MODD_Consultants2Member', window );">Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January  16, 2019 to January 15, 2022	 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Total fair value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Options were fully vested as of the grant date, as disclosed above.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Total fair value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MODD_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MODD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116855757&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116859318&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MODD_Consultants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MODD_Consultants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MODD_Consultants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MODD_Consultants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6763456288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,706,628<span></span>
</td>
<td class="nump">$ 6,553,768<span></span>
</td>
<td class="nump">$ 4,296,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">15,590<span></span>
</td>
<td class="nump">16,804<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">5,716,128<span></span>
</td>
<td class="nump">6,569,358<span></span>
</td>
<td class="nump">4,313,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">75,961<span></span>
</td>
<td class="nump">75,948<span></span>
</td>
<td class="nump">13,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Security deposit</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="nump">83,633<span></span>
</td>
<td class="nump">83,628<span></span>
</td>
<td class="nump">20,972<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">5,799,761<span></span>
</td>
<td class="nump">6,652,986<span></span>
</td>
<td class="nump">4,334,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">253,474<span></span>
</td>
<td class="nump">178,929<span></span>
</td>
<td class="nump">14,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Payable to related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">253,474<span></span>
</td>
<td class="nump">178,929<span></span>
</td>
<td class="nump">15,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">253,474<span></span>
</td>
<td class="nump">178,929<span></span>
</td>
<td class="nump">15,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock</a></td>
<td class="nump">17,870<span></span>
</td>
<td class="nump">17,840<span></span>
</td>
<td class="nump">15,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">9,898,776<span></span>
</td>
<td class="nump">9,684,578<span></span>
</td>
<td class="nump">5,011,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Common stock issuable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(4,370,359)<span></span>
</td>
<td class="num">(3,248,161)<span></span>
</td>
<td class="num">(708,663)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">5,546,287<span></span>
</td>
<td class="nump">6,474,057<span></span>
</td>
<td class="nump">4,318,981<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 5,799,761<span></span>
</td>
<td class="nump">$ 6,652,986<span></span>
</td>
<td class="nump">$ 4,334,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6757086736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,122,198)<span></span>
</td>
<td class="num">$ (249,566)<span></span>
</td>
<td class="num">$ (2,539,498)<span></span>
</td>
<td class="num">$ (659,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">194,428<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">532,108<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,714<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
<td class="nump">14,468<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Shares for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Increase/Decrease in current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">6,090<span></span>
</td>
<td class="nump">10,248<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
<td class="num">(23,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilitiesAbstract', window );"><strong>Decrease in current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">74,545<span></span>
</td>
<td class="nump">1,704<span></span>
</td>
<td class="nump">163,974<span></span>
</td>
<td class="num">(109,748)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(840,421)<span></span>
</td>
<td class="num">(236,219)<span></span>
</td>
<td class="num">(1,807,934)<span></span>
</td>
<td class="num">(791,131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(6,719)<span></span>
</td>
<td class="num">(6,170)<span></span>
</td>
<td class="num">(77,124)<span></span>
</td>
<td class="num">(15,119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(213)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(6,719)<span></span>
</td>
<td class="num">(6,170)<span></span>
</td>
<td class="num">(77,124)<span></span>
</td>
<td class="num">(15,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,142,666<span></span>
</td>
<td class="nump">4,731,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment to related party, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(516)<span></span>
</td>
<td class="num">(516)<span></span>
</td>
<td class="num">(20,740)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(516)<span></span>
</td>
<td class="nump">4,142,150<span></span>
</td>
<td class="nump">4,711,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="num">(847,140)<span></span>
</td>
<td class="num">(242,905)<span></span>
</td>
<td class="nump">2,257,092<span></span>
</td>
<td class="nump">3,904,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at the beginning of the period</a></td>
<td class="nump">6,553,768<span></span>
</td>
<td class="nump">4,296,676<span></span>
</td>
<td class="nump">4,296,676<span></span>
</td>
<td class="nump">392,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at the end of the period</a></td>
<td class="nump">5,706,628<span></span>
</td>
<td class="nump">4,053,771<span></span>
</td>
<td class="nump">6,553,768<span></span>
</td>
<td class="nump">4,296,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid during the year for income tax payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the year for interest payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>66</ContextCount>
  <ElementCount>193</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - REORGANIZATION AND PRIVATE PLACEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ReorganizationAndPrivatePlacement</Role>
      <ShortName>REORGANIZATION AND PRIVATE PLACEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/AccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - PAYABLE TO RELATED PARTY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PayableToRelatedParty</Role>
      <ShortName>PAYABLE TO RELATED PARTY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - ROYALTY AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RoyaltyAgreement</Role>
      <ShortName>ROYALTY AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - LEASE AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/LeaseAgreement</Role>
      <ShortName>LEASE AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/StockholdersEquity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxes</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - ACCRUED EXPENSES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/AccruedExpensesDetailsNarrative</Role>
      <ShortName>ACCRUED EXPENSES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/AccruedExpenses</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - PAYABLE TO RELATED PARTY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PayableToRelatedPartyDetailsNarrative</Role>
      <ShortName>PAYABLE TO RELATED PARTY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/PayableToRelatedParty</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/StockholdersEquityTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/StockholdersEquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/StockholdersEquityTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="modd-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>modd-20190630.xml</File>
    <File>modd-20190630.xsd</File>
    <File>modd-20190630_cal.xml</File>
    <File>modd-20190630_def.xml</File>
    <File>modd-20190630_lab.xml</File>
    <File>modd-20190630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6751465504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the available information and other
factors, management believes it is more likely than not that the net deferred tax assets at, June 30, 2019 and March 31, 2019,
will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets
at June 30, 2019 and March 31, 2019. At June 30, 2019 and March 31, 2019, the Company had federal net operating loss carryforwards
of approximately $1,098,000 and $817,000 respectively, expiring beginning in 2037.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Deferred tax assets consist of the following components:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 51.9pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31, 2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 76%; padding-left: 8.65pt"><font style="font-size: 8pt">Net loss carryforward</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">1,098,000</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">817,000</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt"><font style="font-size: 8pt">Valuation allowance</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(1,098,000</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(817,000</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><font style="font-size: 8pt">Total deferred tax assets</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the available information and other
factors, management believes it is more likely than not that the net deferred tax assets at, March 31, 2019 and 2018, will not
be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets at, March
31, 2019 and 2018. At March 31, 2019 and 2018, the Company had federal net operating loss carry-forwards of approximately $817,000
and &#160;$182,500, respectively, expiring beginning in 2037.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Deferred tax assets consist of the following components:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 51.9pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">March 31,</font><br />
<font style="font-size: 8pt">2019</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">March 31,</font><br />
<font style="font-size: 8pt">2018</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 76%; padding-left: 8.65pt"><font style="font-size: 8pt">Net loss carryforward</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">817,000</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">182,500</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-bottom: 1pt; padding-left: 8.65pt"><font style="font-size: 8pt">Valuation allowance</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(817,000</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(182,500</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><font style="font-size: 8pt">Total deferred tax assets</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6711050768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2019</b></font><br />
<font style="font-size: 8pt"><b>(UNAUDITED)</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31, 2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 76%"><font style="font-size: 8pt">Computer equipment and software</font></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">25,028</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; text-align: right"><font style="font-size: 8pt">20,565</font></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Office equipment</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">49,724</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">49,724</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap"><font style="font-size: 8pt">Machinery and equipment</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">24,194</font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right"><font style="font-size: 8pt">21,937</font></td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">Less: accumulated depreciation</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(22,985</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(16,278</font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">75,961</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">75,948</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">March 31,</font><br />
<font style="font-size: 8pt">2019</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt">March 31,</font><br />
<font style="font-size: 8pt">2018</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="width: 76%"><font style="font-size: 8pt">Computer equipment and software</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">20,565</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; text-align: right"><font style="font-size: 8pt">15,103</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 8pt">Office equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">49,724</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td><font style="font-size: 8pt">Machinery and equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">21,937</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">Less: accumulated depreciation</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(16,278</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(1,844</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">75,948</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">13,259</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of earnings per share</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2019</b></font><br />
<font style="font-size: 8pt"><b>(UNAUDITED)</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2018</b></font><br />
<font style="font-size: 8pt"><b>(UNAUDITED)</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="width: 76%; padding-bottom: 2.5pt; padding-left: 17.3pt"><font style="font-size: 8pt"><b>Net Loss</b></font></td>
    <td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(1,122,198</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(249,566</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 8pt"><b>Net Loss Per Share</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-bottom: 2.5pt; padding-left: 8.65pt"><font style="font-size: 8pt"><b>Basic and Diluted:</b></font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.06</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.02</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Weighted average number of shares used in computing basic and diluted net loss </b></font><br />
<font style="font-size: 8pt"><b>per share:</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="padding-bottom: 2.5pt; padding-left: 8.65pt"><font style="font-size: 8pt">Basic</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">17,847,740</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">15,983,273</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 8.65pt"><font style="font-size: 8pt">Diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">17,847,740</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">15,983,273</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31,</b></font><br />
<font style="font-size: 8pt"><b>2019</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>March 31,</b></font><br />
<font style="font-size: 8pt"><b>2018</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; width: 76%; padding-bottom: 2.5pt; padding-left: 34.6pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Net Loss</b></font></td>
    <td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(2,539,498</font></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; width: 8%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(659,246</font></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Net Loss Per Share</b></font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Basic and Diluted:</b></font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.15</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double"><font style="font-size: 8pt">$</font></td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">(0.05</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"><font style="font-size: 8pt"><b>Weighted average number of shares used in computing basic and diluted net loss per share:</b></font></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 8.65pt; text-align: right; text-indent: -8.65pt">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEECC">
    <td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"><font style="font-size: 8pt">Basic</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">16,589,633</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">13,336,309</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-bottom: 2.5pt; padding-left: 17.3pt; text-indent: -8.65pt"><font style="font-size: 8pt">Diluted</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">16,589,633</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">13,336,309</font></td>
    <td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
